scientific program • symposia - American Society for Reproductive ...

Short and Simple 

Short: Mean duration of treatment — 5.4 days 1* 

Simple: Only GnRH antagonist available in a 

ready-to-use pre-fi lled syringe 1 

• Rapidly absorbed — 

approximately 1 hour after dosing 1 

• Rapidly reversible — 

within 48 hours of discontinuation, 

pituitary hormones (LH and FSH) 

are fully recovered 1 

• Small injection volume – 0.5 mL 1 

• Room temperature storage 1 

*Results from a multicenter, open-label randomized study to assess the effi cacy and safety of 

Ganirelix Acetate Injection in women undergoing controlled ovarian hyperstimulation. Range 2-14 days. 

Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled 

ovarian hyperstimulation. 

SELECTED SAFETY INFORMATION 

• Ganirelix Acetate Injection is contraindicated in patients with a known hypersensitivity to Ganirelix Acetate or to any 

of its components, to GnRH or any other GnRH analog, and in patients with known or suspected pregnancy. 

• Only physicians experienced in infertility treatment should prescribe Ganirelix Acetate Injection. Before starting 

treatment with Ganirelix, pregnancy must be excluded. 

• Cases of hypersensitivity reactions, including anaphylactoid reactions with the fi rst dose, have been reported during 

post-marketing surveillance. The packaging of this product contains natural rubber latex which may cause 

allergic reactions. 

• The most common adverse events occurring in ≥1% of patients treated with Ganirelix in clinical trials (N=794) include: 

abdominal pain (gynecological) 4.8%, fetal death 3.7%, headache 3.0%, ovarian hyperstimulation syndrome (OHSS) 

2.4%, vaginal bleeding 1.8%, injection site reaction 1.1%, nausea 1.1%, abdominal pain (gastrointestinal) 1.0%. 

Please see adjacent page for brief summary of full Prescribing Information. 

Reference: 1. Ganirelix Acetate Injection [package insert]. Roseland NJ: Organon USA Inc. 

Copyright © 2010, N.V. Organon, a subsidiary of Merck & Co., Inc. All rights reserved. Printed in USA. GX2046 8/10

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

� �� 

�� 

� �� 

� �� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

� �� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

� �� 

�� 

�� 

�� 

�� 

� �� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

��

DENVER 

Welcome to 

Welcome to Denver – the Mile High City – where a thriving arts and cultural scene, 300 days of sunshine, and the 

Rocky Mountain backdrop combine for the world’s most spectacular playground. Denver is as laid-back as it is 

sophisticated. It’s a place where engineers rub elbows with rock climbers at local brewpubs, at art festivals, or 

while strolling along downtown’s 16th Street pedestrian mall. Free shuttles give visitors quick access to world-class 

art and culture, wine bars, restaurants, and nighttime entertainment and music in Larimer Square or historic LoDo. 

Upscale shopping awaits at Cherry Creek, while Denver’s eight professional sports teams showcase this city’s 

active spirit. Denver’s 850 miles of paved biking and walking paths, the largest system of its kind in the country, 

connect visitors to unique attractions, parks and diverse neighborhoods. One trip is all it takes to fall in love with 

this great city. For more information on the Denver area VISITDENVER.org. 

Did You Know? 

• Denver has the largest city park system in the country with more than 200 parks within the city and 14,000 acres of parks in the 

nearby mountains, including spectacular Red Rocks Amphitheatre. Other mountain parks include Echo Lake, at the base of the 

Mount Evans highway – the highest road in North America – and Buffalo Bill’s Grave on top of Lookout Mountain. 

• There are more than 850 miles of off-street, paved bike paths in Denver, 90 golf courses and one of the nation’s largest urban-trail 

systems. 

• The Denver Performing Arts Complex covers four square blocks and serves as the second largest in the country, with 10 venues 

seating more than 10,000 people for opera, symphony, ballet, Tony Award-winning theatre and touring Broadway shows. 

• Denver has several world-class art museums, including the Denver Art Museum’s astonishing Hamilton Building, designed by 

world-famous architect Daniel Libeskind, and the Museum of Contemporary Art | Denver, designed by David Adjaye (his first 

building in the United States). 

• Denver is one of only two cities (Philadelphia is the other) to have eight professional sports teams: NFL Denver Broncos; NBA 

Denver Nuggets; NHL Colorado Avalanche; MLB Colorado Rockies; MLS Colorado Rapids; MLL Colorado Outlaws; NLL Colorado 

Mammoth; and Professional Rugby’s Glendale Raptors. 

• Denver brews more beer than any other city – more than 17 million barrels a year and 100 different beers per average day. 

Denver Weather 

• Denver has 300 days of sunshine annually – more annual hours of sun than San Diego or Miami Beach. 

• Denver has an average daily high of 45 degrees in February and receives only 15.8 inches of precipitation a year – about the 

same as Los Angeles. 

Photos and information is courtesy of the Travel and Vistor Bureau of Denver, Colorado.

TABLE OF CONTENTS 

President’s Message, Officers, Board of Directors, and Administration . . . . . . . . . . . . . . . . . . . . 4 

Scientific Program and Abstract Review Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 

ASRM Annual Meeting Policies and Disclaimers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 

Continuing Medical Education Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 

Audience Response System (AR) Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 

Registration and Other Important Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 

Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 

Daily Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 

Opening Ceremony and Reception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 

Postgraduate Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 

CME/CE Section . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 

Plenary Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 

Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 

Interactive Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 

Video Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 

Oral Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97 

Prize Papers, Prize Videos, and In-Training Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121 

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 

Roundtable Luncheons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 

Future Meeting Dates/ASRM 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166 

Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167 

Spouse/Guest Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183 

ASRM Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184 

Participant and Spouse/Partner Disclosures Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 

Abstracts Topic Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190 

Abstracts Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194 

Non-Oral/Poster Presenters Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 

Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225 

AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE 

1209 Montgomery Highway • Birmingham, AL 35216-2809 

Phone (205) 978-5000 • Fax (205) 978-5005 • Email asrm@asrm.org • URL www.asrm.org 

PROPERTY OF: ________________________________________________________________________ 

ADDRESS: ____________________________________________________________________________ 

______________________________________________________________________________________ 

______________________________________________________________________________________ 

Address while attending the meeting: ___________________________________________ Room #:________ 

Cell phone number: ___________________________________________

WELCOME 

William E. Gibbons, M.D. 

ASRM President 

2009-2010 

OFFICERS 

President 


President-Elect 

Rogerio A. Lobo, M.D. 

Vice President 

Dolores J. Lamb, Ph.D. 

Immediate Past President 

R. Dale McClure, M.D. 

Past President 

G. David Adamson, M.D. 

Secretary 

Catherine Racowsky, Ph.D., H.C.L.D. 

Treasurer 

Stuart S. Howards, M.D. 

It is my great pleasure to welcome you to the 66th Annual Meeting of the American 

Society for Reproductive Medicine in Denver, Colorado. The meeting theme is 

“Taking Reproductive Medicine to New Heights.” Our wide variety of postgraduate 

courses, lectures, symposia, roundtables, debates, abstracts, posters and videos will 

focus attention on the latest scientific developments in the field of reproductive 

medicine and their translation to clinical medicine. 

Topics include psychological care of the infertility patient, optimization of clinical 

care of the PCOS patient, premature ovarian failure, environmental, occupational 

and dietary impacts on fertility and pregnancy, third-party reproduction, 

laparoscopic surgery techniques, male infertility, microsurgery, cross-border care, 

culture media enhancement, oocyte/embryo vitrification, contraception, menopause, 

hormone therapy, endometriosis care, reproductive ethics and numerous additional 

offerings in all areas of reproductive medicine. 

I am confident this year’s offerings, combined with the beauty of Denver and its 

many attractions, as well as the opportunity to connect with colleagues and friends, 

will make this a most memorable meeting. All of us at ASRM extend a warm 

welcome to you here in Denver, Colorado! 

OFFICERS, BOARD OF DIRECTORS, AND 

ADMINISTRATION 


4 

DIRECTORS 

Ann J. Davis, M.D. 

Michael P. Diamond, M.D. 

Richard J. Paulson, M.D. 

Nanette F. Santoro, M.D. 

William D. Schlaff, M.D. 

Rebecca Z. Sokol, M.D., M.P.H. 

Nanette F. Santoro, M.D. (SREI) 

James M. Goldfarb, M.D. (SART) 

Anthony A. Luciano, M.D. (SRS) 

Nancy L. Brackett, Ph.D., H.C.L.D. (SMRU) 

EXECUTIVE DIRECTOR 

Robert W. Rebar, M.D. 

CHIEF OPERATING OFFICER 

Nancy R. Frankel, B.S., M.B.A. 

SCIENTIFIC DIRECTOR 

Andrew R. La Barbera, Ph.D., H.C.L.D.

SCIENTIFIC PROGRAM & ABSTRACT REVIEW COMMITTEE 

POSTGRADUATE PROGRAM 

COMMITTEE 

Thomas M. Price, M.D. 

Postgraduate Program Chair 

Hugh S. Taylor, M.D. 

Postgraduate Program Co-Chair 

Kirk C. Lo, M.D. 

Postgraduate Program Coordinating 

Chair 


Executive Director 

Andrew R. La Barbera, Ph.D., H.C.L.D. 

Scientific Director 

Penelope Fenton, M.A. 

Project Coordinator 

SCIENTIFIC PROGRAM 

COMMITTEE 

Robert N. Taylor, M.D., Ph.D. 

Scientific Program Chair 

Richard S. Legro, M.D. 

Interactive Sessions Chair 

Robert D. Oates, M.D. 

Roundtables Chair 

Lisa M. Halvorson, M.D. 

At Large 

Linda R. Nelson, M.D., Ph.D. 

At Large 

Mark Sigman, M.D. 

At Large 

R. Stan Williams, M.D. 

SART Program Chair 

Marcelle I. Cedars, M.D. 

SREI Program Chair 

Gary N. Frishman, M.D. 

SRS Program Chair 

Nancy L. Brackett, Ph.D., H.C.L.D. 

SMRU Program Chair 

Sangita K. Jindal, B.S., M.S., Ph.D. 

Reproductive Biology 

Professional Group 

Michael S. Stahler, M.B.A., Ph.D. 

Reproductive Laboratory 

Technologists Professional Group 

Julianne E. Zweifel, Ph.D. 

Mental Health Professional Group 

Nancy A. Harrington, R.N.C. 

Nurses Professional Group 

Margaret Swain, R.N., J.D. 

Legal Professional Group 


President, ASRM 


Executive Director 

Andrew R. La Barbera, Ph.D., H.C.L.D. 

Scientific Director 

C. Lee Hutchison, M.A. 

Program Coordinator 

VIDEO COMMITTEE 

Steven J. Palter, M.D., Chair 

Tien-cheng A. Chang, Ph.D. 

Tommaso Falcone, M.D. 

Emilio Fernandez, M.D. 

Antonio R. Gargiulo, M.D. 

Philip S. Li, M.D. 

Marius Meintjes, D.V.M., Ph.D. 

Charles E. Miller, M.D. 

Ceana H. Nezhat, M.D. 

Dana A. Ohl, M.D. 

David L. Olive, M.D. 

Marc P. Portmann, M.T. 

Togus Tulandi, M.D. 

Paul J. Turek, M.D. 

ABSTRACT REVIEW 

COMMITTEES 

Ashok Agarwal, Ph.D. 

Ayman Al-Hendy, M.D., Ph.D. 

Larissa Ali, M.S. 

Rebecca H. Allen, M.D. 

Anthony Anderson, M.Sc. 

Linda D. Applegarth, Ed.D. 

David F. Archer, M.D. 

Marjan Attaran, M.D. 

Mira Aubuchon, M.D. 

Cynthia Austin, M.D. 

Valerie L. Baker, M.D. 

G. David Ball, Ph.D. 

Kurt T. Barnhart, M.D., M.S.C.E. 

G. Wright Bates, M.D. 

David E. Battaglia, Ph.D. 

Barry D. Behr, Ph.D. 

Kristin R. Behymer, M.S. 

Sandra M. Bello, M.D. 

Kristin A. Bendikson, M.D. 

Susan H. Benoff, Ph.D. 

Marc Bernhisel, M.D. 

Lauri D. Black, M.S. 

Charla M. Blacker, M.D. 

Silvina M. Bocca, M.D., Ph.D. 

Nancy L. Brackett, Ph.D. 

John D. Brannian, Ph.D. 

Kaylon L. Bruner-Tran, Ph.D. 

Orhan Bukulmez, MD 

Serdar E. Bulun, M.D. 

Samantha F. Butts, M.D. 

Bruce R. Carr, M.D. 

Colleen L. Casey, M.D. 

Peter R. Casson, M.D. 

William H. Catherino, M.D., Ph.D. 


Grace M. Centola, Ph.D. 

Tien-cheng “Arthur” Chang, Ph.D. 

Guatam Chauduri, M.D., Ph.D. 

Greg L. Christensen, Ph.D. 

Gregory M. Christman, M.D. 

Karine Chung, M.D. 

5 

Pak H. Chung, M.D. 

Charles Coddington, MD 

Amber R. Cooper, M.D. 

Sharon N. Covington, M.S.W. 

Latasha B. Craig M.D. 

Gina M. Davis, M.S. 

Owen K. Davis, M.D. 

Nina N. Desai, Ph.D., H.C.L.D. 

Laura Detti, M.D. 

Todd Deutch, M.D. 


Dimitri Dozortsev, M.D., Ph.D. 

Ken Drury, Ph.D. 

Anil K. Dubey, Ph.D. 

Antoni J. Duleba, M.D. 

Daniel A. Dumesic, M.D. 

David A. Dumesic, M.D. 

Gary DeVane, M.D. 

Alison B. Edelman, M.D. 

Sharon G. Edwards, R.N., B.S.N. 

Navid Esfandiari, D.V.D., Ph.D. 


Huai Liang Feng, D.V.M., Ph.D. 

Robin N. Fogle, M.D. 


Ghina S. Ghazeeri, M.D. 


Elizabeth S. Ginsburg, M.D. 

Kathryn J. Go, Ph.D. 

Benjamin Gocial, M.D. 

James M. Goldfarb, M.D. 

Marc Goldstein, M.D. 

Frank Gonzalez, M.D. 

David A. Grainger, M.D. 

Dorothy A. Greenfeld, L.C.S.W. 

Stephen J. Greenhouse, M.D. 

Daniel R. Grow, M.D. 

Alex Hartman, M.D. 

Michael J. Heard, M.D. 

John S. Hesla, M.D. 

Timothy N. Hickman, M.D. 

David L. Hill, Ph.D. 

Carin V. Hopps, M.D. 

Mark D. Hornstein, M.D. 

Heather Huddleston, M.D. 

Mark R. Hughes, M.D., Ph.D. 

Maria M. Jackson, R.N., B.S., M.A. 

Grace M. Janik, M.D. 

Jeffrey T. Jensen, D.O. 

Julia Johnson, M.D. 

Emily Jungheim, M.D. 

Andrea Kalfoglou, Ph.D. 

Hey Joo Kang, M.D. 

David S. Karabinus, Ph.D., H.C.L.D. 

Eugene Katz, M.D. 

Mandy Katz-Jaffe, Ph.D. 

Raymond W. Ke, M.D. 

Dawn A. Kelk, Ph.D. 

Edward Kim, M.D.

SCIENTIFIC PROGRAM & ABSTRACT REVIEW COMMITTEE 

Sheryl A. Kingsberg, Ph.D. 

Simon Kipersztok, M.D. 

Nancy A. Klein, M.D. 

Gail Knudson, M.D. 

Peter N. Kolettis, M.D. 


Mark G. Larman, Ph.D. 

Susan E. Lanzendorf, Ph.D. 

Dan I. Lebovic, M.A., M.D. 

Richard S. Legro, M.D. 

Michael J. Levy, M.D. 

Frederick L. Licciardi, M.D. 

Paul C. Lin, M.D. 

Teresa Barry Longley, B.S.N.,M.S.N. 

Michael L. Lydic, M.D. 

Beth A. Malizia, M.D. 

Kerri L. Marquard, M.D. 

Megan McCoy, M.S. 

Elizabeth A. McGee, M.D. 

Jeffrey L. McKeeby, M.D. 

Laurie J. McKenzie, M.D. 

Janet McLaren, M.D. 

John D. Meeker, Ph.D. 

Wael Abdel Megid, M.D. 

Li Meng, Ph.D. 

Madgy P. Milad, M.D. 

Dean E. Morbeck, Ph.D., H.C.L.D. 

Arlene J. Morales, M D. 

Suheil J. Muasher, M.D. 

Santiago Munne, Ph.D. 


Craig S. Niederberger, M.D. 

Nicole Noyes, M.D. 

Randall R. Odem, M.D. 


Kevin G. Osteen, Ph.D. 

Yutaka Osuga, M.D., Ph.D. 

Lubna Pal, M.D. 

Alan S. Penzias, M.D. 

Kimball O. Pomeroy, Ph.D. 

Elizabeth Puscheck, M.D. 

Alexander M. Quaas, M.D. 

Catherine Racowsky, Ph.D. 

Veronica A. Ravnikar, M.D. 

Alice Rhoton, M.D. 

Paolo F. Rinaudo, M.D., Ph.D. 

Mitchell P. Rosen, M.D. 

Jay I. Sandlow, M.D. 

Glenn L. Schattman, M.D. 

Katherine D. Schoyer, M.D. 

Danny J. Schust, M.D. 

Bert Scoccia, M.D. 

James H. Segars, M.D. 

David B. Seifer, M.D. 

Kathy Sharpe-Timms, B.S.,M.S.,Ph.D. 

Dian Shepperson Mills, M.A. 

Mark Sigman, M.D. 

Kaylen M. Silverberg, M.D. 

Joe Leigh Simpson, M.D. 

Steven D. Spandorfer, M.D. 

6 

Amy E.T. Sparks, Ph.D. 

Laurel Stadtmauer, M.D.,Ph.D. 

Michael Stahler, Ph.D. HCLD 

Michael P. Steinkampf, M.D. 

Judy Stern, Ph.D. 

Pamela Stratton, M.D. 

H. Irene Su, M.D. 

Eric S. Surrey, M.D. 

Jason Swain, Ph.D. 

Hugh Taylor, M.D. 

J. Kevin Thibodeaux, Ph.D. 

Michael A. Thomas, M.D. 

James P. Toner, M.D. 

Nathan Treff, Ph.D. 

Kelton Tremellen, Ph.D.,M.B.B.S. 


William C. Venier, M.Sc. 

Michael Vernon, Ph.D. 

Elizabeth B. West, R.N.C., B.S.N. 

Lynn Westphal, M.D. 

Eric A. Widra, M.D. 

R. Stan Williams, M.D. 

Gilbert B. Wilshire, M.D. 

David Wininger, Ph.D. 

Julie J. Wirth, Ph.D. 

Terri L. Woodard, M.D. 

Bill Yee, M.D. 

Sarah Zornetzer, M.S. 

The American Society for Reproductive Medicine’s 

official photographer, 

Robb D. Cohen Photography & Design, LLC, 

will be taking photographs throughout the meeting. 

These photos are the property of ASRM and may be 

used in future ASRM promotional materials at 

ASRM’s discretion.

CERTIFICATE OF 

ATTENDANCE 

PROOF OF ATTENDANCE 

IS AVAILABLE AT THE 

REGISTRATION DESK UNTIL 

WEDNESDAY AFTERNOON 

AT 4:00 P.M. 

CME, REGISTRATION AND 

OTHER INFORMATION

ASRM ANNUAL MEETING POLICIES AND DISCLAIMERS 

CANCELLATION POLICY 

The American Society for Reproductive Medicine reserves the right to cancel this activity due to unforeseen 

circumstances. In the event of such cancellation, the full enrollment fee will be returned to the registrant. 

REFUND/NON-ATTENDANCE POLICY 

Cancellations received before or by September 27th will receive a full refund minus a $50 processing fee. 

Cancellations received after September 27th will not be eligible for a refund. 

ADA STATEMENT 

The American Society for Reproductive Medicine fully complies with the legal requirements of the ADA and 

the rules and regulations thereof. Accommodations for Disabilities: Please notify the American Society for 

Reproductive Medicine, 1209 Montgomery Highway, Birmingham, Alabama USA, telephone 1-205-978- 

5000, a minimum of 10 working days in advance of the event if a reasonable accommodation for a disability is 

needed. 

EQUAL OPPORTUNITY STATEMENT 

The American Society for Reproductive Medicine values and promotes diversity among its 

members, officers and staff. The Society prohibits discrimination toward any member or 

employee due to race, color, religion, age, gender, sexual orientation, national origin, citizenship, disability, 

military status or other basis prohibited by law. The Society strives to achieve gender, racial and ethnic balance 

in hiring and governance. The Society maintains policies, procedures and personnel actions that conform 

to the letter and spirit of all laws and regulations pertaining to equal opportunity and nondiscrimination in 

employment, appointments and election to office. 

DISCLAIMER STATEMENT 

The content and views presented in this educational activity are those of the faculty/authors and do not 

necessarily reflect those of the American Society for Reproductive Medicine. This material is prepared based 

upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, 

healthcare professionals and other individuals should review and consider other publications and materials on 

the subject matter before relying solely upon the information contained within this educational activity to make 

clinical decisions about individual patients. 

LEAD RETRIEVAL/PLASTIC SCAN CARD 

The lead retrieval/plastic scan card is your electronic business card for use with participating exhibitors in the 

exhibit hall. The card is encoded with your personal information including name, organization, address, fax, 

phone, and email. To provide exhibitors with this information scan this card into the electronic reader at their 

booth which will collect your personal contact information. Do not allow exhibitors to scan this card if you do 

not wish to share your information. 

HOTEL REBATE 

Hotel rates include a convention rebate that helps defray convention costs. 

7

PROCEDURE TO OBTAIN CME/CE CREDITS 

Dear Annual Meeting Scientific Program Participant: 

The Accreditation Council for Continuing Medical Education now requires that ASRM 

document learning for participants in CME programs. Thus, the procedure for claiming CME/ 

CE credits has changed. We ask your cooperation in following the steps below to ensure that 

your credits are provided correctly to you. 

1. Within 3 days after the Annual Meeting, you will be sent an email asking you to complete an 

online evaluation of the Postgraduate and Scientific Programs. A personalized web link to the 

evaluation will be provided in your email. Please do not share this unique link. 

2. In late November, you will be sent a second email with a personalized web link asking you to 

complete the post-test on the content of the Postgraduate and Scientific Programs. This test 

is identical to the pre-test you received prior to the meeting and will enable ASRM to assess 

the effectiveness of the Postgraduate and Scientific Programs as learning activities. For your 

convenience, the test questions are printed with their corresponding activity listings in the 

course syllabi (Postgraduate Courses) or in the blue CME Section of the Final Program 

(Scientific Program). 

After both steps have been completed, you will be able to claim your CME/CE credits and/or 

ACOG Cognates and receive a printable CME certificate. Please note that you must provide 

your 10-digit ACOG Membership Number to have your ACOG Cognates reported to ACOG. 

Results of both the evaluation and the post-test are anonymous. 

Both steps must be followed completely by December 31, 2010 in order to receive CME/CE 

credits. Please be aware that some email systems flag emails with Web links as junk mail and 

you may need to check your junk-email folder for your notifications. 

__________________________________________________________________________________________ 

Please DO NOT forward the links. In case of difficulty please email pfenton@asrm.org. 

*****Final date to receive CME credits = December 31, 2010***** 

CONTINUING EDUCATION (CME/CE) INFORMATION 

Genetic Counselor CEUs: This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval 

of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) acceepts CEUs approved by NSGC for purposes of 

recertification. Approval for the requested CEUs and Contact Hours is currently pending. 

8


NEEDS ASESSMENT AND 

MEETING DESCRIPTION 

The theme of the 2010 Annual Meeting 

of the American Society for Reproductive 

Medicine is “Taking Reproduction to 

New Heights,” a reference to the new 

scientific and clinical heights to which 

we aspire for reproductive health and 

the alpine venue of our Society’s 66th 

Annual Meeting. The 2010 meeting 

is specifically designed to meet the 

educational needs of both practitioners 

and scientists within the fields of 

reproductive medicine and biology. 

Educational objectives and learning events 

in the meeting are intentionally designed 

broadly to include both male and female 

reproductive health and investigation. 

The many learning events are designed 

to address educational needs within the 

varied fields of reproductive medicine and 

biology, including infertility, reproductive 

endocrinology, reproductive organ surgery, 

menopause, contraception, pediatric and 

adolescent gynecology, mental health, 

embryology, and reproductive medical 

practice administration. This year’s 

program will include symposia featuring 

the Centers for Disease Control and 

Prevention and the National Institute of 

Child Health and Human Development 

that specifically address the impact of the 

scientific and technological advances in 

reproductive medicine and their influence 

on society and global health. The 2010 

Annual Meeting location is the vibrant, 

modern and centrally located city of 

Denver. Educational sessions will allow 

for the sharing of information from 

international experts in their fields through 

a variety of modalities: plenary lectures, 

postgraduate courses, symposia, debates, 

oral and poster presentations, as well as 

less formal roundtable sessions. To ensure 

the greatest educational opportunities for 

introspection and discussion, substantial 

time for interaction among participants 

and presenters is scheduled. 

Educational programs in the 2010 Annual 

Meeting are designed to inform learners 

about advances in a broad array of 

areas in reproductive medicine, biology 

and surgery with the ultimate goal of 

enhancing the quality of patient care and 

improving outcomes in reproductive 

health. A sample of the topics to be 

covered includes: steroid hormone action, 

stem cell research, technological advances 

in reproductive surgery including robotics 

and adhesion prevention, effects of 

appetite and diet on reproduction, genderspecific 

aspects of cardiovascular disease 

and impact of infertility diagnoses and 

therapies, the ethics of cross-border 

reproductive healthcare, molecular 

genetics of male and female gametes and 

the early embryo, medical and public 

health ramifications of menopause, 

new innovations in contraception, 

ovarian stimulation, oocyte and sperm 

cryopreservation, and integration of 

medical and psychological care of the 

couple undergoing reproductive medical 

care. 

A series of special sessions of oral 

and poster presentations will inform 

participants about the results of recently 

completed basic science and clinical trials 

with relevance to biologists and clinicians 

specializing in reproductive medicine. The 

Scientific Program of the 2010 ASRM 

Annual Meeting will stimulate open 

discussion and vigorous exchange of ideas 

in a vibrant multicultural atmosphere. 

LEARNING OBJECTIVES 

At the conclusion of the 2010 Annual 

Meeting Scientific Program of the 

American Society for Reproductive 

Medicine, participants should be able to: 

1. Describe the safety and implications of 

ART on embryo imprinting and 

obstetrical outcomes. 

2. Describe how the modern treatment 

of clinical male and female reproductive 

dysfunction includes genetic, 

biochemical, anatomic, and behavioral 

assessment and introduces evidencebased 

approaches to medical and 

surgical therapies. 

3. Enumerate the molecular mechanisms 

underlying reproductive function and 

describe how these functions are targets 

for potential new therapeutics. 

4. Assess recent advances in operative 

techniques and instrumentation that may 

lead to better correction of reproductive 

pathology. 

5. Describe how cross-border reproductive 

care can impact all members of the 

healthcare team including male and 

female reproductive medical specialists, 

scientists, mental health specialists, 

technologists, adjunctive medical 

9 

practitioners including nurses, and 

specialists in administration and 

business. 

ACCREDITATION 

Continuing Education Credit Information 

will be located in the front of each 

Postgraduate Course syllabus and the 

Final Program. 

CE/CME Credit reporting is now done 

online. You will receive an email 

requesting you to log-in to complete 

evaluations of the Postgraduate and 

Scientific Programs and claim your AMA, 

ACOG, NASW and Nursing credits, or to 

request a Certificate of Attendance. The 

Website contains detailed instructions on 

how to complete the report, and you will 

be able to print or email a certificate to the 

email address you provided at registration. 

Final date to request credit is 

December 31, 2010. 

Credits other than those specified below 

are the responsibility of each attendee. 

Commercially Supported Symposia 

Commercially Supported Symposia 

presented at the Annual Meeting of the 

ASRM are a part of the Scientific Program 

unless otherwise noted. 

The Accreditation Council for 

Continuing Medical Education 

(ACCME) 

The American Society for Reproductive 

Medicine is accredited by the 

Accreditation Council for Continuing 

Medical Education to provide continuing 

medical education for physicians. 

The American Medical Association 


Medicine designates the Scientific 

Program for a maximum of 21.75 AMA 

PRA Category 1 Credits, the one-day 

Postgraduate Program for a maximum 

of 6.5 AMA PRA Category 1 Credits. 

Physicians should only claim credit 

commensurate with the extent of their 

participation in the activity. 

The American College of 

Obstetricians and Gynecologists 

The American College of Obstetricians 

and Gynecologists has assigned 22 

cognates to the Scientific Program and 

7 cognates to the one-day Postgraduate 

Program.


American Board of Bioanalysis 

(ABB) 


Medicine has been approved to provide 

Professional Enrichment Education 

Renewal (PEER) credit through the 

American Board of Bioanalysis. 19.75 

PEER CEUs will be recognized for 

postgraduate courses 1, 8, 9, and 19. PEER 

credit forms for eligible postgraduate 

courses and for the Scientific Program will 

be available at the American Association 

of Bioanalysts (AAB) booth in the Exhibit 

Hall. ABB certification exams will be 

administered Friday, October 22, 2010. 

American Psychological Association 

(APA) 

The Mental Health Professional Group 

(MHPG) of the American Society for 

Reproductive Medicine is approved 

by the American Psychological 

Association to sponsor continuing 

education for psychologists. Those 

attending MHPG courses 2 or 13 will be 

offered APA credits for psychologists. The 

MHPG maintains responsibility for their 

program and its content. 

National Association of Social 

Workers (NASW) 

Mental Health Professional Group 

postgraduate courses 2 and 13 are 

approved by the National Association of 

Social Workers (Provider # 886496548) 

for 6.5 Continuing Education Contact 

Hours. 

Nursing Credits 

Nurses’ Professional Group postgraduate 

course 9 has been approved for 6.5 credit 

hours by the Continuing Education 

Approval Program of the National 

Association of Nurse Practitioners in 

Women’s Health. Nurses’ Professional 

Group postgraduate course 19 has 

been approved for 6.5 credit hours and 

2.25 pharmacology credit hours by the 

Continuing Education Approval Program 

of the National Association of Nurse 

Practitioners in Women’s Health. The 

Scientific Program has been approved 

for a maximum of 21.75 contact hours 

including 14.0 hours of pharmacology 

credit by the Continuing Education 

Approval Program of the National 

Association of Nurse Practitioners in 

Women’s Health. 

10 

Note: No credits will be given for 

Association of Reproductive Managers 

Continuing Education Course PG21. 

CERTIFICATE OF 

ATTENDANCE 

Proof of attendance is available on request 

from J. Spargo at the registration desk. 

Continuing Education Credit information 

is located in the front of the Postgraduate 

Course syllabi and the Final Program and 

online. 

Continuing education/continuing medical 

education credit is not offered during 

meals, breaks, receptions/cocktail parties, 

training sessions, satellite meetings or 

any private group meeting (e.g., council 

meetings, invitation-only meetings, 

editorial board meetings, etc.). In 

addition, CME/CE credit is not offered 

during poster sessions, oral abstract 

presentations, or roundtable luncheon 

discussions. 

This symbol indicates a postgraduate 

course that qualifies for CME credit. 

This symbol indicates a postgraduate 

course that qualifies for CE credit. 

This symbol indicates an activity using 

our Audience Response System. Bring 

your cell phone with you. 

Continuing medical education is a lifelong learning modality designed to enable physicians to remain current with 

medical advances. The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to 

practice the best medicine and provide the best, most current care to patients. 

As an accredited CME provider, ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing 

Medical Education (ACCME). CME activities now must first, address specific, documented, clinically important gaps in 

physician knowledge, competence or performance; second, be documented to be effective at increasing physician 

knowledge, skill or performance; and third, conform to the ACCME Standards for Commercial Support. 

ASRM must not only obtain complete disclosure of commercial and financial relationships pertaining to reproductive 

medicine but also resolve any perceived conflicts of interest. All postgraduate course faculty members and all organizers, 

moderators and speakers in the Scientific Program have completed disclosures of commercial and financial relationships 

with manufacturers of pharmaceuticals, laboratory supplies and medical devices and with commercial providers of 

medically-related services. The disclosures were reviewed by the Subcommittee for Standards of Commercial Support of 

the ASRM CME Committee, which resolved perceived potential conflicts of interest. 

The next few years will be an exciting time for the community of reproductive medicine practitioners as we adapt to the 

changing environment of healthcare and CME. The American Medical Association is advancing a transition of CME from 

a system of credits based on hours of attendance to a system based on improvement in physician performance. 

ADMISSION BADGES 

Name badges will be issued for the Postgraduate and Scientific Programs and are required for admission. Spouse/guest badges will 

be issued and are required for admission to spouse/guest activities and the Exhibit Hall. Badges will be required for entrance into the 

Opening Reception. 

PHOTO/AUDIO/VIDEO RECORDING 

Photographing or audio/video recording of any session for personal or commercial purposes without 

permission is prohibited. 

CME 

CE

Disclosure Statements/Conflict of Interest Policy 

Honoraria 

The following speakers may receive 

honoraria and/or discounted or free 

registration: 

• Plenary Speakers 

• Postgraduate Course Faculty 

• Symposia Speakers 

• Interactive Session Speakers 

The following speakers do not 

receive honoraria: 

• Roundtable Presenters 

• Abstract Presenters 

• Video Presenters 

Disclosure Statements 

Postgraduate Faculty, Symposia 

Speakers, Plenary Lecturers, Abstract 

Authors, Abstract Graders, Roundtable 

Presenters, Video Presenters, 

and Interactive Speakers are 

required to disclose commercial 

relationships or other activities that 

might be perceived as potential 

conflicts of interest. 

Postgraduate course faculty 

disclosures wiill be listed in the course 

syllabi. 

Symposium speakers’ disclosures will 

be presented in handout materials, 

as well as on slides. 

Disclosures from speakers in the 

Plenary Sessions, Interactive Sessions, 

Roundtables, Videos and Symposia 

will be published in the Final Program. 

Abstract authors’ disclosures will be 

published in the 2010 Program 

Supplement. 

Each presenter should reveal his/her 

disclosure information during his/her 

presentation, preferably with the 

visual aid of a slide. 

Roundtable presenters should 

provide a copy of their disclosure 

forms to the participants at their 

table. 


2010 Conflict of Interest Policy 

for Invited Speakers 

As a provider of continuing medical education (CME) accredited 

by the Accreditation Council for Continuing Medical Education 

(ACCME), the American Society for Reproductive Medicine must 

ensure balance, independence, objectivity and scientific rigor in all 

its educational activities. All presenters must disclose to the learners 

any commercial or financial interests and/or other relationships 

with manufacturers of pharmaceuticals, laboratory supplies and/or 

medical devices. All relationships, whether or not they directly apply 

to this CME event, must be disclosed. All non-FDA approved uses of 

products must be clearly identified. Disclosures may be made in the 

form of a slide, printed material, or oral statement. 

The intent of this disclosure is not to prevent a speaker with a 

commercial or financial interest from making a presentation. The intent 

is to assist ASRM in resolving conflicts of interest and to provide learners 

with information on which they can make their own judgments 

regarding any bias. Although ASRM reviews and resolves potential 

conflicts of interest, it remains for the audience to determine whether 

the speaker’s interests or relationships may influence the presentation 

with regard to exposition or conclusion. 

Disclosures will be revealed to the learners. For postgraduate 

courses, disclosure information will be provided in the syllabus. For 

other activities, where no syllabus or other similar printed material is 

available, disclosures must be made verbally to the audience by the 

speakers, preferably with the visual aid of a slide. 

For those situations where there is no potential for conflict of interest, 

the portion of the form that so states should be completed. In those 

situations where a speaker does not complete a form or refuses to 

complete a form, the individual is ineligible to participate as a speaker 

in the CME activity. 

Speakers should also reveal to the audience any “off label” uses 

(not approved by the FDA) of any drugs or products discussed. 

Abstract authors’ disclosures are listed in the 

2010 Program Supplement. Speakers in the 

Symposia and Interactive, Video, Roundtable 

and Abstract Sessions have also complied with 

ASRM policies and their disclosures are on file in 

the ASRM office. The speaker should reveal this 

information during his/her presentation, preferably 

with the visual aid of a slide. 

11

Look for this symbol as an indicator of an activity using our Audience Response 

System. When you see it, please be sure to bring your cell phone with you. 

Audience Response System Instructions 

Sessions using Audience Response will ask learners to use their cell phones/Smartphones 

(Blackberry/iPhone/Android) to text message their responses. 

“DIAL” “TEXT” 

answer code 

11111 

12 

11111 

22222 

33333 

Note:  Standard text 

International Users: 

messaging rates and/or 

• First try using the US text number 22333 

surcharges may apply. 

• UK +44 76 2480 6527 

• Asia, Africa, Middle East, Australia, South & Central America +61 429 883 441

REGISTRATION AND OTHER IMPORTANT MEETING INFORMATION 

Unless otherwise 

indicated, all 

rooms are in the 

Colorado 

Convention Center. 

____________________________ 

Please note that all abstracts and 

participant disclosures have been 

printed in the Final Program as 

they were submitted to ASRM. 

Only apparent misspellings have 

been corrected. 

____________________________ 

PHOTO/AUDIO/VIDEO 

RECORDING 

Photographing and/or audio/ 

video recording of any session for 

personal or commercial purposes 

without permission is prohibited. 

____________________________ 

REGISTRATION 

On-site Registration Desk: 

Colorado Convention Center 

Friday, October 22 

2:00 pm - 8:00 pm 

Saturday, October 23 

7:00 am - 7:00 pm 

Sunday, October 24 

7:00 am - 7:30 pm 

Monday, October 25 

7:00 am - 5:00 pm 

Tuesday, October 26 

7:00 am - 5:00 pm 

Wednesday, October 27 

8:00 am - 1:00 pm 

____________________________ 

EXHIBITS 

The Exhibit Hall will be open: 

Monday, October 25: 

9:30 am - 5:00 pm 

Tuesday, October 26: 

9:00 am - 5:00 pm 

Wednesday, October 27: 

9:00 am - 2:00 pm 

For the safety of your child and 

in order to maintain the scientific 

nature of the display, no children 

under the age of 16 (except infants 

under 6 months of age carried in 

arms at all times) will be allowed 

in the Exhibit Hall. Strollers 

and infants in backpacks are not 

permitted in the Exhibit Hall at 

anytime. 

____________________________ 

BADGE COLORS 

Attendee designations are indicated 

by the following colors: 

Member Red 

Non-member Grey 

Resident/Student Blue 

Exhibitor Green 

Staff/Vendor Purple 

Spouse/Guest Yellow 

Media Orange 

PG Course Only Clear 

(PG course #s will be indicated 

on the badge and on the course 

syllabus cover.) 

____________________________ 

13 

ASRM OFFICE 

Room: 612 

Office Hours: 


7:30 am - 7:00 pm 


7:30 am - 6:00 pm 

Monday, October 25 and 


7:30 am - 6:00 pm 


7:30 am - 5:00 pm 

____________________________ 

SPEAKER READY ROOM 

Room: 301 

Hours: 

Friday, October 22 

12:00 pm - 5:00 pm 


7:00 am - 7:00 pm 

Sunday October 24 

7:00 am - 5:00 pm 

Monday, October 25 and 


8:00 am - 5:30 pm 


8:00 am - 12:00 pm 

____________________________ 

ASRM PRESS OFFICE 

Room: 303 

Hours: 


3:00 pm - 6:00 pm 

(credential pick-up only) 

Monday, October 25 through 


8:00 am - 5:30 pm

REGISTRATION AND OTHER IMPORTANT MEETING INFORMATION 

INTERNET CAFÉ 

Access the Internet and connect with various colleagues and attendees 

at the Internet Café. 

Location: 


Friday 2:00 pm - 8:00 pm • Saturday & Sunday 7:00 am -7:00 pm 

Monday & Tuesday 7:00 am -7:00 pm • Wednesday 7:30 am - 5:00 pm 

____________________________ 

ASRM BOOTH #835 

Stop by the ASRM Booth in the Exhibit Hall and join or renew your membership, 

browse our publications, and learn about all the Society has to offer. 

____________________________ 

GROUP AND AFFILIATED SOCIETY MEMBERS’ MEETINGS 

Rooms are located in the Colorado Convention Center. 

SUNDAY, OCTOBER 24 

5:15 pm - 6:00 pm 

Association of Reproductive Managers 

Professional Group, Room 401 

Fertility Preservation Special Interest Group, Room 501 

Preimplantation Genetic Diagnosis 

Special Interest Group, Room 205 (Starts at 4:00 p.m.) 

Mental Health Professional Group, Room 505 

Nurses’ Professional Group, Room 207 

MONDAY, OCTOBER 25 

8:15 am - 8:45 am 

Society for Assisted Reproductive Technology, Room 607 

Chinese Special Interest Group, Room 201 

Reproductive Immunology Special Interest Group, 

Room 207 

Complementary and Alternative Medicine Group, 

Room 203 

Health Disparities Group, Room 205 

Database Management Solutions, Room 605 

6:15 pm - 7:00 pm 

Society of Reproductive Surgeons, Room 605 

Contraception Special Interest Group, Room 405 

Environment and Reproduction Special Interest Group, 

Room 207 

Genetic Counseling Special Interest Group, Room 607 

Pediatric and Adolescent Gynecology 

Special Interest Group, Room 503 

Sexuality Special Interest Group, Room 601 

Reproductive Biology Professional Group and 

Reproductive Laboratory Technologists Group (combined 

meeting), Room 603 

14 

European Society for Human 

Reproduction and Embryology, Room 505 

Early Pregnancy Group, Room 205 

Legal Professionals Group, Room 4C 

Regenerative Medicine Group, Room 403 

Turkish Group, Room 4B 

TUESDAY, OCTOBER 26 

8:15 am - 8:45 am 

Latin American Association for Reproductive Medicine, 

Room 4B 

6:15 pm - 7:00 pm 

Society for Male Reproduction and Urology, Room 4E 

Society for Reproductive Endocrinology and Infertilty, 

Room 605 

Androgen Excess Special Interest Group, Room 601 

Endometriosis Special Interest Group, Room 603 

Fibroids Special Interest Group, Room 201 

Imaging in Reproductive Medicine 

Special Interest Group, Room 607 

Menopause Special Interest Group, Korbel Ballroom 1 

Middle East Fertility Society, Room 205 

Nutrition Special Interest Group, Room 207 

Indian Group, Room 203 

WEDNESDAY, OCTOBER 27 

10:00 am - 10:30 am 

American Society for Reproductive Medicine, 

Four Seasons Ballroom 1

The American Society for 

Reproductive Medicine would 

like to thank 

Bayer HealthCare 

Pharmaceuticals 

for their support of 

ASRM’s 

66th Annual Meeting Reception 

FLOOR PLANS

COLORADO CONVENTION CENTER FLOORPLANS 

LOWER LEVEL 0 

15

COLORADO CONVENTION CENTER FLOORPLANS 

STREET LEVEL 1 

16

HYATT REGENCY AT THE COLORADO CONVENTION CENTER 

FLOORPLANS 

THIRD FLOOR

HYATT REGENCY AT THE COLORADO CONVENTION CENTER 

FLOORPLANS 

FOURTH FLOOR

1. Brown Palace Hotel & Spa 

321 17th Street 

2. Comfort Inn Downtown 


3. Courtyard by Marriott, 

Denver Downtown 


4. Crowne Plaza Denver 

1450 Glenarm Place 

5. Grand Hyatt Denver 

Downtown 

1750 Welton Street 

DENVER HOTEL MAP 

6. Hilton Garden Inn Denver 

Downtown 

1400 Welton Street 

7. Hotel Monaco Denver 

1717 Champa Street at 

17th 

8. Hotel Teatro 


9. Hyatt Regency at 

Colorado Convention 

Center 

(Headquarters Hotel) 


10. Magnolia Hotel Denver 


11. Marriott Denver City 

Center 

1701 California Street 

12. Sheraton Denver 

Downtown 

1550 Court Place 

13. The Curtis 

1405 Curtis Street 

14. West Tabor Center 

1672 Lawrence Street

Sign up for Automatic Dues 

Renewal with ASRM! 

Don’t let your membership lapse; ASRM will 

renew yearly for you at NO EXTRA COST. 

For more information, visit the 

ASRM Booth #835 or contact Dottie Beatty at 

(205) 978-5000 x 136 or dbeatty@asrm.org. 

SREI MEMBERS’ PRACTICE RETREAT 

FRIDAY, OCTOBER 22, 2010 • 10:30 AM - 4:45 PM • HYATT REGENCY HOTEL, MINERAL F 

Co-Chairs: 

Steven T. Nakajima, M.D. 

Kevin J. Doody, M.D. 

Learning Objectives: 

At the end of this retreat, participants should be able to: 

1. Distinguish differences among different private practice models. 

2. List strategies to improve office work flow and staff morale. 

3. Determine key elements in an employment contract. 

4. Identify important aspects to consider when hiring a new partner. 

Target Audiences: 

1. SREI members in clinical practice settings, three-five years post-fellowship, and in 

their first or transitioning into their second post-fellowship position. 

2. Any SREI member who would like to improve their clinical practice setting. 

Prerequisite: 

Must be a current member of SREI 

20 

Faculty: 

David A. Riley, M.D. 

Melissa Ann Esposito, M.D., F.A.C.O.G. 

Eric Knochenhauer, M.D. 

Gabe San Roman, M.D. 

Lisa Rinehart, R.N., J.D. 

Registration Fee: 

$150

ASRM would like to thank our 

generous supporters of the 

66 th Annual Meeting in Denver, Colorado: 

Ruby Supporter 

Merck 

Pfizer 

Platinum Supporters 

Bayer HealthCare Pharmaceuticals 

EMD Serono 

Watson Pharma, Inc. 

Gold Supporters 

Boehringer Ingelheim Pharmaceuticals 

Ferring Pharmaceuticals 

Silver Supporters 

Irvine Scientific 

Unisense FertiliTech 

Bronze Supporters 

Abbott Laboratories 

Femasys 

Genesis Genetics Institute 

Ultrasonix 

Vivere Health 

DAILY SCHEDULE

SATURDAY, OCTOBER 23 

2010 ASRM ANNUAL MEETING • DAILY SCHEDULE 

8:15 am - 5:00 pm 

POSTGRADUATE PROGRAM COURSES 1-11 

Lunch is from Noon-1:00 pm 

Courses PG1-PG11 are one-day courses on Saturday. 

Courses PG11 is a surgical hands-on course. 

(See the Postgraduate section of the program on page 33 for complete 

information and location of all courses.) 

ASRM 2010 Annual Meeting Opening Ceremony 

Sunday, October 24, 2010 • 6:30 pm 

Colorado Convention Center • Four Seasons Ballroom 

Followed by the Opening Reception 

A special thank you to 


for their support of the Opening Reception. 

21 

SUNDAY, OCTOBER 24 

8:15 am - 5:00 pm 

POSTGRADUATE PROGRAM COURSES 12-21 

Lunch is from Noon-1:00 pm 

Courses PG12-PG21 are one-day courses on Sunday. 

Courses PG 14 is a surgical hands-on course. 

Courses PG 20 is a hands-on course. 

(See the Postgraduate section of the program on page 33 for complete 

information and location of all courses.) 

5:15 pm – 6:00 pm 

MEMBERS’ MEETINGS 

• Association of Reproductive Managers, Room 401 

• Preimplantation Genetic Diagnosis Special Interest 

Group, Room 205 

• Mental Health Professional Group, Room 505 

• Nurses’ Professional Group, Room 207 

• Fertility Preservation Special Interest Group, Room 501 

6:30 pm 

OPENING CEREMONY & OPENING RECEPTION 

Colorado Convention Center Four Seasons Ballroom 

ASRM 2010 Meeting Badge 

will be required for entry.

MONDAY, OCTOBER 25 


8:15 am - 8:45 am • MEMBERS’ MEETINGS 

• Society for Assisted Reproductive Technology, Room 607 

• Chinese Special Interest Group, Room 201 

• Reproductive Immunology Special Interest Group, Room 207 

• Complementary and Alternative Medicine Group, Room 203 

• Health Disparities Group, Room 205 

• Database Management Solutions, Room 605 

9:00 am - 10:30 am • PLENARY SESSION 1 • 

CME 

FOUR SEASONS BALLROOM 1 

9:00 am - 9:45 am 

The President’s Guest Lecture 

Nuclear Receptor Coactivators in Physiology and Pathology 

Bert W. O’Malley, M.D. 

Baylor College of Medicine 

Endowed by a 1987 grant from Ortho Women’s Health 

9:45 am - 10:30 am 

Herbert H. Thomas Lecture 

Targeting Steroidogenesis in Endometriosis 


Northwestern University 

Endowed by a 1990 grant from Astra-Zeneca 

10:30 am – 11:15 am • BREAK - VISIT EXHIBITS • HALL F 

11:15 am – 1:00 pm • SCIENTIFIC PROGRAM PRIZE PAPER ORAL 

ABSTRACT PRESENTATIONS • FOUR SEASONS BALLROOM 4 

11:15 am – 1:00 pm 

SOCIETY OF REPRODUCTIVE SURGEONS TELESURGERY • 


Office Hysteroscopy: Septum, Uterine Synechiae, Polyps, Tubal 

Occlusion in an Office Setting 

Keith B. Isaacson, M.D. 

Supported by an educational grant from Karl Storz Endoscopy 

11:15 am – 1:00 pm • SYMPOSIUM • KORBEL BALLROOM 1 CME 

Debate: Open vs. Closed Gamete Donation 

Presented by the Mental Health Professional Group 

Judith Kottick, M.S.W. (Chair) 

Elaine R. Gordon, Ph.D. 

Shelley S. Lee, Ph.D. 

11:15 am – 1:00 pm • SYMPOSIUM • ROOM 201 

CME 

The Ever-changing Face of REI 

Presented by the Association of Reproductive Managers Professional Group 

Lisa A. Rinehart, R.N. (Chair) 

John S. Rinehart, M.D., Ph.D., J.D. 

Joseph J. Travia, Jr., M.B.A. 


CME 

Management of the Menopause: To Treat or Not to Treat- 

That Remains the Question 

Presented by the Nurses’ Professional Group 

Jacqueline N. Gutmann, M.D. (Chair) 

Julie D. Lamb, M.D. 

11:15 am – 12:00 pm • CONTRACEPTION DAY KEYNOTE LECTURE • 

ROOM 405 

CME 

A Good Man: Gregory Pincus and the Development of Oral 

Contraception 

Leon Speroff, M.D. 

12:00 pm – 1:00 pm • CONTRACEPTION DAY WORKSHOP • CME 

ROOM 405 

New Concepts in the Treatment of Abnormal Uterine 

Bleeding: A Case Presentation 

A Joint Session presented by the Contraception Special Interest Group 

and the Society of Reproductive Surgeons 

Kristen A. Matteson, M.D., M.P.H. (Chair) 


1:00 pm – 2:45 pm • LUNCH BREAK 

1:00 pm – 2:30 pm • LUNCHEON SYMPOSIUM • 

CME 

KORBEL BALLROOM 2 (This is a ticketed event.) 

Unexplained Infertility: Individualizing Treatment for a 

Successful Outcome 

22 

Marcelle I. Cedars, M.D. (Chair) 


Bradley J. Van Voorhis, M.D. 

Supported by an educational grant from EMD Serono, Inc., and Merck 

1:15 pm – 2:15 pm • MEET THE PROFESSOR INTERACTIVE SESSION • 

ROOM 201 

CME 



1:15 pm – 2:15 pm • INTERACTIVE SESSION • ROOM 401 CME 

Emergency IVF vs. Ovarian Tissue Freezing 

A Joint Session presented by the Society for Assisted Reproductive 

Technology, the Fibroid Special Interest Group and the Imaging in 

Reproductive Medicine Special Interest Group 

Karine Chung, M.D. (Chair) 

Jacques G. Donnez, M.D. 


Dror Meirow, M.D. 


Identification and Treatment of Hypothalamic Anovulation 

Presented by the Society for Reproductive Endocrinology and Infertility 

Sarah L. Berga, M.D. 

Samuel A. Pauli, M.D. 


Fertility Decision Making for BRCA Carriers 

A Joint Session presented by the Society For Reproductive Endocrinology and 

Infertility and the Genetic Counseling Special Interest Group 

Glen L. Schattman, M.D. (Chair) 



Genomics vs. Metabolomics in Embryo Selection for eSET 

Presented by the Reproductive Biology Professional Group 

Sangita K. Jindal, Ph.D. (Chair) 

Dagan Wells, Ph.D. 

Emre Seli, M.D. 


Mechanical Hair Removal: What Our Patients are Doing 

and What We Should Know About It 

A Joint Session presented by the Mental Health Professional Group 

and the Androgen Excess Special Interest Group 

Lauri A. Pasch, Ph.D. (Chair) 



Environmental Toxins and Risk of Infertility, Pregnancy Loss 

and Gynepathology 

A Joint Session presented by the Environment and Reproduction 

Special Interest Group 

Susan H. Benoff, Ph.D. (Chair) 

Stacey A. Missmer, Sc.D. 

Russ B. Hauser, M.D., Sc.D., M.P.H. 


Testosterone Replacement in Hypoactive Sexual Desire Disorder: 

An Interactive Debate 

Presented by the Sexuality Special Interest Group 

Elizabeth E. Puscheck, M.D. (Chair) 

John E. Buster, M.D. 


1:15 pm – 2:15 pm • ROUNDTABLE LUNCHEONS • HALL F 

(ROUNDTABLE AREA) 

2:45 pm – 3:30 pm • PLENARY SESSION 2 • 

CME 


American Urological Association Bruce Stewart Memorial Lecture 

Future of Surgery 

Richard M. Satava, M.D. 

University of Washington 

2:45 pm – 3:30 pm • CONTRACEPTION DAY SPECIAL SESSION • 

ROOM 405 

CME 

U.S. Medical Eligibility Criteria for Contraception 

Kathryn M. Curtis, Ph.D. 

Centers for Disease Control and Prevention


3:30 pm – 4:15 pm • BREAK - VISIT EXHIBITS • HALL F 

4:15 pm – 6:15 pm • ABSTRACT SESSIONS 

• Contraception Special Interest Group, Room 405 

• Nurses’ Professional Group, Room 403 

• Reproductive Biology Professional Group, Room 603 


• Clinical Female Infertility and Gynecology, Room 207 

• Male Factor: ART, Room 601 

• Male Reproduction and Urology, Room 4C 

• Cryopreservation and Frozen Embryo Transfer: ART, Room 203 

• Other: ART, Room 205 

• Outcome Predictors - Clinical: ART 1, Room 501 

• Outcome Predictors - Laboratory: ART, Room 503 

• Ovarian Stimulation: ART, Room 201 

• Procedures and Techniques - Laboratory: ART, Room 4E 

4:15 pm – 6:15 pm • KEN RYAN ETHICS SYMPOSIUM • CME 

KORBEL BALLROOM 1 

Cross-Border Care 

Presented by the ASRM Ethics Committee 

Leslie P. Francis, J.D., Ph.D. (Chair) 

Lorna A. Marshall, M.D. 

Glenn Cohen, M.D. 

Judith F. Daar, J.D. 

4:15 pm – 6:15 pm • SYMPOSIUM • KORBEL BALLROOM 2 CME 

Eunice Kennedy Shriver National Institute of Child Health and 

Human Development Research Update: Male and Female 

Reproductive Health 

Presented by the National Institute of Child Health and Human Development 

Research 

Gregory M. Christman, M.D. (Chair) 

Louis V. DePaolo, Ph.D. 



Linda C. Giudice, M.D., M.Sc., Ph.D. 

4:15 pm – 6:15 pm • SYMPOSIUM • FOUR SEASONS BALLROOM 4 

FDA Regulation: Timely Topics 

CME 

Martha Wells, M.P.H., R.A.C. (Chair) 

Samuel Barone, M.D. 

Jacob F. Mayer, Ph.D. 

Richard Weiskopf, R.A.C. 

4:15 pm – 6:15 pm • SYMPOSIUM • ROOM 505 

CME 

Starting a Family in Times of Decreasing Fertility 

Presented by the European Society for Human Reproduction and Embryology 

Pier-Giorgio Crosignani, M.D. (Chair) 

Johannes L. Evers, M.D. 

Henri Leridon, Ph.D. 

Wolfgang Lutz, Ph.D. 

5:45 pm – 6:15 pm 

SOCIETY FOR MALE REPRODUCTION AND UROLOGY MINISYMPOSIUM 

• ROOM 401 

CME 

Clinical Decision Making for the Male with a Partner of 

Advancing Age 


6:15 pm – 7:00 pm • MEMBERS’ MEETINGS 

• Society of Reproductive Surgeons, Room 605 


• Environment and Reproduction Special Interest Group, Room 207 

• Genetic Counseling Special Interest Group, Room 607 

• Pediatric and Adolescent Gynecology Special Interest Group, 

Room 503 

• Sexuality Special Interest Group, Room 601 

• Reproductive Biology Professional Group and Reproductive 

Laboratory Technologists Group (combined meeting), Room 603 

• European Society for Human Reproduction and Embryology, 

Room 505 

• Early Pregnancy Group, Room 205 

• Legal Professional Group, Room 4C 

• Regenerative Medicine Group, Room 403 

• Turkish Group, Room 4B 

23 

TUESDAY, OCTOBER 26 

7:00 am – 9:00 am • POSTER PRESENTATIONS • HALL F (POSTER AREA) 

Continental Breakfast Provided 

7:15 am – 8:45 am • SYMPOSIUM WITH COFFEE • ROOM 401 

Hormone Therapy for Aging Women 

Lubna Pal, M.B.B.S., M.R.C.O.G., M.S. 

Hadine Joffe, M.D., M.Sc. 

Ann E. Kearns, M.D., Ph.D. 

Supported by an educational grant from Abbott 

7:15 am – 8:45 am • SYMPOSIUM WITH COFFEE • ROOM 403 

Progesterone Supplementation 


Carol B. Lesser, R.N.C. 

Supported by an educational grant from Watson Pharma, Inc. 

8:15 am - 8:45 am • MEMBERS’ MEETINGS 

• Latin American Association for Reproductive Medicine, 

Room 4B 

9:00 am – 10:30 am • PLENARY SESSION 3 • 

CME 


9:00 am - 9:45 am 

Sex Differences in Cardiovascular Disease 

Virginia M. Miller, Ph.D. 

Mayo Clinic 

Endowed by a 1992 grant from Wyeth 

9:45 am - 10:30 am 

Genotypes and Phenotypes in PCOS 

Andrea Dunaif, M.D. 

Northwestern University/The Feinberg School of Medicine 

Endowed by a 1992 grant from EMD Serono, Inc. 


11:15 am – 1:00 pm • FOUR SEASONS BALLROOM 2 

SCIENTIFIC PROGRAM PRIZE PAPER ORAL ABSTRACT PRESENTATIONS 

11:15 am – 1:00 pm • MENOPAUSE DAY WORKSHOP • CME 


Traditional Hormone Therapy: Is There Still a Need? 


Mayo Clinic 

Selective Estrogen Receptor Modulators and Tissue Selective 

Estrogen Complexes 


Yale University 

CME 

CME 


CME 

Wrinkled Parents: Medical, Ethical, and Psychological Issues of 

Parenting at an Older Age 


Andrea Mechanick Braverman, Ph.D. (Chair) 


Richard T. Scott, Jr., M.D. 


CME 

Why Age Matters: Medical and Psychological Concerns for 

Conception 

A Joint Session presented by the Nurses Professional Group and the Mental 

Health Professionals Group 

Patricia A. Mendell, L.C.S.W., M.S.W. (Chair) 

Margaret G. Garrisi, M.D. 



CME 

The Impact of New Communication Technologies on the Field 

of Infertility 

Presented by the Association of Reproductive Managers 


Robert R. Strickland, M.Ed. (Chair) 

Kira Copperman, L.M.S.W. 

11:15 am – 1:00 pm • ASRM VIDEO SESSION I • 

CME 


1:00 pm – 2:45 pm • LUNCH BREAK


1:15 pm – 2:15 pm • MEET THE PROFESSOR • ROOM 201 



1:15 pm – 2:15 pm • MENOPAUSE DAY INTERACTIVE SESSION • 


CME 

Cardiovascular Risk in Menopause: Clinical Tools and 

Effects of Hormone Therapy 

Presented by the Menopause Special Interest Group 



Aneuploidy Screening for Recurrent Pregnancy Loss 

Presented by the Preimplantation Genetic Diagnosis Special Interest Group 



Oligospermia: The Benefit of Diagnosing and Treating the Male 

A Joint Session presented by the Society for Male Reproduction 

and Urology and the Society for Reproductive Endocrinology 

and Infertility 

Stanton C. Honig, M.D. (Chair) 

Robert E. Brannigan, M.D. 



Eradication of Endometriosis with Surgery: Best Techniques 

Presented by the Society of Reproductive Surgeons 

Gary N. Frishman, M.D. (Chair) 


Anthony A. Luciano, M.D. 


Unique Challenges in the Care of the Oncofertility Patient 

Presented by the Fertility Preservation Special Interest Group 

Nicole L. Noyes, M.D. (Chair) 

Clarisa R. Gracia, M.D. 


Clinical Challenges in the Controlled Ovarian Stimulation 

in Poor and High Responders 

Presented by the Latin American Association for Reproductive Medicine 

(ALMER) 

Carlos E. Sueldo, M.D. (Chair) 


Claudio A. Benadiva, M.D. 


Legal Implications of ART Laboratory Errors 

A joint session presented by the Reproductive Laboratory Technologists 

Special Interest Group and the Legal Professional Group 

Michael S. Stahler, Ph.D. (Chair) 

Nidhi Desai, J.D. 

Jacob F. Mayer, Jr., Ph.D. 


Reproductive Options and Legal Issues of Same Sex Couples 

Presented by the Women’s Council 

Deborah L. Smith, M.D. (Chair) 

Melissa B. Brisman, J.D. 

Arlene J. Morales, M.D. 

1:15 pm – 2:15 pm • ROUNDTABLE LUNCHEONS • HALL F 


CME 



Society of Reproductive Surgeons Lecture 

Postoperative Adhesions: Pathogenesis, Prevalence and Prevention 


Wayne State University 

CME 

Endowed by a 1999 grant from Ethicon Endo-Surgery, Inc. 

2:45 pm – 3:30 pm • MENOPAUSE DAY KEYNOTE LECTURE • 


What Can a SWAN Teach Us About Menopause? 


University of Colorado Denver 

3:30 pm – 4:15 pm • BREAK - VISIT EXHIBITS • HALL F 

CME 

24 


• Society for Assisted Reproductive Technology, 

Four Seasons Ballroom 4 

• Society of Reproductive Surgeons/Debate, Room 205 

• Endometriosis Special Interest Group, Room 501 


• Menopause Special Interest Group, Korbel Ballroom 1 

• Pediatric and Adolescent Gynecology Special Interest Group, 

Room 601 

• Sexuality Special Interest Group, Room 4C 

• Reproductive Immunology Interest Group, Room 4B 

• SMRU Traveing Scholars, Room 4E 

• REI Fellows/REI, Room 605 


• Procedures and Techniques - Clinical: ART, Room 603 

• Reproductive Biology: Animal and Experimental Models, 

Room 607 

4:15 pm – 6:15 pm • ASRM VIDEO SESSION II • 

CME 



CME 

Infertility as a Public Health Priority 

Maurizio Macaluso, M.D., Dr.P.H. (Chair) 

Centers for Disease Control and Prevention 

Linda C. Giudice, M.D., Ph.D., M.Sc. 

Lawrence S. Ross, M.D. 

Joanne C. Armstrong, M.D. 

Nina Larsen, M.S.P.H., S.A.I.C. 


CME 

Controlled Ovarian Stimulation in Difficult Cases: Merits and 

Complications 

Presented by the Middle East Fertility Society 

Shawky Z. Badawy, M.D. (Chair) 

Botros B. Rizk, M.D. 

Luciano Nardo, M.D. 


CME 

Human Oocyte Cryopreservation and In Vitro Maturation 

David F. Albertini, Ph.D. (Chair) 

Thomas L. Toth, M.D. 

Ri-Cheng Chian, Ph.D. 


CME 

Does the Beginning Predict the End? Emergence and 

Treatment of PCOS in Adolescence 

Presented by the Society for Gynecologic Investigation 

Kathleen M. Hoeger, M.D. (Chair) 

Anuja Dokras, M.D., Ph.D. 

R. Jeffrey Chang, M.D. 


CME 

ART Similarities and Differences Around The World 

Presented by the International Committee for Monitoring Assisted 

Reproductive Technology 

G. David Adamson, M.D. (Chair) 

Sheryl Vanderpoel, M.D., Ph.D. 

Ragaa T. Mansour, M.D. 

Karl Gosta-Nygien, M.D. 

Fernando Zegers-Hochschild, M.D. 

Jacques de Mouzon, M.D. 

Osamu Ishihara, M.D., Ph.D. 

Ian D. Cooke, M.D. 

5:45 pm – 6:15 pm • SOCIETY FOR MALE REPRODUCTION CME 

AND UROLOGY MINISYMPOSIUM • KORBEL BALLROOM 2 

Complicated Sperm Retrieval: Tricks of the Trade 

Peter N. Schlegel, M.D.


6:15 pm – 7:00 pm • MEMBERS’ MEETINGS 

• Society for Male Reproduction and Urology, Room 4E 

• Society for Reproductive Endocrinology and Infertility, Room 605 

• Androgen Excess Special Interest Group, Room 601 


• Fibroid Special Interest Group, Room 201 

• Imaging in Reproductive Medicine Special Interest Group, 

Room 607 


• Nutrition Special Interest Group, Room 207 

• Middle East Fertility Society, Room 205 

• Indian Group, Room 203 

25 

WEDNESDAY, OCTOBER 27 

6:30 am – 7:45 am • WOMEN’S COUNCIL BREAKFAST • 

HYATT REGENCY HOTEL CAPITAL 4 

7:00 am – 9:00 am • POSTER PRESENTATIONS • HALL F (POSTER AREA) 


9:00 am – 9:45 am • PLENARY SESSION 5 • 

CME 


Ghrelin, Aging and Reproduction 

Roy G. Smith, Ph.D. 

Scripps Research Institute Florida 

Endowed by a 1990 grant from TAP Pharmaceutical 

9:45 am – 10:00 am • ASRM AWARDS CEREMONY • 


10:00 am – 10:30 am • ASRM MEMBERS’ MEETING • 



11:15 am – 12:00 pm • SPECIAL RESEARCH PRESENTATIONS • 

ROOM 505 

11:15 am 

Evaluating Risks and Benefits of Hormone Replacement Therapy in 

Healthy Postmenopausal Chinese Women Using Population-based 

Healthcare Data 

H. Irene Su, M.D., M.S.C.E. 

ASRM/Ortho Women’s Health & Urology Research Grant in Reproductive 

Medicine, 2009 – 2010 

11:30 am 

Derivation of Induced Pluripotent Stem (iPS) Cells from Mouse and 

Human Amniocytes 

Raymond M. Anchan, M.D., Ph.D. 

ASRM/EMD Serono Research Grant in Reproductive Medicine, 2008 – 2010 

11:45 am 

In Vitro Derivation of Primordial Germ Cells and Gametes from 

Ethically-Derived Inducible Stem Cells 

Sana M. Salih, M.D. 

ASRM/EMD Serono Research Grant in Reproductive Medicine, 2008 – 2010 

12:00 pm 

The Consequences of Chronic Cytotoxic and Biologic Treatments 

on Ovarian Function in Rheumatoid Arthritis and Juvenile Idiopathic 

Patients 


Society for Reproductive Endocrinology and Infertility T-32 Grant, 2008 – 2010 

12:15 pm 

Oxidative Stress and Ovarian Aging in Women with PCOS 

Erica B. Johnstone, M.D. 


12:30 pm 

Mechanical Bowel Preparation for Gynecologic Laparoscopy: A 

Prospective Randomized Trial of Oral Sodium Phosphate Solution 

versus Single Sodium Phosphate Enema 

Linda C. Yang, M.D 

AAGL/SRS Jay M. Cooper Endowed Award for the Best Prize Paper on 

Minimally Invasive Gynecology 


CME 

Preparing to Enter the REI Arena 



Rita Gruber, B.A. 


CME 


Preimplantation Genetic Diagnosis – Meeting the 

Educational, Emotional and Treatment Needs of the 

PGD Patient 


Kelly L. Lehl, R.N. (Chair) 

Danielle Young, M.S., C.G.C. 

Adrienne J. Kramer, R.N.



CME 

Addressing the Counseling Needs of Patients 

Considering PGD: The Complementary Roles of Genetic 

Counselors and Mental Health Professionals 

A Joint Session presented by the Mental Health Professional Group and the 

Genetic Counseling Special Interest Group 

Julianne E. Zweifel, Ph.D. (Chair) 

Jill M. Fischer, M.S., B.S. 

Lauri A. Pasch, Ph.D. 

Patricia Hershberger, Ph.D., A.P.R.N., B.C. 

11:15 am – 1:00 pm • AAGL FILM FESTIVAL • 

CME 


1:15 pm – 2:15 pm • LUNCH BREAK 

1:15 pm – 2:15 pm • MEET THE PROFESSOR • ROOM 201 CME 




Traditional Chinese Remedies for Endometriosis: 

Mechanisms and Efficacy of Herbs and Acupuncture 

A Joint Session presented by the Chinese Special Interest Group 

and the Endometriosis Special Interest Group 

Pamela Stratton, M.D. (Chair) 

Caihong Ma, M.D. 


Fibroids and Imaging Technology: Diagnostic and 

Therapeutic Innovations/Surgical vs. Non-surgical Treatment 

of Fibroids in the Infertile Couple 

A Joint Session presented by the Fibroid Special Interest Group and the 

Imaging Special Interest Group 

Laurel A. Stadtmauer, M.D., Ph.D. (Chair) 

Gloria Richard Davis, M.D. 

Elizabeth A. Stewart, M.D. 


Optimizing Fertility in an Artificial World: The Role of Calories 

and Nutrients in Managing Obesity and Low Body Weight 

Presented by the Nutrition Special Interest Group 

Gilbert B. Wilshire, M.D. (Chair) 

Dian Shepperson-Mills, M.A. 


Screening for Autoimmunity in Recurrent Pregnancy Loss: 

Cash Cow or Evidence-based Medicine? 

Presented by Reproductive Immunology Special Interest Group 

Danny J. Schust, M.D. (Chair) 

William H. Kutteh, M.D., Ph.D. 



Alternative Approaches to Manage a Couple’s Fertility: 

Helping the Mind and Body Work Together 

A Joint presentation by the Society for Assisted Reproductive Technology and 

the Mental Health Professional Group 

Christopher S. Sipe, M.D. (Chair) 

Alice D. Domar, Ph.D. 


How Might We Think About Sex Selection? 

Case Studies and Perspectives on a Current Controversy 

Sujatha Jesudason, Ph.D. (Chair) 

Lisa H. Harris, M.D., Ph.D. 

Miriam W. Yeung, M.P.A. 


Fertility and Sterility: Googled 

Alan H. DeCherney, M.D. 

1:15 pm – 2:15 pm • ROUNDTABLE LUNCHEONS • HALL F CME 




Society for the Study of Reproduction Exchange Lecture 

Endometriosis: Lessons from a Primate Model 

Asgerally T. Fazleabas, Ph.D. 

Michigan State University 

26 

3:30 pm – 3:45 pm BREAK (NO EXHIBITS) 


• Society for Male Reproduction and Urology, Room 4C 

• Society for Reproductive Endocrinology and Infertility, Room 4E 


• Reproductive Laboratory Technologist Professional Group, 

Room 503 


• Environment and Reproduction Special Interest Group, Room 203 



Room 603 

• Nutrition Special Interest Group, Room 403 


• Ovarian Stimulation: Poor Responders, Room 601 

• Preimplantation Genetic Diagnosis Special Interest Group, 

Room 207 

• Reproductive Biology: Human Studies, Room 501 

• Reproductive Surgery, Room 505 


CME 

Advances in Reproductive Surgery 

Keith B. Isaacson, M.D. (Chair) 




3:45 pm – 5:45 pm • ASRM SYMPOSIUM • ROOM 405 CME 

Stem Cells in Reproduction 

Dolores J. Lamb, Ph.D. (Chair) 

Carlos A. Simon, M.D. 

Kirk Cheng Lo, M.D. 

3:45 pm – 5:45 pm • ASRM SYMPOSIUM • 

CME 


Epigenetics, Imprinting and Adverse Perinatal Outcomes: 

Implications, Certainties and Uncertainties in ART 

Catherine Racowsky, Ph.D. (Chair) 


Kenneth J. Moise, Jr., M.D. 

Anja Pinborg, M.D. 

5:15 pm – 5:45 pm • SOCIETY FOR MALE REPRODUCTION CME 

AND UROLOGY MINISYMPOSIUM • ROOM 4C 

Developments in Male Reproduction as Seen Through the 

Retrospectoscope 

Arnold M. Belker, M.D.

CONTRACEPTION DAY 

MONDAY, OCTOBER 25, 2010 

50 Years of Oral Contraception: 

Celebrating the Past and Looking to the Future 

Supported by an educational grant from TEVA Women’s Health Research 

11:15 am – 12:00 pm • CONTRACEPTION DAY KEYNOTE LECTURE • ROOM 405 

A Good Man: Gregory Pincus and the Development of Oral Contraception 

Moderator: Jeffrey T. Jensen, M.D. 


Oregon Health and Science University 

12:00 pm – 1:00 pm • CONTRACEPTION DAY WORKSHOP • ROOM 405 

New Concepts in the Treatment of Abnormal Uterine Bleeding: A Case Presentation 

A joint session presented by the Contraception Special Interest Group and the Society of Reproductive Surgeons 

Moderator: Kristen A. Matteson, M.D., M.P.H. 


1:15 pm – 2:15 pm • ROUNDTABLES 

Contraceptive Controversies 

Bliss Kaneshiro, M.D., M.P.H. 

Contraception for Women with Complex Medical Problems 

Stephanie B. Teal, M.D., M.P.H. 

Contraception for Adolescents 

Tabetha Harken, M.D. 

2:15 pm – 2:45 pm • BREAK 

2:45 pm – 3:30 pm • CONTRACEPTION DAY SPECIAL SESSION • ROOM 405 

U.S. Medical Eligibility Criteria for Contraception 



3:30 pm – 4:15 pm • BREAK • EXHIBIT HALL 

4:15 pm – 6:15 pm • CONTRACEPTION ORAL ABSTRACT SESSION • ROOM 405 

6:15 pm – 7:00 pm • CONTRACEPTION SPECIAL INTEREST GROUP MEMBERS’ MEETING • 

ROOM 405

MENOPAUSE DAY 

TUESDAY, OCTOBER 26, 2010 

Redefining the Spectrum of Menopause 

for the 21st Century 

7:15 am - 8:45 am • SYMPOSIUM WITH COFFEE • ROOM 401 

Hormone Therapy for Aging Women 

Supported by an educational grant from Abbott 

Lubna Pal, M.B.B.S., M.R.C.O.G., M.S. 

Yale Reproductive Endocrinology 


Harvard Medical School, Massachusetts General Hospital 


Mayo Clinic 

11:15 am - 1:00 pm • MENOPAUSE DAY WORKSHOP • KORBEL BALLROOM 1 

Moderator: Peter R. Casson, M.D. 

Traditional Hormone Therapy: Is There Still a Need? 


Mayo Clinic 

Selective Estrogen Receptor Modulators and Tissue Selective Estrogen Complexes 



1:15 pm – 2:15 pm • MENOPAUSE DAY INTERACTIVE SESSION • KORBEL BALLROOM 1 

Cardiovascular Risk in Menopause: Clinical Tools and Effects of Hormone Therapy 



University of California San Francisco 

2:15 pm – 2:45 pm • BREAK 

2:45 pm – 3:30 pm • MENOPAUSE DAY KEYNOTE LECTURE • KORBEL BALLROOM 1 

What Can a SWAN Teach Us About Menopause? 

Moderator: Veronica A. Ravnikar, M.D. 



3:30 pm – 4:15 pm • BREAK • EXHIBIT HALL 

4:15 pm – 6:15 pm • MENOPAUSE ORAL ABSTRACT SESSION • KORBEL BALLROOM 1 

6:15 pm – 7:00 pm • MENOPAUSE SPECIAL INTEREST GROUP MEMBERS’ MEETING • 

KORBEL BALLROOM 1

MEMBERS’ MEETINGS 

Sunday, October 24, 2010 5:15 pm – 6:00 pm 

• Association of Reproductive Managers, Room 401 


• Preimplantation Genetic Diagnosis Special Interest Group, 

Room 205 (Starts at 4:00 p.m.) 

Monday, October 25, 2010 8:15 am – 8:45 am 

• Society for Assisted Reproductive Technology, Room 607 

• Chinese Special Interest Group, Room 201 

• Reproductive Immunology Special Interest Group, 

Room 207 

Monday, October 25, 2010 6:15 pm – 7:00 pm 

• Society of Reproductive Surgeons, Room 605 


• Environment and Reproduction Special Interest Group, 

Room 207 


• Pediatric and Adolescent Gynecology Special Interest 

Group, Room 503 

• Sexuality Special Interest Group, Room 601 

• Latin American Association for Reproductive Medicine, 

Room 4B 

• Society for Male Reproduction and Urology, Room 4E 

• Society for Reproductive Endocrinology and Infertility, 

Room 605 




Locations listed next to group. 



29 

• Reproductive Biology Professional Group and 

Reproductive Laboratory Technologists Professional Group 

(combined meeting), Room 603 

• European Society for Human Reproduction and 

Embryology, Room 505 

• Early Pregnancy Group, Room 205 

• Legal Professional Group, Room 4C 

• Regenerative Medicine Group, Room 403 

• Turkish Group, Room 4B 

Tuesday, October 26, 2010 6:15 pm – 7:00 pm 



Room 607 


• Middle East Fertility Society, Room 205 

• Nutrition Group, Room 207 

• Indian Group, Room 203 

Wednesday, October 27, 2010 10:00 am – 10:30 am 

ASRM Members’ Meeting 


President: William E. Gibbons, M.D. 

• Complementary and Alternative Medicine Group, 

Room 203 

• Health Disparities Group, Room 205 

• Database Management Solutions, Room 605 

Tuesday, October 26, 2010 8:15 am – 8:45 am 



• Nurses’ Professional Group, Room 207

Special Presentation 

�� 


Editor-in-Chief, Fertility and Sterility 

�� 

“Fertility and Sterility: Googled” 

Wednesday, October 27 th , 1:15 pm 

Colorado Convention Center, Room 503 

�� 

Join Dr. DeCherney for an informal discussion of the 

past, present and future of medical communications .

2010 ASRM SERVICE and STAR AWARDS 

SERVICE AWARD 

The ASRM Service Award is given to ASRM members, nominated by their peers, who have 

continuously contributed 10 or more years of service to ASRM from 2000 – 2009 by serving 

on ASRM, affiliate society, professional group and/or special interest group boards and/or 

committees. 


G. David Ball, H.C.L.D., Ph.D. 

Valerie Baker, M.D. 

Charles C. Coddington, M.D. 

David Curole, M.D. 

Marc A Fritz, M.D. 

Douglas D. Glover, M.D. 

David Grainger, M.D., M.P.H. 


Ashok Agarwal, Ph.D. 

Susan Benoff, Ph.D. 

Nancy L. Brackett, Ph.D., H.C.L.D. 

Andrea Braverman, Ph.D. 

Richard P. Dickey, M.D., Ph.D. 

W.P. Dmowski, M.D., Ph.D. 

Daniel Dumesic, M.D. 

Karen R. Hammond, D.N.P., 

C.R.N.P., N.P. 

Timothy Hickman, M.D. 

George A. Hill, M.D. 

Stuart Howards, M.D. 

William Hurd, M.D. 

Bradley Hurst, M.D. 

Elaine Ishida, R.N.C., N.P. 


Jeffrey M. Goldberg, M.D. 

Karen R. Hammond, D.N.P., 

C.R.N.P., N.P. 

Timothy Hickman, M.D. 


Bradley Hurst, M.D. 

Guillermo Marconi, M.D. 

Kutluk Oktay, M.D. 

Howard McClamrock, M.D. 

Edward E. Moore, M.D. 

Craig Niederberger, M.D. 

John T. Queenan, Jr., M.D. 


Judy Stern, Ph.D. 

Eric Surrey, M.D. 

Bill Yee, M.D. 

STAR AWARD 

The Star Award is given to ASRM members, nominated by their peers, who have continuously 

contributed 10 or more years of presentations from 2000 – 2009 at ASRM’s Annual Meeting. 

Ester Polak de Fried, M.D. 

Richard T. Scott, M.D. 

Shehua Shen, M.D. 

Carlos E. Sueldo, M.D. 

Takumi Takeuchi, M.D., Ph.D. 

Ilan Tur-Kaspa, M.D. 

Chii-Ruey Tzeng, M.D. 

Lynn Westphal, M.D. 

To the above listed individuals, ASRM gratefully says Thank You for your service 

and dedication to ASRM and for your important contributions to the Society’s 

continued success.

New Member/First Time Attendee Reception 

New ASRM members and first time Annual Meeting attendees are invited to 

a reception to meet and greet ASRM board members, leadership of the 

affiliated societies, and the officers of the professional and special interest 

groups. This reception will take place during the Tuesday morning poster 

session in the Colorado Convention Center 

from 8:00 am until 9:00 am. 

Join the ASRM Leadership for coffee & conversation. 

ASRM 2010 

100% COTTON • LONG SLEEVES • SPECIAL ANNUAL MEETING ATTENDEE PRICE JUST $15 

2010 ASRM T-shirts available for 

purchase at the ASRM Booth #835

POSTGRADUATE COURSE LOCATIONS 

COURSE 1 CONTROVERSIES IN IN VITRO FERTILIZATION: A CRITICAL ASSESSMENT • ROOM 505 

COURSE 2 PSYCHOLOGICAL INTERVENTIONS FOR INFERTILITY PATIENTS • ROOM 401 

COURSE 3 METABOLIC MANAGEMENT IN POLYCYSTIC OVARY SYNDROME: STRATEGIES TO OPTIMIZE 

CLINICAL CARE • ROOM 201 

COURSE 4 THE NEXT 20 YEARS OF MALE INFERTILITY TREATMENT: A LOOK INTO THE CRYSTAL BALL • 

ROOM 403 

COURSE 5 PREMATURE OVARIAN FAILURE (PRIMARY OVARIAN INSUFFICIENCY) • ROOM 501 

COURSE 6 ULTRASOUND IMAGING IN REPRODUCTIVE MEDICINE PART I • ROOM 601 

COURSE 7 CRYOBIOLOGY, CRYOPHYSICS AND QUALITY CONTROL CONCERNS OF GAMETE, EMBRYO 

AND TISSUE VITRIFICATION • ROOM 405 

COURSE 8 ENVIRONMENTAL, OCCUPATIONAL AND DIETARY IMPACTS ON FERTILITY AND PREGNANCY 


COURSE 9 WHEN IT TAKES MORE THAN TWO TO TANGO: PEARLS AND PERILS OF THIRD-PARTY 

REPRODUCTION • ROOM 205 

COURSE 10 CODING FOR REPRODUCTIVE MEDICINE PRACTICES • ROOM 207 

COURSE 11 LAPAROSCOPIC SUTURING IN THE VERTICAL ZONE: A HANDS-ON COURSE • ROOM 605 

COURSE 12 SIMPLE IVF: HOW TO MAKE THE PROCESS LESS STRESSFUL, MORE AFFORDABLE AND LESS 

COMPLICATED FOR PATIENTS? • ROOM 405 

COURSE 13 PRACTICING POLITICS: AN INTERACTIVE COURSE ON ETHICS AND COUNSELING ISSUES IN 

ART • ROOM 505 

COURSE 14 MALE INFERTILITY MICROSURGERY: A HANDS-ON COURSE • ROOM 605 

COURSE 15 ULTRASOUND IN REPRODUCTIVE MEDICINE PART II • ROOM 503 

COURSE 16 SEXUAL DISORDERS OF OLDER WOMEN: NEW STRATEGIES FOR RESTORING WHAT TIME TAKES 

AWAY • ROOM 403 

COURSE 17 ONCOFERTILITY: A BRIGHTER FUTURE FOR SURVIVORS OF CHILDHOOD CANCERS • 

ROOM 501 

COURSE 18 THE ENRICHMENT OF CULTURE MEDIA: TOWARD THE BEST ENVIRONMENT FOR IVF EMBRYOS? 


COURSE 19 THE REI PATIENT: THERE’S MORE TO THE PATIENT THAN INFERTILITY • ROOM 207 

COURSE 20 OOCYTE/EMBRYO VITRIFICATION: A HANDS-ON WORKSHOP • ROOM 601 

COURSE 21 2010 BACK TO THE BASICS - MANAGING A REPRODUCTIVE ENDOCRINOLOGY AND 

INFERTILITY PRACTICE • ROOM 401 

POSTGRADUATE PROGRAM

43 RD ANNUAL POSTGRADUATE PROGRAM 

GENERAL POSTGRADUATE COURSE INFORMATION 

Dates: 



Hours: 

8:15 am-5:00 pm 

Lunch is from Noon - 1:00 pm in: 


located in Korbel Ballroom 2. 

Breaks are from: 

10:00 am - 10:30 am 

3:00 pm - 3:30 pm 

Courses PG1-PG11 are one-day courses on Saturday. 

Courses PG12-PG21 are one-day courses on Sunday. 

PG21 will not earn CME/CE credits. 

33 

Postgraduate Program Faculty Instructions 

Revised PowerPoints: 

Saturday Courses: 

Any updated or revised PowerPoints for Saturday courses 

MUST be brought to the Speaker Ready Room, in the 

Colorado Convention Center, Room 301 Friday, 12:00 p.m. – 

5:00 pm. 

No revised PowerPoints for Saturday courses will be 

accepted on Saturday morning. 

Sunday Courses: 

Any updated or revised PowerPoints for Sunday courses 

may be taken to the Speaker Ready Room, in the Colorado 

Convention Center, Room 301, on Saturday. No revised 

PowerPoints for Sunday courses will be accepted on Sunday 

morning. 

COURSE LOCATION NOTES: 

All courses will be held in the Colorado Convention Center. 

Registration and Badge Pickup 

Friday, October 22 Registration will be open 2:00pm – 

8:00pm, in the Colorado Convention Center. 

Saturday, October 23 Registration will be open 7:00 am – 

7:00 pm, in the Colorado Convention Center. 

Sunday, October 24 Registration will be open 7:00 am – 

7:30 pm, in the Colorado Convention Center. 

All faculty, participants and course monitors must register 

and receive badges to be permitted access to postgraduate 

course venues. 

Bags, badges and syllabi for pre-registered and onsite 

registered faculty, participants and monitors are available in 

the lobby of the Colorado Convention Center. 

Postgraduate Course Chairs 

There will be one audiovisual technician assigned to every 

two postgraduate courses and to every course using the 

ARS. 

Chairs will be responsible for activating presentations from 

a computer in each lecture hall. Lighting will be preset, 

to avoid the necessity to dim. Course Monitors will be 

requested to assist Course Chairs if circumstances should 

necessitate further darkening of a lecture hall.


Developed in Cooperation with the Society for Assisted Reproductive Technology 

FACULTY 

Elizabeth S. Ginsburg, M.D., Chair 

Glenn L. Schattman M.D. 

Eric S. Surrey M.D. 

ACGME COMPETENCY 

Medical Knowledge 

NEEDS ASSESSMENT AND COURSE DESCRIPTION 

There is tremendous controversy regarding infertility treatment. Patients facing IVF for infertility are often desperate and 

request treatments that have minimal or no proven benefit. Physicians, faced with conflicting information regarding such 

adjunctive treatments, may choose to use some or all of these in the absence of expert advice. 

The goal of this course, designed for healthcare professionals who provide infertility counseling and treatment, is to act 

as a mini-seminar on practice guidelines. Participants will review the literature and make recommendations based on the 

current state of the art. The course will arm participants with the knowledge to competently counsel patients about the 

topics covered, and will help them make decisions about whether to offer the adjunctive treatments covered, to refer 

patients for them (e.g., for acupuncture), or whether to discourage their use. 


At the conclusion of this course, participants should be able to: 

1. Discuss the outcomes of randomized studies on various drugs used during IVF treatment, including baby aspirin, DHEA, 

luteal estrogen supplementation and growth hormone. 

2. Describe the applications and limitations of ovarian reserve testing, interpret the results of those tests and explain the 

results in terms of expected IVF outcome. 

3. Quote pregnancy rates in randomized studies of PGS, list the possible sources of error of PGS analysis and discuss new 

technologies available for genetic screening of embryos and quality of the outcomes data currently available. 

4. Discuss the mean age of patients who have conceived with cryopreserved oocytes, as well as the expected oocyte 

survival and pregnancy rates based on published literature. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Mental Health Professional Group 

FACULTY 

Alice D. Domar, Ph.D., Chair 

Jacky Boivin, Ph.D., Co-Chair 

Tara Cousineau, Ph.D. 

Christopher Newton, Ph.D. 


Patient Care 

One-Day Courses 

Saturday, October 23 rd 

CONTROVERSIES IN IN VITRO FERTILIZATION: A CRITICAL ASSESSMENT 

Course PG1 (Saturday) • ROOM 505 

PSYCHOLOGICAL INTERVENTIONS FOR INFERTILITY PATIENTS 



Recent research supports the presence of significant psychological symptoms in the infertile population. Anxiety, depression 

or both are present in 40% of new infertility clinic patients, and these symptoms tend to increase as the duration and 

intensity of treatment increases. Distress is the primary reason that patients terminate treatment, and the more distressed 

the patient, the less likely the treatment is to be successful. Research has shown that psychological interventions can lead 

to increases in pregnancy rates, but despite this evidence and patients’ strong desire for psychosocial help, only a small 

proportion of patients seek out psychological services. Thus, tailored, appropriate interventions are not being delivered to 

patients in need. 

This course, designed for mental health professionals, as well as for nurses and other health care professionals who deal 

with infertility patients, will elucidate and propose methods for dealing with the complex psychological issues facing infertility 

patients. Appropriate screening methodologies will be presented and the different interventions available to these patients 

34 

CME 

CME 

CE


for different contexts will be the focal point of the course. A variety of different interventions will be described and the 

applicability of different interventions for specialized populations will be explored. 



1. Identify emotional needs of patients. 

2. Describe contexts in which patients may require psychosocial support. 

3. Match the appropriate type of psychosocial intervention with context. 

4. Identify patients who are at greater risk for high distress and likely to benefit from more in-depth counselling. 

________________________________________________________________________________________________________________________ 

METABOLIC MANAGEMENT IN POLYCYSTIC OVARY SYNDROME: STRATEGIES TO OPTIMIZE CLINICAL CARE 

Course PG3 (Saturday) • ROOM 201 CME 

Developed in Cooperation with the Androgen Excess Special Interest Group and the Androgen Excess Society 

FACULTY 

Frank González, M.D., Chair 

Sidaka E. Kasim-Karakas, M.D. 

Anuja Dokras-Jagasia, M.D., Ph.D. 

Antoni J. Duleba, M.D. 



Patient Care 


Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-age women. A significant number 

of women with the disorder are afflicted with metabolic abnormalities that promote the endocrine findings, so it is crucial 

for practitioners in reproductive medicine to gain an understanding of metabolism as it pertains to PCOS, which will in turn 

facilitate early detection and optimal treatment to improve the health of these women. 

This course, designed for physicians in primary care, obstetrics and gynecology and reproductive endocrinology, will 

provide the participant with the foundation for performing an optimal metabolic evaluation and determining appropriate 

treatment plans for patients with PCOS. Faculty will review the latest concepts pertaining to abnormal metabolism in PCOS 

and management strategies for improvement of metabolic status to enhance fertility and prevent disease in women with 

the disorder. Topics to be discussed include the prevalence of metabolic abnormalities in PCOS and their contribution 

to fertility impairment and development of medical and obstetrical illness; diagnostic modalities currently available to 

identify metabolic derangement; emerging paradigms underpinning the development of PCOS; treatment approaches 

to enhance fertility and lower the risk of medical and obstetrical illness by improving metabolic status and heterogeneity of 

metabolic aberration in PCOS, with emphasis on practical treatment combinations for individualized care. 



1. Describe metabolic abnormalities associated with PCOS, along with their impact on fertility and promotion of medical 

disease. 

2. Perform an appropriate metabolic evaluation on patients with PCOS. 

3. Develop sound multidisciplinary treatment plans for patients with PCOS that manage anovulatory infertility and prevent 

disease by improving metabolic status. 

________________________________________________________________________________________________________________________ 

35


Developed in Cooperation with the Society for Male Reproduction and Urology 

FACULTY 

Edward D. Kim, M.D., Chair 

Ajay K. Nangia, M.D. 

Robert D. Oates, M.D. 

Larry I. Lipshultz, M.D. 



Patient Care 

Interpersonal and Communication Skills 


Many of the treatments for male infertility are perceived by the public and physicians to have a limited success rate in 

comparison to assisted reproductive technologies. There is a perception among practicing urologists that the role of the 

urologist in the treatment of the infertile couple may become further limited without significant therapeutic advances. The 

challenge over the next 20 years, for male patients and their physicians, is to identify these clinically meaningful diagnostic 

tests and therapeutic interventions. 

This course is designed for physicians, laboratory scientists, nurses, and other healthcare professionals of any specialty 

who deal with the issue of male infertility in their practices. At the completion of this course, participants will be equipped to 

assess clinical practice needs in male infertility over the next 20 years, with special emphasis on advances that are practical 

and potentially therapeutic. Topics to be covered include identification of fertility concerns for the aging male; potential 

translational research from the bench to the bedside; advances in medical therapy; surgical and diagnostic advances for 

the infertile male and potential advances in contraceptive management. 



1. Assess which potential advances are practical in the genetic assessment and treatment of the infertile male. 

2. Determine the role of potential advances in medical therapy, such as hormonal therapy and nutritional supplements. 

3. Appraise the role of surgical and diagnostic advances for the infertile male. 

4. Identify specific fertility concerns for the aging male. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Society for Reproductive Endocrinology and Infertility 

FACULTY 

Marcelle I. Cedars, M.D., Chair 

Lawrence M. Nelson, M.D. 


THE NEXT 20 YEARS OF MALE INFERTILITY TREATMENT: A LOOK INTO THE CRYSTAL BALL 




Patient Care 


PREMATURE OVARIAN FAILURE (PRIMARY OVARIAN INSUFFICIENCY) 



Premature ovarian failure (POF) occurs in 1% of the female population under the age of 40. After the onset of symptoms, it 

is not unusual for diagnosis to be delayed for many years. Even after a diagnosis has been made, counseling an affected 

patient and designing the most appropriate treatment plan are often difficult. 

This course, designed for all health care professionals who deal with women of reproductive age, will provide participants 

with the information they need to optimize diagnosis, counseling and treatment planning for POF patients. Faculty members 

will present an up-to-date discussion of the etiologies of POF and how POF may relate to the spectrum of ovarian aging 

associated with reduced fertility (often termed “diminished ovarian reserve”). Possible etiologies of POF and the most 

appropriate diagnostic strategies will be discussed, as well as possible long-term risks (infertility, osteoporosis, cardiovascular 

disease), available treatment regimens, and future avenues for research. In addition, interesting cases (including cases from 

the audience) will be presented. 

36 

CME




1. Identify patients at risk for premature ovarian failure and confirm the diagnosis. 

2. Describe long-term implications of POF and available treatment options. 

3. Counsel patients regarding the realistic chances for pregnancy and available therapeutic options. 

4. Discuss specific clinical cases and future avenues of research. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the American Institute of Ultrasound in Medicine 

FACULTY 

Elizabeth Puscheck, M.D., Chair 

Ilan Tur-Kaspa, M.D., Co-Chair 

Edmond Confino, M.D. 

Steven Goldstein, M.D. 

Bradley VanVoorhis, M.D. 



Patient Care 

ULTRASOUND IMAGING IN REPRODUCTIVE MEDICINE PART I 



Ultrasound has become an integral component not just of assisted reproductive technologies (ART), but also in the dayto-day 

practice of reproductive medicine, infertility and gynecology. In 2009, new practice guidelines for ultrasound in 

reproductive medicine were published by the American Institute for Ultrasound in Medicine (AIUM). Members of the Society 

for Reproductive Endocrinology and Infertility, the ASRM Imaging Special Interest Group and ASRM have expressed a 

strong desire for CME credits in ultrasound that would prepare reproductive medicine professionals and gynecologists for 

accreditation by the AIUM. 

The objective of this course is to provide a comprehensive survey of the use of ultrasound in the female pelvis for 

physicians, nurses and ultrasonographers actively involved in reproductive medicine, infertility and gynecology. The faculty 

will review critically the application of ultrasound to the infertility evaluation, diagnosis, treatments and complications. 

Ultrasound has been a key diagnostic tool in early pregnancy evaluation and monitoring, as well as in assessing pregnancy 

complications. Other gynecologic findings on ultrasound, such as congenital uterine anomalies, ovarian masses, tubal 

disease and other uterine pathologies, will be discussed along with their impact on fertility. Interactive discussion of clinical 

cases and controversies will provide participants an opportunity to discuss the use of ultrasound in the assessment and 

treatment of reproductive problems that occur throughout a female’s reproductive period. Specific topics to be addressed 

in Part I include the following: 

• Role of ultrasound in the infertility evaluation 

• Abnormal uterine bleeding 

• Congenital uterine anomalies 

• The role of ultrasound in successful embryo transfer 

• Ultrasound imaging of the ovary in infertility treatments 

• Menopausal dilemmas: how ultrasound changed clinical management 

• Ovarian masses: distinguishing benign from malignant 

• Imaging for modern management of tubal infertility 



1. Summarize the appropriate use of ultrasound in the evaluation of infertility, uterine abnormalities and the pathology of 

the reproductive tract. 

2. Describe the proper assessment of early pregnancy and list findings on early pregnancy assessments that are associated 

with poor outcomes. 

3. Discuss new developments in ultrasound, the importance of 3D ultrasound and Doppler blood flow assessment in 

reproductive medicine. 

4. List the requirements and benefits of a clinical practice attaining accreditation in ultrasound. 

________________________________________________________________________________________________________________________ 

37


Developed in Cooperation with the Reproductive Biology Professional Group and the Reproductive Laboratory Technologists 


FACULTY 

Mitchel C. Schiewe, Ph.D., H.C.L.D., E.L.D., Chair 

Gregory M. Fahy, Ph.D. 

William F. Rall, Ph.D. 

Pierre Comizzoli, D.V.M., Ph.D. 




The general perception of vitrification (VTF) technology by physicians is that it is a simple, rapid technique for cryopreserving 

blastocysts and oocytes that achieves high levels of success based on current published reports. However, these scientific 

reports represent a scientific bias regarded as having a “technical signature,” meaning that success is dictated by the 

technician/laboratory doing the procedures. 

This course, aimed at physicians in obstetrics and gynecology and oncology, as well as nurses and laboratory scientists 

and technicians, will educate participants about basic cryobiology principles and quality control concerns, allowing 

them to better assess the overall usefulness of a vitrification device/system for clinical use. Participants will learn that 

there are inherent defects to most of the VTF devices being pushed into the ART industry by commercial companies that 

adversely influence their technical simplicity/reliability, and in turn, their routine effectiveness. Discussions will focus on time 

management and organizational issues needed to optimize vitrification success, and the need for future research and 

development in oocyte, embryo, stem cell and reproductive tissue cryopreservation. 



1. Summarize the developmental history of and the cryobiological/cryophysical principles behind vitrification technology, in 

contrast to standard slow-freeze preservation. 

2. Compare and contrast various vitrification methods that have been developed and applied, by rating various pros and 

cons that should be considered in establishing a VTF program. 

3. Discuss laboratory good tissue-handling practices (GTPs) and quality control concerns of VTF, and how they influence 

intra- and inter-laboratory success. 

4. Assess overall quality management in striving to develop a standard “global” vitrification methodology that minimizes 

“technical signature” worldwide. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with Environment and Reproduction Special Interest Group 

FACULTY 

Russ Hauser, M.D., Sc.D., M.P.H., Chair 

Jorge E. Chavarro, M.D., Sc.M., Sc.D. 

Tina Kold Jensen, Ph.D. 

John D. Meeker, Sc.D. 



Patient Care 

CRYOBIOLOGY, CRYOPHYSICS AND QUALITY CONTROL CONCERNS OF GAMETE, 

EMBRYO AND TISSUE VITRIFICATION 


ENVIRONMENTAL, OCCUPATIONAL AND DIETARY IMPACTS ON FERTILITY AND PREGNANCY 



The information generated by basic researchers, epidemiologists and clinicians on the impact of environmental chemicals, 

diet and lifestyle factors on fertility and pregnancy continues to grow, but the translation of this knowledge into clinical 

practice and policy continues to lag behind the research by months or years. Some clinicians remain uncertain of the 

potential impact of the environment on fertility and pregnancy outcomes, and there is also uncertainty on the proper 

advice to give patients regarding these potential risk factors. Physicians need to be educated about chemical toxicants 

and incorporate exposure evaluation into routine patient assessment. With appropriate knowledge, physicians in the field 

of obstetrics and gynecology may be able to reduce the risk of congenital anomalies and reduce subfertility/time to 

38 

CME


pregnancy. 

The goal of this course, developed for obstetricians and gynecologists, as well as other reproductive health professionals, is 

to provide participants with the latest information on environmental and dietary impacts on reproductive health. Leaders in 

the field will present the most recent data on environmental chemicals, diet and lifestyle and their impact on fertility. 



1. Summarize sources, reproductive health risks and current regulations of human exposure to phthalates and bisphenol A. 

2. Assess the nutritional and metabolic factors associated with male and female fertility and the extent to which dietary 

interventions may be useful in the management of infertile men and women. 

3. Explain time to pregnancy (TTP) and measures of semen quality, the advantages and disadvantages of their use and 

their relationship to lifestyle factors and persistent chemical exposure. 

4. Describe occupational risk factors for male and female fertility. 

________________________________________________________________________________________________________________________ 

WHEN IT TAKES MORE THAN TWO TO TANGO: PEARLS AND PERILS OF THIRD-PARTY REPRODUCTION 

Course PG9 (Saturday) • ROOM 205 CE 

Developed in Cooperation with the Nurses’ Professional Group 

FACULTY 

Karen R. Hammond, D.N.P., C.R.N.P., Chair 

Dawn Duncan, R.N., B.S.N. 

Maria Jackson, R.N., M.A. 

Aimee Weston, B.S.N., R.N. 




An interdisciplinary team including physicians, nurses, psychologists and other healthcare professionals is involved in 

screening and treatment for third-party reproduction. Infertility nurses often act as case managers and play an important 

role in the screening and selection process. They are often the healthcare professionals who spend the most time with each 

donor and are often involved in donor/recipient matching. However, changing laws and screening recommendations, 

as well as limited genetics education, can hinder effective patient care. Nurses and other healthcare providers 

involved in the care of patients undergoing third-party reproduction procedures should have a command of practice 

standards, professional guidelines and federal regulations to provide optimal care and minimize patient risks. This one-day 

postgraduate course will assist nurses and other healthcare providers with the management of third-party reproduction 

programs and will include topics such as oocyte donation, use of donor sperm, embryo donation, gestational carrier, donor 

disclosure and other pertinent third-party reproduction issues. 



1. Describe current trends in third-party reproduction. 

2. Summarize essential elements to include in policies and procedures for third-party reproductive programs. 

3. Describe the role of the nurse in third-party reproduction, including gamete donor and gestational carrier screening. 

________________________________________________________________________________________________________________________ 

39


Developed in Cooperation with the American Society for Reproductive Medicine Coding Committee 

FACULTY 

John T. Queenan, Jr., M.D., Chair 


Brian Allen, B.G.S. 


Systems-based Practice 


Every reproductive medicine practice has a legal and ethical obligation to follow a specific set of rules and regulations that 

determines how reimbursements are calculated. Failure to follow these rules can result in unfair practices to patients and/or 

legal consequences from government or third party payers. Due to the complexity of the rules and regulations that apply, 

many practices do not have the time or the resources to devote to the correct coding of diagnoses and procedures. For 

this reason, reimbursement is at stake, with consequences including overbilling or underbilling due to lack of adequate 

knowledge. 

This course, designed for physicians, practice managers, billers, office mangers, sonographers, laboratory managers and 

physician assistants, provides the latest information on accurate and compliant billing practices, with a focus on minimizing 

errors and maximizing quality improvement. Topics to be discussed include the correct reporting of diagnosis codes and 

the selection of appropriate procedure codes, and the information technology and systems-based resources available to 

improve accuracy in patient billing practices. Examples of negotiation leading to additional third-party payer coverage will 

also be covered in a case-presentation format. 



1. Demonstrate the correct coding of diagnostic conditions that are typically encountered in the practice of reproductive 

endocrinology. 

2. Identify the correct CPT codes for surgical procedures provided in the practice of reproductive endocrinology, as well as 

resources available to aid with correct procedural coding. 

3. Explain the rules and regulations required by third-party payers, and adhere to documentation guidelines verifying that 

physician services were rendered according to medical necessity and the requirements of CPT. 

4. List the proper steps for obtaining insurance authorization for services provided. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Society of Reproductive Surgeons 

FACULTY 

Grace M. Janik, M.D., Chair 

Charles H. Koh, M.D., Co-Chair 

Keith B. Isaacson, M.D. 

Ceana Nezhat, M.D. 


Patient Care 

CODING FOR REPRODUCTIVE MEDICINE PRACTICES 


LAPAROSCOPIC SUTURING IN THE VERTICAL ZONE: A HANDS-ON COURSE 


*Note: There is not a printed syllabus for this course.* 


The requirement of suturing at laparotomy for reproductive surgery is self evident, but this is the main deterrent to 

performing reproductive surgery by laparoscopy; in fact inability to suture via laparoscopy is a deficiency in ALL branches 

of laparoscopic surgery – whether urology or general surgery. This deficit has been the main driver of robotic laparoscopic 

surgery as an expensive enabler. 

This course has been designed for reproductive surgeons who would like to advance their laparoscopic skills by being 

able to confidently perform laparoscopic suturing. The progressive algorithm for laparoscopic suturing presented in this 

course has been tested nationally and internationally over many years and has resulted in proficiency with intracorporeal 

knotting in less than 3 minutes by over 80% of attendees. The methodology employed and relative hand positions and 

movements are immediately transferable from the trainer to the operating room. The course equips all attendees 

with improved suturing skills and insights into their application during surgery. In addition to single-stitch placement, 

continuous suturing and microsuturing will be covered enabling the participants to use these skills to perform laparoscopic 

myomectomy as well as tubal reconstructive surgery. Didactic lectures will improve participants’ knowledge and the handson 

component will provide direct clinical skills improvement. 

40 

CME 

CME




1. Explain the ergonomics, theory and rational for reproducible laparoscopic suturing. 

2. Apply skills learned to relevant reproductive surgery including myomectomy and tubal surgery. 

3. Apply skills acquired to management of bowel, bladder and ureteral complications by appropriate suture repair. 

4. Demonstrate measurable improvement in laparoscopic suturing skills. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Middle East Fertility Society 

FACULTY 

Suheil J. Muasher, M.D., Chair 

Mohamed Aboulghar, M.D. 

James P. Toner, M.D., Ph.D. 

Angelique J. Goverde, M.D. 


Patient Care 


One-Day Courses 

Sunday, October 24 th 

SIMPLE IVF: HOW TO MAKE THE PROCESS LESS STRESSFUL, 

MORE AFFORDABLE AND LESS COMPLICATED FOR PATIENTS? 

Course PG12 (Sunday) • ROOM 405 


In vitro fertilization is an underutilized service in the United States due to high cost, lack of insurance coverage for many 

patients and the physical and psychological burdens of the treatment. Mild stimulation protocols offer many advantages to 

patients, including affordability, convenience and fewer complications. There is a need to educate IVF practitioners on the 

use of these protocols and the similar success rates achieved compared with conventional stimulation. 

This course for reproductive medicine specialists, nurses and fellows will use both lectures and interactive discussions in 

presenting ways to simplify IVF treatment. Faculty will discuss various stimulation protocols, as well as the natural cycle and 

its variants. Other topics to be covered include in-depth cost analysis of IVF in the United States and possible cost-cutting 

measures; minimizing the incidence of multiple pregnancy and ovarian hyperstimulation syndrome; and simplifying luteal 

phase support for IVF. 



1. Summarize the reasons that IVF service needs to be more patient-friendly and affordable. 

2. Compare the different mild stimulation protocols and their multiple advantages, including similar success rates to 

conventional stimulation. 

3. Clarify for patients ways in which to minimize the risk of multiple pregnancy and ovarian hyperstimulation syndrome. 

4. Describe luteal phase support and list strategies to simplify the treatment. 

________________________________________________________________________________________________________________________ 

41 

CME


Developed in Cooperation with the Mental Health Professional Group 

FACULTY 

Andrea M. Braverman, Ph.D., Co-Chair 

Elizabeth Grill, Psy.D., Co-Chair 

Susan L. Crockin, J.D. 

Lindsay Childress-Beatty, Ph.D., J.D. 


Patient Care 



Recently, headlines have appeared all over the world with the news of the “Octo Mom.” Other faces of infertility, however, 

may be even more familiar to us: young cancer survivors who freeze embryos prior to chemotherapy to preserve their 

chances of having a family; men who, after lifetimes spent practicing safe sex, find that they have no sperm and are 

considering the use of donors; childless women in their 40s struggling to make sense of their reproductive options and 

younger women who want to freeze their eggs in hopes of preserving their future fertility. Recent advances in medication, 

microsurgery and in vitro fertilization are providing new hope for many people, but with these advances, psychosocial, legal 

and ethical issues become more complex and the issues that challenge ART professionals have become more apparent. 

The need of professionals in the field to be conversant in the ethical and legal issues has never been more pressing. 

This course is designed to meet the needs of family practice physicians, attorneys, social workers, and other healthcare 

professionals who may counsel patients regarding fertility concerns. Topics to be covered include ethical and legal issues, in 

addition to innovative counseling approaches for the most compelling areas of assisted reproductive technology. 



1. Identify key ethical issues that exist in assisted reproductive technology (ART). 

2. Summarize different approaches and varied solutions to issues in the provision of ART services. 

3. Describe legal issues relevant to the provision of good mental health services in ART. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Society of Reproductive Surgeons 

FACULTY 

Mark Sigman, M.D., Chair 

Peter N. Schlegel, M.D., Co-Chair 

Peter T. K. Chan, M.D. 

Philip S. Li, M.D. 

Jay I. Sandlow, M.D. 


Patient Care 

PRACTICING POLITICS: AN INTERACTIVE COURSE ON ETHICS AND COUNSELING ISSUES IN ART 


MALE INFERTILITY MICROSURGERY: A HANDS-ON COURSE 



Male infertility procedures require microsurgical skills, but many practicing urologists have not had microsurgical training. 

Even surgeons who are comfortable with microsurgery often have no mechanism to learn newer microsurgical techniques. 

Although simple techniques such as testicular biopsy are learned during residency, many clinicians have had no formal 

training in more advanced techniques such as vasovasostomy and sperm retrieval. In addition, because of the variety of 

available sperm retrieval techniques, many clinicians are unclear about the indications for particular techniques, often due 

to confusion between obstructive and non-obstructive azoospermia. 

This course has been designed for urologists who want to learn new techniques and those who want to refine their skills. 

It will give participants the ability to learn basic microsurgical skills and practice actual vasovasostomy and microsurgical 

sperm retrieval techniques on animal vas and testes. The faculty will demonstrate and then assist attendees learning 

these procedures. Didactic lectures will improve participants’ knowledge and the hands-on component will provide the 

opportunity for direct improvement in clinical skills. 

42 

CME 

CE 

CME




1. List the indications for individual sperm retrieval techniques. 

2. Demonstrate the use of the operating microscope. 

3. Perform vasovasostomy and microsurgical testicular sperm retrieval. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the American Institute of Ultrasound in Medicine 

FACULTY 

Ilan Tur-Kaspa, M.D., Chair 

Elizabeth E. Puscheck, M.D., Co-Chair 

Steven Goldstein, M.D. 

Alexander Hartman, M.D. 

Ilan Timor-Tritsch, M.D. 



Patient Care 

ULTRASOUND IN REPRODUCTIVE MEDICINE PART II 

Course PG15 (Sunday) • ROOM 503 CME 


Ultrasound has become an integral component not just of assisted reproductive technologies (ART), but also in the dayto-day 

practice of reproductive medicine, infertility and gynecology. In 2009, new practice guidelines for ultrasound in 

reproductive medicine were published by the American Institute for Ultrasound in Medicine (AIUM). Members of the Society 

for Reproductive Endocrinology and Infertility, the ASRM Imaging Special Interest Group and ASRM have expressed a 

strong desire for CME credits in ultrasound that would prepare reproductive medicine professionals and gynecologists for 

accreditation by the AIUM. 

The objective of this course is to provide a comprehensive survey of the use of ultrasound in the female pelvis for 

physicians, nurses and ultrasonographers actively involved in reproductive medicine, infertility and gynecology. The faculty 

will review critically the application of ultrasound to the infertility evaluation, diagnosis, treatments and complications. 

Ultrasound has been a key diagnostic tool in early pregnancy evaluation and monitoring, as well as in assessing pregnancy 

complications. Other gynecologic findings on ultrasound, such as congenital uterine anomalies, ovarian masses, tubal 

disease and other uterine pathologies, will be discussed along with their impact on fertility. Interactive discussion of clinical 

cases and controversies will provide participants an opportunity to discuss the use of ultrasound in the assessment and 

treatment of reproductive problems that occur throughout a female’s reproductive period. Specific topics to be addressed 

in Part II include the following: 

• AIUM/ACOG Guidelines for sonohysterography in reproductive medicine 

• Abnormal uterine bleeding: ultrasound or biopsy 

• Knobology 

• Ovulation induction and embryo transfer in ART 

• Fibroids and adenomyosis 

• 3D ultrasound 

• Endometrium and ART 

• Ultrasound of the fallopian tube 



1. Summarize the appropriate use of ultrasound in the evaluation of infertility, uterine abnormalities and the pathology of 

the reproductive tract. 

2. Describe the proper assessment of early pregnancy and list findings on early pregnancy assessments that are associated 

with poor outcomes. 

3. Discuss new developments in ultrasound, the importance of 3D ultrasound and Doppler blood flow assessment in 


4. List the requirements and benefits of a clinical practice attaining accreditation in ultrasound. 

________________________________________________________________________________________________________________________ 

43


SEXUAL DISORDERS OF OLDER WOMEN: NEW STRATEGIES FOR RESTORING WHAT TIME TAKES AWAY 


Developed in Cooperation with the Menopause Special Interest Group and the Sexuality Special Interest Group 

FACULTY 

John E. Buster, M.D., Chair 

Allen D. Seftel, M.D. 

Sheryl A. Kingsberg, Ph.D. 

Cornelius O. Granai, III, M.D. 


Patient Care 


There is little awareness of FSD and HSDD among physicians caring for older women. Most physicians consider these 

conditions to be intractable and difficult to treat, so they avoid discussing it. Few are familiar with the endocrinology of 

HSDD, its link to decline in androgen production, its adverse psychological impact on many aging women, or the role of an 

aging male partner. 

This course is aimed at physicians and other healthcare practitioners who care for aging women, especially those in 

obstetrics and gynecology, family practice and internal medicine. Attendees will be better equipped to recognize, discuss 

and treat FSD and HSDD in their patients. Topics to be covered include endocrinology and management of HSDD; safety 

and complications of androgen therapy, including the results of clinical trials; effects of depression and anti-depressants 

on HSDD; the impact of HSDD on the family and the workplace; treatment options for HSDD in survivors of gynecologic 

malignancies and the significance of declining sexual desire and erectile dysfunction in the aging male partner. 



1. Describe the endocrinology of HSDD as it relates to aging, genetics and decline in androgen production. 

2. Assess the pharmacologic and psychosocial factors contributing to HSDD for each patient and discuss appropriate 

therapeutic approaches. 

3. Explain the role of the male partner in HSDD and describe appropriate therapeutic interventions. 

4. Identify current treatment options for survivors of gynecologic malignancies with HSDD. 

5. List the ICD-9 codes that apply to HSDD-related diagnoses. 

________________________________________________________________________________________________________________________ 

ONCOFERTILITY: A BRIGHTER FUTURE FOR SURVIVORS OF CHILDHOOD CANCERS 


Developed in Cooperation with the Pediatric and Adolescent Gynecology Special Interest Group and the Fertility Preservation 


FACULTY 

Benjie B. Mills, M.D., Co-Chair 

Clarisa R. Gracia, M.D., M.S.C.E., Co-Chair 

Jill P. Ginsberg, M.D. 

Marybeth Gerrity, Ph.D., M.B.A. 





Because survival of childhood cancers has dramatically increased in the last 30 to 40 years, the focus of care now goes 

beyond the cancer treatments to the quality of life that comes afterward. It is estimated that 1 in 900 reproductive-age 

adults will be survivors of a childhood cancer. Approximately 6 to 8% of female childhood cancer survivors will have acute 

ovarian failure (cessation of ovarian function by the end of treatment) from cancer treatment. Others will have decreased 

reproductive potential and premature ovarian failure after therapy is completed. As the number of survivors increases, so 

does the likelihood that these patients and their families will be seeking information about and treatment for fertility issues. 

Healthcare providers from various specialities will need the factual knowledge to counsel and treat these patients. 

Designed for physicians and other healthcare professionals specializing in oncology, pediatrics, family medicine and 

obstetrics and gynecology, this course will provide participants with the latest information regarding fertility preservation 

techniques and issues, which they can use to teach their colleagues and set up guidelines for providing services to 

oncology patients. Case studies will be used as a springboard for discussion of specific needs for attendees’ institutions. This 

course will also provide guidance on getting services started, as well as a breakout session to discuss with other participants 

ideas they have for practical implementation of patient services. 

44 

CME 

CME




1. Describe the current technology available for fertility preservation in pediatric, adolescent and reproductive-age 

oncology patients. 

2. Explain infertility, subfertility and fertility preservation in terms that patients and their families will understand. 

3. List the barriers oncologists face when counseling patients about a newly diagnosed cancer and address ways in which 

access to fertility preservation services can be provided. 

4. Identify areas in his/her own institution that are in need of improvement and synthesize potential solutions. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the European Society for Human Reproduction and Embryology 

FACULTY 

M. Cristina Magli, Ph.D., Chair 

Henry Leese, Ph.D. 

Daniel R. Brison, Ph.D. 

Carlos E. Plancha, M.D. 

Luca Gianaroli, M.D. 



THE ENRICHMENT OF CULTURE MEDIA: TOWARD THE BEST ENVIRONMENT FOR IVF EMBRYOS? 

Course PG18 (Sunday) • ROOM 201 CME 


Early attempts to culture embryos to the blastocyst stage confirmed that the culture media used were suboptimal. More 

recently, culture media formulations have been modified with major improvements in ART outcomes. Several commercially 

available formulations of sequential culture media were developed on the assumption that the embryo experiences 

changing energy requirements during its growth. Unfortunately, the composition of these media is usually not released and 

a general concern arises on the non-physiological concentrations of additives. Clinical laboratory professionals must be 

aware of the possible implications on embryonic/fetal development related to culture media by investigating the effects 

associated with the additives and the corresponding concentrations. 

The goal of this course, developed for clinical embryologists and other laboratory professionals, is to give participants the 

information they need to justify selection of the culture medium to be used in their laboratory. Faculty will cover the subject 

of culture media in detail, including the effect of metabolites and components at the respective concentrations. 



1. Summarize the physiology of oocyte maturation and embryo development. 

2. Identify the metabolic requirements necessary for embryo development. 

3. Examine the effects of each supplementation component on culture media. 

4. List the possible negative consequences of the use of supplements at non-physiological concentrations in culture media. 

________________________________________________________________________________________________________________________ 

45


Developed in Cooperation with the Nurses’ Professional Group 

FACULTY 

Karen R. Hammond, D.N.P., C.R.N.P., Chair 

Nicholas A. Cataldo, M.D. 

Shalini S. Gunawardena, R.N., B.S.N. 




Evaluation and treatment of infertility commonly requires frequent office visits and can be very time consuming. Patients 

seeking care for infertility treatment are at risk for neglecting the other components of healthcare. It is incumbent upon 

healthcare providers to have an extensive knowledge of the total patient, not just the fertility aspects. With the recent 

changes in guidelines for health screening and a growing knowledge base of the non-reproductive impact of infertility on 

overall health, providers must stay abreast of the latest information to provide optimal quality patient care. Targeted for the 

practicing nurse and other reproductive health professionals, this postgraduate course will address preconception health, 

diet, exercise, medications, complementary and alternative medicine, health maintenance and the non-reproductive 

health impact of infertility. Since few dedicated resources are currently available to address these common issues, this 

course will provide detailed information by experienced faculty members, as well as facilitate networking beyond the 

course. 



1. Identify the role of dietary, lifestyle and environmental elements in preconception health. 

2. Examine health maintenance strategies and interventions for reproductive-age women. 

3. Describe the role of complementary and alternative medicine in reproductive endocrinology. 

4. Describe the non-reproductive health impact of infertility and effects of various medical conditions on fertility and 

beyond. 

________________________________________________________________________________________________________________________ 

Developed in Cooperation with the Reproductive Laboratory Technologists Professional Group and the Reproductive Biology 


FACULTY 

Michael A. Lee, M.S., T.S., E.L.D., Chair 

Sangita K. Jindal, Ph.D., Co-Chair 

Vladimir Isachenko, Ph.D. 

Mitchel C. Schiewe, Ph.D., H.C.L.D., E.L.D. 


Patient Care 

THE REI PATIENT: THERE’S MORE TO THE PATIENT THAN INFERTILITY 


OOCYTE/EMBRYO VITRIFICATION: A HANDS-ON WORKSHOP 



The techniques of oocyte and embryo vitrification have been developed in multiple laboratories. While aseptic vitrification 

methods and devices with established simplicity, low cost, safety and effectiveness are available, it can be difficult for 

clinicians and laboratories to reliably compare the advantages and disadvantages of the different technologies free of 

commercial influence. 

This course, designed for nurses, laboratory scientists and technicians, as well as specialists in obstetrics and gynecology, 

oncology and embryology, will provide clinicians and reproductive biologists hands-on practice in reliable, consistent, 

aseptic, simple techniques and storage devices. Experts in vitrification techniques will demonstrate three proven aseptic 

methods of vitrification and provide one-on-one tutoring to participants practicing each technique at hands-on work 

stations. After participants have practiced the methods, they will be better able to assess the pros, cons and potential 

applications of each technique in their own clinical practices. 



1. Explain cryobiological/cryophysical principles behind vitrification technology and contrast vitrification to standard slowfreeze 

preservation. 

46 

CE 

CME


2. Assess and implement various vitrification methods after careful comparison of various parameters that should be 

considered in establishing a vitrification program. 

3. Discuss laboratory good tissue-handling practices (GTPs) and quality control concerns of vitrification and describe how 

they influence intra- and inter-laboratory success with the methods and devices used in the hands-on workshop. 

4. Assess overall quality management in striving to develop a standard “global” vitrification technique that minimizes 

“technical signature” worldwide through the use of various vitrification techniques. 

________________________________________________________________________________________________________________________ 

2010 BACK TO THE BASICS - MANAGING A REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY PRACTICE 


Developed in Cooperation with the Association of Reproductive Managers 

FACULTY 

Lisa A. Rinehart, R.N., B.S.N., J.D., Chair 

Maria Elena Amado, B.A. 

Francisco Arredondo, M.D. 

Robert Strickland, M.Ed. 


Reproductive medicine facilities face daily challenges to ensure excellence in patient care. Managers must be innovative 

in daily operations to enable their practices to survive in an ever-changing economy. Limited management training for 

clinical, administrative, nursing and laboratory staff can be an obstacle to achieving a successful assisted reproductive 

technology program. 

Designed for practice managers and other staff in supervisory positions of reproductive medicine practices, the goal of 

this course is to redefine basic administrative issues in reproductive medicine with updated information on new technology 

and other techniques that can improve basic managerial skills. Topics to be discussed include the latest marketing trends, 

electronic medical records, basic risk management protocols and standard operational procedures. 



1. Assess new marketing tools and evaluate the best marketing approach for each individual reproductive endocrinology 

and infertility practice. 

2. Identify new technology that can help improve efficiency with the use of electronic medical records in their practices. 

3. Apply basic tools for a safe risk-management protocol, assess elements of risk and implement solutions for their 

reproductive endocrinology and infertility practice. 

4. Discuss new trends in fundamental managerial skills and determine which best serves each individual facility. 

________________________________________________________________________________________________________________________ 

47

Don’t Go Home Empty-Handed! 

In addition to the invaluable information you will take home from our Scientific Program offerings, 

don’t go home without an Annual Meeting memento for your children, spouse, coworkers, or yourself! 

To purchase these items, visit the ASRM booth #835 located in the Exhibit Hall during exhibit hours. 

ASRM Lunch Cooler 

Durable, soft and constructed of a nylon 

blend for easy cleaning, the ASRM lunch 

cooler features the standard ASRM logo on 

an ASRM red background. Zippered with an 

easy-to-carry handle, the cooler keeps your 

food items cool and provides plenty of room 

for lunch, snacks and drinks. • $5 USD 

ASRM Teddy Bear 

Soft, cuddly, and each with a personality 

of its own, the ASRM teddy bear makes a 

perfect gift for a child, collector, or a great 

addition to your office, desk or bookcase. 

Dressed in an ASRM logo t-shirt he (or she) 

sits 10” high. • $10 USD 

ASRM T-shirt 

Made from 100% cotton, the ASRM 2010 

Annual Meeting t-shirt with long sleeves 

comes in an array of men’s and women’s 

sizes and features this year’s Annual Meeting 

logo. Take one home and recall the Annual 

Meeting every time you wear it. Makes a 

great gift for others as well. • $15 USD 


1209 Montgomery Highway • Birmingham, AL 35216 

TEL (205) 978-5000 • FAX (205) 978-5005 • asrm@asrm.org • www.asrm.org

CME/CE SECTION 

PLENARY SESSIONS 

SYMPOSIA 

INTERACTIVE SESSIONS 

VIDEO PROGRAM 


PLENARY SESSIONS

SCIENTIFIC PROGRAM • PLENARY SESSIONS 

Monday, October 25, 2010 9:00 am – 10:30 am 

Plenary Session 1 

9:00 am 

PRESIDENT’S GUEST LECTURE 

NUCLEAR RECEPTOR COACTIVATORS IN PHYSIOLOGY AND 

PATHOLOGY 

Endowed by a 1987 grant from Ortho Women’s Health 

Bert W. O’Malley, M.D. 


Introducer: William E. Gibbons, M.D. 

Needs Assessment and Description 

Steroid hormones, which play critical roles in human 

reproductive health and disease – including infertility, 

endometriosis and cancer – interact with nuclear receptor 

coactivators to elicit cellular responses in reproductive 

tissues. Not only are mutant forms of these coactivators 

possible causes of disease, but the coactivators and 

nuclear receptors represent potential targets for 

pharmacotherapeutics. Surveys indicate that reproductive 

medicine physicians in practice generally are not aware of 

the latest advances in steroid hormone action. This session 

will update physicians and allied health professionals on the 

basic biology of nuclear receptor coactivators in order to 

advance the application of this knowledge to the diagnosis 

and treatment of reproductive disease. 

Learning Objectives 

At the conclusion of this presentation, participants should be 

able to: 

1. Summarize importance of nuclear receptor coregulators 

in physiology. 

2. List major disease applications of coregulator deficiencies. 



TEST QUESTION: 

A 50-year-old woman presents with an aggressive breast 

cancer. In addition to assessing the concentration of 

estrogen receptor and progesterone receptor, to assess the 

rate of progression of the cancer and choice of therapy, I 

will do the following in my practice after participating in this 

session: 

a. Measure CARM1 coactivator in the tumor cells. 

b. Look at RNA polymerase activity in the tumor cells. 

c. Measure SRC-3(AIB1) coactivator in the tumor cells. 

d. Only measure the levels of estrogen receptor and 

progesterone receptor. 

e. Not applicable to my area of practice. 


Moderator: William E. Gibbons, M.D. 

49 

9:45 am 

HERBERT H. THOMAS LECTURE 

TARGETING STEROIDOGENESIS IN ENDOMETRIOSIS 

Endowed by a 1990 grant from Astra Zenecca 


Northwestern University Feinberg School of Medicine 

Introducer: Robert N. Taylor, M.D., Ph.D. 


In order for healthcare providers to diagnose and treat 

endometriosis, they must be able to translate knowledge of 

basic endometrial physiology and pathology into clinical 

practice. In this presentation, the key molecular mechanisms 

in endometriosis and steroid biology will be linked to 

improvement in patient care. 



able to: 

1. List medical treatment options for endometriosis. 

2. Identify pathologies related to steroid receptors in 

endometriosis. 

3. Define emerging new diagnostics and treatments related 

to steroid biology. 



Patient Care 


A 56-year-old gravida 0 woman who had a long-standing 

history of severe endometriosis presents with severe 

chronic pelvic pain and vaginal spotting due to persistent 

vaginal cuff endometriosis refractory to radical surgical 

excision or existing medical treatments. She had total 

abdominal hysterectomy and bilateral oophorectomy 

20 years ago because of endometriosis. Since then, 

endometriosis has persisted at the vaginal cuff, despite 

three attempts of surgical resection or treatment with 

a progestin. Endometriosis recently caused bilateral 

ureteral blockage and hydronephrosis, leading to bilateral 

segmental ureteral resection and reimplantation. She has 

a body mass index of 30 kg/m2 and a vaginal speculum 

examination revealed a 3 cm cuff lesion that is histologically 

confirmed as endometriosis. Laboratory studies were 

as follows: serum FSH, 78 U/L; estradiol, 37 pg/mL. A 

nephrology consult revealed borderline kidney function; 

an intravenous pyelography ruled out ureteral blockage; 

a bone mineral densitometry study ruled out osteoporosis. 

After participating this session I will do the following in my 

practice: 

a. Perform an anterior pelvic exenteration. 

b. Attempt to treat with an aromatase inhibitor plus a 

bisphosphonate for at least 6 months. 

c. Attempt a six month course of depot GnRH agonist 

therapy with or without add back. 

d. Attempt a six month course of depot 

medroxyprogesterone acetate. 

e. Not applicable to my area of practice.


Monday, October 25, 2010 11:15 am – 12:00 pm 

Contraception Day Keynote Lecture 

A GOOD MAN: GREGORY PINCUS AND THE DEVELOPMENT 

OF ORAL CONTRACEPTION 


Oregon Health and Science University 


Most clinicians are unaware of the history of oral 

contraception. The story of the birth control pill provides an 

appreciation for the enormous personal and social impact 

of this achievement, and an understanding of the early 

efforts of hormonal contraceptive research in the political 

and social climate of the time. 


At the conclusion of the presentation, attendees should be 

able to: 

1. Summarize the contribution of Gregory Pincus to the 

development of oral contraception. 

2. Relate the importance of producing and testing synthetic 

progestational drugs. 

3. Relate the contributions of the entire development 

team: Katharine McCormick, John Rock, and Celso- 

Ramon Garcia. 

4. Describe the political conflicts surrounding the 

development of the oral contraceptive. 



AMERICAN UROLOGICAL ASSOCIATION BRUCE STEWART 

MEMORIAL LECTURE 

FUTURE OF SURGERY 

Richard M. Satava, M.D. 

University of Washington 

Introducer: Nancy L. Brackett, M.D. 


There is a lack of knowledge about the emerging 

technologies in both the healthcare and non-healthcare 

fields such that practicing physicians are not able to 

anticipate the new technologies that will revolutionize 

(either dramatically change or make obsolete) their current 

practice. New technologies that are under development 

but not yet available to practicing physicians will be 

discussed in order to help prepare them for the coming 

revolution that will significantly change their practice 

patterns. 

Room 405 


Moderator: Nancy L. Brackett, M.D. 

50 




Which one of the following statements correctly describes 

the development of oral contraception? 

a. The investigators tried to duplicate the effect of LH on 

ovulation. 

b. The first preparations contained estradiol and 

progesterone because they retain full potency when 

taken orally. 

c. Oral contraception was patented by the Searle 

Company. 

d. For many years, the source of oral progestins was the wild 

yam in Mexico. 

e. The continuous treatment regimen was conceived by 

Gregory Pincus. 



able to: 

1. Identify the revolutionary technologies that are currently 

under development in laboratories but yet to be 

published that will dramatically impact clinical practice. 

2. Participate in the debates and guideline development 

on the moral and ethical issues that disruptive future 

technologies pose to the medical profession. 




Which one of the following represents an emerging 

technology that has dramatic implications for clinical 

practice? 

a. Suspended animation 

b. Biomedical photonics 

c. Intracellular surgery 

d. Microrobotics 

e. Video holograms




9:00 am 

SEX DIFFERENCES IN CARDIOVASCULAR DISEASE: 

WHAT ARE THE IMPLICATIONS FOR REPRODUCTIVE MEDICINE? 

Endowed by a 1992 grant from Wyeth 


Mayo Clinic 

Introducer: Rogerio A. Lobo, M.D. 


Scientific and medical evidence indicates that some 

types of cardiovascular disease occur only in women 

(preeclampsia of pregnancy) and some more frequently in 

women than in men (Takotsubu cardiomyopathy, diastolic 

heart failure), while others occur more frequently in men 

than in women but may present differently in each sex 

(myocardial infarction). The results of membership surveys 

indicate a desire for broader topics and new concepts 

in general medical care of women to enhance the 

reproductive practitioner’s ability to provide optimal patient 

care. 



able to: 

1. Identify specific cardiovascular diseases that differ 

between females and males. 

2. Describe how sex steroid hormones affect vascular 

function. 

9:45 am 

GENOTYPES AND PHENOTYPES IN PCOS 

Endowed by a 1992 grant from EMD Serono, Inc. 


Northwestern University Feinberg School of Medicine 

Introducer: Richard S. Legro, M.D. 


There have been major technological advances in the study 

of genetic disorders over the past decade. Polycystic ovary 

syndrome (PCOS) is a complex genetic disease. Recent 

studies have identified additional phenotypes in the families 

of women with PCOS and have begun to map susceptibility 

genes for the disorder. This lecture will update participants 

on the genetic analyses of PCOS. 



able to: 

1. Explain the evidence that PCOS has a genetic 

susceptibility. 

2. Define the phenotypes in the families of women with 

PCOS. 

3. Summarize genetic analyses of PCOS. 


Moderator: Sarah L. Berga, M.D. 

51 




Women with polycystic ovary syndrome (PCOS) may 

exhibit endothelial dysfunction leading to increased 

risk of cardiovascular disease. Synthesis of nitric oxide 

in endothelial cells sustains endothelial function. Which 

statement best describes how sex steroids affect production 

of endothelial nitric oxide? 

a. Testosterone through binding to androgen receptors 

increases synthesis of endothelium-derived nitric oxide. 

b. Testosterone through conversion to 17ß estradiol 

decreases synthesis of endothelium-derived nitric oxide 

synthase. 

c. 17ß estradiol through conversion to testosterone increases 

synthesis of endothelium-derived nitric oxide synthase. 

d. 17ß estradiol through binding to estrogen receptors 

increases synthesis of endothelium-derived nitric oxide 

synthase. 

e. Progesterone through binding to glucocorticoid receptors 

increases synthesis of endothelium-derived nitric oxide. 



Patient Care 


You have just made the diagnosis of PCOS and impaired 

glucose tolerance in a 21-year-old woman. Her parents are 

alive and well and she has two sisters and two brothers. She 

asks you whether her family members are at risk for PCOS or 

its associated disorders. After participating in this session, in 

my practice I would tell this patient the following: 

a. There is no risk to male first degree relatives in PCOS 

families. 

b. There is no risk to female first degree relatives in PCOS 

families. 

c. Her brothers are at increased risk for infertility. 

d. Her father is at increased risk for type 2 diabetes. 

e. Her mother is at increased risk for early menopause. 

f. Not applicable to my area of practice.




THE SOCIETY OF REPRODUCTIVE SURGEONS LECTURE 

POSTOPERATIVE ADHESIONS: PATHOGENESIS, PREVALENCE 

AND PREVENTION 

Endowed by a 1999 grant from Ethicon Endo-Surgery, Inc. 


Wayne State University 

Introducer: Anthony A. Luciano, M.D. 


Absence of imagining modalities and biomarkers to 

diagnose postoperative adhesion development has greatly 

limited the opportunity to identify the frequency with which 

postoperative adhesions develop, and recognition of the 

extent of the problem, as well as success of approaches 

to limit/prevent their development. Despite FDA approval 

of agents to reduce postoperative adhesions, use of such 

agents remains extremely limited. 


At the conclusion of this symposium, participants should be 

able to: 

1. Estimate the frequency of postoperative adhesion 

development after procedures performed by laparotomy 

and laparoscopy. 

2. Describe factors that enhance or reduce the likelihood of 

postoperative adhesions. 


Moderator: Anthony A. Luciano, M.D. 

52 



Patient Care 


A 15-year-old female patient has a 7 cm left ovarian mass, 

which on ultrasound is consistent with a dermoid cyst. In 

counseling the girl and her parents regarding the likelihood 

of adhesion development to the ovary after ovarian 

cystectomy, after participating in this session in my practice 

I will advise the following: 

a. There is only a very small likelihood of adhesion 

development to the ovary. 

b. If adhesions to the ovary develop, they would not affect 

her future fertility. 

c. Adhesions are far more likely to occur if the procedure is 

conducted by laparotomy as opposed to laparoscopy. 

d. Adhesions are far more likely to occur if the procedure is 

conducted by laparoscopy as opposed to laparotomy. 

e. She is more likely than not to have adhesions develop to 

ovary regardless of whether the cystectomy is performed 

at laparotomy or laparoscopy. 




Menopause Day Keynote Lecture 

WHAT CAN A SWAN TEACH US ABOUT MENOPAUSE? 




There have been few population-based studies of the 

menopausal transition. The Melbourne Healthy Women’s 

Study, the Seattle Women’s Health Project, and the Penn 

Ovarian Aging Study have all made contributions to our 

understanding of the process of the menopausal transition, 

from hormonal changes to a broad array of psychosocial 

endpoints. However, all of the prior studies have had 

cohorts in the hundreds, not thousands, of women, limiting 

conclusions that can be made. Moreover, none of the 

prior work has included ethnic minority representation in 

significant numbers. The Study of Women’s Health Across 

the Nation, or SWAN, is a multi-ethnic, community-based 

observational study of women who have been examined 

annually for the past 15 years. Women entered the study at 

ages 42-52 when they were still cycling reasonably regularly. 

By now, almost the entire cohort has completed the 

menopausal transition. SWAN was specifically designed to 

address the large gap in knowledge about the menopausal 

experience for community-dwelling women, and is one 

of the first studies to provide estimates of the common 

menopausal symptoms in the U.S. population, their duration, 

and the degree to which they may be associated with 

subsequent disease risk. This information is virtually all new, 

and merits dissemination and discussion in a forum such as 

the ASRM. 

Korbel Ballroom 1 

53 


At the conclusion of the symposium, participants should be 

able to: 

1. Describe the staging system for reproductive aging. 

2. Identify the chief symptoms experienced by women at 

each stage of the menopausal transition. 

3. Discuss the relative differences in overall and specific 

symptomatology based upon race/ethnicity. 

4. Develop a predictive model for subsequent health 

challenges for women who are traversing the 

menopause. 



Patient Care 


A 49-year-old woman presents with 5 months of 

amenorrhea. She notes weight loss of 15 lbs and lack of 

sexual interest for the past few months. She describes little 

pleasure in her work or home activities. You suspect major 

depression and tell her so, but she denies this possibility 

because she has “never been depressed a day” in her life. 

After participating in this session, I will do the following in my 

practice: 

a. Recommend she try hormone therapy because it will 

improve her mood, regardless of the etiology. 

b. Recommend an antidepressant despite her denial of 

depressive symptoms. 

c. Be concerned that hypothyroidism was a cause of her 

symptoms. 

d. Counsel the patient that late perimenopause is the time 

of highest risk of new-onset of major depression. 

e. Consult a psychiatrist immediately. 





9:00 am 

GHRELIN, AGING AND REPRODUCTION 

Endowed by a 1990 grant from TAP Pharmaceutical 



Introducer: Robert N. Taylor, M.D. 


It is important for physicians and basic scientists to be aware 

of the continually emerging role for ghrelin in all aspects of 

physiology that have both direct and indirect relevance to 




able to: 

1. Discuss the emerging significance of the hormone ghrelin. 

2. Summarize the pivotal role of ghrelin in aging of the 

central nervous and immune systems. 

3. Describe ghrelin’s regulation of reproductive function. 

4. Explain how declining endogenous ghrelin activity can be 

restored by treatment with stable ghrelin mimetics. 

SOCIETY FOR THE STUDY OF REPRODUCTION EXCHANGE 

SPEAKER 

ENDOMETRIOSIS: LESSONS FROM A PRIMATE MODEL 

Asgerally T. Fazleabas, Ph.D. 

Michigan State University 

Introducer: Linda Giudice, M.D., Ph.D. 


Endometriosis continues to be an enigmatic disease whose 

etiology and pathophysiology are still not completely 

understood. This is partially due to the extended period 

associated with confirmation of the diagnosis. Therefore, a 

need exists to develop appropriate models, such as nonhuman 

primates, in which endometriosis can be induced, 

leading to a clearer understanding of the mechanisms of 

its initiation and development, along with its diagnosis and 

treatment. 



able to: 

1. Summarize the advantages and disadvantages of 

utilizing a non-human primate model to understand the 

pathogenesis of endometriosis. 

2. Discuss the potential mechanisms by which epigenetic 

changes and progesterone resistance are manifested in 

the eutopic endometrium and the resulting consequence 

on embryo-maternal dialogue. 


Moderator: William E. Gibbons, M.D. 

54 




Which one of the following accurately describes the role of 

ghrelin in reproduction? 

a. The interplay between ghrelin, leptin, NPY and insulin 

appears to be regulated such that NPY neurons respond 

to ghrelin. 

b. Ghrelin increases oxidative stress on specific peripheral 

nerve and brain cells. 

c. Ghrelin has proliferative effects on specific testicular 

cell types and is a positive regulator of male reproductive 

function. 

d. Ghrelin acts directly and/or indirectly, depending on 

the target cell, to “fine tune” the action of sex steroids, 

neuropeptides and neurotransmitters. 

e. Ghrelin has no effect on ovarian steroidogenesis, 

hormone production and release, or ovarian cell 

proliferation and apoptosis. 

Wednesday, October 27, 2010 2:45 pm – 3:30 pm 



Moderator: Linda Giudice, M.D., Ph.D. 




Induction of endometriosis in a non-human primate model 

following deposition of menstrual tissue into the peritoneal 

cavity results in: 

a. A completely unaltered eutopic endometrial 

environment. 

b. Progressive changes in steroid hormone responsiveness 

that are reflected in gene expression patterns in the 

eutopic endometrium. 

c. Immediate suppression of ovulation and menstrual 

cyclicity. 

d. The ability of the endometrium to continue to respond 

to embryonic signals in spite of the loss of progesterone 

responsiveness. 

e. Persistence of the disease in the absence of the ovaries 

and continuous menstrual seeding.

ASRM Career Center 

(Position Placement) 

Visit the ASRM Career Center located in the 

ASRM Booth #835 to post your resume, search 

for jobs, or advertise an open position. 

Job seekers may use this service for free, while 

employers pay a nominal fee for posting jobs. 

Still looking for a position after the meeting? 

Visit the ASRM Career Center on our website 

year-round at www.asrm.org. 


SYMPOSIA

OFFICE HYSTEROSCOPY: SEPTUM, UTERINE SYNECHIAE, 

POLYPS, TUBAL OCCLUSION IN AN OFFICE SETTING 

Surgeon: Keith B. Isaacson, M.D. 

Newton Wellesley Hospital 

Newton, MA 

SCIENTIFIC PROGRAM • SYMPOSIA 


Society of Reproductive Surgeons Telesurgery 


Reproductive medicine specialists must be able to utilize 

the most current evidence-based techniques in minimally 

invasive reproductive surgery. This session will demonstrate 

office-based techniques for assessment and care of the 

female reproductive tract. 



able to: 

1. Describe intrauterine conditions that can impact embryo 

implantation. 

2. List the advantages and disadvantages of different 

methods to evaluate the uterine cavity. 

3. Describe the technique of office hysteroscopy. 

4. Identify office-based hysteroscopic procedures that 

enhance embryo implantation rates. 


Moderators: Grace M. Janik, M.D.,and Linda Bradley, M.D. 

55 



Patient Care 


Symposium 


DEBATE: OPEN VS. CLOSED GAMETE DONATION 


Judith Kottick, M.S.W. (Chair) 

Fertility Counseling & Consulting Services 


American Fertility Association 

Shelley S. Lee, Ph.D. 

NYU Fertility Center 


There has been an ongoing debate among reproductive 

professionals regarding the risks and benefits of anonymity 

vs. non-anonymity in the field of gamete donation. On 

one side of the controversy are those who prefer closed 

donation as a means of maintaining privacy and providing 

legal protection for the donor, parents, and child. It also 

offers the recipients the capability to make the donor 

“invisible,” allowing them the option not to disclose to their 

children and project themselves onto their child as sole 

parents without intrusion of a third party. The opposing view 

champions openness as an approach that maintains a 

child’s right to access information about his or her genetic 

origins, to establish their true self-identity and to provide the 

opportunity to exchange pertinent knowledge that may be 

helpful in various ways including satisfying a child’s curiosity 

and obtaining relevant medical information. The goal of this 

symposium is to provide reasoned arguments on both sides 

of the debate that can help inform the policies of donor 

programs and assist mental health professionals in serving 

the best interests of their patients. 


After participating in this session, in my practice I will use 

hysteroscopic evaluation of the uterine cavity because it 

provides the following advantages over saline sonography: 

a. Higher sensitivity and specificity 

b. Enhanced view of the myometrium and adnexa 

c. Assessment of endometrial vascularity and cervical canal 

d. Higher post procedure pregnancy rates 




able to: 

1. Summarize the evolution of anonymity in gamete 

donation. 

2. Describe and identify the continuum of anonymous to 

non-anonymous arrangements in gamete donation. 

3. Identify the advantages and disadvantages of anonymity 

for donors, recipients and offspring. 

4. Identify the advantages and disadvantages of nonanonymity 

for donors, recipients and offspring. 




A couple asks whether it is wise to meet their egg donor. 

Friends and family are discouraging the meeting but they 

are curious and want to understand the primary advantage 

for them electing to meet the donor. After participating 

in this session, in my practice I will tell this couple that the 

advantage of meeting their egg donor is that it 

a. Protects their right to privacy and minimizes confusion. 

b. Avoids the threat of the donor’s interference. 

c. Protects the child’s privacy and allows the child to select 

his/her heritage. 

d. Offers a more honest and richer birth story to the 

offspring. 




Symposium 

THE EVER-CHANGING FACE OF REPRODUCTIVE 

ENDOCRINOLOGY AND INFERTILITY 



Reproductive Medicine Institute, LLC 

John S. Rinehart, M.D., Ph.D., J.D. 


Joseph J. Travia, Jr., M.B.A. 

IntegraMed Specialty Heathcare Services 


This symposium will address the multitude of changes in the 

practice of reproductive endocrinology and fertility over 

the past 25 years, and how practice structures continue to 

evolve to meet patient needs and market demand. 

As reproductive technology advanced, so did the 

delivery system and the priorities of fertility care. Today, 

we are faced with more than the need to provide skilled 

practitioners and higher success rates for our patients. 

REI specialists and their staff must also address issues of 

shifting treatment paradigms (increased use of IVF and 

third party reproduction); increasing medical guidelines; 

the influence of economics on treatment options; reduced 

reimbursement options; market competition; decisions on 

practice expansion, consolidation, or closure; increasing 

business expenses; and, significantly – the need to survive in 

a changing medical marketplace. 

Discussion will include a review of the enormous changes 

in our medical specialty and address essential elements of 

a successful office-based fertility practice, which include 

education, ethics, economics, and strategic planning for 

practice development. 

Room 201 


At the conclusion of this session, participants should be able 

to: 

1. Discuss the major changes in the delivery of fertility care 

over the last 25 years. 

2. Identify several external factors that drive the current 

models of fertility practices. 

3. Develop a framework for strategic planning of a 

successful fertility practice. 

56 




Changes in office-based REI practice include adherence 

to the regulatory guidelines of multiple agencies, including 

CLIA, OSHA and which one of the following: 

a. Government Accountability Office (GAO) 

b. Health Resources and Services Administration (HRSA) 

c. Agency for Healthcare Research and Quality (AHRQ) 

d. Food and Drug Administration (FDA) 

e. Office of Scientific and Technical Information (OSTI) 


Symposium 

Room 505 

MANAGEMENT OF THE MENOPAUSE: TO TREAT OR NOT TO 

TREAT - THAT REMAINS THE QUESTION 


Jacqueline N. Gutmann, M.D. (Chair) 

Reproductive Medicine Associates of Philadelphia 

Julie D. Lamb, M.D. 

University of Wisconsin 


The halting of the Women’s Health Initiative (WHI) led to a 

flurry of articles in newspapers and professional journals, and 

informal discussion about the safety and appropriateness 

of hormone therapy (HT) for menopausal women. Though 

several years have passed and hundreds of papers 

addressing the use of HT have been published since the 

initial WHI publication, controversy and questions regarding 

the safety of HT remain. This symposium will examine the role 

of HT in the management of the menopause. Discussion will 

also focus on counseling patients regarding the risks and 

benefits of HT. 


At the conclusion of this session, participants should be able 

to: 

1. Describe the risks and benefits of hormone therapy in the 

management of the menopause. 

2. Apply this information to aid in counseling women 

regarding management of the menopause. 





A 52-year-old healthy woman presents with amenorrhea of 

9 months’ duration, hot flushes, night sweats and irritability 

interfering with her daily activities. She has tried a number 

of over-the-counter preparations designed to reduce 

menopausal symptoms but has experienced no relief. She 

is interested in other treatment options, including hormone 

therapy. After participating in this session, I will do the 

following in my practice: 

a. Advise her that treatment with hormone therapy is 

associated with an increased risk of colon cancer. 

b. Advise her that treatment with hormone therapy is 

associated with an increased risk of hemorrhagic stroke. 

c. Advise her that treatment with hormone therapy is 

associated with an increased risk of cardiovascular 

disease. 

d. Advise her that treatment with hormone therapy is 

associated with an increased risk of pulmonary embolus. 

e. Advise her that treatment with hormone therapy is 

associated with an increased risk of non-vertebral 

fractures. 




Contraception Day Workshop 

NEW CONCEPTS IN THE TREATMENT OF ABNORMAL UTERINE 

BLEEDING: A CASE PRESENTATION 

A Joint Session presented by the Contraception Special Interest Group and 

the Society of Reproductive Surgeons 

Kristen Matteson, M.D., M.P.H. (Chair) 

Brown University, Women and Infants’ Hospital 

Gary N. Frishman , M.D. 

The Warren Alpert Medical School of Brown University 


Alternatives to hysterectomy for abnormal uterine bleeding 

in reproductive age women are growing. Recently, the 

levonorgestrel intrauterine device was approved for 

heavy menstrual bleeding in the United States. There is 

debate surrounding the role of endometrial ablation and 

the levonorgestrel intrauterine device. There is a need to 

educate practitioners in reproductive medicine on the 

advantages and disadvantages of these treatments. 


At the conclusion of the presentation, attendees should be 

able to: 

1. Describe the true definition of dysfunctional uterine 

bleeding (DUB) vs. abnormal uterine bleeding (AUB) and 

what the controversy is about. 

UNEXPLAINED INFERTILITY: INDIVIDUALIZING TREATMENT 

FOR A SUCCESSFUL OUTCOME 

Supported by an Educational Grant from EMD Serono, Inc., and Merck 

Marcelle I. Cedars, M.D. (Chair) 

Department of Obstetrics, Gynecology and Reproductive Sciences, 

University of California, San Francisco 


Stanford University Medical Center 

Bradley J. Van Voorhis, M.D. 

University of Iowa Carver College of Medicine 


Up to 30% of couples who are unable to conceive are 

determined to have unexplained infertility. Traditionally, the 

diagnosis is made only after the basic infertility evaluation 

fails to reveal an obvious abnormality. In the absence of 

a correctable abnormality, the treatment for unexplained 

infertility is, by default, empiric. Proposed treatment 

regimens include intrauterine insemination (IUI), ovulation 

induction with oral or injectable medications, combination 

of IUI with ovulation induction, and assisted reproductive 

technologies (ART). There is a need to help physicians 

evaluate empiric therapies and understand when to use 

each of the available approaches because conception 

may occur even without treatment. In a survey conducted 

by ASRM in 2008, members identified personal practice gaps 

involving use of assisted reproductive technologies (ART) to 

treat causes of infertility. 

The objective of this educational activity for reproductive 

endocrinologists and other clinicians involved in ART is to 

review the current approaches to enable them to select the 

most appropriate, evidence-based treatment regimens for 

their patients with unexplained infertility. 

Room 405 

57 

2. Compare and contrast medical and surgical therapies for 

abnormal uterine bleeding. 

3. Select the best treatment for patients in their practice. 



Patient Care 


A 36-year-old gravida 1, para 1, obese female who 

smokes cigarettes complains of 9 months of increasing 

menstrual bleeding lasting 9 days with blood clots. Her 

menses are regular. She was found to have normal TSH 

levels, a normal endometrial biopsy, and no abnormalities 

on sonohysterogram. She is mildly anemic. She desires 

pregnancy in the future. After participating in this session, in 

my practice I will: 

a. Recommend nonsteroidal anti-inflammatory drugs 

(NSAIDs) 

b. Prescribe combined oral contraceptives 

c. Prescribe cyclic progestins 

d. Prescribe a levonorgestrel IUD 

e. Perform an endometrial ablation 

f. Not applicable to my area of practice. 


Luncheon Symposium 

Korbel Ballroom 2 • This is a ticketed event. 



able to: 

1. Appropriately counsel patients regarding treatment 

options for unexplained infertility. 

2. Develop a cost-effective treatment strategy. 

3. Discuss the risks and benefits of gonadotropin stimulation 

with intrauterine insemination (IUI). 



Patient Care 


A 32-year-old, gravida 0 woman presents to your office 

for treatment of infertility. She has been trying to conceive 

for the past 12 months without success. Her gynecologist 

has performed a hysterosalpingogram, which was normal, 

and found the patient to be ovulatory with regular, cyclic, 

predictable menses at a 30-32 day interval. The male 

partner had a normal semen analysis. 

On physical examination, the patient has a BMI of 31 kg/m kg/m2 , 

but otherwise is normal. Laboratory results include: FSH 6.5 

pg/mL; estradiol 32 pg/mL; TSH 1.88 µIU/mL 

After participating in this session, in my practice I will do the 

following to enhance fertility in this situation: 

a. Recommend the patient lose weight to optimize BMI 

between 20-25 kg/m kg/m2 . 

b. Proceed to treatment with clomiphene citrate – IUI. 

c. Proceed to laparoscopy to exclude endometriosis. 

d. Proceed to IVF. 




Contraception Day Special Session 

U.S. MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTION 


Centers for Disease Control 


CDC has been working with the World Health Organization 

for the past 15 years to develop evidence-based global 

guidance on the safety of contraceptive method use 

for women with medical conditions. The WHO Medical 

Eligibility Criteria for Contraceptive Use is now in its fourth 

editioin, is used widely around the world and is available 

in 13 different languages. WHO encourages adaptation of 

this guidance at the lcoal level, and this has been done by 

several countries including the United Kingdom. In February 

2009, CDC held a meeting of U.S. family planning experts 

to adapt the WHO guidance for specific use in the United 

States. The purpose of this presentation is to describe the 

WHO guidance, discuss the need for adaptation in United 

States and the process for this adaptation, and talk about 

plans for publication, dissemination, and implementation 

of the new U.S. Medical Eligibility Criteria for Contraceptive 

Use, expected to be released in late 2009/early 2010. 



able to: 

1. Identify two new medical conditions added to the U.S. 

Medical Eligibility Criteria for Contraceptive Use that are 

not included in the WHO guidance. 

2. Explain the numeric scheme used to represent the 

recommendations in the WHO and U.S. Medical Eligibility 

Criteria for Contraceptive Use. 

Room 405 

58 



Patient Care 


A 25-year-old woman presents for contraception and states 

that she wants to use the vaginal ring. She is generally 

healthy except for a particular medical condition. 

Upon consulting the U.S. Medical Eligibility Criteria for 

Contraceptive Use Use, , you find that the vaginal ring is given a 

Category 2 for this woman’s particular medical condition. 


following: 

a. Tell the patient she can use the vaginal ring; there is no 

restriction for use of the vaginal ring among women with 

her medical condition. 

b. Tell the patient she can generally use the vaginal ring; 

the advantages of using the vaginal ring outweigh the 

theoretical or proven risks among women with her 

medical condition. 

c. Tell the patient generally she should not use the ring, 

unless there are no other contraceptive methods that are 

available or acceptable to her; the theoretical or proven 

risks usually outweigh the advantages of using the vaginal 

ring among women with her medical condition. 

d. Tell the patient she should not use the ring; there are 

unacceptable health risks among women with her 

condition who use the vaginal ring. 

e. Refer the patient to a specialist in her medical condition. 


CROSS-BORDER CARE 

Presented by the ASRM Ethics Committee 

Leslie P. Francis, J.D., Ph.D. (Chair) 

University of Utah 

Lorna A. Marshall, M.D. 

Pacific NW Fertility & IVF Specialists 

Glenn Cohen, M.D. 

Harvard Law School 

Judith P. Daar, J.D. 

Whittier College of Law 



Ken Ryan Ethics Symposium 


“Medical tourism” is increasing as patients seek care abroad 

that is unaffordable or unavailable for them at home. 

Infertility care is no exception to this trend. Tourism raises 

many ethical questions, including quality, informed consent, 

referrals, and the obligation to treat patients on their return. 

This symposium will bring together experts on reproductive 

tourism to discuss these ethical issues. 



able to: 

1. Describe reasons patients engage in medical tourism. 

2. Identify the ethical issues for infertility specialists raised by 

medical tourism. 

FDA REGULATION: TIMELY TOPICS 

Presented by the Food and Drug Administration 

Martha Wells, M.P.H., R.A.C. (Chair) 

Reglera LLC 

Samuel Barone, M.D. 

Food and Drug Administration 


Jones Institute 

Richard Weiskopf, R.A.C. 

Reglera LLC 


FDA requirements for reproductive donors have been 

effective since 2005. Reports from FDA inspections indicate 

that there is still a misunderstanding by ART clinics as to 

how to address compliance with these requirements. This 

symposium will provide clarification for frequently asked 

questions related to FDA’s requirements. 



able to: 

1. Summarize which infectious disease tests are required for 

reproductive donors and when they need to be 

performed. 

2. Assess the value of performing internal audits to prevent 

FDA compliance problems. 


59 

3. Discuss ethical choices for infertility specialists whose 

patients seek care abroad. 





practice: 

a. Never discuss the possibility that patients might wish to 

seek care abroad that is unavailable or unaffordable for 

them at home. 

b. Discourage patients from seeking infertility treatment 

abroad because of concerns about quality of care. 

c. Discuss with patients the possibility that they might wish 

to seek care abroad that is unavailable or unaffordable 

for them at home and explore the risks and benefits of this 

possibility with them. 

d. Encourage patients to go abroad for care they cannot 

afford at home. 

e. Ignore the possibility of medical tourism. 



Symposium 


3. Restate the FDA requirements relevant to embryo 

donation and assess suggested best practices. 



Patient Care 


A sexually intimate couple forms embryos using the wife’s 

oocytes and sperm from a close friend for their own use. 

They cryopreserved four embryos that were not transferred. 

The wife was not tested or screened. FDA-required testing 

and screening were completed on the directed semen 

donor, and he was found ineligible because of a positive 

hepatitis C test. The couple now wishes to anonymously 

donate the cryopreserved embryos. After participating in 

this session, I will do the following in my practice: 

a. Allow these embryos to be donated if the directed 

semen donor is tested again. 

b. Allow these embryos to be donated if the recipients are 

willing to consent to accept the embryos. 

c. Not allow these embryos to be donated, as they are 

not in compliance with the exemption allowing embryo 

donation. 

d. Allow these embryos to be donated if the wife is now 

screened and tested and required labeling is addressed. 




Symposium 


EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD 

HEALTH AND HUMAN DEVELOPMENT RESEARCH UPDATE: 

MALE AND FEMALE REPRODUCTIVE HEALTH 

Gregory M. Christman, M.D. (Chair) 

University of Michigan Medical Center 

Louis V. DePaolo, Ph.D. 

Reproductive Sciences Branch Center for Population Research, NICHD, NIH 


University of Michigan Medical School 


Baylor College of Medicine, Houston, TX 




Two common blocks to the timely advancement of 

medicine and clinical practice via scientific research 

have been identified. The first is the gap and delay from 

basic science discovery to initial translational testing in 

patients. The second block occurs with the dissemination 

and full integration of clinical research evidence into 

everyday practice. One of the key missions of the NICHD is 

to advance and improve reproductive health in men and 

women through basic discovery and clinical research. This 

approach is complemented by recent efforts to help move 

research forward through these two blocks so that important 

new discoveries are applied quickly and that inferior 

clinical practices are abandoned. Although the NICHD is 

the foremost sponsor of reproductive health research for 

men and women, many practitioners are unaware of the 

current efforts of the NICHD to help speed the pace of basic 

discovery, translation, and education of the reproductive 

health care provider in evidence-based medicine. 

60 



able to: 

1. Examine the current initiatives and programs of the NICHD 

to advance male and female reproductive health. 

2. Describe the current clinical trials that have been 

developed and are now underway by the NICHD 

Reproductive Medicine Network for conditions impacting 

male and female infertility. 

3. Appraise the current status of using endometrial histology, 

gene expression, proteomics, and biomarkers to diagnose 

endometriosis without diagnostic surgery and the 

potential of these novel assessments to guide future 

therapy. 

4. Summarize the current role of genetic testing in the 

assessment of men with abnormal semen parameters 

and the influence of test results in guiding current practice 

recommendations. 



Systems Based Practice 


The NICHD seeks to advance reproductive health research 

in 2010 by: 

a. Devoting all of its efforts to promote new basic discovery 

via molecular biology technology. 

b. Focusing primarily on disorders with no currently available 

treatments. 

c. Develop a portfolio in male and female reproductive 

health spanning investigator initiated research, clinical 

trial networks and specialized research centers, 

with training across the full spectrum of providers and 

researchers. 

d. Transitioning federal research support to industry and 

private foundations. 

e. Keeping researchers focused by avoiding distraction by 

limiting interaction of investigators between various 

NICHD sponsored research initiatives.

STARTING A FAMILY IN TIMES OF DECREASING FERTILITY 

Presented by the European Society for Human Reproduction and 

Embryology 

Pier-Giorgio Crosignani, M.D. (Chair) 

Fondazione Ospedale Maggiore Polizlinico 

Johannes L.H. Evers, M.D. 

Maastricht University 

Henri Leridon, Ph.D. 

Institut national d’études démographiques 

Wolfgang Lutz, Ph.D. 

International Institute for Applied Systems Analysis 



Symposium 

Room 505 


Fertility rates are falling in many countries. Europe is the 

continent with the lowest total fertility rate (TFR). Every single 

one of the 25 member countries in the extended European 

Union has reached the final stage of demographic transition 

characterized by low mortality, low fertility and high life 

expectancy. There is great concern that the increasing ratio 

of aging dependants to wage earners will inevitably lead to 

economic decline. In this symposium trends in fertility rates 

will be assessed, and possible health and social factors will 

be explored. Also the impact of fertility health care and 

social interventions designed to increase fertility rates will 

be reviewed. Factors impacting lower fertility include the 

instability of modern partnerships, improved professional 

opportunities for women, lower perceived ideal family 

size, higher population density, government support of 

medical fertility care and family-oriented tax measures. 

Easily accessible fertility care can bridge the gap between 

desired and observed family size but has only a limited 

effect on the TFR of a population. Societal and health 

care support of families and of couples trying to conceive, 

although improving the quality of life for individuals, does 

not help combat the graying of society. 

CLINICAL DECISION MAKING FOR THE MALE WITH A 

PARTNER OF ADVANCING AGE 


The Turek Clinic 


Prospective, randomized, controlled clinical trials have not 

been undertaken, and may not be feasible in the future, 

to examine whether classic therapy for male infertility or 

assisted reproductive technology (ART) achieves better 

pregnancy outcomes. In the absence of this critical Level I 

evidence, how do clinicians decide which therapy is best 

for male infertility in the setting of advanced maternal age? 



able to: 

1. Estimate the time it takes to make and ejaculate a human 

sperm based on recent heavy-water labeling studies. 

2. Summarize the current single-institution literature on the 

effectiveness of vasectomy reversal for vasectomyrelated 

male infertility and advanced maternal age. 

61 



able to: 

1. Explain the stages of demographic transition. 

2. Critically appraise the effect of fertility care and assisted 

reproduction on declining TFR. 

3. Differentiate between benefits for families as opposed to 

benefits for the demographic composition of society as a 

whole. 




The demographic transition model (DTM) is a theoretical 

model used to explain the transformation of countries from 

high birth rates and high death rates to low birth rates and 

low death rates as part of the economic development of a 

country from a pre-industrial to an industrialized economy. 

This demographic transition, which occurred in Europe and 

other developed societies in the 19th and 20th centuries, 

is characterized by five stages in which changes in birth 

rate, death rate, population size and life expectancy occur. 

Which is the sequence of the following two stages? 

a. A declining birth rate preceding an increasing death rate 

b. A declining birth rate preceding a declining death rate 

c. An increasing birth rate preceding an increasing death 

rate 

d. An increasing birth rate preceding a declining death rate 

e. A declining birth rate following an increasing death rate 

f. A declining birth rate following a declining death rate 

g. An increasing birth rate following an increasing death 

rate 

h. An increasing birth rate following a declining death rate 


Society for Male Reproduction and Urology Mini-symposium 

Room 401 

3. Explain how classic surgical treatments for male infertility, 

including vasectomy reversal and varicocele repair, 

compare to IVF-ICSI using decision and Markov modeling. 



Patient Care 



practice: 

a. Treat male factor infertility without regard to coexisting 

female partner issues. 

b. Recommend assisted reproduction to all couples with 

male infertility and female partners over the age of 40 

years. 

c. Recommend that female partners over age 40 years 

undergo infertility evaluation prior to embarking on 

vasectomy reversal. 

d. Routinely perform varicocele repair for infertility in men 

with anovulatory partners of advanced maternal age. 

e. Perform advanced sperm-function testing in men with 

normal semen analyses and partners of advance 

maternal age. 


HORMONE THERAPY FOR AGING WOMEN: 

FOCUS ON SKELETON AND SLEEP IN AGING WOMEN 

Supported by an Educational Grant from Abbott 

Lubna Pal, M.B.B.S., M.R.O.G., M.S. 

Yale University School of Medicine 


Harvard Medical School, Mass General 


Mayo Clinic 



Symposium with Coffee 


Aging is accompanied by bodily changes seemingly 

resulting from gradually declining levels of a multitude of 

hormones including sex steroids, growth hormone, adrenal 

steroids and insulin-like growth factor. Alterations in the 

metabolic milieu accompany the changing hormone 

profile of aging. Sex steroids are well known to play a pivotal 

role not just in maintenance of female physiology and sex 

organs, and bones, but are also relevant to the physiology 

of the brain. The common menopausal symptoms such as 

hot flushes, night sweats and dyspareunia relating to vaginal 

atrophy set in relatively early in the process of reproductive 

senescence, relate to a decline in reproductive hormones, 

and respond to menopausal hormone therapy. Disordered 

sleep, depression and osteoporosis are relatively covert 

entities that too relate to the age related changing 

landscape of reproductive hormones, but are additionally 

impacted upon by processes of chronological aging. 

Recent years have witnessed a blossoming of strategies, 

hormonal and non hormonal, in the management of 

osteoporosis, allowing clinicians increasing flexibility in 

providing individualized management for prevention of 

fragility fractures. An overall deterioration in quality of life 

is commonly described in the context of aging and loss 

of ovarian function is suggested as contributory to the 

underlying processes that remain poorly understood. Sleep 

disturbances are increasingly appreciated in the context 

of aging in general, and menopause in particular, and 

recognized to partly contribute to the decline in quality of 

life in aging populations. 



able to: 

1. Discuss the relevance of estrogen and progesterone for 

the sleep-wake physiology of the brain and for the bones. 

2. Differentiate between preventive versus therapeutic 

strategies for skeletal health, identify the spectrum of 

therapeutic options available to minimize fragility 

fractures in aging women, and be able to select the 

optimal therapy for an individual patient. 

3. Summarize the importance of sleep hygiene for overall 

wellbeing of the aging population, appreciate the 

relevance of sleep history in routine clinical assessment. 

4. Identify therapeutic options and strategies that may 

facilitate improved sleep in symptomatic women. 

Room 401 



Patient Care 

62 

TEST QUESTIONS: 

A 56-year-old woman returns for her annual visit. She had 

a wrist fracture when she fell on the ice last winter and has 

no chronic medical problems. Her medications include 

an estradiol patch that was initiated 6 years ago following 

total abdominal hysterectomy and bilateral salpingo- 

oophorectomy for fibroids. She drinks 3, 8-oz glasses of milk 

daily and takes a multivitamin. She has never had a bone 

density assessment. 

After participating in this session, in my practice I will counsel 

this patient that her risk of future fracture: 

a. Is best estimated using FRAX 

b. Requires a DXA measurement to assess 

c. Is best managed by adding a bisphosphonate 

d. Is increased because of wrist fracture 

e. Is lowered by increasing her calcium intake 


An 83-year-old woman with a recent left hip fracture is 

referred for osteoporosis management. She took steroids for 

polymyalgia rheumatica for 1.5 years ending 3 years ago. 

Past medical history: hypertension, hyperlipidemia. 

Medications: hydrochlorothiazide, simvastatin 

Lab tests: normal calcium, creatinine. 

DXA: right femoral neck t-score -2.4 

You discuss optimizing calcium and vitamin D intake and 

recommend prescription medication. 

After participating in this session, in my practice I will 

discuss the following with the patient regarding the drug 

denosumab: 

a. It lowers risk of fracture more than alendronate 

b. It is associated with lower risk of GI side effects than 

alendronate 

c. There is no risk of osteonecrosis of the jaw 

d. The risk of cellulitis is increased 

e. There is a higher risk of hypocalcemia than alendronate 


A 47-year-old perimenopausal woman reports difficulty 

falling sleep nearly every night for over a month. She does 

not have hot flushes and she is not depressed. She has tried 

several techniques including sleep hygiene measures. After 

participating in this session, in my practice, I will prescribe 

the following in this situation: 

a. Thyroxine 

b. Progesterone 

c. Short-term trial of non-benzodiazepine hypnotic agents 

d. Not applicable to my area of practice. 

A 53-year-old postmenopausal woman reports being sleepy 

during the day, snoring, unrefreshing sleep, and occasional 

hot flushes. She has gained 10 pounds over the past few 

years. After participating in this session, in my practice I will 

evaluate for the following in this patient: 

a. Gastro-esophageal reflux 

b. Sleep apnea 

c. Narcolepsy 

d. Chronic fatigue syndrome 


PROGESTOGEN SUPPLEMENTATION 

Supported by an Educational Grant from Watson Pharma, Inc. 


Brigham and Women’s Hospital 

Carol B. Lesser, M.S.N., R.N.C. 

Boston IVF 



Symposium with Coffee 

Needs Assessment 

Progesterone is essential to prepare the uterine 

endometrium for implantation and to maintain pregnancy. 

It converts the proliferative endometrium to the secretory 

endometrium, maintaining the uterine glands. Progesterone 

also maintains the uterine myometrium in a quiescent state 

during pregnancy, preventing contractions and expulsion 

of the fetus. Thus, progesterone supplementation has 

come to be used widely to prevent recurrent miscarriage 

and preterm birth and to reduce implantation failure. 

According to the Practice Committee of the American 

Society for Reproductive Medicine, however, “progesterone 

supplementation necessarily is empiric and has been 

applied liberally in clinical circumstances wherein 

the amount or duration of P production is reasonably 

suspect.” Data are conflicting as to whether progesterone 

supplementation associated with assisted reproductive 

technologies is necessary or even beneficial. Nonetheless, 

hundreds of websites promote the use of progesterone with 

claims such as “All women free of medical complication 

can benefit from progesterone supplementation.” Clinicians 

and patients are confused about the clinical utility of 

progestogens and also about the dosage, duration and 

type of progestogen to use in particular situations. For this 

reason, the ASRM issued a report addressing the evidencebased 

uses of progestogens and the risks associated with 

progestogen administration. The goal of this symposium is 

Room 403 

63 

to provide clinicians in reproductive endocrinology and 

infertility, including physicians, nurses and allied health 

professionals, with current perspectives on the use of natural 

and synthetic progestogens. 



able to: 

1. Describe the physiologic changes in circulating 

progesterone levels in women. 

2. Summarize what is known about the appropriate use 

of progestogens in women with infertility and recurrent 

miscarriage and abnormal uterine bleeding. 

3. Outline appropriate treatment regimens for the use of 

progestogens in various clinical conditions. 



Patient Care 


After participating in this symposium, in my practice I will use 

progesterone supplementation to: 

a. Increase the likelihood of pregnancy in women with 

irregular menstrual cycles. 

b. Increase the likelihood of delivery in IVF if used until 12 

weeks’ gestation. 

c. Cause secretory changes in the endometrium of women 

who do not ovulate to prevent endometrial hyperplasia 

or carcinoma. 

d. Improve delivery rates in women using clomiphene 

citrate treatment. 


Tuesday, October 26, 2010 11:15 am – 1:00 pm 

Menopause Day Workshop 

TRADITIONAL HORMONE THERAPY: IS THERE STILL A NEED? 


Mayo Clinic 

SELECTIVE ESTROGEN RECEPTOR MODULATORS AND TISSUE 

SELECTIVE ESTROGEN COMPLEXES 




Women and their physicians are increasingly confused as 

to the actual risks/benefits of hormone therapy. They seek 

reliable information while also exploring alternative therapies 

for menopausal symptom relief. Despite considering 

healthcare providers the most reliable source of information, 

women expressed low confidence in their ability to give 

sufficient information and to describe alternative therapies. 

Large gaps exist between patient expectations and 

provider preparedness to guide patient decision making. 



able to: 

1. Describe our current understanding of the risks and 

benefits of menopausal hormone therapy. 


2. Review new options for menopausal hormone therapy, 

including the recent results of clinical trials using SERMs 

and TSECs. 


Patient Care 


The risk of breast cancer was elevated in: 

a. Those receiving estrogen alone in the Women’s Health 

Initiative (WHI) 

b. Women taking Raloxifene 

c. Women taking Tamoxifen 

d. Women using combination hormone therapy (estrogen 

and progestin) in the WHI 

Tissue Specific Estrogen Complexes have been 

demonstrated in large prospective clinical trials to: 

a. Preserve bone mineral density 

b. Alleviate hot flushes 

c. Provide amenorrhea rates that are comparable to 

placebo treatment 

d. All of the above



Symposium 

Room 403 

WRINKLED PARENTS: MEDICAL, ETHICAL AND 

PSYCHOLOGICAL ISSUES OF PARENTING AT AN OLDER AGE 


Andrea M. Braverman, Ph.D. (Chair) 

Robert Wood Johnson Medical School 


Whittier College of Law 

Richard T. Scott, Jr., M.D., H.C.L.D. 

Robert Wood Johnson Medical School 


The introduction of ovum donation and gestational carrier 

offered new opportunities for women to parent at an older 

age. The concept of older parenting has changed and 

“older” is open to debate as to whether we are referring to 

parenting in their 40s, 50s or beyond. Medical, legal, ethical 

and psychosocial issues change as parents begin their 

childbearing at older ages, and intended parents need to 

be counseled realistically about the challenges they may 

face. 



able to: 

1. Identify the medical issues of fertility and pregnancy at an 

older age. 

2. Appraise the legal and ethical considerations of older 

parenting. 

WHY AGE MATTERS: MEDICAL AND PSYCHOLOGICAL 

CONCERNS FOR CONCEPTION 

Presented jointly by the Nurses’ Professional Group and 

the Mental Health Professionals Group 

Patricia A. Mendell, L.C.S.W., M.S.W. (Chair) 

Private Practice 

Margaret G. Garrisi, M.D. 

Institute for Reproductive Medicine & Science of St. Barnabas 


University of Southern California Keck School of Medicine 


Patient caregivers in reproductive medicine are challenged 

by the various published methods for assessing ovarian 

reserve (including hormonal studies, challenge tests, ovarian 

volume, and antral follicle counts) and by the ongoing 

debate about the medical and obstetrical safety for 

patients attempting pregnancy in their forties and fifties. In 

addition, for patients over forty there is controversy about 

how best to provide psychological preparation and support 

on their quest to parenthood. 



able to: 

1. Discuss assessment of ovarian reserve and implications for 

pregnancy. 

2. Review additional medical screening requirements in the 

older patient attempting pregnancy. 

3. Explore the psychological concerns for pregnancy and 

parenthood after 40. 

64 

3. Summarize the psychological and emotional 

considerations of older parenting and the attending thirdparty 

considerations. 





A 61-year-old woman wishes to begin building her family. 


practice at the initial consultation with this patient: 

a. Discuss the medical risks of pregnancy and the 

psychosocial and emotional impacts of ovum donation 

and non-genetic parenting. 

b. Perform standardized psychologic testing prior to any 

counseling. 

c. Recommend the woman pursue ovum donation. 

d. Recommend the woman pursue adoption. 



Symposium 

Room 503 



Patient Care 



A healthy 40-year-old woman presents with secondary 

infertility. A preliminary medical screening and partner 

evaluation does not yield any significant findings. At age 

30, she delivered a healthy baby at term. One year later 

she started birth control pills and then discontinued them 

after 8 years in an attempt to achieve a pregnancy. They 

have been attempting pregnancy with appropriately timed 

intercourse for the past year without any success. She has 

a high-powered job, and reports “feeling stressed” and 

fatigued. She is 5-10 pounds overweight. After participating 

in this session, I will do the following in my practice: 

a. Tell the patient her job is causing too much stress. She 

needs to relax and be referred to a therapist to learn 

stress reduction techniques. 

b. Tell the patient she has not waited long enough. Taking 

the birth control pills for 8 years improved her egg 

reserves, since she wasn’t ovulating during that time. 

c. Recommend lifestyle modification. She should restrict 

dietary fat and sugar and walk 30 minutes/day. These 

interventions will result in a pregnancy. 

d. Tell the patient this is due to her advanced age - a 

healthy 30-year-old woman will have a 20% chance of 

conception each month, whereas a 40-year-old woman 

will have a 5-10% chance of conception/month. 

e. Tell the patient she should have adopted a child last year 

before attempting conception as adopting a child often 

leads to spontaneous conception. 


THE IMPACT OF NEW COMMUNICATION TECHNOLOGIES 

ON THE FIELD OF FERTILITY 


Robert R. Strickland, M.Ed. (Chair) 

Pacific Fertility Center 

Kira Copperman, L.M.S.W. 

KBC Consulting 



Symposium 


Social media technologies are developing at a rapid pace. 

Professionals in the fertility medicine world must assess 

their knowledge, skills, and abilities about new marketing 

opportunities and identify the impact these emerging 

options will have on their practices. It will be crucial to 

make good business decisions with limited dollars that will 

have a short-term return on the investment and a long-term 

impact on continued success. The foundation of such a 

program must have a strong written policy that serves as 

a cornerstone in the marketing plan. This session examines 

newly-emerging social media technologies, a policy to 

mitigate the risk and maximize the reward, and examples 

that are helping define the fertility medicine world today. 



able to: 

1. Identify at least three new forms of emerging social media 

technology that will impact a fertility marketing plan. 

2. Describe the key components of a written social media 

policy for a business/medical organization. 

3. Define the new technologies that will influence 

understanding and education about the field of fertility 

medicine. 

Room 401 



65 


New forms of emerging social media technology that will 

impact a fertility marketing campaign are: 

a. Television, Radio, and Newspapers 

b. You Tube, Facebook, and LinkedIn 

c. Droid, Blackberry, and iPhone 

d. Books, Magazines, and Printed Brochures 

e. Seminars, lectures, and facility tours 

The key components of a written organizational social 

media policy that mitigates risk and maximizes reward 

include information about: 

a. Things to say and not to say, reminder that all comments 

will be monitored, and approved ways to express 

personal opinions. 

b. How to Tweet, Blog, Text Message, and use Wikipedia. 

c. Ways to get dismissed/terminated due to using social 

media at work inappropriately. 

d. Disciplinary action steps, universal truths, and approved 

words to get your opinion across to the reader. 

e. Terms of Use/User Agreement, Disclaimers, Guidelines, 

Privacy Policy, Copyright Policy, Antitrust Policy, 

Trademarks, and Employee Code of Conduct. 

Which new social media technologies will impact the field 

of infertility the most? 

a. Mobile devices including cell telephones with 

applications. 

b. Web Pages, Wikipedia, and other ways to gather topic 

information. 

c. Text messaging including tweets and blogging. 

d. LinkedIn 

e. All of the above.

INFERTILITY AS A PUBLIC HEALTH PRIORITY 

Presented by the Centers for Disease Control and Prevention (CDC) 

Maurizio Macaluso, M.D., Dr.P.H. (Chair) 




Lawrence S. Ross, M.D. 

University of Illinois Chicago 

Joanne C. Armstrong, M.D. 

Aetna Health, Inc. 

Nina Larsen, M.S.P.H. 




Symposium 


In 2002, two million American women of reproductive 

age were infertile. Infertility is also common among men. 

A CDC working group found that considerable gaps and 

opportunities exist in surveillance, research, communication, 

and program and policy development. In May 2010, the 

CDC released an “Outline of a National Action Plan for 

the Prevention, Detection and Management of Infertility.” 

The overall goal of the National Action Plan is to promote 

and preserve the ability of Americans to conceive, and the 

ability of American women to carry a pregnancy to term 

and deliver a healthy child. The purpose of this symposium is 

to give an overview of infertility as a public health concern, 

and discuss priorities for surveillance, research and action 

in areas such as environmental and occupational causes 

of infertility, male infertility, and policy. The symposium will 

also provide an opportunity to discuss progress with the 

development of the National Action Plan. 

CONTROLLED OVARIAN STIMULATION IN DIFFICULT CASES: 

MERITS AND COMPLICATIONS 

Presented by the Middle East Fertility Society 

Shawky Z. Badawy, M.D. (Chair) 

State University of New York Upstate Medical Center 

Botros B. Rizk, M.D., M.A. 

University of South Alabama 

Luciano Nardo, M.D. 

University of Connecticut School of Medicine 


Ovarian stimulation is a key medical therapy in assisted 

reproductive technology. This symposium will address 

commonly used protocols for treating poor responders, as 

well as the management of ovarian stimulation in patients 

with polycystic ovary syndrome (PCOS). In addition, the 

latest information on ovarian hyperstimulation syndrome 

(OHSS) and its treatment will be discussed. 



able to: 

1. Describe protocols to manage poor responders with 

controlled ovarian stimulation. 

Room 203 



able to: 

1. Discuss priorities for infertility prevention research. 

2. Discuss policy solutions to improve access to care and to 

increase the safety of infertility treatment. 

3. Identify the main objectives of the National Action Plan. 



66 



Topic Priority Statement 

1: Chlamydia infection and 

tubal infertility 

2: Environmental exposures 

and disruption of the 

ovarian function 

3: Male factor infertility and 

chronic disease 

4: Elective single embryo 

transfer as a strategy 

for reducing multifetal 

pregnancie 

pregnancies 

5: Adverse outcomes of 

non-ART infertility 

treatment 

Select the best combination: 

(a) 1-A, 2-B, 3-C, 4-D, 5-E 

(b) 1-B, 2-A, 3-D, 4-E, 5-C 

(c) 1-C, 2-A, 3-E, 4-B, 5-D 

(d) 1-D, 2-C, 3-A, 4-B, 5-E 

(e) 1-E, 2-D, 3-C, 4-A, 5-B 

A: Research is needed 

B: Public health intervention 

is possible immediately 

C: Epidemiologic 

surveillance needs to be 

enhanced 

D: Provider awareness 

needs to be prom promoted oted 

E: Insurance incentives can 

reduce costs to society 


Symposium 

Room 405 

2. Explain protocols for ovarian stimulation of patients with 

polycystic ovarian syndrome. 

3. Identify new lines of treatment of ovarian hyperstimulation 

syndrome. 



Patient Care 


A 29-year-old woman undergoing her first IVF trial using a 

GnRH antagonist protocol had 24 oocytes retrieved. After 

participating in this session, I will use the following for luteal 

phase support: 

a. No luteal phase support 

b. Vaginal progesterone 

c. Vaginal progesterone and estrogen 

d. Small doses of hCG 

e. GnRH agonist 

f. Not applicable to my area of practice

HUMAN OOCYTE CRYOPRESERVATION AND IN VITRO 

MATURATION 

David F. Albertini, Ph.D. (Chair) 

Kansas University Medical Center 

Thomas L. Toth, M.D. 

Massachusetts General Hospital 

Ri-Cheng Chian, Ph.D. 

McGill University 



Symposium 

Room 401 


Strategies for human ARTs have relied upon the use 

of controlled ovarian hyperstimulation for decades to 

maximize oocyte yield. The growing sense that “more” 

(oocytes) may not be “better” for live birth outcome has led 

to the notion that low stimulation or natural cycle retrievals 

may improve oocyte quality and prospects for pregnancy. 

This change in strategy provides further impetus for the 

optimization of oocyte in vitro maturation. Coupled with 

the flexibility afforded in patient management by embryo 

cryopreservation, storage of oocytes is viewed as an 

emergent and essential assisted reproductive technology. 

Thus, this symposium will critically examine both the practice 

and outcomes for human oocyte cryopreservation and in 

vitro maturation providing participants with a glimpse of 

advances being made in this area. 

DOES THE BEGINNING PREDICT THE END? EMERGENCE 

AND TREATMENT OF PCOS IN ADOLESCENCE 

Presented by the Society for Gynecologic Investigation 

Kathleen M. Hoeger, M.D. (Chair) 

University of Rochester Medical Center 


University of Pennsylvania 

R. Jeffrey Chang, M.D. 

University of California, San Diego 


Polycystic ovary syndrome (PCOS) is a common disorder 

that has its initial presentation in adolescence. While there 

are a large number of publications addressing the disease 

process and treatment in adult women with PCOS, there is 

relatively little focused on the adolescent. The diagnosis and 

treatment options for PCOS are different in the adolescent 

and the clinician is often left with little objective data to 

inform decisions. There is therefore a need to update the 

membership on the current state of knowledge surrounding 

early pathology, natural history and treatment of PCOS in 

adolescence. 



able to: 

1. Identify the common presentation dilemmas for PCOS in 

adolescence. 

67 



able to: 

1. Review past and current technologies available for the 

IVM and cryopreservation of human oocytes. 

2. Summarize the risks and benefits afforded by these 

procedures in practical translational terms. 

3. Demonstrate the advantages and disadvantages 

of current protocols as related to the development 

and application of new technologies for oocyte 

cryopreservation and IVM. 




When a mature (metaphase-2) human oocyte has been 

thawed following vitrification, after participating in this 

symposium, in my practice I will initiate either IVF or ICSI: 

a. After 3 hours of recovery following slow-freeze 

cryopreservation. 

b. As soon as possible when complete equilibration has 

been accomplished. 

c. Within one hour of recovery when the spindle and polar 

body are readily visible. 

d. At variable times, as the best time is not known. 



Symposium 

Room 505 

2. Recommend treatment options for best management of 

PCOS for the short- and long-term consequences 

identified in the adolescent. 



Patient Care 


A 15-year-old girl presents for concerns about irregular 

menses, weight gain, worsening acne and emergence of 

facial hair. She is found to have a body mass index (BMI) of 

32 kg/m kg/m2 and and there there is a hirsutism hirsutism score score of 8 on the modified 

Ferriman-Gallwey scale. Acanthosis nigricans is noted. 

Hormonal evaluation includes normal follicle stimulating 

hormone (FSH), thyroid stimulating hormone (TSH) and 

prolactin concentrations. A testosterone level is mildly 

elevated at 82 ng/dL. Normal 17-hydroxyprogesterone 

concentration is noted. After participating in this session, I 

will do the following in my practice: 

a. Order a fasting insulin level. 

b. Perform an ovarian ultrasound. 

c. Perform a fasting glucose and hemoglobin A1c (HgA1c), 

or 2-hour glucose tolerance test. 

d. Perform a body composition measurement. 

e. Perform an adrenal evaluation. 




Symposium 

ART SIMILARITIES AND DIFFERENCES AROUND THE WORLD 

Presented by the International Committee for Monitoring Assisted 

Reproductive Technology 

G. David Adamson, M.D. (Chair) 

Fertility Physicians of Northern California in Palo Alto and San Jose, 

California 

Sheryl Vanderpoel, M.D., Ph.D. 

World Health Organization 

Ragaa T. Mansour, M.D. 

The Egyptian IVF-ET Center 

Karl Gosta-Nygren, M.D. 

Sophiahemmet 

Fernando Zegers-Hochschild, M.D. 

The Clinica Las Condes 

Jacques de Mouzon, M.D. 

Cochin-Saint-Vincent De Paul 

Osamu Ishihara, M.D. 

Saitama Medical School 

Ian D. Cooke, M.D. 

University of Sheffield, Jessop Hospital 


ART is now widely practiced globally, yet wide variations in 

treatment access, efficacy and safety are reported by the 

International Committee Monitoring ART (ICMART). These 

differences occur because of socioeconomic, religious, 

cultural, regulatory and other variations among countries. 

Increased understanding of the practice of ART globally can 

help enable practitioners to improve access, efficacy and 

safety of ART in their own countries. 

Room 403 



able to: 

1. Identify 5 major factors affecting ART treatments globally 

and compare the influence of these factors on 3 countries 

from different continents. 

2. Describe why infertility is a disease and a public health 

issue. 

3. Critique different perspectives on the balance between 

efficacy of ART (live birth rates) and safety of ART (multiple 

pregnancies). 




Society for Male Reproduction and Urology Mini-Symposium 

COMPLICATED SPERM RETRIEVAL: TRICKS OF THE TRADE 

Peter N. Schlegel, M.D. 

Cornell University 


Testicular sperm extraction (TESE) is a difficult procedure with 

highly variable success rates. 

The potential to improve practice by discussion of “tricks of 

the trade” could enhance delivery of patient care. 



able to: 

1. Describe the role of microsurgery in sperm retrieval for 

non-obstructive azoospermia. 

2. Identify techniques that can be used during microTESE to 

enhance sperm retrieval results. 



Patient Care 


68 


After participating in this symposium, I will do the following in 

my practice: 

a. Treat all ART patients with the same protocol, regardless 

of race. 

b. Respond to patient questions regarding the cost of IVF 

treatment outside United States that it is almost always 

more cost-effective for them to travel abroad to obtain 

ART treatment. 

c. Tell patients infertility is an elective procedure that is 

managed entirely separately from other aspects of their 

reproductive care. 

d. Maximize the chance for pregnancy, even if it means 

that the patient is at high risk of multiple birth. 

e. Inform patients that optimal care requires a balance 

between efficacy and safety of treatment. 



A patient with non-obstructive azoospermia and his 

partner would like to use his sperm for conception. After 

participating in this session, in my practice I will advise the 

patient that the chance of sperm retrieval is highest in non- 

obstructive azoospermia patients with: 

a. Spermatic cord injury and limited testosterone 

production. 

b. Diffuse maturation arrest and normal FSH. 

c. Prior failed biopsies. 

d. Sertoli cell-only. 

e. Deletions of AZFa and AZFb regions. 



Wednesday, October 27, 2010 11:15 am – 1:00 pm 

Special Research Presentations 

11:15 am 

EVALUATING RISKS AND BENEFITS OF HORMONE 

REPLACEMENT THERAPY IN HEALTHY POSTMENOPAUSAL 

CHINESE WOMEN USING POPULATION-BASED HEALTHCARE 

DATA 

ASRM/Ortho Research Grant in Reproductive Medicine, 2009-2010 

H. Irene Su, M.D., M.S.C.E. 

University of California, San Diego 

11:30 am 

DERIVATION OF INDUCED PLURIPOTENT STEM (iPS) CELLS FROM 

MOUSE AND HUMAN AMNIOCYTES 

ASRM/EMD Serono Research Grant in Reproductive Medicine, 2008-2010 

Raymond M. Anchan, M.D., Ph.D. 

Brigham and Women’s Hospital/Harvard Medical School 

11:45 am 

IN VITRO DERIVATION OF PRIMORDIAL GERM CELLS AND 

GAMETES FROM ETHICALLY-DERIVED INDUCIBLE STEM CELLS 

ASRM/EMD Serono Research Grant in Reproductive Medicine, 2008-2010 

Sana M. Salih, M.D. 

University of Wisconsin, Madison 

PREPARING TO ENTER THE REI ARENA 




Rita Gruber, B.A. 

RMA of New Jersey, LLC 


Surgery Center at Waltham, a division of IVF Boston 


Although reproductive medicine is ever-changing through 

new science and technology, especially in recent 

years, one fundamental paradigm remains the same – 

physicians are the key drivers of both patient care and 

revenue. Indeed, the most powerful tool in healthcare is 

the physician’s pen, which makes physician recruiting a 

strategic priority for every RE practice. 

In addition to recruiting physicians, RE practices must also 

hire other high-quality professionals. Such individuals need 

the right skill set and a fundamentally positive orientation 

to work with others in a multidisciplinary team environment 

to achieve the goals and objectives of their team and 

the practice. The physicians and other professionals we 

hire today are the lifeblood of our practice tomorrow. For 

candidates, making the right career decision with the best 

employer can be almost as critical as finding a life partner. 

This symposium will review the strategies, preparation, and 

processes integral in attracting the key talent necessary 

to support our common patient-focused goals in a highly 

competitive market. 

Room 505 

69 

12:00 pm 

THE CONSEQUENCES OF CHRONIC CYTOTOXIC AND 

BIOLOGIC TREATMENTS ON OVARIAN FUNCTION IN 

RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC PATIENTS 



Tennessee Women’s Care 

12:15 pm 

OXIDATIVE STRESS AND OVARIAN AGING IN WOMEN WITH 

PCOS 


Erica B. Johnstone, M.D. 

University of Utah 

12:30 pm 

MECHANICAL BOWEL PREPARATION FOR GYNECOLOGIC 

LAPAROSCOPY: A PROSPECTIVE RANDOMIZED TRIAL OF ORAL 

SODIUM PHOSPHATE SOLUTION VERSUS SINGLE SODIUM 

PHOSPHATE ENEMA 

AAGL/SRS Jay M. Cooper Endowed Award for the Best Prize Paper on 

Minimally Invasive Gynecology 

Linda C. Yang, M.D. 

Beth Israel Deaconess Medical Center 


Symposium 

Room 501 



able to: 

1. Prepare employers to appropriately attract key talent to 

an RE practice. 

2. Identify in candidates the right competencies 

to contribute to patient success and the ability to 

accommodate the practice culture. 

3. Prepare for the interview process from the perspective of 

an employer and prospective candidate. 

4. Identify appropriate expectations from an offer of 

employment and on-boarding process. 




After participating in this session, the three (3) necessary 

components of “best practices” in professional recruitment I 

will use in my practice are: 

a. Employment Brand, Interview Protocols, and Pre-Hire 

Assessment. 

b. Employment Brand, Sourcing Program, and Pre-Hire 

Assessment. 

c. Sourcing Program, Interview Protocols, and Pre-Hire 

Assessment. 

d. Not applicable to my area of practice.

PREIMPLANTATION GENETIC DIAGNOSIS - MEETING THE 

EDUCATIONAL, EMOTIONAL AND TREATMENT NEEDS OF 

THE PGD PATIENT 


Kelly L. Lehl, R.N. (Chair) 

Colorado Center for Reproductive Medicine 

Danielle Young, M.S., C.G.C. 

Colorado Center for Reproductive Medicine 

Adrienne J. Kramer, R.N. 

Reproductive Medical Associates of New Jersey 



Symposium 

Room 405 


Advancements in preimplantation genetic diagnosis (PGD) 

technologies have resulted in an increase of IVF patients 

requesting genetic testing of their embryos. An IVF cycle 

with PGD requires unique nursing care that differs from 

standard practices. This warrants an update on the PGD 

process and how it impacts the nurse’s role in caring for 

such patients. 



able to: 

1. List the indications for PGD. 

2. Differentiate the various PGD technologies. 

3. Identify the unique needs of a PGD patient in order to 

implement necessary protocol changes. 

ADDRESSING THE COUNSELING NEEDS OF PARENTS 

CONSIDERING PGD: THE COMPLEMENTARY ROLES OF GENETIC 

COUNSELORS AND MENTAL HEALTH PROFESSIONALS 

A Joint Session presented by the Mental Health Professional Group and the 

Genetic Counseling Special Interest Group 

Julianne Zweifel, Ph.D. (Chair) 

University of Wisconsin 

Jill M. Fischer, M.S., G.C.G. 

Clinical Genetic Services 

Lauri A. Pasch, Ph.D. 

UCSF Center for Reproductive Health 

Patricia Hershberger, Ph.D., A.P.R.N., B.C. 

University of Illinois at Chicago 


Preimplantation genetic diagnosis (PGD) became an 

established technique within ASRM in 2001. Since that 

time, the indications for its use have increased with a 

corresponding increase in the number of clinics offering 

this technology. Although PGD offers information, it is 

not without limitations, complications, and risks. The 

goal of this symposium is to synthesize technical and 

applied information/experience regarding PGD from the 

perspectives of the genetics counselor, mental health 

professional, and clinical researcher in an effort to aid 

clinicians who work with couples using PGD. 

70 



Patient Care 


A 33-year-old woman who desires pregnancy has had 

24 months without conception. She has a history of three 

first-trimester pregnancy losses. Cytogenetic studies on the 

products of conception revealed trisomy 18 in one of the 

miscarriages. The patient has a normal blood karyotype. 

Her day-3 FSH level is 12.4 mIU/mL. After participating in this 

session, in my practice, PGD would be indicated for this 

patient because of her: 

a. Elevated FSH level. 

b. Two-year history of infertility. 

c. Maternal age of 34 years at delivery. 

d. Previous aneuploid pregnancy. 

e. Familial Robertsonian translocation. 



Symposium 

Room 403 



able to: 

1. Summarize basic information that is currently available 

through the use of PGD, including the strengths and 

limitations of this technology and the information that it 

provides. 

2. Implement recommendations for mental health 

professionals’ collaborative work with genetics counselors 

and clinical work with patients considering/utilizing PGD. 

3. Describe and integrate research findings on couples’ 

decision making regarding PGD. 





After participating in this session in my practice I will: 

a. Perform preimplantation genetic testing for selection of 

hair and eye color. 

b. Perform preimplantation genetic testing to select gender 

solely for family balancing. 

c. Perform preimplantation genetic testing for assessing risk 

of cerebral palsy. 

d. Perform preimplantation genetic testing to identify 

inherited diseases. 


ADVANCES IN REPRODUCTIVE SURGERY 

Keith B. Isaacson, M.D. (Chair) 

Newton-Wellesley Hospital 


Fertility Physicians of Northern California in Palo Alto and San Jose, 



Cleveland Clinic Foundation 


Reproductive Specialty Center 



Symposium 

Room 401 


This symposium will provide the latest evidence-based data 

on the value of reproductive surgery that complements 

advanced reproductive technologies. Specifically, 

the session will examine the current role of surgery for 

endometriosis and uterine fibroids as well as tubal surgery 

with IVF and hysteroscopic procedures in maximizing fertility 

outcomes for patients. 

STEM CELLS IN REPRODUCTION 

Dolores J. Lamb, Ph.D. (Chair) 

Baylor College of Medicine, Houston, TX 

Carlos A. Simon, M.D. 

Prince Felipe Research Centre 

Kirk Cheng-lun Lo, M.D. 

McGill University 


Stem cells derived from adult tissues maintain the selfrenewal 

properties required for the prevention of local 

tissue degeneration. These stem cells are present in many 

somatic tissues, including hematopoietic, hepatic, neural, 

epithelial, muscle and testis. In the testis, in addition to 

Leydig cell progenitors, a second unique type of stem cell 

exists: the spermatogonial stem cell. These cells are unique 

in that they can restore spermatogenesis as well as regain 

pluripotency. One of the main challenges in preserving 

human spermatogonial stem cells prior to gonadotoxic 

therapy in pre-pubertal cancer patients is the inability to 

mature these stem cells to spermatozoa. This symposium 

will focus on the origins and differentiation of testicular stem 

cells and the experimental models for preservation of fertility 

in male cancer patients. 

71 



able to: 

1. Summarize the latest data on endometriosis staging and 

management. 

2. Describe surgical management for uterine fibroids for 

infertility. 

3. Identify the role of tubal surgery with IVF. 

4. List fertility-enhancing hysteroscopic procedures. 



Patient Care 


After participating in this session, in my practice I will 

perform uterine fibroid surgery for fertility enhancement 

when: 

a. The fibroid is either a type I, I or II submucosal fibroid. 

b. The fibroid is pressing on the tubes and ovaries. 

c. The fibroid is intramural and the patient has unexplained 

infertility. 

d. Not applicable to my area of practice. 


Symposium 

Room 405 



able to: 

1. Differentiate between adult and embryonic stem cells 

and their potential to regenerate somatic tissues and 

germ cells. 

2. Compare and contrast various experimental methods for 

preservation of fertility in male cancer patients. 



Patient Care 


After participating in this session, in my clinical pratice I will 

offer a male cancer patient desiring to preserve his fertility 

the following option that has been proven to be effective: 

a. Spermatogonial stem cell transplantation. 

b. Cryopreservation of ejaculated sperm prior to initiation of 

chemotherapy. 

c. Extraction and cryopreservation of spermatogonial stem 

cells prior to the initiation of chemotherapy. 

d. Cryopreservation of bone marrow stem cells. 

e. In vitro culture of residual spermatogonial stem cells after 

chemotherapy. 




Symposium 


EPIGENETICS, IMPRINTING AND ADVERSE PERINATAL 

OUTCOMES: IMPLICATIONS, CERTAINTIES AND UNCERTAINTIES 

IN ART 

Catherine Racowsky, Ph.D. (Chair) 

Brigham & Women’s Hospital in Boston, Massachusetts 


National Institutes of Child Health and Human Development 

Kenneth J. Moise, Jr., M.D. 

Member, Texas Children’s Fetal Center 


Anja Pinborg 

Copenhagen University Hospital 


While the majority of reports provide reassurance that 

assisted reproductive technologies are safe, emerging data 

suggest increased risks of imprinting disorders, as well as 

other adverse perinatal outcomes in children conceived 

from ART. Reproductive specialists need to be updated 

on these risks in order to provide appropriate patient 

counseling, and to consider practice-pattern changes for 

improved patient care. 



able to: 

1. Summarize the risks and potential causes of epigenetic 

changes and imprinting disorders in children conceived 

from ART. 

2. Compare neonatal outcomes of singletons conceived 

after fresh versus cryopreserved embryo transfer. 

3. Describe adverse perinatal outcomes associated with 

monozygotic twinning. 

DEVELOPMENTS IN MALE REPRODUCTION AS SEEN 

THROUGH THE RETROSPECTOSCOPE 

Arnold M. Belker, M.D. (Chair) 

University of Louisville School of Medicine in Louisville, Kentucky 


Physicians who are new to the field of reproduction 

generally accept presently known facts without knowledge 

of the historical development of the field. The simultaneous 

development of IVF and subsequently intracytoplasmic 

sperm injection (ICSI) with urologic microsurgery resulted in 

the current state-of-the-art of the male reproductive field. 

This discussion will concern the historical development of 

the methods currently available to help men with impaired 

reproductive status have their own children. 



able to: 

1. Describe the historical development of methods to help 

subfertile men have children. 

2. Select appropriate therapy for subfertile men using an 

understanding of the historical development of various 

treatment methods. 

72 



Patient Care 


A 38-year-old woman, gravida 0, has undergone two 

failed intracytoplasmic sperm injection (ICSI) attempts 

with her 42-year-old partner who is severely oligospermic. 

It is recommended that their embryos undergo assisted 

hatching on their third ICSI attempt. They have recently 

read about an increase in the incidence of Beckwith- Beckwith- 

Wiedemann syndrome in children born from ART. They 

also have concerns regarding possible uterine receptivity 

issues in a stimulated cycle and are wondering whether 

they should freeze all their embryos and then undertake a 

cryopreserved embryo transfer. Before attempting their third 

cycle, after participating in this session, in my practice I will 

do the following in this situation: 

a. Recommend that the couple have all their embryos 

screened for Beckwith-Wiedemann. 

b. Counsel the couple that IVF may be beneficial. 

c. Tell the couple that neonates born following frozen 

embryo transfer have improved outcomes compared 

with fresh embryo transfer. 

d. Tell the couple that assisted hatching is not associated 

with an increased risk of monozygotic twinning. 



Society for Male Reproduction and Urology Mini-Symposium 

Room 4C 




In-vitro fertilization developed as a result of: 

a. A serendipitous observation that quickly resulted in the 

uniform adoption of IVF. 

b. A determined and prolonged effort by a basic scientist 

and gynecologist to achieve IVF in humans. 

c. A laboratory accident. 

d. Observations in a patient with obstructive azoospermia.


INTERACTIVE SESSIONS

SCIENTIFIC PROGRAM • INTERACTIVE SESSIONS 


Meet the Professor Interactive Session 

TARGETING STEROIDOGENESIS IN ENDOMETRIOSIS 




Interactive Session 

EMERGENCY IVF VS. OVARIAN TISSUE FREEZING 

Presented jointly by the Society for Assisted Reproductive Technology, 

the Fibroid Special Interest Group, and the Imaging in Reproductive 

Medicine Special Interest Group 

Karine Chung, M.D. (Chair) 

University of Southern California Keck School of Medicine 

Jacques G. Donnez, M.D. 

Catholic University of Louvain 


Brigham and Women’s Hospital 

Dror Meirow, M.D. 

Tel Aviv University, Israel 


American Society of Clinical Oncology guidelines 

recommend that patients facing cancer be offered, 

among other options, in vitro fertilization and ovarian 

tissue freezing. There are no clinical trials comparing and 

contrasting these approaches. In order to optimally care for 

patients, clinicians require up-to-date information in order 

to appropriately counsel and treat patients presenting for 

potential fertility preservation. 


At the conclusion of this interactive session, participants 

should be able to: 

1. List two rapid ovulation-induction protocols for 

emergency IVF and discuss in which patient populations 

each would be used. 

2. Discuss current methods of ovarian tissue freezing. 

3. List 3 advantages and 3 disadvantages of both 

emergency IVF and ovarian tissue freezing in patients 

requesting fertility preservation. 

Room 201 

Room 401 



Patient Care 

73 



Patient Care 


A 38-year-old married woman with estrogen receptor- receptor- 

positive breast cancer is referred by her oncologist for 

fertility preservation. She has one positive lymph node and 

wants to begin chemotherapy as soon as possible. After 

participating in this session, in my practice I will offer this 

patient: 

a. IVF with microdose leuprolide stimulation. 

b. IVF with a gonadotropin-releasing hormone (GnRH) 

antagonist and letrozole. 

c. Natural cycle IVF. 

d. Minimal stimulation IVF. 

e. Laparoscopy with oophorectomy and ovarian tissue 

freezing. 





IDENTIFICATION AND TREATMENT OF HYPOTHALAMIC 

ANOVULATION 

Presented by the Society for Reproductive Endocrinology and Infertility 

Sarah L. Berga, M.D. 

Emory University School of Medicine 

Samuel A. Pauli, M.D. 

Emory University School of Medicine 


Functional forms of hypothalamic anovulation, often 

termed stress-induced anovulation, are a common, but 

commonly unrecognized, cause of infertility. Behaviors 

linked to functional hypothalamic anovulation (FHA) include 

exercise, undernutrition, and psychological stress. FHA is 

theoretically reversible with behavior modification, but 

most patients are treated conventionally with ovulation 

induction and hormone replacement when fertility is not 

immediately desired. Neither the long-term individual health 

consequences of persistent FHA nor the maternal and fetal 

consequences of ovulation induction in women with FHA 

are widely appreciated. 




1. Explain how metabolic compromise and psychogenic 

challenge synergize to induce hypothalamic 



FERTILITY DECISION-MAKING FOR BRCA CARRIERS 

Presented jointly by the Society For Reproductive Endocrinology and 

Infertility and the Genetic Counseling Special Interest Group 

Glen L. Schattman, M.D. (Chair) 

Cornell University Medical Center 




BRCA carriers have a significant lifetime risk for both breast 

and ovarian cancers, and identification of a BRCA mutation 

usually prompts decisions about prophylactic surgery 

and medications. Female BRCA carriers of childbearing 

age must also determine whether and how to undergo 

cancer prophylaxis in light of plans for childbearing. ART 

may provide additional options to these women [embryo 

cryopreservation, preimplantation genetic diagnosis (PGD), 

surrogacy, egg donation], and patients’ use of these options 

may be controversial. This session will review the various 

options for fertility decision making in the context of positive 

BRCA status, and highlight areas of uncertainty. 




1. Summarize the ART options, and their attendant risks and 

benefits, available for BRCA carriers considering cancer 

prophylaxis. 

2. Assess the psychosocial impact of the family history on 

fertility decision making and factors influencing decisions 

about PGD. 

Room 405 

Room 501 



Patient Care 


74 

hypogonadism and anovulation. 

2. Identify which behaviors and attitudes compromise fertility 

and by what mechanisms. 

3. Counsel patients with functional hypothalamic 

amenorrhea / anovulation about the benefits and 

limitations of pharmacologic versus nonpharmacologic 

strategies for wellness and fertility. 



Patient Care 


After participating in this session, in my practice I will use 

the following treatment for restoration of ovulatory cycles 

and conception in a woman with functional hypothalamic 

amenorrhea/stress-induced anovulation: 

a. Oral contraceptives 

b. Stress management techniques 

c. Metformin 

d. Psychiatric referral 

e. Bisphosphonate use 



A 30-year-old, recently married woman has been identified 

as a BRCA1 mutation carrier. She has a family history of 

both ovarian cancer and breast cancer. She is seeking 

options for fertility, although she is not yet ready to become 

pregnant. She is contemplating both mastectomy and 

salpingo-oophorectomy for cancer risk reduction. After 

participating in this session I would counsel this patient that 

with these options: 

a. There is a possible increased risk of diminished ovarian 

reserve, but likely no effect of gonadotropins on cancer 

risk. 

b. There is no difference in ovarian reserve, and likely no 

effect of gonadotropins on cancer risk. 

c. There is a possible increased risk of diminished ovarian 

reserve, and limited data on the effect of gonadotropins 

on cancer risk. 

d. There is no difference in ovarian reserve, and limited data 

on the effect of gonadotropins on cancer risk. 

e. There is possible increased risk of diminished ovarian 

reserve, and likely an increased risk for cancer with use of 

gonadotropins. 

f. There is no difference in ovarian reserve, and likely an 

increased risk for cancer with use of gonadotropins. 

g. Not applicable to my area of practice.




GENOMICS VERSUS METABOLOMICS IN EMBRYO SELECTION 

FOR ELECTIVE SINGLE EMBRYO TRANSFER (eSET) 

Presented by the Reproductive Biology Professional Group 

Sangita K. Jindal, Ph.D. (Chair) 

Albert Einstein College of Medicine 

Dagan Wells, Ph.D. 

University of Oxford 

Emre Seli, M.D. 

Yale School of Medicine 


Decreasing multiple gestations while maintaining or 

improving overall pregnancy rates remains one of the most 

significant contemporary goals in the treatment of infertility. 

Practitioners need to achieve an understanding of the 

emerging technologies for embryo viability assessment in 

ART laboratory. 




1. Summarize the need for an improvement in embryo 

assessment in the ART laboratory. 

2. Outline the emerging diagnostic modalities for the 

assessment of embryo viability. 

Room 503 

75 



Patient Care 




MECHANICAL HAIR REMOVAL: WHAT OUR PATIENTS ARE 

DOING AND WHAT WE SHOULD KNOW ABOUT IT 

Presented jointly by the Mental Health Professional Group and 

the Androgen Excess Special Interest Group 

Lauri A. Pasch, Ph.D. (Chair) 



University of Wisconsin, Madison 


Hirsutism is the presence of excess coarse hair in females, 

distributed on the chin, upper lip, chest, abdomen or back. 

Hirsutism is a common manifestation of the underlying 

endocrine disorder, polycystic ovary syndrome. In addition 

to pharmacological treatments (e.g., hormone therapy), 

mechanical methods of hair removal (e.g., plucking, 

shaving, laser treatment) play a central role in treatment 

of hirsutism. In many cases, mechanical removal is used 

adjunctively with pharmacological methods, because 

pharmacological treatment is only partially or temporarily 

effective. Although gynecologists and reproductive 

endocrine physicians are not direct providers of mechanical 

hair removal, knowledge about these procedures, and their 

risks and benefits, is essential to providing complete care to 

hirsute patients. In addition, understanding the psychosocial 

burden associated with hirsutism will help physicians assist 

their patients in choosing the best individualized course of 

treatment. 




1. Describe the use patterns of mechanical hair removal 


A 35-year-old woman and her husband, who have never 

achieved pregnancy, have gone through two IVF-ET cycles 

in your practice. In both cycles, the patient responded well 

and had good fertilization resulting in several high-quality 

embryos, of which one was transferred back to the patient. 

They requested a single-embryo transfer (SET) for each 

cycle, because multifetal reduction is not an option for 

them. Neither cycle resulted in pregnancy and the couple’s 

inability to conceive remains unexplained. The patient 

desires one more IVF-SET attempt before discussing other 

procreative options. 


following in this situation: 

a. Consider genomic assessment of embryo viability. 

b. Consider metabolomic assessment of embryo viability. 

c. Consider a third cycle with no additional assessment of 

embryo viability. 

d. Discuss all of the above with the couple, as none has yet 

been proven to result in improved outcome in this 

situation. 


Room 505 

techniques and their relative risks and benefits. 

2. Describe the psychosocial burden associated with 

hirsutism. 

3. Formulate an approach to integrative individualized care 

for the hirsute patient. 



Patient Care 



A 35-year-old healthy woman with amenorrhea, polycystic 

ovaries by ultrasound, and significant “male-pattern” hair 

growth on her chin, upper back, and chest presents with 

concerns about the underlying cause of these symptoms and 

her future fertility. She has relatively light skin and dark hair. After 

participating in this session, I will do the following in this situation: 

a. Recommend laser treatment as the first line of treatment 

because of her skin tone and hair color, if it is financially 

feasible for her. 

b. Use hormone therapy in combination with spironolactone 

during the time when she is not trying to get pregnant. 

c. Clarify the patient’s current goals with her and formulate 

a plan that best meets them, mindful that recommending 

treatments without consideration of goals could leave 

the patient feeling misunderstood. 

d. Tell the patient that mechanical methods of treatment 

are often used, but that she needs to discuss them with a 

cosmetologist who knows more about them. 

e. Tell the patient that hirsutism is not a threat to her health, 

most treatments for hirsutism are only partially effective, 

and she will need to learn to accept her unwanted hair. 





ENVIRONMENTAL TOXINS AND RISK OF INFERTILITY, 

PREGNANCY LOSS AND GYNEPATHOLOGY 

Presented jointly by the Environment and Reproduction Special Interest 

Group 

Susan H. Benoff, Ph.D. (Chair) 

New York University School of Medicine 

Stacey A. Missmer, Sc.D. 

Harvard Medical School 

Russ B. Hauser, M.D., Sc.D., M.P.H. 

Harvard School of Public Health 


Exposure of animal models to low levels of toxicants 

typically found in the environment [such as current-use 

pesticides, phthalates, bisphenol A, and dioxins (TCDD)] 

adversely affects reproductive health. However, the effect 

of these “background” exposures on fertility, pregnancy 

outcomes, and the development of endometriosis or uterine 

fibroids remains controversial. These disorders contribute 

significantly to public health care costs. The general 

population prevalence of endometriosis is estimated to be 

5-10%; however, among those presenting with infertility or 

pelvic pain that is refractory to medical management, the 

prevalence may be as high as 40%. Conservative estimates 

suggest that the prevalence of uterine fibroids is 25%, while 

within subpopulations the prevalence has been observed to 

be > 70%. In addition, fibroids are the primary indication for 

one third of hysterectomies. Clarifying associations between 

toxicant exposures and infertility and these disease states 

may lead to etiologic insights that could benefit diagnosis 

and treatment, and minimize co-morbid consequences. 

Key research issues include exposure timing and dose 

assessment, case definitions and selection of valid control 

populations. Clinicians may not know if environmental 

toxicant exposures have contributed to a woman’s 

infertility or gynepathology and currently are not able to 

provide answers to patients’ questions concerning disease 

remediation and prevention of further complications with 

respect to toxin exposures. 

Room 403 

76 




1. Describe the complexities of exposure measurement and 

study design in investigations of the relationship between 

environmental toxicants and infertility and 

gynepathology. 

2. Summarize the contribution of developmental timing of 

exposure, metabolism, and lifestyle characteristics to the 

female reproductive effects of different toxicants. 

3. Identify areas where critical information is lacking and 

specify needs for future studies. 




A clinician working in a community where most residents 

are employed by the local chemically based industrial 

plant believes that she is observing a rate of endometriosis 

that is greater than would be expected among her 

patients. Increasingly, the patients want to know if 

anything they or their families did could have caused the 

endometriosis. The clinician would also like to determine if 

there are life changes that they should be recommending 

and have begun to collect serum samples in which 

tetrachlorodibenzodioxin (TCDD) levels will be measured. 

Which of the following design and data collection elements 

should NOT be included to conduct a valid investigation of 

the relation between dioxins and endometriosis? 

a. Enrollment of laparoscopically confirmed endometriosis 

case women. 

b. Enrollment of laparoscopically disconfirmed control 

women. 

c. Enrollment of both fertile and subfertile control women 

d.Collection of anthropometric and cigarette-use details 

during childhood, adolescence and adulthood. 

e. Collection of details of geographic residence during 

childhood, adolescence and adulthood.




TESTOSTERONE REPLACEMENT IN HYPOACTIVE SEXUAL 

DESIRE DISORDER: AN INTERACTIVE DEBATE 

Presented jointly by the Sexuality Special Interest Group 

Elizabeth E. Puscheck, M.D. (Chair) 

University Women’s Care-Detroit 

John E. Buster, M.D. 

Women and Infants Hospital 


University of Colorado Denver School of Medicine 


Many physicians consider female sexual dysfunction and 

hypoactive sexual desire disorder (HSDD) to be intractable 

and difficult to treat. They generally avoid discussing it 

with their patients. Few are familiar with the endocrinology 

of HSDD (ICD-9 code, 799.82), the impact of age-linked 

decline in androgen production, and the adverse 

psychological impact of HSDD on the lives and partners of 

older women. Finally, most physicians are unaware of wellpowered 

clinical trials documenting Level I effectiveness 

and safety of transdermal testosterone. This therapy is 

controversial, and there is need for a debate forum, which 

will provide an environment for an objective assessment of 

therapy risks and benefits. 




1. Identify the clinical circumstances of women most likely to 

benefit from testosterone as part of their hormonal 

therapy. 

2. Counsel women considering testosterone therapy for 

HSDD about the reasons for possible lack of efficacy and 

the short- and long-term health concerns. 

3. Prescribe transdermal testosterone. 

Room 203 

77 



Patient Care 



Four months ago and on your recommendation, a 48-year- 48-year- 

old divorced woman, gravida 3, para 3, underwent total 

hysterectomy and bilateral salpingo-oophorectomy 

for menorrhagia. She has begun a new and exciting 

relationship where sexual activity is very important. After 

the surgery, you treated her for vasomotor symptoms with 

transdermal estradiol, 0.0375 mg per day. She reports 

now that her relationship is in jeopardy because she has 

completely lost interest in sex since her surgery. After 

participating in this session in my practice I will do the 


a. Discontinue the transdermal estradiol and prescribe 

micronized oral estradiol. 

b. Prescribe a mood elevator for depression. 

c. Add testosterone gel to the transdermal estradiol. 

d. Refer her to a psychiatrist for supportive therapy. 

e. Prescribe a 1/20 oral contraceptive. 





GENOTYPES AND PHENOTYPES IN PCOS 




Menopause Day Interactive Session 

CARDIOVASCULAR RISK IN MENOPAUSE: CLINICAL TOOLS 

AND EFFECTS OF HORMONE THERAPY 





Therapy for menopausal symptoms is focused on treating 

the underlying cause or symptoms and the selection 

of hormonal versus non-hormonal treatments must be 

tailored to a woman’s specific circumstances, with special 

consideration of her cardiovascular risk. Cardiovascular 

disease (CVD) is still the largest single cause of death among 

women and accounts for 1/3 of the deaths. Physicians need 

guidance in prescribing menopausal hormone therapy and 

interpreting the alternative approaches to management 

of menopause. In a 2009 survey of practicing reproductive 

care physicians, only 34% correclty identified the role 

of menopausal hormone therapy in prevention and risk 

reduction. This session will discuss the clinical use of hormone 

therapy in the menopausal woman in light of cardiovascular 

risk. 

Room 201 



Patient Care 


78 




1. Discuss the risks and benefits of hormone therapy in the 

menopausal woman. 

2. Counsel patients regarding the available data on 

cardiovascular risk and hormone therapy. 

3. Discuss the timing hypothesis and its impact on treatment 

decisions. 



Patient Care 


A 37-year-old woman has stopped oral contraceptive 

pills to attempt conception. She fails to menstruate and 

ultimately is diagnosed with primary ovarian insufficiency. 

She is started on hormone therapy and ultimately adopts a 

child. She presents for her well woman visit at age 43 having 

been on hormone therapy for 5 years. After participating in 

this session, in my practice I will advise the following for this 

patient: 

a. Stop hormonal therapy as she has taken this for more 

than 5 years and her risks now increase. 

b. Switch to oral contraceptive pills which have less risk. 

c. Stop hormone therapy, see if she has symptoms and then 

can restart only if symptoms recur. 

d. Continue hormone therapy at this time. 





ANEUPLOIDY SCREENING FOR RECURRENT PREGNANCY LOSS 

Presented by the Preimplantation Genetic Diagnosis Special Interest Group 




Although the immunology of recurrent pregnancy loss 

has been a topic for intense discussion for over 50 years, 

there remain few noncontentious, specific immunologic 

tests or treatments for the disorder. The same is true for the 

more modern question of immune causes and treatments 

for infertility and IVF failure. Practitioners continue to 

be confused about what specific tests to order and 

treatments to offer. What should be ordered to diagnose 

the antiphospholipid syndrome? Should we be assessing 

all patients with recurrent pregnancy loss and infertility for 

autoimmune thyroid disease and celiac disease? Should we 

send an antinuclear antibody (ANA) or rheumatoid factor 

test? Are treatments with leukocyte immunization or IVIG 

accepted or banned? In this session, two respected voices 

in the field of reproductive immunology will assess these and 

other tests and treatments for autoimmunity in recurrent 

pregnancy loss and fertility patients, giving their own 

practice guidelines in a multiple-question debate format. 

Audience participation will be encouraged. 

Room 405 

79 




1. List the advantages and disadvantages of testing for 

antithyroid antibodies, celiac disease, rheumatoid 

diseases, and the antiphospholipid syndrome in patients 

with a history of recurrent pregnancy loss (RPL), infertility 

and/or recurrent IVF failure. 

2. List the advantages and disadvantages of IVIG, leukocyte 

immunization, corticosteroid, thyroid hormone and 

antithrombotic therapy in patients with RPL, infertility or IVF 

failure of a presumed autoimmune etiology. 



Patient Care 


Which antiphospholipid antibodies have been shown to be 

associated with recurrent pregnancy loss? 

a. IgG Anticardiolipin 

b. IgM Anticardiolipin 

c. Lupus anticoagulant 

d. All of the above 

e. None of the above




OLIGOSPERMIA: THE BENEFIT OF DIAGNOSING AND 

TREATING THE MALE 

A Joint Session presented by the Society for Male Reproduction and Urology 

and the Society for Reproductive Endocrinology and Infertility 

Stanton C. Honig, M.D. (Chair) 

University of Connecticut 

Robert E. Brannigan, M.D. 

Northwestern University, Feinberg School of Medicine 


University of Colorado 


While some recent reports have called for a limited role for 

the urologist in evaluating and treating infertile men, the 

urologist must continue to have a central role in providing 

the comprehensive care that infertile couples deserve. 

Identification of significant medical pathology, evaluation 

for underlying genetic causes, and provision of treatment for 

treatable causes of oligospermia are examples of the role of 

the urologist in diagnosing and treating the infertile male. 

ERADICATION OF ENDOMETRIOSIS WITH SURGERY: 

BEST TECHNIQUES 

Presented by the Society of Reproductive Surgeons 

Gary N. Frishman, M.D. (Chair) 

The Warren Alpert Medical School of Brown University 

Ceana Nezhat, M.D. 

Northside Hospital 

Anthony Luciano, M.D. 

University of Connecticut School of Medicine 


Reports of new approaches to diagnosis and treatment 

of endometriosis are published regularly. Some warrant 

practice pattern changes and the need to educate 

practitioners in reproductive medicine. There is a wide 

variety of practice patterns in the surgical treatment of 





1. Describe and judge treatment options for endometriomas 

2. Summarize and compare treatment options for different 

stages of endometriosis, including resection versus 

ablation. 

3. Review instrumentation and energy sources in eradicating 


Room 403 

80 




1. Identify common treatable causes of oligospermia. 

2. Describe the role of the urologist in the evaluation of the 

infertile male. 



Patient Care 



Room 401 


A 35-year-old male has a semen analysis that demonstrated 

a volume of 3.0 mL, sperm density of 1 x 106 sperm/mL, 

motility of 40%, and borderline morphology. He and his 

partner desire pregnancy. After participating in this session, 

in my practice I will do the following: 

a. Schedule the patient for varicocele surgery. 

b. Order a Y-chromosome microdeletion assay. 

c. Prescribe 3 months of clomiphene citrate therapy for the 

male partner. 

d. Perform a prostate-specific antigen (PSA) test. 

e. Recommend the couple move to IVF with ICSI. 




Patient Care 


A 32-year-old gravida 0 woman presents with infertility of 18 

months duration and signs and symptoms consistent with 

a 3 cm left endometrioma and endometriosis in her pelvis. 

She is considering a surgical approach. After participating in 

this session, in my practice I will: 

a. Perform fenestration and coagulation and stripping of 

the cyst wall (cystectomy) as this will give comparable 

results for fertility and pain relief. 

b. Prescribe a gonadotropin-releasing hormone (GnRH) 

agonist, such as leuprolide acetate, given for 6 months, 

as this will give a comparable pregnancy rate compared 

with surgical therapy. 

c. Remove the entire lesion if attempts are made to excise 

any endometriosis found. 

d. Consider pain management more important than fertility 

therapy. 

e. Tell the patient that if she elects observation, there is a 

50% chance her endometriosis will resolve spontaneously. 





UNIQUE CHALLENGES IN THE CARE OF THE ONCOFERTILITY 

PATIENT 

Presented by the Fertility Preservation Special Interest Group 

Nicole L. Noyes, M.D. (Chair) 

New York University School of Medicine 

Clarisa R. Gracia, M.D. 

University of Pennsylvania 


Fertility preservation ranks as one of the greatest 

concerns for women and girls newly diagnosed with a 

treatable malignancy. As technological advancements 

continue in this field, more patients are pursuing fertility 

preservation than ever before. Consequently, reproductive 

endocrinologists must be keenly aware of particular 

clinical situations that may be encountered. In this session, 

we will present a series of clinical scenarios to illustrate 

management complexities and offer suggestions for optimal 

patient care. 




1. Outline options for female fertility preservation. 

2. Offer fertility preservation options to patients with specific 

cancer diagnoses. 

CLINICAL CHALLENGES IN THE CONTROLLED OVARIAN 

STIMULATION IN POOR AND HIGH RESPONDERS 

Presented by the Latin American Association for Reproductive Medicine 

(ALMER) 

Carlos E. Sueldo, M.D. (Chair) 

University of California San Francisco-Fresno 


Colorado Center of Reproductive Medicine 

Claudio A. Benadiva, M.D. 

University of Connecticut 


Controlled ovarian stimulation in poor responders, as well 

as in young polycystic ovary syndrome (PCOS) patients 

undergoing assisted reproductive technology procedures, 

constitutes a great challenge for clinicians. Several protocols 

have been proposed, and their proper utilization is a matter 

of great interest, as they should optimize the pregnancy 

rates while keeping potential complications at a minimum. 




1. Identify the best ART protocol for ovarian stimulation of 

hyper-responders in order to minimize the risks of severe 

ovarian hyperstimulation syndrome (OHSS). 

2. Select the protocol most likely to optimize the ovarian 

response among patients with compromised ovarian 

reserve. 

Room 501 

81 



Patient Care 


A 32-year-old single woman previously treated with 

standard chemotherapy (ABVD) for Hodgkin’s lymphoma 

has now been diagnosed with Stage IV recurrent disease 

requiring bone marrow transplantation for potential cure. 

A discussion of this patient’s fertility preservation options 

should include: 

a. Medical prognosis 

b. Partner status 

c. Oocyte cryopreservation 

d. Embryo cryopreservation 

e. All of the above 



Room 207 



Patient Care 


A 29-year-old infertile female with diagnosed PCOS 

has failed to conceive after several cycles of ovulation 

induction with different oral and injectable agents. No other 

infertility factors are present. She had controlled ovarian 

stimulation for ART using recombinant follicle-stimulating 

hormone (r-FSH) after ovarian suppression with leuprolide 

acetate, but the cycle was cancelled due to the risk of 

severe OHSS. During her next cycle, she is using a lower dose 

of r-FSH initiated after oral contraceptives. Gonadotropin- 

releasing hormone (GnRH) antagonist was started on her 

6th day of stimulation; today her leading follicles are in the 

16-19 mm range with a serum estradiol of 4,200 pg/mL. After 

participating in this session, in my practice at 35-36 hours 

prior to oocyte aspiration, I will administer: 

a. r-HCG 250 µg subcutaneously (SC) 

b. HCG 5,000 units 

c. HCG 10,000 units 

d. Leuprolide acetate 1 mg SC 

e. HCG 1,000 units 

f. Not applicable to my practice




LEGAL IMPLICATIONS OF ART LABORATORY ERRORS 

A joint session presented by the Reproductive Laboratory Technologists 

Professional Group and the Legal Professional Group 

Michael Stahler, Ph.D. (Chair) 

EmbryoWorks 

Nidhi Desai, J.D. 

Ballard, Desai, Bush-Joseph and Horwich 

Jacob F. Mayer, Jr., Ph.D. 

Eastern Virginia Medical School 


This session will offer insight and strategies for addressing the 

issue of laboratory errors in A.R.T. While such laboratory errors 

are rare, the legal, financial and emotional consequences 

can be enormous for both the A.R.T. center and the 

couple(s) involved. This session will help participants 

recognize the greatest areas of risk, and provide 

approaches that they may utilize to reduce the occurrence 

of laboratory errors. 




1. Describe what defines a laboratory mistake and 

summarize the strategies and systems that help reduce 

the potential for laboratory errors. 

2. Discuss the substantial legal consequences of A.R.T. 

laboratory errors, including lawsuits 

3. List a set of communication actions in the event that a 

laboratory error occurs. 


Patient Care 

Room 203 

82 


An embryologist working in the ART laboratory has several 

cases for the day. The first procedure is to perform ICSI on 

the eggs of a patient who has tubal factor with one prior 

ART pregnancy and normal semen parameters for her 

partner. The following day the same embryologist performs 

a fertilization check and finds that 12 of 15 of the patient’s 

eggs have fertilized normally. In documenting the results 

on the patient’s worksheet, the embryologist realizes that 

the incorrect sperm (i.e. not her partner’s) have been used 

to inject the eggs. The embryologist is extremely upset and 

discusses the incident with his laboratory coworkers. After 

much internal debate they inform the Laboratory Director 

of the error, who in turn informs the Medical Director. 



a. Immediately call and inform the couple whose eggs 

were incorrectly inseminated and offer them a free cycle. 

I would also immediately terminate the embryologist 

who made the error. I would not involve the couple 

whose sperm was used to incorrectly inseminate the 

eggs. 

b. Immediately have the individuals involved (Laboratory 

Director, Medical Director and Embryologist) meet and 

discuss the situation in detail, initiate an investigation into 

how the error occurred, identify any gaps in the process, 

document in writing a corrective action plan, perform a 

disciplinary action on the involved embryologist that 

would include removal from performing laboratory 

procedures for some period of time, and then call both 

couples involved in the error. 

c. Immediately be upset and worried, but would inform 

the laboratory to report to the couple involved that 

no fertilization took place, perhaps offer a discount on a 

second ART cycle, and leave it at that. 

d. Inform the laboratory to wait to continue to culture the 

fertilized eggs to see how embryo development 

progressed. At some point prior to ET I would make a 

decision whether to inform the couple what happened 

or whether to simply not perform a transfer of any 

embryos and simply inform the patients that their embryos 

were not suitable for ET and wait to see what response 

the couple pursues. 





REPRODUCTIVE OPTIONS AND LEGAL ISSUES OF 

SAME-SEX COUPLES 

Presented by the Women’s Council 

Deborah L. Smith, M.D. (Chair) 

Rocky Mountain Fertility Center 

Melissa B. Brisman, Esq. 

Melissa B. Brisman, Esq., LLC 

Arlene J. Morales, M.D. 

Fertility Specialists Medical Group 


The procreative desires of same-sex couples have unique 

concerns that need to be addressed. These warrant 

practice pattern changes and the need to educate 

practitioners in reproductive medicine on the changing 

medical, legal and federal regulations [U.S. Food and 

Drug Administration (FDA)testing] involving the treatment 

of same-sex couples. Specifically, the changing legal 

environment may affect procreative choices for some 

same-sex couples; therefore, additional educational 

activities designed to update physicians regarding these 

unique challenges are warranted. 




1. Identify the ancillary professionals needed to address the 

unique issues of reproductive care of same-sex couples. 

2. Develop a comprehensive multidisciplinary approach to 

procreative management of reproductive care for samesex 

couples. 

Room 505 



83 


A same-sex male couple living abroad has contacted 

a surrogacy agency to arrange for an egg donor and 

gestational carrier treatment cycle. The agency contacts 

the physician to make arrangements after a legal contract 

is arranged between a previously proven gestational carrier 

and a previously proven egg donor. Both the oocyte donor 

and gestational carrier are married. The same sex couple 

desire to create embryos using sperm from both, dividing 

the number of oocytes fertilized evenly between the two. 

The gestational carrier lives in the city where the physician 

practices, the donor lives on the opposite coast in the 

United States and the same-sex couple lives in France. 

The physician is asked by the agency to evaluate the 

gestational carrier and conduct a phone interview with the 

donor. After participating in this session, in my practice I will 

do the following in this situation: 

a. Establish a physician-patient relationship with all the 

parties involved, including the same-sex male couple, 

and the gestational carrier and the egg donor and their 

spouses. 

b. Establish patient care only with the gestational carrier 

and egg donor. 

c. Be obligated only to the same-sex couple. 

d. Not be involved unless all four individuals have had a visit 

with the physician in person. 

e. Have no involvement with the spouses of the gestational 

carrier and egg donor. 





GHRELIN, AGING AND REPRODUCTION 





TRADITIONAL CHINESE REMEDIES FOR ENDOMETRIOSIS: 

MECHANISMS AND EFFICACY OF HERBS AND ACUPUNCTURE 

A Joint Session presented by the Chinese Special Interest Group and the 

Endometriosis Special Interest Group 

Pamela Stratton, M.D. (Chair) 

National Institute of Child Health and Human Development 

Caihong Ma, M.D. 

Peking University Third Hospital 


Endometriosis is a challenging medical problem worldwide. 

In Western medicine, nonsurgical management of 

endometriosis is disappointing. Traditional Chinese medicine 

(TCM) has over five thousand years of history, and it 

has been an effective treatment option in managing 

endometriosis in Asia. However, its efficacy and mechanisms 

are not well understood, and it has not been well-accepted 

in the Western world. 




1. Outline the basic concepts of TCM. 

2. Summarize the mechanisms of TCM in the treatment of 


Room 201 

Room 405 

84 





Patient Care 


Traditional Chinese medicine (TCM) includes internal 

and external treatments. Internal treatment consists of 

syndrome-differentiated treatment, periodic therapy, and 

specially prescribed herb remedies. The TCM external 

treatment consists of Chinese herbal enema, medicinal 

plaster and acupuncture. In response to a patient asking 

about TCM for treating endometriosis, after participating in 

this session, in my practice I will: 

a. Explain that in TCM, the pathogenesis of endometriosis 

may include Qi stagnation and blood stasis, cold 

accumulation and blood stasis, kidney deficiency and 

blood stasis and interior obstruction of stagnant heat. 

b. Tell the patient that auricular seed-embedding has no 

effect in treating endometriosis. 

c. Explain that Shangqiu (SP 3), Fei Yang (UB 58), and Cheng 

Jian (CV 24) are commonly-used acupuncture points in 

treating endometriosis. 

d. Explain that the principle of TCM in treating endometriosis 

is to focus on increasing body fluids to prevent blood 

stasis. 





FIBROIDS AND IMAGING TECHNOLOGY: DIAGNOSTIC AND 

THERAPEUTIC INNOVATIONS/SURGICAL VS. NONSURGICAL 

TREATMENT OF FIBROIDS IN THE INFERTILE COUPLE 

Presented jointly by the Fibroid Special Interest Group and the Imaging 


Laurel A. Stadtmauer, M.D., Ph.D. (Chair) 

Jones Institute for Reproductive Medicine 

Gloria Richard Davis, M.D. 

Meharry Medical College 

Elizabeth A. Stewart, M.D. 

Mayo Clinic 


The impact of intramural uterine fibroids on fertility is not 

fully understood. Myomectomy has been the standard 

treatment for symptomatic patients desiring fertility; however 

the impact of myomectomy on fertility, as well as on IVF 

outcome, needs further clarification. Newer technologies 

such as MRI-guided focused ultrasound treatment (FUS) 

and uterine artery embolization (UAE) are currently under 

study in subjects with fibroids who still desire fertility. It will be 

important for clinicians to be aware of the latest data on 

the impact of these technologies on ovarian and uterine 

function and pregnancy outcomes, as well as appropriate 

indications and patient selection for these newer 

technologies. 



able to: 

1. Summarize the current literature regarding the impact 

of fibroids on fertility and the outcomes of myomectomy 

(abdominal, laparoscopic, or hysteroscopic) as they 

affect fertility, as well as on IVF outcomes. 

2. Discuss the indications for MRI-guided high intensity FUS or 

UAE or other newer technologies in fibroid management 

of infertile patients. 

Room 401 

85 

3. Inform patients of the risks associated with each 

procedure and its impact on potential fertility. 

4. Counsel infertile couples regarding various options once 

the fibroids are diagnosed including: observation (no 

intervention) and proceeding with fertility treatments; 

newer noninvasive treatments for fibroids in those desiring 

fertility; or myomectomy prior to fertility treatments. 



Patient Care 


A 38-year-old gravida 0 woman presents with menorrhagia 

and 2 years of infertility. A diagnostic ultrasound reveals 

multiple fibroids, the largest of which is 4 cm subserosal. 

There are 3 additional intramural fibroids that are 1-2 cm 

each, and one is 2.5 cm submucosal, type 1. Laboratory 

evaluation shows her hemoglobin level is 11 mg/dL, 

pregnancy test is negative, and TSH and prolactin levels 

are normal. Hysterosalpingography (HSG) documented 

patent tubes. Her husband’s semen analysis is normal. After 

participating in this session, in my practice I will: 

a. Counsel the patient to continue to try to get pregnant 

using ovulation predictor kits and timed intercourse. 

b. Prescribe leuprolide depot therapy for 3 months, then 

abdominal myomectomy. 

c. Perform hysteroscopic myomectomy and reevaluate 

after a few months of aggressive infertility therapy if not 

pregnant. 

d. Use MRI-guided high-intensity focused ultrasound to the 

largest fibroid only. 

e. Use UAE to treat all of the fibroids concurrently and then 

use fertility drugs. 





OPTIMIZING FERTILITY IN AN ARTIFICIAL WORLD: THE ROLE 

OF CALORIES AND NUTRIENTS IN MANAGING OBESITY AND 

LOW BODY WEIGHT 

Presented by the Nutrition Special Interest Group 

Gilbert B. Wilshire, M.D. (Chair) 

Mid-Missouri Reproductive Medicine and Surgery 

Dian Shepperson-Mills, Cert. Ed., B.A., Dip. I.O.N., M.A. 

The Endometriosis and Fertility Clinic 


Obesity in women—and especially obesity associated with 

polycystic ovary syndrome (PCOS) and insulin resistance—is 

a very common and widespread phenomenon. Women 

with this condition have a special metabolism and “one-sizefits-all” 

dietary recommendations for the general population 

fall short when treating these women in particular. 

Nutritional advice for special subsets of patients is evolving 

as scientific evidence and data mount, and there is much 

confusion among practitioners with regard to the current 

state-of-the-art in nutritional recommendations, since 

conflicting views abound. 

Low weight in women associated with infertility has been 

identified from American body mass index data. Causes 

of low weight are varied, and may be due to dieting, 

malabsorption of nutrients, extreme exercise or eating 

disorders. We will look at research pertaining to low body 

weight and infertility and how nutritional counseling may 

support dietary advice given to this group. 

SCREENING FOR AUTOIMMUNITY IN RECURRENT PREGNANCY 

LOSS: CASH COW OR EVIDENCE-BASED MEDICINE? 

Presented by the Reproductive Immunology Special Interest Group 

Danny J. Schust, M.D. (Chair) 

University of Missouri 

William H. Kutteh, M.D., Ph.D. 

University of Tennessee Health Sciences Center, Memphis 


UMDNJ-Robert Wood Johnson Medical School 


Although the immunology of recurrent pregnancy loss (RPL) 

has been a topic for intense discussion for over 50 years, 

there remain few noncontentious, specific immunologic 

tests or treatments for the disorder. The same is true for the 

more modern question of immune causes and treatments 

for infertility and IVF failure. Practitioners continue to 

be confused about what specific tests to order and 

treatments to offer. What should be ordered to diagnose 

the antiphospholipid syndrome? Should we be assessing 

all RPL and fertility patients for autoimmune thyroid disease 

and celiac disease? Should we send antinuclear antibody 

(ANA) or rheumatoid factor tests? Are treatments with 

leukocyte immunization or IVIG accepted or banned? 

In this symposium, two respected voices in the field of 

reproductive immunology will assess these and other tests 

and treatments for autoimmunity in recurrent pregnancy loss 

and fertility patients, giving their own practice guidelines in a 

multiple question debate format. Audience participation will 

be encouraged. 

Room 607 

86 




1. Identify the common metabolic issue that links obesity, 

ovulatory dysfunction, and resistance to weight loss. 

2. Formulate strategies for effective clinical compliance for 

positive outcomes. 

3. Examine and develop nutritional advice and counseling 

strategies for both overweight women with PCOS and 

low-weight women in the practice in order to improve 

their fertility outcomes. 



Patient Care 


After participating in this session, in my practice, I will: 

a. Assess nutritional status only in female patients with PCOS 

who are overweight/obese. 

b. Ascertain the nutritional status of the both the patient 

and her partner as part of the initial infertility workup. 

c. Prescribe folic acid and multivitamin therapy for 

all infertility patients without performing a nutritional 

evaluation. 

d. Not assess the nutritional status of the infertile couple. 

e. Not applicable in my area of practice 



Room 505 




1. List the advantages and disadvantages of testing for 

antithyroid antibodies, celiac disease, rheumatoid 

diseases, and the antiphospholipid syndrome in patients 

with a history of recurrent pregnancy loss, infertility and/or 

recurrent IVF failure. 

2. List the advantages and disadvantages of IVIG, leukocyte 

immunization, corticosteroid, thyroid hormone and 

antithrombotic therapy in patients with RPL, infertility or IVF 

failure of a presumed autoimmune etiology. 


Medical Knowledge, Patient Care 


A 29-year-old, G3 P0030 woman comes to your office 

for advice about recurrent pregnancy loss. All of her 

losses have occurred at 8-10 weeks’ gestation and 

after documentation of fetal heart tones. Two of the 

losses were passed spontaneously, one required uterine 

evacuation. None of the fetal tissues were karyotyped. After 

participating in this session as part of my standard work-up 

for recurrent pregnancy loss in my practice, I will test for: 

a. IgA anticardiolipin antibody 

b. Anti-thyroid peroxidase antibodies 

c. Lupus anticoagulant 

d. Anti-nuclear antibodies (ANA) 

e. Anti-trophoblast antibodies 

f. Not applicable to my area of practice




ALTERNATIVE APPROACHES TO MANAGE A COUPLE’S 

FERTILITY: HELPING THE MIND AND BODY WORK TOGETHER 

Presented jointly by the Society for Assisted Reproductive Technology and 

the Mental Health Professional Group 

Christopher S. Sipe, M.D. (Chair) 

Fertility Centers of Illinois 


Boston IVF 


Physicians focus on the body and the mechanics of fertility, 

while mental health experts concentrate on the mind’s 

impact in reproduction. Both are critical to a couple’s 

success. Medical specialists and mental health providers 

need to develop an integrated approach to assist couples 

in navigating their fertility journey. 




1. Debate evidence-based methods to support couples 

in balancing their psychological needs with infertility 

treatments. 

2. Differentiate between mind/body approaches that can 

increase the efficacy of infertility treatment and those that 

may be harmful. 

HOW MIGHT WE THINK ABOUT SEX SELECTION? CASE STUDIES 

AND PERPECTIVES ON A CURRENT CONTROVERSY 

Sujatha Jesudason, Ph.D. (Chair) 

Generations Ahead 

Lisa H. Harris, M.D., Ph.D. 

University of Michigan 

Miriam W. Yeung 

National Asian Pacific American Women’s Forum 


The ASRM ethics committee has developed practice 

guidelines related to sex selection, as has the American 

Congress of Obstetricians and Gynecologists (ACOG). 

However, for a variety of reasons, these guidelines may be 

difficult for health care providers to implement in a clinical 

setting, and some providers have debated whether sex 

selection for “nonmedical” reasons is ever appropriate. 

At a minimum, additional specific recommendations for 

counseling and engagement with patients would help 

providers integrate the general guidelines into their practice. 

As a critical first step, this session will provide an opportunity 

to discuss scenarios under which sex selection may occur 

and evaluate possible responses. 

Room 501 

87 



Patient Care 


A 39-year-old woman with a three-year history of primary 

infertility has undergone two unsuccessful clomiphene/ 

intrauterine insemination (IUI) cycles, 3 follicle-stimulating 

hormone (FSH)/IUI cycles and 2 IVF cycles. Her first IVF cycle 

resulted in 6 eggs being retrieved with two quality embryos 

transferred, but no pregnancy. Her most recent cycle 

produced 7 eggs, with 3 embryos transferred, yet again 

no pregnancy. Her day-3 FSH level a year ago was 9.1 

and is now 11.2. She presents to review her treatments. She 

says that she is emotionally spent, and is wondering if her 

psychological state is contributing to her treatment failures. 

After participating in this session, in my practice I will: 

a. Recommend starting another IVF cycle immediately due 

to the rise in FSH level. 

b. Suggest alternative therapies, such as meditation, 

acupuncture, or mind/body group. 

c. Move to using donor eggs because of the lack of success 

and her rising FSH level. 

d. Recommend another IVF cycle in conjunction with 

alternative therapies. 

e. Suggest she take time off to emotionally recover and 

restart IVF treatments at a later date. 




Room 403 




1. Summarize the current ASRM ethics guidelines related to 

sex selection. 

2. Assess whether additional guidance is needed to address 

specific scenarios. 




After participating in this session I will do the following in my 

practice: 

a. Provide preimplantation genetic diagnosis (PGD) for sex 

selection or preconception sperm-sorting technology to 

anyone who requests it under any circumstance. 

b. Follow the ASRM guidelines for providing sex selection as 

closely as possible. 

c. Provide sex selection and evaluate requests for sex 

selection on a case-by-case basis based on my own 

personal instincts about the family situation. 

d. Evaluate sex selection requests based on criteria other 

than the ASRM guidelines. 





FERTILITY AND STERILITY: GOOGLED 


National Institute of Child Health and Human Development 


The verb “Googled” indicates how dramatically the world 

has changed as a result of the intrusion of the computer 

into everyday life. Nowhere is this more apparent than in 

publications. Newspapers, magazines and books have all 

been dramatically altered. In the next five years, we will not 

recognize Fertility and Sterility, since it is being “Googled.” 




1. Describe the effect of open access online publication on 

research and healthcare practice. 

Room 503 

88 




Which of the following statements best describes your 

current use of the biomedical literature? 

a. Read only printed journals. 

b. Read printed journals and download selected articles 

from online journals. 

c. Read primarily online journals. 

d. Rely primarily on online excerpted summaries of journal 

articles. 

e. Do not read journals, either print or online.

2010 VIDEO PROGRAM 

Tuesday, October 26 th 

ASRM Video Session I 

11:15 am – 1:00 pm 


ASRM Video Session II 

4:15 pm – 6:15 pm 


Wednesday, October 27 th 

AAGL Film Festival Video Session 

11:15 am – 1:00 pm 


The Video Program will take place in the 

Colorado Convention Center. 


VIDEO SESSIONS

ASSISTED REPRODUCTIVE TECHNOLOGY: 

CRYOPRESERVATION 

Moderators: Tien Cheng “Arthur” Chang, E.L.D., Ph.D., and 

Marius Meintjes, D.V.M, Ph.D. 

V-1 11:15 AM 

OOCYTE CRYOPRESERVATION: FLOURESCENT CONFOCAL 

MICROSCOPY OF THE HUMAN SPINDLE APPARATUS AND 

MITOCHONDRIA IN HUMAN OOCYTES BEFORE AND AFTER 

SLOW-FREEZE: THE LANDA FREEZING TECHNOLOGY. 

A.-T. H. La1 , D. G. Diaz1 , M. C. Rodriguez-Karl1 , S. Karl2 , R. A. 

Koch2 . 1West Coast Fertility Centers, Fountain Valley, CA; 

2Biological Science, California State University, Fullerton, 

Fullerton, CA. 

OBJECTIVE: To investigate the cytoskeletal apparatus of MII 

oocytes, specifically the meiotic spindle, before and after 

cryopreservation using a patented slow-freeze method 

called the LANDA Technology. 

DESIGN: Under IRB oversight, MII oocytes were obtained 

for cryopreservation from women age < 37 years with 

day 3 FSH < 10. PrOH was used as the cryoprotectant 

agent with temperature and sucrose modifications 

encompassing The LANDA Freezing Technology. Working 

with a local university, the donated oocytes were imaged 

by polscope to document the spindle location in the 

fresh oocytes and after thawing the frozen oocytes. Using 

immunohisotochemistry (IHC) we applied fluorophores 

to the meiotic spindle (Monoclonal Anti-Alpha-Tubulin- 

FITC Conjugate); secondly, to the chromosomes (Sytoxblue 

nucleic acid) and thirdly to the mitochondria (Mito 

Tracker Orange CMTMRos). We characterized the integrity 

of the meiotic spindle; the chromosomal alignment and 

mitochondrial homogeneity respectively. Images were 

captured using the Leica TCS SP2 Laser Scanning Spectral 

Confocal Microscope. The objective was a 63X oil 1.4 NA. 

using a Argon/Krypton laser at wavelengths of 488nm 

& 458nm (tubulin & sytox) and Helium/Neon laser at 

543nm (mitotracker). Optical sections were collected at 

0.1µm intervals through the entire spindle of each oocyte 

and reconstructed as 3-dimensional projections utilizing 

a Z-stacking technique for assignment of spindle and 

chromosomal structures. 

MATERIALS AND METHODS: In both the fresh control oocytes 

and the frozen/thawed study oocytes, there was equivalent 

preservation of the meiotic spindle tubulin structure and 

orderly chromosomal alignment along the metaphase 

plate. The mitochondria were distributed homogeneously 

with no evidence of dispersion in either the fresh oocytes 

or after thawing the frozen oocytes. These results are 

encouraging for oocyte cryopreservation using the new 

modified slow freeze/rapid thaw protocol known as the 

Landa Freezing Technology. 

__________________________________________________________ 

V-2 11:24 AM 

WARMING EMBRYOS VITRIFIED IN ANOTHER LAB – KEY 

ASPECTS OF THREE POPULAR VITRIFICATION SYSTEMS. 

X. Yang, M. J. Abeyta, T. Choi, S. Benedict, S. Shen. 

Department of Obstetrics, Gynecology, and Reproductive 

Sciences, University of California, San Francisco, San 

Francisco, CA. 

VIDEO PROGRAM 


ASRM Video Session I 


89 

OBJECTIVE: Vitrification is quickly becoming the 

cryopreservation method of choice for human embryos and 

oocytes. However, there is little uniformity among vitrification 

systems. Numerous devices have been developed 

attempting to maximize cooling rates. Therefore, when 

patients transfer their care to different programs, you are 

likely to receive embryos vitrified using a device that you are 

not familiar with. This unfamiliarity creates uncertainty when 

performing warming procedures. Our purpose in this video is 

to highlight the key aspects of several vitrification methods. 

We focus on the details and tips involved in the physical 

handling of the vitrification devices. 

DESIGN: The vitrification systems shown in this video are 

CryoTop (Kitazato BioPharma, Japan), high security 

vitrification (HSV) straw (Cryo Bio System, France), and 

CryoTip (Irvine Scientific, USA). CryoTop is an open system 

and contains a thin, flat and transparent sheet where the 

embryo is loaded. We show how minimum volume is used 

in this device to achieve maximum cooling and warming 

rate. High security vitrification (HSV) is a closed system which 

eliminates any potential contamination from liquid nitrogen; 

however, retrieving the inner gutter during warming can be 

a challenge. In this video we demonstrate how to effectively 

perform the procedure. CryoTip is also a closed system; 

rather than being loaded onto a surface, the embryo is 

aspirated into a finely pulled tip. We illustrate the technical 

details of the cooling and warming procedures. 

MATERIALS AND METHODS: In this video we addressed some 

unique and important aspects of these devices. Reading 

the manufacturer instructions and speaking to the lab that 

performed the vitrification to obtain information regarding 

protocol modifications is a good start. Understanding the 

position of the embryo on the device and how it was vitrified 

is very helpful. Additionally, paying attention to the key 

aspects of the warming procedures we described in this 

video will ensure your success. 

__________________________________________________________ 


MISCELLANEOUS 



V-3 11:39 AM 

CHROMOSOME TRANSFER IN MATURE OOCYTES. 

M. Tachibana1 , M. Sparman1 , S. Mitalipov1,2,3 . 1Division of 

Repro Sci, Oregon National Primate Research Center, 

Oregon Health & Science University, Beaverton, OR; 2Oregon Stem Cell Center, Oregon Health & Science University, 

Beaverton, OR; 3Departments of Obstetrics and Gynecology 

and Molecular and Medical Genetics, Oregon Health & 

Science University, Beaverton, OR. 

OBJECTIVE: We recently demonstrated feasibility of isolation 

and transfer of chromosomes between mature metaphase 

II (MII) primate oocytes (Tachibana et al. Nature, 2009). 

After fertilization, manipulated oocytes were capable of 

producing healthy offspring or embryonic stem cells. In 

this video, we show detailed procedures for isolation and 

transfer of spindle-chromosomal complexes between 

rhesus MII oocytes for introduction of our novel assisted 

reproductive technology.

DESIGN: In brief, the spindle-chromosomal complex is 

visualized using a polarized microscope and extracted into 

a membrane enclosed karyoplast. Chromosomes are then 

reintroduced into an enucleated recipient egg (cytoplast), 

derived from unrelated female, by karyoplast-cytoplast 

membrane fusion. Newly reconstructed oocytes consist of 

nuclear genetic material from one female and cytoplasmic 

components, including mitochondria and mitochondrial 

DNA (mtDNA), from another female. 

MATERIALS AND METHODS: The protocol was initially 

developed for monkey oocytes but can also be applied 

for other species including humans. Potential clinical 

applications include mitochondrial gene replacement 

therapy to prevent transmission of mtDNA mutations and 

treatment of infertility caused by cytoplasmic defects in 

oocytes. 

__________________________________________________________ 

V-4 11:49 AM 

CRISIS STRIKES: EMERGENCY READINESS IN AN IVF UNIT. 

J. Doyle, A. West, P. Hojnowski-Diaz, J. Petrozza. Division 

of Reproductive Medicine, Department of Obstetrics and 

Gynecology, Massachusetts General Hospital, Boston, MA. 

OBJECTIVE: The objective of this movie is to prepare an IVF 

unit for the rare occurrence of a sudden, life-threatening 

emergency. 

DESIGN: Review of the lessons learned from a simulated 

emergency occurring on a typical IVF unit facilitated the 

definition of an Emergency Action Plan (or EAP) that could 

be enacted in the event of a crisis. The actions steps that 

arose in piecemeal fashion during management of the 

simulated emergency were identified and compiled into 

a checklist that represents the EAP. We also review the 

preparatory steps we took in anticipation of a medical 

emergency occurring. 

MATERIALS AND METHODS: An EAP specific to a unit is crucial 

for a rapid and appropriate crisis response. Checklists are 

a very useful device for ensuring all aspects of a situation 

are addressed, and nothing is overlooked. The key actions 

steps of the EAP include performing frequent time checks, 

mobilizing additional support staff in the facility, designating 

a sole individual as the coordinator of the different teams, 

mobilizing emergency equipment, notifying ancillary 

support teams and facilities, informing family members of 

the situation occurring, and documenting the emergency 

response times and events. Preparatory steps that allow a 

rapid emergency response include centralization of crucial 

equipment, telephone numbers, and other resources; 

consideration of space and staff constraints; and defining 

appropriate exit routes. A second lesson learned from 

the simulation is that clear communication is crucial for a 

coordinated response. This is the foundation for effectively 

determining roles, how quickly the response is initiated, and 

how the sequence of events is tethered together. We found 

that this is best achieved by designating one individual 

as the team leader for logistic management of the 

emergency. Finally, practicing the Emergency Action Plan 

is the best way of identifying omissions and obstacles that 

would otherwise be difficult to anticipate in your specific 

facility. 

__________________________________________________________ 

VIDEO PROGRAM 

90 


TIME LAPSE IMAGING STUDIES 



V-5 12:02 PM 

TIME-LAPSE CINEMATOGRAPHY OF DYNAMIC CHANGES 

OCCURRING DURING IN VITRO DEVELOPMENT OF HUMAN 

EMBRYOS – PART 2. 

Y. Mio. Reproductive Centre, Mio Fertility Clinic, Yonago, 

Tottori, Japan. 

OBJECTIVE: The purpose of this study was to clarify 

developmental changes of early human embryos using 

time-lapse cinematography (TLC), which is a novel 

technique developed by our group. At last year’s meeting 

of the American Society for Reproductive Medicine, we 

presented some data focused on dynamic analyses in 

the early stage of human embryonic development, up to 

the 4-cell stage. In this presentation, we cover dynamic 

changes from the 1st cleavage to expanded blastocyst 

stage. 

DESIGN: For human ova, fertilization and cleavage, 

development of the blastocyst, and hatching, as well as 

consequent changes were repeatedly photographed at 

intervals of to 5 to 6 days using an inverse microscope under 

stabilized temperature and pH. Photographs were taken 

at 30 frames per second and the movies were studied. The 

frozen embryos used for TLC (n=108) were donated from 

couples who did not have any furthter clinical use. This study 

was approved by the ethics committee of the Japanese 

Institution for Standardizing ART (JISART). 

MATERIALS AND METHODS: TLC has increased our 

understanding of the morphological mechanisms of 1st/2nd 

cleavage, formation of blastocoel cavity, and behavior 

of human blastocysts, and has identified the increased 

risk of monozygotic twin pregnancy based on prolonged 

incubation in vitro to the blastocyst stage. 

__________________________________________________________ 

V-6 12:11 PM 

CLINICAL USE OF TIME-LAPSE MICROSCOPY TO EVALUATE PRE- 

IMPLANTATION EMBRYO DEVELOPMENT. 

M. Meseguer1 , K. S. Pedersen2 , J. Herrero1 , M. Cruz3 , A. 

Tejera1 , N. B. Ramsing2 . 1Clinical Embriology Laboratory, IVI 

Valencia, Valencia, Spain; 2 , Unisense Fertilitech, Aahrus, 

Aarhus N, Denmark; 3Clinical Embriology Laboratory, IVI 

Alicante, Alicante, Spain. 

OBJECTIVE: Time-lapse observation opens up the 

opportunity for optimizing current morphological grading as 

well as providing novel kinetic parameters which may aid 

in the selection of viable embryos. In order to compare a 

large numbers of embryos, with as little variation in culture 

conditions as possible, we have used the the EmbryoScope 

Embryo monitoring System. 

DESIGN: The EmbryoScope is a tri-gas IVF incubator with a 

built-in camera which is designed to automatically acquire 

images at defined time points. The instrument allows 

simultaneous incubation and observation of 72 embryos 

from 6 patients without removing the embryos from the 

controlled environment. Embryos are loaded into a special 

EmbryoSlide before placing them into the instrument. Each 

slide holds up to 12 embryos in discrete numbered wells. 

Each slide fits into a discrete slot in the slideholder. After 

closing the embryochamber, the CO2 level is re-established 

within 3 minutes. In this study we acquired images every

20 minutes of 7 different focal planes for at least 68 hrs for 

each embryo. We have monitored the development of 1643 

embryos from 158 couples. All couples were undergoing 

their first IVF treatment with ICSI. 

MATERIALS AND METHODS: The image acquisition and 

time-lapse analysis system makes it possible to determine 

exact timing of embryo cleavage in a clinical setting. It 

shows promise as a tool to select embryos with improved 

implantation probabilities based on the exact timing of 

the first cleavages and other parameters visible in time 

lapse. Ongoing studies are evaluating the timing of 

second, third and fourth cleavage. We are also analyzing 

the pattern of nucleus distribution in blastomeres. These 

and similar analyses by other groups will allow us to 

generate a multivariable model to estimate the possibility 

of implantation. This tool will be used for a prospective 

randomized study that will ultimately determine if 

implantation rates can be improved by time-lapse analysis. 

__________________________________________________________ 

V-7 12:21 PM 

TIME-LAPSE IMAGING OF TRIPRONUCLEAR EMBRYOS: 

MECHANISMS OF FORMATION AND ABNORMAL 

DEVELOPMENT. 

R. S. Weinerman1 , M. E. Fino1 , Y. Kramer1 , K. C. Gunsalus2 , 

C. McCaffrey1 , N. Noyes1 . 1NYU Fertility Center, New York 

University School of Medicine, New York, NY; 2NYU Center for 

Genomics and Systems Biology, New York University, New 

York, NY. 

OBJECTIVE: This video presents examples of abnormal 

embryo development in tri-pronuclear embryos originating 

from IVF ± ICSI as viewed using time-lapse microscopy (TLM). 

The mechanisms of tri-pronuclear embryo formation are 

explained and resulting developmental phenotypes are 

highlighted. Specific topics reviewed include mitotic spindle 

formation, early embryo fragmentation and early embryo 

arrest. 

DESIGN: Our research laboratory routinely employs TLM 

as a means to study early embryogenesis. Our standard 

clinical IVF practice is to assess all oocytes for evidence 

of fertilization and to document pronuclear status 18 h 

post-insemination by either conventional insemination or 

ICSI. Those zygotes containing >3 pronuclei are deemed 

unsuitable for uterine replacement and are sometimes 

designated for continued culture and monitoring using TLM, 

if the patient had signed IRB-approved informed consent 

for research on this material. These abnormal zygotes are 

placed in a stage-top incubator and viewed using highdefinition 

microscopy. Images are captured every 240-420 

seconds and time-lapse digital recordings are analyzed 

for phenotypic abnormalities. Representative findings from 

seventy tri-pronuclear embryos are displayed in this video, 

along with an explanation for observed events. 

MATERIALS AND METHODS: TLM is a powerful tool to analyze 

early embryo development. Analysis of TLM images 

recorded from tri-pronuclear embryos provides important 

insight into the mechanisms of early mitotic and other 

developmental events. 

__________________________________________________________ 

UROLOGY 

Moderators: Paul Turek, M.D., and Dana Ohl, M.D. 

V-8 12:36 PM 

NO-NEEDLE LOCAL ANESTHESIA FOR ADULT MALE 

CIRCUMCISION. 

P. Masson 1 , Y. Peng 2 , P. S. Li 1 , Y. Cheng 3 , L. Tian 4 , M. 

VIDEO PROGRAM 

91 

Goldstein1 . 1Center for Male Reproductive Medicine 

and Microsurgery, Department of Urology, and Institute 

of Reproductive Medicine, Weill Cornell Medical College 

of Cornell University, New York, NY; 2Department of 

Sexual Medicine, Yijishan Hospital, Wuhu, Anhui, China; 

3Department of Urology, First Hospital of Ningbo, Ningbo, 

Zhejiang, China; 4Department of Urology, Beijing Chaoyang 

Hospital, Beijing, China. 

OBJECTIVE: We employed a jet injection technique for local 

anesthesia for adult male circumcision (MC). This method 

eliminates the use of a needle, and may reduce the fear of 

local anesthesia injection used for MC. 

DESIGN: Sixty men seeking voluntary adult MC were 

recruited for the study from June to September 2009. 

A MadaJet Medical Injector (MADA Medical Products, 

Carlstadt. New Jersey, USA) was used to deliver a high 

pressure spray of 0.1 mL of 2% plain lidocaine solution 

directly through the penile skin circumferentially around the 

proximal third of the penis. All men underwent adult MC 

using the Shang Ring (Wu Hu SNNDA Medical Treatment 

Appliance Technology Co., LTD., Wu Hu City, China) and 

were evaluated for safety, efficacy, and acceptability of 

the anesthesia. Pain was measured using the visual analog 

scale. The average volume of anesthetic solution (2% 

lidocaine) delivered per jet injection was 0.1 mL, with a 

mean total of 0.9 mL for each circumcision procedure. More 

than 85% of men did not require supplemental anesthesia. 

The onset of anesthesia was approximately 45 seconds from 

the time the injections were completed. Mean pain scores 

for immediate postoperative, 24-hour postoperative, ring 

removal, and post-ring removal events were 0.1, 6.8, 2.2, 

and 0.9, respectively. Four patients (6.67%) developed mild 

urethral bleeding that resolved with pressure, resulting in a 

modification of technique. 

MATERIALS AND METHODS: No-needle jet injection is safe 

and effective for adult MC. The technique efficiently delivers 

local anesthesia with rapid onset to adult men undergoing 

circumcision. This needle-free approach may enhance the 

popularity of adult MC. 

__________________________________________________________ 

V-9 12:43 PM 

VIDEO TECHNIQUE FOR ROBOTIC ASSISTED VASOVASOSTOMY. 

S. J. Parekattil, K. B. Priola, H. Atalah, M. S. Cohen. Urology, 

University of Florida, Gainesville, FL. 

OBJECTIVE: Microsurgical vasovasostomy is a technically 

demanding procedure. Previous studies have shown the 

possible benefit in the use of robotic assistance during 

such procedures. This video presents a technique for 

robotic assisted vasovasostomy (RAVV) and compares two 

endpoints to standard microsurgical vasovasostomy (MVV) 

in a prospective control study. 

DESIGN: The primary endpoint was operative duration; 

the secondary endpoint was motile sperm counts postoperatively 

at 2,5, 9 & 12 months. This video presents a 

step-by-step technique guide for RAVV. There were 26 RAVV 

cases versus 20 MVV cases. 92% patency was achieved 

in the RAVV cases and 80% in MVV (>1 million sperm/high 

power field). Mean operative duration was significantly 

decreased in RAVV at 100 min (70-180) compared to MVV 

at 127 min (105-150), p=0.003. Mean post-operative total 

motile sperm counts were not significantly higher in RAVV 

versus MVV, but the rate of post-operative sperm count 

recovery was significantly faster in RAVV.

MATERIALS AND METHODS: Robotic assisted vasovasostomy 

(RAVV) appears to provide improved surgical efficiency and 

increased rate of recovery for post-operative motile sperm 

counts. Further evaluation and longer follow up is needed to 

assess its clinical potential, reproducibility and the true costbenefit 

ratio 

__________________________________________________________ 

V-10 12:49 PM 

TECHNIQUE OF ROBOTIC ASSISTED MICROSURGICAL 

DENERVATION OF THE SPERMATIC CORD FOR CHRONIC 

ORCHIALGIA. 

S. J. Parekattil, K. J. Priola, H. N. Atalah, M. S. Cohen. 

Urology, University of Florida, Gainesville, FL. 

OBJECTIVE: Recent studies by Levine et al. have shown that 

microsurgical denervation of the spermatic cord (MDSC) 

is an effective treatment option for chronic orchialgia. This 

video presents a detailed technique guide and outcomes 

for a robotic assisted MDSC approach (RMDSC). 

DESIGN: Four-arm technique for RMDSC was developed 

utilizing the DaVinci Si high definition system (Intuitive 

VIDEO PROGRAM 

92 

Surgical, Sunnyvale, CA). This video presents a step by step 

guide of the key surgical components of teh procedure. 

Analysis of 113 RMDSC cases from Oct-Feb was performed 

(median follow up 6 months: range 3 to 18). Selection 

criteria were: chronic testicular pain (>3 months), failed 

standard pain management treatments and negative 

urologic workup. Prospective outcomes research study 

with the primary endpoint of elimination in pain impacting 

quality of life (assessed utilizing a standardized validated 

pain assessment tool: PIQ-6, QualityMetric Inc., Lincoln, RI) 

and the secondary endpoint of operative duration was 

performed. Pain was assessed utilizing the PIQ-6 and VAS 

preoperatively and then postoperatively at 1, 3, 6, 9 &12 

months. 

MATERIALS AND METHODS: Robotic assisted microsurgical 

denervation of the spermatic cord is feasible and the 

preliminary results appear promising. The four arm robotic 

approach allows the microsurgeon to maneuver multiple 

instruments simultaneously including a micro Doppler probe. 

Longer follow-up and further evaluation is warranted. 

__________________________________________________________ 


ASRM Video Session II 

REPRODUCTIVE SURGERY: ROBOTICS 

Moderators: Tommaso Falcone, M.D., and Togas Tulandi, M.D. 

V-11 4:15 PM 

ROBOTIC RESECTION OF URETERAL ENDOMETRIOSIS. 

J. Reddy1 , A. C. Frick1 , R. J. Stein2 , M. F. R. Paraiso1 , T. 

Falcone1 . 1Obstetrics, Gynecology and Women’s Health 

Institute, Cleveland Clinic, Cleveland, OH; 2Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, 

OH. 

OBJECTIVE: Deeply infiltrating endometriosis describes a 

specific, infiltrative form of the disease that may involve 

the uterosacral ligaments, rectovaginal septum, bowel, 

or lower urinary tract. In recent case series of women 

with deeply infiltrative endometriosis, the lower urinary 

tract was affected in 0.3-6% of cases. Endometriosis most 

commonly involves the bladder, followed by the ureters, 

kidneys and then the urethra. Although the incidence of 

ureteral endometriosis is rare, progressive compression and 

obstruction can compromise renal function potentially 

leading to renal failure. The objectives of our video are 

to review the signs and symptoms of lower urinary tract 

endometriosis, specifically focusing on the ureter and to 

demonstrate our surgical technique for performing a robotic 

ureteroneocystostomy using a Boari Flap. 

DESIGN: Robotic ureteroneocystostomy using a Boari flap 

has been our approach for the operative management of 

women with complex, distal ureteral endometriosos. 

MATERIALS AND METHODS: Complex, distal ureteral 

endometriosis can be safely treated using a minimally 

invasive approach such as robotic ureteroneocystostomy 

using a Boari flap. The key to a successful outcome is a 

tension-free anastomosis. Robotic assistance facilitates the 

technical aspects of the operation. 

__________________________________________________________ 


V-12 4:22 PM 

ROBOT-ASSISTED LAPAROSCOPIC MYOMECTOMY AFTER 

UTERINE FIBROID EMBOLIZATION FOR REMOVAL OF A 

CERVICAL MYOMA. 

S. S. Srouji, B. V. Rossi, S. K. O’Horo, A. R. Gargiulo. Obstetrics 

and Gynecology, Brigham and Women’s Hospital, Boston, 

MA. 

OBJECTIVE: Surgical resection of cervical myomas 

is associated with significant risk of blood loss and 

hysterectomy. We describe a technique utilizing uterine 

fibroid embolization (UFE) with a temporary agent to 

decrease blood loss and to allow for safe robot-assisted 

surgical removal of a 14.5 cm cervical myoma. 

DESIGN: Given the bleeding risks and subsequent 

complications of performing a cervical myomectomy, 

UFE was performed 2 days preoperatively with Gelfoam, a 

temporary occluding agent. A temporary agent was utilized 

given that this was a nulliparous patient who wished to 

retain her fertility, and did not desire permanent of occlusion 

of her uterine vessels. Utilizing our previously described hybrid 

technique for excision of large myomas, we performed 

a laparoscopic myomectomy followed by robot-assisted 

closure of the cervical defect. Although preoperative use 

of leuprolide acetate resulted in attenuation of the uterine 

arteries, embolization was successful. The robot-assisted 

laparoscopic myomectomy and cervical reconstruction 

was performed with an estimated blood loss of 200 cc. 

Use of the robot was essential in allowing for accurate 

reconstruction given the three dimensional visualization 

and ability to accurately place sutures at acute angles. 

The tumor was a benign leiomyoma weighing 627 gm. 

The patient was admitted after surgery and discharged 

the following day. She had an uneventful postoperative 

recovery. 

MATERIALS AND METHODS: Preoperative temporary 

embolization is a technique to potentially minimize blood 

loss during complicated myomectomies. Given the location

and size of this fibroid, the success of this procedure was 

dependent upon the use of our hybrid robot-assisted 

technique. Adequate manipulation of this large posterior 

cervical mass was possible during the conventional 

laparoscopic portion, while use of the robot was essential 

for performing an anatomically correct reconstruction at an 

otherwise prohibitive angle. 

__________________________________________________________ 

V-13 4:30 PM 

ROBOT-ASSISTED SUBMUCOSAL MYOMECTOMY. 

A. R. Gargiulo, B. V. Rossi, S. Mahalingaiah, S. S. Srouji. 

Center for Infertility and Reproductive Surgery, Brigham and 

Women’s Hospital/Harvard Medical School, Boston, MA. 

OBJECTIVE: To describe an advanced technique of robotassisted 

laparoscopic myomectomy that allows excision 

of submucosal myomata through the breach created by 

enucleation of a larger transmural myoma. 

DESIGN: We present a recent case in which MRI of the pelvis 

identified a sizable transmural myoma greatly disrupting 

the size and shape of the uterine cavity, in conjunction 

with several intracavitary lesions. Faced with the equally 

unpractical alternatives of a laparoscopic myomectomy 

followed by a hysteroscopic myomectomy or vice versa, we 

opted to proceed with a robot-assisted nucleation of the 

larger myoma and employ the resulting myometrial breach 

as the point of entry for exploration of the uterine cavity 

and complete enucleation of the submucosal lesions. An 

excellent postoperative effect is demonstrated at follow-up 

flexible hysteroscopy. 

MATERIALS AND METHODS: This robot-assisted submucosal 

myomectomy technique can spare patients the need for a 

second surgical session under those circumstances in which 

a transmural myoma distorts a uterine cavity containing 

submucosal lesions. As such, we feel that it should be part of 

the reproductive surgeon’s armamentarium. 

__________________________________________________________ 

V-14 4:35 PM 

ROBOTIC ASSISTED LAPAROSCOPIC SEGMENTAL BLADDER 

RESECTION FOR DEEP INFILTRATING ENDOMETRIOSIS. 

M. L. Lewis, C. Nezhat, A. Veeraswamy, S. Kotikela. Center 

for Minimally Invasive and Robotic Surgery, Palo Alto, CA. 

OBJECTIVE: Extragenital endometriosis has been seen more 

commonly in the literature as more surgeons are trained 

to recognize its atypical presentation. This video describes 

a case of bladder endometriosis in a young reproductive 

age woman with a one year history of hematuria and cyclic 

dysuria. 

DESIGN: A single surgical case was recorded in real-time 

video. The da Vinci robotic system was used for the entire 

operation in its four-arm configuration. Preoperative MRI was 

used to identify the lesion and guide dissection. 

MATERIALS AND METHODS: Patient history is essential to 

establishing a differential diagnosis of bladder endometriosis. 

With proper evaluation and consultation these patients can 

achieve excellent results. Robotic assisted laparoscopic 

segmental bladder resection is ideal for deep infiltrating 


__________________________________________________________ 

V-15 4:43 PM 

ROBOTICALLY ASSISTED TUBAL ANASTOMOSIS. 

M. Catenacci, T. Falcone. The Cleveland Clinic Foundation, 

Cleveland, OH. 

OBJECTIVE: Robotic tubal anastomosis can offer a 

VIDEO PROGRAM 

93 

minimally invasive procedure for patients desiring tubal 

ligation reversal. This video demonstrates our technique for 

performing a robotic tubal anastomosis using the newest da 

Vinci Surgical Systems and a tubal luminal stent.. 

DESIGN: The da Vince robot can now be docked using a 

side docking technique that allows for improved access 

to the uterine manipulator. Standard robotic equipment 

needed includes: two 5 mm robotic trocars, monopolar 

cautery hook, monopolar cautery scissors, two microneedle 

drivers, and robotic graspers. Generally, three of the four 

robotic arms are needed, a uterine manipulator that allows 

for chromotubation is needed, and placement of an 

accessory assistant port is needed. A Modified Novy Cornual 

Cannulation Set can be used as an optional luminal stent. 

This can aid in the muscularis suture placement. 

MATERIALS AND METHODS: The Modified Novy Cornual 

Cannulation Set can be used as a luminal stent to aid in 

suture placement during robotic tubal anastomosis. The 

newest of the da Vinci Surgical Systems has an improved 

design and can now be docked at the patient’s side 

allowing for access to the uterine manipulator. 

__________________________________________________________ 

NEW TECHNIQUES, TECHNOLOGIES, AND 

PROCEDURES-1 


V-16 4:59 PM 

SUCCESSFUL OVARY TRANSPLANTATION IN GENETICALLY NON- 

IDENTICAL SISTERS REQUIRING IMMUNOSUPPRESSION. 

D. Meirow1 , S. J. Silber2 . 1Sheba Medical Center, Sakler 

Medical School Tel Aviv, Tel Aviv, Israel; 2Infertility Center of 

St. Louis, St. Luke’s Hospital, St. Louis, MO. 

OBJECTIVE: We have already reported on nine cases of 

ovarian transplantation between identical twins, and 

3 cases of frozen ovarian autotransplantation, all of 

which normally, producing 11 healthy babies so far. This 

represents the first ovary transplant case that required 

immunosuppression. 

DESIGN: This video demonstrates our first case of ovarian 

transplantation between non-identical sisters who required 

immunosuppression. The video discusses these techniques 

and issues for ovarian transplantation between non-identical 

siblings, and also the technique for ovarian vitrification. 

MATERIALS AND METHODS: The ovary functioned normally 

despite immunosuppression, but no pregnancy has yet 

occurred and we have a time limit on how long we will keep 

her immunosuppressed. Also vitrification of spare ovarian 

tissue is a preferred method for cryopreservation in these 

cases. 

__________________________________________________________ 

V-17 5:07 PM 

THE TERUMO PRECISION-DRIVE ARTICULATING INSTRUMENT 

MAY BE USED TO FACILITATE LAPAROSCOPIC SURGERY IN 

GYNECOLOGY. 

M. E. Pavone, M. Milad. Obstretrics and Gynecology, 

Northwestern University, Chicago, IL. 

OBJECTIVE: T=The Terumo Precision-Drive Articulating 

Instrument is designed to provide motorized rotation and 

articulation for endoscopic suture placement, knot tying, 

dissection and mono and bi-polar electrosurgery. 

DESIGN: This video highlights the use of the Terumo 

Precision-Drive Articulating Instrument (not FDA approved) 

in performing laparoscopic gynecologic surgery.

Using cadaveric models, we demonstrate a simulated 

laparoscopic myomectomy and hysterectomy. 

MATERIALS AND METHODS: With a hand-activated device, 

the Terumo Precision-Drive Articulating Instrument can 

provide both articulation and rotation, allowing for 

improved range of motion. This new device may optimize 

dissection, desiccation, suturing and knot tying during 

common gynecologic procedures. It may also allow for 

the placement of fewer ports and for easier and more 

accurate suture placement. This instrument may be a simple 

and effective alternative to either conventional or roboticassisted 

gynecologic procedures. 

__________________________________________________________ 

V-18 5:16 PM 

COMPLETE IN-OFFICE INFERTILITY ASSESSMENT WITH THE 

FEMVUE SONO TUBAL EVALUATION SYSTEM. 

C. E. Miller, M. Genis. The Advanced IVF Institute, Naperville, 

IL. 

OBJECTIVE: The optimal evaluation of the infertile female 

includes the visualization of ovaries with follicles, evaluation 

of the uterine anatomy, including myometrium and 

uterine cavity assessment, and the determination of 

fallopian tube patency. Traditional transvaginal ultrasound, 

hystrosonography and hysterosalpingography procedures 

can be combined to achieve these objectives. However, 

the accomplishment of all three procedures generally 

requires separate patient visits to the office and an 

ambulatory radiology facility. A new unique transvaginal 

ultrasound technique is described within that accomplishes 

all components of visualization assessment in a single “inoffice” 

visit. 

DESIGN: The technique is performed with the FemVue 

Sono Tubal Evaluation System which consists of an 

intrauterine cornual selective catheter and a saline-air 

sonographic contrast media instillation syringe device. 

Initially, the FemVue system can be used to evaluate 

the uterine cavity by placing the FemVue catheter 

transcervically. Normal saline is then instilled into the 

cavity through the FemVue catheter to allow ultrasonic 

visualization. The FemVue catheter is then placed with the 

delivery sheath to the uterine fundus for fallopian tube 

evaluation. The pre-shaped catheter is advanced towards 

the targeted cornua followed by the filling with saline of 

the isolation balloon. The FemJect instillation syringe is 

then connected to the catheter for the administration of 

continuous saline and air. 

MATERIALS AND METHODS: The saline-air contrast is initially 

seen exiting the catheter tip and filling the cornu with 

either cornual space distention or immediate flow into the 

proximal portion of the selected fallopian tube. The salineair 

train is followed to more distal segments of the fallopian 

tube eventually observing the saline-air contrast exiting 

into the peritoneal cavity. The balloon is then deflated, the 

catheter retracted into the delivery sheath and the FemVue 

rotated 180° to evaluate the contralateral fallopian tube. 

__________________________________________________________ 

V-19 5:24 PM 

RECONSTRUCTION OF VAGINAL ATRESIA USING LABIAL 

FASCIOCUTANEOUS FLAPS. 

E. J. Simons 1 , S. Y. Reddy 1 , J. Serletti 2 , B. DuBeshter 1 . 

1 Department of Obstetrics and Gynecology, University of 

Rochester Medical Center, Rochester, NY; 2 Department of 

Plastic Surgery, Hospital of the University of Pennsylvania, 

Philadelphia, PA. 

VIDEO PROGRAM 

94 

OBJECTIVE: Surgical approaches to resection of a transverse 

vaginal septum and vaginoplasty for vaginal atresia vary 

widely. Although the literature does not decisively support 

any single technique over the others, the Grunberger 

method involving transposition of fasciocutaneous flaps 

from the labia minora has been shown to be associated 

with minimal post-operative tissue contracture, adequate 

vaginal dimensions, and acceptable post-operative sexual 

function (Wierrani and Grunberger, 2003). This video is 

designed to demonstrate an alternate vaginoplasty method 

similar to the Grunberger method, in which preoperative 

placement of tissue expanders in the labial area is 

performed to optimize the fasciocutaneous flaps. 

DESIGN: This video introduces the concepts of diagnosis of 

transverse vaginal septum through a careful physical exam 

and use of preoperative adjunctive imaging to distinguish 

this condition from other congenital anomalies of the 

lower genital tract. The video demonstrates the effect of 

preoperative tissue expansion in the labial area to create 

mobile, vascularized tissue flaps. A technique for resection 

of a thick transverse vaginal septum and the transposition 

of the tissue flaps to create the neovagina are also shown. 

The result is a non-hair bearing epithelium, which over time, 

begins to resemble normal vaginal mucosa histologically. 

MATERIALS AND METHODS: This video provides an 

educational tool to assist surgeons in performing a 

vaginoplasty procedure that minimizes tissue contracture 

and optimizes vaginal size, sexual function, and cosmetic 

outcome. 

__________________________________________________________ 

V-20 5:33 PM 

THE DIAGNOSIS OF UTERINE ANOMALIES USING VIRTUAL 

HYSTEROSALPINGOGRAPHY. 

P. Carrascosa1 , M. Baronio2 , C. Capunay1 , C. M. Sueldo3 , 

S. Papier2 , C. Sueldo2,3 . 1CT Studies, Diagnostico Maipu, 

Vicente Lopez, Buenos Aires, Argentina; 2 , CEGYR, Buenos 

Aires, Argentina; 3OB-GYNECOLOGY, Univ. California San 

Francisco-Fresno, Fresno, CA. 

OBJECTIVE: Virtual endoscopic studies in humans are 

established techniques to evaluate different organ 

systems. Our group first described its application for the 

study of the female reproductive tract among infertile 

patients (Carrascosa et al 2007) and since then published 

extensively on the use of this diagnostic technique. The 

objective of our study was to demostrate the value of virtual 

hysterosalpingography (VHS) among those patients that 

underwent the procedure and were found to have either a 

bicornuate uterus or a septate uterus. Emphasis was placed 

in identifying the uterine fundus and establishing if it was 

flat, convex or had a minor indentation (less than 10 mm) 

consistent with the diagnosis of uterine septum. 

DESIGN: Virtual hysterosalpingography was performed 

in 32 patients with uterine malformations, by injecting a 

diluted solution (10 ml) 1:10 of iodine contrast material in 

saline through a 5F HSG catheter and scanning for about 5 

seconds per patient, using a 64-row scanner (Brilliance 64, 

Phillips Medical, Ohio, USA). Image reconstruction followed 

at the work station (multiplanar recoonstructions, 3-D 

volume rendering and video endoscopy images) as shown 

in this video presentation, allowed a clear visualization of 

the endocervix, the uterine cavity with a clear separation 

of the two horns, delineating the thickness and length of 

the septum if one was present and establishing patency of

the fallopian tubes. Also, it clearly demostrates the external 

uterine fundus that differentiates a bicornuate from a 

septate uterus. 

MATERIALS AND METHODS: The images shown in this video 

presentation, specifically the multiplanar reconstruction 

and 3-D volume rendering, clearly differentiates between 

septate and bicornuate uterus allowing practitioners to 

implement the most appropiate medical management. 

We conclude from this preliminary experience, that Virtual 

Hysterosalpingography appears to be a helpful diagnostic 

technique in the differential diagnosis of common uterine 

anomalies. 

__________________________________________________________ 

NEW TECHNIQUES, TECHNOLOGIES, AND 

PROCEDURES-2 


V-21 5:44 PM 

LAPAROSCOPIC TUBAL REANASTOMOSIS: EVOLUTION OF THE 

TECHNIQUE AT BRIGHAM AND WOMEN’S HOSPITAL. 

A. R. Gargiulo, S. S. Srouji, E. H. Yanushpolsky. Center for 

Infertility and Reproductive Surgery, Brigham and Women’s 

Hospital/Harvard Medical School, Boston, MA. 

OBJECTIVE: To describe the strategies employed to 

successfully transition from classic microsurgical to 

conventional laparoscopic and then from conventional 

laparoscopic to robot-assisted laparoscopic techniques of 

tubal reanastomosis. 

DESIGN: Two cases of laparoscopic tubal reanastomosis 

are presented sequentially: a conventional laparoscopic 

case from 2004 and a robot-assisted case from 2010. Both 

cases are considered representative of our best technical 

achievement on each technique after several years of 

practice and improvements. Our firm goals in the transition 

from open to minimally invasive approach to tubal 

reanastomosis have been to: 1) always operate on a tubal 

stent, 2) secure orientation by applying a minimum of two 

reanastomosis sutures per tube and 3) use the thinnest safely 

employable suture. 

MATERIALS AND METHODS: Laparoscopic tubal 

reanastomosis has replaced the classic microsurgical 

approach in many high-specialty centers, with significant 

advantages for patients in terms of postoperative recovery. 

However, the objective technical challenges of this delicate 

operation have brought about various modifications of the 

original microsurgical technique. This video illustrates our 

best effort at the conventional laparoscopic technique and 

demonstrates how the robot-assisted technique allows us to 

replicate the classic microsurgical technique with no need 

for modifications. 

__________________________________________________________ 

V-22 5:52 PM 

WITHDRAWN 

__________________________________________________________ 

VIDEO PROGRAM 

95 

V-23 5:56 PM 

A LARGE ENDOMETRIOMA OF THE RIGHT HEMIDIAPHRAGM. 

S. Kotikela, M. L. Lewis, A. Veeraswamy, C. Nezhat. Center 

for Minimally Invasive and Robotic Surgery, Palo Alto, CA. 

OBJECTIVE: Describe an usual case of diaphragmatic 


DESIGN: Laparoscopic resection of the endometrioma. 

MATERIALS AND METHODS: Recognizing atypical 

presentations of extragenital endometriosis will help improve 

patient outcomes and lifestyle. 

__________________________________________________________ 

V-24 5:59 PM 

A SURGICAL PROCEDURE TO CONSERVE THE UTERUS FOR 

FUTURE PREGNANCY IN PATIENTS SUFFERING FROM MASSIVE 

ADENOMYOSIS. 

S. J. Silber2 , H. Osada1 , T. Kakinuma3 , M. Magaosjo1 , K. Kato3 , 

O. Kato3 . 1Infertility Center of St. Louisa, St. Luke’s Hospial, St. 

Louis, MO; 2Department of Ob/Gyn, Nihon University School 

of Medicine, Tokyo, Japan; 3 , Kato Ladies Clinic, Tokyo, 

Japan. 

OBJECTIVE: The usual treatment for severe adenomyosis 

has usually been hysterectomy, because there is no line of 

demarcation of diseased from normal tissue. Yet many such 

women wish to retain their uterus and some even wish to 

bear childen. 

DESIGN: This report evaluates the efficacy of a new method 

of adenomyomectomy, where adenomyotic tissues are 

radically excised and the uterine wall is reconstructed by 

a triple-flap method, without overlapping suture lines, to 

prevent uterine rupture in subsequent pregnancies. This is 

a prospective case series followed for 10 years from June 

1998 to August 2008 of one hundred four women with severe 

adenomyosis verified histologically and with MRI (magnetic 

resonance imaging). 

MATERIALS AND METHODS: There was a dramatic reduction 

in both dysmenorrhea and hypermenorrhea, and all 

patients returned to having normal menstrual cycles. Of 26 

women who wished to conceive, 16 became spontaneously 

pregnant, 14 (53.8%) went to term and delivered a 

healthy baby, and there were no cases of uterine rupture. 

Adenomyosis symptoms recurred in only 4 out of 104 cases. 

The procedure thus resulted in a dramatic reduction in 

symptoms, and allowed a significant proportion of women 

who wished to conceive to go to term without uterine 

rupture.

Best Endoscopic Surgical Videos of the AAGL 

This session will highlight the best reproductive surgical 

videos from the 2010 Annual Meeting of the AAGL. A 

variety of innovative laparoscopic and hysteroscopic 

procedures and techniques will be presented. Topics will 

include techniques for reproductive surgery, endometriosis, 

myomectomy, management of mullerian anomalies, 

advanced anatomy reviews, and endoscopic surgery for 

obstetrical indications among others. The session is designed 

for all levels of gynecologic and urologic surgeons. 

__________________________________________________________ 

MULLERIAN ANOMALIES AND MISC. 

AAGL-V1 11:15 am 

LAPAROSCOPIC OVARIAN TRANSPOSITION 

Olivier G, Joseph N, Arnaud W. Gynécologie, SIHCUS- 

CMCO, Schiltigheim, France. 


CREATION OF SIGMOID NEOVAGINA USING A 

LAPAROSCOPIC TECHNIQUE 

Hohl MK, Teufelberger G. Gynecology, Kantonsspital Baden, 

Baden, Switzerland. 


LAPAROSCOPIC VECCHIETTI PROCEDURE USING NEW 

TRACTION DEVICE 

1 Fedele L, 1 Frontino G, Zurawin RK. 1 Obstetrics and Gynecology, 

University of Milan, Milan, Italy; 2 Obstetrics and Gynecology, 

Baylor College of Medicine, Houston, TX, United States. 


AVASCULAR PLANES OF THE PELVIS 

Park AJ, Falcone T, Barber MD. Obstetrics & Gynecology, 

Cleveland Clinic, Cleveland, OH. 

__________________________________________________________ 

DISCUSSION 11:41 am 

__________________________________________________________ 

OBSTETRICAL ENDOSCOPY 


TRANSCERVICAL EMBRYOSCOPY 

Abdala LT, Ruiz JA, Espinosa H. Laparoscopy, Clinica 

Bautista, Barranquilla, Atlantico, Colombia. 


LAPAROSCOPIC CERVICO-ISTHMUS CERCLAGE FOR 

INCOMPETENT CERVIX 

Stanford EJ, Saitis D. Gynecologic Specialties, University of 

Tennessee, Memphis, TN. 

VIDEO PROGRAM 


AAGL Film Festival Video Session 


Moderators: David Olive, M.D., and Ceana Nezhat, M.D. 

96 


LAPAROSCOPIC CERCLAGE TIPS AND TRICKS FROM 17 CASES 

Xia E. Hysteroscopic Center, Fuxing Hospital, Capital Medical 

University, Beijing, China. 

__________________________________________________________ 

DISCUSSION 12:06 pm 

__________________________________________________________ 

ADVANCED LAPAROSCOPIC TECHNIQUES 

AAGL-V8 12:11 pm 

LAPAROSCOPIC TYPE 2 SUBMUCOSAL MYOMECTOMY 

Cholkeri-Singh A, Miller CE. Ob/Gyn, Advocate Lutheran 

General Hospital, Park Ridge, IL. 

AAGL-V9 12:18 pm 

LAPAROSCOPIC MANAGEMENT OF THE RETAINED LEFT OVARY 

Hudgens JL, Pasic R, Metzinger D, Helm W, Justice T. 

Obstetrics, Gynecology, and Women’s Health, University of 

Louisville, Louisville, KY. 

AAGL-V10 12:26 pm 

LAPAROSCOPIC MANAGEMENT OF ECTOPIC PREGNANCY 

UNUSUAL ANATOMIC LOCATION 

Suzuki Y, Einarsson JI. Obstetrics and Gynecology, the 

Division of Minimally Invasive Gynecologic Surgery, Brigham 

and Women’s Hospital, Boston, MA. 

__________________________________________________________ 


__________________________________________________________ 

ENDOMETRIOSIS 

AGGL-V11 12:36 pm 

LAPAROSCOPIC RESECTION OF CYSTIC ADENOMYOSIS 

Ball E, Giles D, Janik G, Koh C. Reproductive Specialty Center, 

Milwaukee, WI. 

AGGL-V12 12:42 pm 

LAPAROSCOPIC EXCISION OF BLADDER ENDOMETRIOSIS 

1,2 1 1 Heidemann NL, Liu CY. Chattanooga Women’s Surgery 

Center, Chattanooga, TN; 2Tennessee Women’s Care, 

Nashville, TN. 

AGGL-V13 12:49 pm 

EXCISIONAL SURGERY FOR DEEPLY INFILTRATING 

ENDOMETRIOSIS WITH CUL-DE-SAC OBLITERATION 

Deura I, Miki M, Hada T, Ohta Y, Takaki Y, Kanao H, Andou M. 

Gynecology, Kurashiki Medical Center, Kurashiki, Okayama, 

Japan 

__________________________________________________________ 


__________________________________________________________

2010 Corporate Member Council 


Amgen 

Anecova SA 


Boehringer Ingelheim 

Cook Medical 

Elsevier, Inc. 

EMD Serono, Inc. 

Ferring Pharmaceuticals Inc. 

Freedom Fertility Pharmacy 

Good Start Genetics 

Quadrant HealthCom, Inc. 

Merck 

Pfizer 

Teva Women’s Health 

Ther-Rx 

Upsher-Smith Laboratories 

Walgreens 

Watson Pharma, Inc. 

ORAL ABSTRACTS

ORAL ABSTRACTS 


Prize Paper Candidates’ Oral Abstract Presentations 


Moderators: Elizabeth A. McGee, M.D., and Eric D. Levens, M.D. 

The following seven papers are candidates for the ASRM Scientific Program Prize Paper Awards. 

Seven additional candidates will be presented during the Prize Paper Candidates’ session on Tuesday morning. 

O-1 11:15 AM 

PREGNANCY RATES ACROSS MULTIPLE TREATMENT CYCLES: 

DATA FROM THE FAST TRACK AND STANDARD TREATMENT 

(FASTT) TRIAL. 

M. B. Goldman 1 , M. M. Regan 2 , M. M. Alper 3 , K. L. Thornton 3 , 

R. H. Reindollar 1 . 1 Obstetrics & Gynecology, Dartmouth- 

Hitchcock Medical Center, Lebanon, NH; 2 Biostatistics & 

Computational Biology, Dana-Farber Cancer Institute, 

Boston, MA; 3 Boston IVF, Waltham, MA. 

O-2 11:30 AM 

SUCCESSFUL PROPAGATION OF HUMAN PREPUBERAL 

SPERMATOGONIAL STEM CELLS. 

H. Sadri-Ardekani1,2 , M. M. Akhondi2 , F. van der Veen1 , D. 

G. de Rooij1 , A. M. M. van Pelt1 , S. Repping1 . 1Center for 

Reproductive Medicine, Department of Obstetrics and 

Gynecology, Academic Medical Center, University of 

Amsterdam, Amsterdam, Netherlands; 2Reproductive Biotechnology Research Center, Avicenna Research 

Institute, ACECR, Tehran, Islamic Republic of Iran. 

O-3 11:45 AM 

DONORS’ INTERACTIONS WITH NURSING AND PHYSICIANS 

AFFECTS IMMEDIATE WILLINGNESS TO DONATE AGAIN AND 

ATTITUDES ONE YEAR POST RETRIEVAL. 

A. M. Braverman1,2 , D. Taylor1,2 , R. A. Nicholson1 , B. Galen1 , 

R. T. Scott, Jr1,2 . 1Reproducitve Medicine Associates of 

New Jersey, Morristown, NJ; 2Division of Reproductive 

Endocrinology, Department of Obstetrics and Gynecology 

and Reproductive Science, Robert Wood Johnson Medical 

School UMDNJ, New Brunswick, NJ. 

O-4 12:00 PM 

UNIDIRECTIONAL BARBED SUTURE VERSUS CONTINUOUS 

SUTURE WITH INTRACORPOREAL KNOTS IN LAPAROSCOPIC 

MYOMECTOMY: RANDOMIZED CONTROLLED TRIAL. 

S. Ferrero, V. Remorgida, F. Alessandri. Department of 

Obstetrics and Gynecology, San Martino Hospital and 

University of Genoa, Genoa, GE, Italy. 

97 

O-5 12:15 PM 

A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL 

DEMONSTRATING SIGNIFICANTLY INCREASED CLINICAL 

PREGNANCY RATES FOLLOWING 24 CHROMOSOME 

ANEUPLOIDY SCREENING: BIOPSY AND ANALYSIS ON DAY 5 

WITH FRESH TRANSFER. 

R. T. Scott, Jr., 1,2 , X. Tao1 , D. Taylor1,2 , K. M. Ferry1 , N. R. 

Treff1,2 . 1Reproductive Medicine Associates of New Jersey, 

Morristown, NJ; 2UMDNJ-Robert Wood Johnson Medical 

School, New Brunswick, NJ. 

O-6 12:30 PM 

GnRH ANTAGONIST (CETROTIDE) INSTEAD OF AGONIST TO 

PREPARE RECIPIENTS FOR EMBRYO TRANSFER: A PROSPECTIVE, 

RANDOMIZED, CONTROLLED TRIAL. 

I. Tur-Kaspa, R. Najeemuddin, A. Cohen, N. Tkachenko, M. 

Fowler. Institute for Human Reproduction (IHR), Chicago, IL. 

O-7 12:45 PM 

FSH AT TIME OF hCG TRIGGER IMPROVES OOCYTE 

DEVELOPMENTAL COMPETENCE: A DOUBLE BLIND 

RANDOMIZED CONTROL TRIAL. 

J. D. Lamb, S. Shen, G. Cheng, L. Jalalian, M. I. Cedars, 

M. P. Rosen. Department of Obstetrics, Gynecology 

and Reproductive Sciences, University of California, San 

Francisco, San Francisco, CA.

• Contraception Special Interest Group 

• Nurses’ Professional Group 

• Reproductive Biology Professional Group 

• Fertility Preservation Special Interest Group 

• Clinical Female Infertility and Gynecology 

• Male Factor: ART 

• Male Reproduction and Urology 

• Cryopreservation and Frozen Embryo Transfer: ART 

• Other: ART 

• Outcome Predictors - Clinical: ART 1 

• Outcome Predictors - Laboratory: ART 

• Ovarian Stimulation: ART 

• Procedures and Techniques - Laboratory: ART 

__________________________________________________________ 

CONTRACEPTION SPECIAL INTEREST GROUP 


Moderators: Jeffrey T. Jensen, M.D. 

Rebecca H. Allen, M.D. 

O-8 4:15 PM 

PROPHYLACTIC ADMINISTRATION OF SUBANTIMICROBIAL 

DOSE DOXYCYCLINE TO PREVENT UNSCHEDULED BLEEDING IN 

CONTINUOUS ORAL CONTRACEPTIVE PILL USERS. 

B. Kaneshiro1 , A. Edelman2 , N. Carlson3 , M. Nichols2 , J. Jensen2 . 

1Department of Obstetrics and Gynecology, University of Hawaii, 

Honolulu, HI; 2Department of Obstetrics and Gynecology, Oregon 

Health and Science University, Portland, OR; 3Department of 

Biostatistics and Informatics, University of Colorado Denver, Aurora, 

CO. 

O-9 4:30 PM 

THE RISK OF VENOUS THROMBOEMBOLISM IN USERS OF A 

DROSPIRENONE-CONTAINING ORAL CONTRACEPTIVE WITH A 

24-DAY REGIMEN – RESULTS FROM THE INAS-OC STUDY. 

J. Dinger, K. Bardenheuer, S. Moehner. ZEG - Berlin Center for 

Epidemiology and Health Research, Berlin, Germany. 

O-10 4:45 PM 

THE EFFECT OF ORAL CONTRACEPTIVE PILLS ON ADIPOKINES 

AND ADIPOCYTE DIFFERENTIATION FACTORS IN NORMAL AND 

OBESE FEMALE RHESUS MONKEYS. 

K. A. Shaw, J. D. Hennebold, A. B. Edelman. Obstetrics & 

Gynecology, Oregon Health Science University, Portland, OR. 

O-11 5:00 PM 

CO-INCUBATION OF OOCYTES WITH THE SELECTIVE 

PHOSPHODIESTERASE 9 (PDE9) INHIBITOR BAY 73-6691 

(BAY) AND LOW LEVELS OF cGMP BLOCKS SPONTANEOUS 

RESUMPTION OF MEIOSIS IN VITRO. 

C. B. Hanna1 , S. Yao1 , X. Wu1 , J. T. Jensen2 . 1Reproductive Sciences, 

Oregon National Primate Research Center, Beaverton, OR; 

2Department of Obstetrics & Gynecology, Oregon Health & Science 

University, Portland, OR. 

O-12 5:15 PM 

A DOSE-FINDING, CROSS-OVER STUDY TO EVALUATE THE 

EFFECT OF A TRANSDERMAL NESTORONE®-ESTRADIOL 

(NES/E2) GEL ON OVULATION SUPPRESSION AND ASSESS 

ACCEPTABILITY IN HEALTHY OVULATING WOMEN. 

R. B. Merkatz 1 , R. Sitruk-Ware 6 , D. Mishell 2 , V. Brache 3 , D. Taylor 4 , C. 

Jesam Gaete 5 . 1 Reproductive Health, The Population Council, 

New York, NY; 2 Profamilia, Santo Domingo, Dominican Republic; 

3 Obstetrics and Gynecology, LA County/USC Medical Center, 

Los Angeles, CA; 4 Instituto Chileno de Medicina Reproductiva, 

Santiago, Chile. 



Abstract Sessions 

98 

O-13 5:30 PM 

EVALUATION OF EXPOSURE TO ETHINYL ESTRADIOL (EE) WITH 

A LOW DOSE COMBINATION TRANSDERMAL CONTRACEPTIVE 

DELIVERY SYSTEM (AG200-15) COMPARED TO LOW-DOSE 

COMBINATION ORAL CONTRACEPTIVE. 

D. F. Archer 1 , F. Z. Stanczyk 2 , A. Rubin 3 , L. J. Flood 3 , D. R. Mishell 2 , 

M. Foegh 3 . 1 Jones Institute for Reproductive Medicine and 

Endocrinology, Eastern Virginia Medical School, Norfolk, VA; 2 Keck 

School of Medicine Obstetrics and Gynecology, University of 

Southern California, Los Angeles, CA; 3 Agile Therapeutics, Princeton, 

NJ. 

O-14 5:45 PM 

OVULATION RESUMPTION AFTER MEDICAL ABORTION WITH 

MIFEPRISTONE AND MISOPROSTOL. 

S. P. Sober 1 , S. J. Ratcliffe 1 , M. D. Creinin 2 , C. A. Schreiber 1 . 

1 Department of Obstetrics and Gynecology, University of 

Pennsylvania, Philadelphia, PA; 2 Department of Obstetrics, 

Gynecology and Reproductive Sciences, University of Pittsburgh, 

Pittsburgh, PA. 

O-15 6:00 PM 

POTENTIAL IMPACT OF USING FOLATE-FORTIFIED ORAL 

CONTRACEPTIVES ON RISK OF NEURAL TUBE DEFECTS IN THE 

UNITED STATES. 

R. Lynen4 , R. A. Farkouh1 , T. N. Taylor2 , J. Graham1 , A. Colligs3 , M. 

Lindemann3 . 1Health Economics, RTI Health Solutions, Research 

Triangle Park, NC; 2Department of Pharmacy Practice, Wayne State 

University, Detroit, MI; 3Bayer Schering Pharma AG, Berlin, Germany; 

4US Health Economics & Outcomes Research, Bayer HealthCare 

Pharmaceuticals Inc., Wayne, NJ. 

__________________________________________________________ 

NURSES’ PROFESSIONAL GROUP 

ROOM 403 

Moderators: Elizabeth B. West, R.N.C., B.S.N. 

Maria M. Jackson, R.N., B.S., M.A. 

O-16 4:15 PM 

CIGARETTE SMOKING AND ORAL CONTRACEPTIVE (OC) USE 

FOR ART: NATIONAL PRACTICE PATTERNS AND RESTRICTIONS. 

K. R. Hammond1 , N. A. Cataldo2 . 1Alabama Fertility Specialists, PC, 

Birmingham, AL; 2Birmingham Healthcare, Birmingham, AL. 

O-17 4:30 PM 

INFLUENCE OF FERTILITY STATUS, LIVING CHILDREN, AND PRIOR 

LOSS ON THE EMOTIONAL IMPACT OF MISCARRIAGE. 

C. S. Huffman, K. M. Swanson, T. A. Schwartz. School of Nursing, The 

University of North Carolina at Chapel Hill, Chapel Hill, NC. 

O-18 4:45 PM 

A SURVEY OF FERTILITY PRACTICES AND HOW THEY USE 

ELECTRONIC COMMUNICATION. 

K. B. Copperman 1 , L. Nohr Beck 2 , D. Ryan 3 , M. Acosta 3 , M. Sileo 2 , A. 

B. Copperman 3 . 1 KBC Consulting, New York, NY; 2 Fertile Hope and 

Livestrong, Austin, TX; 3 Reproductive Medicine Associates of New 

York, NY, NY. 

O-19 5:00 PM 

THE ENDOCARE QUESTIONNAIRE: A VALID AND RELIABLE 

INSTRUMENT TO EVALUATE THE PATIENT-CENTEREDNESS OF 

ENDOMETRIOSIS CARE. 

E. A. F. Dancet 1 , L. Ameye 2 , W. Sermeus 3 , M. Welkenhuysen 1 , T. M. 

D’Hooghe 1 . 1 Leuven University Fertility Centre, UZ. Leuven, Leuven, 

Vlaams-Brabant, Belgium; 2 Gynecology and Obstetrics, UZ. Leuven, 

Leuven, Vlaams-Brabant, Belgium; 3 Center for Health Services and 

Nursing Research, Catholic University Leuven, Leuven, Vlaams- 

Brabant, Belgium.

O-20 5:15 PM 

DOES SURGICAL MANAGEMENT OF A MISSED ABORTION 

PROVIDE A MORE RAPID RETURN TO FERTILITY TREATMENT 

THAN MEDICAL MANAGEMENT IN A FERTILITY PRACTICE? 

H. I. G. Cotton 1 , L. Grunfeld 1,2 , C. A. McDonald 1 , G. Vela 1,2 , M. 

Acosta de la Greca 1 , A. B. Copperman 1,2 . 1 Reproductive Medicine 

Associates of New York, New York, NY; 2 Department of OBGYN and 

Reproductive Science, Mount Sinai School of Medicine, New York, 

NY. 

O-21 5:30 PM 

A STUDY OF PERCEPTIONS, EXPERIENCES, AND SATISFACTION 

WITH HEALTHCARE AMONG WOMEN WITH POLYCYSTIC OVARY 

SYNDROME (PCOS). 

E. W. Sterling 1 , T. Vincent 2 , C. DeZarn 3 , M. Perloe 2 . 1 My Fertility Plan, 

Marietta, GA; 2 Georgia Reproductive Specialists, Atlanta, GA; 

3 PCOS Association, Englewood, CO. 

O-22 5:45 PM 

EFFECT OF REMOTE ACCESS E-LEARNING MODULES ON 

CLINICAL OUTCOMES AND ORGANIZATIONAL EFFICIENCY. 

C. M. Bergh 1 , A. McGuire 1 , P. A. Bergh 1,2 , R. T. Scott 1,2 . 1 Reproductive 

Medicine Associates of New Jersey, Morristown, NJ; 2 Division 

of Reproductive Endocrinology, Department of Obstetrics and 

Gynecology, UMDNJ-Robert Wood Johnson Medical School, New 

Brunswick, NJ. 

O-23 6:00 PM 

THE MEN’S LOUNGE IMPROVEMENT PROJECT – DID WE GET IT 

RIGHT? 

S. Levy, B. Campbell. The Center for Infertility and Reproductive 

Surgery, Brigham and Women’s Hospital, Boston, MA. 

__________________________________________________________ 

REPRODUCTIVE BIOLOGY PROFESSIONAL GROUP 

ROOM 603 

Moderators: Jeffrey T. Jensen, M.D. 

Kristen A. Ivani, Ph.D. 

O-24 4:15 PM 

ESTABLISHMENT AND CHARACTERIZATION OF HUMAN GERM 

CELLS DERIVED FROM EMBRYONIC STEM CELLS (hESCs). 

N. D. Tran, D. Laird, M. Kissner, D. Supramanyam, M. Conti, R. 

Blelloch. Obstetrics and Gynecology, Center for Reproductive 

Sciences, University of California, San Francisco Medical Centre, San 


O-25 4:30 PM 

CENTROMERE PROTEIN A (CENP-A) DYNAMICS IN HUMAN 

PLURIPOTENT STEM CELL SELF RENEWAL, DIFFERENTIATION AND 

DNA REPAIR. 

G. Ambartsumyan 1,2 , S. Diaz Perez 2 , A. Clark 2 . 1 Ob/Gyn, UCLA, Los 

Angeles, CA; 2 MCDB, UCLA, Los Angeles, CA. 

O-26 4:45 PM 

DERIVATION OF EMBRYONIC STEM CELLS FROM PRE- 

IMPLANTATION GENETIC DIAGNOSIS EMBRYOS: POSSIBLE BUT 

INEFFICIENT. 

B. M. Lannon 1,2 , K. MacCutcheon 2 , A. S. Penzias 1,2 , K. Eggan 3 . 1 Dept. 

of Obstetrics & Gynecology; Div. of Reproductive Endocrine & 

Infertility, Beth Israel Deaconess Medical Center, Boston, MA; 2 Boston 

IVF, Waltham, MA; 3 Department of Stem Cell & Regenerative 

Biology, Harvard University, Cambridge, MA. 

O-27 5:00 PM 

EFFICIENCY OF HUMAN EMBRYONIC STEM CELL DERIVATION 

(hESC): OPTIMIZATION OF THE ICM ISOLATION AND CULTURE 

CONDITIONS. 

N. Zaninovic, Q. Zhan, Z. Rosenwaks. Center for Reproductive 

Medicine and Infertility, Weill Cornell Medical College of Cornell 

University, New York, NY. 


99 

O-28 5:15 PM 

TELOMERE DNA IS SIGNIFICANTLY REDUCED IN ANEUPLOID 

HUMAN OOCYTES AND EMBRYOS. 

N. R. Treff, J. Su, D. Taylor, T. Molinaro, R. T. Scott, Jr. Reproductive 

Medicine Associates of New Jersey, Morristown, NJ. 

O-29 5:30 PM 

THE HUMAN OOCYTE EXPRESSES A UNIQUE CLASS OF 

PROTEINS THAT PROTECT THE GENOME FROM GENETIC 

REARRANGEMENTS AND INSERTIONAL MUTAGENESIS. 

Z. Williams 1,2 , P. Puvvula 2 , S. Rouhanifard 2 , Z. Rosenwaks 1 , T. Tuschl 2 . 

1 Center For Reproductive Medicine and Infertility, Weill-Cornell 

Medical Center, New York, NY; 2 Laboratory of RNA Molecular 

Biology, The Rockefeller University, New York, NY. 

O-30 5:45 PM 

HUMAN OOCYTES CRYOPRESERVATION: EVALUATION OF 

MEIOTIC SPINDLES, CHROMOSOMAL ALIGNMENT, AND 

MITOCHONDRIAL DISTRIBUTION BEFORE AND AFTER SLOW- 

FREEZE PROTOCOL. 

A.-T. H. La 1 , D. G. Diaz 1 , M. C. Rodriguez-Karl 1 , S. Karl 2 , R. A. Koch 2 . 

1 West Coast Fertility Centers, Fountain Valley, CA; 2 Biological 

Science, California State Unversity, Fullerton, Fullerton, CA. 

O-31 6:00 PM 

THE TYPES OF CHROMOSOME ABNORMALITY IN BLASTOCYSTS 

GENERATED BY INFERTILE PATIENTS. 

G. L. Harton1 , S. Al-Farawaty2 , N.-N. Goodall1 , S. Tormasi1 , D. Wells2 , 

E. Fragouli2 . 1Reprogenetics LLC, Livingston, NJ; 2Reprogenetics UK, 

Oxford, United Kingdom. 

__________________________________________________________ 

FERTILITY PRESERVATION SPECIAL INTEREST GROUP 

ROOM 605 

Moderators: Jacques G. Donnez, M.D. 

David W. Lee, M.D. 

O-32 4:15 PM 

FOLLICLE “BURN OUT”: A NOVEL MECHANISM OF 

CHEMOTHERAPY INDUCED OVARIAN DAMAGE. 

D. Meirow1 , L. Philosof-Kalich1,2 , A. Carmely1 , M. Bartal1 , H. Roness1 . 

1Obstrics and Gynecology, Sheba Medical Center, Ramat Gan, 

Israel; 2Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel. 

O-33 4:30 PM 

THE PREVALENCE OF SELF-REPORTED REPRODUCTIVE 

IMPAIRMENT IN YOUNG FEMALE CANCER SURVIVORS 

THROUGHOUT CALIFORNIA. 

J. M. Letourneau 1 , P. M. Katz 2 , J. F. Smith 1,3 , K. Oktay 4 , M. I. Cedars 1 , 

M. P. Rosen 1 . 1 Department of Obstetrics, Gynecology, and 

Reproductive Sciences, University of California San Francisco School 

of Medicine, San Francisco, CA; 2 Department of Medicine, University 

of California San Francisco School of Medicine, San Francisco, 

CA; 3 Department of Urology, University of California San Francisco 

School of Medicine, San Francisco, CA; 4 Department of Obstetrics 

and Gynecology, New York Medical College, Valhalla, NY. 

O-34 4:45 PM 

RESTORATION OF FERTILITY AFTER CHEMOTHERAPY-INDUCED 

OVARIAN FAILURE USING PERIPHERAL BLOOD STEM CELLS. 

A. E. Archibong 1 , C. Sharan 1 , A. Al-Hendy 1 . 1 Obstetrics and 

Gynecology, Meharry Medical College, Nashville, TN; 2 Center for 

Women’s Health Research, Meharry Medical College, Nashville, TN. 

O-35 5:00 PM 

LONG-TERM OUTCOMES AND SAFETY OF LETROZOLE-FSH 

PROTOCOL IN WOMEN WITH BREAST CANCER UNDERGOING 

FERTILITY PRESERVATION: A PROSPECTIVE-CONTROLLED STUDY. 

K. Oktay 1 , S. Lee 1 , J. Y. Kim 1 , F. Moy 2 . 1 Institute for Fertility Preservation/ 

Department of Obstetrics & Gynecology, New York Medical 

College, Valhalla, NY; 2 Biometrics, Data Management and PK/PD 

Unit/Department of Pathology, New York Medical College, Valhalla, 

NY.

O-36 5:15 PM 

PREVENTION OF CHEMOTHERAPY-INDUCED APOPTOTIC 

FOLLICULAR DEATH IN HUMAN OVARY BY CERAMIDE- 

INDUCED DEATH PATHWAY INHIBITORS. 

R. Soleimani, E. Heytens, K. Oktay. Laboratory of Molecular 

Reproduction, Institute for Fertility Preservation, Department of 

Obstetrics & Gynecology, New York Medical College, Valhalla, NY. 

O-37 5:30 PM 

VITRIFICATION OF RHESUS MACAQUE OVARIAN CORTEX 

USING NON-PERMEATING POLYMERS MAINTAINS TISSUE 

MORPHOLOGY AND PROMOTES FOLLICLE DEVELOPMENT 

DURING ENCAPSULATED 3-DIMENSIONAL (3D) CULTURE. 

R. R. Yeoman, A. Y. Ting, M. S. Lawson, M. B. Zelinski. Division of 

Reproductive Sciences, Oregon National Primate Research Center, 

Oregon Health & Sciences University, Beaverton, OR. 

O-38 5:45 PM 

LONG-TERM FOLLOWUP OF AUTOLOGOUS, NON-HUMAN 

PRIMATE OVARIAN TISSUE TRANSLANTS AND REPRODUCTIVE 

COMPETENCE IN OFFSPRING BORN FROM OVARIAN TISSUE 

TRANSPLANTATION. 

D. M. Lee 1,2 , C. Thomas 2 , R. Yeoman 2 , D. P. Wolf 2 , R. Stouffer 2 , M. 

Zelinski 2 . 1 Obstetrics & Gynecology, Pediatrics, Oregon Health 

and Science University, Portland, OR; 2 Oregon National Primate 

Research Center, Beaverton, OR. 

O-39 6:00 PM 

FLUORESCENCE-ACTIVATED CELL SORTING MAY ALLOW 

SEPARATION OF MALIGNANT LEUKEMIC CELLS FROM A 

TESTICULAR CELL SUSPENSION. 

S. L. Dovey1,2 , H. Valli2 , B. P. Hermann2 , K. Orwig1,2 . 1Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh 

Medical Center/Magee Womens Hospital, Pittsburgh, PA; 2Magee Womens Research Institute, Pittsburgh, PA. 

__________________________________________________________ 

CLINICAL FEMALE INFERTILITY AND GYNECOLOGY 

ROOM 207 

Moderators: Gordon Wright Bates, Jr., M.D. 

Ghina S. Ghazeeri, M.D. 

O-40 4:15 PM 

THE ECONOMIC IMPACT OF SCREENING FOR FETAL 

KARYOTYPIC ABNORMALITIES IN WOMEN PRESENTING WITH 

THEIR SECOND PREGNANCY LOSS. 

N. Foyouzi, M. I. Cedars, M. Rosen, H. G. Huddleston. Department 

of Obstetrics, Gynecology and Reproductive Sciences, University of 

California San Francisco, San Francisco, CA. 

O-41 4:30 PM 

ABSORPTION OF VAGINAL PROGESTERONE GEL DURING 

SEXUAL INTERCOURSE: A PROSPECTIVE, RANDOMIZED, 

CONTROLLED TRIAL. 

K. A. Leake, M. Elliot, J. Barker, P. B. Marshburn, R. S. Usadi, B. S. Hurst. 

Department of Obstetrics & Gynecology, Carolinas Medical Center, 

Charlotte, NC. 

O-42 4:45 PM 

CHLAMYDIA TRACHOMATIS SEROLOGY SCREENING IN 

INFERTILITY IS A SIGNIFICANT PROGNOSTICATOR OF 

PREGNANCY IN NON-IVF CYCLES. 

M. Durante, M. D. Keltz. Div. Reproductive Endocrinology, Dept. 

Obstetrics and Gynecology, St. Luke’s-Roosevelt Hospital Center, 

Columbia College of Physicians and Surgeons, New York, NY. 

O-43 5:00 PM 

HYPERGLYCOSYLATED hCG IN EARLY PREGNANCY AND ITS 

USE AS A DIAGNOSTIC MARKER FOR ECTOPIC PREGNANCY. 

L. A. Rubal 1 , M. D. Sammel 2 , P. Takacs 3 , F. Stanczyk 1 , K. Barnhart 2,4 , 

K. Chung 1 . 1Dept of Obstetrics and Gynecology, University of 

Southern California, Los Angeles, CA; 2 Ctr for Clinical Epidemiology 

& Biostatistics, University of Pennsylvania, Philadelphia, PA; 3 Dept of 


100 

Obstetrics and Gynecology, University of Miami, Miami, FL; 4 Dept of 

Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, 

PA. 

O-44 5:15 PM 

LONG-TERM QUALITY OF LIFE AND SAFETY OF A NEW 

TRANEXAMIC ACID MENORRHAGIA TREATMENT. 

K. Muse 1 , J. Gersten 2 , A. Waldbaum 3 , R. G. Mabey 4 , A. Lukes 5 , K. 

Moore 6 . 1 Department of Obstetrics and Gynecology, University 

of Kentucky Medical Center, Lexington, KY; 2 New Age Medical 

Research Corporation, Miami, FL; 3 Downtown Women’s Health 

Care, Denver, CO; 4 Private Practice, Las Vegas, NV; 5 Carolina 

Women’s Research and Wellness Center, Durham, NC; 6 Xanoydyne 

Pharmaceuticals, Inc., Newport, KY. 

O-45 5:30 PM 

A 12-MONTH, OPEN-LABEL TRIAL OF FLIBANSERIN IN 

NORTH AMERICAN WOMEN WITH GENERALIZED ACQUIRED 

HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD): THE 

SUNFLOWER TRIAL. 

C. Jayne1 , J. Simon2 , L. Taylor3 , T. Kimura4 , R. Pyke4 , L. Lesko4 . 

1 2 Vanguard Urologic Institute, Houston, TX; James A Simon, George 

Washington University, Women’s Health & Research Consultants ® , 

Washington, DC; 3Dean Foundation for Health Research and 

Education, Middleton, WI; 4Boehringer Ingelheim Pharmaceuticals, 

Inc., Ridgefield, CT. 

__________________________________________________________ 

MALE FACTOR: ART 

ROOM 601 

Moderators: Suheil J. Muasher, M.D. 


O-46 4:15 PM 

SPERMATOGONIA STEM CELLS IN OBSTRUCTIVE AND 

NONOBSTRUCTIVE AZOOSPERMIA; A PRELIMINARY STUDY. 

E. Shlush1 , G. Faragi2 , G. Groisman3 , A. Ellenbogen1 . 1Obstetrics and Gynecology, IVF UNIT, Hadera, Israel; 2Department of Urology, 

Hadera, Israel; 3Department of Pathology, Hadera, Israel. 

O-47 4:30 PM 

MAGNETIC ACTIVATED SORTING SELECTION (MACS) OF 

NON-APOPTOTIC SPERM (NAS) IMPROVES PREGNANCY 

RATES IN HOMOLOGOUS INTRAUTERINE INSEMINATION (IUI). 

PRELIMINARY DATA. 

L. Romany, M. Meseguer, S. Garcia-Herrero, A. Pellicer, N. Garrido. 

Instituo Universitario IVI, Valencia, Spain. 

O-48 4:45 PM 

INTRACYTOPLASMIC MORPHOLOGICALLY-SELECTED SPERM 

INJECTION (IMSI) BENEFITS ON SEVERE MALE FACTOR 

PROFILED ACCORDING TO THE 2010 WHO REFERENCE VALUES. 

R. C. S. Figueira 1 , A. Setti 2 , D. Braga 1,2 , F. Pasqualotto 3 , A. Iaconelli, 

Jr 1 , E. Borges, Jr 1,2 . 1 Fertility - Assisted Fertilization Center, Sao Paulo, 

SP, Brazil; 2 Sapientiae Institute - Educational and Research Center in 

Assisted Reproduction, Sao Paulo, SP, Brazil; 3 Caxias do Sul University, 

Caxias do Sul, RS, Brazil. 

O-49 5:00 PM 

QUANTITATIVE SHOTGUN PROTEOMIC ANALYSIS OF SEMINAL 

PLASMA FROM MEN SUBMITTED TO INTRACYTOPLASMIC 

SPERM INJECTION (ICSI). 

T. B. Soler 1 , E. G. Lo Turco 1 , M. N. Eberlin 2 , J. S. Garcia 2,4 , G. H. M. F. 

Souza 2,3 , R. P. Bertolla 1 . 1 Division of Urology, Human Reproduction 

Section, Sao Paulo Federal University, Sao Paulo, SP, Brazil; 2 ThoMSon 

Mass Spectrometry Laboratory, Institute of Chemistry, University of 

Campinas, Campinas, SP, Brazil; 3 Mass Spectrometry Applications 

Research and Development Laboratory, Waters Corporation, 

Alphaville, SP, Brazil; 4 Department of Exact Sciences, Alfenas Federal 

University, Alfenas, MG, Brazil.

O-50 5:15 PM 

PREIMPLANTATION GENETIC SCREENING ON PATIENTS WITH 

MEIOTIC DISORDERS. 

M. Esbert 1 , F. Vidal 2 , M. Riqueros 1 , A. Pellicer 3 , A. Ballesteros 1 , G. 

Calderon 1 . 1 IVI-Barcelona, Barcelona, Spain; 2 Universitat Autonoma 

de Barcelona, Bellaterra, Spain; 3 IVI-Valencia, Valencia, Spain. 

O-51 5:30 PM 

SPERM ORGANELLE MORPHOLOGIC ABNORMALITIES: 

CONTRIBUTING FACTORS AND EFFECTS ON ICSI OUTCOMES. 

D. Braga 1,2 , R. C. S. Figueira 1 , C. Martinhago 3 , A. Setti 2 , A. Iaconelli, 

Jr 1 , E. Borges, Jr 1,2 . 1 Fertility - Assisted Fertilization Center, Sao Paulo, 

SP, Brazil; 2 Sapientiae Institute - Educational and Research Center in 

Assisted Reproduction, Sao Paulo, SP, Brazil; 3 RDO Medical Diagnosis, 

Sao Paulo, SP, Brazil. 

O-52 5:45 PM 

ATTEMPTS TO REVIVE NON-MOTILE SPERMATOZOA RESILIENT 

TO MOTILITY ENHANCERS. 

Q. V. Neri, J. Kocent, Z. Rosenwaks, G. D. Palermo. The Ronald O 

Perelman & Claudia Cohen Center for Reproductive Medicine, Weill 

Cornell Medical College, New York, NY. 

O-53 6:00 PM 

EVALUATION OF INTRACYTOPLASMIC SPERM INJECTION 

OUTCOMES IN MEN WITH HYPOGONADOTROPIC 

HYPOGONADISM: 5 YEARS’ EXPERIENCE. 

N. Dokuzeylul, S. Kahraman, S. Ozkan, G. Karlikaya, H. Karagozoglu, 

A. Ersahin. ART and Reproductive Genetics Center, Memorial 

Hospital, Istanbul, Turkey. 

__________________________________________________________ 

MALE REPRODUCTION AND UROLOGY 

ROOM 4C 

Moderators: Barrett E. Cowan, M.D. 

Sheldon F. Marks, M.D. 

O-54 4:15 PM 

SPERMATOGONIA STEM CELL IDENTIFICATION IN 

HETEROSPECIFIC MODEL. 

Q. V. Neri1 , J. C. Y. Hu1 , P. N. Schlegel2 , Z. Rosenwaks1 , G. D. Palermo1 . 

1The Ronald O Perelman & Claudia Cohen Center for Reproductive 

Medicine, Weill Cornell Medical College, New York, NY; 2Brady Urology, Weill Cornell Medical College, New York, NY. 

O-55 4:30 PM 

DOES ISOLATED TERATOZOOSPERMIA WARRANT THE USE OF 

INTRACYTOPLASMIC SPERM INJECTION (ICSI)? 

B. Hodes-Wertz, C. Mullin, A. Adler, A. S. Berkeley, J. Grifo. NYU 

Fertility Center, New York University, New York, NY. 

O-56 4:45 PM 

ANEUPLOIDY RATES IN EJACULATED AND TESTICULAR 

SPERMATOZOA IN PATIENTS WITH HIGH SPERM DNA DAMAGE. 

S. I. Moskovtsev 1,2 , N. Alladin 1 , K. C. Lo 3 , K. Jarvi 3 , J. B. M. Mullen 2 , 

C. L. Librach 1,4 . 1 CReATe Fertility Center, Toronto, ON, Canada; 

2 Department of Pathology and Laboratory Medicine, Mount Sinai 

Hospital, Toronto, ON, Canada; 3 Division of Urology, Department 

of Surgery, Mount Sinai Hospital, Toronto, ON, Canada; 4 Division 

of Reproductive Endocrinology and Infertility, Department of 

Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre, 

Toronto, ON, Canada. 

O-57 5:00 PM 

EFFECT OF BODY MASS INDEX ON SPERM QUALITY. 

J. R. Pariz, R. M. Fariello, C. F. Lima, D. M. Spaine, R. P. Bertolla, R. 

Fraietta. Division of Urology, Human Reproduction Section, Sao 

Paulo Federal University, Sao Paulo, SP, Brazil. 

O-58 5:15 PM 

THE GENDER GAP IN THE TIME COSTS OF INFERTILITY 

TREATMENT: EXAMINATION OF A PROSPECTIVE U.S. COHORT. 

M. L. Eisenberg 1 , J. F. Smith 2 , N. Sadetsky 1 , S. G. Millstein 3 , R. D. 

Nachtigall 4 , P. P. Katz 5 . 1 Urology, University of California San 


101 

Francisco, San Francisco, CA; 2 Urology and Obstetrics, Gynecology 

and Reproductive Sciences, University of California San Francisco, 

San Francisco, CA; 3 Pediatrics, University of California San Francisco, 

San Francisco, CA; 4 Obstetrics, Gynecology and Reproductive 

Sciences, University of California San Francisco, San Francisco, CA; 

5 Medicine, University of California San Francisco, San Francisco, CA. 

O-59 5:30 PM 

MICRODISSECTION TESE: THE LEARNING CURVE. 

W. Hsiao, R. Ramasamy, J. A. Ricci, P. N. Schlegel. Department of 

Urology, Center for Male Reproductive Medicine, Weill Cornell 

Medical College, New York, NY. 

__________________________________________________________ 

CRYOPRESERVATION AND FROZEN EMBRYO TRANSFER: ART 

ROOM 203 

Moderators: Valerie L. Baker, M.D. 

John S. Hesla, M.D. 

O-60 4:15 PM 

ASSESSMENT OF AUTOPHAGE, APOPTOSIS AND DNA 

DAMAGE/REPAIR PROCESS IN CRYOPRESERVED OVARIAN 

CORTEX. 

S. S. Kim1 , D. Limback2 , L. He1 , D. Albertini2 . 1OB/GYN, University of 

Kansas Medical Center, Kansas City, KS; 2Physiology, University of 

Kansas Medical Center, Kansas City, KS. 

O-61 4:30 PM 

USING SIBLING OOCYTES TO EVALUATE TWO VITRIFICATION 

SOLUTIONS FOR OOCYTE CRYOPRESERVATION: SINGLE 

PERMEABLE CRYOPROTECTANT VERSUS MIXTURE OF 

PERMEABLE CRYOPROTECTANTS. 

C.-C. Chang, D. P. Bernal, G. Wright, C. W. Elsner, A. A. Toledo, Z. P. 

Nagy. Reproductive Biology Associates, Atlanta, GA. 

O-62 4:45 PM 

OBESITY IS ASSOCIATED WITH LOWER LIVE BIRTH RATES IN 

FRESH, BUT NOT FROZEN EMBRYO TRANSFER CYCLES. 

M. Maguire 1,2 , J. Csokmay 1,2 , M. Hill 1,2 , J. Segars 1,2 , A. Armstrong 1,2 . 

1 The Eunice Kennedy Shriver National Institute of Child Health and 

Human Development, National Institutes of Health, Bethesda, 

MD; 2 Department of Obstetrics and Gynecology, Division of 

Reproductive Endocrinology and Infertility, Walter Reed Army 

Medical Center, Washington, DC. 

O-63 5:00 PM 

FRESH VERSUS FROZEN SIB-PAIR ANALYSIS OF BIRTHWEIGHT IN 

SINGLETON LIVEBIRTHS AS A RESULT OF IVF. 

K. E. O’Neill, S. E. Lanzendorf, R. R. Odem, A. R. Cooper. Obstetrics 

and Gynecology, Washington University School of Medicine, Saint 

Louis, MO. 

O-64 5:15 PM 

COMPREHENSIVE CHROMOSOME SCREENING SIGNIFICANTLY 

IMPROVES IMPLANTATION RATES FOLLOWING FROZEN 

BLASTOCYST TRANSFER. 

J. M. Stevens, E. S. Surrey, D. A. Minjarez, R. L. Gustofson, W. B. 

Schoolcraft, M. G. Katz-Jaffe. Colorado Center for Reproductive 

Medicine, Lone Tree, CO. 

O-65 5:30 PM 

HIGH SURVIVAL OF HUMAN HATCHED BLASTOCYSTS AFTER 

BLASTOCOELE COLLAPSE PRIOR TO VITRIFICATION USING A 

CLOSED SYSTEM. 

C. A. Guerrero 3 , T. Ferguson 1 , S. Chantilis 1 , K. Lee 1 , J. Goldstein 1 , 

D. Hammitt 1,2,3 . 1 ARTS Program, Texas Health Presbyterian Hospital 

Dallas, Dallas, TX; 2 ARTS Program, Texas Health Presbyterian Hospital 

Plano, Plano, TX; 3 ARTS Program, Texas Health Harris Methodist Fort 

Worth, Fort Worth, TX.

O-66 5:45 PM 

DEVELOPMENT OF A PREDICTIVE MODEL FOR DONOR’S 

VITRIFIED OOCYTE’S SURVIVAL IN AN EGG-BANK. 

A. Cobo, N. Garrido, A. Pellicer, J. Remohí. IVI, Instituto Universitario 

IVI- Valencia, Valencia, Spain. 

O-67 6:00 PM 

WHEN DOES CHROMOSOMAL MOSAICISM OCCUR 

THROUGHOUT HUMAN EMBRYONIC DEVELOPMENT? 

M. Nagayoshi1 , A. Tanaka1 , S. Awata1 , I. Tanaka1 , H. Kusunoki2 , S. 

Watanabe3 . 1Saint Mother Hospital, Kitakyushu, Fukuoka, Japan; 

2Faunal Diversity Sciences, Graduate School of Agriculture, Kobe 

University, Kobe, Hyogo, Japan; 3Department of Anatomical 

Science, Hirosaki University Graduate School of Medicine, Hirosaki, 

Aomori, Japan. 

__________________________________________________________ 

OTHER: ART 

ROOM 205 

Moderators: Eric A. Widra, M.D. 


O-68 4:15 PM 

EFFICACY OF VAGINAL PROGESTERONE INSERTS 

(ENDOMETRIN ® ) COMPARED TO INTRAMUSCULAR 

PROGESTERONE IN OIL FOR LUTEAL SUPPORT IN IVF PATIENTS. 

C. E. Miller2 , K. J. Doody1 , E. Zbella3 , B. Webster4 , M. R. Bush5 , J. 

Scobey6 . 1Center for Assisted Reproduction, Bedford, TX; 2The IVF 

Institute-Chicago, Naperville, IL; 3Women’s Medical Research 

Group, Clearwater, FL; 4A Woman’s Center for Reproductive 

Medicine, Baton Rouge, LA; 5Conceptions Reproductive Associates 

of Colorado, Littleton, CO; 6Ferring Pharmaceuticals Inc., 

Parsippany, NJ. 

O-69 4:30 PM 

PROGESTERONE VAGINAL GEL VS. INTRAMUSCULAR 

PROGESTERONE IN OIL FOR LUTEAL SUPPORT IN IVF: A LARGE, 

PROSPECTIVE TRIAL. 

K. Silverberg, T. C. Vaughn, L. Hansard, N. Burger, T. Minter. Texas 

Fertility Center, Austin, TX. 

O-70 4:45 PM 

FMR1 TRINUCLEOTIDE REPEAT SIZE IS PREDICTIVE OF OVARIAN 

RESPONSE. 

M. Luna 1 , G. Vela 1,2 , B. Sandler 1,2 , L. Grunfeld 1,2 , T. Mukherjee 1,2 , A. B. 

Copperman 1,2 . 1 Reproductive Medicine Associates of New York, 

New York, NY; 2 Department of OBGYN and Reproductive Science, 

Mount Sinai School of Medicine, New York, NY. 

O-71 5:00 PM 

DIFFERENTIAL GENE EXPRESSION PROFILES BETWEEN HUMAN 

EMBRYO ON DAY-3 AND TROPHOBLAST CELLS ON DAY-5: 

SPECIFIC MOLECULAR SIGNATURE. 

S. Assou 1 , D. Haouzi 1 , F. Pellestor 1 , H. Dechaud 2 , J. De Vos 1,3 , S. 

Hamamah 1,2,3 . 1 CHU Montpellier, Institute for Research in Biotherapy, 

Hôpital Saint-Eloi, INSERM U847, Montpellier, France; 2 CHU 

Montpellier, Unité Biologie Clinique d’AMP - DPI, Hôpital Arnaud de 

Villeneuve, Montpellier, France; 3 CHU Montpellier, Unité de Thérapie 

Cellulaire, Hôpital Saint Eloi, Montpellier, France. 

O-72 5:15 PM 

A COMPARISON OF IVF TRIPLETS; ELECTIVELY VS. 

SPONTANEOUSLY REDUCED TO TWIN GESTATIONS. 

B. Ata 1 , S. L. Tan 1 , L. J. Rasillo 2 , S. Sukhdeo 1 , W. Y. Son 1 , M. H. Dahan 1 . 

1 McGill Reproductive Centre, Dept. of Obstetrics and Gynecology, 

McGill University, Montreal, QC, Canada; 2 Instituto Medica Fertil, 

San Luis Potosi, Mexico. 


102 

O-73 5:30 PM 

EPIGENETIC RISKS IN ASSISTED REPRODUCTIVE TECHNOLOGIES 

(ART): RESULTS FROM A FRENCH COHORT COMPOSED OF 15 

162 CHILDREN CONCEIVED BY IN VITRO FERTILIZATION OR 

INTRACYTOPLASMIC SPERM INJECTION. 

G. B. Viot 1 , S. Epelboin 2 , F. Olivennes 3 . 1 Génétique, Maternité Port- 

Royal, Paris, France; 2 Gynécologie-Obstétrique, Hôpital Bichat, Paris, 

France; 3 Gynécologie-Obstétrique, Cabinet Privé, Paris, France. 

O-74 5:45 PM 

PATIENT INTEREST IN AN INCENTIVIZED SINGLE EMBRYO 

TRANSFER PROGRAM AT THE UNIVERSITY OF UTAH. 

J. A. Dorais 1 , S. E. Gurtcheff 2 , C. Milroy 2 , A. Hammoud 2 , M. Gibson 2 , 

C. M. Peterson 2 . 1 Department of Obstetrics and Gynecology, 

University of Utah, Salt Lake City, UT; 2 Department of Obstetrics and 

Gynecology, Division of Reproductive Endocrinology and Infertility, 

University of Utah, Salt Lake City, UT. 

O-75 6:00 PM 

DEFINING CELL FATE AND EMBRYONIC GENOME ACTIVATION 

BY GLOBAL SINGLE-CELL CDNA ANALYSIS OF BLASTOMERES 

FROM 5 TO 8-CELL HUMAN EMBRYOS. 

A. Galán1 , D. Montaner2 , M. E. Póo1 , V. Ruiz1 , D. Valbuena1 , C. 

Simón1 . 1Valencia Node of the Spanish Stem Cell Bank, Prince 

Felipe Research Centre (CIPF), Valencia, Spain; 2Bioinformatics Department, Prince Felipe Research Centre (CIPF), Valencia, Spain. 

__________________________________________________________ 

OUTCOME PREDICTORS- CLINICAL: ART 1 

ROOM 501 

Moderators: Eric S. Surrey, M.D. 

Glenn L. Schattman, M.D. 

O-76 4:15 PM 

DISCORDANCE BETWEEN ANTIMULLERIAN HORMONE (AMH) 

AND DAY 3 FOLLICLE STIMULATING (FSH) LEVELS IN THE 

ASSESSMENT OF OVARIAN RESERVE. 

B. Leader1,2 , Q. Baca3 , D. Seifer4 , V. L. Baker2,5 . 1Clinical Research, 

ReproSource, Inc, Woburn, MA; 2Rachel’s Well, Marietta, GA; 3Dept of Biochemistry and Molecular Pharmacology, Harvard Medical 

School, Boston, MA; 4Genesis Fertility & Reproductive Medicine, 

Brooklyn, NY; 5Obstetrics and Gynecology, Stanford Medical School, 

Stanford, CA. 

O-77 4:30 PM 

TRANSCRIPTOMIC ANALYSIS OF HUMAN CUMULUS CELLS AS 

BIOMARKERS OF OOCYTE AND EMBRYO QUALITY. 

S. Hamamah 1,2 . 1 CHU Montpellier, Institute for Research in 

Biotherapy, Hôpital Saint-Eloi, INSERM U847, Université MONTPELLIER1, 

Montpellier, France; 2 CHU Montpellier, Unité Biologie Clinique d’AMP 

- DPI, Hôpital Arnaud de Villeneuve, Montpellier, France. 

O-78 4:45 PM 

FIRST CLINICAL APPLICATION OF SNP MICROARRAY BASED 

24 CHROMOSOME ANEUPLOIDY SCREENING OF HUMAN 

BLASTOCYSTS. 

W. B. Schoolcraft 1 , N. R. Treff 2,3 , K. Ferry 2 , J. M. Stevens 1 , M. G. Katz- 

Jaffe 1 , R. T. Scott 2,3 . 1 Colorado Center for Reproductive Medicine, 

Lone Tree, CO; 2 Reproductive Medicine Associates of New Jersey, 

Morristown, NJ; 3 UMDNJ-Robert Wood Johnson Medical School, New 

Brunswick, NJ. 

O-79 5:00 PM 

CUMULATIVE LIVE-BIRTH RATES (CLBR) CONSIDERING 

THE TOTAL NUMBER OF EMBRYOS REPLACED IN 26504 

CONSECUTIVE OVUM DONATION CYCLES (OD). 

N. Garrido1,2 , J. Bellver1,2 , J. Remohi1,2 , C. Simon1,2 , A. Pellicer1,2 . 

1 2 Instituto Universitario IVI Valencia, Valencia, Spain; IVI Foundation, 

Valencia, Spain.

O-80 5:15 PM 

SELECTION OF YOUNG PATIENTS USING STRICT CRITERIA 

ALLOWS AN EXCELLENT CHANCE OF PREGNANCY WHEN 

TRANSFERRING A SINGLE EMEBRYO WHILE AVOIDING A HIGH 

RISK OF MULTPLE GESTATION. 

T. C. Vaughn, K. M. Silverberg, L. J. Hansard, N. Z. Burger, T. Minter, T. 

Turner. Texas Fertility Center, Austin, TX. 

O-81 5:30 PM 

DEFINING EARLY ßhCG DYNAMICS IN IVF-CONCEIVED 

MONOZYGOTIC (MZ) PREGNANCIES. 

G. Vela 1,2 , M. Luna 1,2 , E. D. Flisser 1 , F. Arredondo 3 , B. Sandler 1,2 , A. B. 

Copperman 1,2 . 1 Reproductive Medicine Associate of New York, New 

York, NY; 2 Department of OBGYN and Reproductive Science, Mount 

Sinai School of Medicine, New York, NY; 3 Reproductive Medicine 

Associates of Texas, San Antonio, TX. 

O-82 5:45 PM 

A DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME (PCOS) 

IS ASSOCIATED WITH AN INCREASED LIKELIHOOD OF 

PREGNANCY LOSS WITH ASSISTED REPRODUCTION. 

R. J. Chason 1 , K. S. Richter 2 , E. A. Widra 2 , J. H. Segars 1 . 1 Program in 

Reproductive and Adult Endocrinology, Eunice Kennedy Shriver 

National Institute of Child Health and Human Development, 

National Institutes of Health, Bethesda, MD; 2 Shady Grove Fertility 

Reproductive Science Center, Rockville, MD. 

O-83 6:00 PM 

IS MATERNAL EDUCATION ASSOCIATED WITH IN VITRO 

FERTILIZATION (IVF) CYCLE COMPLETION AND OUTCOMES? 

S. Mahalingaiah1 , K. F. Berry1 , D. W. Cramer1 , M. D. Hornstein1 , 

S. A. Missmer1,2,3 . 1Department of Obstetrics, Gynecology, and 

Reproductive Biology, Brigham and Women’s Hospital and Harvard 

Medical School, Boston, MA; 2Channing Laboratory, Department 

of Medicine, Brigham and Women’s Hospital and Harvard Medical 

School, Boston, MA; 3Department of Epidemiology, Harvard School 

of Public Health, Boston, MA. 

__________________________________________________________ 

OUTCOME PREDICTORS-LABORATORY: ART 

ROOM 503 

Moderators: Kimball O. Pomeroy, Ph.D. 

Kathryn J. Go, Ph.D. 

O-84 4:15 PM 

WHAT’S THE SCORE?: A QUANTITATIVE MEANS TO ASSESS 

EMBRYO QUALITY (EQ). 

J. M. Knopman, L. C. Krey, C. McCaffrey, N. Noyes, B. Hodes-Wertz, 

J. A. Grifo. OB/GYN, NYU Langone Medical Center, New York, NY. 

O-85 4:30 PM 

WHEN ANTIMULLERIAN AND FOLLICLE STIMULATING HORMONE 

OFFER A DISCREPANT PROGNOSIS OF OVARIAN RESERVE, IN 

VITRO FERTILIZATION OUTCOMES ARE WORSE THAN WHEN 

BOTH VALUES PREDICT POOR OVARIAN RESERVE. 

I. D. Harris, S. Wang, L. Roth, R. Alvero, P. McShane, W. D. Schlaff. 

Obstetrics and Gynecology, University of Colorado Hospital, Denver, 

CO. 

O-86 4:45 PM 

HUMAN EMBRYONIC SECRETOME CHARACTERIZATION BY 

GEL-FREE PROTEOMICS APPROACH. 

S. S. Cortezzi 1 , J. S. Garcia 2 , G. H. M. F. Souza 3 , D. Braga 1,4 , M. N. 

Eberlin 5 , E. Borges, Jr 1,4 . 1 Sapientiae Institute – Educational and 

Research Center in Assisted Reproduction, Sao Paulo, SP, Brazil; 

2 Department of Exact Sciences, Alfenas Federal University, Alfenas, 

MG, Brazil; 3 Mass Spectrometry Applications Research and 

Development Laboratory, Waters Corporation, Barueri, SP, Brazil; 

4 Fertility - Assisted Fertilization Center, Sao Paulo, SP, Brazil; 5 ThoMSon 

Mass Spectrometry Laboratory - Institute of Chemistry, State 

University of Campinas, UNICAMP, Campinas, SP, Brazil. 


103 

O-87 5:00 PM 

THE USE OF ANTI MULLERIAN HORMONE AS A PREDICTOR FOR 

IVF OUTCOME IN EGG DONORS. 

T. Singer, E. Rauch, D. Goldschlag, I. Cholst, H.-C. Liu, Z. Rosenwaks. 

The Center for Reproductive Medicine and Infertility, Weill Cornell 


O-88 5:15 PM 

ASSESSMENT OF DAY 5 MORPHOLOGY GRADING AND 

METABOLOMIC VIABILITY SCORE AS PREDICTORS OF 

IMPLANTATION OUTCOME IN WOMEN UNDERGOING IN VITRO 

FERTILIZATION (IVF). 

E. Seli 1 , L. D. Botros 2 , M. A. Henson 2 , K. H. Judge 2 , D. H. Sakkas 2 , 

Metabolomics Study Group 2 . 1 Obstetrics, Gynecology, and 

Reproductive Sciences, Yale University School of Medicine, New 

Haven, CT; 2 Molecular Biometrics, Inc., New Haven, CT. 

O-89 5:30 PM 

SPERM MOTILITY IS NOT COMPROMISED IF COLLECTED IN 

MEDIA AND DELIVERED TO THE LABORATORY WITHIN 6 HOURS. 

R. Pyrzak 1 , R. P. Dickey 1,2 . 1 The Fertility Institute of New Orleans, 

Mandeville, LA; 2 Obstetrics and Gynecology, Louisiana State 

University, New Orleans, LA. 

O-90 5:45 PM 

UNCOMPLICATED SINGLETON PREGNANCIES CONCEIVED 

SPONTANEOUSLY AND THROUGH ASSISTED REPRODUCTION 

TECHNOLOGIES (ART) HAVE COMPARABLE FIRST TRIMESTER 

SCREENING PROFILES FOR DOWN SYNDROME. 

O. Oktem 1 , T. Barut 1 , E. Palaoglu 2 , B. Urman 1 . 1 Women’s Health 

Center Assisted Reproduction Unit, American Hospital, Istanbul, 

Turkey; 2 Clinical Laboratory, American Hospital, Istanbul, Turkey. 

O-91 4:30 PM 

DAY 5 BLASTOCYST MORPHOLOGY CORRELATES WITH 

COMPREHENSIVE CHROMOSOME CONSTITUTION AND 

OUTCOME. 

S. McCormick1,2 , J. Stevens1,2 , M. Rawlins2 , R. Smith2 , W. B. 

Schoolcraft1,2 , M. G. Katz-Jaffe1,2 . 1Colorado Center for Reproductive 

Medicine, Lone Tree, CO; 2Fertility Laboratories of Colorado, Lone 

Tree, CO. 

__________________________________________________________ 

OVARIAN STIMULATION: ART 

ROOM 201 

Moderator: Emily S. Jungheim, M.D. 

O-92 4:15 PM 

FLEXIBLE GnRH ANTAGONIST PROTOCOL VERSUS GnRH 

AGONIST LONG PROTOCOL IN PATIENTS AT HIGH RISK OF 

OVARIAN HYPERSTIMULATION SYNDROME: A PROSPECTIVE 

RANDOMIZED CONTROLLED TRIAL. 

S. Ferrero, L. H. Abbamonte, M. R. Privamera, S. Levi, P. L. Venturini, 

P. Anserini. Department of Obstetrics and Gynecology, San Martino 

Hospital and University of Genoa, Genoa, GE, Italy. 

O-93 4:30 PM 

CYCLE SCHEDULING WITH ORAL CONTRACEPTIVE PILLS IN 

GnRH ANTAGONIST PROTOCOL VS LONG PROTOCOL: A 

RANDOMIZED, CONTROLLED TRIAL. 

J. A. Garcia-Velasco, A. Bermejo, F. Ruiz-Flores, J. Martinez-Salazar, A. 

Requena, A. Pellicer. IVI-Madrid, Rey Juan Carlos University, Madrid, 

Spain. 

O-94 4:45 PM 

REAPPRAISAL OF IVF STIMULATION IN GOOD PROGNOSIS 

PATIENTS – A PROSPECTIVE RANDOMIZED STUDY TO COMPARE 

MILD VERSUS STANDARD LONG PROTOCOL. 

S. Ghosh Dastidar, S. Maity, B. Ghosh Dastidar. GD Institute for Fertility 

Research, Kolkata, West Bengal, India.

O-95 5:00 PM 

IS BIGGER BETTER: THE ASSOCIATION BETWEEN FOLLICLE SIZE 

AND LIVEBIRTH RATE FOLLOWING IVF. 

J. M. Knopman, J. A. Grifo, N. Noyes, E. Fino, C. Mullin, A. S. Berkeley. 

OB/GYN, NYU Langone Medical Center, New York, NY. 

O-96 5:15 PM 

LOW-DOSE METFORMIN IMPROVES PREGNANCY RATE IN IVF 

REPEATERS WITHOUT POLYCYSTIC OVARY SYNDROME: ITS 

INDICATION AND MECHANISM. 

M. Jinno, A. Watanabe, N. Eguchi, N. Hatakeyama, J. Hirohama, E. 

Hiura. Women’s Clinic Jinno, Choufu City, Tokyo, Japan. 

O-97 5:30 PM 

THE VALUE OF DELAYING hCG ADMINISTRATION TO ENABLE 

MATURATION OF MEDIUM SIZED FOLLICLES IN PATIENTS 

UNDERGOING SUPEROVULATION FOR IVF/ICSI. 

A. O. Awonuga, V. I. Shavell, A. N. Imudia, D. T. Hobson, T. Woodard, 

E. E. Puscheck. Obstetrics and Gynecology, Wayne State University, 

Detroit, MI. 

O-98 5:45 PM 

A COMPARISON OF THE OUTCOME OF IN VITRO MATURATION 

OF OOCYTES AND IN VITRO FERTILIZATION TREATMENTS IN THE 

SAME PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME. 

A. Ellenbogen, R. Atamna, O. Fainaru, E. Shlush, N. Rothfarb, M. 

Michaeli. Obstetrics and Gynecology, IVF UNIT, Hadera, Israel. 

O-99 6:00 PM 

IMPACT OF EXOGENOUS GONADOTROPHIN STIMULATION ON 

FOLLICULAR FLUID CYTOKINE PROFILES. 

E. N. Baskind1 , V. Sharma1 , N. Orsi2 , S. Barber3 . 1The Leeds Centre 

for Reproductive Medicine, Leeds Teaching Hospitals NHS Trust, 

Leeds, United Kingdom; 2Perinatal Research Group, Leeds Institute 

of Molecular Medicine, Leeds, United Kingdom; 3Department of 

Statistics, University of Leeds, Leeds, United Kingdom. 

__________________________________________________________ 

PROCEDURES AND TECHNIQUES-LABORATORY: ART 

ROOM 4E 

Moderators: Grace M. Centola, Ph.D. 

Michael W. Vernon, Ph.D., H.C.L.D. 

O-100 4:15 PM 

GENERATION AND CHARACTERIZATION OF DISEASE-SPECIFIC 

HUMAN EMBRYONIC STEM CELLS FROM GENETICALLY 

ABNORMAL EMBRYOS. 

C. Hansis1 , C. E. Rice1 , R. Lehmann2 , J. A. Grifo1 . 1Obstetrics and 

Gynecology/REI, NYU School of Medicine, New York, NY; 2Cell Biology (Skirball), NYU School of Medicine, New York, NY. 

O-101 4:30 PM 

ANALYSIS OF mRNA IN HUMAN POLAR BODIES. 

P. C. Klatsky1 , G. M. Wessel2 , J. Robins1 , J. Wittmyer1 , S. A. Carson1 . 

1Center for Reproduction & Infertility, Alpert Medical School 

of Brown University, Women & Infants Hospital, Providence, RI; 

2Molecular Biology, Cell Biology, & Biochemistry, Brown University, 

Providence, RI. 

O-102 4:45 PM 

EFFECT OF ARTIFICIAL COLLAPSE AND EQUILIBRATION 

TIMES ON SURVIVAL OF HUMAN BLASTOCYSTS FOLLOWING 

VITRIFICATION USING A CLOSED DOUBLE STRAW SYSTEM. 

C. A. Guerrero 3 , O. Perez 2 , J. M. D. Goldstein 1 , S. Chantilis 1 , K. Lee 1 , 




Worth, Fort Worth, TX. 


104 

O-103 5:00 PM 

IS INTRACYTOPLASMIC MORPHOLOGICALLY SELECTED SPERM 

INJECTION (IMSI) DETRIMENTAL FOR PREGNANCY OUTCOME? 

A.-M. Junca 1 , M. Dumont 1 , D. Cornet 2 , S. Douard 3 , J. De Mouzon 4 , 

N. Prisant 1 . 1 Biologie de la Reproduction, Laboratoire d’Eylau-Paris 

UNILABS, Paris, France; 2 Médecine de la Reproduction, Clinique de 

la Muette, Paris, France; 3 Médecine de la Reproduction, Clinique 

Pierre Cherest, Neuilly sur Seine, Hauts de Seine, France; 4 Service de 

Gynecologie Obstetrique II Médecine de la Reproduction, INSERM, 

Paris, France. 

O-104 5:15 PM 

RE-FREEZING BLASTOCYSTS: A PROSPECTIVE RANDOMIZED 

STUDY COMPARING SLOW FREEZING AND VITRIFICATION. 

C. A. Guerrero 3 , R. Young 3 , T. Ferguson 1 , S. Chantilis 1 , A. Rodriguez 2 , 





O-105 5:30 PM 

DONOR OOCYTES CRYO-STORED OVER SIX MONTHS PROVIDE 

SIMILAR RESULTS TO SHORTER STORAGE DURATION: A SIBLING 

OOCYTE STUDY PROVIDES EVIDENCE ON QUARANTINE 

OPTION. 

C.-C. Chang, J. M. Kahn, D. P. Bernal, D. Mitchell-Leef, R. J. Straub, Z. 

P. Nagy. Reproductive Biology Associates, Atlanta, GA. 

O-106 5:45 PM 

STRESS FOR STRESS TOLERANCE: IMPROVING CELL SURVIVAL 

BY SUBLETHAL STRESS TREATMENT OF EGGS BEFORE 

VITRIFICATION – PILOT STUDY. 

C. Pribenszky 1 , S. Mátyás 2 , E. Losonczi 3 , C. Stanca 4 , I. Bock 4 , G. Vajta 5 . 

1 Veterinary Science, St. István University, Budapest, Hungary; 2 Kaáli 

Institute, Budapest, Hungary; 3 ARTechnic Co., Debrecen, Debrecen, 

Hungary; 4 Biotalentum Ltd., Gödöllo, Hungary; 5 Beijing Genomics 

Institute, Shensen, Shenzen, China. 

O-107 6:00 PM 

ENVIRONMENTAL FACTORS AND MANUAL MANIPULATIONS 

DURING PREPARATION INFLUENCE EMBRYO CULTURE MEDIA 

OSMOLALITY. 

J. E. Swain 1,4 , L. Cabrera 1 , X. Xu 1 , G. D. Smith 1,2,3,4 . 1 Obstetrics & 

Gynecology, University of Michigan, Ann Arbor, MI; 2 Urology, 

University of Michigan, Ann Arbor, MI; 3 Physiology, University of 

Michigan, Ann Arbor, MI; 4 Reproductive Sciences Program, University 

of Michigan, Ann Arbor, MI. 

__________________________________________________________



Prize Paper Oral Abstract Presentations 


Moderator: Emre Seli, M.D. 

The following seven papers are candidates for the ASRM Scientific Program Prize Paper Awards. 

Seven additional candidates will be presented during the Prize Paper Candidates’ session on Monday morning. 

O-108 11:15 AM 

LEIOMYOMA FIBROSIS INHIBITED BY LIAROZOLE, A RETINOIC 

ACID METABOLIC BLOCKING AGENT. 

W. H. Catherino 1,2 , M. Malik 1 , J. Britten 1 , M. Gilden 1 , J. Segars 1,2 , D. 

McCarthy-Keith 1,2 . 1 Department of Obstetrics and Gynecology, 

Uniformed Services University, Bethesda, MD; 2 Program in 



Bethesda, MD. 

O-109 11:30 AM 

USAGE OF PREIMPLANTATION GENETIC DIAGNOSIS AND 

PREIMPLANATION GENETIC SCREENING IN THE US 2007-2008. 

A SART WRITING GROUP PAPER. 

E. S. Ginsburg 1 , C. Racowsky 1 , J. Goldfarb 2 , J. E. Stern 3 . 1 Obstetrics 

and Gynecology, Brigham & Women’s Hospital, Boston, MA; 

2 Obstetrics and Gynecology, Cleveland Clinic Fertility Center, 

Beechwood, OH; 3 Obstetrics and Gynecology, Dartmouth Medical 

Center, Lebanon, NH. 

O-110 11:45 AM 

NATIONAL STUDY OF FACTORS INFLUENCING ASSISTED 

REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES WITH MALE 

FACTOR INFERTILITY. 

A. K. Nangia 1 , B. Luke 2 , W. Abdel Megid 3 , J. F. Smith 4 , W. Mak 5 , J. E. 

Stern 6 . 1 Urology, University of Kansas Medical Center, Kansas City, 

KS; 2 Obstetrics, Gynecology and Reproductive Medicine and 

Epidemiology, Michigan State University, East Lansing, MI; 3 Wisconsin 

Fertility Institute, Middletown, WI; 4 Urology, University of California, 

San Francisco, San Francisco, CA; 5 Division of Reproductive 

Endocrinology and Infertility, University of Pennsylvania, Philadelphia, 

PA; 6Obstetrics and Gynecology, Dartmouth-Hitchcock Medical 

Center, Lebanon, NH. 

O-111 12:00 PM 

SIMVASTATIN REDUCES STEROIDOGENESIS IN RAT OVARIAN 

THECA-INTERSTITIAL CELLS. 

I. Ortega1,2 , A. B. Cress1 , A. Sokalska1,3 , B. C. Moeller1 , S. D. Stanley1 , A. 

J. Duleba1 . 1Ob/Gyn, Sacramento, CA; 2IVI Madrid, Madrid, Spain; 

3Karol Marcinkowski University of Medical Sciences, Poznan, Wlkp, 

Poland. 

105 

O-112 12:15 PM 

DOES THE OVARIAN PROFILE PRIOR TO CHEMOTHERAPY 

INFLUENCE THE DYNAMICS OF FOLLICULAR DEPLETION AND 

RECOVERY? A LONGITUDINAL STUDY OF AMH AND AFC IN 60 

YOUNG LYMPHOMA PATIENTS. 

C. Decanter 1 , F. Morschhauser 2 , P. Pigny 3 , G. Robin 1 , C. Lefebvre 1 , 

D. Dewailly 1 . 1 Reproductive Medicine, Lille University Hospital, Lille, 

Nord, France; 2 Haematology, Lille University Hospital, Lille, Nord, 

France; 3 Endocrine and Metabolism Laboratory, Lille University 

Hospital, Lille, Nord, France. 

O-113 12:30 PM 

COST ANALYSIS OF IN VITRO FERTILIZATION (IVF) VERSUS 

BILATERAL TUBAL REANASTOMOSIS (BTA) TO ACHIEVE A LIVE 

BIRTH. 

C. E. Alford, J. M. Csokmay, J. H. Segars, A. Y. Armstrong. Program 

in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver, 


National Institutes of Health, Bethesda, MD. 

O-114 12:45 PM 

MULTIPLE MARKER TEST FOR THE ACCURATE DIAGNOSIS OF 

ECTOPIC PREGNANCY. 

M. E. Rausch 1 , M. Sammel 2 , P. Takacs 3 , K. Chung 4 , A. Shaunik 1 , K. 

Barnhart 1 . 1 Obstetrics and Gynecology, University of Pennsylvania 

School of Medicine, Philadelphia, PA; 2 Biostatistics and 

Epidemiology, University of Pennsylvania School of Medicine, 

Philadelphia, PA; 3 Obstetrics and Gynecology, University of Miami 

School of Medicine, Miami, FL; 4 Obstetrics and Gynecology, 

University of Southern California, Keck School of Medicine, Los 

Angeles, CA.

• Society for Assisted Reproductive Technology 

• Reproductive Surgery (SRS) 

• Endometriosis Special Interest Group 

• Genetic Counseling Special Interest Group 

• Menopause 

• Pediatric and Adolescent Gynecology Special Interest 

Group 

• Reproductive Immunology Special Interest Group 

• SMRU Traveling Scholars/MRU 

• Reproductive Endocrinology and Infertility Fellows 


• Procedures and Techniques - Clinical: ART 

• Reproductive Biology: Animal and Experimental Models 

• Sexuality Special Interest Group 

• Reproductive Endocrinology and Infertility 

__________________________________________________________ 

SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY 


Moderators: R. Stanford Williams, M.D. 

James M. Goldfarb, M.D., M.B.A. 

O-115 4:15 PM 

A SUBSET OF THE CUMULUS CELL TRANSCRIPTOME IS 

PREDICTIVE OF EUPLOID HUMAN OOCYTE REPRODUCTIVE 

POTENTIAL. 

N. R. Treff1,2 , J. Su1 , A. Lonczak1 , D. Taylor1,2 , R. T. Scott, Jr1,2 . 

1Reproductive Medicine Associates of New Jersey, Morristown, NJ; 

2UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ. 

O-116 4:30 PM 

NON-INVASIVE BLASTOCYST SECRETOME ANALYSIS REFLECTS 

COMPREHENSIVE CHROMOSOME ANEUPLOIDY. 

S. McReynolds 1 , L. Kiemele 3 , J. Stevens 2 , K. Hansen 3 , W. B. 

Schoolcraft 2 , M. G. Katz-Jaffe 1,2 . 1 Colorado Foundation for Fertility 

Research, Lone Tree, CO; 2 Colorado Center for Reproductive 

Medicine, Lone Tree, CO; 3 University of Colorado Denver, Aurora, 

CO. 

O-117 4:45 PM 

THE EFFICACY OF ASSISTED OOCYTE ACTIVATION WITH 

IMMOTILE TESTICULAR SPERMATOZOA. 

T. Takeuchi, H. Suzuki, M. Tanaka, H. Iwamoto, A. Yoshida. The 

Reproduction Center, KIba Park Clinic, Koto-ku, Tokyo, Japan. 

O-118 5:00 PM 

HEALTHY DELIVERIES FOLLOWING VITRIFICATION OF BIOPSIED 

BLASTOCYTS. 

T. Schlenker 1,2 , J. Stevens 2 , M. Rawlins 2 , S. McCormick 2 , M. G. Katz- 

Jaffe 1,2 , W. B. Schoolcraft 1,2 . 1 Colorado Center for Reproductive 

Medicine, Lone Tree, CO; 2 Fertility Laboratories of Colorado, Lone 

Tree, CO. 

O-119 5:15 PM 

A DELETED FORM OF FOLLICLE STIMULATING HORMONE (FSH) 

RECEPTOR, FOUND IN WOMEN WITH LOW RESPONSE TO FSH, 

IMPAIRS THE FUNCTION OF THE NORMAL RECEPTOR WHEN 

CO-EXPRESSED IN VITRO. 

M. Lalioti, T. Gerasimova, D. Anastasakis, D. Zattas, E. Seli, D. Sakkas. 

Obstetrics, Gynecology and Reproductive Sciences, Yale University 

School of Medicine, New Haven, CT. 

O-120 5:30 PM 

WHAT TO DO WITH EMBRYOS ORIGINATING FROM ONE 

PRONUCLEUS OR INITIAL NO FERTILIZATION? 

U. A. Kayisli, M. S. Tabak, T. Gerasimova, M. Lalioti, D. Sakkas, 

P. Patrizio. Yale Fertility Center, Department of Ob, Gyn & 

Reproductive Sciences, New Haven, CT. 


Tuesday, October 26, 2010 4:15 pm –6:15 pm 


106 

O-121 5:45 PM 

MICRODOSE FLARE-UP VERSUS ANTAGONIST PROTOCOLS FOR 

POOR RESPONDER PATIENTS: A META-ANALYSIS. 

E. Kovanci, W. E. Gibbons. Obstetrics and Gynecology, Baylor 

College of Medicine, Houston, TX. 

O-122 6:00 PM 

THE NEW ERA IN ART: INVO. 

E. E. Lucena, A. M. Saa, D. E. Navarro, C. A. Pulido, A. M. Moran. 

Colombian Center Fertility and Sterility, Bogota, Colombia. 

__________________________________________________________ 

REPRODUCTIVE SURGERY (SRS) 

ROOM 205 

Moderators: Camran R. Nezhat, M.D. 

Bala Bhagavath, M.D. 

O-123 4:15 PM 

HYALURONAN SYNTHESIS MIGHT BE ALTERED DURING A CO2 

PNEUMOPERITONEUM AT A HIGH INTRAPERITONEAL PRESSURE. 

S. Matsuzaki, R. Botchorishvili, K. Jarodn, E. Maleysson, G. Mage, M. 

Canis. CHU Clermont-Ferrand, Clermont-Ferrand, Auvergne, France. 

O-124 4:30 PM 

OVARY TRANSPLANTATION RESULTS: FRESH VS FROZEN. 

S. J. Silber 1 , M. Kuwayama 2 , N. Kagawa 2 , J. Zhang 1 , R. G. Gosden 1 . 

1 Infertility Center of St. Louis, St. Luke’s Hospial, St. Louis, MO; 2 Kato 

Ladies Clinic, Tokyo, Japan. 

O-125 4:45 PM 

OBSTETRICS/GYNECOLOGY (OB/GYN) RESIDENTS’ 

PERCEPTION OF ROBOTIC-ASSISTED LAPAROSCOPY IN 

RELATION TO LAPAROSCOPIC TRAINING. 

R. J. Bagley, J. M. Goldberg. Obstetrics and Gynecology, Cleveland 

Clinic Foundation, Cleveland, OH. 

O-126 5:00 PM 

PEDICLED OMENTAL FLAPS AND AUTOLOGOUS FREE OMENTAL 

GRAFTS IN THE PELVIS SURVIVE AND DO NOT INCREASE 

ADHESION FORMATION IN AN ANIMAL MODEL. 

A. P. Bailey, A. K. Schutt, D. W. Stovall. Obstetrics & Gynecology, 

University of Virginia, Charlottesville, VA. 

O-127 5:15 PM 

LAPAROSCOPIC SURGERY IMPROVES OUTCOME AND 

DIAGNOSTIC ACCURACY IN UNEXPLAINED INFERTILITY. 

B. A. Lessey 1 , D. A. Forstein 1 , P. B. Miller 1 , M. N. Egbuniwe 2 , R. 

Dodds 3 . 1 Obstetrics and Gynecology, Division Reproductive 

Endocrinology and Infertility, Greenville Hospital System, Greenville, 

SC; 2 Georgetown University, School of Medicine, Washington, DC; 

3 Clemson University, Clemson, SC. 

O-128 5:30 PM 

COMPLICATIONS AND COSTS ASSOCIATED WITH 

ADHESIOLYSIS AT THE TIME OF REPEAT CESAREAN DELIVERY. 

M. Wilson 1 , V. Sikirica 2 , M. S. Broder 3 , E. Y. Chang 3 , P. Hinoul 2 , D. 

Robinson 2 . 1 The Christie NHS Foundation Trust, Manchester, United 

Kingdom; 2 Ethicon, Inc., Somerville, NJ; 3Phar, LLC, Beverly Hills, CA. 

O-129 5:45 PM 

ROBOTIC-ASSISTED, LAPAROSCOPIC AND OPEN 

MYOMECTOMY: A COMPARISON OF SURGICAL OUTCOMES. 

E. E. Barakat 1 , M. A. Bedaiwy 2 , S. Zimberg 3 , B. Nutter 1 , T. Falcone 1 . 

1 Obstetrics, Gynecology and Women’s Health Institute, Cleveland 

Clinic Foundation, Cleveland, OH; 2 Obstetrics and Gynecology, 

University Hospitals Case Medical Center,Case Western Reserve 

University, Cleveland, OH; 3 Minimally Invasive Gynecology, 

Cleveland Clinic Florida, Fort Lauderdale, FL.

O-130 6:00 PM 

MICROARRAY EXPRESSION PROFILING IN ADHESION AND 

NORMAL PERITONEAL TISSUES. 

D. R. Ambler 1 , A. M. Golden 2 , K. K. Masker 2 , J. S. Gell 1 , G. S. Gerhard 2 , 

D. J. Carey 2 . 1 Obstetrics and Gynecology, Geisinger Medical 

Center, Danville, PA; 2 Weis Center for Health Research, Geisinger 

Medical Center, Danville, PA. 

__________________________________________________________ 

ENDOMETRIOSIS SPECIAL INTEREST GROUP 

ROOM 501 

Moderators: Pamela Stratton, M.D. 

Dan I. Lebovic, M.D., M.A. 

O-131 4:15 PM 

CHANGES IN THE SIZE OF RECTOVAGINAL ENDOMETRIOTIC 

NODULES INFILTRATING THE RECTUM DURING HORMONAL 

THERAPIES. 

S. Ferrero, P. L. Venturini, V. Remorgida. Department of Obstetrics 

and Gynecology, San Martino Hospital and University of Genoa, 

Genoa, GE, Italy. 

O-132 4:30 PM 

MAGNETIC RESONANCE ENTEROCLYSIS IMAGING 

VERSUS RECTAL WATER CONTRAST TRANSVAGINAL 

ULTRASONOGRAPHY IN THE DIAGNOSIS OF RECTOSIGMOID 

ENDOMETRIOSIS. 

S. Ferrero 1 , E. Biscaldi 2 , P. L. Venturini 1 , G. A. Rollandi 2 , V. Remorgida 1 . 

1 Department of Obstetrics and Gynecology, San Martino Hospital 

and University of Genoa, Genoa, GE, Italy; 2 Department of 

Radiology, Galliera Hospital, Genoa, GE, Italy. 

O-133 4:45 PM 

AROMATASE INHIBITOR PLUS GnRH ANALOG IN THE 

TREATMENT OF RELAPSE OF ENDOMETRIOSIS IN PATIENTS NO 

RESPONDER TO OTHER THERAPY: A CONTROLLED TRIAL. 

F. Scarpellini, M. Sbracia. CERM-Hungaria IVF Center, Rome, Italy. 

O-134 5:00 PM 

CNS SENSITIZATION AND MYOFASCIAL DYSFUNCTION IN 

PATIENTS WITH ENDOMETRIOSIS AND CHRONIC PELVIC PAIN. 

I. Khachikyan 1 , N. Sinaii 2 , J. Shah 3 , R. Ortiz 3 , J. Segars 1 , P. Stratton 1 . 

1 Program in Reproductive and Adult Endocrinology, NICHD, NIH, 

Bethesda, MD; 2 Biostatistics and Clinical Epidemiology Service, 

CC,NIH, Bethesda, MD; 3 Rehabilitation Medicine, CC, NIH, 

Bethesda, MD. 

O-135 5:15 PM 

SERUM MARKERS OF OXIDATIVE STRESS IN INFERTILE WOMEN 

WITH ENDOMETRIOSIS AND CONTROLS. 

F. C. Donabela 1 , A. Z. Andrade 1 , J. K. Rodrigues 1 , L. A. Dib 1 , A. A. 

Jordão, Jr 3 , P. A. Navarro 1,2 . 1 Dept. of Ob/Gyn, Faculty of Medicine 

of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; 

2 National Institute of Hormones and Woman’s Health, CNPq, 

Ribeirão Preto, SP, Brazil; 3 Nutrition and Metabolism Laboratory, 

Faculty of Medicine of Ribeirão Preto, University of Sao Paulo, 

Ribeirão Preto, SP, Brazil. 

O-136 5:30 PM 

PPAR-GAMMA ACTIVATION INHIBITS PROLIFERATION OF 

ENDOMETRIOTIC EPITHELIAL AND STROMAL CELLS AND IS PRO- 

APOPTOTIC IN ENDOMETRIOTIC STROMAL CELLS IN VITRO. 

S. K. Kavoussi 1 , S. D. Stephen 2 , J. Lee 2 , S. K. Banu 2 , J. A. Arosh 2 , 

D. I. Lebovic 3 . 1 Austin Fertility & Reproductive Medicine, Austin, 

TX; 2 Department of Integrative Biosciences, Reproductive 

Endocrinology & Cell Signaling Laboratory, College of Veterinary 

Medicine & Biomedical Sciences, Texas A&M University, College 

Station, TX; 3 Division of Reproductive Endocrinology & Infertility, 

Department of Obstetrics & Gynecology, The University of Wisconsin, 

Madison, WI. 


O-137 5:45 PM 

SIMVASTATIN REDUCES ESTROGEN RECEPTOR ALPHA GENE 

EXPRESSION IN HUMAN ENDOMETRIAL STROMAL CELLS. 

A. Sokalska 1,2 , A. Cress 1 , J. Villanueva 1 , A. J. Duleba 1 . 1 Ob/Gyn, 

University of California Davis, Sacramento, CA; 2 Ob/Gyn, Karol 

Marcinkowski University of Medical Sciences, Poznan, Wlkp, Poland. 

O-138 6:00 PM 

RETINOID ACID SUPPRESSES GROWTH OF ENDOMETRIOTIC 

IMPLANTS IN AN IMMUNOCOMPETENT MOUSE MODEL OF 


F. Wieser, Z. Shen, N. Sidell. Gynecology and Obstetrics, Emory 

Universioty School of Medicine, Atlanta, GA. 

__________________________________________________________ 

GENETIC COUNSELING SPECIAL INTEREST GROUP 

ROOM 201 

Moderators: Gina M. Davis, M.S. 

Lauri D. Black, M.S. 

O-139 4:15 PM 

DIRECT ASSOCIATION BETWEEN UNBALANCED SPERM AND 

EMBRYOS AMONG MALE TRANSLOCATION CARRIERS. 

D. Young1,2 , M. Linden2 , J. Stevens2 , W. Kearns3 , W. B. Schoolcraft1 , 

M. Katz-Jaffe1,2 . 1Colorado Center for Reproductive Medicine, Lone 

Tree, CO; 2Fertility Laboratories of Colorado, Lone Tree, CO; 3The Center for Preimplantation Genetics, Rockville, MD. 

O-140 4:30 PM 

COMPLEX CHROMOSOME LESION DELINEATED BY ARRAY CGH 

IN A WOMAN WITH PRIMARY OVARIAN INSUFFICIENCY. 

M. E. Ochalski, A. N. G. Wakim, A. Rajkovic, U. Surti. Obstetrics, 

Gynecology and Reproductive Sciences, UPMC-Magee Women’s 

Hospital, Pittsburgh, PA. 

O-141 4:45 PM 

CHROMOSOME 2 INVERSION AND IN VITRO CYCLE 

OUTCOMES. 

A. Cadar 1 , A. Usman 1 , S. G. Somkuti 2 , R. B. Keep 2 , M. Sobel 2 , L. 

Barmat 2 . 1 Obstetrics and Gynecology, Albert Einstein Medical 

Center, Philadelphia, PA; 2 Abington Memorial Hospital, Abington, 

PA. 

O-142 5:00 PM 

ARE WE UNDERESTIMATING THE PREVALENCE OF ANEUPLOIDY- 

RELATED MISCARRIAGES? A DESCRIPTION OF CYTOGENETIC 

RESULTS FROM PRODUCTS OF CONCEPTION (POC) AFTER 

DILATION AND CURETTAGE (D&C). 

M. D. Werner 1 , A. Reh 2 , M. A. Perle 3 , J. Grifo 2 . 1 Obstetrics and 

Gynecology, New York University Medical Center, NY, NY; 2 NYU 

Fertility Center, New York University Medical Center, NY, NY; 

3 Pathology, New York University Medical Center, NY, NY. 

O-143 5:15 PM 

THE EFFECT OF INTRACYTOPLASMIC SPERM INJECTION 

ON GENDER IN IVF CYCLES IN PATIENTS UNDERGOING 

PREIMPLANTATION GENETIC SCREENING (PGS). 

T. Singer, J. Huang, M. Noel, A. Melnick, Z. Rosenwaks, S. D. 

Spandorfer. The Center for Reproductive Medicine and Infertility, 

Weill Cornell Medical Center, New York, NY. 

O-144 5:30 PM 

PRECONCEPTION SCREENING AND PREIMPLANTATION 

GENETIC DIAGNOSIS (PGD): FOR WHAT ARE YOU REALLY 

GETTING TESTED? 

J. Fischer, S. Munne, G. L. Harton. Reprogenetics, Livingston, NJ. 

O-145 5:45 PM 

NONDISCLOSURE PGD FOR LATE ONSET AUTOSOMAL 

DOMINANT DISEASES. 

R. Najeemuddin 

107 

1,2 , I. Tur-Kaspa1,3 . 1Institute for Human Reproduction, 

Chicago, IL; 2Department of OB/Gyn, Wayne State University/Detroit 

Medical Center, Detroit, MI; 3Department of OB/Gyn, University of 

Chicago, Chicago, IL.

O-146 6:00 PM 

PGD FOR HLA TYPING: SUGGESTED CLINICAL GUIDELINES ON 

WHEN, WHERE AND TO WHOM IT SHOULD BE OFFERED. 

I. Tur-Kaspa 1,3 , R. Najeemuddin 1,2 . 1 Institute for Human Reproduction, 

Chicago, IL; 2 Department of OB/Gyn, Wayne State University/Detroit 

Medical Center, Detroit, MI; 3 Department of OB/Gyn, University of 

Chicago, Chicago, IL. 

__________________________________________________________ 

MENOPAUSE 


Moderators: Kristin L. Wright, M.D. 

Staci E. Pollack, M.A., B.A., M.S. 

O-147 4:15 PM 

AGE OF NATURAL MENOPAUSE IN BRCA1/2 MUTATION 

CARRIERS. 

W. T. Lin1 , M. Beattie2 , L.-M. Chen1 , M. Cedars1 , K. Oktay3 , M. Rosen1 . 

1Obstetrics, Gynecology, and Reproductive Sciences, University 

of California, San Francisco, San Francisco, CA; 2Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer 

Center, University of California, San Francisco, San Francisco, CA; 

3Department of Obstetrics & Gynecology, Westchester Medical 

Center-New York Medical College, Hawthorne, NY. 

O-148 4:30 PM 

ESTROGEN THERAPY AND CARDIOVASCULAR DISEASE: COULD 

ARTERIAL EXPRESSION OF INTERLEUKIN 17 PROVIDE SOME 

ANSWERS TO THE TIMING HYPOTHESIS? A STUDY OF EARLY 

AND LATE MENOPAUSE IN NON-HUMAN PRIMATES. 

A. Sophonsritsuk 1,2 , S. E. Appt 1 , T. B. Clarkson 1 , T. C. Register 1,2 . 

1 Comparative Medicine/Pathology and the Primate Center, Wake 

Forest University School of Medicine, Winston Salem, NC; 2 Molecular 

Genetics & Genomics Program, Wake Forest University School of 

Medicine, Winston Salem, NC. 

O-149 4:45 PM 

EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS 

ON METABOLIC PARAMETERS: A RANDOMIZED, PLACEBO- 

CONTROLLED CLINICAL TRIAL IN POSTMENOPAUSAL WOMEN. 

H. S. Taylor 1 , S. Mirkin 2 , A. Chines 2 . 1 Yale University School of Medicine, 

New Haven, CT; 2 Pfizer, Inc, Collegeville, PA. 

O-150 5:00 PM 

INCREASED LONGEVITY OF OLD INFERTILE MICE AFTER ALLO- 

TRANSPLANTATION OF YOUNG MICE OVARIES. 

N. Kagawa 1 , M. Kuwayama 1 , Y. Ikeda 1 , H. Nagashima 2 , S. J. Silber 3 , 

O. Kato 1 . 1 Kato Ladies’ Clinic, Shinjuku, Tokyo, Japan; 2 St. Luke’s 

Hospital, St. Louis, MO; 3 Meiji University, Kawasaki-shi, Kanagawa, 

Japan. 

O-151 5:15 PM 

EFFECT OF SOY SUPPLEMENTATION ON REGIONAL LEAN AND 

FAT MASS AND RESTING METABOLIC RATE IN CAUCASIAN AND 

AFRICAN AMERICAN POSTMENOPAUSAL WOMEN. 

C. K. Sites, A. B. Knee. Obstetrics and Gynecology, Baystate Medical 

Center, Tufts University School of Medicine, Springfield, MA. 

O-152 5:30 PM 

ANTRAL FOLLICLE COUNT IS ASSOCIATED WITH SUBSEQUENT 

MENOPAUSE: THE CARDIA WOMEN’S STUDY. 

M. Wellons 1 , G. W. Bates 1 , C. E. Lewis 1 , P. Schreiner 2 , B. Sternfeld 3 , 

D. Siscovick 4 . 1 University of Alabama, Birmingham, Birmingham, 

AL; 2 University of Minnesota, Minneapolis, MN; 3 Kaiser Permanente 

Division of Research, Oakland, CA; 4 University of Washington, 

Seattle, WA. 


108 

O-153 5:45 PM 

URINARY MARKERS OF OVARIAN AGING AND PREDICTING 

NATURAL FERTILITY. 

A. Z. Steiner 1 , A. Herring 2 , J. Kesner 3 , J. W. Meadows 3 , S. Hoberman 2 , 

D. D. Baird 4 . 1 Obstetrics and Gynecology, University of North 

Carolina, Chapel Hill, NC; 2 Biostatistics, University of North Carolina, 

Chapel Hill, NC; 3 National Institute for Occupational Safety & Health, 

Cincinnati, OH; 4 Epidemiology Branch, NIEHS/NIH, Research Triangle 

Park, NC. 

__________________________________________________________ 

PEDIATRIC AND ADOLESCENT GYNECOLOGY SPECIAL 

INTEREST GROUP 

ROOM 601 

Moderators: Michael J. Heard, M.D. 

Laura Detti, M.D. 

O-154 4:15 PM 

PARATUBAL CYSTS CORRELATE CLINCALLY WITH 

HYPERANDROGENISM AND PCOS. 

J. L. Bercaw1 , S. N. Mediwala2 , S. M. Xiomara1 , R. L. Young1 , M. 

Marcelli2 , J. E. Dietrich1 . 1Obstetrics and Gynecology, Baylor College 

of Medicine, Houston, TX; 2Medicine, Baylor College of Medicine, 

Houston, TX. 

O-155 4:30 PM 

THE CLINICAL PRESENTATION OF ADNEXAL TORSION IN THE 

PEDIATRIC AND ADOLESCENT POPULATION. 

B. V. Rossi 1 , E. J. D. Henderson 2 , D. Zurakowski 2 , M. R. Laufer 2 . 

1 Department of Obstetrics and Gynecology, Brigham and Women’s 

Hospital, Boston, MA; 2 Department of Surgery, Children’s Hospital of 

Boston, Boston, MA. 

O-156 4:45 PM 

UTILITY OF ULTRASOUND (US) AND MAGNETIC RESONANCE 

IMAGING (MRI) VERSUS SURGERY FOR CHARACTERIZATION 

OF MULLERIAN ANOMALIES (MA). 

X. M. Santos 1 , J. L. Bercaw 1 , R. Krishnamurthy 2 , J. E. Dietrich 1 . 

1 Department of Obstetrics and Gynecology, Baylor College of 

Medicine, Houston, TX; 2 Department of Radiology, Baylor College of 

Medicine, Houston, TX. 

O-157 5:00 PM 

THE ROLE OF ANTI-MÜLLERIAN HORMONE (AMH) IN 

PREPUBERTAL GONADAL RESERVE SCREENING. 

M. A. Bedaiwy 1 , R. Z. Mahfouz 2 , H. R. Kubaney 2 , G. E. Plautz 2 , W. 

Hurd 1 , T. Falcone 2 . 1 Department of Obstetrics and Gynecology, 

Case Western Reserve University School of Medicine, Cleveland, 

OH; 2 Department of Obstetrics and Gynecology, Cleveland Clinic 

Foundation, Cleveland, OH. 

__________________________________________________________ 

REPRODUCTIVE IMMUNOLOGY SPECIAL INTEREST 

GROUP 

ROOM 4B 

Moderators: Steven L. Young, M.D., Ph.D. 


O-158 4:15 PM 

ETANERCEPT IMMUNOTHERAPY IN WOMEN WITH A HISTORY OF 

RECURRENT MISCARRIAGE. 

M. Jerzak 1 , M. Klochowicz 2 , A. Górski 2 , W. Baranowski 1 . 1 Department 

of Gynecology and Gynecological Oncology, Military Institute of 

Medicine, Warsaw, Poland; 2 Department of Clinical Immunology, 

Transplantation Institute, University School of Medicine, Warsaw, 

Warsaw, Poland.

O-159 4:30 PM 

RECURRENT MISCARRIAGE ASSOCIATED WITH 

ANTIPHOSPHOLIPID ANTIBODIES: ASSESSMENT OF 

ENDOMETRIAL AND SUBENDOMETRIAL CHARACTERISTICS 

BY THREE-DIMENSIONAL ULTRASONOGRAPHY AND POWER 

DOPPLER ANGIOGRAPHY. 

L. Chen 1 , S. Quan 1 , H. Li 1 , S. Chen 1 , C. Luo 1 , Y. Qiu 2 . 1 Center for 

Reproductive Medicine, Dept. of Obs/Gyn, Nanfang Hospital, 

Southern Medical University, Guangzhou, Guangdong Province, 

China; 2 Division of Obs/Gyn Ultrasound Imaging, Dept. of Obs/ 

Gyn, Nanfang Hospital, Southern Medical University, Guangzhou, 

Guangdong Province, China. 

O-160 4:45 PM 

ABNORMAL PINOPODE AND CYTOKINE EXPRESSION 

AFFECTING ENDOMETRIAL RECEPTIVITY IN IDIOPATHIC 

RECURRENT SPONTANEOUS MISCARRIAGE. 

S. Mukherjee, S. Rajani, B. N. Chakravarty. Reproductive Medicine, 

Institute of Reproductive Medicine, Kolkata, West Bengal, India. 

O-161 5:00 PM 

CHARACTERIZATION OF A RECURRENT PREGNANCY LOSS 

GENE EXPRESSION SIGNATURE IN PERIPHERAL BLOOD 

LEUKOCYTES (PBL). 

K. H. Maas 1 , S. Krieg 2 , C. Dosiou 3 , N. Nayak 5 , G. C. Linda 4 , R. B. Lathi 2 . 

1 Obstetrics and Gynecology, Stanford University Medical Center, 

Stanford, CA; 2 Obstetrics and Gynecology, Division of Reproductive 

Endocrinology and Infertility, Stanford Fertility and Medicine Center,, 

Stanford University Medical Center, Palo Alto, CA; 3 Division of 

Endocrinology, Department of Internal Medicine, Stanford University 

Medical Center, Stanford University Medical Center, Stanford, CA; 

4 Dept OB/GYN/Reproductive Sciences, University of California, San 

Francisco, San Francisco, CA; 5 Division of Maternal-Fetal Medicine, 

Translational Research, Department of Obstetrics and Gynecology, 

Stanford University Medical Center, Stanford, CA. 

O-162 5:15 PM 

ENDOMETRIOSIS-ASSOCIATED INFERTILITY: DOUBLE 

INTRAUTERINE INSEMINATION OVERCOMES THE 

PHYSIOLOGICAL BARRIER TO PREGNANCY IN PATIENTS 

POSITIVE FOR ANTIENDOMETRIAL ANTIBODIES. 

M. J. Subit 1 , P. Gantt 1 , M. Broce 2 , G. Randall 1 . 1 Obstetrics and 

Gynecology, West Virginia University – Charleston Division, 

Charleston, WV; 2 Center for Health Services and Outcomes 

Reseach, Charleston Area Medical Center Health Education and 

Research Institute, Charleston, WV. 

O-163 5:30 PM 

ABNORMALTh17 PATHWAY IN INFERTILE PATIENTS WITH 

MINIMAL/MILD ENDOMETRIOSIS. 

C. G. Andreoli 1 , V. K. Genro 1 , C. A. B. de Souza 2 , T. Michelon 1 , J. P. 

Bilibio 1 , J. S. L. Cunha-Filho 1,2 . 1 UFRGS, Porto Alegre, RS, Brazil; 2 HCPA, 

Porto Alegre, RS, Brazil. 

O-164 5:45 PM 

ALTERATIONS IN ANTIBODY IMMUNE RESPONSES AND 

TROPHOBLAST ANTIGENS RECOGNIZED IN WOMEN WITH 

RECURRENT PREGNANCY LOSS. 

R. D. Saunders 1 , C. Gercel-Taylor 1 , S. Atay 2 , S. T. Nakajima 1 , D. D. 

Taylor 1 . 1 Obstetrics, Gynecology and Women’s Health, University of 

Louisville, Louisville, KY; 2 Microbiology and Immunology, University of 

Louisville, Louisville, KY. 

O-165 6:00 PM 

PRO-ANGIOGENIC NATURAL KILLER CELLS (CD56brightCD16-) 

ACCUMULATE IN FOLLICULAR FLUID OF ANTRAL FOLLICLES IN 

PATIENTS UNDERGOING IN VITRO MATURATION (IVM) CYCLES. 

O. Fainaru, S. Hantisteanu, R. Atamna, M. Michaeli, E. Karchovski, 

A. Ellenbogen. Department of Obstetrics and Gynecology, IVF Unit, 

Hillel-Yaffe Medical Center, Hadera, Israel. 

__________________________________________________________ 


109 

SMRU TRAVELING SCHOLARS/MRU 

ROOM 4E 

Moderators: Nancy L. Brackett, Ph.D., H.C.L.D. 

Susan H. Benoff , Ph.D. 

O-166 4:15 PM 

MEN WITH Y-MICRODELETIONS CAN DISPLAY CO-EXISTING 

GENOMIC SYNDROMES DUE TO GAINS OR LOSSES IN THE 

PSEUDOAUTOSOMAL REGIONS. 

C. J. Jorgez1 , J. W. Weedin3 , A. Mielnik3 , L. I. Lipshultz1 , P. N. Schlegel3 , 

D. J. Lamb1,2 . 1Urology, Baylor College of Medicine, Houston, TX; 

2Molecular and Cell Biology, Baylor College of Medicine, Houston, 

TX; 3Urology, Weill Cornell Medical College, New York, NY. 

O-167 4:30 PM 

THE USE OF FIBEROPTIC CONFOCAL FLUORESCENT 

MICROSCOPY FOR MICRODISSECTION TESTICULAR SPERM 

EXTRACTION (microTESE) IN A MURINE MODEL. 

R. P. Smith, P. K. Kavoussi, R. A. Costabile, W. D. Steers, J. C. Herr, J. J. 

Lysiak. Urology, University of Virginia, Charlottesville, VA. 

O-168 4:45 PM 

DIETARY FATS AND SEMEN QUALITY AMONG MEN ATTENDING 

A FERTILITY CLINIC. 

J. A. Attaman 1 , T. L. Toth 1 , R. Hauser 2 , J. E. Chavarro 3 . 1 Vincent 

Obstetrics and Gynecology, Massachusetts General Hospital, 

Harvard Medical School, Boston, MA; 2 Department of Environmental 

Health, Harvard School of Public Health, Boston, MA; 3 Channing 

Laboratory, Department of Medicine, Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA. 

O-169 5:00 PM 

A NOVEL DELETION ON Yq11.221 IS ASSOCIATED WITH SEVERE 

OLIGOZOOSPERMIA AND AZOOSPERMIA. 

K. I. Aston 1 , D. T. Carrell 1,2,3 . 1 Andrology and IVF Laboratories 

Department of Surgery, University of Utah School of Medicine, Salt 

Lake City, UT; 2 Department of Obstetrics and Gynecology, University 

of Utah School of Medicine, Salt Lake City, UT; 3 Department of 

Physiology, University of Utah School of Medicine, Salt Lake City, UT. 

O-170 5:15 PM 

THE EFFECTS OF BENIGN PROSTATIC HYPERTROPHY ON THE 

ANATOMY OF THE EJACULATORY DUCT. 

M. G. McIntyre 1 , B. Coulter 1 , H. Fisch 2 . 1 Medical Universtiy of South 

Carolina, Charleston, SC; 2 Weill Cornell Medical College, New York, 

NY. 

O-171 5:30 PM 

DO IVF OR IVF TECHNOLOGIES INCREASE RISK OF 

MISCARRIAGE (MC) AND ANEUPLOIDY (ANP)? TEN YEAR 

OUTCOME ANALYSIS OF ICSI AND EXTENDED EMBRYO 

CULTURE AT A LARGE, UNIVERSITY-BASED IVF CENTER. 

K. Devine, A. Reh, O. Tan, C. McCaffrey, N. Noyes. NYU Fertility 

Center, Department of OB/Gyn, NYU School of Medicine, New York, 

NY. 

__________________________________________________________ 

REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY 

FELLOWS 

ROOM 605 

Moderators: Marcelle I. Cedars, M.D. 


O-172 4:15 PM 

OVARIAN AGING AND SOMATIC AGING: ARE THERE SYSTEMIC 

HEALTH IMPLICATIONS OF REDUCED OVARIAN RESERVE? 

E. B. Johnstone 1 , M. P. Rosen 1 , C. Addauan-Andersen 1 , B. Sternfeld 2 , 

R. Reijo Pera 3 , M. I. Cedars 1 . 1 Obstetrics, Gynecology, and 

Reproductive Sciences, University of California San Francisco, San 

Francisco, CA; 2 Division of Research, Kaiser Permanente, Oakland, 

CA; 3 Obstetrics & Gynecology, Stanford University, Palo Alto, CA.

O-173 4:35 PM 

ADAM12 AS A NOVEL MARKER FOR THE DIAGNOSIS OF 

ECTOPIC PREGNANCY. 

M. E. Rausch 1 , M. Sammel 2 , L. Beer 3 , A. Shaunik 1 , D. Speicher 3 , K. 

Barnhart 1 . 1 Obstetrics and Gynecology, University of Pennsylvania 

School of Medicine, Philadelphia, PA; 2 Biostatistics and 

Epidemiology, University of Pennsylvania School of Medicine, 

Philadelphia, PA; 3 The Wistar Institute, Philadelphia, PA. 

O-174 4:55 PM 

OOCYTE AND EMBRYO QUALITY IN OBESE PATIENTS 

UNDERGOING IN VITRO FERTILIZATION (IVF). 

D. K. Shah 1 , S. Missmer 1,2,3 , K. Berry 1 , C. Racowsky 1 , E. S. Ginsburg 1 . 

1 Division of Reproductive Endocrinology and Infertility, Department 

of Obstetrics and Gynecology, Brigham and Women’s Hospital, 

Boston, MA; 2 Department of Epidemiology, Harvard School of 

Public Health, Boston, MA; 3 Department of Medicine, Brigham and 

Women’s Hospital and Harvard Medical School, Boston, MA. 

__________________________________________________________ 

OUTCOME PREDICTORS - CLINICAL: ART 2 

ROOM 207 

Moderators: Charles C. Coddington, M.D. 

Heather Huddleston, M.D. 

O-175 4:15 PM 

A THICKENED ENDOMETRIAL STRIPE ON DAY 3 OF LEUPROLIDE 

ACETATE DOWN-REGULATED IVF CYCLES IS ASSOCIATED WITH 

REDUCED CLINICAL PREGNANCY AND LIVE BIRTH RATES. 

J. Y. J. Huang, T. Singer, R. Abdallah, Z. Williams, O. Davis, Z. 

Rosenwaks. The Ronald O Perelman and Claudia Cohen Center for 

Reproductive Medicine, Weil Cornell Medical College, New York, 

NY. 

O-176 4:30 PM 

A NATIONAL STUDY OF THE EFFECT OF INCREASING 

OBESITY ON THE RESPONSE TO AND OUTCOME OF ASSISTED 

REPRODUCTIVE TECHNOLOGY (ART). 

B. Luke 1 , M. B. Brown 2 , S. A. Missmer 3 , O. Bukulmez 4 , R. Leach 1 , J. 

E. Stern 5 . 1 Obstetrics, Gynecology, and Reproductive Biology, 

Michigan State University, East Lansing, MI; 2 Biostatistics, University 

of Michigan, Ann Arbor, MI; 3 Obstetrics, Gynecology, and 

Reproductive Biology, Brigham & Women’s Hospital, Boston, 

MA; 4 Obstetrics and Gynecology, University of Florida College of 

Medicine, Gainesville, FL; 5 Obstetrics and Gynecology, Dartmouth- 

Hitchcock Medical Center, Lebanon, NH. 

O-177 4:45 PM 

THE EFFECT OF TAXOL ON PREDIVISION OF SISTER 

CHROMATIDS AND BLASTOCYST FORMATION IN HUMAN IVM 

OOCYTES. 

A. Tanaka 1 , M. Nagayoshi 1 , S. Awata 1 , I. Tanaka 1 , S. Watanabe 2 , 

H. Kusunoki 3 . 1 Saint Mother Hospital, Kitakyushu, Fukuoka, Japan; 

2 Department of Anatomical Science, Hirosaki University School 

of Medicine, Hirosaki, Aomori, Japan; 3 Faunal Diversity Sciences, 

Graduate School of Agriculture, Kobe University, Kobe, Hyogo, 

Japan. 

O-178 5:00 PM 

SIBLING IMMATURE OOCYTES EXHIBIT HIGHER RATES OF 

CHROMOSOMAL ANEUPLOIDIES. 

R. Smith 1,2 , J. Stevens 2 , T. Schlenker 2 , S. McCormick 2 , W. B. 

Schoolcraft 1 , M. Katz-Jaffe 1,2 . 1 Colorado Center for Reproductive 

Medicine, Lone Tree, CO; 2 Fertility Laboratories of Colorado, Lone 

Tree, CO. 

O-179 5:15 PM 

PERSONALIZED PREDICTION OF LIVE BIRTH OUTCOMES IN IVF. 

P. Banerjee 1 , B. Choi 2 , R. B. Lathi 1 , L. M. Westphal 1 , W. H. Wong 3 , M. W. 

M. Yao 1 . 1 Obstetrics and Gynecology, Stanford University, Stanford, 

CA; 2 Applied Physics, Stanford University, Stanford, CA; 3 Statistics, 

Stanford University, Stanford, CA. 


110 

O-180 5:30 PM 

TRENDS AND CORRELATES OF GOOD PERINATAL OUTCOMES 

AMONG SINGLETON INFANTS CONCEIVED THROUGH ART IN 

THE US, 2000-2005. 

T. Durant 1 , J. E. Anderson 1 , J. Goldfarb 2 , M. Macaluso 1 . 1 Division of 

Reproductive Health, Centers for Disease Control and Prevention, 

Atlanta, GA; 2 Cleveland Clinic Fertility Center, Society for Assisted 

Reproductive Technology, Beachwood, OH. 

O-181 5:45 PM 

CRITERIA TO SELECT QUALITY BLASTOCYST TO TRANSFER: A 

SART STUDY. 

G. M. Grunert 1 , C.-C. C. Wun 2 , W. Gibbons 3 , R. C. Dunn 1 , W.-S. 

A. Wun 1 . 1 Fertility Specialists of Houston, Houston, TX; 2 Phmarma 

Inovation, Sugar LandNew York, TX; 3 Obstetrics and Gynecology, 

Baylor College of Medicine, Houston, TX; 4 Partners HealthCare 

System, Inc., Boston, MA. 

O-182 6:00 PM 

ANALYSIS OF ENDOMETRIAL THICKNESS IN PREDICTING 

OUTCOME OF IN VITRO FERTILIZATION AND EMBRYO 

TRANSFER: A RETROSPECTIVE STUDY. 

F. P. Rodrigues, D. S. Zylbersztejn, G. M. Collier, F. M. Vigo, R. R. Filho, 

R. Fraietta. Human Reprodutcion Section, Universidade Federal de 

São Paulo, São Paulo, Brazil. 

__________________________________________________________ 

PROCEDURES AND TECHNIQUES-CLINICAL: ART 

ROOM 603 

Moderators: Bill Yee, M.D. 

Randall R. Odem, M.D. 

O-183 4:15 PM 

METFORMIN PRETREATMENT IMPROVES IN VITRO MATURATION, 

IN VITRO FERTILIZATION AND EMBRYO TRANSFER (IVM-IVF) 

CLINICAL OUTCOME IN PCO PATIENTS BY INCREASING THE 

NUMBER OF OOCYCTES RETRIEVED. 

A. I. Fukuda1 , K. Sugihara1 , M. Ida1 , A. Haruki1 , Y. Morimoto2 . 1Center for Reproductive Endocrinology and Infertility, IVF Osaka Clinic, 

Higashi-osaka City, Osaka, Japan; 2Center for Reproductive 

Endocrinology and Infertility, IVF Namba Clinic, Osaka, Japan. 

O-184 4:30 PM 

MITIGATING SIDE EFFECTS OF ART. 

Q. V. Neri, Z. Rosenwaks, G. D. Palermo. The Ronald O Perelman & 

Claudia Cohen Center for Reproductive Medicine, Weill Cornell 


O-185 4:45 PM 

OUTCOMES OF COMMON OVARIAN STIMULATION 

PROTOCOLS AMONG WOMEN WITH A GOOD ART 

PROGNOSTIC PROFILE. 

M. Macaluso 1 , D. Grow 2 , T. Durant 1 , A. Kulkarni 1 . 1 Division of 

Reproductive Health, Centers for Disease Control and Prevention, 

Atlanta, GA; 2 Department of Obstetrics and Gynecology, Baystate 

Medical Center, Springfield, MA. 

O-186 5:00 PM 

SIGNIFICANT PARAMETERS AFFECTING LIVEBIRTH RATE 

IN INTRAUTERINE INSEMINATION (IUI) AND IN VITRO 

FERTILIZATION (IVF) USING DONOR’S SPERM: A RETROSPECTIVE 

STUDY IN MORE THAN 12.000 CYCLES. 

N. Garrido 1 , C. Gonzalez-Ravina 2 , A. Pellicer 1 , P. Cuapio 3 , J. C. 

Martinez 4 , A. Pacheco 5 . 1 Laboratory of Andrology, IVI Valencia, 

Valencia, Spain; 2 Laboratory of Andrology, IVI Sevilla, Sevilla, 

Spain; 3 Laboratory of Andrology, IVI Mexico, Mexico DF, Mexico; 

4 Laboratory of Andrology, IVI Murcia, Murcia, Spain; 5 Laboratory of 

Andrology, IVI Madrid, Madrid, Spain.

O-187 5:15 PM 

USE OF ESSURE MICRO-INSERT FOR TREATMENT OF 

HYDROSALPINX PRIOR TO IN VITRO FERTILIZATION: A 

MULTICENTER IDE/IRB OFF-LABEL STUDY. 

D. I. Galen 1 , N. M. Khan 2 . 1 Research Division, Reproductive Science 

Center of the San Francisco Bay Area, San Ramon, CA; 2 Research 

Division, Shady Grove Fertility Reproductive Science Center, 

Rockville, MD. 

O-188 5:30 PM 

CLINICAL OUTCOMES OF IMSI IN PREVIOUS ICSI FAILURES. 

J. B. A. Oliveira 1,2,3 , C. G. Petersen 1,2,3 , A. L. Mauri 1,2 , F. C. Massaro 1,2 , 

R. Baruffi 1,2 , J. G. Franco, Jr 1,2,3 . 1 Center for Human Reproduction 

Prof. Franco Jr, Ribeirao Preto, Sao Paulo, Brazil; 2 Paulista Center for 

Diagnosis Research and Training, Ribeirao Preto, Sao Paulo, Brazil; 

3 Department of Gynecology and Obstetrics Botucatu Medical 

School, São Paulo State University - UNESP, Botucatu, Sao Paulo, 

Brazil. 

O-189 5:45 PM 

ANALYSIS OF DAY 2 and 5 EMBRYO CULTURE MEDIA SAMPLES 

USING AN IN-CLINIC NEAR INFRARED (NIR) SPECTROSCOPY 

PROCEDURE. 

K. Judge, L. Botros, M. Henson, P. Roos, D. Sakkas, Metabolomics 

Study Group. Molecular Biometrics Inc., New Haven, CT. 

O-190 6:00 PM 

RISK LEVEL OF INTRACYTOPLASMIC SPERMATID INJECTION 

FOR NON-MOSAIC KLINEFELTER SYNDROME PATIENTS. 

M. Sasaki, A. Tanaka, M. M. D. Nagayoshi, S. Awata, I. Tanaka. Saint 

Mother Hospital, Kitakyushu, Fukuoka, Japan. 

__________________________________________________________ 

REPRODUCTIVE BIOLOGY: ANIMAL AND EXPERIMENTAL 

MODELS 

ROOM 607 

Moderators: Mark G. Larman, Ph.D. 

Wael A. Megid, M.D. 

O-191 4:15 PM 

ENHANCING SOMATIC NUCLEAR REPROGRAMMING BY 

DNA DEMETHYLATION WITH MicroRNA (miRNA) AND DNA 

METHYLTRANSFERASE KNOCKDOWN. 

Z. He, H.-C. Liu, Y. Tang, Z. Rosenwaks. The Center for Reproductive 

Medicine and Infertility, Weill Medical College of Cornell University, 

New York, NY. 

O-192 4:30 PM 

PREGNANCIES AND OUTCOMES OF UTERINE ALLO- 

TRANSPLANTATION AND ASSISTED REPRODUCTION IN SHEEP. 

E. R. Ramirez 1 , D. K. Nassetti 2 , M. B. R. Nessetti 3 , M. A. Khatamee 4 , V. 

Z. Ramirez 5 , H. A. Ramirez 5 . 1 Obstetrics and Gynecology, St. John’s 

Regional Medical Center, Oxnard, CA; 2 Obstetrics and Gynecology, 

St. Elizabeths Medical Center, Lincoln, NE; 3 Obstetrics - Pediatrics 

- Family Medicine - Medical Psychology, Nebraska Mental Health 

Center, Lincoln, NE; 4 Obstetrics and Gynecology and Infertility, 

New York University Medical School, New York, NY; 5 Obstetrics and 

Gynecology, Universidad de La Salle, Pasadena, TX. 

O-193 4:45 PM 

IMPACT OF INSULIN RESISTANCE ON CUMULUS CELLS AND 

OOCYTES IN MICE. 

S. H. Purcell, K. H. Moley. Department of Obstetrics and Gynecology, 

Washington University in St. Louis, St. Louis, MO. 

O-194 5:00 PM 

MITOCHONDRIAL CHANGES IN AGED OOCYTES AND 

IMPROVEMENT OF FERTILITY RATE THROUGH AUTOLOGOUS 

PLATELETS MITOCHONDRIAL MICROINJECTION. 

F. Li1, W. E. Ford 1 , F. S. Duran 2 , F. J. Castora 2 , H. W. Jones 3 , J. R. 

Swanson 1,3 . 1 Biological Sciences, Old Dominion University, Norfolk, 

VA; 2 Physiological Sciences, Eastern Virginia Medical School, Norfolk, 


111 

VA; 3 The Jones Institute for Reproductive Medicine, Eastern Virginia 

Medical School, Norfolk, VA. 

O-195 5:15 PM 

MITOCHONDRIA IN THE OFFSPRING OF OLD MICE EXHIBIT 

ALTERATIONS SIMILAR TO THOSE SEEN IN THEIR MOTHERS. 

E. Burstein 1,2,4 , Y. Bentov 1,2,4 , S. Omari 1,3 , T. Yavorska 1,3 , A. Jurisicova 1,3,4 , 

R. F. Casper 1,2,3,4 . 1 Research, Samuel Lunenfeld Research Institute 

(SLRI), Toronto, ON, Canada; 2 Reproductive Endocrinology, Toronto 

Centre for Advanced Reproductive Techniques (TCART), Toronto, 

ON, Canada; 3 Physiology, University of Toronto, Toronto, ON, 

Canada; 4 Obstetrics & Gynecology, University of Toronto, Toronto, 

ON, Canada. 

O-196 5:30 PM 

PROLIFERATION OF GRANULOSA CELLS IN SMALL FOLLICLES 

AFTER FSH TREATMENT IN THE MACACA MULATTA. 

E. McGee 1 , M. Clemmer 2 , A. Zeleznik 2 . 1 Obstetrics and Gynecology, 

Virginia Commonwealth University, Richmond, VA; 2 Reproductive 

Physiology, University of Pittsburgh, Pittsburgh, PA. 

O-197 5:45 PM 

MOUSE EMBRYOS AND IN VITRO STRESS: DOES MOUSE STRAIN 

MATTER? 

Z. Khan, D. E. Morbeck, D. L. Walker, J. R. Fredrickson, E. A. Stewart, 

C. C. Coddington. Obstetrics and Gynecology, Division of 

Reproductive Endocrinology and Infertility, Mayo Clinic, Rochester, 

MN. 

O-198 6:00 PM 

DISTRIBUTION AND CODISTRIBUTION OF TAC-2 AND ERa IN 

NEURONS OF THE ADULT FEMALE MURINE BRAIN. 

J. C. Skorupski1, M. L. Greenwald-Yarnell4, C. M. Patterson2, M. G. 

Myers, Jr2,3. 1Obstetrics and Gynecology, University of Michigan, 

Ann Arbor, MI; 2Internal Medicine, University of Michigan, Ann Arbor, 

MI; 3Molecular and Integrative Physiology, University of Michigan, 

Ann Arbor, MI; 4Program of Neuroscience, University of Michigan, 

Ann Arbor, MI. 

__________________________________________________________ 

SEXUALITY SPECIAL INTEREST GROUP 

ROOM 4C 

Moderators: Gail Knudson, M.D. 

Charla M. Blacker, M.D. 

O-199 4:15 PM 

CEREBRAL ACTIVATION PATTERNS IN WOMEN WITH 

HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) VERSUS 

WOMEN WITH NORMAL SEXUAL FUNCTION. 

T. L. Woodard1 , N. T. Nowak2 , S. D. Moffat2 , M. P. Diamond1 , 

M. E. Tancer3 , R. Balon3 . 1Obstetrics and Gynecology, Wayne 

State University School of Medicine, Detroit, MI; 2Department of 

Psychology, Behavioral and Cognitive Neuroscience, Wayne State 

University, Detroit, MI; 3Department of Psychiatry, Wayne State 

University School of Medicine, Detroit, MI. 

O-200 4:30 PM 

DOCTOR-PATIENT ALIGNMENT & SATISFACTION WITH 

DISCUSSIONS ABOUT WOMEN’S DISTRESSING DECREASED 

SEXUAL DESIRE. 

M. A. Perelman 1 , S. R. Hahn 2 , S. J. Parish 3 , S. A. Kingsberg 4 , E. R. 

Goldfischer 5 , R. Sadovsky 6 . 1 Department of Psychiatry, Reproductive 

Medicine and Urology, The New York Presbyterian Hospital, Weill 

Medical College of Cornell University, New York, NY; 2 Department of 

Clinical Medicine & Psychiatry, Albert Einstein College of Medicine, 

New York, NY; 3 Albert Einstein College of Medicine, New York, NY; 

4 Division of Behavioral Medicine, Case Western Reserve University 

School of Medicine, Cleveland, OH; 5 Hudson Valley Urology Center, 

New York, NY; 6 SUNY-Downstate Medical Center, New York, NY.

O-201 4:45 PM 

THE EFFECT OF LIFELONG DYSMENORRHEA ON SEXUAL 

FUNCTION IN WOMEN WITH CHRONIC PELVIC PAIN. 

S. Malik, B. W. Fenton. Obstetrics & Gynecology, Summa Health 

System, Akron, OH. 

O-202 5:00 PM 

FEMALE SEXUAL DYSFUNCTION SCREENING TOOL SURVEY. 

S. A. Kingsberg 1 , M. L. Krychman 2 . 1 Division of Behavioral Medicine, 

Case Western Reserve University School of Medicine, Cleveland, 

OH; 2 University of Southern California, Newport Beach, CA. 

__________________________________________________________ 

REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY 

ROOM 605 

Moderators: Bruce R. Carr, M.D. 

William H. Catherino, M.D., Ph.D. 

O-203 5:15 PM 

INHIBITORY SMAD7 EXPRESSION IS UPREGULATED BY 

TREATMENT WITH TGFß IN GRANULOSA CELLS. 

M. Quezada, E. McGee. Obstetrics and Gynecology, Virginia 

Commonwealth University, Richmond, VA. 

O-204 5:30 PM 

IDENTIFICATION OF DNA-REGULATORY ELEMENTS IN THE 

PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) 

GENE PROMOTER WHICH CONFER GATA RESPONSIVENESS. 

R. L. Thomas, C. M. Grafer, W. Zheng, L. M. Halvorson. Obstetrics 

& Gynecology, University of Texas Southwestern Medical Center, 

Dallas, TX. 


112 

O-205 5:45 PM 

THE PROMISE OF REPROGRAMMING HUMAN PRIMORDIAL 

GERM CELLS FOR THE TREATMENT OF INFERTILITY. 

B. B. Swelstad 1 , F. F. Liu 1 , X. Yuan 2 , M. R. Hiller 1 , J. D. Gearhart 4 , 

C. L. Kerr 1,3 . 1 Department of Gynecology and Obstetrics, Johns 

Hopkins Hospital, Baltimore, MD; 2 Department of Hematology, 

Johns Hopkins Hospital, Baltimore, MD; 3 Stem Cell Program, Institute 

for Cell Engineering, Baltimore, MD; 4 Department of Cell and 

Developmental Biology and Department of Animal Biology, Institute 

of Regenerative Medicine, Philadelphia, PA. 

O-206 6:00 PM 

ROLE OF SUSHI DOMAIN CONTAINING 3 (SUSD3) IN BREAST 

CANCER AND AROMATASE INHIBITOR RESPONSIVENESS. 

I. Moy 1 , S. Huang 2 , S. E. Bulun 1 . 1 Division of Reproductive Biology 

Research, Northwestern University Feinberg School of Medicine, 

Chicago, IL; 2 Department of Preventive Medicine, Northwestern 

University Feinberg School of Medicine, Chicago, IL. 

__________________________________________________________

• Society for Male Reproduction and Urology 

• Society for Reproductive Endocrinology and Infertility 

• Mental Health Professional Group 

• Reproductive Laboratory Technologist Professional 

Group 

• Androgen Excess Special Interest Group 

• Environment and Reproduction Special Interest Group 

• Fibroid Special Interest Group 

• Imaging in Reproductive Medicine Special Interest 

Group 

• Preimplantation Genetic Diagnosis 


• Ovarian Stimulation - Poor Responders: ART 

• Reproductive Biology: Human Studies 

• Reproductive Surgery (SRS) 

• Nutrition Special Interest Group 

__________________________________________________________ 

SOCIETY FOR MALE REPRODUCTION AND UROLOGY 

ROOM 4C 

Moderators: Keith A. Jarvi, M.D. 

Douglas T. Carrell, Ph.D. 

O-207 3:45 PM 

EVALUATION OF A NEW METHOD OF GENERATING iPS CELLS 

DERIVED FROM ADULT TESTIS TISSUE FROM INFERTILE MEN. 

H. Kobayashi, K. Nagao, Y. Oka, T. Tai, N. Ishii. Urology, Toho 

University, Tokyo, Japan. 

O-208 4:00 PM 

MUTATIONS IN THE MSH5 MISMATCH REPAIR GENE IN NON- 

OBSTRUCTIVE AZOOSPERMIC MEN (NOA). 

S. Mukherjee 1 , J. W. Weedin 1 , J. B. Addai 1 , L. I. Lipshultz 1 , D. J. Lamb 1,2 . 

1 Department of Urology, Baylor College of Medicine, Houston, 

TX; 2 Department of Molecular and Cell Biology, Baylor College of 


O-209 4:15 PM 

SEMEN CHARACTERISTICS OF A LARGE COHORT SHOW 

PROTAMINE 1 (P1) TO PROTAMINE 2 (P2) RATIO IS 

INDEPENDENT OF OTHER SPERM PARAMETERS. 

L. Nanassy 1 , D. Carrell 1,2,3 . 1 Andrology and IVF Laboratories, 

Department of Surgery, University of Utah School of Medicine, Salt 

Lake City, UT; 2 Department of Obstetrics and Gynecology, University 

of Utah School of Medicine, Salt Lake City, UT; 3 Department of 

Physiology, University of Utah School of Medicine, Salt Lake City, UT. 

O-210 4:30 PM 

INCREASED SPERM DNA DAMAGE IS ASSOCIATED WITH 

PROTAMINE PACKAGING ANOMALIES. 

M. M. Peart, K. R. Chohan. Department of Pathology, SUNY Upstate 

Medical University, Syracuse, NY. 

O-211 4:45 PM 

PQUANTITATIVE SHOTGUN PROTEOMIC ANALYSIS OF SEMINAL 

PLASMA FROM MEN WITH SPINAL CORD INJURY-INDUCED 

ANEJACULATION. 

B. F. da Silva 1 , C. R. Ferreira 2 , M. N. Eberlin 2 , J. S. Garcia 2,4 , G. H. M. 

F. Souza 2,3 , R. P. Bertolla 1 . 1 Division of Urology, Human Reproduction 

Section, Sao Paulo Federal University, Sao Paulo, SP, Brazil; 2 ThoMSon 

Mass Spectrometry Laboratory, Institute of Chemistry, University of 

Campinas, Campinas, SP, Brazil; 3 Mass Spectrometry Applications 

Research and Development Laboratory, Waters Corporation, 

Alphaville, SP, Brazil; 4 Department of Exact Sciences, Alfenas Federal 

University, Alfenas, MG, Brazil. 




113 

O-212 5:00 PM 

CADMIUM ALTERS TESTICULAR EXPRESSION OF GENES 

REGULATING THE STRUCTURE AND FUNCTION OF THE ACTIN 

CYTOSKELETON. 

S. H. Benoff 1 , J. L. Marmar 2 , G. M. Centola 3 , I. R. Hurley 1 . 1 Research, 

Feinstein Institute for Medical Research, Manhasset, NY; 2 Surgery, 

Cooper University Hospital, Camden, NJ; 3 Clinical Laboratory, New 

England Cryogenic Center, Newton, MA. 

__________________________________________________________ 

SOCIETY FOR REPRODUCTIVE ENDOCRINOLOGY AND 

INFERTILITY 

ROOM 4E 

Moderators: Kurt T. Barnhart, M.D. 

Elizabeth A. McGee, M.D. 

O-213 3:45 PM 

RACIAL/ETHNIC DIFFERENCES IN OVARIAN RESERVE MARKERS. 

M. P. Rosen1 , E. B. Johnstone1 , C. Addauan-Andersen1 , B. Sternfeld2 , 

C. McCulloch3 , M. I. Cedars1 . 1Obstetrics, Gynecology, and 


Francisco, CA; 2Division of Research, Kaiser Permanente, Oakland, 

CA; 3Epidemiology & Biostatistics, University of California San 

Francisco, San Francisco, CA. 

O-214 4:00 PM 

IS ANTRAL FOLLICLE COUNT (AFC) A MARKER OF OOCYTE 

QUALITY? FERTILE WOMEN HAVE HIGHER AFCS THAN INFERTILE 

WOMEN. 

E. B. Johnstone 1 , M. P. Rosen 1 , C. Addauan-Andersen 1 , B. 

Sternfeld 2 , C. McCulloch 3 , M. I. Cedars 1 . 1 Obstetrics, Gynecology & 


Francisco, CA; 2 Division of Research, Kaiser Permanente, Oakland, 

CA; 3 Epidemiology & Biostatistics, University of California San 


O-215 4:15 PM 

EXTENSIVE ANALYSIS OF AGE-RELATED HORMONAL CHANGES 

SHOWS A SLOWING IN THE PACE OF AMH DECREASE AFTER 

33 YEARS OF AGE, WHICH CONTRASTS WITH THE EXPECTED 

FOLLICLE LOSS ACCELERATION AFTER MID-THIRTIES. 

R. Fanchin 1 , M. Grynberg 1 , P. Cohen-Bacrie 2 , F. Lamazou 1 , R. 

Frydman 1 , M. Faddy 3 . 1 Ob-Gyn & Reproductive Medicine, Hospital 

A. Beclere, Clamart, Ile de France, France; 2 Lab. Eylau, Lab. Eylau, 

Paris, Ile de France, France; 3 Centre for Statistics, Queensland 

University of Technology, Brisbane, Queensland, Australia. 

O-216 4:30 PM 

RISK FACTORS FOR DIMINISHED OVARIAN RESERVE AND THE 

ROLE OF ENDOMETRIOSIS. 

K. Lin 1 , B. Samantha 2 , M. D. Sammel 2 , K. T. Barnhart 2 . 1 Obstetrics 

and Gynecology, University of Washington, Seattle, WA; 2 Obstetrics 

and Gynecology; Center for Clinical Epidemiology and Biostatics, 

University of Pennsylvania, Philadelphia, PA. 

O-217 4:45 PM 

ADDITION OF LOW DOSE OF METFORMIN TO THE ORAL 

CONTRACEPTIVE HAS NO GREAT ADVANTAGE IN TERMS 

OF CARDIOVASCULAR RISK MARKERS IN WOMEN WITH 

POLYCYSTIC OVARY SYNDROME REGARDLESS INSULIN 

RESISTANCE. 

C. S. Vieira, J. B. F. Fernandes, G. M. Soares, W. P. Martins, M. F. Silvade-Sá, 

R. A. Ferriani. Obstetrics and Gynecology, University of São 

Paulo, Ribeirao Preto, Sao Paulo, Brazil.

O-218 5:00 PM 

THE LEVELS OF HORMONES AND CYTOKINES IN FOLLICULAR 

FLUID ARE ASSOCIATED TO BODY MASS INDEX, 

INDEPENDENTLY OF AGE AND DOSE OF GONADOTROPHIN 

ADMINISTERED. 

T. C. S. Bonetti 1 , J. P. Klaine 1 , R. Salomao 2 , D. P. A. F. Braga 3 , E. 

Borges, Jr 3 , I. D. C. G. Silva 1 . 1 Laboratory of Molecular Gynecology - 

Gynecology Department, Universidade Federal de Sao Paulo, Sao 

Paulo, SP, Brazil; 2 Laboratory of Immunology - Medicine Department, 

Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil; 3 Fertility - 

Assisted Fertilization Center, Sao Paulo, SP, Brazil. 

O-219 5:15 PM 

HYDATID OF MORGAGNI: A POSSIBLE UNDERESTIMATED 

CAUSE OF UNEXPLAINED INFERTILITY. 

S. M. Rasheed 1 , A. M. Abdelmonem 2 . 1 Obstetrics & Gynaecology, 

Sohag Faculty of Medicine, Sohag University, Sohag, Egypt; 

2 Obstetrics & Gynaecology, Sohag Faculty of Medicine, Sohag 

University, Sohag, Egypt. 

O-220 5:30 PM 

A NOVEL IN VITRO MODEL OF HUMAN IMPLANTATION: AN 

ENDOMETRIUM-LIKE THREE-DIMENSIONAL (3D) CULTURE 

SYSTEM FOR ATTACHMENT/INVASION OF TROPHOBLAST-LIKE 

CELLS. 

H. Wang 1 , F. Pilla 2 , S. Martinez-Escribano 2 , S. Bocca 1 , S. Oehninger 1 , J. 

A. Horcajadas 2,3 . 1 Obstetrics and Gynecology, The Jones Institute for 

Reproductive Medicine/EVMS, Norfolk, VA; 2 Fundación IVI, Valencia, 

Spain; 3 iGenomix, Valencia, Spain. 

__________________________________________________________ 

MENTAL HEALTH PROFESSIONAL GROUP 

ROOM 607 

Moderators: Dorothy A. Greenfeld, M.S.W. 

Kris Bevilacqua, Ph.D. 

O-221 3:45 PM 

THE IMPACT OF FERTILITY COUNSELING AND FERTILITY 

PRESERVATION ON LONG-TERM PSYCHOSOCIAL OUTCOMES 

IN YOUNG FEMALE CANCER SURVIVORS. 

J. M. Letourneau1 , P. P. Katz2 , J. F. Smith1,3 , E. Ebbel1 , M. I. Cedars1 , 

M. P. Rosen1 . 1Department of Obstetrics, Gynecology, and 

Reproductive Sciences, University of California San Francisco School 

of Medicine, San Francisco, CA; 2Department of Medicine, University 

of California San Francisco School of Medicine, San Francisco, 

CA; 3Department of Urology, University of California San Francisco 

School of Medicine, San Francisco, CA. 

O-222 4:00 PM 

LONGITUDINAL FOLLOW-UP OF THE INTRUSIVENESS OF 

THE INFERTILITY EXPERIENCE: PREDICTORS AND GENDER 

DIFFERENCES. 

U. E. Van den Broeck 1 , L. Pasch 2 , P. Katz 2 , S. Millstein 2 , T. D’Hooghe 1 , 

K. Demyttenaere 1 . 1 Leuven University Fertility Centre, University 

Hospitals Leuven, Leuven, Belgium; 2 Department of Psychiatry, 

University of California - San Francisco, San Francisco, CA. 

O-223 4:15 PM 

HOW DO DONORS’ EXPERIENCES IMMEDIATELY POST 

RETRIEVAL INFORM THEIR ATTITUDES ONE YEAR LATER? 

A. M. Braverman 1,2 , D. Taylor 1,2 , R. A. Nicholson 1 , B. Galen 1 , R. T. Scott, 

Jr 1,2 . 1 Reproductive Medicine Associate of New Jersey, Morristown, 

NJ; 2 Division of Reproductive Endocrinology, Department of 

Obstetrics and Gynecology and Reproductive Science, Robert 

Wood Johnson Medcial School - UMDNJ, New Brunswick, NJ. 


114 

O-224 4:30 PM 

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY 2 (MMPI- 

2) SUPPLEMENTARY SCALE PROFILES OF APPLICANTS TO A 

GESTATIONAL CARRIER (GC) PROGRAM. 

T. H. Simpson 1 , T. L. Raque-Bogdan 2 , E. J. Mindes 1 , C. B. Toll 1 , K. S. 

Richter 1 , S. N. Covington 1 . 1 Shady Grove Fertility Reproductive 

Science Center, Rockville, MD; 2 Department of Counseling and 

Personnel Services, University of Maryland, College Park, College 

Park, MD. 

O-225 4:45 PM 

THE RELATIONSHIP BETWEEN STRESS AND IVF OUTCOME. 

A. D. Domar 1 , K. L. Backman 1 , D. Friscia 2 , J. Orav 3 , J. Nikolovski 2 . 

1 Domar Center for Mind/Body Health, Boston IVF, Waltham, MA; 

2 Johnson & Johnson Consumer and Personal Products Worldwide, 

Division of Johnson & Johnson Consumer Companies, Inc., Skillman, 

NJ; 3 Department of Medicine, Brigham and Woman’s Hospital, 

Boston, MA. 

O-226 5:00 PM 

ACCESS TO FERTILITY PRESERVATION AND POST- 

CHEMOTHERAPY ASSISTED REPRODUCTION IN WOMEN WITH 

BREAST CANCER. 

S. Lee 1 , E. Heytens 1 , S. Ozkavukcu 1 , A. Rosen 1 , F. Moy 2 , K. Oktay 1 . 

1 Institute for Fertility Preservation/Department of Obstetrics & 

Gynecology, New York Medical College, Valhalla, NY; 2 Biometrics, 

Data Management and PK/PD Unit/Department of Pathology, New 

York Medical College, Valhalla, NY. 

O-227 5:15 PM 

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY 2 

(MMPI-2) SCORES COMPARING OOCYTE DONOR (OD) AND 

GESTATIONAL CARRIER (GC) APPLICANTS. 

S. N. Covington 1 , S. C. Klock 2 . 1 Shady Grove Fertility Reproductive 

Science Center, Rockville, MD; 2 Feinberg School of Medicine, 

Northwestern University, Chicago, IL. 

O-228 5:30 PM 

DOES MENTAL HEALTH AND NURSING COUNSELING 

INFLUENCE OVUM DONOR RECIPIENTS’ PREFERENCES FOR 

THEIR DONORS? 

A. M. Braverman 1,2 , B. Galen 1 , D. Taylor 1,2 , R. Nicholson 1 , R. T. Scott, 

Jr 1,2 . 1 Reproductive Medicine Associates of New Jersey, Morristown, 

NJ; 2 Division of Reproductive Endocrinology, Department of 

Obstetrics and Gynecology and Reproductive Science, Robert 

Wood Johnson Medical School - UMDNJ, New Brunswick, NJ. 

__________________________________________________________ 

REPRODUCTIVE LABORATORY TECHNOLOGIST 

PROFESSIONAL GROUP 

ROOM 503 

Moderators: Dmitri J. Dozortsev, M.D., Ph.D. 

Sangita K. Jindal, Ph.D. 

O-229 3:45 PM 

HUMAN OOCYTES CRYOPRESERVATION: 5 YEAR OUTCOME OF 

HUMAN OOCYTE CRYOPRESERVATION WITH A NOVEL SLOW – 

FREEZE PROTOCOL: 2005-2010. 

D. G. Diaz, A.-T. H. La, M. C. Rodriguez-Karl, M. Reynoso, M. Ruiz, J. E. 

Moody. West Coast Fertility Centers, Fountain Valley, CA. 

O-230 4:00 PM 

EFFECT OF VITRIFICATION ON HUMAN OOCYTES: A 

METABOLIC PROFILING STUDY. 

A. Cobo 1 , F. Dominguez 2 , D. Castellò 1 , J. M. de los Santos 1 , C. Simón 1 , 

J. Remohí 1 . 1 IVI, Instituto Universitario IVI- Valencia, Valencia, Spain; 

2 Embryomics, Bilbao, Biskaia, Spain.

O-231 4:15 PM 

EMBRYO RESPIRATION MEASUREMENTS USED FOR 

QUANTIFICATION OF EMBRYO QUALITY; EMBRYO 

RESPIRATION CORRELATES WITH ONGOING PREGNANCY AND 

IMPLANTATION IN OOCYTE DONATION PROGRAM. 

A. Tejera 1 , J. Herrero 1 , N. B. Ramsing 3 , N. Garrido 2 , N. Grau 1 , M. 

Meseguer 1 . 1 Clinical Embryology Laboratory, IVI Valencia, Valencia, 

Spain; 2 Statistics Department, IVI Valencia, Valencia, Spain; 

3 Unisense Fertilitech, Aahrus, Aahrus N, Denmark. 

O-232 4:30 PM 

PROPANEDIOL IS AN EFFICIENT SUBSTITUTE FOR DIMETHYL 

SULFOXIDE IN THE VITRIFICATION OF HUMAN OOCYTES AND 

CLEAVAGE STAGE EMBRYOS. 

C. A. Guerrero 3 , D. Ward 1 , S. Chantilis 1 , K. Lee 1 , J. Goldstein 1 , D. 

Hammitt 1,2,3 . 1 ARTS Program, Texas Health Presbyterian Hospital 




O-233 4:45 PM 

OBSTETRIC AND PERINATAL OUTCOME OF BABIES BORN AFTER 

OOCYTE VITRIFICATION. 

A. Cobo, M. Meseguer, M. Morgan, S. Fortuño, V. Serra, J. Remohí. 

IVI-Instituto Universitario IVI, Valencia, Valencia, Spain. 

O-234 5:00 PM 

ASSESSMENT OF EFFECT OF FOLLICULAR FLUID TEMPERATURE 

AT EGG RETRIEVAL ON BLASTOCYST DEVELOPMENT, 

IMPLANTATION AND LIVE BIRTH RATES. 

R. Sherbahn. Advanced Fertility Center of Chicago, Gurnee, IL. 

O-235 5:15 PM 

EARLY CLEAVAGE (EC) IS A BETTER PREDICTOR OF POSITIVE 

PREGNANCY OUTCOME THAN EMBRYO NUMBER. 

K. E. Tucker, E. M. Rijnders, K. A. M. Jansen. IVF, Reinier de Graaf 

Group, Voorburg, ZH, Netherlands. 

O-236 5:30 PM 

HIGH SURVIVABILITY OF VITRIFIED HUMAN OOCYTES AND 

CLEAVAGE STAGE EMBRYOS AFTER EXPOSURE TO SHIPPING 

CONDITIONS IN A DRY SHIPPER FOR 96 HOURS. 

C. A. Guerrero 3 , S. Chantilis 1 , J. Goldstein 1 , K. Lee 1 , J. Douglas 2 , D. 

Hammitt 1,2,3 . 1 ARTS Program, Texas Health Presbyterian Hospital 




__________________________________________________________ 

ANDROGEN EXCESS SPECIAL INTEREST GROUP 

ROOM 201 

Moderators: Frank González, M.D. 


O-237 3:45 PM 

RELATIONSHIP OF OVARIAN MORPHOLOGY TO DEGREE OF 

MENSTRUAL CYCLE DYSFUNCTION AND INSULIN RESISTANCE 

IN POLYCYSTIC OVARY SYNDROME (PCOS). 

K. M. Brennan1,2 , M. Brower2 , M. Pall1, U. Ezeh1 , C. A. Torralba1 , R. 

Azziz1 . 1Obstetrics and Gynecology, Division of REI, Cedars Sinai 

Medical Center, Los Angeles, CA; 2Obstetrics and Gynecology, 

Division of REI, UCLA, Los Angeles, CA. 

O-238 4:00 PM 

ANDROGEN ADMINISTRATION INDUCES 

LIPOPOLYSACCHARIDE TOLERANCE AND INCREASED 

MONONUCLEAR CELL SENSITIVITY IN NORMAL 

REPRODUCTIVE-AGE WOMEN. 

F. González, J. K. Daniels, B. E. Hilary, K. S. Nair. Departments of 

Obstetrics and Gynecology (F.G., J.K.D.), Laboratory Medicine 

and Pathology (H.E.B.), and Internal Medicine (K.S.N.), College of 

Medicine, Mayo Clinic, Rochester, MN. 


115 

O-239 4:15 PM 

TRANSPLANTATION OF Akt2 KNOCKOUT OVARIES INTO WILD 

TYPE MICE RESULTS IN A REPRODUCTIVE PHENOTYPE SIMILAR 

TO POLYCYSTIC OVARY SYNDROME WITH LOCAL OVARIAN 

INSULIN RESISTANCE. 

X. Wu. Obstetrics and Gynecology, Heilongjiang University of 

Chinese Medicine, Harbin, Heilongjiang, China. 

O-240 4:30 PM 

BODY FAT DISTRIBUTION AND LEAN BODY MASS (BY CT SCAN) 

AS A DETERMINANT OF INSULIN RESISTENCE BY FSIVGTT IN 

POLYCYSTIC OVARY SYNDROME. 

U. Ezeh 1 , D. Dumesic 1 , J. Gombein 1,3 , D. Dey 1 , D. Berman 1 , R. Azziz 1,2 . 

1 Center for Androgen Related Disorders, Department of Obstetrics 

and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA; 

2 Department of Obstetrics and Gynecology, David Geffen School of 

Medicine at UCLA, Los Angeles, CA; 3 Department of Biomathmatics, 

UCLA, Los Angeles, CA. 

O-241 4:45 PM 

UNDERSTANDING THE PRESENTATION OF POLYCYSTIC 

OVARIAN SYNDROME (PCOS) IN THE ADOLESCENT 

POPULATION: RESULTS FROM A MULTISPECIALTY ADOLESCENT 

PCOS PROGRAM. 

B. W. Rackow 1 , E. J. Duran 2 , C. A. Flannery 3 , T. S. Burgert 2 . 1 Dept. of 

Obstetrics, Gynecology and Reproductive Sciences, Yale University 

School of Medicine, New Haven, CT; 2 Dept. of Pediatrics, Yale 

University School of Medicine, New Haven, CT; 3 Dept. of Internal 

Medicine, Yale University School of Medicine, New Haven, CT. 

O-242 5:00 PM 

PREDICTORS OF WEIGHT LOSS IN OBESE WOMEN WITH 

POLYCYSTIC OVARY SYNDROME AS COMPARED TO OBESE 

NORMAL WOMEN. 

K. I. Cheang 1 , K. S. Morel 2 , S. Kelly 3 , S. N. Sistrun 3 , J. E. Nestler 4 . 

1 Pharmacotherapy and Outcomes Research, Virginia 

Commonwealth University, Richmond, VA; 2 Obstetrics and 

Gynecology, Virginia Commonwealth University Health System, 

Richmond, VA; 3 Virginia Commonwealth University Health System, 

Richmond, VA; 4 Internal Medicine, Virginia Commonwealth 

University, Richmond, VA. 

O-243 5:15 PM 

USE OF FASTING BLOOD GLUCOSE LEVELS TO DETECT THE 

PRESENCE OF GLUCOSE INTOLERANCE IN POLYCYSTIC OVARY 


J. Mehta 1 , A. Ketefian 1 , M. Pall 1,2 , U. Ezeh 1 , R. Azziz 1,2 . 1 Center For 

Androgen Related Disorders: Department of Obstetrics and 

Gynecology, Cedars Sinai Medical Center, Los Angeles, CA; 

2 Department of Obstetrics and Gynecology, David Geffen School 

of Medicine at UCLA, Los Angeles, CA. 

O-244 5:30 PM 

THERAPEUTIC IMPLICATIONS OF VITAMIN D AND CALCIUM 

FOR POLYCYSTIC OVARY SYNDROME (PCOS). 

L. Pal, A. Berry, L. Coraluzzi, E. Kuston, J. Shaw, N. Williams. Obstetrics, 

Gynecology & Reproductive Sciences, Yale University School of 

Medicine, New Haven, CT. 

__________________________________________________________ 

ENVIRONMENT AND REPRODUCTION SPECIAL INTEREST 

GROUP 

ROOM 203 

Moderators: Victor Y. Fujimoto, M.D. 

Kaylon L Brunner-Tran, M.D. 

O-245 3:45 PM 

CHARACTERIZING THE ROLE OF VITAMIN D LEVELS ON IVF 

OUTCOMES: STIMULATION, EMBRYO, OR ENDOMETRIUM? 

B. Rudick, S. A. Ingles, F. Stanczyk, K. Chung, R. Paulson, K. 

Bendikson. Division of Reproductive Endocrinology and Infertility, 

Department of Obstetrics and Gynecology, University of Southern 

California, Los Angeles, CA.

O-246 4:00 PM 

ASSOCIATION OF POLYCHLORINATED BIPHENYLS (PCBS) 

WITH ADVERSE REPRODUCTIVE OUTCOMES DURING IN VITRO 


S. Mahalingaiah 1 , A. Maity 5 , K. F. Berry 1 , P. L. Williams 5 , S. A. 

Missmer 1,2,3 , R. Hauser 4,6 . 1 Department of Obstetrics, Gynecolgy, and 

Reproductive Biology, Brigham and Women’s Hospital and Harvard 

Medical School, Boston, MA; 2 Channing Laboratory, Department 

of Medicine, Brigham and Women’s Hospital and Harvard Medical 

School, Boston, MA; 3 Department of Epidemiology, Harvard School 

of Public Health, Boston, MA; 4 Department of Environmental Health, 

Harvard School of Public Health, Boston, MA; 5 Department of 

Biostatistics, Harvard School of Public Health, Boston, MA; 6 Vincent 

Memorial Obstetrics and Gynecology Service, Massachusetts 

General Hospital and Harvard Medical School, Boston, MA. 

O-247 4:15 PM 

ASSOCIATION OF PERSISTENT ORGANIC 

POLLUTANTS HEXACHLOROBENZENE (HCB), 

DICHLORODIPHENYLTRICHLOROETHANE (DDT), AND 

DICHLORODIPHENYLDICHLOROETHANE (DDE) WITH IN VITRO 

FERTILIZATION (IVF) OUTCOMES. 

S. Mahalingaiah 1 , A. Maity 5 , K. F. Berry 1 , P. L. Williams 5 , S. A. 

Missmer 1,2,3 , R. Hauser 4,6 . 1 Department of Obstetrics, Gynecology, 

and Reproductive Biology, Brigham and Women’s Hospital and 

Harvard Medical School, Boston, MA; 2 Channing Laboratory, 

Department of Medicine, Brigham and Women’s Hospital and 

Harvard Medical School, Boston, MA; 3 Department of Epidemiology, 

Harvard School of Public Health, Boston, MA; 4 Department of 

Environmental Health, Harvard School of Public Health, Boston, 

MA; 5 Department of Biostatistics, Harvard School of Public Health, 

Boston, MA; 6 Vincent Memorial Obstetrics and Gynecology Service, 

Massachusettes General Hospital and Harvard Medical School, 

Boston, MA. 

O-248 4:30 PM 

URINARY METABOLITES OF DI(2-ETHYLHEXYL) PHTHALATE ARE 

ASSOCIATED WITH INCREASED RISK OF IMPLANTATION FAILURE 

AMONG WOMEN UNDERGOING IVF. 

S. R. Ehrlich 1 , J. D. Meeker 2 , P. L. Williams 3 , D. Wright 4 , J. Petrozza 4 , R. 

Hauser 1,4 . 1 Environmental Health, Harvard School of Public Health, 

Boston, MA; 2 Environmental Health Sciences, University of Michigan 

School of Public Health, Ann Arbor, MI; 3 Biostatistics, Harvard School 

of Public Health, Boston, MA; 4 The Fertility Center, Vincent Memorial 

Obstetrics and Gynecology, Massachusetts General Hospital, 

Boston, MA. 

O-249 4:45 PM 

LAPTOP EXPOSITIONS AFFECT MOTILITY AND INDUCE DNA 

FRAGMENTATION IN HUMAN SPERMATOZOA IN VITRO BY A 

NON-THERMAL EFFECT: A PRELIMINARY REPORT. 

C. Avendaño, A. Mata, A. M. Juarez Villanueva, V. S. Martínez, C. A. 

Sanchez Sarmiento. Nascentis Medicina Reproductiva, Córdoba, 

Córdoba, Argentina. 

O-250 5:00 PM 

POLYCHLORINATED BIPHENYLS AND SEMEN QUALITY – LIFE 

STUDY. 

G. M. Buck Louis 1 , S. Kim 1 , Z. Chen 1 , A. M. Sweeney 2 , D. Barr 3 , S. 

M. Schrader 4 . 1 Division of Epidemiology, Statistics & Prevention 

Research, Eunice Kennedy Shriver National Institure of Child Health 

& Human Development, Rockville, MD; 2 Epidemiology, Texas A & M 

Rural School of Public Health, College Station, TX; 3 Emory University, 

Atlanta, GA; 4 NIOSH, CDC, Cincinatti, OH. 

O-251 5:15 PM 

RISKS OF UROGENITAL ANOMALIES IN MALE RELATIVES OF 

FEMALES WITH MULLERIAN ANOMALIES. 

A. O. Hammoud 1 , H. Nezam 1 , C. M. Peterson 1 , D. Carrell 2 , M. Gibson 1 . 

1 Reproductive Endocrinology and Infertility, University of Utah, Salt 

Lake City, UT; 2 Andrology and IVF Laboratory, University of Utah, Salt 

Lake City, UT. 


116 

O-252 5:30 PM 

EARLY LIFE EXPOSURE OF MALE MICE TO DIOXIN AFFECTS 

PLACENTAL DEVELOPMENT IN UNEXPOSED PREGNANT FEMALE 

PARTNERS LEADING TO PRETERM BIRTH. 

K. L. Bruner-Tran, M. E. McConaha, T. Ding, K. G. Osteen. OB/ 

GYN, Women’s Reproductive Health Research Center, Vanderbilt 

University Medical School, Nashville, TN. 

__________________________________________________________ 

FIBROID SPECIAL INTEREST GROUP 

ROOM 205 

Moderators: Estella Parrott, M.D. 


O-253 3:45 PM 

SERUM VITAMIN D3 LEVEL INVERSELY CORRELATES WITH TOTAL 

FIBROID TUMOR BURDEN IN WOMEN WITH SYMPTOMATIC 

UTERINE FIBROID. 

M. S. Abdelraheem1,2 , A. Al-Hendy2 . 1OB/GYN, Sohag Medical 

School, Naser, Sohag, Egypt; 2OB/GYN, Meharry Medical College, 


O-254 4:00 PM 

AGE AND RACIAL/ETHNIC DIVERSITY IN UTERINE LEIOMYOMA. 

N. Foyouzi 1 , E. B. Johnstone 1 , M. Rosen 1 , C. Addauan-Andersen 1 , 

B. Sternfeld 2 , M. Cedars 1 . 1 Department of Obstetrics, Gynecology 

and Reproductive Sciences, University of California San Francisco, 

San Francisco, CA; 2 Kaiser Permanente Division of Research, Kaiser 

Permanente Northern California, Oakland, CA. 

O-255 4:15 PM 

VITAMIN D RECEPTOR (VDR) IS OVER-EXPRESSED IN THE 

CENTER OF UTERINE FIBROIDS. 

L. Feng 1 , F. L. Jayes 1 , S.-H. Jung 2 , P. C. Leppert 1 . 1 Department 

of Obstetrics and Gynecology, Duke University, Durham, NC; 

2 Biostatistics, Duke Univerity, Durhman, NC. 

O-256 4:30 PM 

AN ENHANCED LEIOMYOMA CELL RESPONSE TO OSMOTIC 

STRESS IS CENTRAL TO THE MECHANISM OF GONADOTROPHIC 

RELEASING HORMONE ANALOGUE TREATMENT. 

D. M. McCarthy-Keith 1,2 , J. Britten 2 , M. Malik 2 , J. H. Segars 1 , W. H. 

Catherino 1,2 . 1 Program in Reproductive and Adult Endocrinology, 


Human Development, NIH, Bethesda, MD; 2 Obstetrics and 

Gynecology, Uniformed Services University of the Health Sciences, 

Bethesda, MD. 

O-257 4:45 PM 

VITAMIN D TREATMENT INDUCES DRAMATIC SHRINKAGE OF 

UTERINE LEIOMYOMAS GROWTH IN THE EKER RAT MODEL. 

S. K. Halder, C. Sharan, A. Al-Hendy. Department of Obstetrics and 

Gynecology, Meharry Medical College, Nashville, TN. 

O-258 5:00 PM 

SUBCUTANEOUS GRAFTS OF HUMAN UTERINE FIBROIDS 

IN SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE 

DEVELOP AN EXTENSIVE CAPILLARY NETWORK AND DISPLAY 

PHYSIOLOGICAL RESPONSIVENESS TO MIFEPRISTONE. 

C. S. Keator 1 , T. Belcik 2 , J. R. Lindner 2 , J. T. Jensen 1,3,4 , O. D. Slayden 1,4 . 

1 Division of Reproductive Sciences, Oregon National Primate 

Research Center, Beaverton, OR; 2 Division of Cardiovascular 

Medicine, Oregon Health & Science University, Portland, OR; 

3 Women’s Health Research Unit, Oregon Health & Science 

University, Portland, OR; 4 Department of Obstetrics and Gynecology, 

Oregon Health & Science University, Portland, OR. 

O-259 5:15 PM 

WHY THE BULGE?: THE DIFFERENTIAL EXPRESSION OF 

ELASTIC FIBRIL COMPONENTS IN LEIOMYOMA (LEIO) AND 

MYOMETRIUM (MYO) AND EFFECTS OF ESTRADIOL TREATMENT. 

E. E. Marsh, J. Wu, G. Ekpo, S. E. Bulun. Obstetrics and Gynecology, 

Feinberg School of Medicine - Northwestern University, Chicago, IL.

O-260 5:30 PM 

LEIOMYOMA CELLS SHOW ATTENUATED MECHANOSENSING, 

BUT AN INCREASED DEPENDENCE ON RHO-GEF ACTIVATION 

COMPARED TO MYOMETRIAL CELLS. 

C. M. Owen 1 , J. M. Norian 1 , X. C. Guo 1 , M. Malik 2 , W. H. Catherino 2 , 

J. H. Segars 1 . 1 Program in Reproductive and Adult Endocrinology, 


Human Development, NIH, Bethesda, MD; 2 Obstetrics and 


Bethesda, MD. 

__________________________________________________________ 

IMAGING IN REPRODUCTIVE MEDICINE SPECIAL INTEREST 

GROUP 

ROOM 603 

Moderators: Laura Detti, M.D. 

Todd D. Deutch, M.D. 

O-261 3:45 PM 

DETECTION OF OPTIMAL EMBRYO PLACEMENT BY THREE 

DIMENSIONAL ULTRASOUND IN DONOR EGG RECIPIENTS: 

PREDICTION OF PREGNANCY. 

R. García-Guzman, J. Hernández, L. Cabrera, A. Palumbo. Centro 

de Asistencia a la Reproducción Humana de Canarias, La Laguna, 

S/C de Tenerife, Spain. 

O-262 4:00 PM 

DIAGNOSTIC PERFORMANCE OF CT VIRTUAL HYSTEROSCOPY 

IN 69 CONSECUTIVE PATIENTS. 

M. Baronio 2 , P. Carrascosa 1 , C. Capuñay 1 , J. Vallejos 1 , C. Sueldo 2 , 

J. Carrascosa 1 . 1 Diagnostico Maipu, Vicente Lopez, Buenos Aires, 

Argentina; 2 C.E.G.Y.R., C.A.B.A., Buenos Aires, Argentina. 

O-263 4:15 PM 

THE ULTRASONOGRAPHIC APPEARANCE OF A “MANTLE 

SHAPE” IS AN OMINOUS SIGN OF THE PRESENCE OF EXTENSIVE 

DEEPLY INFILTRATING ENDOMETRIOSIS. 

L. P. Chamié 1 , R. M. A. Pereira 2 , A. Zanatta 2 , A. M. Rocha 2 , P. 

Serafini 2,3 . 1 Fleury Medicina e Saúde, São Paulo, Brazil; 2 Huntington 

Medicina Reprodutiva, São Paulo, Brazil; 3 Disciplina de Ginecologia, 

Faculdade de Medicina da Universidade de São Paulo, São Paulo, 

Brazil. 

O-264 4:30 PM 

INTRAOPERATIVE THREE-DIMENSIONAL SONOHISTEROGRAPHY: 

A NEW TECHNIQUE TO MONITOR HYSTEROSCOPIC 

METROPLASTY. 

J. Guerrero 1 , R. Garcia 1 , J. Hernandez 1 , L. Iaconianni 2 , A. Palumbo 1 . 

1 Centro de Asistencia a la Reproducción Humanana de Canarias, 

La Laguna, S/C de Tenerife, Spain; 2 Centro Ecografico EcoB.I., 

Roma, Italy. 

O-265 4:45 PM 

STARTING POINT AND OBSTETRIC OUTCOME OF 

MONOCHORIONIC TWINNING (MCT). SPONTANEOUS VS. IVF 

PREGNACIES. 

M. G. Yuri 1 , E. Young 2 , M. Marconi 2 , A. Valcarcel 3 , R. C. Inza 2 , G. Van 

Thillo 2 . 1 Gynecology Sonography Department Chief, Instituto de 

Ginecología y Fertilidad - IFER, Ciudad Autonoma de Buenos Aires, 

Buenos Aires, Argentina; 2 Gynecology, Instituto de Ginecología y 

Fertilidad - IFER, Ciudad Autonoma de Buenos Aires, Buenos Aires, 

Argentina; 3 Biology, Instituto de Ginecología y Fertilidad - IFER, 

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina. 

O-266 5:00 PM 

FEMVUE SONO TUBAL EVALUTION SYSTEM FOR SELECTIVE 

SONOHYSTEROSALPINGOGRAPHY IN THE OFFICE SETTING. 

A. K. Parsons 1 , D. B. Shapiro 2 , C. E. Miller 3 , J. Marcus 4 , M. Harris 5 , S. 

Roseff 6 . 1 University of South Florida, Tampa, FL; 2 Reproductive Biology 

Associates, Atlanta, GA; 3 The Advanced IVF Institute, Naperville, 

IL; 4 North Atlanta Women’s Specialists, Johns Creek, GA; 5 Women’s 

Health Research, Phoenix, AZ; 6 Palm Beach Center for Reproductive 

Medicine, Wellington, FL. 


117 

O-267 5:15 PM 

COMPARATIVE STUDY OF EMBRYO QUALITY, BLASTOCYST 

AND ONGOING PREGNANCY RATES IN OOCYTE DONATION 

PATIENTS SHARING EMBRYOSCOPE AND STANDARD 

INCUBATOR. 

C. María 1 , G. Nicolás 1 , P.-C. Inmaculada 1 , R. Niels 2 , M. Manuel 1 , M. 

Marcos 1 . 1 Embryology, IVI Alicante, Alicante, Spain; 2 Embryology, 

Unisense Fertilitech, Aarhus, Aarhus, Denmark. 

O-268 5:30 PM 

THREE DIMENSIONAL SONOGRAPHIC EVALUATION OF 

ADENOMYOSIS: THE JUNCTIONAL ZONE FEATURES IN INFERTILE 

PATIENTS. 

C. Exacoustos 1 , E. Zupi 1 , L. Brienza 1 , D. Luciano 2 , E. Vaquero 1 , D. 

Arduini 1 . 1 Obsterics and Gynecology, Università degli Studi di Roma 

Tor Vergata, Rome, Italy; 2 Obsterics and Gynecology, University of 

Connecticut, Farmington, CT. 

__________________________________________________________ 

PREIMPLANTATION GENETIC DIAGNOSIS 

ROOM 207 

Moderators: Nathan R. Treff, Ph.D. 


O-269 3:45 PM 

FIRST BABIES BORN AFTER PREIMPLANTATION MICROARRAY 

ANALYSIS (PMA) FOR CHROMOSOME TRANSLOCATION 

CARRIERS. 

R. Treff1,3 , B. Levy1,2 , N. K. Kasabwala1 , J. Su1, H. Garnsey1 , R. T. Scott1,3 . 

1Reproductive Medicine Associates of New Jersey, Morristown, NJ; 

2Pathology & Cell Biology, Columbia University-College of Physicians 

& Surgeons, New York, NY; 3Department of Obstetrics Gynecology 

& Reproductive Science, UMDNJ-Robert Wood Johnson Medical 

School, New Brunswick, NJ. 

O-270 4:00 PM 

CHROMOSOME TOPOLOGY IN HUMAN BLASTOMERES. 

RELATIONSHIP BETWEEN NUCLEAR DISTRIBUTION AND 

ANEUPLOIDY. 

M. Milán, P. Mir, V. Peinado, J. Remohí, A. Pellicer, C. Rubio. Institut 

Universitari IVI Valencia, Valencia, Spain. 

O-271 4:15 PM 

VALIDATION AND FIRST CLINICAL APPLICATION OF 

KARYOMAPPING FOR PREIMPLANTATION DIAGNOSIS (PGD) 

OF GAUCHER DISEASE COMBINED WITH 24 CHROMOSOME 

SCREENING. 

A. H. Handyside 1 , J. Grifo 2 , R. Prates 3 , S. Tormasi 3 , J. Fischer 3 , S. 

Munne 3 . 1 London Bridge Fertility, Gynaecology and Genetics 

Centre, London Bridge, London, United Kingdom; 2 New York 

University School of Medicine Fertility Center, New York, NY; 

3 Reprogenetics LLC, Livingston, NJ. 

O-272 4:30 PM 

EFFECTS OF ADVANCED MATERNAL AGE ARE ABROGATED 

IN 122 PATIENTS UNDERGOING TRANSFER OF EMBRYOS WITH 

EUPLOID MICROARRAY SCREENING RESULTS AT CLEAVAGE 

STAGE. 

M. Rabinowitz 1 , A. Beltsos 4 , D. Potter 2 , M. Bush 3 , C. Givens 5 , D. 

Smotrich 6 . 1 Gene Security Network, Redwood City, CA; 2 Huntington 

Reproductive Center, Laguna Hills, CA; 3 Conceptions Reproductive 

Associates, Littleton, CO; 4 Fertility Centers of Illinois, Chicago, IL; 

5 Pacific Fertility Center, San Francisco, CA; 6 La Jolla IVF, La Jolla, CA.

O-273 4:45 PM 

SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY 

PREIMPLANTATION GENETIC SCREENING (PGS): A 

COMPARISON BETWEEN ABNORMAL DAY-3 BLASTOMERES 

AND CORRESPONDING INNER CELL MASS AND 

TROPHECTODERM CELLS. 

K.-H. D. Nguyen 1 , R. Ross 2 , A. Benner 3 , Y. Zhao 4 , P. Brezina 4 , W. G. 

Kearns 3 . 1 Medical Genetics, National Human Genome Research 

Institute, National Institutes of Health, Bethesda, MD; 2 La Jolla IVF, 

La Jolla, CA; 3 Shady Grove Center for Preimplantation Genetics, 

Rockville, MD; 4 Gynecology, Johns Hopkins University School of 

Medicine, Baltimore, MD. 

O-274 5:00 PM 

PREIMPLANTATION GENETIC DIAGNOSIS (PGD) FOR 

RECIPROCAL TRANSLOCATIONS USING ARRAY COMPARATIVE 

GENOME HYBRIDIZATION (aCGH). 

T. Escudero, C. Pere, F. Jill, R. Prates, S. Tormasi, M. Santiago. 

PGDTeam, Reprogenetics L.L.C., Livingston, NJ. 

O-275 5:15 PM 

A COMPARISON OF PREGNANCY RATES BETWEEN PATIENTS 

THAT BANK EMBRYOS PRIOR TO PGS AND THOSE THAT DO 

NOT. 

T. H. Taylor, S. V. Hallowell, I. P. Glassner, J. J. Orris, M. J. Glassner, J. D. 

Wininger. Main Line Fertility, Bryn Mawr, PA. 

O-276 5:30 PM 

PREIMPLANTATION GENETIC DIAGNOSIS USING ARRAY CGH 

SIGNIFICANTLY INCREASES ONGOING PREGNANCY RATES PER 

TRANSFER. 

S. Munne 1 , M. Surrey 2 , J. Grifo 3 , E. Marut 4 , M. Opsahl 5 , T. H. Taylor 6 . 

1 Reprogenetics, Livingston, NJ; 2 ART Reproductive Center, Beverly 

Hills, CA; 3 NYU Fertility Center, New York University, New York, NY; 

4 Fertility Centers of Illinois, Highland Park, IL; 5 Northwest Center 

for Reproductive Sciences, Kirkland, WA; 6 Main Line Fertility and 

Reproductive Medicine, Bryn Mawr, PA. 

__________________________________________________________ 

OUTCOME PREDICTORS - CLINICAL: ART 3 

ROOM 605 

Moderator: Charles C. Coddington, M.D. 

O-277 3:45 PM 

EMBRYO CULTURE MEDIA AND NEONATAL BIRTH WEIGHT 

FOLLOWING IN VITRO FERTILIZATION (IVF). 

J. L. Eaton1,2 , E. S. Lieberman2,3 , C. Stearns3 , M. Chinchilla2,3 , C. 

Racowsky2,3 . 1Department of Obstetrics and Gynecology, Beth Israel 

Deaconess Medical Center, Boston, MA; 2Harvard Medical School, 

Boston, MA; 3Department of Obstetrics and Gynecology, Brigham 

and Women’s Hospital, Boston, MA. 

O-278 4:00 PM 

NATIONAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) 

CYCLE LINKAGE. 

B. Luke 1 , M. B. Brown 2 , E. Wantman 3 , A. Lederman 3 , W. E. Gibbons 4 , 

J. E. Stern 5 . 1 Michigan State University, East Lansing, MI; 2 University 

of Michigan, Ann Arbor, MI; 3 Redshift Technologies, Inc., New York, 

NY; 4 Baylor College of Medicine, Houston, TX; 5 Dartmouth-Hitchcock 

Medical Center, Lebanon, NH. 

O-279 4:15 PM 

PREDICTING LIVE BIRTH, PRETERM AND LOW BIRTH WEIGHT 

INFANT AFTER IN-VITRO FERTILISATION: A PROSPECTIVE STUDY 

OF 144,018 TREATMENT CYCLES. 

S. M. Nelson 1 , D. A. Lawlor 2 . 1 Reproductive & Maternal Medicine, 

University of Glasgow, Glasgow, Scotland, United Kingdom; 2 MRC 

Centre for Causal Analysis in Translational Epidemiology, University of 

Bristol, Bristol, England, United Kingdom. 


118 

O-280 4:30 PM 

ELECTIVE SINGLE BLASTOCYST TRANSFER (eSBT) ELIMINATES 

TWINNING WITHOUT COMPROMISING THE PREGNANCY RATE 

(PR) IN GOOD PROGNOSIS PATIENTS. 

C. M. Mullin, J. A. Grifo, A. S. Berkeley. NYU Fertility Center, New York 


O-281 4:45 PM 

IN VITRO MATURATION (IVM) OF OOCYTES IN HUMANS: 

McGILL REPRODUCTIVE CENTRE EXPERIENCE FOR THE LAST 

SEVEN YEARS (2003-2009). 

M. H. Dahan, W.-Y. Son, H. Holzer, E. Demirtas, J.-T. Chung, S. L. 

Tan. McGill Reproductive Center, McGill University, Montreal, QC, 

Canada. 

O-282 5:00 PM 

OOCYTE TO LIVE BIRTH EFFICIENCY OF AUTOLOGOUS IN 

VITRO FERTILIZATION. 

M. J. Tucker, K. S. Richter, E. A. Widra, M. J. Levy. Shady Grove Fertility 


O-283 5:15 PM 

LEADER OF THE PACK: LEAD EMBRYO DEVELOPMENT ON DAY 5 

(D5) BEST DETERMINES OUTCOME IN OOCYTE DONATION (OD) 

CYCLES. 

B. Hodes-Wertz, J. Knopman, C. Mccaffrey, L. Krey, F. Licciardi, J. A. 

Grifo. NYU Fertility Center, New York University, New York, NY. 

O-284 5:30 PM 

THE EFFECT OF STATE MANDATED INSURANCE COVERAGE ON 

THE USE OF ICSI IN THE USA. 

A. K. Nangia1 , B. Luke2 , W. Abdel Megid3 , J. F. Smith4 , W. Mak5 , J. E. 

Stern6 . 1Urology, University of Kansas Medical Center, Kansas City, 

KS; 2Obstetrics, Gynecology, Reproductive Endocrinology and 

Epidemiology, Michigan State University, East Lansing, MI; 3Wisconsin Fertility Institute, Middletown, WI; 4Urology, University of California, 

San Francisco, San Francisco, CA; 5Division of Reproductive 

Endocrinolgy, University of Pennsylvania, Philadelphia, PA; 

6Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, 

Lebanon, NH. 

__________________________________________________________ 

OVARIAN STIMULATION - POOR RESPONDERS: ART 

ROOM 601 

Moderators: Orhan Bukulmez, M.D. 

David B. Seifer, M.D. 

O-285 3:45 PM 

A RELIABLE DEFINITION OF POOR OVARIAN RESPONSE TO 

OVULATION INDUCTION. 

P. H. M. Bianchi 1 , A. M. Rocha 1 , J. R. Alegretti 1,2 , T. Domingues 1 , E. L. A. 

Motta 1,2 , P. Serafini 1,3 . 1 Huntington Medicina Reprodutiva, São Paulo, 

Brazil; 2 Departamento de Ginecologia, Universidade Federal de São 

Paulo, São Paulo, Brazil; 3 Disciplina de Ginecologia, Universidade 

Federal de São Paulo, São Paulo, Brazil. 

O-286 4:00 PM 

IMPACT OF OBESITY ON ASSISTED REPRODUCTIVE OUTCOMES 

OF POOR RESPONDERS. 

J. Y. J. Huang, T. Singer, Z. Williams, S. Spandorfer, D. Owen, Z. 


Reproductive Medicine, Wel Cornell Medical Center, New York, NY.

O-287 4:15 PM 

CLINICAL SIGNIFICANCE OF CONCORDANCES AND 

DISCORDANCES BETWEEN FOLLICLE STIMULATING HORMONE 

(FSH) AND ANTI-MÜLLERIAN HORMONE (AMH) IN ASSESMENT 

OF OVARIAN RESERVE (OR). 

N. Gleicher 1,2 , A. Weghofer 1,3 , D. H. Barad 1,4 . 1 Center for Human 

Reproduction & Foundation for Reproductive Medicine, New York, 

NY; 2 Department of Obstetrics, Gynecology and Reproductive 

Sciences, Yale University School of Medicine, New Haven, CT; 

3 Department of Obstetrics and Gynecology, Vienna University 

School of Medicine, Vienna, Innere Stadt, Austria; 4 Department 

of Epidemiology and Social Medicine; Department of Obstetrics, 

Gynegology and Women’s Health, Albert Einstein College of 

Medicine, Bronx, NY. 

O-288 4:30 PM 

A LEGAL-ETHICAL ANALYSIS OF RIGHTS OF REPRODUCTIVE 

ENDROCRINOLOGISTS TO REFUSE OVULATION INDUCTION TO 

PATIENTS WITH DIMINISHED OVARIAN RESERVE. 

S. F. Karipcin, A. Hossain, J. Y. Phelps. Obstetrics and Gynecology, 

University of Texas Medical Branch, Galveston, TX. 

O-289 4:45 PM 

A NEW IVF STIMULATION PROTOCOL IMPROVES LIVE BIRTH 

RATE IN WOMEN WITH DIMINISHED OVARIAN RESERVE (DOR). 

P. S. Dudley, A. C. Thyer, L. B. Davis, N. A. Klein, A. R. Criniti, M. R. 

Soules. Seattle Reproductive Medicine, Seattle, WA. 

O-290 5:00 PM 

DEHYDROEPIANDROSTERONE (DHEA) SUPPLEMENTATION FOR 

POOR RESPONDERS – HOW DOES IT WORK? 

J. H. Hyman 1 , E. J. Margalioth 2 , R. Rabinowitz 3 , A. Tsafrir 2 , N. Algur 1 , 

T. Eldar-Geva 1 . 1 Reproductive Endocrinology and Genetics Unit, 

Shaare Zedek Medical Center, Jerusalem, Israel; 2 IVF Unit, Shaare 

Zedek Medical Center, Jerusalem, Israel; 3 Gynecological Ultrasound 

Unit, Shaare Zedek Medical Center, Jerusalem, Israel. 

O-291 5:15 PM 

A LETROZOLE CHALLENGE TEST TO AID SELECTION OF 

GONADOTROPIN DOSE IN CONTROLLED OVARIAN 

STIMULATION (COS) CYCLES. 

Y. H. Bentov 1,2,3 , E. Burstein 1,2,3 , N. Esfandiari 1,2 , R. F. Casper 1,2,3 . 

1 Toronto Centre for Advanced Reproductive Technology, Toronto, 

ON, Canada; 2 Division of Reproductive Sciences, Department 

of Obstetrics and Gynecology, University of Toronto, Toronto, 

ON, Canada; 3 Samuel Lunenfeld Research Institute, Toronto, ON, 

Canada. 

O-292 5:30 PM 

EFFECTS OF DEPOT LEUPROLIDE ACETATE ON OOCYTE HARVEST 

IN PATIENTS WITH ENDOMETRIOSIS. 

E. F. McAdory, D. A. Forstein, H. L. Higdon III, P. B. Miller, B. A. Lessey, 

W. R. Boone. Obstetrics and Gynecology, University Medical Group, 

Greenville Hospital System, Greenville, SC. 

__________________________________________________________ 

REPRODUCTIVE BIOLOGY: HUMAN STUDIES 

ROOM 501 

Moderators: Dean E. Morbeck , Ph.D., H.C.L.D. 


O-293 3:45 PM 

WITHDRAWN 

O-294 4:00 PM 

SHIFT IN APPEARANCE OF NUCLEOLAR CHANNEL SYSTEMS IN 

WOMEN FOLLOWING OVARIAN HYPERSTIMULATION WITH AND 

WITHOUT LUTEAL HORMONAL SUPPLEMENTATION. 

G. Zapantis1,3 , M. Szmyga2 , E. A. Rybak3 , D. Kreiner1 , N. Santoro4 , U. T. 

Meier2 . 1East Coast Fertility, Plainview, NY; 2Department of Anatomy 

and Structural Biology, Albert Einstein College of Medicine, Bronx, 

NY; 3Department of Obstetrics, Gynecology and Women’s Health, 

Albert Einstein College of Medicine, Bronx, NY; 4Department of 

Obstetrics and Gynecology, University of Colorado at Denver, 

Aurora, CO. 


119 

O-295 4:15 PM 

THE ENDOCRINE PROFILE OF IN-VITRO MATURATION 

TREATMENT CYCLES. 

C. Ortega 1 , L. Guzman 2 , F. Albuz 2 , P. Devroey 1 , J. Smitz 2 , M. De Vos 1 . 

1 Centre for Reproductive Medicine, UZ Brussel, Brussels, Belgium; 

2 Laboratory of Follicular Biology, UZ Brussel, Brussels, Belgium. 

O-296 4:30 PM 

ENDOMETRIUM RECEPTIVITY IN IN-VITRO MATURATION (IVM) 

TREATMENT. 

M. De Vos 1 , L. Guzman 2 , F. Albuz 2 , C. Bourgain 3 , J. Smitz 2 , P. Devroey 1 . 

1 Centre for Reproductive Medicine, UZ Brussel, Brussels, Belgium; 

2 Laboratory of Follicular Biology, UZ Brussel, Brussels, Belgium; 

3 Department of Pathology, UZ Brussel, Brussels, Belgium. 

O-297 4:45 PM 

GENE EXPRESSION PROFILE IN HUMAN CUMULUS CELLS 

OF IMMATURE AND MATURE OOCYTE UNDER IN VIVO 

MATURATION: CLINICAL APPLICATIONS. 

Z. G. Ouandaogo 1 , S. Assou 1 , D. Haouzi 1 , T. Anahory 2 , H. Dechaud 2 , 

S. Hamamah 3 . 1 Early Embryo Development and Human Embryo 

Stem Cells, Institute for Research in Biotherapy, INSERM U847 Hopital 

Saint-Eloi, Montpellier, Herault, France; 2 UFR Medecine, University of 

Montpellier 1 , Montpellier, Herault, France; 3 ART/PGD Division, CHU, 

Hopital Arnaud de Villeneuve, Montpellier, Herault, France. 

O-298 5:00 PM 

ADAMTS-1: A NEW HUMAN OVULATORY GENE AND A 

CUMULUS MARKER FOR FERTILIZATION CAPACITY. 

E. Maman, Y. Yung, M. Brengauz, S. Konopnicki, J. Dor, A. Hourvitz. 

Obstetric and Gynecology, Sheba Medical Center, Ramat Gan, 

Israel. 

O-299 5:15 PM 

ANALYSIS OF COMPACTION INITIATION IN HUMAN EMBRYOS 

USING TIME-LAPSE CINEMATOGRAPHY. 

K. Iwata, K. Yumoto, T. Mochida, Y. Miura, Y. Iba, Y. Mio. 

Reproductive Centre, Mio Fertility Clinic, Yonago, Tottori, Japan. 

O-300 5:30 PM 

MITOCHONDRIAL DNA IS SIGNIFICANTLY INCREASED IN 

ANEUPLOID HUMAN EMBRYOS. 

J. Su 1 , X. Tao 1 , G. Baglione 1 , N. R. Treff 1,2 , R. T. Scott, Jr 1,2 . 

1 Reproductive Medicine Associates of New Jersey, Morristown, NJ; 

2 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ. 

__________________________________________________________ 

REPRODUCTIVE SURGERY (SRS) 

ROOM 505 

Moderators: Jeffery M. Goldberg, M.D. 


O-301 3:45 PM 

COMPARISON OF ROBOT-ASSISTED LAPAROSCOPIC 

MYOMECTOMY (RALM) TO CLASSIC ROBOTIC MYOMECTOMY. 

S. S. Srouji, N. Robinson, A. R. Gargiulo. Obstetrics and Gynecology, 

Brigham and Women’s Hospital, Boston, MA. 

O-302 4:00 PM 

IMPROVING AUTOLOGOUS OVARIAN TRANSPLANTATION 

WITH FROZEN-BANKED TISSUE: ROBOTIC ASSISTANCE AND THE 

UTILIZATION OF A HUMAN REGENERATIVE MATRIX. 

K. Oktay, R. Soleimani, S. Lee, S. Ozkavukcu, M. M. Brito, S. Babayev. 

Institute for Fertility Preservation/Department of Obstetrics & 

Gynecology, New York Medical College, Valhalla, NY. 

O-303 4:15 PM 

INCIDENCE OF MUSCULOSKELETAL INJURIES IN ROBOTIC 

ASSISTED LAPAROSCOPIC SURGERY COMPARED TO 

CONVENTIONAL LAPAROSCOPY. 

G. E. Ekpo1 , S. Nayak1 , C. Fitzgerald2 , M. Milad1 . 1Obstetrics and 

Gynecology, Northwestern Memorial Hospital, Chicago, IL; 2Physical Medicine and Rehabilitation, Northwestern Memorial Hospital, 

Chicago, IL.

O-304 4:30 PM 

FALLOPOSCOPIC TUBOPLASTY (FT) IS A NOVEL, PATIENT 

FRIENDLY AND EFFECTIVE TREATMENT FOR TUBAL FACTOR 

INFERTILITY. 

M. Komai 1 , C. Komatsubara 1 , K. Sugihara 1 , A. Haruki 1 , A. Fukuda 1 , 

Y. Morimoto 2 . 1 IVF Osaka Clinic, Higashi-Osaka, Osaka, Japan; 2 IVF 

Namba Clinic, Osaka, Japan. 

O-305 4:45 PM 

EFFECTS OF MYOMECTOMY ON IN VITRO FERTILIZATION 

OUTCOMES. 

M. Catenacci, T. Falcone, B. Nutter. The Cleveland Clinic 


O-306 5:00 PM 

MONOPOLAR ELECTROSURGERY THROUGH SINGLE PORT 

LAPAROSCOPY MAY RESULT IN VISCERAL BURNS. 

B. Abu-Rafea 1,2 , G. A. Vilos 2 , O. Al-Obeed 1 , A. AlSheikh 1 . 1 Obstetrics 

and Gynecology, General Surgery, Pathology, King Saud University, 

Riyadh, Central, Saudi Arabia; 2 Obstetrics and Gynecology, The 

University of Western Ontario, London, ON, Canada. 

O-307 5:15 PM 

HYSTEROSCOPY IS EFFECTIVE TOOL TO DETECT AND TREAT 

THE ABNORMALITIES OF UTERINE CAVITY OF IMPLANTATION 

FAILURE PATIENTS IN IVF FROM OUR EXPERIENCE OF 200 

CASES. 

K. Sugihara1 , T. Himeno1 , M. Ida1 , A. Haruki1 , A. Fukuda1 , Y. Morimoto2 . 

1 2 IVF Osaka Clinic, Higashi-Osaka, Osaka, Japan; IVF Namba Clinic, 

Osaka, Japan. 

O-308 5:30 PM 

LOW COMPLICATION RATE OF TRANSVAGINAL HYDRO- 

LAPAROSCOPY. 

M. Bloechle, S. G. Marr. Fertility Center at Kaiser Wilhelm Memorial 

Church, Berlin, Germany. 

__________________________________________________________ 

NUTRITION SPECIAL INTEREST GROUP 

ROOM 403 

Moderators: Gilbert B. Wilshire, M.D. 

Dian Shepperson-Mills, M.A. 

O-309 3:45 PM 

SEASONAL 25(OH)D LEVELS IN WOMEN OF REPRODUCTIVE 

AGE. 

K. A. Reynolds, F. Turley, M. Abdallah, G. Hofmann. Obstetrics and 

Gynecology, Bethesda Hospital, Cincinnati, OH. 

O-310 4:00 PM 

A PILOT STUDY TO EVALUATE POLYUNSATURATED FATTY ACID 

PROFILES IN IVF PATIENTS: EFFECT ON EMBRYO MORPHOLOGY 

AND PREGNANCY. 

M. B. Baker 1 , K. Chung 1 , K. A. Bendikson 1 , M. Harris 2 , N. Opper 1 , R. J. 

Paulson 1 . 1 Department of Obstetrics and Gynecology, Division of 

Reproductive Endocrinology and Infertility, University of Southern 

California, Los Angeles, CA; 2 Department of Food Science and 

Nutrition, Colorado State University, Fort Collins, CO. 


120 

O-311 4:15 PM 

PRE-TREATMENT SERUM FATTY ACID LEVELS AND IN VITRO 

FERTILIZATION (IVF) TREATMENT OUTCOME. 

J. E. Chavarro 1 , A. F. Vitonis 2 , H. Campos 3 , D. W. Cramer 2 , M. D. 

Hornstein 2 , S. A. Missmer 2 . 1 Channing Laboratory, Department 

of Medicine, Brigham and Women’s Hospital, Harvard Medical 

School, Boston, MA; 2 Department of Obstetrics, Gynecology and 

Reproductive Biology, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA; 3 Department of Nutrition, Harvard 

School of Public Health, Boston, MA. 

O-312 4:30 PM 

EFFECT OF SOY SUPPLEMENTATION ON DIETARY 

MACRONUTRIENTS AND TRACE ELEMENTS IN 

POSTMENOPAUSAL WOMEN. 

O. Martinez 1 , B. E. Darnell 2 , A. B. Knee 1 , C. K. Sites 1 . 1 Obstetrics and 

Gynecology, Baystate Medical Center, Tufts University School of 

Medicine, Springfield, MA; 2 General Clinical Research Center, 

University of Alabama at Birmingham, Birmingham, AL. 

O-313 4:45 PM 

WITHDRAWN 

O-314 5:00 PM 

BODY MASS INDEX (BMI) AND EARLY TREATMENT OUTCOMES 

IN WOMEN UNDERGOING IN VITRO FERTILIZATION (IVF). 

J. E. Chavarro1 , S. Ehrlich2 , J. A. Attaman3 , T. L. Toth3 , J. Petrozza3 , R. 

Hauser2 . 1Channing Laboratory, Department of Medicine, Brigham 

and Women’s Hospital, Harvard Medical School, Boston, MA; 

2Department of Environmental Health, Harvard School of Public 

Health, Boston, MA; 3Vincent Memorial Obstetrics and Gynecology 

Service, Massachusetts General Hospital, Harvard Medical School, 

Boston, MA. 

O-315 5:15 PM 

OVARIAN RESERVE IN EXTREMELY OBESE WOMEN 

UNDERGOING WEIGHT LOSS INTERVENTION: INTERPLAY 

BETWEEN REPRODUCTIVE BIOMARKERS, ADIPOKINES, AND 

MEASURES OF ADIPOSITY. 

L. A. Kondapalli 1 , K. C. Allison 2 , D. B. Sarwer 2 , J. C. Spitzer 2 , A. 

Dokras 1 , S. F. Butts 1 . 1 Division of Reproductive Endocrinology and 

Infertility, University of Pennsylvania, Philadelphia, PA; 2 Center for 

Weight and Eating Disorders, Department of Psychiatry, University of 

Pennsylvania, Philadelphia, PA. 

O-316 5:30 PM 

ADIPOCYTES – CONDITIONED MEDIA MODULATES THE 

CELLULAR AND MOLECULAR RESPONSES IN HUMAN 

ENDOMETRIAL GLANDULAR EPITHELIAL CELLS. 

S. Nair, A. Al-Hendy. Obstetrics & Gynecology, CWHR, Meharry 

Medical College, Nashville, TN. 

__________________________________________________________

PRIZE PAPERS, IN-TRAINING & 

PRIZE VIDEO AWARDS

PRIZE PAPERS, IN-TRAINING, AND PRIZE VIDEOS AWARDS 2010 

DESCRIPTION OF AWARDS 

Please note that to be considered for these awards, one author must be a member in good standing of the ASRM. 

ORAL PRESENTATIONS 

Candidates for two Scientific Program Prizes will be selected by the Scientific Program Committee from all abstracts submitted to the 

meeting regardless of designation of group for initial review. These oral presentations will be judged at the meeting and selection will be 

determined by the Scientific Program Prize Paper Committee. The presenters of the two Scientific Program Prize papers will be awarded: 

• $1,000 

• One-year free ASRM membership 

• Free registration for ASRM 2011 in Orlando, FL 

POSTER PRESENTATIONS 

Posters must be put up on the appropriate boards on Sunday, October 24, between 12:00 noon and 5:00 p.m. or on Monday, October 25, 

between 8:00 a.m. and 12:00 noon, and must remain in place for the entire meeting. Posters must be removed by 2:00 p.m. on Wednesday, 

October 27. The ASRM cannot be responsible for removing or returning posters. Posters will be judged by the Scientific Program Committee 

beginning at 12:00 noon Monday. The awardees will receive: 

• First Prize: $500 

• Second Prize: $300 

• Third Prize: $200 

RESIDENT IN-TRAINING AWARD 

This award will recognize the presenter of an exceptional abstract who is currently a resident in training in the field of obstetrics and 

gynecology or urology. Candidates who wish their abstract to be considered for this award must check the “Resident In-Training Award” 

check box in the online Abstract Submitter. The awardee will receive: 

• $500 


• Free registration to ASRM 2010 in Denver, CO 

IN-TRAINING AWARDS FOR RESEARCH 

Five In-Training Awards for Research will be granted in recognition of outstanding research conducted by individuals who are in-training. 

Candidates who wish their abstract to be considered for one of these awards must check the “In-Training Award for Research” check 

box in the online Abstract Submitter. He/she must be the presenting author (first) and must be a medical student, resident, fellow or 

undergraduate, graduate or postdoctoral student. Each awardee will receive: 



• Free registration to ASRM 2011 in Orlando, FL 

SRS IN-TRAINING AWARDS FOR RESEARCH 

Three (3) SRS In-Training Awards for research will be granted. The purpose of these awards is to recognize outstanding research conducted 

by individuals in-training. Candidates who wish their abstract to be considered for one of these awards must check the “SRS In-Training 

Award for Research” check box in the online Abstract Submitter. He/she must be the presenting author (first) and must be a medical 

student, resident, fellow or undergraduate, graduate or postdoctoral student, and must attend ASRM 2010 in Denver and present the 

abstract. Each awardee will receive: 


• One-year free ASRM and SRS membership 

• Free registration to the 2010 ASRM Annual Meeting in Denver, CO 

SMRU TRAVELING SCHOLARS AWARD PROGRAM 

The objective of these awards is to expose residents/fellows, graduate students and postdoctoral fellows to new scientific information 

pertinent to the study of reproductive medicine. Candidates who wish their abstract to be considered for one of these awards must 

submit the abstract to the Male Reproduction and Urology: Traveling Scholars category. He/she must also submit a copy of their CV, a 

letter of recommendation from their research mentor, and a statement of career goals with the abstract through the online program. The 

presenting (first) author must be a resident, fellow or undergraduate, graduate or postdoctoral student. The first author must be willing to 

present an oral presentation and must attend the SMRU sponsored activities presented during the 2010 Annual Meeting. Previous Traveling 

Scholars may not submit an abstract as the first author. Each awardee will receive reimbursement of some expenses for attendance to 

ASRM 2010: 

• Meeting registration fee 

• Registration fee to the SMRU Postgraduate Course and one Roundtable 

• Limited financial support for travel, lodging and incidentals 

AFFILIATED SOCIETIES 

The Society for Assisted Reproductive Technology, The Society for Reproductive Endocrinology and Infertility, The Society of Reproductive 

Surgeons, and the Society for Male Reproduction and Urology will select prize papers for an award of $500 each. 

PROFESSIONAL AND SPECIAL INTEREST GROUPS 

Several of these groups select prize papers for cash awards. 

VIDEO PRESENTATIONS 

The committee will select an overall first prize award video ($1,000) and a runner-up ($500). Individual category recognition may be 

identified by a certificate. To be considered for an award, one author must be a member in good standing of the ASRM at the time of 

submission. 

121


2010 ASRM PRIZES 

SART Prize Paper 

O-115, Tuesday, October 26, 2010 – Time: 4:15 pm 

A Subset of the Cumulus Cell Transcriptome is Predictive of Euploid Human Oocyte Reproductive Potential. 

N. R. Treff, J. Su, A. Lonczak, D. Taylor, R. T. Scott, Jr. Reproductive Medicine Associates of New Jersey, Morristown, NJ, UMDNJ-Robert Wood 

Johnson Medical School, New Brunswick, NJ. 

SREI Prize Paper 

O-213, Wednesday, October 27, 2010 - Time: 3:45 pm 

Racial/Ethnic Differences in Ovarian Reserve Markers. 

M. P. Rosen, E. B. Johnstone, C. Addauan-Andersen, B. Sternfeld, C. McCulloch, M. I. Cedars. Obstetrics, Gynecology, and Reproductive 

Sciences, University of California San Francisco, San Francisco, CA; Division of Research, Kaiser Permanente, Oakland, CA; Epidemiology & 

Biostatistics, University of California San Francisco, San Francisco, CA. 

SMRU Prize Paper 

O-56, Monday, October 25, 2010 – Time: 4:45 pm 

Aneuploidy Rates in Ejaculated and Testicular Spermatozoa in Patients with High Sperm DNA Damage. 

S. I. Moskovtsev, N. Alladin, K. C. Lo, K. Jarvi, J. B. M. Mullen, C. L. Librach. CReATe Fertility Center, Toronto, ON, Canada; Department 

of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; Division of Urology, Department of Surgery, Mount 

Sinai Hospital, Toronto, ON, Canada; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, 

Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 

SRS Prize Paper 

O-04, Monday, October 25, 2010 – Time: 12:00 pm 

Unidirectional Barbed Suture Versus Continuous Suture with Intracorporeal Knots in Laparoscopic Myomectomy: Randomized 

Controlled Trial. 

S. Ferrero, V. Remorgida, F. Alessandri. Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Genoa, 

GE, Italy. 

Reproductive Immunology SIG Prize Paper 

O-158, Tuesday, October 26, 2010 – Time: 4:15 pm 

Etanercept Immunotherapy in Women with a History of Recurrent Miscarriage. 

M. Jerzak, M. Klochowicz, A. Górski, W. Baranowski. Department of Gynecology and Gynecological Oncology, Military Institute of Medicine, 

Warsaw, Poland; Department of Clinical Immunology, Transplantation Institute, University School of Medicine, Warsaw, Warsaw, Poland. 

Mental Health Profession Group Prize Paper 

O-221, Wednesday, October 27, 2010 – Time: 3:45 pm 

The Impact of Fertility Counseling and Fertility Preservation on Long-Term Psychological Outcomes in Young Female Cancer 

Survivors. 

J. M. Letourneau, P. P. Katz, J. F. Smith, E. Ebbel, M. I. Cedars, M. P. Rosen. Department of Obstetrics, Gynecology, and Reproductive 

Sciences, University of California San Francisco School of Medicine, San Francisco, CA; Department of Medicine, University of California San 

Francisco School of Medicine, San Francisco, CA; Department of Urology, University of California San Francisco School of Medicine, San 


ASRM Resident In-Training Award 

O-63, Monday, October 25, 2010 - Time: 5:00 pm 

Fresh Versus Frozen SIB-Pair Analysis of Birthweight in Singleton Livebirths as a Result of IVF. 

K. E. O’Neill, S. E. Lanzendorf, R. R. Odem, A. R. Cooper. Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, 

MO. 

SRS In-Training Awards for Research 

O-126, Tuesday, October 26, 2010 - Time: 5:00 pm 

Pedicled Omental Flaps and Autologus Free Omental Grafts in the Pelvis Survive and Do Not Increase Adhesion Formation in 

an Animal Model. 

A. P. Bailey, A. K. Schutt, D. W. Stovall. Obstetrics & Gynecology, University of Virginia, Charlottesville, VA. 


Robotic-Assisted, Laparoscopic and Open Myomectomy: A Comparison of Surgical Outcomes. 

E. E. Barakat, M. A. Bedaiwy, S. Zimberg, B. Nutter, T. Falcone. Obstetrics, Gynecology and Women’s Health Institute, Cleveland Clinic 

Foundation, Cleveland, OH; Obstetrics and Gynecology, University Hospitals Case Medical Center,Case Western Reserve University, 

Cleveland, OH; Minimally Invasive Gynecology, Cleveland Clinic Florida, Fort Lauderdale, FL. 


Microarray Expression Profiling in Adhesion and Normal Peritoneal Tissues. 

D. R. Ambler, A. M. Golden, K. K. Masker, J. S. Gell, G. S. Gerhard, D. J. Carey. Obstetrics and Gynecology, Geisinger Medical Center, 

Danville, PA; Weis Center for Health Research, Geisinger Medical Center, Danville, PA. 

122


ASRM In-Training Awards for Research 


The Impact of Fertility Counseling and Fertility Preservation on Long-Term Psychosocial Outcomes in Young Female Cancer 

Survivors. 

J. M. Letourneau, P. P. Katz, J. F. Smith, E. Ebbel, M. I. Cedars, M. P. Rosen. Department of Obstetrics, Gynecology, and Reproductive 

Sciences, University of California San Francisco School of Medicine, San Francisco, CA; Department of Medicine, University of California San 

Francisco School of Medicine, San Francisco, CA; Department of Urology, University of California San Francisco School of Medicine, San 


O-148, October 26, 2010 - Time: 4:30 pm 

Estrogen Therapy and Cardiovascular Disease: Could Arterial Expression of Interleukin 17 Provide Some Answers to the 

Timing Hypothesis? A Study of Early and Late Menopause in Non-Human Primates. 

A. Sophonsritsuk, S. E. Appt, T. B. Clarkson, T. C. Register. Comparative Medicine/Pathology and the Primate Center, Wake Forest University 

School of Medicine, Winston Salem, NC; Molecular Genetics Genomics Program, Wake Forest University School of Medicine, Winston Salem, 

NC. 


Association of Polychlorinated Biphenyls (PCBS) with Adverse Reproductive Outcomes During In Vitro Fertilization (IVF). 

S. Mahalingaiah, A. Maity, K. F. Berry, P. L. Williams, S. A. Missmer, R. Hauser. Department of Obstetrics, Gynecolgy, and Reproductive Biology, 

Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; Channing Laboratory, Department of Medicine, Brigham and 

Women’s Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard School of Public Health, Boston, MA; 

Department of Environmental Health, Harvard School of Public Health, Boston, MA; Department of Biostatistics, Harvard School of Public 

Health, Boston, MA; Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital and Harvard Medical School, 

Boston, MA. 


Access to Fertility Preservation and Post-Chemotherapy Assisted Reproduction in Women with Breast Cancer. 

S. Lee, E. Heytens, S. Ozkavukcu, A. Rosen, F. Moy, K. Oktay. Institute for Fertility Preservation/Department of Obstetrics Gynecology, New 

York Medical College, Valhalla, NY; Biometrics, Data Management and PK/PD Unit/Department of Pathology, New York Medical College, 

Valhalla, NY. 

O-24, Monday, October 25, 2010 - Time: 4:15 pm 

Establishment and Characterization of Human Germ Cells Derived From Embryonic Stem Cells (hESCs). 

N. D. Tran, D. Laird, M. Kissner, D. Supramanyam, M. Conti, R. Blelloch. Obstetrics and Gynecology, Center for Reproductive Sciences, 

University of California, San Francisco Medical Centre, San Francisco, CA. 

First Prize for Technical Achievement in Video 2010 

V-3, Tuesday, October 26, 2010 – Time: 11:39 am 

Chromosome Transfer in Mature Oocytes. 

M. Tachibana 1 , M. Sparman 1 , S. Mitalipov 1,2,3 . 1 Division of Repro Sci, Oregon National Primate Research Center, Oregon Health & Science 

University, Beaverton, OR; 2 Oregon Stem Cell Center, Oregon Health & Science University, Beaverton, OR; 3 Departments of Obstetrics and 

Gynecology and Molecular and Medical Genetics, Oregon Health & Science University, Beaverton, OR. 

Honorable Mention for Technical Achievement in Video: Assisted Reproductive Technology Category 

V-5, Tuesday, October 26, 2010 – Time: 12:02 pm 

Time-Lapse Cinematography of Dynamic Changes Occurring During In Vitro Development of Human Embryos - Part 2. 

Y. Mio. Reproductive Centre, Mio Fertility Clinic, Yonago, Tottori, Japan. 

Honorable Mention for Technical Achievement in Video: Surgery Category 

V-11, Tuesday, October 26, 2010 – Time: 4:15 pm 

Robotic Resection of Ureteral Endometriosis. 

J. Reddy 1 , A. C. Frick 1 , R. J. Stein 2 , M. F. R. Paraiso 1 , T. Falcone 1 . 1 Obstetrics, Gynecology and Women’s Health Institute, Cleveland Clinic, 

Cleveland, OH; 2 Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. 

123

NOTES 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________

RESIDENT REPORTER PROGRAM 

The 23rd Annual ASRM Resident Reporter Program allows 

OB/GYN residents to attend the ASRM Annual Meeting and 

various activities while at the meeting, including postgraduate 

courses, special programs, speaker sessions, symposia, and 

scientific sessions of interest to them, and all 

Annual Meeting social and networking events. 

Supported by educational grants from Merck and Pfizer 

POSTERS

New Member/First Time 

Attendee Reception 

New ASRM members and first time Annual 

Meeting attendees are invited to a reception 

to meet and greet ASRM board members, 

leadership of the affiliated societies, and the 

officers of the professional and 

special interest groups. This reception will take 

place during the Tuesday morning poster 

session in Hall F (Poster Area) of the 


from 8:00 am until 9:00 am. 

Join the ASRM Leadership for 

coffee & conversation.

HALL F (POSTER AREA) • COLORADO CONVENTION CENTER 

POSTERS ON THE LEFT SIDE OF THE POSTER AREA 

CONTINUED ON NEXT PAGE

HALL F (POSTER AREA) • COLORADO CONVENTION CENTER 

POSTERS ON THE RIGHT SIDE OF THE POSTER AREA 

CONTINUED FROM PREVIOUS PAGE

ASRM invites you to meet the poster presenters of posters P-1 

through P-300 on Tuesday morning and enjoy a continental 

breakfast. Authors of posters P-301 through P-600 will present 

their posters Wednesday morning. 

Please note that on Monday, posters will be open from 12:00 

pm until 5:00pm. On Tuesday, posters will be open from 7:00 

am until 5:00 pm. On Wednesday, posters will open at 7:00 

am and will conclude at 2:00 pm. 

ASRM cannot be responsible for removing and/or returning 

posters. All posters not removed will be discarded. 

__________________________________________________________ 

TUESDAY TOPICS AND POSTER NUMBERS: 

Contraception/Family Planning: P-1 thru P-5 

Ovarian Function: P-6 thru P-8 

Ovarian Reserve: P-9 thru P-25 

Cancer: P-26 thru P-33 

Fertility Preservation: P-34 thru P-48 

Cryopreservation: P-49 thru P-92 

Genetic Counseling: P-93 thru P-98 

Preimplantation Genetic Diagnosis: P-99 thru P-119 

Male Reproductive Urology: P-120 thru P-137 

Sperm Biology: P-138 thru P-144 

Oocyte Biology: P-145 thru P-161 

Oocyte Maturation: P-162 thru P-173 

Oxidative Stress: P-174 thru P-184 

Fertilization: P-185 thru P-187 

Embryo Biology: P-188 thru P-196 

Embryo Culture: P-197 thru P-206 

Ovarian Stimulation: P-207 thru P-213 

ART - Ovarian Stimulation: P-214 thru P-250 

ART - General: P-251 thru P-265 

Embryo Transfer: P-266 thru P-281 

Implantation: P-282 thru P-286 

Luteal Phase Support: P-287 thru P-291 

Pregnancy Loss and Termination: P-292 thru P-300 

__________________________________________________________ 

CONTRACEPTION/FAMILY PLANNING 

P-1 THE EFFECT OF AGE, RACE, AND FOLIC ACID-CONTAINING 

SUPPLEMENTS ON RED BLOOD CELL FOLATE LEVELS AMONG 

UNITED STATES WOMEN OF CHILD BEARING AGE. 

R. Lynen4 , T. N. Taylor1 , R. A. Farkouh2 , S. D. Candrilli2 , J. Graham2 , A. 

Colligs3 . 1Department of Pharmacy Practice, Wayne State University, 

Detroit, MI; 2Health Economics, RTI Health Solutions, Research 

Triangle Park, NC; 3Global Health Economics and Outcomes 

Research, Women’s Health, Bayer Schering Pharma AG, Berlin, 

Germany; 4Medical Affairs Women’s Healthcare, Bayer HealthCare 

Pharmaceuticals Inc., Wayne, NJ. 



Poster Presentations and Reception 

Abstracts P-1 through P-300 

Hall F (Poster Area) 


Supported by an educational grant from Merck. 

128 

P-2 MANAGEMENT OF PREGNANCY IN NIH INTRAMURAL 

CLINICAL TRIALS THAT POSE MORE THAN MINIMAL RISK TO 

WOMEN OF CHILDBEARING POTENTIAL (WOCP). 

P. Stratton 1 , M. R. Vieira 2 , S. Liu 2 , A. Idriss 3 , A. DeCherney 1 , B. Karp 2 . 

1 Program in Reproductive and Adult Endocrinology, Bethesda, MD; 

2 Department of Social Work, Bethesda, MD; 3 CNS IRB, Bethesda, MD; 

4 Unit in Computer Support Services, Bethesda, MD. 

P-3 TRENDS IN LONG-TERM REVERSIBLE INTRAUTERINE 

DEVICE (IUD) AND PERMANENT POST-PREGNANCY 

CONTRACEPTION AT ONE UNIVERSITY TEACHING HOSPITAL, 

2005-2007. 

M. K. Baldwin, A. Edelman. Obstetrics & Gynecology, Oregon Health 

& Science University, Portland, OR. 

P-4 EPIDEMIOLOGY STUDY OF PREVALENCE RATE, 

TREND AND INFLUENCING FACTOR OF INFERTILITY IN ANHUI 

PROVINCE. 

Y. Cheng 1 , L. Hou 2 , X. Jiang 1 , Y. Zhao 2 . 1 National Research Institute 

for Family Planning, Bejing, China; 2 Peking Medical Union College,, 

Beijing, China. 

P-5 LENGTH OF TIME AFTER INSERTION OF THE 

LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM FOR IT TO 

SIGNIFICANTLY ALTER CERVICAL MUCUS QUALITY AND SPERM 

PENETRATION. 

M. Natavio 1 , D. Taylor 1 , P. Blumenthal 2 , R. Lewis 1 , A. Melamed 1 , D. 

Mishell 1 . 1 University of Southern California, Los Angeles, CA; 2 Stanford 

University, Palo Alto, CA. 

__________________________________________________________ 

OVARIAN FUNCTION 

P-6 DIFFERENTIAL EXPRESSION OF BRAIN DERIVED 

NEUROTROPHIC FACTOR (BDNF) AND ITS RECEPTOR TRKB 

IN LUTEINIZED HUMAN MURAL AND CUMULUS GRANULOSA 

CELLS. 

E. Buyuk1 , N. Santoro2 , M. J. Charron1,3 , S. K. Jindal1 . 1Department of 

Obstetrics and Gynecology and Women’s Health, Albert Einstein 

College of Medicine/Montefiore’s Institute for Reproductive 

Medicine and Health, Hartsdale, NY; 2Department of Obstetrics 

and Gynecology, University of Colorado at Denver, Aurora, CO; 

3Department of Biochemistry, Albert Einstein College of Medicine, 

Bronx, NY. 

P-7 AMPHIREGULIN STIMULATES CUMULUS-OOCYTE 

EXPANSION AND OOCYTE MATURATION IN RHESUS 

MACAQUES. 

M. C. Peluffo 1 , R. L. Stouffer 1,2 , M. B. Zelinski 1 , J. D. Hennebold 1,2 . 

1 Division of Reproductive Sciences, Oregon National Primate 

Research Center, Beaverton, OR; 2 Department of Obstetrics and 

Gynecology, Oregon Health & Science University, Portland, OR. 

P-8 THE INCIDENCE OF GENUINE EMPTY FOLLICLE 

SYNDROME. 

B. Yu 1 , K. S. Richter 2 , E. A. Widra 2 , A. DeCherney 1 , J. H. Segars 1 . 

1 Program of Adult and Reproductive Endocrinology, Eunice 

Kennedy Shriver National Institute of Child Health and Human 

Development, National Institutes of Health, Bethesda, MD; 2 Shady 

Grove Fertility Reproductive Science Center, Rockville, MD. 

__________________________________________________________

OVARIAN RESERVE 

P-9 DIMINISHED OVARIAN RESERVE IS NOT ASSOCIATED 

WITH INCREASED RISKS OF PRETERM BIRTH OR LOW BIRTH 

WEIGHT. 

K. C. Calhoun, A. Z. Steiner. Obstetrics and Gynecology, Division 

of Reproductive Endocrinology & Infertility, The University of North 

Carolina at Chapel Hill, Chapel Hill, NC. 

P-10 REDUCED NEUROTROPHIN RECEPTOR TRKA GENE 

EXPRESSION IN HUMAN GRANULOSA CELLS: A NOVEL 

MARKER OF DIMINISHING OVARIAN RESERVE? 

E. Buyuk 1 , N. Santoro 2 , M. J. Charron 1,3 , S. K. Jindal 1 . 1 Department of 

Obstetrics and Gynecology, Albert Einstein College of Medicine/ 

Montefiore Institute for Reproductive Medicine and Health, 

Hartsdale, NY; 2 Department of Obstetrics and Gynecology, 

University of Colorado at Denver, Aurora, CO; 3 Biochemistry, Albert 

Einstein College of Medicine, Bronx, NY. 

P-11 BLOOD TYPE O IS ASSOCIATED WITH DIMINISHED 

OVARIAN RESERVE (DOR). 

E. J. Nejat 1 , S. K. Jindal 1,3 , E. Buyuk 1 , D. S. Berger 3 , L. Pal 1,2 . 1 Obstetrics 

& Gynecology and Women’s Health, Albert Einstein College of 

Medicine, Bronx, NY; 2 Obstetrics, Gynecology and Reproductive 


3 Montefiore Institute for Reproductive Medicine & Infertility, 

Montefiore Medical Center, Hartsdale, NY. 

P-12 ASSESMENT OF OVARIAN RESERVE IN PATIENTS WITH 

BEHCET’S DISEASE. 

A. P. Cil 1 , M. Sonmezer 2 , M. Kocak 3 , A. A. Karabulut 3 , F. Akbiyik 4 , K. 

Oktay 5 . 1 OB-GYN, Kirikkale University, Kirikkale, Turkey; 2 OB-GYN, 

Ankara University, Ankara, Turkey; 3 Dermatology, Kirikkale University, 

Kirikkale, Turkey; 4 Biochemistry, Hacettepe University, Ankara, Turkey; 

5OB-GYN, Institute for Fertility Preservation, Valhalla, NY. 

P-13 ABNORMAL OVARIAN RESERVE PARAMETERS AND 

PREGNANCY LOSS RATES IN WOMEN ≥ 35 UNDERGOING IVF. 

T. D. Deutch, R. Sherbahn. Advanced Fertility Center of Chicago, 

Gurnee, IL. 

P-14 ANTI-MULLERIAN HORMONE (AMH), ANTRAL 

FOLLICLE COUNT (AFC) AND AGE PREDICT IVF OUTCOMES 

SIGNIFICANTLY BETTER THAN FOLLICLE STIMULATING 

HORMONE (FSH). 

R. Gada, D. Morbeck, M. Amols, N. Rollene, J. Jensen, C. 

Coddington. Reproductive Endocrinology and Infertility, Mayo 

Clinic, Rochester, MN. 

P-15 THE RATIO OF DIFFERENCE IN THE NUMBER OF 

RETRIEVED OOCYTES BETWEEN TWO OVARIES TO TOTAL 

OOCYTES AND SUCCESS OF IVF CYCLES. 

S. A. Choe, S.-Y. Ku, S. H. Kim, Y. M. Choi, J. G. Kim, S. Y. Moon. 

Obstetrics and Gynecology, Seoul National University, Chongno-gu, 

Seoul, Korea. 

P-16 OBESITY IS ASSOCIATED WITH LOWER SERUM AMH 

LEVELS IN WOMEN WITH DIMINISHED OVARIAN RESERVE 

(DOR). 

E. Buyuk 1 , D. B. Seifer 2 , E. Illions 1 , R. Grazi 2 , H. Lieman 1 . 1 Department 

of Obstetrics and Gynecology and Women’s Health, Albert Einstein 


Medicine and Health, Hartsdale, NY; 2 Genesis Fertility & 

Reproductive Medicine, Brooklyn, NY. 

P-17 OVARIAN RESERVE ASSESMENT IN PATIENTS WITH 

MULTIPLE SCLEROSIS. 

A. P. Cil 1 , A. Leventoglu 2 , M. Sonmezer 3 , A. Uzdogan 4 , Z. B. Guler 1 , K. 

Oktay 5 . 1 OB-GYN, Kirikkale University, Kirikkale, Turkey; 2 Neurology, 

Ufuk University, Ankara, Turkey; 3 OB-GYN, Ankara University, Ankara, 

Turkey; 4 Biochemistry, Hacettepe University, Ankara, Turkey; 5 OB- 

GYN, Kirikkale University, Kirikkale, Turkey; 6 OB-GYN, Institute for 

Fertility Preservation, Valhalla, NY. 


129 

P-18 SERUM MARKERS OF OVARIAN AGING ARE 

ASSOCIATED WITH NATURAL FERTILITY. 

A. Z. Steiner 1 , A. H. Herring 2 , S. Hoberman 2 , F. Z. Stanczyk 3 , D. D. 

Baird 4 . 1 Obstetrics and Gynecology, University of North Carolina, 

Chapel Hill, NC; 2 Biostatistics, University of North Carolina, Chapel 

Hill, NC; 3 Obstetrics and Gynecology, University of Southern 

California, Los Angeles, CA; 4 Epidemiology Branch, NIEHS/NIH, 

Research Triangle Park, NC. 

P-19 BODY MASS INDEX AND ITS ASSOCIATION WITH 

OVARIAN PRIMORDIAL FOLLICLE NUMBER. 

K. R. Hansen 1 , L. B. Craig 1 , N. A. Klein 2 . 1 Department of Obstetrics 

and Gynecology, Section of Reproductive Endocrinology and 

Infertility, University of Oklahoma Health Sciences Center, Oklahoma 

City, OK; 2 Seattle Reproductive Medicine, Seattle, WA. 

P-20 PREGNANCY IN THE SETTING OF LOW AND 

UNDETECTABLE SERUM ANTI-MULLERIAN HORMONE (AMH). 

J. R. Crochet, K. C. Hawkins, M. C. Peavey, T. M. Price, D. K. Walmer, 

S. D. Copland. Obstetrics and Gynecology, Duke University Hospital, 

Durham, NC. 

P-21 AGE SPECIFIC MEANS AND STANDARD DEVIATIONS 

OF SERUM ANTIMULLERIAN HORMONE (AMH) FOR 15,234 

WOMEN PRESENTING TO FERTILITY CENTERS WITHIN THE UNITED 

STATES. 

B. Leader 1,2 , V. Baker 2,3 , D. Seifer 4 . 1 ReproSource, Inc, Woburn, MA; 

2 Rachel’s Well, Marietta, GA; 3 Obstetrics and Gynecology, Stanford 

Medical School, Stanford, CA; 4 Genesis Fertility & Reproductive 

Medicine, Brooklyn, NY. 

P-22 NORMAL OVARIAN RESERVE DOES NOT PREDICT A 

LOWER INCIDENCE OF COMPREHENSIVE CHROMOSOME 

ANEUPLOIDIES. 

M. G. Katz-Jaffe, E. S. Surrey, D. A. Minjarez, R. L. Gustofson, J. M. 

Stevens, W. B. Schoolcraft. Colorado Center for Reproductive 


P-23 ANTI-MULLERIAN HORMONE LEVELS ARE A USEFUL 

PROGNOSTIC TOOL FOR OVARIAN RESPONSE IN WOMEN 

ABOVE 40 YEARS OLD. 

P. Fettback 1,2 , E. Carrilho 1 , C. M. Gomes 1,2 , A. M. Rocha 1 , E. L. A. 

Motta 1,3 , P. Serafini 1,2 . 1 Huntington Medicina Reprodutiva, São Paulo, 

Brazil; 2 Disciplina de Ginecologia, Faculdade de Medicina da 

Universidade de São Paulo, São Paulo, Brazil; 3 Departamento de 

Ginecologia, Universidade Federal de São Paulo, São Paulo, Brazil. 

P-24 ANTIMULLERIAN HORMONE (AMH) IS A PREDICTOR 

OF THE NUMBER OF EGGS RETRIEVED AND D3 EMBRYOS IN 

WOMEN WITH FLUCTUATING AND PERSISTENTLY ELEVATED FSH 

LEVELS. 

E. Buyuk 1 , D. B. Seifer 2 , R. Grazi 2 , H. Lieman 1 . 1 Department of 

Obstetrics and Gynecology and Women’s Health, Albert Einstein 


Medicine and Health, Hartsdale, NY; 2 Genesis Fertility & 

Reproductive Medicine, Brooklyn, NY. 

P-25 CLINICAL APPLICATION OF AMH AS A PREDICTOR OF 

COH OUTCOME: THE FIRST CLINICAL ASSAY DATA IN KOREA. 

J. R. Lee 1 , C. S. Suh 1,2 , D. Y. Hwang 3 , K. C. Kim 3 , W. D. Lee 4 , S. H. 

Kim 2 . 1 Department of Obstetrics and Gynecology, Seoul National 

University Bundang Hospital, Seongnam, Gyeonggi-do, Korea; 

2 Department of Obstetrics and Gynecology, Seoul National 

University College of Medicine, Seoul, Korea; 3 Hamchoon Women’s 

Clinics, Seoul, Korea; 4Maria Infertility Hospital, Seoul, Korea. 

__________________________________________________________ 

CANCER 

P-26 Cdc25A MAY PLAY A CRITICAL ROLE IN MEIOSIS AND 

OOCYTE MATURATION. 

K. Boyle DiPaola1 , M. Yin2 , M. El Bahassi2 , P. Stambrook2 . 1Obstetrics and Gynecology, Reproductive Endocrinology, University of 

Cincinnati, Cincinnati, OH; 2Molecular Genetics, Biochemistry, and 

Microbiology, University of Cincinnati, Cincinnati, OH.

P-27 MALE CRYOPRESERVATION: CLINICAL RELEVANCE OF 

CANCER IMPACT ON SPERMATOGENESIS. 

G. M. Emerson, E. Mocanu. IVF Unit, Human Assisted Reproduction 

Ireland, Dublin, Ireland. 

P-28 CRYOPRESERVATION AND IN VITRO DEVELOPMENT 

ABILITY OF IVM OOCYTES FROM GENDER IDENTITY DISORDER 

AND CANCER PATIENTS. 

N. Kagawa 1 , M. Kuwayama 1 , S. J. Silber 2 , C. Mori 1 , Y. Takehara 1 , 

O. Kato 1 . 1 Kato Ladies’ Clinic, Shinjuku, Tokyo, Japan; 2 St. Luke’s 

Hospital, St. Louis, MO. 

P-29 EVALUATION OF THE MEITOIC SPINDLE (MS) AND 

ZONA PELLUCIDA (ZP) TO IDENTIFY A RELATIONSHIP BETWEEN 

FERTILITY AND MALIGNANCY IN WOMEN UNDERGOING 

OOCYTE CRYOPRESERVATION (OC). 

M. D. Werner 1 , A. Reh 2 , P. A. Labella 2 , Y. Kramer 2 , J. A. Grifo 2 , N. 

Noyes 2 . 1 Obstetrics and Gynecology, NYU, NY, NY; 2 NYU Fertility 

Center, NY, NY. 

P-30 TRANSCRIPTION ELONGATION INITIATION FACTORS: 

POTENTIAL LOW PENETRANCE GENES IN BREAST CANCER. 

POSSIBLE UTILITY IN PREIMPLANTATION GENETIC SCREENING 

OF EMBRYOS PRIOR TO AN IVF CYCLE. 

K. Boyle DiPaola 1 , Y. Q. Li 2 , M. El Bahassi 2 , P. Stambrook 2 . 1 Obstetrics 

and Gynecology, University of Cincinnati, Cincinnati, OH; 2 Molecular 

Genetics, Biochmistry, and Microbiology, University of Cincinnati, 

Cincinnati, OH. 

P-31 OVARIAN STIMULATION FOR FERTILITY PRESERVATION 

REACHES SIMILAR OUTCOMES THAN NORMAL IVF PATIENTS. 

AN AGE-MATCHED CASES AND CONTROLS STUDY. 

E. Martinez 1 , J. Domingo 2 , A. Pellicer 3,4 , J. Garcia-Velasco 5 , N. 

Garrido 3 , E. Munoz 1 . 1 Reproductive Medicine, IVI Vigo, Vigo, 

Pontevedra, Spain; 2 Reproductive Medicine, IVI Las Palmas, 

Las Palmas, Gran Canaria, Gran Canaria, Spain; 3 Reproductive 

Medicine, Instituto Valenciano de Infertilidad, University of Valencia, 

Valencia, Spain; 4 Obstetrics and Gynecology, University Hospital La 

Fe, Valencia, Spain; 5 Reproductive Medicine, IVI Madrid, Madrid, 

Spain. 

P-32 SULFATASE ACTIVITY IN BENIGN AND MALIGNANT 

OVARIAN TISSUE. 

O. Abulafia, G. Salame, T. Shah, Y.-C. Lee, O. Muneyyirci-Delale, V. L. 

Nacharaju. Obstetric and Gynecology, Downstate Medical Center, 

Brooklyn, NY. 

P-33 REPRODUCTIVE HEALTH AND ENDOCRINE DISRUPTION 

IN BREAST CANCER CARE. 

M. Sreedevi 1 , A. Uy 2 , E. Radeke 2 , A. Patel 1 , H. Zaren 3 . 1 Obstetrics/ 

Gynecology, John H Stroger Jr Hospital of Cook County, Chicago, 

IL; 2 Medical Oncology, John H Stroger Jr Hospital of Cook County, 

Chicago, IL; 3 Oncology, St. Joseph’s/Candler Hospital, Savannah, 

GA. 

__________________________________________________________ 

FERTILITY PRESERVATION 

P-34 DELIVERY OF VASCULAR ENDOTHELIAL GROWTH 

FACTOR (VEGF) TO SHAM OVARIAN TISSUE AUTOGRAFTS IN 

NON-HUMAN PRIMATES: OPTIMAL METHOD OF DELIVERY AND 

DOSE. 

D. Lee1,2 , M. Burns1,2 , C. Thomas2 , R. Yeoman2 , M. Zelinski2 , R. Stouffer2 . 

1Obstetrics & Gynecology, Pediatrics, Oregon Health and Science 

University, Portland, OR; 2Reproductive Sciences, Oregon National 

Primate Research Center, Beaverton, OR. 

P-35 IN VITRO EFFECTS OF BONE MORPHOGENETIC 

PROTEIN 15 (BMP-15) AND BMP-15 COMBINED WITH GROWTH 

DIFFERENTIATING FACTOR 9 ON HUMAN PRIMORDIAL 

FOLLICLES. 

A. Kedem 2 , B. Fisch 1 , R. Garor 1 , A. Ben Haroush 1 , R. Abir 1 . 1 Infertility 

and IVF Unit, Schneider Hospital for Women, Rabin Medical Center 

and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, 

Israel; 2 Department of Obstetrics & Gynecology, Infertility and IVF 


130 

Unit, Sheba Medical Center and Sackler Faculty of Medicine, Tel 

Aviv University, Ramat Gan, Israel. 

P-36 ARE WOMEN FROM CERTAIN SOCIO-DEMOGRAPHIC 

BACKGROUNDS MORE LIKELY TO UNDERGO FERTILITY 

PRESERVATION? 

J. M. Letourneau 1 , P. M. Katz 2 , J. F. Smith 1,3 , C. E. McCulloch 4 , M. 

I. Cedars 1 , M. P. Rosen 1 . 1 Department of Obstetrics, Gynecology, 

and Reproductive Sciences, University of California San Francisco 

School of Medicine, San Francisco, CA; 2 Department of Medicine, 

University of California San Francisco School of Medicine, San 

Francisco, CA; 3 Department of Urology, University of California San 

Francisco School of Medicine, San Francisco, CA; 4 Department of 

Epidemiology and Biostatistics, University of California San Francisco 

School of Medicine, San Francisco, CA. 

P-37 FERTILITY PRESERVATION TREATMENT OPTIONS: WHAT 

DO PATIENTS ACTUALLY UNDERSTAND ABOUT THEIR CHOICES? 

U. Balthazar 1 , M. A. Fritz 1 , T. Bardsley 2 , J. E. Mersereau 1 . 1 Reproductive 

Endocrinology and Infertility, University of North Carolina at Chapel 

Hill, Chapel Hill, NC; 2 School of Public Health, University of North 

Carolina at Chapel Hill, Chapel Hill, NC. 

P-38 SERUM ANTI-MULLERIAN HORMONE LEVELS DO 

NOT CORRELATE WITH CYCLOPHOSPHAMIDE-INDUCED 

PRIMORDIAL FOLLICULAR DESTRUCTION IN MICE PRETREATED 

WITH CETRORELIX. 

K. S. Moon 1 , Y. Zhou 2 , S. Mumford 3 , J. H. Segars 1 , A. Y. Armstrong 1 . 

1 Program in Reproductive and Adult Endocrinology, Eunice 


Development, Bethesda, MD; 2 Department of Clinical Investigation, 

Walter Reed Army Medical Center, Washington, DC; 3 Epidemiology 

Branch, Eunice Kennedy Shriver National Institute of Child Health 

and Human Development, Bethesda, MD. 

P-39 THE AVERAGE COST OF FERTILITY PRESERVATION FOR 

FEMALE CANCER PATIENTS. 

L. N. Beck 1 , M. Sileo 1 , A. B. Copperman 2 . 1 Livestrong, Austin, TX; 2 RMA 

of New York, New York, NY. 

P-40 DECISION MAKING UNDER DURESS: WHAT PREDICTS 

DECISIONAL CONFLICT AMONG FERTILITY PRESERVATION 

PATIENTS? 

U. Balthazar 1 , M. A. Fritz 1 , T. Bardsley 2 , J. E. Mersereau 1 . 1 Reproductive 

Endocrinology, University of North Carolina at Chapel Hill, Chapel 

Hill, NC; 2 School of Public Health, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 

P-41 SIMPLIFIED CLOSED DOUBLE-STRAW SYSTEM FOR 

OOCYTE, EMBRYO AND BLASTOCYST VITRIFICATION. 

O. Perez 2 , C. A. Guerrero 3 , T. Ferguson 1 , J. Douglas 2 , A. Rodriguez 2 , 





P-42 KANSAS PHYSICIAN ATTITUDES AND PRACTICE 

PATTERNS RELATING TO ONCOLOGY PATIENTS AND FERTILITY 

PRESERVATION. 

T. Von Wald 1,2 , L. Frazier 1,2 , A. Paschal 1 , L. Hopper 1,2 , D. Grainger 1,2 . 

1 Obstetrics and Gynecology, University of Kansas School of 

Medicine-Wichita, Wichita, KS; 2 Preventive Medicine and Public 

Health, University of Kansas School of Medicine-Wichita, Wichita, KS. 

P-43 GONADOTROPIN-RELEASING HORMONE ANALOG 

CO-TREATMENT FOR PRESERVATION OF OVARIAN FUNCTION 

DURING GONADOTOXIC CHEMOTHERAPY: A SYSTEMATIC 

REVIEW AND META-ANALYSIS. 

M. A. Bedaiwy 1 , A. M. Abou-Setta 2 , N. Desai 4 , W. Hurd 1 , S. A. El- 

Nashar 3 , T. Falcone 4 . 1 Department of OB/GYN, University Hospitals 

Case Medical Center, Case Western Reserve University, Cleveland, 

OH; 2 Alberta Research Centre for Health Evidence (ARCHE), 

University of Alberta, Edmonton, AB, Canada; 3 Department of 

OB/GYN, Assiut University Hospitals., Assiut, Egypt; 4 OB/Gyn, The 

Cleveland Clinic Foundation, Cleveland, OH.

P-44 EFFICIENCY OF USING VITRIFIED DONOR OOCYTES 

FROM CRYOPRESERVED OOCYTE BANK. 

Y. Shu, W. Peng, J. Zhang. New Hope Fertility Center, New York, NY. 

P-45 LAPROENDOSCOPIC SINGLE SITE (LESS) GONADAL 

SPARING SURGERY. 

M. A. Bedaiwy 1 , P. F. Escobar 2 . 1 Department of Obstetrics and 

Gynecology, Case Western Resrve University, Cleveland, OH; 

2 Department of Obstetrics and Gynecology, The Cleveland Clinic 


P-46 SPINGOSINE-1-PHOSPHATE ENHANCES NEO- 

ANGIOGENESIS IN HUMAN OVARIAN TRANSPLANTS IN SCID 

MICE. 

R. Soleimani, E. Heytens, K. Oktay. Laboratory of Molecular 

Reproduction, Institute for Fertility Preservation, Department of 


P-47 OOCYTE RETRIEVAL AND CRYOPRESERVATION FOR 

UNMARRIED FEMALE CANCER PATIENTS. 

S. Teramoto 1 , H. Kamiya 2 , M. Ochi 3 , Y. Fujino 4 , K. Yano 5 , T. 

Utsunomiya 6 . 1 Shimbashi YUME Clinic, Minato-ku, Tokyo, Japan; 

2 Kamiya Ladies Clinic, Sapporo, Hokkaido, Japan; 3 Ochi YUME Clinic 

Nagoya, Nagoya, Aichi, Japan; 4 Fujino Ladies Clinic, Suita, Osaka, 

Japan; 5 Yano Maternity Clinic, Matsuyama, Ehime, Japan; 6 St. Luku 

Clinic, Oita, Japan. 

P-48 ELECTIVE OOCYTE FREEZING FOR THE PRESERVATION 

OF FERTILITY: AN IRB APPROVED PILOT STUDY OF OVER 200 

CLIENTS. 

J. Barritt 1,2 , M. Luna 1,2 , B. Sandler 1,2 , T. Mukherjee 1,2 , M. Duke 1,2 , A. B. 

Copperman 1,2 . 1 Reproductive Medicine Associate of New York, New 

York, NY; 2 Department of OBGYN and Reproductive Science, Mount 

Sinai School of Medicine, New York, NY. 

__________________________________________________________ 

CRYOPRESERVATION 

P-49 EVALUATION OF THE FIRST ONE HUNDRED AND THIRTY 

ONE LIVE BIRTHS FOLLOWING OOCYTE CRYOPRESERVATION 

FROM A SINGLE IVF PROGRAM UTILIZING A STANDARDIZED 

VITRIFICATION TECHNIQUE. 

H. I. Kort, D. B. Shapiro, A. A. Toledo, D. Mitchell-leef, J. Chang, Z. P. 


P-50 CONFOCAL MICROSCOPY OF MEIOTIC SPINDLE 

AND ITS RECOVERY TIME OF HUMAN OOCYTES AFTER 

VITRIFICACION. 

S. Cubillos 1 , S. Sanchez 1 , W. Suastegui 1 , J. Pedraza 1 , F. Caldino 2 , 

S. Cuneo 2 . 1 Laboratorio de Reproduccion Asistida SA de CV, 

Concibe Reproduccion Asistida, Mexico, DF, Mexico; 2 Clinica de 

Reproduccion Asistida SA de CV, Concibe Reproduccion Asistida, 

Mexico, DF, Mexico. 

P-51 CRYOPRESERVATION OF HUMAN SPERMATOZOA 

BY VITRIFICATION: IMPACTS ON SPERM PARAMETERS AND 

APOPTOSIS. 

M. A. Khalili 1 , M. Adib 1 , M. Ramezani 2 . 1 Research and Clinical Center 

for Infertility, Shahid Sadoughi University of Medical Sciences, 

Yazd, Islamic Republic of Iran; 2 Department of Biology, University of 

Payam-nour, Yazd, Ireland. 

P-52 DOES SLOW FREEZING-THAWING ALTER THE GENE 

EXPRESSION PROFILE OF HUMAN METAPHASE II OOCYTES? 

M. Cecile 1 , A. Said 1 , H. Delphine 1 , D. Hervé 2 , D. V. John 1 , H. 

Samir 2 . 1 CHU Montpellier, Institut de Recherche en Biothérapie, 

Hôpital Saint-Eloi, Montpellier, Languedoc Roussillon, France; 

2 CHU Montpellier, Département de Médecine et Biologie de 

la Reproduction, Hôpital Arnaud de Villeneuve, Montpellier, 

Languedoc Roussillon, France. 


131 

P-53 DOES THE DURATION OF CRYOPRESERVATION IMPACT 

HUMAN SPERM DNA INTEGRITY AND APOPTOSIS FOLLOWING 

THAWING? 

T. M. Said 1 , B. Mullen 2 , A. P. Del Valle 1 . 1 Andrology Laboratory & 

Reproductive Tissue Bank, The Toronto Institute for Reproductive 

Medicine, Toronto, ON, Canada; 2 Department of Laboratory 

Medicine & Pathobiology, University of Toronto, Toronto, ON, 

Canada. 

P-54 OOCYTE VITRIFICATION: SIMILAR RESULTS USING A 

STRAW OR CRYOLOCK. 

T. H. Taylor, S. V. Hallowell, I. P. Glassner, J. J. Orris, M. J. Glassner, J. D. 

Wininger. Main Line Fertility, Bryn Mawr, PA. 

P-55 THE CLINICAL OUTCOMES OF VITRIFIED BLASTOCYSTS 

ON IN VITRO MATURATION CYCLES. 

I. H. Bae, H.-J. Yoon, H.-J. Kim, J.-H. Cha, W.-D. Lee, J.-H. Lim. Maria 

Fertility Hospital, Dongdaemun-Gu, Seoul, Korea. 

P-56 RECONSIDERING CRYOPRESERVATION FOR POOR 

QUALITY EMBRYOS: COULD VITRIFICATION MODIFY THE 

CRITERIA? 

L. Kopcow, M. Gómez Peña, G. Terrado, I. de Zúñiga, M. Horton, 

C. Bisioli. Reproductive Medicine, Pregna Medicina Reproductiva, 

Buenos Aires, Argentina. 

P-57 VARIABLES INFLUENCING PREGNANCY RATE AFTER 

OOCYTE CRYOPRESERVATION. 

S. Ferrero, M. R. Privamera, S. Levi, A. J. Nicoletti, L. H. Abbamonte, 

P. Anserini. Department of Obstetrics and Gynecology, San Martino 

Hospital and University of Genoa, Genova, GE, Italy. 

P-58 WHAT IS THE OPTIMAL STAGE FOR EMBRYO 

VITRIFICATION-A COMPARISON OF EMBRYO SURVIVAL 

AND CLINICAL OUTCOMES WITH DAY 3 CLEAVAGE VERSUS 

BLASTOCYST STAGE VITRIFICATION. 

N. Desai, T. Falcone, J. Goldberg, C. Austin, J. Goldfarb. OB- 

GYN/Women’s Health Institute, Cleveland Clinic Foundation, 

Beachwood, OH. 

P-59 COMPARISON OF VITRIFICATION EFFICIENCY USING 

THIN PLASTIC STRIP (TPS) AND ELECTRON MICROSCOPE (EM) 

GRID ON MOUSE BLASTOCYSTS. 

J. Lee, Y. Hur, S. Yoon, C. Hur, W. Lee, J. Lim. Research, Maria 

Hospital, Seoul, Dongdaemun-gu, Korea; Maria Research Center, 

Maria Hospital, Seoul, Dongdaemun-gu, Korea; Maria Clinical 

Center, Maria Hospital, Seoul, Dongdaemun-gu, Korea. 

P-60 DEVELOPMENT OF A MURINE MODEL TO STUDY THE 

INFLUENCE OF MATERNAL BODY ON EMBRYO CYTOPLASMIC 

COMPOSITION. 

J. Weathers 1 , N. Zimmerer 1 , S. D. Prien 2 . 1 Animal and Food Sciences, 

Texas Tech University, Lubbock, TX; 2 Ob/Gyn, Texas Tech University 

Health Sciences Center, Lubbock, TX. 

P-61 IMPACT OF EMBRYO QUALITY IN FRESH VERSUS 

VITRIFIED OOCYTES IN AN EGG DONATION PROGRAM. 

S. M. Giordana 1 , M. F. Insua 1 , B. Lotti 1 , N. Fernandez Peri 1 , A. Pellicer 2 , 

F. D. Neuspiller 1 . 1 IVI Buenos Aires, Ciudad Autónoma de Buenos 

Aires, Buenos Aires, Argentina; 2 IVI Valencia, Valencia, Spain. 

P-62 THE OOCYTE CRYO-BANKING IS A PRACTICAL WAY 

TO BENEFIT MORE PATIENTS WHO NEED DONOR OOCYTES. 

C.-C. Chang, T. A. Elliott, G. Wright, D. B. Shapiro, H. I. Kort, Z. P. 


P-63 THE TIME OF CRYOPRESERVATION DO NOT INCREASE 

THE DAMAGE IN FROZEN OVARIAN TISSUE FOR FERTILITY 

PRESERVATION. 

J. R. Campos, B. R. Carvalho, J. C. Rosa-e-Silva, A. A. Vireque, R. A. 

Ferrani, A. C. J. S. Rosa-e-Silva. Obstetrics and Gynecology, Faculty 

of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão 

Preto, São Paulo, Brazil.

P-64 COMPARISON OF FROZEN-THAWED EMBRYO 

CYCLES FOLLOWING MULTIPLE BANKING AND SINGLE-CYCLE 

BANKING PROTOCOLS. 

B. S. Shapiro, S. T. Daneshmand, F. Garner, M. Aguirre, C. Hudson. 

Fertility Center of Las Vegas, Las Vegas, NV. 

P-65 PREGNANCY AND DELIVERY RATES OF FROZEN- 

THAWED EMBRYOS FERTILIZED WITH FRESH- OR FROZEN- 

THAWED TESTICULAR SPERM. 

M. K. Kim 1 , S.-H. Lee 1 , H.-S. Lee 1 , I. O. Song 2 , J. T. Seo 3 , Y.-S. Park 1 . 

1 Laboratory of Reproductive Biology and Infertility, Cheil General 

Hospital and Women’s Healthcare Center, Kwandong University 

College of Medicine, Seoul, Republic of Korea; 2 Department of 

Obstetrics and Gynecology, Cheil General Hospital and Women’s 

Healthcare Center, Kwandong University College of Medicine, 

Seoul, Republic of Korea; 3 Department of Urology, Cheil General 

Hospital and Women’s Healthcare Center, Kwandong University 

College of Medicine, Seoul, Republic of Korea. 

P-66 EDUCATING ONCOLOGISTS ABOUT MALE INFERTILITY 

INCREASES SPERM CRYOPRESERVATION RATES PRIOR TO 

CANCER TREATMENT. 

L. E. Wagner 1 , C. Bormann 2 , S. Salih 2 , D. I. Lebovic 2 , J. E. Zweifel 2 , D. H. 

Williams IV 1,2 . 1 Urology, University of Wisconsin Hospitals and Clinics, 

Madison, WI; 2 Reproductive Endocrinology and Infertility, University 

of Wisconsin Hospitals and Clinics, Madison, WI. 

P-67 CRYOPRESERVATION OF INDIVIDUAL SPERMATOZOA 

FOR MEN WITH COMPROMISED SPERMATOGENESIS. 

J. C. Y. Hu, Q. V. Neri, J. Kocent, Z. Rosenwaks, G. D. Palermo. The 

Ronald O Perelman & Claudia Cohen Center for Reproductive 

Medicine, Weill Cornell Medical College, New York, NY. 

P-68 TRANSFER (ET) OF PREVIOUSLY CRYOPRESERVED 

OOCYTES OR ZYGOTES RESULTS IN PREGNANCY OUTCOMES 

SIMILAR TO THAT OF FRESH BLASTOCYSTS (BLAST) IN IVF. 

B. Hodes-Wertz, N. Noyes, C. Mullin, C. McCaffrey, J. Grifo. NYU 


P-69 THE EFFICIENCY OF OOCYTE VITRIFICATION FOR 

DONOR OOCYTE CYCLES AND OOCYTE BANKING IN ART. 

T. Schlenker 1,2 , J. Stevens 1,2 , M. G. Katz-Jaffe 1,2 , W. B. Schoolcraft 1,2 . 

1 Colorado Center for Reproductive Medicine, Lone Tree, CO; 

2 Fertility Laboratories of Colorado, Lone Tree, CO. 

P-70 COMPARISON OF CLINICAL OUTCOME OF 

BLASOCYST VITRIFICATION WITH SLOW FREEZING AND FRESH 

EMBRYO TRANSFER. 

K. Kaskar, Y. Ren, L. Gong, G. Haddad, I. Gill, W. Wang. Houston 

Fertility Institute/Tomball Hospital, Tomball, TX. 

P-71 EMBRYO DEVELOPMENT AND PREGNANCY OUTCOME 

OF SIBLING PRONUCLEAR STAGE FROZEN AND FRESH HUMAN 

EMBRYOS. 

N. Esfandiari, A. Gokturk, Z. Nazemian, M. H. Javid, A. Sultan, 

R. F. Casper. IVF and Andrology, Toronto Centre for Advanced 

Reproductive Technology (TCART), Toronto, ON, Canada. 

P-72 IS THERE A ROLE FOR VITRIFICATION OF ALL EMBRYOS 

IN CYCLES OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART)? 

A. E. Zabala, L. A. Blanco, G. Arenas, G. Rey Valzacchi, A. 

Ahumada, R. H. Asch. Procrearte, Ciudad Autonoma de Buenos 

Aires, Buenos Aires, Argentina. 

P-73 CLINICAL OUTCOMES OF NATURAL VERSUS 

PROGRAMMED FROZEN-THAWED EMBRYO TRANSFERS (FET): A 

5-YEAR REVIEW. 

J. Zuk, N. Noyes, C. M. Mullin, J. M. Knopman, J. A. Grifo. NYU Fertility 

Center, New York, NY. 

P-74 COMPARISON OF VITRIFICATION AND SLOW 

FREEZING PROTOCOL FOR OOCYTE CRYOPRESERVATION. 

R. Azambuja, L. Okada, J. Michelon, M. Badalotti, F. Badalotti, A. 

Petracco. Fertilitat-Centro de Medicina Reprodutiva, Porto Alegre, 

RS, Brazil. 


132 

P-75 VITRIFICATION OF HUMAN AND MOUSE EMBRYOS 

USING THE RAPID-I. 

B. Balaban 1 , A. Isiklar 1 , B. Urman 1 , D. K. Gardner 2 , M. G. Larman 2 . 

1 Assisted Reproduction Unit, Istanbul, Nisantasi, Turkey; 2 Department 

of Zoology, University of Melbourne, Parkville, Victoria, Australia. 

P-76 ACCUMULATION OF OOCYTES AS STRATEGY OF 

MANAGEMENT FOR POOR RESPONDERS (PR) PATIENTS. 

A. Cobo, N. Garrido, J. Crespo, M. de los Santos, A. Pellicer, J. 

Remohí. IVI, Instituto Universitario IVI- Valencia, Valencia, Spain. 

P-77 A NOVEL VITRIFICATION METHOD USING A 

MICROFILTRATION MEMBRANE (MFM) ENABLES A SIMPLE 

MANIPULATION OF HUMAN EMBRYOS. 

A. Amo 1 , S. Hashimoto 1 , H. Nagashima 2 , M. Takahashi 3 , N. 

Sasayama 4 , Y. Morimoto 1 . 1 IVF Namba Clinic, Osaka, Japan; 2 Meiji 

University, Kawasaki, Kanagawa, Japan; 3 National Agricultural 

Research Center for Kyushu Okinawa Region, Koshi, Kumamoto, 

Japan; 4 Nipro Corporation Research & Development Laboratory, 

Kusatsu, Shiga, Japan. 

P-78 COMPARISON OF DIFFERENT VITRIFICATION/ 

WARMING TECHNIQUES USING MOUSE BLASTOCYSTS. 

B. Behr, J. Gebhardt, J. Watt, Q. Zhao, V. Reddy, J. Dasig. OB/GYN, 

IVF Program, Stanford University Hospital, Palo Alto, CA. 

P-79 COMPARATIVE VITRIFICATION (VTF) OF MOUSE 

EMBRYOS WITH S3-BL and RAPID VIT SOLUTIONS BY 

MICROSECURE VTF (µS-VTF). 

M. C. Schiewe, N. Nugent, S. Zozula. IVF Lab, Southern California 

Institute for Reproductive Sciences, Newport Beach, CA. 

P-80 OOCYTE CRYOPRESERVATION: AN ALTERNATIVE 

MODEL FOR GAMETE DONATION. 

J. M. Knopman, N. Noyes, P. LaBella, F. Licciardi, J. A. Grifo. OB/GYN, 

NYU Langone Medical Center, New York, NY. 

P-81 VIABILITY OF VITRIFIED-THAWED DAY 3 HUMAN 

EMBRYOS FOLLOWING 24 HOUR CULTURE AND TRANSFER. 

E. S. Michael, M. T. Lao, A. Michael, T. Michael, T. Tao. Astra Fertility 

Clinic, Mississauga, ON, Canada. 

P-82 EVALUATION OF ASEPTIC BLASTOCYST VITRIFICATION 

IN PREIMPLANTATION GENETIC DIAGNOSIS PATIENTS. 

L. Van Landuyt, E. Van den Abbeel, D. Stoop, W. Verpoest, P. 

Devroey, G. Verheyen. Centre for Reproductive Medicine, UZ 

Brussel, Jette, Brussel, Belgium. 

P-83 DONOR OOCYTE CRYOPRESERVATION: A 

RANDOMIZED CLINICAL TRIAL COMPARING MICROSECURE 

VITRIFICATION (µS VTF) to CHOLINE-ENRICHED CJ3 SLOW- 

FREEZING (SF). 

M. C. Schiewe, N. Nugent, S. Zozula, J. J. Stachecki, R. E. Anderson. 

Southern California Institute for Reproductive Sciences, Newport 

Beach, CA; Southern California Center for Reproductive Medicine, 

Newport Beach, CA; Thyo-Galileo Research Laboratories, LLC, 

Livingston, NJ. 

P-84 HIGH RECOVERY AND SURVIVAL RATES OF MOUSE 

AND HUMAN BLASTOCYSTS VITRIFIED IN A CLOSED SYSTEM. 

W. Wang, K. Kaskar, L. Gong, G. Haddad, I. Gill. Houston Fertility 

Institute/Tomball Hospital, Tomball, TX. 

P-85 THE PREGNANCY RATE IS SIGNIFICANTLY INCREASED 

WHEN THE DURATION OF PROGESTERONE SUPPLEMENTATION 

AND EMBRYONIC AGE ARE SYNCHRONIZED IN DAY 3 FROZEN- 

THAWED EMBRYO TRANSFER. 

E.-M. Cha 1 , S.-K. Kim 1 , J.-H. Lee 1 , I.-H. Park 1 , G.-H. Jeon 2 , K.-H. Lee 1 . 

1 Infertility Lab, MamaPapa & Baby OBGY, Ulsan, Republic of 

Korea; 2 Department of OBGY, College of Medicine, Inje University, 

Haeundae Paik Hospital, Busan, Republic of Korea.

P-86 BEAD VITRIFICATION OF SPERMATOZOA FOR MEN 

WITH SEVERELY COMPROMISED SPERMATOGENESIS. 

J. C. Y. Hu, Q. V. Neri, Z. Rosenwaks, G. D. Palermo. The Ronald O 



P-87 CLINICAL OUTCOME OF DAY 3 AND DAY 5 VITRIFIED 

EMBRYO TRANSFER CYCLES. 

J. H. Lee, Y. J. Jung, H. K. Hwang, M. J. Kook, A. Kang, S. J. Lee. 

Mirae and Heemang OB/GYN Clinic, Seoul, Republic of Korea. 

P-88 UPDATE ON CLINICAL OUTCOMES AND LIVE BIRTHS 

WITH HUMAN EMBRYO VITRIFICATION AT THE 6-8 CELL STAGE: 

EMBRYONIC ACTIVATION AFTER WARMING AND IMPACT ON 

CLINICAL PREGNANCY AND IMPLANTATION. 

N. Desai, F. AbdelHafez, A. Cynthia, J. Goldberg, T. Falcone, J. 

Goldfarb. OB-GYN/Women’s Health Institute, Cleveland Clinic 

Foundation, Beachwood, OH. 

P-89 MULTICELL AND BLASTOCYST SURVIVAL AFTER 

VITRIFICATION: A COMPARISON BETWEEN SOLUTIONS FROM 

TWO DIFFERENT COMMERCIAL SOURCES. 

S. Pae, M. Angle. Laurel Fertility Care, San Francisco, CA. 

P-90 VITRIFICATION YIELDS SUPERIOR EFFICIENCY OF 

HUMAN CLEAVAGE-STAGE EMBRYO CRYOPRESERVATION 

VERSUS SLOW-FREEZING. 

S. Xue, Q. Lyu, Q. Peng, S. Cao, Y. Zhou, Y. Kuang. Reproductive 

Medical Center, Shanghai Ninth People’s Hospital, Shanghai Jiao 

Tong University School of Medicine, Shanghai, China. 

P-91 ALTERATION OF CALCIUM OSCILLATORY ACTIVITY 

IN VITRIFIED/WARMED EGGS MAY INFLUENCE ON THE 

PREIMPLANTATIONAL DEVELOPMENT OF MOUSE EGGS. 

B. Y. Kim, S. Yoon, S. K. Cha, K. H. Kwak, D. R. Lee, T. K. Yoon. Fertility 

Center of CHA Gangnam Medical Center, Seoul, Republic of Korea. 

P-92 CRYOPRESERVATION OF HUMAN EMBRYOS WITH 

VITRIFICATION IS A BETTER METHOD THAN SLOW FREEZING. 

J. J. Zhu, M. Hickey. Hinsdale Center for Reproduction, Hinsdale, IL. 

__________________________________________________________ 

GENETIC COUNSELING 

P-93 CHROMOSOMAL ABNORMALITIES IN SPONTANEOUS 

ABORTIONS AFTER ASSISTED REPRODUCTIVE TREATMENT: 5 

YEAR EXPERIENCES FROM 2005 TO 2009. 

J. W. Kim1 , S. M. Sohn2 , Y. S. Kim1 , T. K. Yoon1 , S. W. Lyu1 , S. H. Shim2 . 

1Fertility Center of CHA Gangnam Medical Center, Department of 

Obstetrics and Gynecology, CHA University, Seoul, Korea; 2Fertility Center of CHA Gangnam Medical Center, Genetics Laboratory, 

CHA University, Seoul, Korea. 

P-94 PREGNANCY CHANCES WITH IN VITRO FERTILIZATION 

(IVF) BASED ON FMR1-GENOTYPE AND AUTOIMMUNITY (AI). 

N. Gleicher 1,2 , I. Lee 1 , A. Weghofer 1,3 , D. H. Barad 1,4 . 1 Center for 

Human Reproduction & Foundation for Reproductive Medicine, 

New York, NY; 2 Department of Obstetrics, Gynecology and 


Haven, CT; 3 Department of Obstetrics and Gynecology, Vienna 

University School of Medicine, Vienna, Innere Stadt, Austria; 

4 Department of Epidemiology and Social Medicine; Department 

of Obstetrics, Gynegology and Women’s Health, Albert Einstein 

College of Medicine, Bronx, NY. 

P-95 X-AUTOSOMAL TRANSLOCATION — A DISTRACTION 

OR A CAUSE OF PRIMARY OVARIAN INSUFFICIENCY? 

W. Vitek 1 , K. Pagidas 1 , G. Gu 2 , J. R. Pepperell 2 , U. Tantravahi 1 , B. 

Plante 1 . 1 Division of Reproductive Endocrinology & Infertility, Women 

& Infants Hospital of Rhode Island, The Warren Alpert Medical 

School of Brown University, Providence, RI; 2 Genetic Associates, 



133 

P-96 FMR1 REPEATS AND OVARIAN FUNCTION: 

COMPARING NUMBER OF CGG REPEATS AND ANTRAL 

FOLLICLE COUNT. 

T. Spitzer, E. Johnstone, G. Davis, M. I. Cedars, V. Y. Fujimoto. 



P-97 PGD OR NATURAL CONCEPTION? WHAT IS 

RECOMMENDED FOR COUPLES WITH RECURRENT 

MISCARRIAGES CAUSED BY TRANSLOCATION 

CHROMOSOMAL ABERRATIONS? 

S. Awata, A. Tanaka, M. Nagayoshi, M. Sasaki, I. Tanaka. Saint 


P-98 THERE IS NO COMPLETE LINKAGE BETWEEN THE 

FOLLICULAR STIMULATING HORMONE RECEPTOR GENE 

POLYMORPHISMS N680S AND THE T307A IN FERTILE WOMEN. 

V. K. Genro 1 , G. P. Rodini 1 , U. S. Matte 2 , F. S. Pereira 1 , C. A. B. de 

Souza 2 , J. S. L. Cunha-Filho 1 . 1 Universidade Federal do Rio Grande 

do Sul, Porto Alegre, Rio Grande do Sul, Brazil; 2 Hospital de Clínicas 

de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil. 

__________________________________________________________ 

PREIMPLANTATION GENETIC DIAGNOSIS 

P-99 TROPHECTODERM BIOPSY FOR ANEUPLOIDY TESTING: 

PRELIMINARY OBSERVATIONS AND ONGOING PREGNANCIES. 

R. F. Feinberg, G. Kovalevsky, C. F. Boylan, S. M. Carney, L. S. 

Morrison, M. P. Portmann. Reproductive Associates of Delaware, 

Newark, DE. 

P-100 CHARACTERIZING THE RELATIONSHIP BETWEEN 

MORPHOLOGIC EMBRYONIC DEVELOPMENT AND PLOIDY 

STATUS AS ASSESSED BY 24 CHROMOSOME MICROARRAY 

PGD. 

K. L. Scott 1 , D. Taylor 1,2 , K. Ferry 1 , N. Treff 1,2 , R. T. Scott 1,2 . 1 Reproductive 

Medicine Associates of New Jersey, Morristown, NJ; 2 Division of 

Reproductive Endocrinology, Department of Obstetrics Gynecology 

and Reproductive Sciences, Robert Wood Johnson Medical School, 

New Brunswick, NJ. 

P-101 CLINICAL RESULTS ON SINGLE CELLS FROM 470 

EMBRYOS USING 23-CHROMOSOME SINGLE NUCLEOTIDE 

POLYMORPHISM (SNP) MICROARRAY PREIMPLANTATION 

GENETIC SCREENING (PGS) FROM 45 PATIENTS. 

A. Benner 1 , C. Chipko 1 , R. Pen 1 , W. G. Kearns 1,2 . 1 Shady Grove Center 

for Preimplantation Genetics, Rockville, MD; 2 Gynecology, Johns 

Hopkins Univ School of Medicine, Baltimore, MD. 

P-102 DOES NEWLY AVAILABLE 24-CHROMOSOME (24C) 

PREIMPLANTATION GENETIC SCREENING (PGS) IMPROVE 

IVF OUTCOMES IN PATIENTS AT RISK FOR ANEUPLOIDY? FIRST 

YEAR’S EXPERIENCE AT A LARGE, UNIVERSITY-BASED CENTER. 

K. Devine, J. Knopman, A. Adler, A. Berkeley, J. Grifo. NYU Fertility 

Center, Department of OB/GYN, NYU School of Medicine, New York, 

NY. 

P-103 YOU CAN’T ALWAYS GET WHAT YOU WANT. CLINICAL 

OUTCOMES IN PGD FOR GENDER VARIETY. 

T. Mukherjee 1,2 , J. Barritt 1,2 , C. A. McDonald 1 , B. Sandler 1,2 , L. 

Grunfeld 1,2 , A. B. Copperman 1,2 . 1 Reproductive Medicine 

Associates of New York, New York, NY; 2 Department of OBGYN and 

Reproductive Science, Mount Sinai School of Medicine, New York, 

NY. 

P-104 VALIDATION OF SINGLE NUCLEOTIDE POLYMORPHISM 

(SNP) MICROARRAY PGD ON SINGLE CELL(S) FROM EMBRYOS. 

W. G. Kearns 1,2 , A. Benner 1 , K.-H. D. Nguyen 3 , C. Chipko 1 , E. Widra 4 , 

R. Leach 1 . 1 Shady Grove Center for Preimplantation Genetics, 

Rockville, MD; 2 Gynecology, Johns Hopkins University School of 

Medicine, Baltimore, MD; 3 Medical Genetics, National Human 

Genome Research Institute, National Institutes of Health, Bethesda, 

MD; 4 Shady Grove Fertility Reproductive Science Center, Rockville, 

MD.

P-105 SINGLE HUMAN BLASTOMERE ALLELE DROPOUT (ADO) 

AND AMPLIFICATION EFFICIENCY BY PCR. 

B. Tazon-Vega, C. Zhang, Z. Rosenwaks, K. Xu. Ronald O. Perelman 

and Claudia Cohen Center for Reproductive Medicine, Weill 

Cornell Medical College of Cornell University, New York, NY. 

P-106 FEASIBILITY OF POLAR-BODY PGD FOR THALASSEMIA 

THROUGH A MODEL OF PARTHENOGENETIC ACTIVATION. 

A. Paffoni 1 , V. Paracchini 2 , S. Ferrari 1 , C. Scarduelli 1 , M. Seia 2 , G. 

Ragni 1 . 1 Infertility Unit, Fondazione IRCCS Ca’ Granda Ospedale 

Maggiore Policlinico, Milan, MI, Italy; 2 Medical Genetics Laboratory, 

Ondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 

Milan, MI, Italy. 

P-107 ARE WE INTRODUCING VARIABLES THAT 

IATROGENICALLY INCREASE THE RATE OF ANEUPLOIDY 

IN WOMEN WITH ADVANCED MATERNAL AGE (AMA) 

UNDERGOING IN VITRO FERTILIZATION (IVF)? 

L. B. Werlin1 , J. B. Whitney1 , E. C. Marello1 , T. E. Nass1 , S. Munne2 . 

1 2 Coastal Fertility Medical Center, Irvine, CA; Reprogenetics LLC, 

Livingston, NJ. 

P-108 CO-CULTURE WITH ENDOMETRIAL EPITHELIAL CELLS 

IMPROVES CLINICAL OUTCOME IN PATIENTS YOUNGER THAN 

41 YEARS FROM PGD PROGRAM. 

A. Mercader, P. Buendia, A. Delgado, L. Escrich, A. Pellicer, C. Simón. 

Preimplantation Genetic Diagnosis, Institut Universitari - IVI Valencia, 

Valencia, Spain. 

P-109 PREIMPLANTATION GENETIC DIAGNOSIS (PGD) IN 

CARRIERS OF PERICENTRIC AND PARACENTRIC INVERSIONS. 

E. Mateu 1 , L. Rodrigo 1 , M. C. Martinez 2 , J. Remohi 1 , A. Pellicer 1 , C. 

Rubio 1 . 1 Instituto Universitario IVI-Valencia, Valencia, Spain; 2 IVI- 

Murcia, Murcia, Spain. 

P-110 IMPROVEMENT IN DIAGNOSTIC ACCURACY USING 

SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAYS 

VERSUS FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 

IN PREIMPLANTATION GENETIC SCREENING (PGS) FOR 

ANEUPLOIDY. 

B. Yu 1 , C. Chipko 2 , K. S. Richter 3 , E. A. Widra 3 , A. DeCherney 1 , W. 

G. Kearns 2,4 . 1 Program in Reproductive and Adult Endocrinology, 


Human Development, National Institutes of Health, Bethesda, MD; 

2 Shady Grove Center for Preimplantation Genetics, Rockville, MD; 

3 Shady Grove Fertility Reproductive Science Center, Rockville, MD; 

4 The Johns Hopkins University School of Medicine, Baltimore, MD. 

P-111 THE UNBELIEVABLE SHRINKING MOSAICISM PROBLEM 

OF PGD. 

T. Escudero 1 , C. Gutierrez 1 , P. Colls 1 , D. Hill 2 , K. Wiemer 3 , M. Santi 1 . 

1 Reprogenetics, Livingston, NJ; 2 ART Reproductive Center, Beverly 

Hills, CA; 3 Northwest Center for Reproductive Sciences, Kirkland, WA. 

P-112 FIRST CLINICAL APPLICATION OF SIMULTANEOUS 

PREIMPLANTATION MITOCHONDRIAL DNA MUTATION LOAD 

AND 24 CHROMOSOME ANEUPLOIDY SCREENING. 

X. Tao 1 , J. Campos 1 , K. M. Ferry 1 , B. Levy 1 , N. R. Treff 1,2 , R. T. Scott, Jr 1,2 . 



P-113 FIRST PREGNANCIES AFTER BLASTOCYST BIOPSY 

AND RAPID 24 CHROMOSOME ANEUPLOIDY SCREENING 

ALLOWING A FRESH TRANSFER WITHIN FOUR HOURS OF 

BIOPSY. 

N. R. Treff 1,2 , X. Tao 1 , D. Taylor 1,2 , K. M. Ferry 1 , R. T. Scott, Jr 1,2 . 



P-114 BLASTOMERE MULTINUCLEATION ON DAY 2 POST EGG 

RETRIEVAL PREDICTS AN INCREASED RISK FOR ANEUPLOIDY 

WITH PGD. 

A. K. Dubey, R. Khaldi, M. Dayal, D. Frankfurter, J. Ambroggio, P. 

Gindoff. Reproductive Endocrinilogy and IVF Center, Dept of Ob/ 

Gyn, Geroge Washington University, Washington, DC. 


134 

P-115 PREIMPLANTATION GENETIC SCREENING (PGS) ON 

FROZEN THAWED BLASTOCYSTS: A CASE SERIES. 

R. B. Lathi, A. A. Milki, L. M. Westphal, J. A. M. Massie, J. Gebhardt, B. 

Behr. Reproductive Endocrinology and Infertility, Stanford University, 

Stanford, CA. 

P-116 PREFERED DAY OF EMBRYO TRANSFER (DAY 4 VS DAY 

5) OF NORMAL PGD EMBRYOS DEPEND ON DEVELPOMENTAL 

STAGE. 

A. K. Dubey, M. Dayal, D. Peak, R. Khaldi, D. Frankfurter, P. Gindoff. 

Reproductive Endocrinology and IVF Center, Dept of Obstretics and 

Gynecology, The Geroge Washington University, Washington, DC. 

P-117 THROMBOPHILIC GENE MUTATION IN WOMEN WITH 

REPEATED IVF FAILURE. 

A. Rezk, N. Fathy, A. Idris, M. Auda, H. Al-Inany. Obstetrics & 

Gynecology, Benha University, Benha, Khalyobia, Egypt. 

P-118 PRE-IMPLANTATION GENETIC SCREENING USING 

MICRO-ARRAY BASED 24 CHROMOSOME ANEUPLOIDY 

SCREENING: ANEUPLOIDY INCIDENCE WITH AND WITHOUT 

MICROSORT ® SPERM SEPARATION. 

C. D. Khoury 1 , J. Frederick 1 , M. Coffler 1 , D. Johnson 2 , D. Karabinus 3 , D. 

A. Potter 1 . 1 HRC Fertility, Laguna Hills, CA; 2 Gene Security Network, 

Redwood, CA; 3Genetics & IVF Institute, Fairfax, VA. 

P-119 WHAT IS THE POTENTIAL OF CRYOPRESERVED 

BLASTOCYSTS DERIVED FROM EMBRYOS BIOPSIED FOR 

PREIMPLANTATION GENETIC DIAGNOSIS? 

D. R. Kinzer, M. M. Alper, B. Barrett. Boston IVF, Waltham, MA. 

__________________________________________________________ 

MALE REPRODUCTIVE UROLOGY 

P-120 LOW DOSE HUMAN CHORIONIC GONADOTROPIN 

PREVENTS AZOOSPERMIA AND MAINTAINS FERTILITY IN 

HYPOGONADAL MEN ON TESTOSTERONE REPLACEMENT 

THERAPY. 

D. Avila1 , P. R. Gittens1 , K. Hwang1 , J. W. Weedin1 , J. A. Rumohr2 , 

L. I. Lipshultz1 . 1Urology, Baylor College of Medicine, Houston, TX; 

2Urology, Kelsey-Seybold Clinic, Houston, TX. 

P-121 ELEVATED FSH IS ASSOCIATED WITH A HIGHER 

UTILIZATION OF ASSISTED REPRODUCTION (IUI OR IVF) BUT 

SIMILAR BIRTH RATES AFTER VASECTOMY REVERSAL. 

W. Hsiao 1,2 , R. Sultan 1 , R. Lee 1 , M. Goldstein 1,2 . 1 Center for Male 

Reproductive Medicine and Microsurgery, Department of Urology, 

Institute of Reproductive Medicine, Weill Cornell Medical College, 

New York, NY; 2 Population Council Center for Biomedical Research, 

New York, NY. 

P-122 COMPARABLE PREGNANCY OUTCOMES BETWEEN 

FRESH AND FROZEN-THAWED EMBRYO TRANSFER DEPEND ON 

EMBRYO QUALITY. 

N. Singhania 1 , E. S. Knochenhauer 1 , P. Vaid 2 , M. Traub 1 . 1 Obstetrics 

and Gynecology, Staten Island University Hospital, Staten Island, 

NY; 2 Assisted Reproductive Unit, Island Reproductive Services, South 

Plainfield, NJ. 

P-123 THE EFFECT OF BODY MASS INDEX ON THE OUTCOMES 

OF VARICOCELECTOMY. 

K. N. Pham, J. I. Sandlow. Department of Urology, Medical College 

of Wisconsin, Milwaukee, WI. 

P-124 ANATOMIC BASIS FOR DENERVATION OF THE 

SPERMATIC CORD FOR CHRONIC ORCHIALGIA: TRIFECTA OF 

PAIN. 

S. J. Parekattil, K. J. Priola, H. N. Atalah, M. S. Cohen, R. W. Allan. 

Urology and Pathology, University of Florida, Gainesville, FL. 

P-125 EFFECTS OF MODIFIED LASER-ASSISTED 

INTRACYTOPLASMIC SPERM INJECTION (LA-ICSI) IN HUMAN 

ART. 

K. H. Choi, J. H. Lee, Y. H. Yang, I. P. Kwak, J. E. Han, D. R. Lee. Fertility 

Center of CHA Gangnam Medical Center, Seoul, Republic of Korea.

P-126 MEN WHO SEEK INFERTILITY CARE MAY NOT 

REPRESENT THE GENERAL U.S. POPULATION: DATA FROM THE 

NATIONAL SURVEY OF FAMILY GROWTH (NSFG). 

J. M. Hotaling 1 , M. L. Eisenberg 2 , S. K. VanDenEden 3 , T. J. Walsh 1 . 

1 Department of Urology, University of Washington, Seattle, WA; 

2 Department of Urology, University of California San Francisco, San 

Francisco, CA; 3Division of Research, Kaiser Permanente of Northern 

California, Oakland, CA. 

P-127 SEXUALLY DIMORPHIC EXPRESSION OF TBX2 AND 

TBX3 IN THE GONADS AND REPRODUCTIVE DUCTS. 

N. C. Douglas 1 , K. Heng 2 , M. V. Sauer 1 , V. E. Papaioannou 2 . 

1 Obstetrics and Gynecology, Columbia University, New York, NY; 

2 Genetics and Development, Columbia Unversity, New York, NY. 

P-128 FUNCTIONAL ASSESSMENT OF A HUMAN IN VITRO 

SERTOLI CELL BASED BLOOD-TESTIS-BARRIER MODEL. 

P. J. Turek 1 , K. Chu 2 , P. F. Dazin 2 , G. A. Rabinowich 4 , C. C. Yan 3 , C. 

M. John 2 . 1 The Turek Clinic, San Francisco, CA; 2 MandalMed Inc, 

San Francisco, CA; 3 Population Council, New York, NY; 4CONICET, 

Buenos Aires, Argentina. 

P-129 PROTEOMIC ANALYSIS OF SEMINAL PLASMA AND ITS 

CORRELATION TO SURGICAL INTERVENTION IN THE TREATMENT 

OF ADOLESCENT VARICOCELE. 

P. T. Del Giudice 1 , B. F. da Silva 1 , L. F. A. Santos 2 , R. Fraietta 1 , F. C. 

Gozzo 2 , R. P. Bertolla 1 . 1 Division of Urology, Human Reproduction 

Section, Sao Paulo Federal University, Sao Paulo, SP, Brazil; 

2 Department of Organic Chemistry, Institute of Chemistry, University 

of Campinas, Campinas, SP, Brazil. 

P-130 FISH ANALYSIS ON HUMAN SPERMATOGENIC CELLS 

IN PATIENTS DIAGNOSED AS NOT HAVING TESTICULAR SPERM 

WITH MD-TESE. 

I. Tanaka, A. Tanaka, M. Nagayoshi, S. Awata, M. Sasaki. Saint 


P-131 OLDER AGE IS ASSOCIATED WITH SIMILAR 

IMPROVEMENTS IN SEMEN PARAMETERS AND HORMONAL 

OUTCOMES AFTER SUBINGUINAL MICROSURGICAL 

VARICOCELECTOMY. 

W. Hsiao 1,2 , J. A. Rosoff 1 , J. R. Pale 1 , E. A. Greenwood 1 , M. 

Goldstein 1,2 . 1 Center for Male Reproductive Medicine and 

Microsurgery, Department of Urology, Institute of Reproductive 

Medicine, Weill Cornell Medical College, New York, NY; 2 Population 

Council Center for Biomedical Research, New York, NY. 

P-132 PROGRESSIVE SPERM DNA DAMAGE AND 

MORPHOLOGICAL ANALYSIS AT HIGH MAGNIFICATION. 

J. B. A. Oliveira 1,2,3 , L. D. Vagnini 2 , C. G. Petersen 1,2,3 , A. L. Mauri 1,2 , 

R. Baruffi 1,2 , J. G. Franco, Jr 1,2,3 . 1 Center for Human Reproduction 

Prof. Franco Jr, Ribeirao Preto, Sao Paulo, Brazil; 2 Paulista Center for 


3 Department of Gynecology and Obstetrics, Botucatu Medical 

School São Paulo State University - UNESP, Botucatu, Sao Paulo, 

Brazil. 

P-133 SPERM RETRIEVAL RATES (SRR) IN NONOBSTRUCTIVE 

AZOOSPERMIA (NOA) ARE RELATED TO TESTICULAR 

HISTOPATHOLOGY RESULTS BUT NOT TO THE ETIOLOGY OF 

AZOOSPERMIA. 

S. C. Esteves, S. Verza, Jr, C. Prudencio, B. Seol. ANDROFERT - 

Andrology & Human Reproduction Clinic, Campinas, Sao Paulo, 

Brazil. 


P-136 CLOMIPHENE CITRATE IS EFFECTIVE IN THE TREATMENT 

OF THE HYPOGONADAL, SUBFERTILE MALE WITH BODY MASS 

INDEX (BMI) >25 KG/M². 

D. Shin 1 , G. Pregenzer 2 , P. Hinds 2 . 1 Department of Urology, 

Hackensack University Medical Center, Hackensack, NJ; 2 Division of 

Urology, UMDNJ-New Jersey Medical School, Newark, NJ. 

P-137 OBESITY NEGATIVELY INFLUENCES THE OUTCOME OF 

MICROSCOPIC VARICOCELECTOMY IN INFERTILE MEN. 

J. W. Weedin1 , K. Hwang1 , D. Avila1 , D. J. Lamb1,2 , L. I. Lipshultz1 . 1Scott Department of Urology, Baylor College of Medicine, Houston, TX; 

2Molecular and Cell Biology, Baylor College of Medicine, Houston, 

TX. 

__________________________________________________________ 

SPERM BIOLOGY 

P-138 SPERM NUCLEAR VACUOLES ARE HOLLOW 

STRUCTURES DEVOID OF NUCLEIC ACIDS THAT ARE NOT 

LINKED TO DEFECTIVE CHROMATIN PACKAGING. 

A. Mesner1 , L. Hesters1 , V. Blin1 , R. Fanchin2 , C. Poüs3 , N. Frydman1 . 

1Service de Biologie et Génétique de la Reproduction, Hôpital 

Antoine Béclère, Clamart Cedex, France; 2Service de Gynécologie- 

Obstétrique et de Médecine de la Reproduction, Hôpital Antoine 

Béclère, Clamart Cedex, France; 3Laboratoire de Biochimie et 

Biologie Cellulaire, Université Paris-sud 11, Châtenay-Malabry 

Cedex, France. 

P-139 DIFFERENTIAL SPERM RNA PROFILES ARE ASSOCIATED 

WITH SUBSEQUENT BLASTOCYST DEVELOPMENT. 

A. Janesch 1 , B. McCallie 1 , J. Crocker 1 , J. Stevens 2 , W. B. 

Schoolcraft 1,2 , M. G. Katz-Jaffe 1,2 . 1 Colorado Foundation for Fertility 

Research, Lone Tree, CO; 2 Colorado Center for Reproductive 


P-140 THE IMPACT OF M540 BODIES ON THE MEASUREMENT 

OF DNA FRAGMENTATION AS A LATE APOPTOTIC MARKER: A 

STUDY COMPARING FERTILE AND INFERTILE SUBJECTS. 

G. Barroso 1 , A. Colin 1 , M. Velazquez 1 , N. Gomez 1 , R. Avila 2 , S. 

Oehninger 3 . 1 Reproductive Health Research Division, Instituto 

Nacional de Perinatología, Mexico, Mexico; 2 Reproductive Health 

Research Division, Nascere Reproductive Center, Mexico, Mexico; 

3 OB-GYN, Eastern Virginia Medical School, Norfolk, VA. 

P-141 SPERM PROTEOMIC PROFILES REFLECT THE 

OCCURRENCE OF DNA FRAGMENTATION. 

J. Crocker 1 , S. McReynolds 1 , J. Borgeson 2 , C. Thompson 2 , W. B. 

Schoolcraft 1,2 , M. G. Katz-Jaffe 1,2 . 1 Colorado Foundation for Fertility 

Research, Lone Tree, CO; 2 Fertility Laboratories of Colorado, Lone 

Tree, CO. 

P-142 RELATION BETWEEN THE GENOTYPE AND THE PROTEIN 

EXPRESSION IN MITOCHONDRIAL PHGPX OF HUMAN 

SPERMATOZOA. 

Y. Kurotaki 1 , H. Imai 2 , T. Takeuchi 3 , A. Yoshida 3 . 1 Research Center, 

Kiba Park Clinic, Koto-ku, Tokyo, Japan; 2 School of Pharmaceutical 

Sciences, Kitasato University, Minato-ku, Tokyo, Japan; 3 Kiba Park 

Clinic, Koto-ku, Tokyo, Japan. 

P-143 DIRECT EFFECTS OF 17 ß-ESTRADIOL (17ßE ) AND 

2 

BISPHENOL A (BPA) ON SPERM QUALITY: EVIDENCE FOR BOTH 

GENOMIC AND NON-GENOMIC ESTROGENIC SIGNALING. 

D. H. Wu 

P-134 ROBOTIC ASSISTED MICROSURGICAL DENERVATION 

OF THE SPERMATIC CORD FOR CHRONIC ORCHIALGIA: 

PROSPECTIVE OUTCOMES RESEARCH STUDY. 

S. J. Parekattil, K. J. Priola, H. N. Atalah, M. S. Cohen. Urology, 

University of Florida, Gaiensville, FL. 

P-135 ROBOTIC ASSISTED VERSUS PURE MICROSURGICAL 

VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY: 

PROSPECTIVE CONTROL TRIAL. 

S. J. Parekattil, K. B. Priola, H. Atalah, M. S. Cohen. Urology, University 

of Florida, Gainesville, FL. 

135 

1 , H.-M. Lam2 , M. A. Thomas1 , S. M. Ho2 . 1Obstetrics and 

Gynecology, University of Cincinnati Academic Health Center, 

Cincinnati, OH; 2Environmental Health, University of Cincinnati, 

Cincinnati, OH. 

P-144 CORRELATION BETWEEN SPERM DAMAGE 

BIOMARKERS AND LARGE NUCLEAR VACUOLES AT HIGH 

MAGNIFICATION. 

J. B. A. Oliveira1,2,3 , R. Baruffi1,2 , L. D. Vagnini2 , A. L. Mauri1,2 , C. G 

Petersen1,2,3 , J. G. Franco, Jr1,2,3 . 1Center for Human Reproduction 

Prof. Franco Jr, Ribeirao Preto, Sao Paulo, Brazil; 2Paulista Center for 


3Department of Gynecology and Obstetrics, Botucatu Medical 

__________________________________________________________ 

School São Paulo State University - UNESP, Botucatu, Sao Paulo, Brazil.

OOCYTE BIOLOGY 

P-145 DELETION OF TSC1 IN OVARIAN SOMATIC CELLS OF 

THE FEMALE REPRODUCTIVE TRACT CAUSES INFERTILITY. 

Y. Tanaka, J. H. Park, P. S. Tanwar, T. Kaneko-Tarui, S. Mittal, J. Teixeira. 

Obstetrics and Gynecology, Massachusetts General Hospital/ 

Harvard Medical School, Boston, MA. 

P-146 EFFECTS AND MOLECULAR MECHANISMS OF 

POSTOVULATORY AGING ON CUMULUS CELLS APOPTOSIS. 

T. Takahashi, M. Amita, S. Hara, H. Igarashi, H. Kurachi. Obstetrics 

and Gynecology, Yamagata University Faculty of Medicine, 

Yamagata, Japan. 

P-147 THE EFFECT OF CRYOPROTECTANTS ON THE OOCYTE 

MICROTUBULAR SYSTEM AND OOCYTE SURVIVAL DURING 

VITRIFICATION. 

C.-C. Chang 1 , C.-J. Lin 2 , S. M. Slayden 1 , H. I. Kort 1 , X. C. Tian 2 , Z. P. 

Nagy 1 . 1 Reproductive Biology Associates, Atlanta, GA; 2 University of 

Connecticut, Storrs, CT. 

P-148 ZONA PELLUCIDA BIREFRINGENCE AND MEIOTIC 

SPINDLE VISUALIZATION AS PREDICTORS OF ICSI OUTCOMES. 

PRELIMINARY RESULTS. 

M. I. Riqueros Arévalo 1 , E. Bonilla Egea 1 , M. Esbert Algam 1 , A. 

Pellicer Martínez 3 , A. Ballesteros Boluda 2 , G. Calderón de Oya 1 . 

1 IVF Laboratory, IVI Barcelona, Barcelona, Spain; 2 Clinical Unit, IVI 

Barcelona, Barcelona, Spain; 3 Clinical Unit, Equipo IVI, Valencia, 

Spain. 

P-149 UPREGULATION OF CONNEXIN 43 BY RETINOIC ACID 

IN PRIMARY CUMULUS GRANULOSA CELLS. 

S. A. Pauli, J. Wu, D. R. Session, J. Yu, R. N. Taylor, N. Sidell. 

Department of Gynecology and Obstetrics: Division of Reproductive 

Endocrinology and Infertility, Emory University School of Medicine, 

Atlanta, GA. 

P-150 DIFFERENTIAL METHYLATION OF PLURIPOTENTCY 

FACTORS IN IN-VITRO MATURED AND VITRIFIED IN-VITRO 

MATURED MOUSE OOCYTES. 

C. Milroy 1 , L. Liu 2 , S. Hammoud 2 , A. Hammoud 1 , D. T. Carrell 2,3 . 

1 Department of Obstetrics and Gynecology, Division of REI, 

University of Utah, Salt Lake City, UT; 2 Department of Surgery, Division 

of Surgery, Andrology and IVF Laboratory, University of Utah, Salt 

Lake City, UT; 3 Department of Physiology, University of Utah, Salt 

Lake City, UT. 

P-151 PREMATURE SEPARATION OF SISTER CHROMATIDS 

(PSSC) ASSOCIATED CHROMOSOME RECOMBINATION 

RATES ARE NOT SIGNIFICANTLY DIFFERENT FROM NORMALLY 

SEGREGATED CHROMOSOMES. 

L. E. Northrop 1,2 , N. R. Treff 1,2 , D. Taylor 1,2 , R. T. Scott, Jr 1,2 . 

1 Reproductive Medicine Assoiciates of New Jersey, Morristown, NJ; 


P-152 CTF18 PLAYS CRITICAL ROLES IN FEMALE 

GAMETOGENESIS AND OVARIAN FOLLICULOGENESIS IN 

MAMMALS. 

O. A. Asemota 1 , T. Singh 1,2 , J. E. Lewis 1 , P. R. Patel 1,2 , E. Berger 1,2 , K. M. 

Berkowitz 1,2 . 1 Obstetrics and Gynecology, Drexel University College 

of Medicine, Philadelphia, PA; 2 Biochemistry and Molecular Biology, 

Drexel University College of Medicine, Philadelphia, PA. 

P-153 LESSON FROM PREIMPLANTATION GENETIC 

SCREENING: SPINDLES MISSORT CHROMOSOMES THE SMALLER 

THEY ARE. 

A. G. Schmutzler, B. Acar, J. Weimer, A. Salmassi, L. Mettler, N. Arnold. 

Women’s Hospital, Christian-Albrechts-University Kiel, Kiel, Germany. 

P-154 EFFECT OF GONADOTROPINS ON APOPTOSIS AND 

GLOBAL DNA METHYLATION IN A DOSE RESPONSE MANNER. 

H. L. Feng 1 , S. Liu 2 , Z.-J. Chen 2 , A. Hershlag 1 . 1 Center for Human 

Reproduction, North Shore University Hospital, NYU School of 

Medicine, Manhasset, NY; 2 Reproductive Medical Center, Provincial 

Hospital Affiliated to Shandong University, Jinan, Shandong, China. 


136 

P-155 MECHANISM OF REGULATION OF THE EGF-LIKE 

GROWTH FACTOR AMPHIREGULIN IN HUMAN GRANULOSA 

CELLS. 

A. M. Zamah 1 , J. Chen 2 , M. Hsieh 2 , M. I. Cedars 1 , M. Conti 2 . 

1 Department of Obstetrics, Gynecology and Reproductive 

Sciences, University of California San Francisco, San Francisco, CA; 

2 UCSF Center for Reproductive Sciences, University of California San 


P-156 OBESITY ON INCREASES LIPID DROPLETS AND 

LIPOTOXICITY RESPONSES IN THE PERIOVULATORY CUMULUS- 

OOCYTE-COMPLEX. 

X. Yang 1,2 , L. L. Wu 2 , K. R. Dunning 2 , R. J. Norman 2 , X. Liang 1 , R. L. 

Robker 2 . 1 Reproductive Centre, The Six Affiliated Hospital of Sun 

Yat-sen University, Guangzhou, Guangdong, China; 2 Obestetrics 

and Gynaecology, The University of Adelaide,Robinson Institute, 

Adelaide, SA, Australia. 

P-157 THE PERPETUALLY “YOUNG” OOCYTE: OVARIAN 

ENVIRONMENTS FOR FOLLICULAR MATURATION AGE BUT NOT 

UNRECRUITED, RESTING PRIMORDIAL FOLLICLES/OOCYTES. 










P-158 EMBRYO WASTAGE RATES REMAIN HIGH IN ASSISTED 

REPRODUCTIVE TECHNOLOGY (ART): A LOOK AT THE TRENDS 

FROM 2002-2007 IN THE UNITED STATES. 

J. L. Kulp, P. Patrizio. Division of Reproductive Endocrinology, Yale 

School of Medicine, New Haven, CT. 

P-159 THE COMPARISON OF GENE EXPRESSION PROFILE 

BETWEEN HUMAN CUMULUS AND GRANULOSA CELLS 

REVEAL NOVEL BIOMARKERS SPECIFIC OF FOLLICULAR 

MICROENVIRONMENT. 

E. Le Meaux 1 , S. Assou 2 , C. Dechanet 1 , J. De Vos 2,3 , H. Dechaud 1 , S. 

Hamamah 1,2 . 1 CHU Montpellier, Unité Biologie Clinique d’AMP - DPI, 

Hôpital Arnaud de Villeneuve, Montpellier, France; 2 CHU Montpellier, 

Institute for Research in Biotherapy, Hôpital Saint-Eloi, INSERM U847, 

Université MONTPELLIER1, Montpellier, France; 3 CHU Montpellier, 

Unité de Thérapie Cellulaire, Hôpital Saint Eloi, Montpellier, France. 

P-160 OOCYTES RETRIEVED AND EMBRYOS TRANSFERRED TO 

BABY: ANALYSIS OF BIOLOGICAL LOSSES DURING ART. 

E. Lara1, J. Sepúlveda 1 , P. Díaz 1 , L. Arenas 1 , P. Galache 1 , P. Patrizio 2 . 

1 Instituto para el Estudio de la Concepción Humana, Monterrey, 

Nuevo León, Mexico; 2 Yale Fertility Center, New Haven, CT. 

P-161 METABOLIC SYNDROME AND DIESTRUS STAGE 

DECREASE OOCYTE QUALITY OF CULTURED ADULT CD1 MICE 

FOLLICLES. 

J. E. Hirshfeld-Cytron 1 , F. Duncan 1 , M. Xu 1 , J. K. Jozefik 1 , L. D. Shea 2 , T. 

K. Woodruff 1 . 1 Obstetrics and Gynecology, Northwestern University 

Feinberg School of Medicine, Chicago, IL; 2 McCormick School of 

Engineering, Northwestern University Feinberg School of Medicine, 

Evanston, IL. 

__________________________________________________________ 

OOCYTE MATURATION 

P-162 IN VITRO MATURATION (IVM) AND PARTHENOGENESIS 

OF ADULT MURINE PRIMARY OVARIAN FOLLICLES IS 

AMELIORATED IN THE ABSENCE OF ANTI-MÜLLERIAN 

HORMONE (AMH). 

J. H. Park1,2 , J. M. Teixeira1,2 . 1Obstetrics and Gynecology, 

Massacusetts General Hospital, Boston, MA; 2Harvard Medical 

School, Boston, MA.

P-163 THE PROGNOSTIC VALUE OF ZONA PELLUCIDA AND 

MEIOTIC SPINDLE BIREFRINGENCES IN IN VIVO AND IN VITRO 

MATURED OOCYTES. 

A. Iaconelli, Jr 1 , D. Braga 1,2 , R. C. S. Figueira 1 , A. Setti 2 , F. Pasqualotto 3 , 

E. Borges, Jr 1,2 . 1 Fertility - Assisted Fertilization Center, Sao Paulo, SP, 

Brazil; 2 Sapientiae Institute - Educational and Research Center in 

Assisted Reproduction, Sao Paulo, SP, Brazil; 3 University of Caxias do 

Sul, Caxias do Sul, RS, Brazil. 

P-164 RECOMBINANT VERSUS URINARY HUMAN CHORIONIC 

GONADOTROPIN FOR FINAL OOCYTE MATURATION 

TRIGGERING IN IVF/ICSI CYCLES. COCHRANE SYSTEMATIC 

REVIEW AND META-ANALYSIS. 

H. Al-Inany 1 , M. A. F. M. Youssef 1,2 , M. Aboulghar 1 , R. Mansour 1 , 

M. Proctor 3 . 1 ObGyn, Cairo University, Cairo, Egypt; 2 Center for 

Reproductive Medicine, University of Amsterdam, Amsterdam, 

Netherlands; 3 Psychological Service, Department of Corrections, 

Grafton, Auckland, New Zealand. 

P-165 A NEW APPROACH TO DETERMINING THE OPTIMAL 

DURATION OF MII ARREST IN VITRO-MATURED HUMAN GV 

OVA. 

N. N. Grau 1 , L. L. Escrich 1 , N. N. Ramsing 2 , A. A. García-Bautista 1 , A. A. 

Pellicer 1 , M. J. M. J. Escribá 1 . 1 IVI Valencia, Valencia, Spain; 2 Unisense 

Fertilitech, Aahruss, Aahruss, Denmark. 

P-166 REAL-TIME EVALUATION OF THE DIFFERENT STAGES OF 

MEIOSIS DURING SPONTANEOUS IN VITRO MATURATION OF 

HUMAN GV OOCYTES. 

L. Escrich, N. Grau, A. Garcia-Bautista, A. Galán, A. Pellicer, M. J. 

Escribá. IVI Valencia, Valencia, Spain. 

P-167 MELATONIN RELEASED FROM GRANULOSA CELLS 

(GCs) MAY HAVE POSITIVE ROLE ON OOCYTE MATURATION IN 

LATE FOLLICULOGENESIS. 

M. K. Kim, E. A. Park, W. Y. Choi, W. S. Lee, T. K. Yoon, D. R. Lee. 

Fertility Center of CHA Gangnam Medical Center, Seoul, Republic 

of Korea. 

P-168 IRREGULAR [Ca2+]i RELEASE IN IN VITRO 

MATURED HUMAN OOCYTES; A POSSIBLE LINK TO POOR 

DEVELOPMENTAL POTENTIAL. 

T. J. Jellerette-Nolan 1 , H. C. Lee 2 , M. Arny 1 , D. Grow 1 , R. Fissore 2 . 

1 Reproductive Endocrinology and Infertility, Baystate Medical 

Center, Springfield, MA; 2 Veterinary and Animal Science, University 

of Massachusetts, Amherst, MA. 

P-169 GONADOTROPIN-MEDIATED DYNAMIC CHANGES 

IN CYTOPLASMIC AND NUCLEAR MATURATION IN VITRO: AN 

ANIMAL MODEL. 

S. Liu 1 , H. L. Feng 1 , Z.-J. Chen 2 , A. Hershlag 1 . 1 Center for Human 

Reproduction, North Shore University Hospital, NYU School of 

Medicine, Manhasset, NY; 2 Reproductive Medical Center, Provincial 

Hospital Affiliated to Shandong University, Jinan, Shandong, 

China. 

P-170 THE CHROMOSOME CONSTITUTION OF IVM EMBRYOS 

GENERATED FROM OOCYTES AT DIFFERENT MATURATION 

INTERVAL. 

X. Y. Zhang, B. Ata, W.-Y. Son, W. Buckett, S. L. Tan, A. Ao. Obstetrics 

and Gyneocology, McGill University, Montreal, QC, Canada; McGill 

Reproductive Center, McGill University, Montreal, QC, Canada; 

Human Genetics, McGill University, Montreal, QC, Canada. 

P-171 GENE EXPRESSION PROFILE IN HUMAN CUMULUS 

CELLS OF IMMATURE AND MATURE OOCYTE UNDER IN VITRO 

MATURATION: CLINICAL APPLICATIONS. 

N. Frydman 1 , L. Hesters 1 , G. Ouandaogo 2 , S. Assou 2 , R. Frydman 1 , 

S. Hamamah 2,3 . 1 APHP, Service d’Histologie Embryologie 

Cytogénétique, Service de Gynécologie obstétrique, Hôpital 

Antoine Béclère, Clamart, France; 2 CHU Montpellier, Institute for 

Research in Biotherapy, Hôpital Saint-Eloi, INSERM U847, Montpellier, 

France; 3 CHU Montpellier, Unité Biologie Clinique d’AMP - DPI, 

Hôpital Arnaud de Villeneuve, Montpellier, France. 


137 

P-172 AROMATIZATION MAINTENANCE DURING 

GRANULOSE-LUTEINIC CELLS CULTURE MAY PROVIDE A 

GOOD CO-CULTURE SYSTEM FOR IN VITRO MATURATION 

PROCEDURES. 

C. O. Campos, A. A. Vireque, J. R. Campos, M. F. S. Sá, R. A. Ferriani, 

C. C. J. S. Rosa-e-Silva. Obstetrics and Gynecology, Faculty of 

Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, 

São Paulo, Brazil. 

P-173 DOES THE PROPORTION OF IMMATURE OOCYTES 

IMPINGE ICSI OUTCOME? 

D. Monahan, Q. V. Neri, Z. Rosenwaks, G. D. Palermo. The Ronald O 



__________________________________________________________ 

OXIDATIVE STRESS 

P-174 OXIDATIVE STRESS MARKERS IN FOLLICULAR FLUID (FF) 

AND ASSISTED REPRODUCTION OUTCOMES IN PATIENTS WITH 

INFERTILITY DUE TO POLYCYSTIC OVARY SYNDROME (PCOS) 

OR TO TUBAL AND/OR MALE FACTOR. 

J. K. Rodrigues1 , L. A. Dib1 , F. C. Donabella1 , R. A. Ferriani1,2 , A. A. 

Jordão, Jr3 , P. A. A. S. Navarro1,2 . 1Dept. of Ob/Gyn, Faculty of 

Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, 

SP, Brazil; 2National Institute of Hormones and Women’s Health, 

CNPq, Brazil; 3Nutrition and Metabolism Laboratory, Faculty of 

Medicine of Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, 

SP, Brazil. 

P-175 AGE-RELATED OXIDATIVE AND INFLAMMATORY 

INTRAFOLLICULAR STATUS: INCREASED LEVELS OF 

PROSTAGLANDIN E SUGGEST A PRO-INFLAMMATORY 

ENVIRONMENT IN OLDER PATIENTS UNDERGOING IVF. 

Í. J. de Zúñiga 1 , D. S. Colaci 1 , L. Kopcow 1 , A. M. Oubiña 1 , G. Terrado 1 , 

A. Motta 2 . 1 Pregna Medicina Reproductiva, Buenos Aires, Argentina; 

2 CEFIBO UBA, Buenos Aires, Argentina. 

P-176 ASSESSMENT OF OXIDATIVE AND INFLAMMATORY 

INTRAFOLLICULAR STATUS IN TOBACCO SMOKING WOMEN. 

I. de Zuñiga 1 , D. Colaci 1 , M. Horton 1 , F. Sobral 1 , C. Bisioli 1 , A. Motta 2 . 

1 Pregna Medicina Reproductiva, Buenos Aires, Argentina; 2 CEFYBO- 

UBA-Conicet, Buenos Aires, Argentina. 

P-177 THE RELATIONSHIP BETWEEN HUMAN OOCYTE 

QUALITY AND THE REDOX OF FOLLICULAR FLUID ALBUMIN. 

J. Otsuki 1 , Y. Nagai 1 , Y. Matsuyama 2 , T. Minami 2 , S. Era 2 . 1 Obstetrics 

and Gynecology, Nagai Clinic, Misato, Saitama, Japan; 

2 Department of Physiology and Biophysics, Gufu University Graduate 

School of Medicine, Yanagido, Gifu, Japan. 

P-178 OXIDIZED LIPOPROTEINS ARE THE ALLEGED PAIN 

MOLECULES IN THE PERITONEAL FLUID OF WOMEN WITH 


N. Santanam, J. Fahrmann, C. Cook, H. King, R. Egleton, B. L. 

Dawley. Joan C Edwards School of Medicine, Marshall University, 

Huntington, WV. 

P-179 THE INFLUENCE OF EJACULATORY ABSTINENCE ON 

OXIDATIVE STRESS IN SEMEN: A MECHANISM THAT EXPLAINS 

IMPROVED PREGNANCY OUTCOMES AFTER INTRAUTERINE 

INSEMINATION? 

A. B. Giddings, B. Hurst, R. Usadi, S. Causby, N. Steuerwald, P. 

Marshburn. Reproductive Endocrinology and Infertility, Carolinas 

Medical Center, Charlotte, NC. 

P-180 INFLUENCE OF PITUITARY SUPPRESSION AND 

CONTROLED OVARIAN HYPERSTIMULATIN (COH) ON 

OXIDATIVE STRESS MARKERS OF INFERTILE PATIENTS WITH 

POLYCYSTIC OVARY SYNDROME (PCOS) AND CONTROLS. 

J. K. Rocrigues 1 , L. A. Dib 1 , V. H. Leira 3 , R. A. Ferriani 1,2 , A. A. Jordão, 

Jr 3 , P. A. A. Navarro 1,2 . 1 Dept. of Ob/Gyn, Faculty of Medicine of 

Ribeirão Preto, University of São Paulo, Ribeirão Preto, Sao Paulo, 

Brazil; 2 National Institute of Hormones and Woman’s Health, CNPq,

Brazil; 3 Nutrition and Metabolism Laboratory, Faculty of Medicine of 

Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, São Paulo, 

Brazil. 

P-181 TESTING SPERM DNA DAMAGE BY TUNEL ASSAY IN 

SPECIFIC CASES OF MALE INFERTILITY. 

R. K. Sharma, S. Gupta, A. Thiyagarajan, E. Sabanegh, A. Agarwal. 

Center for Reproductive Medicine, Glickman Urological and Kidney 

Institute and Obstetrics & Gynecology and Women Health Institute, 

Cleveland, OH. 

P-182 CuZn-SOD INSUFFICIENCY IMPAIRS LUTEAL 

FORMATION AND PROGESTERONE SECRETION LEADING TO 

REDUCED FERTILITY IN FEMALE MICE 

K. Ota 1 , T. Shimizu 2 , Y. Noda 2 , Y. Katagiri 1 , T. Shirasawa 3 , M. Morita 1 . 

1 Obstetrics and Gynecology, Toho University, Omori Medical Center, 

Omori, Tokyo, Japan; 2 Moleculer Gerontology, Tokyo Metropolotan 

Institute of Gerontology, Itabashi, Tokyo, Japan; 3 Juntendo 

University., Bunkyo, Tokyo, Japan. 

P-183 MODERATE INCREASES IN SPERM DNA OXIDATION AS 

CONSEQUENCE OF SWIM-UP AND MAGNETIC ACTIVATED CELL 

SORTING (MACS) PROCEDURES DO NOT IMPAIR PREGNANCY 

CHANCES. 

L. Romany, N. Garrido, S. Garcia-Herrero, A. Pellicer, M. Meseguer. 

Instituto Universitario IVI, Valencia, Spain. 

P-184 SUPLEMENTATION OF ASCORBIC ACID 2-GLUCOSIDE 

(AA2G) TO CRYOMEDIA AND ITS EFFECTS ON POST-THAW 

HUMAN SPERM MOTILITY. 

T. G. Jenkins 1 , K. I. Aston 1 , D. T. Carrell 1,2,3 . 1 Andrology and IVF 

Laboratories Department of Surgery, University of Utah School 

of Medicine, Salt Lake City, UT; 2 Department of Obstetrics and 

Gynecology, University of Utah School of Medicine, Salt Lake 

City, UT; 3 Department of Physiology, University of Utah School of 

Medicine, Salt Lake City, UT. 

__________________________________________________________ 

FERTILIZATION 

P-185 ASSESSING AND RESTORING SPERM FERTILIZING 

COMPETENCE. 

Q. V. Neri, D. Monahan, J. Kocent, J. C. Y. Hu, Z. Rosenwaks, G. 

D. Palermo. The Ronald O Perelman & Claudia Cohen Center for 

Reproductive Medicine, Weill Cornell Medical College, New York, NY. 

P-186 PRESENCE OF ABNORMAL FERTILIZED ZYGOTES 

FOLLOWING INTRACYTOPLASMIC SPERM INJECTION 

MIGHT REPRESENT THE ENTIRE RECRUITED OOCYTE COHORT 

POTENTIAL. 

L. Vingris1 , A. Setti2 , R. C. S. Figueira1 , D. Braga1,2 , A. Iaconelli, Jr1 , E. 

Borges, Jr1,2 . 1Fertility - Assisted Fertilization Center, Sao Paulo, SP, 

Brazil; 2Sapientiae Institute - Educational and Research Center in 

Assisted Reproduction, Sao Paulo, SP, Brazil. 

P-187 FERTILIZATION RATE: A SIMPLE INDIRECT MARKER TO 

PREDICT CLINICAL OUTCOME. 

C. A. Guerrero 3 , S. J. Chantilis 1 , J. S. Goldstein 1 , A. Rodriguez 2 , 

J. Douglas 2 , D. G. Hammitt 1,2,3 . 1 ARTS Program, Texas Health 

Presbyterian Hospital Dallas, Dallas, TX; 2 ARTS Program, Texas Health 

Presbyterian Hospital Plano, Plano, TX; 3 ARTS Program, Texas Health 

Harris Methodist Hospital Fort Worth, Fort Worth, TX. 

__________________________________________________________ 

EMBRYO BIOLOGY 

P-188 HUMAN EMBRYO SPLITTING: PROOF OF 

HOMOZYGOCITY. 

K. Illmensee1,2 , M. Levanduski1,2, C. Konialis3 , C. Pangalos3 , A. 

Vithoulkas2 , V. T. Goudas2 . 1International Fertility Services, RiverVale, 

NJ; 2Genesis Fertility Center, Patras, Greece; 3Intergenetics- Diagnostic Genetic Center, Athens, Greece. 


138 

P-189 ALTERATIONS OF MITOTIC CHECKPOINT GENES PLAY 

A ROLE IN EMBRYONIC CHROMOSOME MOSAICISM. 

R. Loper 1 , N. R. Treff 3,4 , J. C. Parks 2 , R. T. Scott 3,4 , W. B. Schoolcraft 1,2 , 

M. G. Katz-Jaffe 1,2 . 1 Colorado Center for Reproductive Medicine, 

Lone Tree, CO; 2 Colorado Foundation for Fertility Research, Lone 

Tree, CO; 3 Reproductive Medicine Associates of NJ, Morristown, NJ; 


P-190 IN VITRO FERTILIZATION AND CULTURE IS ASSOCIATED 

WITH DECREASED PHOSPHORILATION OF AKTSer473 IN MOUSE 

EMBRYOS. 

X. Liu, A. Donjacour, W. Lin, P. Rinaudo. Obsetrics Gynecology and 

Reproductive Sciences, University of California, San Francisco, San 


P-191 THE RELEVANCE OF REACTIVE OXYGEN SPECIFIES 

LEVELS IN FOLLICULAR FLUID AND CULTURE MEDIA TO 

PREIMPLANTATION EMBRYO QUALITY. 

T.-H. Lee 1,2 , C.-H. Liu 1 , C.-C. Huang 3 , M.-S. Lee 1,2,3 . 1 Department 

of Obstetrics and Gynecology, Chung Shan Medical University 

Hospital, Taichung, Taiwan, Taiwan; 2 Institute of Medicine, Chung 

Shan Medical University, Taichung, Taiwan, Taiwan; 3 Department of 

Infertility Clinic, Lee Women’s Hospital, Taichung, Taiwan, Taiwan. 

P-192 TOTIPOTENT 8CELL HUMAN EMBRYOS MAY BE 

NATURALLY SUSCEPTIBLE TO ANEUPLOIDY. 

A. A. Kiessling 1 , R. Bletsa 2 , B. Desmarais 1 , D. Loutradis 2 . 1 Bedford Stem 

Cell Research Foundation, Somerville, MA; 2 University of Athens 

Medical School, Athens, Greece. 

P-193 LINKING SUCCESSFUL IMPLANTATION WITH THE EXACT 

TIMING OF CELL DIVISION EVENTS OBTAINED BY TIME-LAPSE 

SYSTEM IN THE EMBRYOSCOPE. 

J. Herrero 1 , T. Alberto 1 , N. B. Ramsing 2 , M. J. De los Santos 1 , L. 

Escrich1, M. Meseguer 1 . 1 Clinical Embriology Laboratory, IVI 

Valencia, Valencia, Spain; 2 Unisense FertiliTech, Aarhus, Ahrus N, 

Denmark. 

P-194 FRAGMENTATION OF EMBRYOS IS ASSOCIATED WITH 

NECROSIS AS WELL AS APOPTOSIS. 

H. J. Chi, C. Y. Park, D. Y. Chung, S. Y. Choi, D. J. Chung, S. I. Roh. 

Mizmedi Hospital, Seoul, Korea. 

P-195 WITHDRAWN 

P-196 MULTINUCLEATION HAS A REPETITIVE PATTERN IN 

PATIENTS WITH SUBSEQUENT IN VITRO FERTILIZATION (IVF) 

CYCLES. 

A. Mugica1 , M. Riqueros1 , J. M. Molina1 , A. Ballesteros1 , A. Pellicer2 , G. 

Calderon1 . 1IVI Barcelona, Barcelona, Spain; 2IVI Valencia, Valencia, 

Spain. 

__________________________________________________________ 

EMBRYO CULTURE 

P-197 PREGNANCY RATES AFTER INCUBATION IN NEW TIME- 

LAPSE INCUBATOR (EMBRYOSCOPE) PROVIDING DETAILED 

INFORMATION ABOUT EMBRYO DEVELOPMENT COMPARED TO 

INCUBATION IN A STANDARD INCUBATOR. 

M. Meseguer1 , K. M. Hilligsøe2 , K. S. Pedersen2 , J. Herrero1 , A. Tejera1 , 

N. Garrido1 . 1Clinical Embryology Laboratory, IVI Valencia, Valencia, 

Spain; 2Unisense Fertilitech, Aarhus, Aarhus N, Denmark. 

P-198 EMBRYO DEVELOPMENT AND PREGNANCY RATES 

OF IN VITRO PRODUCED BOVINE EMBRYOS CULTURED IN 

HIGH AND LOW-OXYGEN (O2) ATMOSPHERE TENSION WITH 

SEQUENTIAL MEDIA (SM). 

P. Koyner 1 , J. Pino 1 , R. Berbey 2 . 1 Animal Reproduction and Genetic 

Research Center, David, Chiriqui, Panama; 2 Centro Fecundar, 

Panama, Panama. 

P-199 EFFECT OF IVF LABORATORY AIR QUALITY ON 

PREGNANCY SUCCESS. 

R. P. Dickey 1,2 , J. W. E. Wortham, Jr 3 , A. Potts 1 , A. Welch 1 . 1 The 

Fertility Institute of New Orleans, Mandeville, LA; 2 Obstetrics and

Gynecology, Louisiana State University, New Orleans, LA; 3 Andrology 

and Fertility Consulting Service, Tulsa, OK. 

P-200 IS THERE A BENEFIT IN USING LOW OXYGEN TENSION 

IN TERMS OF OUTCOME? 

J. Liebermann, J. M. Matthews, Y. Wagner, S. R. Sanchez, E. J. Pelts, 

A. Beltsos. Fertility Centers of Illinois, Chicago, IL. 

P-201 WATER EVAPORATION AND OSMOLARITY CHANGE 

OF HUMAN EMBRYO CULTURE MEDIA IN HUMID OR IN DRY 

CULTURE SYSTEMS. 

C. Mori 1 , M. Kuwayama 1 , S. J. Silber 2 , N. Kagawa 1 , Y. Takehara 1 , O. 

Kato 1 . 1 Advanced Medical Research Institute of Fertility, Kato Ladies 

Clinic, Shinjyuku, Tokyo, Japan; 2 Infertility Center of St. Louis, St. Louis, 

MO. 

P-202 A COMPARISON OF MINERAL OIL SYSTEMS FOR USE 

IN EMBRYO CULTURE. 

R. Perkins, A. Finn, B. Kloos, O. Ocali, D. Davies, L. Scott. Embryology, 

Fertility Centers of New England, Reading, MA. 

P-203 DOES LOW OXYGEN CONCENTRATION AFFECT 

BLASTOCYST FORMATION RATE IN PGD (PREIMPLANTATION 

GENETIC DIAGNOSIS) CYCLES? 

M. Bellés Fernández 1 , J. M. Molina Sabater 1 , M. Riqueros Arevalo 1 , 

A. Pellicer Martínez 3 , A. Ballesteros Boluda 2 , G. Calderón de Oya 1 . 

1IVF Laboratory, IVI Barcelona, Barcelona, Spain; 2 Clinical Unit, IVI 

Barcelona, Barcelona, Spain; 3 Clinical Unit, Equipo IVI, Valencia, 

Spain. 

P-204 EFFECTS OF OXYGEN CONCENTRATION ON 

PREGNANCY OUTCOME. 

N. Foyouzi, M. Rosen, M. Cedars, S. Kashyap, S. Shen, P. Rinaudo. 

Department of Obstetrics, Gynecology and Reproductive Sciences, 

University of California San Francisco, San Francisco, CA. 

P-205 EXTENDED CULTURE OF EMBRYOS RESULTS IN 

DETECTION OF BACTERIAL CONTAMINATION OF CULTURES IN 

IVF CYCLES, BUT NOT IN ICSI CYCLES. 

M. J. Arny, L. Ashcraft, D. Duncan, D. R. Grow, C. K. Sites, K. A. Lynch. 

Department of Obstetrics and Gynecology, Baystate Medical 

Center, Springfield, MA. 

P-206 BLASTOCYST CULTURE IS AN EXCELLENT TOOL FOR 

EMBRYOLOGISTS. 

M. Martinez-Burgos 1 , N. Basile 1 , C. Bou 1 , A. Pellicer 2 , J. A. Garcia- 

Velasco 1 . 1 IVI Madrid, Aravaca, Madrid, Spain; 2 IVI Valencia, 


__________________________________________________________ 

OVARIAN STIMULATION 

P-207 OOCYTE-SPECIFIC EXPRESSION OF HIF-1a IS CRITICAL 

FOR THE ONSET OF FOLLICULAR DEVELOPMENT IN VITRO. 

H.-C. Liu, Z. He, Y. Tang, Z. Rosenwaks. The Center for Reproductive 

Medicine and Infertility, Weill Medical College of Cornell University, 

New York, NY. 

P-208 PEAK E2 LEVELS AS A PREDICTOR OF ANEUPLOIDY 

RATES IN IVF-pgs CYCLES. 

T. Singer, J. Y. Huang, A. Melnick, M. Noel, Z. Rosenwaks, S. D. 

Spendorfer. The Center for Reproductive Medicine and Infertility, 

Weill Cornell Medical Center, New York, NY. 

P-209 PREGNANCY RATES AND MULTIPLE PREGNANCY 

RATES: DOES CLOMIPHENE CITRATE (CC) DOSE MATTER? 

M. Ehrenburg 1 , M. A. Bray 2,5,6 , N. Virji 2 , L. Sung 2,4 , G. A. San Roman 1,6 , J. 

R. Stelling 1,2,3,4 . 1 Ob/Gyn, Good Samaritan Hospital Medical Center, 

West Islip, NY; 2 Reproductive Specialists of New York, Mineola, 

NY; 3 Ob/Gyn, SUNY Stony Brook Medical Center, Stony Brook, NY; 

4 Ob/Gyn, Winthrop University Hospital, Mineola, NY; 5 Ob/Gyn, 

The Brooklyn Hospital Center, Brooklyn, NY; 6 Ob/Gyn, Long Island 

College Hospital, Brooklyn, NY. 


139 

P-210 REDUCING THE RISK OF MULTIPLES WITH CONTROLLED 

OVARIAN STIMULATION (COS): UTILIZATION OF CONCURRENT 

LETROZOLE + hMG PROTOCOL FOR IUI WITH OPTION FOR 

FOLLICLE REDUCTION (SFR) AND OOCYTE VITRIFICATION. 

E. B. Johnston-MacAnanny 1 , M. E. Akar 2 , J. Z. Miller 1 , A. Carrillo 1 , 

O. Bozoklu 1 , T. M. Yalcinkaya 1 . 1 Department of Obstetrics and 

Gynecology, Wake Forest Center for Reproductive Medicine, 

Winston-Salem, NC; 2 Department of Obstetrics and Gynecology, 

Akdeniz University School of Medicine, Antalya, Turkey. 

P-211 CLINICAL OUTCOMES WITH A RECOMBINANT 

FOLLICLE-STIMULATING HORMONE (rFSH)/GONADOTROPIN- 

RELEASING HORMONE (GnRH) ANTAGONIST REGIMEN ARE 

UNAFFECTED BY rFSH DOSE TAPERING, COASTING OR 24 

HOUR hCG DELAY. 

S. C. Pang 1 , A. Leader 2 , H. Witjes 3 , M. Mahony 4 , K. Gordon 4 . 

1 Reproductive Science Center of New England, Lexington, MA; 2 The 

Ottawa Fertility Centre, Ottawa, ON, Canada; 3 MSD, Oss, Noord 

Brabant, Netherlands; 4 Merck & Co, Kenilworth, NJ. 

P-212 OVARIAN STIMULATION MAKES A DISRUPTION OF 

IMPRINTING GENES OF MOUSE OOCYTE AND PLACENTA. 

D. Zhang 1 , G. Xu 1 , R. Zhang 1 , Y. Zhu 1 , J. Sheng 2 , H. Huang 1 . 

1 Department of Reproductive Endocrinology, Women’s Hospital, 

School of Medicine, Zhejiang University, Hangzhou, Zhejiang 

Province, China; 2 Department of Pathophysiology, Zhejiang 

University School of Medicine, Hangzhou, Zhejiang Province, China. 

P-213 USE OF NOVEL INTRAVASCULAR CONTRAST REAGENTS 

TO DEFINE VASCULAR PARAMETERS IN RHESUS MACAQUE 

OVARIES DURING CONTROLLED OVARIAN STIMULATION. 

C. V. Bishop 1 , I. Tagge 2 , X. Li 2 , R. L. Stouffer 3 . 1 Division of Reproductive 

Sciences, Oregon National Primate Research Center, Oregon 

Health & Science University, Beaverton, OR; 2 Advanced Imaging 

Research Center, Oregon Health & Science University, Portland, 

OR; 3 Division of Reproductive Sciences, ONPRC, & OBGYN, Oregon 

Health & Science University, Beaverton, OR. 

__________________________________________________________ 

ART - OVARIAN STIMULATION 

P-214 OVARIAN FEATURES AFTER 2 WEEKS, 3 WEEKS AND 4 

WEEKS TRANSDERMAL TESTOSTERONE GEL TREATMENT AND 

THEIR ASSOCIATED EFFECT ON IVF/ICSI OUTCOME IN LOW 

RESPONDERS. 

C.-H. Kim, J.-W. Ahn, H.-Y. Nah, S.-H. Kim, H.-D. Chae, B.-M. Kang. 

Obstetrics and Gynecology, Asan Medical Center, University of 

Ulsan, Seoul, Korea. 

P-215 PREGNANCY AND PRENATAL OUTCOME FOLLOWING 

OVULATION INDUCTION WITH AROMATASE INHIBITOR 

LETROZOLE AND CLOMIPHENE CITRATE (CC). 

Y. Nakajo, Y. Shibuya, S.-S. Yuri, S. Miyatani, M. Honda, K. Kyono. 

Kyono ART Clinic, Sendai, Miyagi, Japan. 

P-216 SOMATOSTATIN ANALOGUE COTREATMENT IS 

EFFECTIVE ON OVARIAN RESPONSE TO CONTROLLED OVARIAN 

STIMULATION IN NONOBESE PATIENTS WITH POLYCYSTIC 

OVARY SYNDROME, BUT NOT IN OBESE WOMEN. 

J.-W. Ahn 1 , C.-H. Kim 1 , E. Park 1 , H.-J. Kang 1 , H.-J. Song 2 , B.-M. Kang 1 . 

1 Obstetrics and Gynecology, Asan Medical Center, University of 

Ulsan, Seoul, Korea; 2 Obstetrics and Gynecology, Seoul Women’s 

Hospital, Bucheon, Gyunggi-do, Korea. 

P-217 NON CONVENTIONAL USES OF HUMAN CHORIONIC 

GONADOTROPHIN (hCG) FOR OVULATION INDUCTION: A 

SYSTEMATIC REVIEW AND META-ANALYSIS. 

S. Agramunt 1 , M. J. Martinez-Zapata 2,3 , J. Vázquez 2,3 , A. Requena 4 , 

M. Checa 1 , J. J. Espinós 3 . 1 Obstetrics and Gynecology Department, 

Hospital del Mar - Parc de Salut Mar, Barcelona, Spain; 2 Centro 

Iberoamericano Cochrane, Barcelona, Spain; 3 Obstetrics and 

Gynecology Department, Hospital de la Santa Creu i Sant Pau, 

Barcelona, Spain; 4 Instituto Valenciano de Infertilidad, IVI Madrid, 

Aravaca, Madrid, Spain.

P-218 ARE ALL HUMAN-DERIVED FSH PRODUCTS THE 

SAME? A SYSTEMATIC REVIEW AND META-ANALYSIS USING 

DIRECT AND ADJUSTED INDIRECT ANALYSES TO DETERIMINE IF 

FOSTIMON ® IS MORE EFFICIENT THAN METRODIN-HP ® . 

H. G. Al-Inany 1 , A. M. Abou-Setta 2 . 1 Department of Obstetrics and 

Gynaecology, Cairo University, Cairo, Egypt; 2 Alberta Research 

Centre for Health Evidence, Univesity of Alberta, Edmonton, AB, 

Canada. 

P-219 3 YEAR EXPERIENCE OF NATURAL CYCLE IVF (NCIVF) 

IN A US FERTILITY PRACTICE. 

M. DiMattina, J. D. Gordon, A. Botes, G. Celia. Dominion Fertility, 

Arlington, VA. 

P-220 WHEN IS FLEXIBILITY IN FOLLICULAR MONITORING 

SAFEST IN IVF CYCLES? 

J. Moulder 1 , J. Doyle 1 , J. Meeker 2 , I. Souter 1 , J. Petrozza 1 . 1 Division of 

Reproductive Medicine, Department of Obstetrics and Gynecology, 

Massachusetts General Hospital, Boston, MA; 2 Department of 

Environmental Health Sciences, University of Michigan School of 

Public Health, Ann Arbor, MI. 

P-221 UTILIZATION AND SUCCESS RATES OF UNSTIMULATED 

IN VITRO FERTILIZATION (IVF) IN THE UNITED STATES: AN 

ANALYSIS OF THE SOCIETY FOR ASSISTED REPRODUCTIVE 

TECHNOLOGY (SART) DATABASE. 

J. D. Gordon, M. DiMattina, A. Botes, G. Celia. Dominion Fertility, 


P-222 FOLLICULAR MICROENVIRONMENT GENE EXPRESSION 

PROFILE ACCORDING TO OVARIAN HYPERSTIMULATION 

PROTOCOLS (hMG VS. recFSH): NEW INDICATORS OF 

OVARIAN RESPONSE. 

H. Dechaud 1 , S. Assou 2 , T. Anahory 1 , B. Hedon 1 , J. De Vos 2,3 , S. 

Hamamah 1,2 . 1 CHU Montpellier, Unité Biologie Clinique d’AMP - DPI, 

Hôpital Arnaud de Villeneuve, Montpellier, France; 2 CHU Montpellier, 

Institute for Research in Biotherapy, Hôpital Saint-Eloi, INSERM U847, 

Université MONTPELLIER1, Montpellier, France; 3 CHU Montpellier, 

Unité de Thérapie Cellulaire, Hôpital Saint Eloi, Montpellier, France. 

P-223 OPINIONS REGARDING UNSTIMULATED IVF: A SURVEY 

OF CLINICS REPORTING TO SART. 

J. D. Gordon, M. DiMattina, A. Botes, G. Celia. Dominion Fertility, 


P-224 ROLE OF GnRH ANTAGONIST IN NATURAL CYCLE IVF. 

T. Okubo1 , T. Sueyoshi1 , J. Fukuda1 , T. Hayashi1 , F. Yelian2 , S. Teramoto1 . 

1 2 Shimbashi YUME Clinic, Tokyo, Minatoku, Japan; Life IVF Center, 

Irvine, CA. 

P-225 OUTPATIENT MANAGEMENT OF SEVERE/CRITICAL 

OVARIAN HYPERSTIMULATION SYNDROME (OHSS) WITH 

PLACEMENT OF PIG TAIL CATHETER. 

M. I. Abuzeid1,2 , S. Joseph2 , M. G. Corrado2 , Y. M. Abuzeid2 , M. 

Ashraf1,2 , P. B. Rizk3 . 1Obstetrics and Gynecology, The Center for 

Reproductive Medicine/IVF Michigan, PC, Flint, MI; 2Reproductive Endocrinology and Infertility, IVF Michgian, PC, Rochester Hills, MI; 

3Obstetrics and Gynecology, University of South Alabama, Mobile, 

AL. 

P-226 ADMINISTRATION OF A GnRH ANTAGONIST DURING 

3 DAYS AT INITIATION OF THE CYCLE: IMPACT ON THE 

STIMULATION IN IVF/ICSI. 

A. Riva, C. Blockeel, M. De Vos, P. Devroey. Centre for Reproductive 

Medicine, Universitair Ziekenhuis Brussel, Brussels, Jette, Belgium. 

P-227 DETERMINATION OF INITIAL GONADOTROPIN DOSE 

BASED ON ANTI-MULLERIAN HORMONE LEVEL. 

J. Deaton 1 , T. H. Taylor 2 , A. Reagan 1 , M. J. Glassner 2 , J. J. Orris 2 , J. D. 

Wininger 1 . 1 Premier Fertility Center, High Point, NC; 2 Main Line Fertility, 

Bryn Mawr, PA. 

P-228 THE INFLUENCE OF LONG-TERM CAFFEINE INTAKE ON 

PREGNANCY RATE EVALUATED USING HUMAN FOLLICULAR 

FLUID HORMONES AND IN VITRO FERTILIZATION IN MICE. 

Y. Yokota 1 , M. Yokota 1 , H. Yokota 1 , M. Makita 1 , S. Sato 1 , Y. Araki 2 . 


140 

1 Yokota Maternity Hospital, Maebashi, Gunma, Japan; 2 The Institute 

for Advanced Reproductive Medical Thechnology, Maebashi, 

Gunma, Japan. 

P-229 DOES HIGHER STARTING DOSE OF FSH STIMULATION 

IMPROVE FERTILITY PRESERVATION CYCLE OUTCOMES IN 

WOMEN WITH BREAST CANCER? 

K. Oktay, S. Lee. Institute for Fertility Preservation/Department of 


P-230 MINIMAL OVARIAN STIMULATION (MINI-IVF) FOR 

IVF UTILIZING VITRIFICATION, AND FROZEN SINGLE EMBRYO 

TRANSFER (SET). 

J. Zhang 1 , L. Chang 1 , Y. Sone 1 , S. J. Silber 3 . 1 New Hope Fertility Center, 

New York, NY; 2 Infertility Center of St. Louis, St. Luke’s Hospital, St. 

Louis, MO. 

P-231 A PROSPECTIVE RANDOMIZED STUDY COMPARING 

CLOMIPHENE CITRATE SUPPLEMENTED WITH RECOMBINANT 

FSH OR LOW-DOSE hCG IN OVARIAN STIMULATION FOR 

INTRUTERINE INSEMINATION. 

G. B. Kabouk, N. F. Donadio, A. Dzik, G. C. Freitas, R. Justen, M. 

Cavagna. Division of Human Reproduction, Women’s Health 

Reference Center, São Paulo, SP, Brazil. 

P-232 COMPARISON OF VITRIFIED/WARMED DONATED 

OOCYTE TREATMENT OUTCOMES IN GnRH-ANTAGONIST 

CYCLES WHERE hCG OR LUPRON WAS USED TO TRIGGER 

OVULATION. 

Z. P. Nagy, C.-C. Chang, H. I. Kort, A. A. Toledo, S. M. Slayden, D. B. 

Shapiro. IVF, Reproductive Biology Associates, Atlanta, GA. 

P-233 NO EVIDENCE TO SUPPORT THE CONCEPT THAT LOW 

SERUM DEHYDROEPIANDROSTERONE (DHEA) SULFATE (S) 

LEVELS ARE ASSOCIATED WITH LESS OOCYTE PRODUCTION OR 

LOWER PREGNANCY RATES. 

E. Borman, J. H. Check, C. Wilson, R. Cohen. OB/GYN, UMDNJ, 

Robert Wood Johnson Med. School at Camden, Div. Repro. Endo. & 

Infertility, Camden, NJ, Melrose Park, PA. 

P-234 EARLY hCG TRIGGER IN HIGH-RESPONDERS: A SAFE 

APPROACH TO HELP PREVENT OVARIAN HYPERSTIMULATION 

SYNDROME (OHSS). 

G. Vela 1,2 , M. Luna 1,2 , E. Soto 2 , L. Grunfeld 1,2 , B. Sandler 1,2 , A. B. 




P-235 SHOULD WE TREAT PATIENTS FOR POOR RESPONSE 

FOLLOWING OVULATION INDUCTION WITH LOW DOSES OF 

RECOMBINANT FSH? 

T. Domingues 1 , P. H. M. Bianchi 1,2 , C. M. Gomes 1,2 , P. Fettback 1,2 , E. 

L. A. Motta 1,3 , P. Serafini 1,2 . 1 Huntington Medicina Reprodutiva, São 

Paulo, Brazil; 2 Disciplina de Ginecologia, Faculdade de Medicina 

da Universidade de São Paulo, São Paulo, Brazil; 3 Departamento de 

Ginecologia, Universidade Federal de São Paulo, São Paulo, Brazil. 

P-236 LATE hCG TRIGGER IS NOT PREDICTIVE OF A 

NEGATIVE OUTCOME IN YOUNG PATIENTS UNDERGONG IVF. 

M. Luna 1,2 , G. Vela 1,2 , J. Ruman 1,2 , B. Sandler 1,2 , L. Grunfeld 1,2 , A. B. 




P-237 USE OF LUTEAL ESTRADIOL PATCH WITH OR WITHOUT 

GnRH ANTAGONIST SUPPRESSION BEFORE GONADOTROPIN 

STIMULATION FOR IVF IN POOR RESPONDERS. 

J. Y. J. Huang 1 , T. Singer 1 , R. Abdallah 1 , Z. Williams 1 , O. Davis 1 , Z. 

Rosenwaks 1 . ; 2 The Ronald O Perelman and Claudia Cohen Center 

for Reproductive Medicine, Weil Cornell Medical College, New York, 

NY. 

P-238 NATURAL CYCLE IVF PRODUCES SIMILAR 

IMPLANTATION RATES COMPARED WITH STIMULATED IVF. 

G. F. Celia, A. Botes, J. D. Gordon, M. DiMattina. Dominion Fertility 

and Endocrinology, Arlington, VA.

P-239 DECREASED GONADOTROPIN REQUIREMENT IN QD 

COMPARED TO BID DOSING: A PROSPECTIVE, RANDOMIZED 

TRIAL. 

F. I. Sharara, M. G. Collins, G. Abdo. Virginia Center for Reproductive 

Medicine, Reston, VA. 

P-240 OUTCOME OF IN VITRO FERTILIZATION TREATMENT 

IN POOR RESPONDERS: NATURAL CYCLE/MILD STIMULATION 

VERSUS STANDARD PROTOCOLS USING GnRH AGONIST OR 

ANTAGONIST. 

D. J. Chung, H. S. Lee, M. H. Kim, H. J. Jeong. Department of 

Obstetrics and Gynecology, MizMedi Hosptial, Seoul, Korea. 

P-241 COMPARISON OF SHORT AND LONG GnRH AGONIST 

PROTOCOLS USING RECOMBINANT FSH FOR IVF/ICSI: A 

CONTROLLED PROSPECTIVE STUDY. 

F. Azem, M. Bloch, D. Kuvalsky, I. Wagman, G. Bibi, A. Amit. Racin IVF 

Unit, Sourasky Medical Center, Tel-Aviv, Israel. 

P-242 COASTING RESULTS IN LOWER PREGNANCY RATES 

AFTER GnRH ANTAGONIST CYCLES COMPARED TO GnRH 

AGONIST CYCLES. 

C. Atabekoglu, M. Sonmezer, B. Ozmen, S. Isbacar, K. Kahraman, S. 

Taskin. Ankara University School of Medicine, Ankara, Turkey. 

P-243 SPERM CONCENTRATION IN OVULATION INDUCTION/ 

INTRAUTERINE INSEMINATION CYCLES (OI/IUI): HOW HIGH IS 

TOO HIGH? 

S. Ghazal 1 , J. O. Doyle 1 , J. D. Meeker 2 , I. C. Souter 1 , J. C. Petrozza 1 . 

1 Obstetrics, Gynecology & Reproductive Biology, Massachusetts 

General Hospital Fertility Center, Boston, MA; 2 Department of 

Environmental Health Sciences, University of Michigan School of 

Public Health, Ann Arbor, MI. 

P-244 SELECTION OF AN OPTIMAL CONTROLLED OVARIAN 

HYPERSTIMULATION METHOD IN RELATION TO THE NUMBER OF 

ANTRAL FOLLICLES IN PATIENTS LESS THAN 40 YEARS OLD. 

S. Awata, A. Tanaka, M. Nagayoshi, M. Sasaki, I. Tanaka. Saint 


P-245 A COMPARISON OF PREGNANCY RATES IN PATIENTS 

AT RISK FOR OHSS TREATED WITH EITHER GnRH- ANTAGONIST 

OR LONG GnRH-AGONIST IVF PROTOCOLS. 

M. H. Dahan, W.-Y. Son, H. Holzer, E. Demirtas, W. Buckett, S. L. 

Tan. McGill Reproductive Center, McGill University, Montreal, QC, 

Canada. 

P-246 COMBINING LUTEAL ESTRADIOL PATCH AND GnRH 

ANTAGONIST SUPPRESSION WITH CO-FLARE AND MICRODOSE 

FLARE STIMULATION FOR IVF IN POOR RESPONDERS. 

J. Y. J. Huang, T. Singer, Z. Williams, R. Abdallah, O. Davis, Z. 


Redroductive Medicine, Weil Cornell Medical College, New York, 

NY. 

P-247 LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: 

CLINICAL SYNDROME OF LACK OF hCG ADMINISTRATION AT 

OOCYTE RETRIEVAL? 

K. A. Reynolds, C. Godby, P. Warikoo, M. Abdallah, G. Hofmann. 

Obstetrics and Gynecology, Bethesda Hospital, Cincinnati, OH. 

P-248 A NOVEL USE OF CETROTIDE ACETATE IN THE 

PREVENTION OF OHSS IN OOCYTE DONORS: A PILOT STUDY. 

F. I. Sharara 1 . 1 Virginia Center for Reproductive Medicine, Reston, 

VA; 2 Dept of OB/GYN, George Washington University, Washington, 

DC. 

P-249 A NEWER APPROACH FOR OVARIAN STIMULATION IN 

POOR RESPONDERS UNDERGOING IVF. 

K. D. E. V. Nayar, A. Agarwal, S. Ved. Akanksha IVF Centre, Mata 

Chanan Devi Hospital, New Delhi, India. 


141 

P-250 THE EFFECTS OF GnRH ANTAGONIST SINGLE 

DOSE (0.25MG) ON THE PREVENTION OF OVARIAN 

HYPERSTIMULATION SYNDROME (OHSS) IN PATIENTS WITH HIGH 

E2 LEVELS BY COH IN A STANDARD GnRH AGONIST LONG 

PROTOCOL. 

Y. Y. Kim, Y. H. Jung, M. H. Kim, J. D. Cho. Obstetrics & Gynecology, 

Ellemedi Infertility Clinic, Changwon, Gyoung Nam, Republic of 

Korea. 

__________________________________________________________ 

ART - GENERAL 

P-251 FETILIZATION RATE AND GOOD QUALITY EMBRYOS 

WERE SIGNIFICANTLY REDUCED IN IVM-MII (IN VITRO 

MATURED METAPHASE II) OOCYTES COMPARED WITH SIBLING 

IN VIVO MATURED MII OOCYTES. 

E. S. Kim, J. S. Kim, S. H. Lee, Y. S. Ahn, E. H. Kang, I. W. Oh. 

International Reproduction Center, Seoul Women’s Hospital, Juan 

4-dong, Namgu, Inchon, Korea. 

P-252 NATURAL CYCLES YIELD BETTER OUTCOMES THAN 

HORMONALLY MANIPULATED ARTIFICIAL CYCLES AFTER 

TRANSFER OF VITRIFIED/WARMED BLASTOCYSTS. 

E. Chang, M. Kim, J. Han, H. Won, W. Lee, T. Yoon. Fertility Center 

of CHA Gangnam Medical Center, Department of Obstetrics and 

Gynecology, CHA University, Seoul, Korea. 

P-253 INSURANCE MANDATES AND ASSISTED REPRODUCTIVE 

TECHNOLOGY (ART): HOW WERE TREATMENTS AND 

OUTCOMES IMPACTED BY IMPLEMENTATION OF A MANDATE IN 

NEW JERSEY? 

N. K. Banks 1 , J. M. Norian 2,4 , A. H. DeCherney 2,3,4 , M. B. Henne 3,4 . 

1 Department of Obstetrics and Gynecology, Georgetown University 

Hospital, Washington, DC; 2 Reproductive Biology and Medicine 

Branch, The Eunice Kennedy Shriver National Institute of Child Health 

and Human Development, National Institute of Health, Bethesda, 

MD; 3 Assisted Reproductive Technology Program, Walter Reed Army 

Medical Center, Washington, DC; 4Department of Obstetrics and 


Bethesda, MD. 

P-254 TIME COSTS OF FERTILITY CARE: THE HIDDEN 

HARDSHIP OF BUILDING A FAMILY. 

J. F. Smith1,3 , M. L. Eisenberg1 , S. G. Millstein4 , R. Nachtigall3 , N. 

Sadetsky1 , P. P. Katz2 . 1Urology, University of California, San Francisco, 

San Francisco, CA; 2Medicine, University of California, San Francisco, 

San Francisco, CA; 3Obstetrics, Gynecology, and Reproductive 

Sciences, University of California, San Francisco, San Francisco, CA; 

4Pediatrics, University of California, San Francisco, San Francisco, 

CA. 

P-255 IMPROVING EGG DONOR SELECTION BY UTILIZING 

AGE-SPECIFIC (AS) OVARIAN RESERVE (OR) ASSESSMENTS 

AND FMR1-STATUS. 



NY; 2 Department of Obstetrics and Gynecology, Vienna University 

School of Medicine, Vienna, Innere Stadt, Austria; 3 Department of 

Epidemiology and Population Health; 4 Department of Obstetrics, 

Gynecology and Women’s Health, Albert Einstein College of 


P-256 HEPATITIS C VIRUS (HCV) STATUS IN NEWBORNS BORN 

TO HCV POSITIVE FEMALES PERFORMING ICSI. 

N. F. Hanafi 1 , H. Saleh 2 . 1 Medical Microbiology & Immunology, 

Faculty of Medicine, Alexandria University, Alexandria, Egypt; 

2 Obstetrics & Gynaecology, Faculty of Medicine, Alexandria 

University, Alexandria, Egypt. 

P-257 ERGONOMICS IN THE IVF LABORATORY. 

R. J. Holmes, D. Kinzer, M. Alper, B. Barrett. Boston IVF, Waltham, 

MA.

P-258 PROSPECTIVE RANDOMIZED COMPARISON OF 

VITRIFIED-THAWED CLEAVAGE EMBRYOS ON DAY THREE USING 

LASER AND ENZYME ASSISTED HATCHING. 

E.-K. Kim, S.-Y. Park, E.-A. Kim, E.-H. Kim, J.-H. Kim, D.-H. Choi. Fertility 

Center, CHA Bundangn MEdical Center, CHA University, Seongnamsi, 

Gyenggi-do, Korea. 

P-259 RELATIONSHIP BETWEEN MEIOTIC SPINDLE 

CHARACTERISTICS IN HUMAN OOCYTES AND TIMING OF THE 

FIRST ZYGOTIC CLEAVAGE AFTER INTRACYTOPLASMIC SPERM 

INJECTION (ICSI). 

H. Tomari, Y. Nagata, K. Uchimura, K. Kunitake, K. Ikebe, K. Honjou. 

Center for Reproductive Medicine, IVF Nagata Clinic, Fukuoka, 

Japan. 

P-260 ROLE OF BCL-2 FAMILY GENES IN SURVIVAL AND 

DEATH OF HUMAN OOCYTES, EMBRYOS ON DAY-3 AND AT 

BLASTOCYST STAGE. 

I. Boumela 1 , S. Assou 1 , T. Anahory 2 , B. Hedon 2 , J. De Vos 1,3 , S. 

Hamamah 1,2 . 1 CHU Montpellier, Institute for Research in Biotherapy; 

INSERM U847; Université Montpellier I, Montpellier, Herault/ 

Languedoc-Roussillon, France; 2 CHU Montpellier, Unité Biologie 

Clinique d’AMP - DPI, Montpellier, Herault/Languedoc-Roussillon, 

France; 3 CHU Montpellier, Unité de Thérapie Cellulaire, Montpellier, 

Herault/Languedoc-Roussillon, France. 

P-261 RE-CRYOPRESERVATION AFTER THE INITIAL FREEZING/ 

THAWING MAY BE DETRIMENTAL TO THE BLASTOCYSTS. 

A. Erdogdu 1 , E. Kovanci 1 , J. Pinho 1 , G. Grunert 2 , R. Dunn 2 , W.-S. Wun 2 . 

1 Department of Obstetrics and Gynecology, Baylor College of 

Medicine, Houston, TX; 2 Fertility Specialists of Houston, Houston, TX. 

P-262 ABSENCE OF FORWARD MOTILITY ‘A’ IN THE SEMEN; 

DOES IT CHANGE THE FATE OF INTRAUTERINE INSEMINATION? 

B. Berker 1 , Y. E. Sükür 1 , C. S. Atabekoglu 1 , M. Sönmezer 1 , C. Ates 2 , 

R. Aytaç 1 . 1 Obstetrics and Gynecology, Ankara University, Ankara, 

Turkey; 2 Biostatistics, Ankara University, Ankara, Turkey. 

P-263 MEASUREMENT OF OXYGEN CONSUMPTION RATE OF 

EMBRYOS TO SELECT THE BEST EMBRYO FOR E-SET. 

M. Koike 1 , Y. Kumasako 1 , K. Goto 1 , H. Ito 2 , T. Utsunomiya 1 , H. Abe 3 . 

1 St-Luke Clinic, Oita, Japan; 2 Department of Obstetrics and 

Gynecology Faculty of Medicine Fukuoka University, Fukuoka, 

Japan; 3 Graduate Program of Human Sensing and Functional 

Sensor Engineering, Graduate School of Science and Engineering, 

Yamagata University, Yonezawa, Yamagata, Japan. 

P-264 ANONYMITY, DISCLOSURE, AND CONTACT WITH 

DONORS: HOW EXPERIENCES OF DONOR-CONCEIVED 

OFFSPRING VARY BY FAMILY TYPE. 

W. Kramer 1 , D. R. Beeson 2 , P. K. Jennings 2 . 1 Donor Sibling Registry, 

Nederland, CO; 2 Department of Sociology and Social Services, 

California State University, East Bay, Hayward, CA. 

P-265 WHAT IS THE OPTIMAL MOMENT FOR IUI IN NATURAL 

CYCLES? HUMAN CHORIONIC GONADOTROPIN OR 

LUTEINIZING MONITORING? PRELIMINARY RESULTS OF A 

RANDOMIZED STUDY. 

D. Kyrou, A. Riva, W. Verpoest, H. M. Fatemi, H. Tournaye, P. Devroey. 

Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, 

Brussels, Belgium. 

__________________________________________________________ 

EMBRYO TRANSFER 

P-266 EFFECT OF ACUPUNCTURE ON RATES OF PREGNANCY 

AMONG WOMEN UNDERGOING IN VITRO FERTILIZATION. 

U. Omodei1 , G. Piccioni2 , S. Tombesi1 , D. Dordoni1 , L. Fallo1 , F. 

Ghilardi1 . 1Centro di Procreazione Assistita, University of Brescia, 

Montichiari (BS), Italy; 2Department of Anestesiology, Spedali Civili, 

Brescia, Brescia, Italy. 


142 

P-267 INCREASING ELECTIVE SINGLE EMBRYO TRANSFERS 

AND REDUCING TWIN PREGNANCIES WITHOUT AFFECTING 

PREGNANCY RATE IN PATIENTS

Verheyen, P. Devroey. Centre for Reproductive Medicine, Free 

University of Brussels, Brussels, Belgium. 

P-278 ELECTIVE SINGLE BLASTOCYST TRANSFER: THE 

ULTIMATE MEASURE OF EFFICACY AND SAFETY WHILE 

MAXIMIZING THE SINGLETON BIRTH RATE. 

J. Liebermann, J. M. Matthews, R. L. Brohammer, S. R. Sanchez, E. J. 

Pelts, M. Uhler. Fertility Centers of Illinois, Chicago, IL. 

P-279 ARE DAY 2 ASSESSMENTS USEFUL IN CHOOSING THE 

BEST EMBRYOS FOR BLASTOCYST TRANSFER? 

D. R. Kinzer, M. Alper, B. Barrett. Boston IVF, Waltham, MA. 

P-280 CLEAVAGE STAGE VERSUS BLASTOCYST STAGE 

EMBRYO TRANSFER IN FROZEN-THAWED ASSISTED 

CONCEPTION CYCLES. 

A. Elassar, C. Benadiva, N. Kummer, A. Diluigi, J. Nulsen, L. Engmann. 

Reproductive Endocrinology and Infertility, Center for Advanced 

Reproductive Services, University of Connecticut Health Center, 

Farmington, CT. 

P-281 GnRH-AGONIST DOWN-REGULATION IS NOT 

ESSENTIAL FOR THE SUCCESS OF FROZEN EMBRYO TRANSFERS. 

J. Ding, N. Rana, W. P. Dmowski. Oak Brook Fertility Center, Oak 

Brook, IL. 

__________________________________________________________ 

IMPLANTATION 

P-282 HOXA10 EXPRESSION IS DECREASED IN 

ENDOMETRIUM OF WOMEN WITH ADENOMYOSIS. 

C. Fischer, U. Kayisli, H. Taylor. Obstetrics, Gynecology, and 


Haven, CT. 

P-283 MECHANISMS CONTROLLING THE INTIMATE 

DIALOGUE BLASTOCYST-UTERINE CAVITY AT THE TIME OF 

IMPLANTATION: TRANSCRIPTOMIC APPROACH. 

H. Delphine 1 , A. Saïd 1 , M. Cécile 1 , D. Hervé 2 , D. V. John 1 , H. 

Samir 2 . 1 CHU Montpellier, Institut de Recherche en Biothérapie, 

Hôpital Saint-Eloi, Montpellier, Languedoc roussillon, France; 

2 CHU Montpellier, Département de Médecine et Biologie de 

la Reproduction, Hôpital Arnaud de Villeneuve, Montpellier, 

Languedoc roussillon, France. 

P-284 CHRONIC ENDOMETRITIS: A COMMON FINDING IN 

GOOD PROGNOSIS PATIENTS WITH FAILED IMPLANTATION 

FOLLOWING IN-VITRO FERTILIZATION. 

D. A. Conway 1,2 , A. Ketefian 1,2 , M. Shamonki 1 . 1 Ob/Gyn, University of 

California at Los Angeles, Los Angeles, CA; 2 Ob/Gyn, Cedars Sinai 

Medical Center, Los Angeles, CA. 

P-285 PREGNANCY OUTCOME FOLLOWING 

COMPREHENSIVE CHROMOSOME ANALYSIS AT THE CLEAVAGE 

AND BLASTOCYST STAGES. 

S. Munne 1 , K. Ketterson 1 , C. Wagner 2 , D. Hill 3 , J. Cohen 1 , D. Wells 4 . 

1 Reprogenetics, Livingston, NJ; 2 Fertility Centers of Illinois, Highland 

Park, IL; 3 ART Reproductive Center, Beverly Hills, CA; 4 Reprogenetics 

UK, Oxford, Oxfordshire, United Kingdom. 

P-286 GLYCODELIN (GLY) AS A SERUM BIOMARKER OF 

SUCCESSFUL EMBRYO IMPLANTATION IN RECIPIENTS OF 

OOCYTE DONATION: A PILOT STUDY. 

N. C. Douglas, J. U. Klein, M. H. Thornton, J. Gosselin, M. Ferin, M. 

V. Sauer. Division of Reproductive Endocrinology and Infertility, 

Columbia University, New York, NY. 

__________________________________________________________ 

LUTEAL PHASE SUPPORT 

P-287 EVALUATION OF THE SINGLE DOSE AND STEADY STATE 

PHARMACOKINETICS OF A PROGESETERONE VAGINAL RING. 

J. Cheung, C. DiLiberti, K. Z. Reape. Teva Women’s Health, Horsham, 

PA. 


143 

P-288 EFFECT OF LUTEAL PHASE SUPPORT IN INTRAUTERINE 

INSEMINATION CYCLES: A PROSPECTIVE RANDOMIZED STUDY. 

S. J. An, J. Y. Jung, H. C. Kwon, H. M. Kim, J. H. Han, S. J. Lee. Mirae 

and Heemang OB/GYN Clinic, Seoul, Republic of Korea. 

P-289 THE BEST LUTEAL PAHSE SUPPORT PROTOCOL FOR 

PATIENTS WHO HAD E2 LEVELS

P-299 MOLECULAR KARYOTYPE OF PRODUCTS OF 

CONCEPTION USING SINGLE NUCLEOTIDE POLYMORPHISM 

MICROARRAYS. 

R. B. Lathi 1 , D. Johnson 2 , J. A. M. Massie 1 , M. Loring 1 , J. Keller 2 , M. 

Rabinowitz 2 . 1 Obstetrics and Gynecology, Stanford University, 

Stanford, CA; 2 Gene Security Network, Redwood City, CA. 


144 

P-300 IMPLICATION OF COMPLEMENT AND COAGULATION 

CASCADE IN SPONTANEOUS EARLY PREGNANCY LOSS. 

J. C. Parks 1 , B. McCallie 1 , A. Janesch 1 , W. B. Schoolcraft 1,2 , M. G. 

Katz-Jaffe 1,2 . 1 Colorado Foundation for Fertility Research, Lone Tree, 

CO; 2 Colorado Center for Reproductive Medicine, Lone Tree, CO.



Poster Presentations and Reception 

Abstracts P-301 through P-600 

ASRM invites you to meet the poster presenters of posters P-1 

through P-300 on Tuesday morning and enjoy a continental 

breakfast. Authors of posters P-301 through P-600 will present 

their posters Wednesday morning. 

Please note that on Monday, posters will be open from 12:00 

pm until 5:00pm. On Tuesday, posters will be open from 7:00 

am until 5:00 pm. On Wednesday, posters will open at 7:00 

am and will conclude at 2:00 pm. 

ASRM cannot be responsible for removing and/or returning 

posters. All posters not removed will be discarded. 

__________________________________________________________ 

WEDNESDAY TOPICS AND POSTER NUMBERS: 

Female Reproductive Endocrinology: P-301 thru P-325 

Reproductive Hormones: P-326 thru P-333 

Obesity and Metabolism: P-334 thru P-338 

Polycystic Ovary Syndrome: P-339 thru P-365 

Endometriosis: P-366 thru P-393 

Reproductive Immunology: P-394 thru P-397 

Female Reproductive Tract: P-398 thru P-403 

Imaging: P-404 thru P-415 

Endometrium: P-416 thru P-432 

Female Reproductive Surgery: P-433 thru P-437 

Leiomyoma: P-438 thru P-449 

Sexuality: P-450 thru P-451 

Mental Health: P-452 thru P-459 

Practice Management: P-460 thru P-464 

Environment and Reproduction: P-465 thru P-477 

Male Factor: P-478 thru P-503 

Sperm Preparation: P-504 thru P-508 

Stem Cells: P-509 thru P-514 

ART - In Vitro Fertilization: P-515 thru P-548 

ART - Procedures and Techniques, Clinical: P-549 thru P-565 

ART - Outcome Predictors, Clinical: P-566 thru P-591 

ART - Outcome Predictors, Laboratory: P-592 thru P-600 

__________________________________________________________ 

FEMALE REPRODUCTIVE ENDOCRINOLOGY 

P-301 THE EFFECT OF CABERGOLINE ON FOLICULAR 

MICROENVIROMENT PROFILE IN PATIENTS WITH HIGH RISK OF 

OHSS. 

E. S. Guvendag Guven1 , S. Dilbaz2 , O. Cinar2 , O. Ozdegirmenci2 , 

S. Aydin2 . 1Obstetrics and Gynecology, Rize University, Faculty of 

Medicine, Rize, Turkey; 2Obstetrics and Gynecology, Etlik Zubeyde 

Hanim Womens’ Health and Teaching Hospital, Ankara, Turkey. 

P-302 hCG RISE IN EARLY PREGNANCY DIFFERS BY RACE. 

M. D. Sammel 1 , M. S. Cary 1 , W. Guo 1 , P. Takacs 2 , K. Chung 3 , K. T. 

Barnhart 4 . 1 Biostatistics and Epidemiology, University of Pennsylvania 

SOM, Philadelphia, PA; 2 Division of Female Pelvic Medicine 

Hall F (Poster Area) 


Supported by Merck. 

145 

andRecosntructive Surgery, University of Miami School of Medicine, 

Miami, FL; 3 OB/GYN Division of Reproductive Endocrinology and 

Infertility, University of Southern California, Los Angeles, CA; 4 OB/GYN 

Division of Reproductive Endocrinology and Infertility, University of 

Pennsylvania School of Medicine, Philadelphia, PA. 

P-303 RECOMBINATION RATES ARE SIGNIFICANTLY HIGHER 

IN IVF CHILDREN FROM WOMEN OLDER THAN 35 YEARS OF 

AGE. 

L. E. Northrop 1,2 , D. Taylor 1,2 , N. R. Treff 1,2 , R. T. Scott, Jr 1,2 . 



P-304 PHARMACODYNAMIC STUDY OF FOUR ORAL 

DOSAGES OF DIENOGEST. 

C. Klipping 1 , I. Duijkers 1 , T. A. Faustmann 2 , S. F. Klein 3 , B. Schuett 4 . 

1 Dinox BV, Groningen, GZ, Netherlands; 2 Global Medical Affairs 

Women’s Healthcare, Bayer Schering Pharma AG, Berlin, BE, 

Germany; 3 Global Biostatistics, Bayer Schering Pharma AG, Berlin, 

BE, Germany; 4 Clinical Pharmacology, Bayer Schering Pharma AG, 

Berlin, BE, Germany. 

P-305 MEAN SERUM FREE TESTOSTERONE AND ESTRADIOL 

LEVELS IN WOMEN WITH SPONTANEOUS 46, XX PRIMARY 

OVARIAN INSUFFICIENCY REMAIN RELATIVELY STABLE AS THE 

TIME SINCE ONSET OF MENSTRUAL IRREGULARITY LENGTHENS. 

B. Yu, S. Sullivan, V. H. Vanderhoof, J. H. Segars, A. DeCherney, L. M. 

Nelson. Program in Adult and Reproductive Endocrinology, Eunice 


Development, National Institutes of Health, Bethesda, MD. 

P-306 RESIDENT EXPERIENCE ON REPRODUCTIVE 

ENDOCRINOLOGY AND INFERTILITY (REI) ROTATIONS AFFECTS 

PERCEIVED KNOWLEDGE. 

A. Z. Steiner 1 , M. A. Fritz 1 , C. K. Sites 2 , C. Coutifaris 3 , B. R. Carr 4 , K. 

Barnhart 3 . 1 Obstetrics and Gynecology, University of North Carolina, 

Chapel Hill, NC; 2 Obstetrics and Gynecology, Baystate Medical 

Center, Springfield, MA; 3 Obstetrics and Gynecology, University of 

Pennsylvania, Philadelphia, PA; 4Obstetrics and Gynecology, UT 

Southwestern Medical Center, Dallas, TX. 

P-307 UNILATERAL OOPHORECTOMY FAILS TO ALTER ANTI- 

MÜLLERIAN HORMONE/ANTRAL FOLLICLE COUNT RATIO, 

SUGGESTING UNCHANGED PER-FOLLICLE AMH PRODUCTION 

IN THE REMAINING OVARY. 

M. W. Grynberg, V. K. Genro, M. Höher, V. Gallot, R. Frydman, R. 

Fanchin. Ob-Gyn and Reproductive Medicine, Hôpital Antoine 

Beclere, Clamart, France. 

P-308 HYPOXIA-INDUCIBLE FACTOR-1a (HIF-1a) 

OVEREXPRESSION INDUCES PREECLAMPSIA-LIKE 

MANIFESTATIONS IN PREGNANT MICE. 

R. Tal1,2,4 , A. Shaish1,2 , I. Barshack2,3 , S. Polak-Charcon3 , A. Afek3 , D. 

Harats1,2 . 1The Bert W. Strassburger Lipid Center, Sheba Medical 

Center, Tel Aviv, Israel; 2Vascular Biogenics Ltd., Or Yehuda, Israel; 

3Institute of Pathology, Sheba Medical Center, Tel Aviv, Israel; 

4Department of Obstetrics and Gynecology, Maimonides Medical 

Center, Brooklyn, NY. 

P-309 A GENOME-WIDE ASSOCIATION SCAN IDENTIFIES 

SEVERAL MATERNAL SUSCEPTBILITY LOCI FOR EMBRYO 

ANEUPLOIDY. 

D. M. Taylor 1,2 , J. W. Pike 1 , K. Kasabwala 1 , L. E. Northrop 1 , N. R. Treff 1,2 , 

R. T. Scott, Jr 1,2 . 1 Reproductive Medicine Associates of New Jersey, 

Morristown, NJ; 2 UMDNJ-Robert Wood Johnson Medical School, New 

Brunswick, NJ.

P-310 THE RELATIONSHIP OF SERUM ANDROGENS AND 

METABOLIC, MORPHOMETRIC, AND FUNCTIONAL PARAMETERS 

IN PREMENOPAUSAL WOMEN. 

J. L. Keller, M. J. Toth, P. R. Casson. Reproductive Endocrinology and 

Infertility, University of Vermont, Burlington, VT. 

P-311 EFFECT OF COMBINED METFORMIN AND ORAL 

CONTRACEPTIVE ON METABOLIC FACTORS AND ENDOTHELIAL 

FUNCTION IN OVERWEIGHT WOMEN WITH POLYCYSTIC OVARY 

SYNDROME. 

D. W. Stovall 1 , P. A. Essah 2 , J. A. Arrowood 2 , K. I. Cheang 3 , S. 

S. Adawadkar 4 , J. E. Nestler 2,4 . 1 Obstetrics and Gynecology, 

University of Virginia, Charlottesville, VA; 2 Internal Medicine, Virginia 

Commonwealth University, Richmond, VA; 3 School of Pharmacy, 

Virginia Commonwealth University, Richmond, VA; 4 Obstetrics and 

Gynecology, Virginia Commonwealth University, Richmond, VA. 

P-312 GENETIC ANALYSIS OF SOHLH1 GENE IN PREMATURE 

OVARIAN FAILURE. 

J. W. Kim 1 , M. Choi 2 , H. J. Won 1 , D. H. Choi 3 , T. K. Yoon 1 , Y. Choi 2 . 

1 Department of Obstetrics, Fertility Center of CHA Gangnam 

Medical Center, Seoul, Korea; 2 Department of Biomedical 

Science, CHA University, Pochon, Gyeonggi, Korea; 3 Department 

of Obstetrics, Fertility Center of CHA Bundang Medical Center, 

Seongnam, Gyeonggi, Korea. 

P-313 ABNORMAL CIRCADIAN RHYTHM OF SALIVARY 

CORTISOL IS CLOSELY RELATED WITH OVARIAN DYSFUNCTION 

AND IVF PREGNANCY LOSS. 

M. Jinno, A. Watanabe, N. Hatakeyama, E. Hiura, N. Eguchi, J. 

Hirohama. Women’s Clinic Jinno, Choufu City, Tokyo, Japan. 

P-314 THE PROGNOSTIC VALUE OF GLYCODELIN AND 

MACROPHAGE-COLONY STIMULATING FACTOR FROM THE 

CERVICO-VAGINAL SECRETIONS AND THE SERUM AS AN 

IMPLANTATION MARKER IN THE ASSISTED REPRODUCTIVE 

TECHNIQUES. 

H. Zeyneloglu, S. Kaya, G. Onalan. Baskent University, Ankara, 

Turkey. 

P-315 IS PROGESTERONE LEVEL AT TRIGGER DAY PREDICTIVE 

OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOME? 

N. Prisant 1 , M. Cohen-Bacrie 1 , F. Olivennes 2 , F.-X. Aubriot 3 , J. 

De Mouzon 4 , P. Cohen-Bacrie 1 . 1 Biologie de la Reproduction, 

Laboratoire d’Eylau-Paris UNILABS, Paris, France; 2 Médecine de la 

Reproduction, Clinique de la Muette, Paris, France; 3 Médecine de 

la Reproduction, Clinique Pierre Cherest, Neuilly sur Seine, Hauts 

de Seine, France; 4 Service de Gynécologie-Obstetrique II et de 

Médecine de la Reproduction, INSERM, Paris, France. 

P-316 HUMAN sFRP4 EXPRESSION IS DOWN-REGULATED BY 

hCG IN GRANULOSA CELLS. 

A. Hourvitz, Y. Yung, E. Maman, M. Brengauz, J. Dor. IVF Unit and 

Reproduction Lab, Sheba Medical Center, Ramat-Gan, Ramat- 

Gan, Israel. 

P-317 DEVELOPMENT OF A NOVEL PROTOCOL FOR 

ISOLATION AND PURIFICATION OF HUMAN GRANULOSA 

CELLS. 

R. A. Chilvers 1 , Y. H. Bodenburg 2 , L. A. Denner 2 , R. J. Urban 2 . 

1 Obstetrics and Gynecology, Division of Reproductive 

Endocrinology, University of Texas Medical Branch, Galveston, TX; 

2 Internal Medicine, Division of Endocrinology, University of Texas 

Medical Branch, Galveston, TX. 

P-318 PREMATURE PROGESTERONE RISE AT hCG INJECTION 

IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) IS RELATED 

TO THE DOWN REGULATION PROTOCOL AND HAS DIFFERENT 

IMPACT ON ART OUTCOME ACCORDING TO PROTOCOL. 

P. Cohen-Bacrie 1 , S. Belloc 1 , A. Hazout 1 , S. Alvarez 2 , C. Nathan 3 , M. 

Cohen-Bacrie 1 . 1 Biologie de la Reproduction, Laboratoire Eylau-Paris 

UNILABS, Paris, France; 2 Médecine de la Reproduction, Clinique de 

la Muette, Paris, France; 3 Médecine de la Reproduction, Clinique 

Pierre Cherest, Neuilly sur Seine, Hauts de Seine, France. 


146 

P-319 ESTROGEN REQUIREMENT IN GIRLS WITH TURNER 

SYNDROME FOR INITIAL UTERINE DEVELOPMENT. 

N. Y. Kim, D.-Y. Lee, M. J. Kim, D. Choi. Department of Obstetrics and 

Gynecology, Samsung Medical Center, Sungkyunkwan University 

School of Medicine, Gangnam-gu, Seoul, Korea. 

P-320 EXPECTATIONS OF WOMEN SEEKING INFERTILITY 

EVALUATION AND TREATMENT. 

P. L. Dougherty, D. W. Stovall. Obstetrics & Gynecology - Division 

of Reproductive Medicine & Surgery, University of Virginia Health 

System, Charlottesville, VA. 

P-321 VALIDATION OF PREDICTION OF LOCATION OF A 

SYMPTOMATIC EARLY GESTATION BASED SOLELY ON CLINICAL 

PRESENTATION. 

K. T. Barnhart 1 , M. D. Sammel 1 , K. Chung 2 , P. Takacs 3 , A. Shaunik 1 , 

K. O’Flynn O’Brien 1 . 1 University of Pennsylvania, Philadelphia, PA; 

2 Division of Reproductive Endocrinology and Infertility, University 

of Southern California, Keck School of Medicine, Los Angeles, CA; 

3 Division of Female Pelvic Medicine and Reconstructive Surgery, 

University of Miami School of Medicine, Miami, FL. 

P-322 SIGNIFICANCE OF CLOSE AND CONTINUOUS 

MONITORING OF FOLLICLE DEVELOPMENT IN THE 

MANAGEMENT OF PREGNANCY-SEEKING PATIENTS WITH 

PREMATURE OVARIAN FAILURE. 

T. Maruyama, K. Miyazaki, H. Oda, S. Nishikawa-Uchida, H. Uchida, 

Y. Yoshimura. Obstetrics and Gynecology, School of Medicine, Keio 

University, Shinjuku-ku, Tokyo, Japan. 

P-323 REDUCE FERTILITY AND SKEWED SEX RATIO IN MICE 

LACKING Umodl1. 

W. Wang, H.-C. Liu, L. Ni, Z. He, Y. Tang, Z. Rosenwaks. The Ronald O. 

Perelman and Claudia Cohen Center for Reproductive Medicine, 

Weill Medical College of Cornell University, New York, NY. 

P-324 FOLLICULAR DEVELOPMENT RETARDATION TREATED 

BY FSH SUPPRESSING AMH EXCESSIVE SECRETION IN PCOS 

GRANULOSA CELLS. 

Y. Li, X. Liang. Reproductive Center, Sixth Affiliated Hospital of Sun 

Yan-Sen University, Guangzhou, Guangdong, China. 

P-325 OVARIAN POLYCYCTIC OVARIES (PCO) PHENOTYPE 

WITH FMR1-ASSOCIATED GENOTYPE AND AUTOIMMUNITY 

(AI): FIRST DIRECT EVIDENCE FOR AUTOIMMUNE-ASSOCIATED 

INFERTILITY. 

N. Gleicher 1,2 , I. Lee 1 , A. Weghofer 1,3 , D. H. Barad 1,4 . 1 Center for 

Human Reproduction & Foundation for Reproductive Medicine, 

New York, NY; 2 Department of Obstetrics, Gynecology and 


Haven, CT; 3 Department of Obstetrics and Gynecology, Vienna 

University School of Medicine, Vienna, Innere Stadt, Austria; 

4 Department of Epidemiology and Social Medicine; Department 

of Obstetrics, Gynegology and Women’s Health, Albert Einstein 

College of Medicine, Bronx, NY. 

__________________________________________________________ 

REPRODUCTIVE HORMONES 

P-326 WHAT IS A NORMAL THYROID STIMULATING 

HORMONE (TSH) LEVEL? EFFECTS OF STRICTER TSH THRESHOLDS 

ON PREGNANCY OUTCOMES AFTER IVF. 

A. Reh1 , A. Danoff2 , J. Grifo1 . 1Obstetrics & Gynecology, Division of 

Reproductive Endocrinology & Infertility, New York University School 

of Medicine, New York, NY; 2Medicine, Division of Endocrinology, 

New York University School of Medicine, New York, NY. 

P-327 GENDER IS MORE INFLUENTIAL THAN HORMONAL 

STATUS IN REGULATING PEAK GROWTH HORMONE (GH) 

RESPONSE TO TRIPLE SECRETAGOGUES. 

N. L. Rollene 1 , D. R. Schroeder 2 , C. C. Coddington 1 , J. D. Veldhuis 3 . 

1 Reproductive Endocrinology, Mayo Clinic, Rochester, MN; 

2 Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; 

3 Endocrine Research Unit, Mayo Clinic, Rochester, MN.

P-328 EVALUATION OF SAFETY AND EFFICACY OF 

MICRONIZED PROGESTERONE IN INDUCTION OF SECRETORY 

CONVERSION OF ENDOMETRIUM AND WITHDRAWAL BLEEDING 

IN WOMEN WITH SECONDARY AMENORRHEA. 

P. Auerbach 1 , L. Zipfel 2 , H.-M. Yang 2 , A. Allgood 2 , C.-Y. Guo 2 . 

1 Thameside OB/GYN Centre, Groton, CT; 2 Abbott Products, Inc. 

(Formerly Solvay Pharmaceuticals, Inc.), Marietta, GA. 

P-329 THE EFFECTS OF HORMONE VARIATION DURING 

THE MENSTRUAL CYCLE ON BRAIN ACTIVATION DURING THE 

PROCESSING OF EMOTIONAL INFORMATION. 

C. E. Broadwell 1 , A. C. Pfaff 2 , A. M. Kutz 2 , H. L. Wilkins 2 , P. A. 

Newhouse 2 , J. A. Dumas 2 . 1 Obstetrics and Gynecology, University 

of Vermont, Burlington, VT; 2 Department of Psychiatry, Clinical 

Neuroscience Center, University of Vermont, Burlington, VT. 

P-330 REGULATION OF CYP17 EXPRESSION AND ACTIVITY IN 

THE HUMAN PLACENTA BY THE Src KINASE PATHWAY. 

J. C. Escobar, S. S. Patel, V. E. Beshay, B. R. Carr. Reproductive 

Endocrinology and Infertility, OBGYN, University of Texas, 

Southwestern Medical Center, Dallas, TX. 

P-331 PROGESTERONE RISE ON THE DAY OF HUMAN 

CHORIONIC GONADOTROPIN ADMINISTRATION IMPAIRS 

PREGNANCY OUTCOME IN GnRH AGONIST CYCLES WHILE 

HAS NO EFFECT ON GnRH ANTAGONIST CYCLES. 

K. Bettahar, C. Rongieres, L. Schindler, J. Ohl, C. Wittemer, L. Moreau. 

Service d’AMP, CMCO-SIHCUS, Schiltigheim, France. 

P-332 EFFECT OF AUTOIMMUNE THYROID DISEASE (AITD) IN 

OLDER, EUTHYROID INFERTILE WOMEN UNDERGOING IN VITRO 


A. Reh1 , S. Im2 , A. Amarosa3 , L. Rolnitzky4 , J. Grifo1 , A. Danoff2 . 

1Obstetrics & Gynecology; Division of Reproductive Endocrinology 

& Infertility, NYU Fertility Center at the NYU School of Medicine, 

New York, NY; 2Medicine; Division of Endocrinology, NYU School of 

Medicine, New York, NY; 3NYU School of Medicine, New York, NY; 

4Environmental Medicine; Division of Biostatistics, NYU School of 

Medicine, New York, NY. 

P-333 CLINICAL PROFILES OF PREMENOPAUSAL BREAST 

CANCER PATIENTS DURING TAMOXIFEN TREATMENT AFTER 

ADJUVANT CHEMOTHERAPY WITH GnRH AGONIST FOR 

OVARIAN PROTECTION. 

N. Y. Kim, D.-Y. Lee, M. J. Kim, D. Choi. Department of Obstetrics and 

Gynecology, Samsung Medical Center, Sungkyunkwan University 

School of Medicine, Gangnam-gu, Seoul, Republic of Korea. 

__________________________________________________________ 

OBESITY AND METABOLISM 

P-334 DOES OBESITY CAUSE ABNORMAL ENDOMETRIAL 

DEVELOPMENT? 

C. E. Alford1 , E. A. Widra2 , M. J. Levy2 , J. H. Segars1 , K. S. Richter2 . 

1Program in Reproductive and Adult Endocrinology, Eunice 

Kennedy Shriver, National Institute of Child Health and Human 

Development, Bethesda, MD; 2Shady Grove Fertility Reproductive 

Science Center, Rockville, MD. 

P-335 IMPACT OF RACE, PATIENT PERCEPTIONS AND 

PHYSICIAN COUNSELING ON FERTILITY TREATMENT OUTCOMES 

AND WEIGHT LOSS. 

E. A. Evans, R. Shah, G. W. Bates. Reproductive Endocrinology and 

Infertility, University of Alabama at Birmingham, Birmingham, AL. 

P-336 OBESITY AND INSULIN RESISTANCE (IR) NEGATIVLEY 

IMPACT CUMULUS OOCYTE COMPLEX (COC) QUALITY. 

K. L. Marquard 1 , Q. Wang 2 , S. Purcell 1 , K. Boehle 1 , K. H. Moley 1 . 

1 Obstetrics and Gynecology/REI, Washington University School of 

Medicine, St. Louis, MO; 2 Genetics, Washington University School of 

Medicine, St. Louis, MO. 

P-337 FOLLICULAR FLUID LEPTIN/ADIPONECTIN RATIO 

AFFECTS EMBRYO QUALITY. 

L. Li, M. Ferin, M. V. Sauer, R. A. Lobo. Department of Obstetrics and 


147 


Columbia University Medical Center, New York, NY. 

P-338 CLINICAL PREGNANCY RATE BUT NOT EMBRYO 

QUALITY IS REDUCED FOLLOWING IVF-ET IN COUPLES WITH 

OVERWEIGHT MALE PARTNER. 

Z. O. Merhi 1,2 , J. Keltz 1 , A. Zapantis 1 , S. Jindal 1,2 , H. Lieman 1,2 , A. 

J. Polotsky 1,2 . 1 Montefiore’s Institute for Reproductive Medicine, 

Montefiore Medical Center, Hartsdale, NY; 2 Obstetrics and 

Gynecology and Women’s Health, Albert Einstein College of 


__________________________________________________________ 

POLYCYSTIC OVARY SYNDROME 

P-339 MITOCHONTRIAL DNA COPY NUMBER IN PERIPHERAL 

BLOOD IN POLYCYSTIC OVARIAN SYNDROME. 

J. W. Lee1 , S. H. Lee2 , D. J. Chung3 , E. S. Kim2 , C. S. Ryu3 , S. M. Kang3 . 

1Department of Family Medicine, Severance Hospital, Yonsei 

University College of Medicine, Seoul, Korea; 2Department of 

Obstetrics and Gynecology, Seoul Women’s Hospital, Incheon, 

Korea; 3Department of Obstetrics and Gynecology, MizMedi 

Hospital, Seoul, Korea. 

P-340 CONTRIBUTION OF ENDOGENOUS LH SECRETION TO 

hCG-STMULATED ANDROGEN PRODUCTION IN WOMEN WITH 


M. A. Rosencrantz, H. I. Su, A. Ramos-Haggan, R. J. Chang. 

Reproductive Medicine, UC San Diego, La Jolla, CA. 

P-341 EXPRESSION OF GLUCOSE TRANSPORTERS (GLUTS) 

IN GRANULOSA CELLS ACCORDING TO INSULIN RESISTANCE 

AND METABOLIC SYNDROME IN PCOS PATEINTS. 

E. Kim 1 , H. H. Seok 2 , D.-R. Lee 2 , T.-K. Yoon 2 , W.-S. Lee 2 , K.-A. Lee 1 . 

1 Department of Biomedical Science, CHA University, Seoul, Korea; 

2 Fertility Center, CHA Gangnam Medical Center, Seoul, Korea. 

P-342 OVULATION INDUCTION WITH CLOMIPHENE, 

METFORMIN, OR A COMBINATION OF THE TWO DOES NOT 

AFFECT HIRSUTISM SCORE OVER A STANDARD COURSE OF 

TREATMENT IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. 

W. D. Schlaff 1 , R. S. Legro 2 , M. P. Diamond 3 , C. Coutifaris 4 , H. Zhang 5 , 

Reproductive Medicine Network 6 . 1 Obstetrics and Gynecology, 

University of Colorado, Aurora, CO; 2 Obstetrics and Gynecology, 

Pennsylvania State University, Hershey, PA; 3 Obstetrics and 

Gynecology, Wayne State University, Detroit, MI; 4 Obstetrics 

and Gynecology, University of Pennsylvania, Philadelphia, PA; 

5 Epidemiology and Public Health, Yale University, New Haven, CT; 

6 Data Coordinating Center, NICHD, New Haven, CT. 

P-343 VITAMIN D DEFICIENCY, METABOLIC SYNDROME 

AND INSULIN RESISTANCE AMONG SAUDI WOMEN WITH 


A. A. Rouzi 1 , M. S. Ardawi 1 . 1 Obstetrics and Gynecology, King 

Abdulaziz University, Jeddah, Western, Saudi Arabia; 2 Clinical 

Biochemistry, King Abdulaziz University, Jeddah, Western, Saudi 

Arabia. 

P-344 VARIANTS IN GENES INVOLVED IN ANDROGEN 

SIGNALING AS GENETIC DETERMINANTS OF POLYCYSTIC 

OVARY SYNDROME (PCOS). 

A. Ketefian 1,2 , M. R. Jones 1 , R. Azziz 1,2 , M. O. Goodarzi 1,2 . 1 Obstetrics 

and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA; 

2 Obstetrics and Gynecology, David Geffen School of Medicine at 

University of California, Los Angeles, CA. 

P-345 THE PHENOTYPE OF POLYCYSTIC OVARY SYNDROME 

(PCOS) IN HISPANIC VS. NON-HISPANIC WHITE WOMEN. 

A. Ketefian 1,2 , C. A. Torralba 1 , M. Pall 1 , U. Ezeh 1 , R. Azziz 1,2 . 1 Center for 

Androgen Related Disorders, Obstetrics and Gynecology, Cedars 

Sinai Medical Center, Los Angeles, CA; 2 Obstetrics and Gynecology, 

David Geffen School of Medicine at UCLA, Los Angeles, CA.

P-346 EFFECT OF OMEGA-3-POLYUNSATURATED FATTY 

ACIDS AND METFORMIN ON OVARIAN MORPHOLOGY AND 

INTRAOVARIAN BLOOD FLOW IN PATIENTS WITH POLYCYSTIC 

OVARY SYNDROME. 

J.-W. Yoon 1 , C.-H. Kim 1 , J.-W. Ahn 1 , H.-J. Kang 1 , H.-J. Song 2 , B.-M. 

Kang 1 . 1 Obstetrics and Gynecology, Asan Medical Center, University 

of Ulsan, Seoul, Korea; 2 Obstetrics and Gynecology, Seoul Women’s 

Hospital, Bucheon, Gyunggi-do, Korea. 

P-347 INSULIN RESISTANCE, HOMOCYSTEINE & PREGNANCY 

LOSS IN POLYCYSTIC OVARIAN SYNDROME (PCOS): ARE THEY 

RELATED? 

S. Rajani, S. Mukherjee, S. Sharma, H. S. Sarkar, S. K. Goswami, B. 

Chakravarty. ART, Institute of Reproductive Medicine, Kolkata, West 

Bengal, India. 

P-348 IN VITRO TESTOSTERONE EXPOSURE SUPPRESSES 

LIPOPOLYSACCHARIDE-STIMULATED CYTOKINE RELEASE FROM 

MONONUCLEAR CELLS OF NORMAL REPRODUCTIVE-AGE 

WOMEN – EVIDENCE OF LIPOPOLYSACCHARIDE TOLERANCE. 

F. González, J. K. Daniels, H. E. Blair, K. S. Nair. Departments of 

Obstetrics and Gynecology (F.G., J.K.D.), Laboratory Medicine 

and Pathology (H.E.B.), and Internal Medicine (K.S.N.), College of 

Medicine, Mayo Clinic, Rochester, MN. 

P-349 ANTI-MÜLLERIAN HORMONE AND INHIBIN B LEVELS 

ARE ELEVATED IN NON-HYPERANDROGENIC ADOLESCENTS 

WITH POLYCYSTIC OVARIAN MORPHOLOGY (PCOM). 

C. Villarroel, P. Lopez, P. Merino, G. Iñiguez, E. Codner. Institute of 

Maternal and Child Research (IDIMI), School of Medicine, University 

of Chile., Santiago, Region Metropolitana, Chile. 

P-350 HIGHER RISK OF PREGNANCY COMPLICATIONS IN 

WOMEN WITH POLYCYSTIC OVARY SYNDROME. 

Y. V. Louwers 1 , N. E. Bakker 1 , C. W. P. M. Hukkelhoven 2 , J. S. E. Laven 1 . 

1 Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, 

Netherlands; 2 The Netherlands Perinatal Registry, Utrecht, 

Netherlands. 

P-351 VALUE OF 1-HOUR VERSUS 2-HOUR INSULIN LEVELS 

DURING THE ORAL GLUCOSE TOLERANCE TEST (OGTT) FOR 

IDENTIFYING THE DEGREE OF HYPERINSULINEMIA (HI) IN PCOS 

WOMEN. 

A. Ketefian1,2 , U. Ezeh1 , C. A. Torralba1 , M. Pall1 , R. Azziz1,2 . 1Center for Androgen Related Disorders, Department of Obstetrics and 

Gynecology, Cedars Sinai Medical Center, Los Angeles, CA; 

2Obstetrics and Gynecology, David Geffen School of Medicine at 


P-352 THE EXPRESSION OF BONE MORPHOGENETIC 

PROTEIN-15 (BMP-15) AND GROWTH AND DIFFERENTIATION 

FACTOR-9 (GDF-9) IN OOCYTES OF WOMEN WITH POLYCYSTIC 

OVARY SYNDROME (PCOS) UNDERGOING IN VITRO 

FERTILIZATION. 

L. Ochuiuto Teixeira de Resende 1 , A. A. Vireque 1 , L. F. Santana 1 , D. 

A. Moreno 2 , R. A. Ferriani 1 , R. M. dos Reis 1 . 1 Department of Obstetric 

and Gynecology, Faculty of Medicine of Ribeirão Preto - University 

of São Paulo, Ribeirão Preto, São Paulo, Brazil; 2 Department of 

Genetic, Faculty of Medicine of Ribeirão Preto - University of São 

Paulo, Ribeirão Preto, São Paulo, Brazil. 

P-353 PREANTRAL FOLLICULAR DEVELOPMENT IS NOT 

ACCELERATED IN WOMEN WITH POLYCYSTIC OVARIAN 

SYNDROME COMPARED WITH NORMAL CONTROLS. 

T. W. McCoy 1 , Y. Siow 2 , S. T. Nakajima 1 , M. E. Fallat 2 , Z. Lei 1 . 1 Obstetrics, 

Gynecology, and Women’s Health, University of Louisville, Louisville, 

KY; 2 Pediatric Surgery, University of Louisville, Louisville, KY. 

P-354 COMPARISON OF AMH SECRETION PATTERNS AND 

MECHANISMS OF FOLLICULAR DEVELOPMENT DISORDER 

BETWEEN PCOS PATIENTS WITH OR WITHOUT LUTEINZING 

HORMONE ELEVATION. 

TY. Li, X. Liang. Reproductive Center, Sixth Affiliated Hospital of Sun 



P-355 TRANSVAGINAL OVARIAN DRILLING FOR SEVERE 

POLYCYSTIC OVARY SYNDROME (PCOS) PRIOR TO IN VITRO 

FERTILIZATION (IVF) IMPROVES OUTCOMES. 

P. Chau, M. D. Keltz. Div. Reproductive Endocrinology, Dept. 

Obstetrics and Gynecology, St. Lukes-Roosevelt Hospital Center, 

Columbia College of Physicians and Surgeons, New York, NY. 

P-356 IMPACT OF THE INSTITUTIONAL RESEARCH 

REVIEW PROCESS ON INITIATING A CLINICAL STUDY: THE 

REPRODUCTIVE MEDICINE NETWORK (RMN) EXPERIENCE WITH 

PREGNANCY IN POLYCYSTIC OVARY SYNDROME I AND II. 

W. D. Schlaff 1 , R. S. Legro 2 , M. P. Diamond 3 , C. Coutifaris 4 , H. 

Zhang 5 , Reproductive Medicine Network 6 . 1 Dept. of Obstetrics 

& Gynecology, University of Colorado, Aurora, CO; 2 Dept. of 

Obstetrics & Gynecology, Pennsylvania State University, Hershey, PA; 

3 Dept. of Obstetrics & Gynecology, Wayne State University, Detroit, 

MI; 4 Dept. of Obstetrics & Gynecology, University of Pennsylvania, 

Philadelphia, PA; 5 Epidemiology and Public Health, Yale University, 

New Haven, CT; 6 Data Coordinating Center, NICHD, New Haven, CT. 

P-357 THECA INSULIN RESISTANCE: DEXAMATHASONE 

INDUCTION AND BERBERINE INTERVENTION. 



P-358 PRETERM DELIVERY IN PREGNANT WOMEN WITH 

POLYCYSTIC OVARIAN SYNDROME (PCOS). 

M. Yamamoto 1 , S. L. Feigenbaum 2 , Y. Crites 3 , G. J. Escobar 5 , A. 

Ferrara 4 , J. C. Lo 4 . 1 Obstetrics and Gynecology, Kaiser Permanente 

Oakland Medical Center, Oakland, CA; 2 Obstetrics and 

Gynecology, The Permanente Medical Group, San Francisco, 

CA; 3 Obstetrics and Gynecology, The Permanente Medical 

Group, Santa Clara, CA; 4 Division of Research, Kaiser Permanente 

Northern California, Oakland, CA; 5 Department of Pediatrics, The 

Permanente Medical Group, Walnut Creek, CA. 

P-359 APOLIPOPROTEIN AS A NOVEL GENE ASSOCIATED 

WITH POLYCYSTIC OVARY SYNDROME. 

K.-H. Baek 1 , Y.-S. Kim 1 , B.-H. Gu 1 , M.-S. Kim 1 , H. Y. Chung 2 , B. C. Choi 2 . 

1 Department of Biomedical Sciences, CHA StemCell Institute, CHA 

University, Seoul, Korea; 2 Obstetrics & Gynecology, Creation & Love 

Women’s Hospital, Gwangju, Korea. 

P-360 INHIBITION OF INSULIN SIGNALING POTENTIATES 

ANDROGENESIS IN PROCINE GRANULOSA CELLS. 



P-361 DOES ELEVATED ALANINE AMINOTRANSFERASE 

PREDICT COMPONENTS OF THE METABOLIC SYNDROME IN 

POLYCYSTIC OVARIAN SYNDROME? 

N. Aziz 1 , H. Jones 2 , V. S. Sprung 2 , A. Irwin 3 , G. J. Kemp 4 , D. 

Cuthbertson 3 . 1 Department of Gynaecology and\Reproductive 

Medicine, Liverpool Women’s Hospital and the University of 

Liverpool, Liverpool, Merseyside, United Kingdom; 2 Research 

Institute for Sport and Exercise Sciences, Liverpool John Moores 

University, Liverpool, Merseyside, United Kingdom; 3 Department of 

Diabetes and Endocrinology, University Hospital Aintree, Liverpool, 

Liverpool, Merseyside, United Kingdom; 4 Magnetic Resonance and 

Image Analysis Research Centre, University of Liverpool, Liverpool, 

Merseyside, United Kingdom. 

P-362 THE SEVERITY OF MENSTRUAL DYSFUNCTION SERVES 

AS A PREDICTOR OF INSULIN RESISTANCE IN THE POLYCYSTIC 

OVARY SYNDROME (PCOS). 

M. A. Brower 1 , K. Brennan 1 , U. Ezeh 2 , M. Pall 2 , R. Azziz 2 . 1 Obstetrics 

and Gynecology, University of California Los Angeles, Los Angeles, 

CA; 2 Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los 

Angeles, CA. 

P-363 DO WOMEN WITH POLYCYSTIC OVARY SYNDROME 

(PCOS) HAVE AN INCREASED RISK OF MISCARRIAGE? 

J. Alvarez 

148 

1 , A. Wu1 , M. Stephenson2 , B. Scoccia1 . 1Division of 

Reproductive Endocrinology and Infertility, University of Illinois 

College of Medicine, Chicago, IL; 2Division of Reproductive 

Endocrinology and Infertility, University of Chicago, Chicago, IL.

P-364 EXPRESSION OF GROWTH DIFFERENTIATION FACTOR 9 

(GDF9) AND BONE MORPHOGENETIC PROTEIN 15 (BMP15) IN 

THE OOCYTES FROM UNSTIMULATED POLYCYSTIC OVARIES. 

L. Wei, X. Liang. Reproductive Center, Sixth Affiliated Hospital of Sun 


P-365 25-HYDROXY VITAMIN D3 [25(OH) D] LEVELS ARE 

RELATED TO BMI IN WOMEN WITH POLYCYSTIC OVARY 


C. M. Wambach 2 , M. E. Pall 1 , K. Valenton 1 , M. Pisarska 1,3 , C. 

Alexander 1 . 1 Obstetrics & Gynecology, Cedars-Sinai Medical Center, 

Los Angeles, CA; 2 Obstetrics & Gynecology, University of California, 

Los Angeles, Los Angeles, CA; 3 David Geffen School of Medicine, 


__________________________________________________________ 

ENDOMETRIOSIS 

P-366 RESVERATROL REDUCES HUMAN ENDOMETRIAL 

STROMAL CELL INVASIVENESS. 

A. Sokalska1,2 , A. Cress1 , K. L. Bruner-Tran3 , K. G. Osteen3 , A. J. 

Duleba1 . 1Ob/Gyn, University of California Davis, Sacramento, CA; 

2Ob/Gyn, University of Medical Sciences, Poznan, Wlkp, Poland; 

3Ob/Gyn, Vanderbilt University School of Medicine, Nashville, TN. 

P-367 ENDOMETRIAL INDIAN HEDGEHOG EXPRESSION IS 

DECREASED IN WOMEN WITH ENDOMETRIOSIS. 

K. M. Smith, R. Alnifaidy, Q. Wei, L. Neiman. Program in Reproductive 

and Adult Endocrinology, National Institute of Child Health and 

Human Development, Bethesda, MD. 

P-368 VAGINAL DANAZOL IN WOMEN WITH RECTOVAGINAL 

ENDOMETRIOSIS AND PAIN SYMPTOMS PERSISTING AFTER 

THE INSERTION OF THE LEVONORGESTREL-RELEASING 

INTRAUTERINE DEVICE. 

S. Ferrero, P. L. Venturini, V. Remorgida. Department of Obstetrics 

and Gynecology, San Martino Hospital and University of Genoa, 

Genoa, GE, Italy. 

P-369 EARLY CHANGES IN MICRO RNA (miRNA) 

EXPRESSION IN THE EUTOPIC ENDOMETRIUM (EUE) IN A 

BABOON MODEL OF INDUCED ENDOMETRIOSIS. 

M. R. Olson 1 , N. M. Vadlapatla 2 , S. K. Khoo 2 , C. Gadisetti 1 , J. H. 

Resau 2 , A. T. Fazleabas 1 . 1 Obstetrics, Gynecology, and Reproductive 

Biology, Michigan State University, Grand Rapids, MI; 2 Laboratory of 

Microarray Technology, Van Andel Institute, Grand Rapids, MI. 

P-370 ASSOCIATION OF WT1 AND INDUCTION OF 

APOPTOSIS IN ENDOMETRIOTIC CELL LINES TREATED WITH MIS. 

S. F. Karipcin 1 , L. Fangxian 1 , M. Borahay 1 , I. Tekedereli 2 , B. Gurates 3 , 

S. G. Kilic 1 . 1 Obstetrics and Gynecology, UTMB in Galveston, 

Galveston, TX; 2 Experimental Therapeutics, The University of 

Texas MD Anderson Cancer Center, Houston, TX; 3 Department of 

Obstetrics & Gynecology, Firat University, Elazig, Turkey. 

P-371 ABERRANT EXPRESSION OF IAP FAMILY IN 

ENDOMETRIOTIC CELLS MAY CAUSE RESISTANCE TO 

APOPTOSIS. 

F. Taniguchi1 , M. Izawa2 , T. Iwabe1 , N. Terakawa1 , T. Harada1 . 

1Ob/Gyn, Tottori University Faculty of Medicine, Yonago, Japan; 

2Biosignaling, Tottori University Faculty of Medicine, Yonago, 

Japan. 

P-372 TRANSFORMING GROWTH FACTOR BETA ENHANCES 

ENDOMETRIAL EPITHELIAL CELL INVASION BY TRANSFORMING 

GROWTH FACTOR BETA RECEPTOR III SIGNALING. 

J. F. Knudtson, P. A. Binkley, R. S. Schenken, N. B. Kirma. Obstetrics 

and Gynecology, University of Texas Health Science Center at San 

Antonio, San Antonio, TX. 

P-373 EPITHELIAL-MESENCHYMAL TRANSITION MIGHT BE 

MICROENVIRONMENT-DEPENDENT DURING THE EVOLUTION 

OF ENDOMETRIOTIC IMPLANTS. 

S. Matsuzaki, C. Darcha, E. Maleysson, M. Canis, G. Mage. CHU 

Clermont-Ferrand, Clermont-Ferrand, Auvergne, France. 


149 

P-374 THE ROLE OF MACROPHAGES IN THE DEVELOPMENT 

OF THE ADHESION PHENOTYPE. 

J. White, Z. Jiang, M. Diamond, G. Saed. OB/GYN, Wayne State 

University, Detroit, MI. 

P-375 SELECTIVE INHIBITION OF PROSTAGLANDIN E2 

RECEPTORS EP2 AND EP4 INHIBITS ADHESION, MIGRATION, 

AND INVASION OF HUMAN ENDOMETRIOTIC CELLS. 

J. A. Arosh, J. Lee, S. K. Banu. Integrative Biosciences, Texas A&M 

University, College Station, TX. 

P-376 LABELED RED BLOOD CELL SCINTIGRAPHY IN THE 

NON-INVASIVE DIAGNOSTICS OF ENDOMETRIOSIS. 

F. Demirel 1 , G. Koca 2 , K. Demirel 2 , H. Aydogmus 1 , M. Korkmaz 2 , B. 

Gokmen 1 . 1 Obstetrics&Gynecology, Ministry of Health Ankara 

Training and Research Hospital, Ankara, Turkey; 2 Nuclear Medicine, 

Ministry of Health Ankara Training and Research Hospital, Ankara, 

Turkey. 

P-377 EFFECT OF RESVERATROL ON THE INDUCTION OF 

ENDOMETRIOSIS IN A RAT MODEL. 

M. Oktem 1 , P. Ozcan 1 , O. Erdem 2 , C. Karakaya 1 , H. Guner 1 , O. 

Karabacak 1 . 1 Obstetrics & Gynecology, Gazi University School of 

Medicine, Çankaya, Ankara, Turkey; 2 Pathology, Gazi University 

School of Medicine, Çankaya, Ankara, Turkey. 

P-378 DETECTION OF THE OXIDATIVE STRESS LEVELS IN 

PATIENTS WITH AND WITHOUT ENDOMETRIOSIS BY ANALYSIS 

OF CONFOCAL MICROSCOPY IMAGES USING A SUPEROXIDE 

PROBE. 

A. C. Azevedo 1 , M. S. Ormanji 2 , R. Fraietta 1 , V. de Freitas 1 , A. 

Agarwal 3 , C. R. A. Bertoncini 2 . 1 Gynecology Department, Human 

Reproduction Sector, Federal University of São Paulo, São Paulo, 

Brazil; 2 CEDEME, Federal University of São Paulo, São Paulo, Brazil; 

3 Glickman Urological Institute, Cleveland Clinic, Cleveland, OH. 

P-379 INCREASE EXPRESSION OF UROPLAKINS IN 

ENDOMETRIUM FROM PATIENTS WITH ENDOMETRIOSIS. 

J. Luk, H. Taylor. Department of Reproductive Endocrinology and 

Infertility, Yale University School of Medicine, New Haven, CT. 

P-380 RELATIONSHIP BETWEEN POLYMORPHISMS OF INSULIN- 

LIKE GROWTH FACTOR (IGF) GENES AND ENDOMETRIOSIS IN 

KOREAN WOMEN. 

J. G. Kim, H. Kim, S.-Y. Ku, S. H. Kim, Y. M. Choi. Department of 

Obstetrics and Gynecology, Seoul National University College of 

Medicine, Seoul, Korea. 

P-381 SPARCL1 DEREGULATED IN ENDOMETRIOSIS LESIONS. 

R. A. Ferriani 1 , J. Meola 1 , G. dos S. Hidalgo 1 , J. C. Rosa e Silva 1 , C. 

C. P. Paz 2 . 1 Gynecology and Obstetrics, School of Medicine of 

Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil; 2 Genetics, School of 

Medicine of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil. 

P-382 INCREASED EXPRESSION OF AROMATASE, 

CYCLOOXYGENASE-2 AND ESTROGEN RECEPTORS IN 

UTEROSACRAL LIGAMENTS AFFECTED BY DEEPLY INFILTRATING 

ENDOMETRIOSIS (DIE): TARGETS FOR MEDICAL MANAGEMENT. 

L. M. Rossi, P. A. G. Ribeiro, C. L. P. Lancellotti, F. A. R. Batista, B. L. 

Carmo, T. Aoki. Obstetric and Gynecology, Faculty of Medical 

Sciences - Santa Casa of São Paulo, São Paulo, Brazil. 

P-383 INTERLEUKIN 1ß (IL1ß) AND TUMOR NECROSIS 

FACTORa (TNFa) PARTIALLY RECAPITULATE EFFECTS OF 

MACROPHAGE CONDITIONED MEDIUM ON CULTURED 

ENDOMETRIAL STROMAL CELLS. 

A. J. Chalpe 1 , C. Law 1 , K. A. Hansen 2 , K. M. Eyster 1,2 . 1 Basic 

Biomedical Sciences, Sanford School of Medicine of the University 

of South Dakota, Vermillion, SD; 2 Obstetrics & Gynecology, Sanford 

School of Medicine of the University of South Dakota, Sioux Falls, SD. 

P-384 EFFECT OF MISTLETOE ON VASCULAR ENDOTHELIAL 

GROWTH FACTOR EXPRESSION IN ENDOMETRIAL STROMAL 

CELLS IN PATIENTS WITH ENDOMETRIOSIS. 

J. M. Moon 1 , M.-R. Kim 2 , J. R. Lee 1 , B. C. Jee 1,3 , C. S. Suh 1,3 , S. H. Kim 3 .

1 Obstetrics and Gynecology, Seoul National University Bundang 

Hospital, Seongnam-si, Gyeonggi-do, Korea; 2 Obstetrics and 

Gynecology, The Catholic University of Korea, Seoul St. Mary’s 

Hospital, Seocho-Gu, Seoul, Korea; 3 Obstetrics and Gynecology, 

Seoul National University, College of Medicine, Seoul National 

University Hospital, Chongno-gu, Seoul, Korea. 

P-385 INFLUENCE OF PITUITARY SUPPRESSION AND 

CONTROLLED OVARIAN HYPERSTIMULATION (COH) ON 

OXIDATIVE STRESS MARKERS OF INFERTILE PATIENTS WITH 

ENDOMETRIOSIS AND CONTROLS. 

F. C. Donabela 1 , A. Z. Andrade 1 , J. K. Rodrigues 1 , L. A. Dib 1 , A. A. 

Jordão, Jr 2 , P. A. Navarro 1,3 . 1 Dept. of Ob/Gyn, Faculty of Medicine 

of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; 

2 National Institute of Hormones and Woman’s Health, CNPq, 

Ribeirão Preto, SP, Brazil; 3 Nutrition and Metabolism Laboratory, 

Faculty of Medicine of Ribeirão Preto, University of Sao Paulo, 

Ribeirão Preto, SP, Brazil. 


P-387 THE ROLE OF CURCUMIN SUPPLEMENTATION 

ON IMPLANT GROWTH AND FERTILIZATION RESULT OF 

EXPERIMENTAL ENDOMETRIOSIS IN MICE. 

H. H. H. Hendarto1 , H. H. K. Kuswojo1 , A. A. S. Sa’adi1 , W. W. R. 

Ramelan2 , I. K. I. K. S. Sudiana3 . 1Department of Obstetric & 

Gynecology Faculty of Medicine, University of Airlangga, Surabaya, 

East Java, Indonesia; 2Faculty of Veterinary, University of Airlangga, 

Surabaya, East Java, Indonesia; 3Laboratory of Pathology, University 

of Airlangga, Surabaya, East Java, Indonesia. 

P-388 DOES THE ENDOMETRIOMAS AFFECT THE OOCYTE 

QUALITY AND EMBRYO CLEAVAGE? 

A. Kassa 1 , M. Ojeda 1 , A. Pellicer 2,3 , J. Garcia-Velasco 4 , N. Garrido 2 , 

E. Munoz 1 . 1 IVF Laboratory/Reproductive Medicine, IVI Vigo, Vigo, 

Pontevedra, Spain; 2 Reproductive Medicine, Instituto Valenciano 

de Infertilidad, University of Valencia, Valencia, Spain; 3 Obstetrics 

and Gynecology, University Hospital La Fe., Valencia, Spain; 

4 Reproducitve Medicine, IVI Madrid, Madrid, Spain. 

P-389 CHANGES IN QUALITY OF LIFE (QOL) IN WOMEN 

WITH SYMPTOMATIC ENDOMETRIOSIS BY PAIN TYPE DURING 

TREATMENT. 

O. Muneyyirci-Delale 1,2 , N. Sinaii 2 , C. Charles 1 , M. Dalloul 1 , N. Osei- 

Tutu 1 , P. Stratton 4 . 1 Obstetrics and Gynecology, SUNY Downstate 

Medical Center, Brooklyn, NY; 2 Obstetrics and Gynecology, Kings 

County Hospital Center, Brooklyn, NY; 3 Biostatistics & Clinical 

Epidemiology Svc, NIH Clinical Center, Bethesda, MD; 4 Program in 

Reproductive and Adult Endocrinology, NIH/NICHD, Bethesda, MD. 

P-390 STRATEGIES TO STIMULATE LOW RESPONDER PATIENTS 

WITH ENDOMETRIOSIS. 

J. Perelló, M. J. Saiz, P. Parés, R. Bordás, P. Viscasillas, J. Calaf. 

Department of Obstetrics and Gynecology, Hospital de la Santa 

Creu i Sant Pau, Barcelona, Spain. 

P-391 PREVALENCE OF METABOLIC SYNDROME AND 

CHANGES IN LIPID PROFILE OF WOMEN WITH ENDOMETRIOSIS 

DURING TREATMENT. 

O. Muneyyirci-Delale 1,2 , N. Sinaii 3 , C. Charles 1 , M. Dalloul 1 , N. Osei- 

Tutu 1 , P. Stratton 4 . 1 Obstetrics and Gynecology, SUNY Downstate 


County Hospital Center, Brooklyn, NY; 3 Biostatistics & Clinical 

Epidemiology Service, NIH Clinical Center, Bethesda, MD; 4 Program 

in Reproductive and Adult Endocrinology, NICHD, Bethesda, MD. 

P-392 SERUM CA-125, IL-8, MICRO-CRP LEVELS AND 

NEUTROPHIL TO LYMPHOCYTE RATIOS IN THE DIAGNOSIS OF 


C. D. Sayan, E. Sarikaya, O. G. Eryilmaz, G. Ozaksit, L. 

Mollamahmutoglu, R. Deveer. Centre for Reproductive Medicine, 

Zekai Tahir Burak Women’s Health Research and Education Hospital, 

Ankara, Altindag, Turkey. 


150 

P-393 COMT VAL-158-MET GENE POLYMORPHISM IS NOT 

ASSOCIATED WITH ENDOMETRIOSIS-RELATED PAIN. 

J. Ding 1 , X. Xu 2 , N. Rana 1 , W. P. Dmowski 1 . 1 The Institute for the Study 

and Treatment of Endometriosis, Oak Brook, IL; 2 Department of 

General Surgery, Rush University Medical Center, Chicago, IL. 

__________________________________________________________ 

REPRODUCTIVE IMMUNOLOGY 

P-394 FETO-MATERNAL IMMUNOLOGIC INTERACTIONS 

MEDIATED BY INDUCIBLE COSTIMULATOR (ICOS) SIGNALING. 

T. Nagamatsu1 , B. F. Barrier2 , D. J. Schust2 . 1Obstetrics and 

Gynecology, Faculty of Medicine, The University of Tokyo, Bunkyoku, 

Tokyo, Japan; 2Obstetrics, Gynecology and Women’s Health, 

University of Missouri, Columbia, MO. 

P-395 VARIATIONS IN CYTOKINE AND ESTROGEN RECEPTOR 

GPR30 EXPRESSION IN MONOCYTES EXPOSED TO DIFFERENT 

ESTROGEN ENVIRONMENTS. 

L. C. Elkins 1 , D. D. Taylor 2 , S. Atay 2 , S. T. Nakajima 1 , C. Gercel-Taylor 2 . 

1 Department of Obstetrics and Gynecology, University of Louisville, 

Louisville, KY; 2 Department of Microbiology and Immunology, 

University of Louisville, Louisville, KY. 

P-396 ASSOCIATION OF CYTOKINES ON INDIVIDUAL 

FOLLICLE FLUID AND CHARACTERISTICS OF IN 

CORRESPONDING VITRO GENERATED EMBRYOS. 

T. C. S. Bonetti 1 , J. P. Klaine 1 , M. Brunialti 2 , D. P. A. F. Braga 3 , E. 

Borges, Jr 3 , I. D. C. G. Silva 1 . 1 Molegular Gynecology Laboratory - 

Gynecology Department, Universidade Federal de Sao Paulo, Sao 

Paulo, SP, Brazil; 2 Immunology Laboratory - Department of Medicine, 

Universidade Federal de Sao Paulo, Sao Paulo, Brazil; 3 Fertility - 

Assisted Fertilization Center, Sao Paulo, SP, Brazil. 

P-397 HLA-G GENE POLYMORPHISMS IN SPONTANEOUS 

MISCARRIAGE. 

V. Garcia 1 , J. M. De los Santos 1 , J. Ferro 2 , J. Martin 3 , A. Pellicer 2 , M. 

De los Santos 1 . 1 FIV, IVI Valencia, Valencia, Spain; 2 Ginecologia y 

Obstetricia, IVI Valencia, Valencia, Spain; 3 Diagnostico Genetico 

Preimplantacional, IVI Valencia, Valencia, Spain. 

__________________________________________________________ 

FEMALE REPRODUCTIVE TRACT 

P-398 HUMAN ADHESION FIBROBLASTS ARE UNDER 

CONSTANT INTRINSIC OXIDATIVE STRESS AS CHARACTERIZED 

BY HIGHER BASELINE NADPH OXIDASE AND HYPOXIA 

INDUCIBLE FACTOR-1a AND LOWER BASELINE SUPEROXIDE 

DISMUTASE. 

N. M. Fletcher, Z. L. Jiang, H. Almahmoud, M. P. Diamond, G. M. 

Saed. Obstetrics and Gynecology, Wayne State University School of 

Medicine, Detroit, MI. 

P-399 NOVEL, ORAL TRANEXAMIC ACID IMPROVES THE 

GENERAL QUALITY OF LIFE (SF-36v2 HEALTH SURVEY 

MEASURES) IN WOMEN WITH MENORRHAGIA. 

K. Muse 1 , J. Gersten 2 , A. Waldbaum 3 , R. G. Mabey 4 , A. Lukes 5 , G. 

Shangold 6 . 1 Obstetrics and Gynecology, University of Kentucky 

Medical Center, Lexington, KY; 2 New Age Medical Research 

Corporation, Miami, FL; 3 Downtown Women’s Health Care, Denver, 

CO; 4 Private Practice, Las Vegas, NV; 5 Carolina Women’s Research 

and Wellness Center, Durham, NC; 6 Xanodyne Pharmaceuticals, 

Inc., Newport, KY. 

P-400 ASSOCIATION BETWEEN ETHNICITY AND PEAK 

ENDOMETRIAL THICKNESS IN INTRAUTERINE INSEMINATION 

CYCLES. 

E. F. Wolff 1 , J. Csokmay 1 , J. H. Segars 1 , K. S. Richter 2 , E. A. Widra 2 . 

1 Program in Reproductive and Adult Endocrinology, NICHD, NIH, 

Bethesda, MD; 2 Shady Grove Fertility Reproductive Science Center, 

Rockville, MD.

P-401 DEFINING “ENDOMETRIAL FACTOR” INFERTILITY: 

PREGNANCY RATES FOLLOWING 2,090 INTRAUTERINE 

INSEMINATION CYCLES CORRELATE WITH ENDOMETRIAL 

THICKNESS. 

E. F. Wolff1, J. H. Segars1, K. S. Richter2, E. A. Widra2. 1Program in 

Reproductive and Adult Endocrinology, NICHD, NIH, Bethesda, MD; 

2Shady Grove Fertility Reproductive Science Center, Rockville, MD. 

P-402 IMPACT OF GLYCEROL-FREE VERSUS GLYCEROL- 

CONTAINING FERTILITY LUBRICANTS ON SPERM FUNCTION, 

INCLUDING ABILITY TO FERTILIZE AND SUPPORT EMBRYO 

DEVELOPMENT IN AN IN VITRO MODEL. 

R. W. Wright, Jr. Center for Reproductive Biology, Washington State 

University, Pullman, WA. 

P-403 EFFECT OF AN ISOTONIC FERTILITY LUBRICANT ON 

SPERM PENETRATION INTO BOVINE CERVICAL MUCUS IN 

VITRO. 

R. W. Wright, Jr. Center for Reproductive Biology, Washington State 

University, Pullman, WA. 

__________________________________________________________ 

IMAGING 

P-404 ENDOMETRIAL/SUBENDOMETRIAL BLOOD FLOW 

INDEXES MEASURED BY 3D POWER DOPPLER ANGIOGRAPHY 

AND INHERITED THROMBOPHILIA AND IN VITRO FERTILIZATION 

OUTCOME. 

A. Nazzaro, A. Salerno. Physiopathology of Human Reproduction, 

“G. Rummo” Hospital, Benevento, Italy. 

P-405 EFFECT OF TRIPLE LINE VS. ISOECHOGENIC TEXTURE 

ON PREGNANCY OUTCOME FOLLOWING EMBRYO TRANSFER 

ACCORDING TO USE OF CONTROLLED OVARIAN STIMULATION 

(COH) OR ESTROGEN/PROGESTERONE REPLACEMENT. 

J. H. Check, C. Dietterich, J. K. Choe, R. Cohen, D. Brasile. OB/GYN, 

UMDNJ, Robert Wood Johnson Med. School at Camden, Div. Repo. 

Endo. & Infertility, Camden, NJ, Melrose Park, PA. 

P-406 COMPARISON OF THREE CANNULAS FOR 

HYSTEROSALPINGOGRAPHY: A PROSPECTIVE, RANDOMIZED 

STUDY. 

S. Lane1, R. L. Clark2, B. S. Hurst1, P. B. Marsburn1, M. Matthews1, 

R. S. Usadi1. 1Department of Obstetrics & Gynecology,Division of 

Reproductive Endocrinology, Carolinas Medical Center, Charlotte, 

NC; 2Department of Radiology, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 

P-407 CORRELATION BETWEEN CT VIRTUAL 

HISTEROSALPINGOGRAPHY AND MAGNETIC RESONANCE 

IMAGING IN THE EVALUATION OF UTERINE ANOMALIES. 

P. Carrascosa1, M. Baronio2, C. Capuñay1, J. Vallejos1, M. Borghi2, 

S. Papier2. 1Diagnostico Maipu, Vicente Lopez, Buenos Aires, 

Argentina; 2C.E.G.Y.R., C.A.B.A., Buenos Aires, Argentina. 

P-408 CT VIRTUAL HYSTEROSALPINGOGRAPHY IN THE 

EVALUATION OF UTERINE MYOMAS. 

M. Baronio1, C. Capuñay2, P. Carrascosa2, C. Sueldo1, J. Vallejos2, 

J. Carrascosa2. 1CEGYR, C.A.B.A., Buenos Aires, Argentina; 

2Diagnostico Maipu, Vicente Lopez, Buenos Aires, Argentina. 

P-409 CT VIRTUAL HYSTEROSALPINGOGRAPHY IN THE 

EVALUATION OF INTRAUTERINE ADHESIONS. 

P. Carrascosa1, M. Baronio2, C. Capuñay1, J. Vallejos1, S. Papier2, 

J. Carrascosa1. 1Diagnostico Maipu, Vicente Lopez, Buenos Aires, 

Argentina; 2C.E.G.Y.R., C.A.B.A., Buenos Aires, Argentina. 

P-410 REDEFINING THE MOUSE EMBRYO ASSAY 

(MEA): NOVEL TIME-LAPSE IMAGERY AND CONTINUOUS 

SURVEILLANCE VS. ‘SNAP SHOT’ OBSERVATION. 

M. D. VerMilyea, J. R. Graham, K. S. Richter, G. L. Mottla, M. J. Tucker. 

Shady Grove Fertility Reproductive Science Center, Rockville, MD. 


151 

P-411 THE INCIDENCE OF ECTOPIC PREGNANCY RATES 

FOLLOWING SALINE INFUSION SONO-HYSTEROGRAPHY (SIS) 

AMONG DIFFERENT INFERTILITY SUBTYPES. . 

J. Parker, D. Eldridge, L. Sanchez, J. Sawmiller, I. Gonzalez, J. 

Anderson. Department of GYN, Womack AMC, Fort Bragg, NC. 

P-412 LOW RADIATION DOSE CT VIRTUAL 

HYSTEROSALPINGOGRAPHY. 

P. Carrascosa 1 , M. Baronio 2 , J. Vallejos 1 , C. Capuñay 1 , C. Sueldo 2 , 

S. Papier 2 . 1 Diagnostico Maipu, Vicente Lopez, Buenos Aires, 

Argentina; 2 C.E.G.Y.R., C.A.B.A., Buenos Aires, Argentina. 

P-413 SERIAL ULTRASONOGRAPHIC EVALUATION OF 

INDIVIDUALLY-IDENTIFIED FOLLICLES IN WOMEN DURING 

OVARIAN STIMULATION. 

A. Baerwald 1 , D. Rouleau 1 , H. Bhatt 2 , H. Lim 2 , A. Gamelin 1 , A. Case 1 . 

1 Obstetrics, Gynecology, and Reproductive Sciences, College of 

Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 

2 Community Health and Epidemiology, College of Medicine, 

University of Saskatchewan, Saskatoon, SK, Canada. 

P-414 AN EXPLORATION OF PREDICTIVE VARIABLES FOR 

INCREASED PAIN DURING HYSTEROSALPINGOGRAM. 

B. W. Porter, L. B. Craig, K. R. Hansen. Dept of OBGYN, University of 

Oklahoma, Oklahoma City, OK. 

P-415 ENDOCAVITARY PATHOLOGY DETECTED BY VIRTUAL 

CT HYSTEROSALPINGOGRAPHY IN PATIENTS WITH UTERINE 

ANOMALIES AND NORMAL MR FINDINGS. 

M. Baronio 1 , P. Carrascosa 2 , J. Vallejos 2 , C. Capuñay 2 , M. Borghi 1 , C. 

Sueldo 1 . 1 CEGYR, C.A.B.A., Buenos Aires, Argentina; 2 Diagnostico 

Maipu, Vicente Lopez, Buenos Aires, Argentina. 

__________________________________________________________ 

ENDOMETRIUM 

P-416 ENDOMETRIAL MORPHOLOGY AND MODULATION OF 

HORMONE RECEPTORS DURING OVARIAN STIMULATION FOR 

ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES. 

L. Detti1 , G. M. Saed2 , N. M. Fletcher2 , M. L. Kruger2 , M. Brossoit2 , M. 

P. Diamond2 . 1Obstetrics and Gynecology, University of Tennessee, 

Memphis, TN; 2Obstetrics and Gynecology, Wayne State University, 

Detroit, MI. 

P-417 PROGESTERONE CONCENTRATION REQUIREMENTS 

FOR NORMAL MID-SECRETORY ENDOMETRIAL STRUCTURE AND 

FUNCTION. 

S. L. Young 1 , U. Balthazar 1 , J. R. A. Sherwin 4 , R. J. Zaino 3 , B. A. Lessey 2 , 

M. A. Fritz 1 . 1 Reproductive Endocrinology & Infertility, UNC at Chapel 

Hill, Chapel Hill, NC; 2 Center for Women’s Medicine, Greenville 

Hospital, Greenville, SC; 3 Pathology, Hershey Medical Center, 

Hershey, PA; 4 The Whittington Hospital, London, England, United 

Kingdom. 

P-418 PROGESTERONE AND TRANSFORMING 

GROWTH FACTOR BETA 1 (TGFB1) REGULATE MATRIX 

METALLOPROTEINASES (MMPS) IN HUMAN ENDOMETRIUM. 

H. Itoh, P. Keller, H. Mogami, A. Lindqvist, R. A. Word. Department 

of Obstetrics and Gynecology, UT Southwestern Medical Center, 

Dallas, TX. 

P-419 EVIDENCE THAT EUTOPIC ENDOMETRIUM DIFFERS IN 

SEVERE VERSUS MILD ENDOMETRIOSIS AND RELEVANCE TO 

FERTILITY. 

L. Aghajanova, L. C. Giudice. Obstetrics, Gynecology and 



P-420 IMPACT OF ESTRADIOL VALERATE/DIENOGEST (E2V/ 

DNG) ON WORK PRODUCTIVITY (WP) AND ACTIVITIES OF 

DAILY LIVING (ADL) IMPAIRMENT IN NORTH AMERICAN 

WOMEN WITH HEAVY AND/OR PROLONGED MENSTRUAL 

BLEEDING (HPMB). 

R. Wasiak 1 , A. Filonenko 2 , J. T. Jensen 3 , A. W. Law 4 , M. Jeddi 5 , D. 

E. Stull 1 . 1 United BioSource Corporation–Europe, London, United

Kingdom; 2 Bayer Schering Pharma AG, Berlin, Germany; 3 Oregon 

Health and Science University, Portland, OR; 4 Bayer HealthCare 

Pharmaceuticals Inc., Wayne, NJ; 5 Bayer Inc., Toronto, ON, Canada. 

P-421 ABERRANT HOXA10 METHYLATION IN PATIENTS WITH 

ASHERMAN’S SYNDROME AND UTERINE SEPTUM: A POSSIBLE 

CONTRIBUTION TO POOR REPRODUCTIVE OUTCOMES. 

J. L. Kulp, H. S. Taylor. Division of Reproductive Endocrinology and 

Infertility, Yale School of Medicine, New Haven, CT. 

P-422 ELEVATED ESTRADIOL IS CORELATED WITH 

HISTOLOGICALLY ADVANCED ENDOMETRIUM AND 

DECREASED ENDOMETRIAL HOXA10 EXPRESSION IN GnRH 

AGONIST CYCLES. 

T. L. B. Spitzer, V. Y. Fujimoto, H. Huddleston, E. Johnstone, M. I. 

Cedars, L. Giudice. Reproductive Sciences, University of California 

San Francisco, San Francisco, CA. 

P-423 MILK FAT GLOBULE EPITHELIAL GROWTH FACTOR 8 

(MFG-E8) REGULATES HUMAN ENDOMETRIAL ENDOTHELIAL 

CELL ADHESION AND PROLIFERATION. 

S. Bocca, S. Anderson, S. Oehninger. Obstetrics and Gynecology, 

The Jones Institute for Reproductive Medicine/EVMS, Norfolk, VA. 

P-424 HYPERANDROGENISM INCREASES GLUT1 EXPRESSION 

IN HUMAN ENDOMETRIAL STROMAL CELLS. 

K. E. O’Neill, A. I. Frolova, K. H. Moley. Obstetrics and Gynecology, 

Washington University Medical School, St. Louis, MO. 

P-425 BIDIRECTIONAL REGULATION OF UNFOLDING PROTEIN 

RESPONSE IN HUMAN ENDOMETRIUM AND ENDOMETRIOSIS. 

E. Guzel 1,2 , N. S. Ocak 1 , M. Basar 1,2 , I. Bozkurt 1 , A. Arici 1 , U. A. Kayisli 1 . 

1 Ob, Gyn & Reproductive Sciences, Yale School of Medicine, New 

Haven, CT; 2 Histology & Embryology, Istanbul University Cerrahpasa 

School of Medicine, Istanbul, Turkey. 

P-426 GLOBAL GENE EXPRESSION ANALYSIS REVEALS 

ABNORMALITIES IN THE EUTOPIC ENDOMETRIUM FROM 

WOMEN WITH ADENOMYOSIS. 

C. N. Herndon, L. Aghajanova, K. C. Vo, L. C. Giudice. Center for 

Reproductive Sciences, Department of Obstetrics, Gynecology and 



P-427 THE avß3 INTEGRIN ASSOCIATES WITH COMPLEMENT 

REGULATORY PROTEIN DECAY ACCELERATING FACTOR (DAF/ 

CD55) AND OSTEOPONTIN (OPN) IN ENDOMETRIAL CELLS 

DURING THE WINDOW OF IMPLANTATION. 

W. A. Palomino 1 , S. L. Young 2 , D. Barros 1 , P. Kohen 1 , L. Devoto 1 , B. 

A. Lessey 3 . 1 Institute for Maternal and Child Research, Faculty of 

Medicine, University of Chile, Santiago, Chile; 2 Department of 

Obstetrics and Gynecology, University of North Carolina at Chapel 

Hill, Chapel Hill, NC; 3 Department of Obstetrics and Gynecology, 

Division of Reproductive Endocrinology and Infertility, Greenville 

Hospital System, Greenville, SC. 

P-428 LIPIDOMIC PROFILING OF ENDOMETRIAL FLUID AS A 

NON-INVASIVE DIAGNOSTIC TOOL OF HUMAN ENDOMETRIAL 

RECEPTIVITY. 

O. Berlanga 1 , T. Garrido 1 , S. Martínez 1 , A. Pellicer 1 , H. B. Bradshaw 2 , 

C. Simón 1 . 1 Fundación Instituto Valenciano de Infertilidad, Valencia, 

Spain; 2 Psychological and Brain Sciences, Indiana University, 

Bloomington, IN. 

P-429 THE ENDOMETRIAL RECEPTIVITY ARRAY (ERA) 

IMPROVES THE ENDOMETRIAL DATING AND PROVIDES AN 

OBJECTIVE METHOD FOR CLINICAL EVALUATION. 

P. Díaz-Gimeno 1 , J. A. Martinez-conejero 2 , N. Garrido 1 , A. Pellicer 1 , 

C. Simón 1 , J. A. Horcajadas 2 . 1 Fundación IVI, Instituto Universitario 

IVI-Universidad de Valencia, Valencia, Spain; 2 iGenomix, Valencia, 

Paterna, Spain. 


152 

P-430 PREGNANCIES CONCEIVED IN WOMEN WITH 

THIN ENDOMETRIA ("5MM MAXIMAL THICKNESS) ARE AT 

INCREASED RISK FOR POOR OBSTETRICAL OUTCOME. 

E. Forman 1 , R. T. Scott, Jr 1,2 . 1 Obstetrics, Gynecology, and 

Reproductive Science, UMDNJ - Robert Wood Johnson Medical 

School, Morristown, NJ; 2 Reproductive Medicine Associates of New 

Jersey, Morristown, NJ. 

P-431 IS INCREASING ENDOMETRIAL LINING THICKNESS 

ADVANTAGEOUS OR DETRIMENTAL TO PREGNANCY 

OUTCOMES IN OOCYTE DONATION CYCLES (OD-IVF)? 

C. M. Mullin, F. Licciardi, A. S. Berkeley. NYU Fertility Center, New York 


P-432 PREVIOUS FRESH CYCLE ENDOMETRIAL CAVITY 

THICKNESS (ECT) IS A SENSITIVE PREDICTOR FOR INADEQUATE 

ECT IN FROZEN EMBRYO TRANSFER (FET) CYCLES. 

P. T. Jimenez, S. B. Schon, A. K. Parker, R. R. Odem, V. S. Ratts, E. S. 

Jungheim. Obstetrics and Gynecology, Washington University, St. 

Louis, MO. 

__________________________________________________________ 

FEMALE REPRODUCTIVE SURGERY 

P-433 PERCUTANEOUS OBSTRUCTED HEMIVAGINA ACCESS 

(POHVA) TO THE DIFFICULT OBSTRUCTED HEMIVAGINA IN 

THE OHVIRA SYNDROME: A NOVEL MINIMALLY INVASIVE 

TECHNIQUE. 

J. Escobar1 , L. Baker2 , E. Wilson1 . 1Reproductive Endocrinology and 

Infertility, OBGYN, University of Texas Southwestern Medical Center, 

Dallas, TX; 2Urology, University of Texas Southwestern Medical Center, 

Dallas, TX. 

P-434 DOES THE TYPE OF LAPAROSCOPIC HYSTERECTOMY 

PROCEDURE INFLUENCE THE RATE OF CONVERSION TO 

LAPAROTOMY? 

A. N. Imudia 1 , D. T. G. Hobson 1 , A. O. Awonuga 1,2 , G. Shade 1 , 

M. P. Diamond 1,2 . 1 Obstetrics and Gynecology, Wayne State 

University School of Medicine, Detroit, MI; 2 Division of Reproductive 

Endocrinology and Infertility, Wayne State University School of 

Medicine, Detroit, MI. 

P-435 LAPAROSCOPIC INTERVENTION IS INEFFECTIVE 

AT IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH 

UNEXPLAINED INFERTILITY. 

T. Fumino, A. Chikawa, A. Teranishi, N. Yamamoto, H. Hamai, M. 

Shigeta. Advanced Fertility Center of Fuchu Nozomi, Izumi, Osaka, 

Japan. 

P-436 THE ANTI-OXIDANT PROPHYLAXIS FOR CELLULAR 

INJURY IN OVARIAN SURFACE EPITHELIUM RESULTING FROM 

CO2 PNEUMOPERITONEUM IN LAPAROSCOPIC RAT MODEL. 

O. Gogsen, S. Kiray, G. Karabay, H. Zeyneloglu. Baskent University, 

Ankara, Turkey. 

P-437 THE UTILITY OF THE SHOCK INDEX TO PREDICT A 

RUPTURED ECTOPIC PREGNANCY. 

S. R. Jaramillo 1 , P. Takacs 1 , N. Chakhtoura 1 , A. Garza-Cavazos 1 , K. 

Barnhart 2 . 1 Obstetrics and Gynecology, University of Miami, Miller 

School of Medicine, Miami, FL; 2 Penn Fertility Care, University of 

Pennsylvania, Philadelphia, PA. 

__________________________________________________________ 

LEIOMYOMA 

P-438 VITAMIN D EXHIBITS ANTIESTROGENIC EFFECTS IN 

HUMAN UTERINE LEIOMYOMA CELLS. 

S. K. Halder, S. Goodwin, A. Al-Hendy. Department of Obstetrics and 

Gynecology, Meharry Medical College, Nashville, TN. 

P-439 OBSTETRIC OUTCOMES OF WOMEN WITH UTERINE 

LEIOMYOMA: DOES FIBROID SIZE OR NUMBER PREDICT 

OUTCOMES? 

Y. Ibrahim, L. Johnson, C. Grotegut, J. Lagoo, M. Behera. Obstetrics 

and Gynecology, Duke University Hospital, Durham, NC.

P-440 STEROIDS AND PALMITIC ACID IN AFRICAN 

AMERICAN WOMEN WITH UTERINE LEIOMYOMATA. 

O. Muneyyirci-Delale 1,2 , A. Choi 1 , C. Charles 1 , C. Hernandez 1 , L. 

Ekwealor 1 , T. Shah 1 . 1 Obstetrics and Gynecology, SUNY Downstate 


County Hospital Center, Brooklyn, NY. 

P-441 MEDICAL TREATMENT OF BENIGN METASTASIZING 

LEIOMYOMA: A CASE SERIES. 

A. M. Martinez 1 , R. J. Chason 2 , A. H. DeCherney 2 , A. M. Venkatesan 3 , 

J. Elkas 4 , A. Armstrong 2 . 1 Department of Obstetrics and Gynecology, 

Saint Barnabas Medical Center, Livingston, NJ; 2 Program in 



National Institutes of Health, Bethesda, MD; 3 Radiology and 

Imaging, National Institutes of Health, Bethesda, MD; 4 Northern 

Virginia Pelvic Surgery Associates, P.C., Annandale, VA. 

P-442 IN-VITRO FERTILIZATION (IVF) OUTCOMES IN PATIENTS 

WITH HYSTEROSCOPIC FIBROID RESECTION (SMR) OR 

POLYPECTOMY. 

L. J. Meyer 2 , M. F. Costantini-Ferrando 1 , G. L. Schattman 1 , Z. 

Rosenwaks 1 . 1 Center for Reproductive Medicine, Weill Cornell 

Medical Center, New York, NY; 2 Department of Obstetrics and 

Gynecology, New York Presbyterian Hospital-Weill Cornell Medical 

Center, New York, NY. 

P-443 LARGE UTERINE FIBROIDS ARE ASSOCIATED WITH 

DELIVERY AT AN EARLIER GESTATIONAL AGE AND INCREASED 

RATE OF CESAREAN SECTION. 

V. I. Shavell, M. Thakur, A. Sawant, M. Singh, E. E. Puscheck, M. P. 

Diamond. Division of Reproductive Endocrinology and Infertility, 

Department of Obstetrics and Gynecology, Wayne State University 

and the Detroit Medical Center, Detroit, MI. 

P-444 A VITAMIN A DAY: THE ROLE OF VITAMIN C 

(ASCORBIC ACID) AND ITS TRANSPORTERS IN THE 

TRANSCRIPTION AND SECRETION OF COLIA1 AND COLIA2 IN 

LEIOMYOMA AND MYOMETRIUM. 

E. E. Marsh 1 , J. Wu 1 , E. Cardozo 1 , R. Nowak 3 , S. E. Bulun 1 , A. Veis 2 . 

1 Obstetrics and Gynecology, Northwestern University Feinberg 

School of Medicine, Chicago, IL; 2 Cellular and Molecular Biology, 

Northwestern University Feinberg School of Medicine, Chicago, 

IL; 3 Animal Sciences, University of Illinois at Urbana Champaign, 

Urbana, IL. 

P-445 EXTRAPERITONEAL TRANSVAGINAL MYOMECTOMY. 

J.-Y. Liu, C.-K. Lin, P.-T. Fu, W.-J. Wu, Y.-S. Lin, G.-J. Wu. Department of 

Obstetrics and Gynecology, Tri-Service General Hospital, National 

Defense Medical Center, Taipei, Taiwan. 

P-446 PILOT STUDY OF MR-GUIDED HIGH INTENSITY 

FOCUSED ULTRASOUND (MRGHIFU) ABLATION OF UTERINE 

FIBROIDS. 

T. Klepac Pulanic 1 , A. Venkatesan 2 , J. Segars 1 , A. Partanen 3 , 

M. Merino 4 , P. Stratton 1 . 1 Program in Reproductive and Adult 

Endocrinology, NICHD, NIH, Bethesda, MD; 2 Dept of Radiology 

and Imaging Services, CC, NIH, Bethesda, MD; 3 Philips Healthcare, 

Cleveland, OH; 4 Laboratory of Pathology, NCI, Bethesda, MD. 

P-447 ALL-TRANSRETINOIC ACID SUPPRESSES UTERINE 

LEIOMYOMA GROWTH. 

J.-Y. Liu, Y.-J. Lee, C.-C. Wu, W.-C. Chen, C.-H. Lee, C.-C. Ou. 

Department of Obstetrics and Gynecology, Tri-Service General 

Hospital, National Defense Medical Center, Taipei, Taiwan. 

P-448 CORRELATION BETWEEN PROGESTERONE RECEPTOR 

DENSITY AND EGF AND TNFa UTERINE MYOMA TISSUE IN 

WOMEN OF REPRODUCTIVE AGE. PRELIMINARY RESULTS. 

A. Rachmawati, A. Biben, T. H. Madjid. Obstetrics & Gynecology 

SubDivison Reproductive Endocrinology and Infertility, Faculty of 

Medicine Universitas Padjadjaran, Bandung, West Java, Indonesia. 


153 

P-449 PREGNANCY OUTCOMES FOLLOWING REPEAT 

MYOMECTOMY. 

J. L. Nodler 1 , S. H. Shomento 1 , J. J. Cooper 2 , G. W. Bates 1 . 

1 Obstetrics and Gynecology, University of Alabama at Birmingham, 

Birmingham, AL; 2 School of Medicine, University of Alabama at 

Birmingham, Birmingham, AL. 

__________________________________________________________ 

SEXUALITY 

P-450 EFFICACY OF FLIBANSERIN 100 mg QHS IN 

PREMENOPAUSAL WOMEN WITH HYPOACTIVE SEXUAL DESIRE 

DISORDER (HSDD): SEXUAL SATISFACTION. 

J. Thorp1 , E. Jolly2 , M. Sand3 . 1University of North Carolina at Chapel 

Hill, Chapel Hill, NC; 2Shirley E. Greenberg Women’s Health Centre, 

The Ottawa Hospital, Ottawa, ON, Canada; 3Boehringer Ingelheim 

Pharmaceuticals, Inc., Ridgefield, CT. 

P-451 FEMALE SEXUAL HEALTH PREDICTS MALE AND FEMALE 

PARTNER SATISFACTION FOLLOWING IPP PLACEMENT. 

P. R. Gittens, D. Avila, K. Hwang, C. Aravind, M. Khera, L. I. Lipshultz. 

Urology, Baylor College of Medicine, Houston, TX. 

__________________________________________________________ 

MENTAL HEALTH 

P-452 GENDER DIFFERENCES IN INFORMATION NEEDS 

AMONG INFERTILE COUPLES: IMPLICATIONS FOR PHYSICIAN 

COUNSELING. 

J. C. Stalling, L. M. Frazier, L. L. Tatpati, T. A. Von Wald, D. A. Grainger. 

Obstetrics and Gynecology, University of Kansas School of 

Medicine-Wichita, Wichita, KS. 


P-454 STRESS AND ANXIETY SCORES IN FIRST AND REPEAT 

IVF CYCLES. 

K. Turner1 , M. F. Reynolds-May2 , E. M. Zitek1 , R. L. Tisdale1 , A. B. 

Carlisle1 , L. M. Westphal1 . 1Gynecology and Obstetrics, Stanford 

University School of Medicine, Stanford, CA; 2Yale University School 

of Medicine, New Haven, CT. 

P-455 STRESS AT THE INITIATION OF FERTILITY TREATMENT 

AFFECTS IVF OUTCOMES. 

R. K. Hunter 1 , M. L. Traub 1,2 , E. S. Knochenhauer 1,2 . 1 Obstetrics and 

Gynecology, Staten Island University Hospital, Staten Island, NY; 

2 Island Reproductive Services, Staten Island, NY. 

P-456 IN VITRO FERTILIZATION (IVF) OUTCOMES AND 

ALCOHOL CONSUMPTION IN RISK DRINKERS: EFFECTS OF A 

RANDOMIZED INTERVENTION. 

B. V. Rossi 1 , G. Chang 2 , K. Berry 1 , H. D. Mark 1 , S. A. Missmer 1 . 

1 Department of Obstetrics and Gynecology, Brigham and Women’s 

Hospital, Boston, MA; 2 Department of Psychiatry, Brigham and 

Women’s Hospital, Boston, MA. 

P-457 PATIENT PAIN PERCEPTION WITH 

HYSTEROSALPINGOGRAM VERSUS HYSTEROSCOPY IN 

INFERTILITY EVALUATION. 

L. M. Brayboy, E. M. Murphy, J. D. Cohen, S. G. Somkuti, M. Sobel, 

L. I. Barmat. Department of Obstetrics and Gynecology, Abington 

Reproductive Medicine, Abington, PA. 

P-458 FACTORS ASSOCIATED WITH THE TRANSITION TO 

SEEKING FERTILITY MEDICAL TREATMENT. FINDINGS FROM THE 

INTERNATIONAL FERTILITY DECISION-MAKING STUDY (IFDMS). 

L. E. Bunting 1 , I. Tsibulsky 2 , J. Boivin 1 . 1 School of Psychology, Cardiff 

University, Cardiff, United Kingdom; 2 Merck Serono S.A., Geneva, 

Switzerland. 

P-459 SEMEN DONORS WHO ARE OPEN TO CONTACT WITH 

THEIR OFFSPRING. 

W. Kramer 1 , K. Daniels 2 , M. Perez-y-Perez 2 . 1 Donor Sibling Registry, 

Nederland, CO; 2 School of Social Work and Human Services, 

University of Canterbury, Christchurch, New Zealand. 

__________________________________________________________

PRACTICE MANAGEMENT 

P-460 ETHNICITY REPORTING PRACTICES OF ASSISTED 

REPRODUCTION CLINICS. 

T. L. B. Spitzer, A. Y. Armstrong, M. I. Cedars, V. Y. Fujimoto. 



P-461 COMPARISON OF THE EFFECTIVENESS OF 

FALLOPIAN TUBE SPERM PERFUSION (FSP) WITH INTRAUTERINE 

INSEMINATION (IUI) IN THE TREATMENT OF NON-TUBAL 

INFERTILITY: A PROSPECTIVE RANDOMIZED STUDY. 

S. Furuya, T. Kagawa, K. Kubonoya. Obstetrics & Gynecology, 

Kubonoya Ob/Gyn Clinic, Kashiwa City, Chiba Prefecture, 

Japan. 

P-462 A COMPARISON OF ABDOMINAL, VAGINAL, 

LAPAROSCOPIC, AND ROBOTIC HYSTERECTOMIES: SURGICAL 

OUTCOMES AND OPERATIVE COST IN A SINGLE INSTITUTION. 

K. N. Wright1 , G. M. Jonsdottir1 , S. Jorgensen2 , J. I. Einarsson1 . 

1Obstetrics and Gynecology, Brigham and Women’s Hospital, 

Boston, MA; 2Harvard School of Public Health, Boston, MA. 

P-463 A RETROSPECTIVE ANALYSIS OF THE EFFECTS OF 

L-METHYLFOLATE AND ACTIVE VITAMIN B12 ON HEMOGLOBIN 

LEVELS THROUGHOUT PREGNANCY. 

S. W. Bentley 1 , A. Hermes 2 , D. Phillips 3 . 1 Women’s Clinic Shoals, 

Sheffield, AL; 2 Gainesville Obstetrics & Gynecology, Gainesville, TX; 

3 Women’s Health Associates, Flowood, MS. 

P-464 END OF A MEANS OR MEANS OF AN END?-TOWARDS 

A BETTER INDEX FOR EVALUATION OF THE POTENTIAL OF 

REPORODUCTIVE HEALTH SCIENTISTS COMPETING FOR POSTS, 

GRANTS OR FELLOWSHIPS. 

A. Y. Shahin. Obstetrics and Gynecology, Women’s Health Center, 

Assiut, Egypt. 

__________________________________________________________ 

ENVIRONMENT AND REPRODUCTION 

P-465 ALL PATIENTS SEEKING INFERTILITY SERVICES SHOULD 

BE IMMUNIZED AGAINST H1N1: ESTIMATION OF THE IMPACT 

OF H1N1 IMMUNIZATION ON MATERNAL MORBIDITY AND 

MORTALITY IN INFERTILITY PATIENTS. 

C. E. Alford, A. H. DeCherney, A. Y. Armstrong. Program in 

Reproductive and Adult Endocrinology, Eunice Kennedy Shriver, 


National Institutes of Health, Bethesda, MD. 

P-466 PERFLUOROOCTANOIC ACID, AN ENVIRONMENTAL 

TOXIN, CONFERS NO ADVERSE EFFECT ON SEMEN 

PARAMETERS. 

S. K. Dahl 1 , J. C. Robins 1 , D. B. Williams 1 , A. Kubatova 2 , D. H. Wu 1 , 

M. A. Thomas 1 . 1 Department of Obstetrics and Gynecology, The 

University of Cincinnati Academic Health Center, Cincinnati, OH; 

2 Chemistry Department, University of North Dakota, Grand Forks, ND. 

P-467 URINARY BISPHENOL A (BPA) CONCENTRATIONS AND 

OVARIAN RESPONSE IN WOMEN UNDERGOING OVULATION 

INDUCTION/INTRAUTERINE INSEMINATION CYCLES (OI/IUI). 

I. Souter1 , I. Dimitriadis1,2 , S. Ehrlich2 , J. C. Petrozza1 , J. B. Ford1,2 , 

R. Hauser1,2 . 1Obstetrics,Gynecology and Reproductive Biology, 

Massachusetts General Hospital-Harvard Medical School, Boston, 

MA; 2Environmental Health, Environmental and Occupational 

Medicine and Epidemiology Program, Harvard School of Public 

Health, Boston, MA. 

P-468 THE RELATIONSHIP OF HAIR MERCURY LEVELS WITH 

EARLY IN VITRO FERTILIZATION (IVF) OUTCOMES. 

D. L. Wright1 , S. Ehrlich2 , K. Berry3 , T. L. Toth1 , C. Amarasiriwardena2 , R. 

Hauser1,2 . 1Vincent Obstetrics and Gynecology Service, Division of 

Reproductive Medicine and IVF, Massachusetts General Hospital, 

Boston, MA; 2Department of Environmental Health, Harvard School 

of Public Health, Boston, MA; 3Center for Infertility and Reproductive 

Surgery, Department of Obstetrics and Gynecology, Brigham and 

Women’s Hospital, Boston, MA. 


154 

P-469 DO CELL PHONES TRULY IMPACT CELLULAR 

FUNCTION? 

L. Penrose, A. Van-Gheem, L. Welch, S. Prien. Ob/Gyn, Texas Tech 

University Health Sciences Center, Lubbock, TX. 

P-470 EFFECT OF CIGARETTE SMOKING ON THE PROTEIN 

PROFILE IN MEN WITH VARICOCELE. 

R. M. Fariello, J. R. Pariz, M. Camargo, E. G. Lo Turco, R. P. Bertolla, A. 

P. Cedenho. Division of Urology, Human Reproduction Section, Sao 

Paulo Federal University, Sao Paulo, SP, Brazil. 

P-471 LEAD TRACE LEVELS FROM ENVIRONMENTAL 

EXPOSURE AND ITS EFFECTS ON HUMAN REPRODUCTION 

OUTCOMES – PRELIMINARY RESULTS. 

A. C. A. Mancebo 1 , M. do C. B. de Souza 1 , M. de F. R. Moreira 2 , H. 

C. Neves 1 , A. L. S. R. Costa 1 , P. C. F. Arêas 1 . 1 G&O Ginecologia e 

Obstetricia da Barra, Rio de Janeiro, RJ, Brazil; 2 Centro de Estudos 

da Saúde do Trabalhador e Ecologia Humana (CESTEH), Fundação 

Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil. 

P-472 PRECONCEPTION RECRUITMENT OF COUPLES 

DESIRING PREGNANCY – CASE FOR THE EXPOSOME. 

G. M. Buck Louis 1 , E. F. Schisterman 1 , A. M. Sweeney 2 , R. Gore- 

Langton 3 , C. D. Lynch 4 , R. Sundaram 1 . 1 Division of Epidemiology, 

Statistics & Prevention Research, Eunice Kennedy Shriver National 

Institure of Child Health & Human Development, Rockville, MD; 

2 Epidemiology & Biostatistics, Texas A & M Rural School of Public 

Health, College Station, TX; 3 EMMES Corporation, Rockville, MD; 

4 Epidemiology, Ohio State College of Public Health, Columbus, OH. 

P-473 HUMAN SPERM SURVIVAL BIOASSAY TO EXAMINE 

TOXICITY OF A NEW LABORATORY EQUIPMENT DISINFECTANT. 

T.-C. Chang, C. A. Eddy, E. S. Jacoby, M. O. de la Pena, R. G. Brzyski, 

R. S. Schenken. Obstetrics and Gynecology, University of Texas 

Health Science Center, San Antonio, TX. 

P-474 EFFECT OF NONYLPHENOL AND OCTYLPHENOL ON 

GENE EXPRESSION OF ENDOMETRIAL CELLS CULTURED FROM 

SHED ENDOMTRIUM. 

C. K. Lim 1 , J. W. Cho 1 , D. S. Ko 1 , H.-S. Lee 1 , J. Y. Han 2 , M. K. Koong 2 . 

1 Laboratory of Reproductive Biology and Infertility, Cheil General 

Hospital & Women’s Healthcare Center, Kwandong University 

College of Medicine, Seoul, Korea; 2 Department of OB/GYN, 

Cheil General Hospital & Women’s Healthcare Center, Kwandong 

University College of Medicine, Seoul, Korea. 

P-475 STATISTICAL MODEL TO PREDICT THE IMPACT OF 

DIFFERENT LIFESTYLE AND ENVIRONMENTAL FACTORS ON 

SEMINAL PARAMETERS. 

R. Iaizzo, A. G. Martinez, A. R. Cattaneo, C. Ruhlmann. Fertilidad San 

Isidro, San Isidro, Buenos Aires, Argentina. 

P-476 CADMIUM: A TOXICANT WITH PARADOXICAL EFFECTS 

ON REPRODUCTION. PRELIMINARY RESULTS. 

M. do C. B. de Souza 1 , A. C. A. Mancebo 1 , M. de F. R. Moreira 2 , H. 

C. Neves 1 , A. L. S. R. Costa 1 , C. A. Henriques 1 . 1 G&O Ginecologia e 

Obstetrícia da Barra, Rio de Janeiro, RJ, Brazil; 2 Centro de Estudos 

da Saúde do Trabalhador e Ecologia Humana (CESTEH), Fundação 

Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil. 

P-477 EXPOSURE TO PHTHALIC ACID ESTERS IN EARLY 

HUMAN PREGNANCY. 

Q. Lu 1 , H. Shen 1 , X. Wang 2 , Y. Zhao 2 , X. Cai 1 . 1 Reproductive Medicine 

Center, Peking University People’s Hospital, Beijing, China; 2 College 

of Environment and Engineering, Beijing University of Technology, 

Beijing, China. 

__________________________________________________________

MALE FACTOR 

P-478 PROGNOSTIC VALUE OF SPERM MORPHOLOGY IN 

INTRAUTERINE INSEMINATION. 

R. V. De Caro, R. Osés, L. V. Sícaro, A. Valcarcel, E. P. Lombardi. 

Department of Gynecology and Infertility, Instituto de Ginecología 

y fertilidad - IFER, Ciudad Autónoma de Buenos Aires, Buenos Aires, 

Argentina. 

P-479 DIFFERENT TRANSCRIPTOMIC FINGERPRINT PROFILE 

BETWEEN SPERM SAMPLES (SS) FROM INFERTILE PATIENTS 

(IP) ACHIEVING OR NOT PREGNANCY AMONG DIFFERENT 

ASSISTED REPRODUCTION TECHNIQUES (ARTs). 

S. Garcia-Herrero, N. Garrido, L. Romany, J. A. Martinez-Conejero, A. 

Pellicer, M. Meseguer. IVI Valencia, Valencia, Spain. 

P-480 INTRAUTERINE INSEMINATION CONFERS LIMITED 

BENEFIT FOR CONCEPTION IN INFERTILE COUPLES WITH 

FEMALE AGE OVER 38 AND LOW SPERM QUALITY. 

C. N. Herndon, A. M. Zamah, S. Shen, M. P. Rosen, M. I. Cedars. 

Division of Reproductive Endocrinology and Infertility, Department 

of Obstetrics, Gynecology and Reproductive Sciences, University of 

California, San Francisco, San Francisco, CA. 

P-481 “PHYSIOLOGIC” (HYALURONIC ACID-CARRIED) ICSI 

RESULTS IN THE SAME EMBRYO QUALITY AND PREGNANCY 

RATES THAN WITH THE USE OF POTENTIALLY TOXIC 

POLYVINYLPYRROLIDONE (PVP). 

Y. Menezo 1 , A.-M. Junca 1 , M. Dumont 1 , J. De Mouzon 2 , P. Cohen- 

Bacrie 1 , M. Ben Khalifa 3 . 1 Biologie de la Reproduction, Laboratoire 

d’Eylau-Paris UNILABS, Paris, France; 2 Service de Gynecologie- 

Obstetrique II Médecine de la Reproduction, INSERM, Paris, France; 

3 ATL Research Dpt, La Verriere, France. 

P-482 TESTICULAR EXPRESSION ANALYSIS OF THE AZF GENES 

IN AZOOSPERMIC MEN SUGGESTS ESSENTIALITY AND SPECIFIC 

FUNCTION FOR DDX3Y, RPS4Y2, CDY2, AND HSFY. 

P. J. Stahl, A. Mielnik, P. N. Schlegel, D. A. Paduch. Urology, Weill 

Cornell Medical College, NY, NY. 

P-483 CLINICAL OUTCOME USING NON-APOPTOTIC 

SPERM SELECTION FOR ICSI PROCEDURES: REPORT OF 1 YEAR 

EXPERIENCE. 

C. Alvarez Sedó 1,2 , H. Uriondo 1 , M. Lavolpe 1 , F. Noblia 1 , S. Papier 1 , 

F. Nodar 1 . 1 CEGYR, Capital Federal, Buenos Aires, Argentina; 

2 Laboratory of Testicular Physiology and Pathology, Center for 

Research in Endocrinology, National Research Council (CONICET), 

Endocrinology Division, Buenos Aires Children’s Hospital, Capital 

Federal, Buenos Aires, Argentina. 

P-484 REPRODUCTIVE POTENTIAL OF AZOOSPERMIC MEN 

UNDERGOING INTRACYTOPLASMIC SPERM INJECTION IS 

DEPENDENT ON THE TYPE OF AZOOSPERMIA. 

C. Prudencio, B. Seol, S. C. Esteves. ANDROFERT - Andrology & 

Human Reproduction Clinic, Campinas, Sao Paulo, Brazil. 

P-485 EFFECT OF AGE ON APOPTOSIS-RELATED PROTEINS IN 

GERM CELLS OF HUMAN TESTES. 

R. Smith 1 , J. Rivera 1 , F. Jeria 1 , K. Baeza 1 , F. Gabler 2 , H. Nicolai 3 . 

1 Institute of Maternal and Child Research., School of Medicine, 

University of Chile, Santiago, Metropolitana, Chile; 2 Department of 

Pathology, School of Medicine, University of Chile. San Borja-Arriarán 

Clinical Hospital, Santiago, Metropolitana, Chile; 3 Department of 

Urology, School of Medicine, University of Chile. San Borja-Arriarán 

Clinical Hospital, Santiago, Metropolitana, Chile. 

P-486 PGS IN PATIENTS WITH TESTICULAR MEIOTIC 

DISORDERS AND FISH ANALYSIS IN SPERM. 

M. Esbert 1 , F. Vidal 2 , L. Rodrigo 3 , A. Pellicer 3 , A. Ballesteros 1 , G. 

Calderón 1 . 1 IVI-Barcelona, Barcelona, Spain; 2 Universitat Autònoma 

de Barcelona, Bellaterra, Spain; 3 IVI-Valencia, Valencia, Spain. 


155 

P-487 SUCCESS OF PERCUTANEOUS SPERM RETRIEVAL AND 

INTRACYTOPLASMIC SPERM INJECTION (ICSI) IN OBSTRUCTIVE 

AZOOSPERMIC (OA) MEN ACCORDING TO THE CAUSE OF 

OBSTRUCTION. 

S. C. Esteves, S. Verza, Jr, C. Prudencio, B. Seoul. ANDROFERT - 

Andrology & Human Reproduction Clinic, Campinas, Sao Paulo, 

Brazil. 

P-488 THE IMPACT OF INFERTILITY ON FAMILY SIZE IN THE 

UNITED STATES: DATA FROM THE NATIONAL SURVEY OF FAMILY 

GROWTH. 

M. L. Eisenberg 1 , J. F. Smith 2 , A. W. Shindel 1 , I. D. Sharlip 1 , B. N. Breyer 1 . 

1 Urology, University of California San Francisco, San Francisco, CA; 

2 Urology, Obstetrics and Gynecology, University of California San 


P-489 MICROSURGICAL EPIDIDYMAL SPERM ASPIRATION 

(MESA) CONFIRM TO BE MORE EFFICIENT THAN TESTICULAR 

SPERM EXTRACTION (TESE) EVEN AFTER FREEZING-THAWING 

PROCEDURE. 

F. Calzi, E. Rabellotti, I. Cino, E. Gismano, C. Brigante, L. De Santis. 

Obstetrics and Gynecology, I.R.C.C.S. Ospedale San Raffaele, 

Milan, MI, Italy. 

P-490 PENTOXIFYLLINE ACTIVATES SPERM MOTILITY IN 

TESTICULAR SPERM FROM PATIENT WITH PRIMARY CILIARY 

DYSKINESIA RESULTING IN TWIN LIVE BIRTH THROUGH IVF-ICSI. 

J. L. Phy 1 , L. K. Smith 2 , J. O. Dorsett 2 . 1 Obstetrics and Gynecology, 

Texas Tech University Health Sciences Center, Lubbock, TX; 2 The 

Centre for Reproductive Medicine, Lubbock, TX. 

P-491 IS SPERM DNA FRAGMENTATION A HIDDEN MALE 

FACTOR IN HUMAN INFERTILITY? 

V. Rawe 1 , C. M. Sueldo 3 , L. Blanco 2 , L. Kanzepolsky 2 , M. Perco 2 , 

C. Sueldo 3 . 1 CREA Reproductive Medicine, Valencia, Spain; 

2 Procrearte, Buenos Aires, Argentina; 3 Ob-Gynecology Department, 

University of California San Francisco-Fresno, Fresno, CA. 

P-492 ANALYSIS OF HUMAN SPERM QUALITY DURING THE 

LAST 5 YEARS IN A SPERM DONATION PROGRAMME. 

C. Gonzalez-Ravina 1 , T. de Ruz 1 , A. Pellicer 2 , N. Prados 1 , M. 

Fernandez-Sanchez 1 . 1 Laboratory of Andrology, IVI Sevilla, Sevilla, 

Spain; 2 Medical-Gynecologist, IVI Valencia, Valencia, Spain. 

P-493 EFFECT OF ANTIOXIDANT AND OXIDATIVE STRESS ON 

THE OUTCOME OF INTRACYTOPLASMIC SPERM INJECTION 

CYCLES. 

M. Nichi 1 , D. Braga 2,3 , A. Setti 2,3 , P. Goes 1 , A. Dalmazzo 1 , E. Borges, 

Jr 2,3 . 1 Animal Reproduction Department, University of Sao Paulo, Sao 

Paulo, Brazil; 2 Fertility - Assisted Fertilization Center, Sao Paulo, Brazil; 

3 Sapientiae Institute - Educational and Research Center in Assisted 

Reproduction, Sao Paulo, Brazil. 

P-494 LONG TERM FOLLOW-UP OF A RANDOMIZED 

CONTROLLED TRIAL ON THE EFFECT ON VARICOCELECTOMY. 

Z. Brown 1 , C. J. G. Wensing 4 , W. P. Th. M. Mali 2 , E. R. te Velde 3 , H. 

C. Romijn 1 , J. S. E. Laven 1 . 1 Division of Reproductive Medicine, 

Department of Obstetrics and Gynaecology, Erasmus Medical 

Centre, Rotterdam, Zuid-Holland, Netherlands; 2 Department of 

Radiology, University Medical Centre Utrecht, Utrecht, Netherlands; 

3 Department of Public Health, Erasmus Medical Centre, Rotterdam, 

Zuid-Holland, Netherlands; 4 Faculty of Veterinary Sciences, University 

Medical Centre Utrecht, Utrecht, Netherlands. 

P-495 EFFECT OF DIETARY DHA SUPPLEMENTATION ON 

SPERM DNA INTEGRITY. 

J. C. Martinez-Soto 1 , J. C. Domingo 2 , B. Cordobilla 2 , L. Palbero 1 , A. 

Pellicer 3 , J. Landeras 1 . 1 IVI Murcia, Murcia, Spain; 2 Biochemistry and 

Molecular Biology, University of Barcelona, Barcelona, Spain; 3 IVI 

Valencia, Valencia, Spain. 

P-496 RELATIONSHIP BETWEEN SEMEN PARAMETERS AND 

OUTCOME OF INTRAUTERINE INSEMINATION (IUI). 

J. Biggs 1 , K. S. Richter 2 , J. Osheroff 2 , E. A. Widra 2 . 1 Department of 

Obstetrics and Gynecology, Georgetown University Hospital,

Washington, DC; 2 Shady Grove Fertility Reproductive Science 

Center, Rockville, MD. 

P-497 DECLINING QUALITY ON SEMEN COLLECTED FOR 

ICSI CYCLE WHEN COMPARED TO PREVIOUS SEMEN ANALYSIS 

COLLECTED FOR INFERTILITY EVALUATION. 

F. Pasqualotto 1 , E. Borges, Jr 2,3 , D. Braga 2,3 , R. Ferreira 2 , A. Iaconelli, 

Jr 2 , E. Pasqualotto 1 . 1 University of Caxias do Sul, Caxias do Sul, RS, 

Brazil; 2 Fertility - Assisted Fertilization Center, Sao Paulo, SP, Brazil; 

3 Sapientiae Insitute - Educational and Research Center in Assisted 

Reproduction, Sao Paulo, SP, Brazil. 

P-498 IMPROVED PREGNANCY RATES IN MALE FACTOR BY 

HYALURONIC ACID BINDING SPERM SELECTION AND MSOME 

IN ART. 

S. Cubillos 1 , S. Sanchez 1 , J. Pedraza 1 , F. Caldiño 1 , S. Cuneo 1 . 

1 Laboratorio de Reproduccion Asistida SA de CV, Concibe 

Reproduccion Asistida, Mexico, DF, Mexico; 2 Clinica de 

Reproduccion Asistida SA de CV, Concibe Reproduccion Asistida, 

Mexico, DF, Mexico. 

P-499 COMPARISON OF FERTILITY OUTCOME OF TESTICULAR 

VS. EJACULATED SPERM IN VIRTUAL AZOOSPERMIA. 

R. Hauser 1 , L. Yogev 1 , A. Bothan 1,2 , H. Yavetz 1 , A. Amit 2 , D. Ben-Yosef 2 . 

1 The Institute for the Study of Fertility, Lis Maternity Hospital, Tel Aviv 

Medical Center, Tel Aviv, Israel; 2 IVF Unit, Lis Maternity Hospital, Tel 

Aviv Medical Center, Tel Aviv, Israel. 

P-500 SPERM HEAD BIREFRINGENCE SELECTION AND 

ANEUPLOIDY. 

L. D. Vagnini 1 , C. G. Petersen 1,2,3 , A. L. Mauri 1,2 , R. Baruffi 1,2 , J. B. 

A. Oliveira 1,2,3 , J. G. Franco, Jr 1,2,3 . 1 Paulista Center for Diagnosis, 

Research and Training, Ribeirao Preto, Sao Paulo, Brazil; 2 Center 

For Human Reproduction Prof. Franco Jr., Ribeirao Preto, Sao 

Paulo, Brazil; 3 Department of Gynecology and Obstetrics, Botucatu 

Medical School São Paulo State University - UNESP, Botucatu, Sao 

Paulo, Brazil. 

P-501 CLINICAL UTILITY OF REACTIVE OXYGEN SPECIES AS A 

DIAGNOSTIC TEST IN THE EVALUATION OF MALE INFERTILITY. 

A. Agarwal, R. K. Sharma, A. Thiyagarajan, S. Gupta, E. Sabanegh. 

Center for Reproductive Medicine, Glickman Urological and 

Kidney Institute and Obstetrics & Gynecology and Women’s Health 

Institute, Cleveland, OH. 

P-502 MALE FACTOR INFERTILITY: DIAGNOSTIC VALUE AND 

RELATIONSHIP BETWEEN CHROMATIN STRUCTURE, MOTILITY 

ATTRIBUTES AND HYALURONIC ACID BINDING SCORE IN 

HUMAN SPERMATOZOA. 

G. B. Huszar 1 , D. Rien 2 , W. Murk 1 , M. Tekcan 1 , N. Sayme 2 . 1 Dept. 

Obstetrics, Gynecology and Reproductive Sciences, Yale University, 

School of Medicine, New Haven, CT; 2 In Vitro Fertilization Center, 

Team-Kinderwunsch-Hanover, Hanover, Germany. 

P-503 COMPARING THE SPERM DNA DECONDENSATION 

(SDDSM) AND SPERM DNA ACCELERATED DECONDENSATION 

(SDADSM) TESTS’ CAPACITY FOR IDENTIFYING INFERTILE MALES 

LIKELY TO BENEFIT FROM ANTI-OXIDANT TREATMENT. 

D. B. Brown 1 , K. M. Gelman 2 , G. F. Whitman-Elia 3 , M. A. Witt 4 , R. J. 

Kordus 3 , S. J. Roseff 5 . 1 AndroJek, Inc., Fort Lauderdale, FL; 2 Infertility 

and Reproductive Medicine of South Broward, Cooper City, 

FL; 3 Advanced Fertility and Reproductive Endocrinology, West 

Columbia, SC; 4 Reproductive Biology Associates, Atlanta, GA; 5 Palm 

Beach Center for Reproductive Medicine, Wellington, FL. 

__________________________________________________________ 

SPERM PREPARATION 

P-504 ULTRA-FAST THAWING OF CRYOPRESERVED SEMEN 

IMPROVES SPERM MOTILITY AND YIELDS LOWER PROPORTIONS 

OF SPERMATOZOA WITH LOW MITOCHONDRIAL POTENTIAL. 

T. S. de Paula1 , A. M. Rocha1 , C. M. Mendes2 , M. E. O. A. D’Ávila2 , P. 

Serafini1,3 , E. L. A. Motta1,4 . 1Huntington Medicina Reprodutiva, São 

Paulo, Brazil; 2Departamento de Reprodução Animal, Faculdade 

de Medicina Veterinária e Zootecnia da Universidade de São 


156 

Paulo, São Paulo, Brazil; 3 Disciplina de Ginecologia, Faculdade 

de Medicina da Universidade de São Paulo, São Paulo, Brazil; 

4 Departamento de Ginecologia, Universidade Federal de São 

Paulo, São Paulo, Brazil. 

P-505 SPERM CAN TAKE THE HEAT BUT NOT THE COLD. 

R. E. Slifkin 1 , C. A. McDonald 1 , L. Valluzzo 1 , A. B. Copperman 1,2 , J. 

Barritt 1,2 . 1 Reproductive Medicine Associate of New York, New York, 

NY; 2 Department of OBGYN and Reproductive Science, Mount Sinai 

School of Medicine, New York, NY. 

P-506 MODIFIABLE FACTORS THAT MAY IMPROVE MOTILE 

YIELD IN SPERM CRYOPRESERVATION. 

J. M. Hotaling, C. H. Muller, E. R. Pagel, H. J. Christianson, T. J. Walsh. 

Department of Urology, University of Washington, Seattle, WA. 

P-507 A NOVEL CLOSED SYSTEM VIAL WITH SENTINEL TEST 

SEGMENT FOR SPERM CRYOPRESERVATION. 

E. J. Woods 1,2 , L. Newton 1 , J. K. Critser 1,3 . 1 General BioTechnology, 

LLC, Indianapolis, IN; 2 Microbiology and Immunology, Indiana 

University School of Medicine, Indianapolis, IN; 3 College of 

Veterinary Medicine, University Of Missouri, Columbia, MO. 

P-508 EFFECT OF SEMEN SAMPLE COLLECTION SITE 

ON SEMEN ANALYSIS PARAMETERS AND INTRAUTERINE 

INSEMINATION (IUI) PREGNANCY RATES. 

J. M. Biggs 1 , K. S. Richter 2 , J. Osheroff 2 , E. A. Widra 2 . 1 Department 

of Obstetrics and Gynecology, Georgetown University Hospital, 

Washington, DC; 2 Shady Grove Fertility Reproductive Science 

Center, Rockville, MD. 

__________________________________________________________ 

STEM CELLS 

P-509 VITRIFICATION OF MOUSE EMBRYO DERIVED ICM 

CELLS: A TOOL FOR PRESERVING EMBRYONIC STEM CELL 

POTENTIAL? 

N. Desai, J. Xu, T. Tsulaia, J. Szeptycki, T. Falcone, J. Goldfarb. 

OB-GYN/Women’s Health Institute, Cleveland Clinic Foundation, 

Beachwood, OH. 

P-510 LACK OF CHECKPOINT CONTROL IN HUMAN 

PLURIPOTENT STEM CELLS: A CAUSE FOR GENOMIC 

INSTABILITY? 

G. Ambartsumyan 1,2 , D. Conway 1 , J. Vincent 3 , A. Clark 2,3 . 1 Ob/Gyn, 

UCLA, Los Angeles, CA; 2 MCDB, UCLA, Los Angeles, CA; 3 MBI, UCLA, 

Los Angeles, CA. 

P-511 DIFFERENTIATION EFFICIENCY INTO GERM- 

LINEAGE CELL FROM PLURIPOTENT STEM CELLS BY BONE 

MORPHOGENETIC PROTEIN (BMP)-4 AND/OR RETINOIC ACID 

(RA). 

Y. E. Go1 , H. J. Lee2 , J. H. Jo1 , S. H. Song2 , Y. S. Kim2 , D. R. Lee1,2 . 

1Department of Biomedical Science, Seoul, Republic of Korea; 

2Fertility Center of CHA Gangnam Medical Center, Seoul, Republic 

of Korea. 

P-512 THE ENRICHMENT OF SPERMATOGONIAL STEM CELLS- 

LIKE CELLS FROM HUMAN EMBRYONIC STEM CELLS. 

J. J. Lim, H. J. Kim, M. S. Shim, J. H. Jo, T. K. Yoon, D. R. Lee. Fertility 

Center of CHA Gangnam Medical Center, Seoul, Republic of Korea. 

P-513 ENDOCRINE AND EPIGENETIC CONTROL 

OF TROPHECTODERM (TE) DIFFERENTIATION FROM 

HUMAN EMBRYONIC STEM CELLS (hESCs): THE ROLE OF 

BONE MORPHOGENIC PROTEIN (BMP4) AND HISTONE 

DEACETYLASES (HDACs). 

T. M. Erb 1 , S. E. Mucko 1 , C. Schneider 1 , P. J. Sammak 2 . 1 Obstetrics, 

Gynecology, and Reproductive Sciences, University of Pittsburgh 

Medical Center, Pittsburgh, PA; 2 Department of Cell Biology and 

Physiology, University of Pittsburgh, Pittsburgh, PA.

P-514 PRIMORDIAL GERM CELL DERIVATION FROM MOUSE 

iPS CELLS AND ASSOCIATED EPIGENETIC CHANGES. 

X. Li 1 , J. Deng 2,3 , L. Sun 1 , D. Diep 3 , K. Zhang 3 , B. Beutler 1 . 1 Department 

of Genetics, The Scripps Research Institute, La Jolla, CA; 2 Obstetric 

& Gynecology Department, Wayne State University, School of 

Medicine, Detroit, MI; 3 Bioengineering Department, University of 

California, San Diego, La Jolla, CA. 

__________________________________________________________ 

ART - IN VITRO FERTILIZATION 

P-515 PERINATAL OUTCOME OF 2140 SINGLETONS BORN 

FROM TRANSFER OF FROZEN-THAWED EMBRYOS (FET) 

CONCEIVED BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART): 

A FRENCH CONTROL STUDY 1998-2008. 

S. Epelboin1 , E. Devouche2 , H. Pejoan3 , G. Viot4 , G. Apter- 

Danon5 , Scientific Committee AMP-Vigilance Reseau Follow-Up6 . 

1Gynecology Obstetrics & ART, Hôpital Bichat-Claude Bernard, 

Paris, Ile de France, France; 2Université Paris-Descartes, Paris, Ile 

de France, France; 3Gynecology Obstetrics & Paediatrics, Hôpital 

Beaujon, Clichy, Ile de France, France; 4Obstetrics Paediatrics & 

Genetics, Hôpital Cochin-Saint Vincent de Paul, Paris, Ile de France, 

France; 5Child Psychiatry, Hôpital Jean Rostand, Sèvres, Ile de 

France, France; 6Reseau Follow-Up, Poissy, Ile de France, France. 

P-516 DAY 3 VS BLASTOCYST EMBRYO TRANSFER: EXTENDED 

EMBRYO CULTURE IS ASSOCIATED WITH AN INCREASED RISK 

OF PRETERM DELIVERY. 

S. Kansal Kalra 1 , S. J. Ratcliffe 2 , K. T. Barnhart 1,2 , C. Coutifaris 1 . 

1 Reproductive Endocrinology, University of Pennsylvania, 

Philadelphia, PA; 2 Center for Clinical Epidemiology and Biostatistics, 

University of Pennsylvania, Philadelphia, PA. 

P-517 ELEVATED ESTRADIOL LEVELS IN AFRICAN-AMERICAN 

WOMEN MAY EXPLAIN THE REDUCED LIVE BIRTH RATES 

FOLLOWING ASSISTED REPRODUCTION. 

K. S. Moon 1 , J. M. Csokmay 1 , A. Y. Armstrong 1 , J. H. Segars 1 , B. J. 

Stegmann 2 . 1 Program in Reproductive and Adult Endocrinology, 


Human Development, Bethesda, MD; 2 Department of Obstetrics 

and Gynecology, Division of Reproductive Endocrinology and 

Infertility, University of Iowa Hospitals and Clinics, Iowa City, 

IA; 3 Department of Obstetrics and Gynecology, Division of 

Reproductive Endocrinology and Infertility, Walter Reed Army 

Medical Center, Washington, DC. 

P-518 THE EFFECT OF SUPPLEMENTATION WITH OMEGA- 

3-POLYUNSATURATED FATTY ACIDS IN INTRACYTOPLASMIC 

SPERM INJECTION CYCLES FOR INFERTILE PATIENTS WITH A 

HISTORY OF UNEXPLAINED TOTAL FERTILIZATION FAILURE. 

C.-H. Kim, J.-W. Yoon, J.-W. Ahn, H.-J. Kang, J.-W. Lee, B.-M. Kang. 

Obstetrics and Gynecology, Asan Medical Center, University of 

Ulsan, Seoul, Korea. 

P-519 ARE THERE PROVIDER-DEPENDENT DIFFERENCES 

IN THE LEARNING CURVE FOR PROFICIENCY WITH OOCYTE 

RETRIEVALS? 

K. S. Moon 1 , B. J. Stegmann 2 , B. J. Yauger 3 , J. H. Segars 1 . 1 Program 

in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver 


Bethesda, MD; 2 Department of Obstetrics and Gynecology, Division 

of Reproductive Endocrinology and Infertility, University of Iowa 

Hospitals and Clinics, Iowa City, IA; 3 Department of Obstetrics and 


Walter Reed Army Medical Center, Washington, DC. 

P-520 FT-IR SPECTROSCOPIC METABOLIC FINGERPRINTIG 

OF HUMAN EMBRYO CULTURE MEDIA COMBINED WITH 

MULTIVARIATE STATISTICAL ANALYSIS TO DISCRIMINATE 

EMBRYOS WITH DIFFERENT REPRODUCTIVE POTENTIAL. 

M. Garcea 1 , M. Gomez Peña 1 , A. Bosch 2 , P. Martina 2 , O. Yantorno 2 , 

C. Bisioli 1 . 1 Pregna Medicina Reproductiva, Ciudad Autonama de 

Buenos Aires, Buenos Aires, Argentina; 2 CINDEFI, Centro Biología 

Aplicada CONICET, La Plata, Buenos Aires, Argentina. 


157 

P-521 COMPARISON OF THE ULTRASHORT GONADOTROPIN- 

RELEASING HORMONE AGONIST-ANTAGONIST PROTOCOL 

WITH MICRODOSE FLARE -UP PROTOCOL IN POOR 

RESPONDERS: A PRELIMINARY STUDY. 

B. Berker1 , C. Iltemir Duvan2 , C. Kaya3 , R. Aytac1 , H. Satiroglu1 . 

1Centre of Artificial Reproduction, Ankara University, Ankara, Turkey; 

2Centre of Artificial Reproduction, Fatih University, Ankara, Turkey; 

3Department of Obstetrics and Gynecology, Ufuk University, Ankara, 

Turkey. 

P-522 ENDOMETRIAL POLYPS SMALLER THAN 2 CM 

INCREASE THE RISK OF BIOCHEMICAL PREGNANCY IN IN- 

VITRO FERTILIZATION (IVF) CYCLES. 

R. T. Abdallah 1 , T. Singer 1 , J. Huang 1 , R. Kudesia 2 , Z. Rosenwaks 1 , S. 

M. D. Spandorfer 1 . 1 The Center for Reproductive Medicine and 

Infertility, Weill Cornell Medical College, New York, NY; 2 Obsterics 

and Gynecology, Weill Cornell Medical College, New York, NY. 

P-523 THE PROBABILITY OF CONCEPTION AFTER 

GONADOTROPIN RELEASING HORMONE (GnRH) AGONIST 

TRIGGER IN HIGH RESPONDERS WITH PEAK ESTRADIOL (E 2 ) 

LEVELS < OR ≥ 4000 PG/ML. 

N. E. Kummer, J. S. Mann, A. A. Elassar, J. C. Nulsen, C. A. Benadiva, 

L. L. Engmann. Obstetrics and Gynecology, Division of Reproductive 

Endocrinology and Infertility, University of Connecticut, Farmington, 

CT. 

P-524 LUTEAL SUPPLEMENTATION WITH A WEEKLY 

PROGESTERONE VAGINAL RING IN INFERTILE WOMEN 

UNDERGOING IN VITRO FERTILIZATION (IVF). 

L. A. Stadtmauer 1 , K. Z. Reape 2 , H. Shu 2 . 1 Jones Institute for 

Reproductive Medicine at Eastern Virginia Medical School, Norfolk, 

VA; 2 Teva Women’s Health Research and Development, Horsham, 

PA. 

P-525 FACTORS PREDICTING SUCCESSFUL INDUCTION OF 

OOCYTE MATURATION AFTER GONADOTROPIN RELEASING 

HORMONE AGONIST (GnRH) TRIGGER. 

N. E. Kummer, J. S. Mann, A. A. Elassar, J. C. Nulsen, C. A. Benadiva, 

L. L. Engmann. Obstetrics and Gynecology, Division of Reproductive 

Endocrinology and Infertility, University of Connecticut Health 

Center, Farmington, CT. 

P-526 MATERNAL AGE AND INSEMINATION METHOD HAVE 

SIGNIFICANT IMPACT ON THE INCIDENCE OF POLY-PRONULCEI 

(PPN). 

W.-S. A. Wun, R. C. Dunn, L. M. Schenk, R. K. Mangal, S. R. Chauhan, 

G. M. Grunert. Fertility Specialists of Houston, Houston, TX. 

P-527 SUCCESS OF ESSURE© MICRO-INSERTS IN THE 

TREATMENT OF HYDROSALPINX PRIOR TO IN VITRO 

FERTILIZATION (IVF)/FROZEN EMBRYO TRANSFER (FET) AND 

PREGNANCY OUTCOMES. 

J. E. Nichols1, J. R. West2. 1Piedmont Reproductive Endocrinology 

Group (PREG), Greenville, SC; 2Conceptus, Inc., Mountain View, CA. 

P-528 IN VITRO FERTILISATION OPTIMISATION: A STRUCTURED 

APPROACH TO REMOVING VARIATION DURING THE IN VITRO 

CULTURE PROCESS USING THE SIX SIGMA INDUSTRIAL MODEL. 

P. B. Kelly, C. Hughes, G. Emerson, E. Mocanu. Hari Unit, Dublin, 

Ireland. 

P-529 THE NATURAL HISTORY OF INFERTILITY TREATMENT IN 

A STATE WITH MANDATED INSURANCE COVERAGE: THE FAST 

TRACK AND STANDARD TREATMENT (FASTT) TRIAL. 

M. B. Goldman 1 , M. M. Regan 2 , M. J. Berger 3 , S. P. Oskowitz 3 , 

R. H. Reindollar 1 . 1 Department of Obstetrics & Gynecology, 

Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2 Biostatistics & 

Computational Biology, Dana-Farber Cancer Institute, Boston, MA; 

3 Boston IVF, Waltham, MA.

P-530 A PROMISING NUCLEAR TRANSFER TECHNIQUE FOR 

REPAIRING AGED OOCYTES. 

A. Tanaka 1 , M. Nagayoshi 1 , S. Awata 1 , I. Tanaka 1 , H. Kusunoki 2 , S. 

Watanabe 3 . 1 Saint Mother Hospital, Kitakyushu, Fukuoka, Japan; 

2 Faunal Diversity Sciences, Graduate School of Agriculture, Kobe 

University, Kobe, Hyogo, Japan; 3 Department of Anatomical 

Science, Hirosaki University Graduate School of Medicine, Hirosaki, 

Aomori, Japan. 

P-531 OOCYTE VITRIFICATION: REPRODUCTIVE OUTCOME IN 

PATIENTS WITH LOW NUMBER OF OOCYTES. 

M. Guidobono 1 , E. P. Lombardi 2 , L. M. Augé 2 , M. P. Zappacosta 2 , L. V. 

Sícaro 2 , E. Young 2 . 1 Biology Lab, Instituto de Ginecología y Fertilidad 

- IFER, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina; 

2 Department of Gynecology and Infertility, Instituto de Ginecología 

y Fertilidad - IFER, Ciudad Autónoma de Buenos Aires, Buenos Aires, 

Argentina. 

P-532 THE EFFECT OF BLASTULATION DAY ON OUTCOME OF 

FRESH AUTOLOGOUS BLASTOCYST TRANSFERS AND TRANSFERS 

OF BLASTOCYSTS DERIVED FROM THAWED BIPRONUCLEAR 

OOCYTES. 

S. T. Daneshmand, B. S. Shapiro, F. C. Garner, M. Aguirre, C. Hudson. 

Fertility Center of Las Vegas, Las Vegas, NV. 

P-533 FERTILIZATION RATE OF SIBLING OOCYTES AFTER 

INTRACYTOPLASMIC SPERM INJECTION (ICSI) OR IN VITRO 

FERTILIZATION (IVF) ON PRIMARY INFERTILITY PATIENTS. 

M. Ribeiro 1 , C. Briton-Jones 1 , N. Buehler 1 , H. Danzer 2 , M. Surrey 2 , D. L. 

Hill 1 . 1 ART Reproductive Center, Beverly Hills, CA; 2 Southern California 

Reproductive Center, Beverly Hills, CA. 

P-534 EVALUATION THE EFFECT OF LOWERED INCUBATOR 

OXYGEN TENSION ON EMBRYO QUALITY. 

C. Madaschi 1 , P. Guilherme 1 , C. P. M. Izzo 2 , L. Y. Yamakami 3 , 

G. Fassolas 2 , C. R. Izzo 2 . 1 Embriology, Centro de Reprodução 

Humana - Originare, São Paulo, Brazil; 2 Clinical Director, Centro de 

Reprodução Humana - Originare, São Paulo, Brazil; 3 Clinical, Centro 

de Reprodução Humana - Originare, São Paulo, Brazil. 

P-535 STUDY OF METHYLATION PATTERNS OF IMPRINTING 

GENES IN CHILDREN BORN AFTER ASSISTED REPRODUCTIVE 

TECHNOLOGIES SHOWS NO IMPRINTING ERRORS. 

S.-L. Chen, H.-Y. Zheng, X.-Y. Shi, F.-R. Wu, Y.-Q. Wu, L.-L. Wang. 

Center for Reproductive Medicine, Gynecology and Obstetrics 

Department, Nanfang Hospital, Southern Medical University, 

Guangzhou, Guangdong, China. 

P-536 AUTOMATED SPERM IMMOBILIZATION FOR HUMAN 

ICSI. 

C. Leung1 , Z. Lu1 , N. Esfandiari2 , R. Casper2 , Y. Sun1 . 1Advanced Micro 

and Nanosystems Lab, University of Toronto, Toronto, ON, Canada; 

2Department of Obstetrics and Gynaecology, University of Toronto, 

Toronto, ON, Canada. 

P-537 EFFECT OF TIME BETWEEN hCG INJECTION AND EGG 

RETRIEVAL IS AGE DEPENDENT. 

D. E. Reichman, S. A. Missmer, K. F. Berry, E. S. Ginsburg, C. Racowsky. 

Department of Obstetrics, Gynecology and Reproductive Biology, 

Brigham and Women’s Hospital, Boston, MA. 

P-538 EXPRESSION OF GENES LINKED TO ADVERSE 

PREGNANCY OUTCOME IN ASSISTED REPRODUCTIVE 

TECHNOLOGY (ART). 

K. M. Brennan 1,2 , F.-T. Kuo 1 , K. Fan 1 , J. Williams III 1 , C. Alexander 1,2 , M. 

D. Pisarska 1,2 . 1 Obstetrics and Gynecology, Division REI, Cedars Sinai 

Medical Center, Los Angeles, CA; 2 Obstetrics and Gynecology, 

Division REI, UCLA, Los Angeles, CA. 

P-539 ELECTIVE SINGLE EMBRYO TRANSFER (eSET) IS AN 

EFFECTIVE APPROACH TO MINIMIZE MULTIPLE PREGNANCIES 

IN HIGH RISK PATIENTS. 

C. M. Briton-Jones 1 , H. Danzer 2 , M. Surrey 2 , D. L. Hill 1 . 1 ART 

Reproductive Center, Beverly Hills, CA; 2 Southern California 

Reproductive Center, Beverly Hills, CA. 


158 

P-540 COMPARISON OF NATURAL CYCLES VERSUS 

MODIFIED NATURAL CYCLES IN POOR RESPONDERS 

UNDERGOING IVF. 

J. Y. J. Huang, T. Singer, R. Abdallah, E. Rauch, Z. Rosenwaks, S. 

Spandorfer. The Ronald O Perelman and Claudia Cohen Center for 

Reproductive Medicine, Weil Cornell Medical College, New York, 

NY. 

P-541 RETROSPECTIVE HEALTH STUDY ON 278 BABIES 

CONCEIVED FOLLOWING CRYOPRESERVED SPERMATID 

INJECTION INTO AN ELECTRICALLY STIMULATED OOCYTE. 

A. Tanaka, M. Nagayoshi, S. Awata, M. Sasaki, I. Tanaka. Saint 


P-542 ARE CRATER ON THE SURFACE OF HUMAN 

SPERM HEADS PHYSIOLOGICAL CHANGES DURING 

SPERMIOGENESIS? 

H. Kusunoki 2 , A. Tanaka 1 , M. Nagayoshi 1 , S. Awata 1 , I. Tanaka 1 , S. 

Watanabe 3 . 1 Saint Mother Hospital, Kitakyushu, Fukuoka, Japan; 


University, Kobe, Hyogo, Japan; 3 Department of Anatomical 

Science, Hirosaki University School of Medicine, Hirosaki, Aomori, 

Japan. 

P-543 COULD THE PERCENTAGE OF NORMAL SPERM AFFECT 

THE CLINICAL OUTCOMES IN CONVENTIONAL IN VITRO 

FERTILIZATION (IVF)? 

D. Pabón 1 , M. Molla 1 , M. Ojeda 1 , J. M. Gacías 1 , A. Pellicer 2 , E. 

Muñoz 1 . 1 Clinic IVI-VIGO, Vigo, Pontevedra, Spain; 2 Clinic IVI, 


P-544 ARTIFICIAL NEURAL NETWORKS FOR THE PREDICTION 

OF IVF OUTCOME USING CLINICAL AND MORPHOLOGICAL 

DATA. 

G. A. Bello 1 , M. G. Rodríguez 1 , M. T. Olivieri 2 , E. H. Rosemberg 2 , 

S. Bronfenmajer 2 . 1 School of Systems Engineering, Universidad 

Metropolitana, Caracas, Miranda, Venezuela; 2 Department of 

Infertility and Gynecology, EMBRIOS, Centro de Fertilidad, Hospital 

de Clinicas Caracas, Caracas, DF, Venezuela. 

P-545 CLINICAL OUTCOME OF WOMEN "37 YEARS WITH 

HYPOGONADOTROPIC HYPOGONADISM UNDERGOING 

INTRACYTOPLASMIC SPERM INJECTION AND IN-VITRO 


N. Dokuzeylul, S. Kahraman, G. Karlikaya, H. Karagozoglu, M. 

Kavrut, A. Ersahin. ART and Reproductive Genetics Center, Istanbul 

Memorial Hospital, Istanbul, Turkey. 

P-546 COMPARISON OF THE SIZE OF THE LEADING FOLLICLE 

AS ASSESSED BY CONVENTIONAL AND AUTOMATED FOLLICLE 

MEASUREMENT METHODS IN WOMEN UNDERGOING 

CONTROLLED OVARIAN STIMULATION FOR IVF. 

B. Ata, E. Shalom Paz, A. Seyhan, S. L. Reinblatt, S. Krishnamurthy, 

S. L. Tan. McGill Reproductive Centre, Dept. of Obstetrics and 

Gynecology, McGill University, Montreal, QC, Canada. 

P-547 ASSESMENT OF CHANGES IN UTERINE AND 

SUBENDOMETRIAL BLOOD FLOWS: THE USE OF PREDICTION 

OUTCOME IN IVF CYCLES. 

A. F. Turkcapar, O. Moraloglu, T. Ozdener, B. Seckin, M. Ugur. Zekai 

Tahir Burak Women’s Health Research and Education Hospital,, 


P-548 PROTEOMIC ANALYSES OF SEMINAL PLASMA AND 

ITS CORRELATION TO PREGNANCY OUTCOME IN IN VITRO 

FERTILIZATION CYCLES. 

T. B. Soler, E. G. Lo Turco, P. T. Del Giudice, B. F. da Silva, R. P. Bertolla, 

A. P. Cedenho. Division of Urology, Human Reproduction Section, 

Sao Paulo Federal University, Sao Paulo, SP, Brazil.. 

__________________________________________________________

ART - PROCEDURES & TECHNIQUES, CLINICAL 

P-549 FIVE-YEAR EXPERIENCE WITH A SINGLE EMBRYO 

TRANSFER (SET) POLICY. 

J. D. K. Kresowik, B. J. Stegmann, A. E. T. Sparks, G. L. Ryan, B. J. 

Van Voorhis. Obstetrics & Gynecology, Division of Reproductive 

Endocrinology & Infertility, University of Iowa Hospitals & Clinics, Iowa 

City, IA. 

P-550 SERUM ANTI-MULLERIAN HORMONE LEVELS 

CORRELATES WITH OVARIAN RESPONSE IN PATIENTS WITH 

HYPOGONADOTROPIC HYPOGONADISM: A PREMILIMINARY 

STUDY. 

M. Sönmezer, B. Ozmen, E. G. Papuccu, S. Ozkavukcu, C. S. 

Atabekoglu. Obstetrics and Gynecology, University of Ankara, 


P-551 IS THE TYPE OF ANESTHESIA USED FOR OOCYTE 

RETRIEVAL ASSOCIATED WITH IVF OUTCOME? A RANDOMIZED 

CONTROLLED TRIAL. 

E. Gouziomitrou, E. Kolibianakis, S. Triantafillidis, S. Masouridou, A. 

Mitsoli, B. Tarlatzis. Unit for Human Reproduction, 1st Dept Ob/Gyn, 

Aristotle University of Thessaloniki, Thessaloniki, Greece. 

P-552 TRANSABDOMINAL FOLLICULAR ASPIRATION FOR 

PATIENTS WITH OVARIES INACCESSIBLE BY TRANSVAGINAL 

ULTRASOUND. 

S. E. Barton 1 , J. A. Politch 2 , C. B. Benson 3 , E. S. Ginsburg 1 , A. 

R. Gargiulo 1 . 1 Department of Obstetrics, Gynecology, and 

Reproductive Biology, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA; 2 Department of Obstetrics and 

Gynecology, Boston University School of Medicine, Boston, MA; 

3 Department of Radiology, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA. 

P-553 UNTIMELY CUMULUS REMOVAL AFFECTS OOPLASMIC 

COMPETENCE. 

J. Kocent, D. Monahan, Q. V. Neri, Z. Rosenwaks, G. D. Palermo. 

The Ronald O Perelman & Claudia Cohen Center for Reproductive 

Medicine, Weill Cornell Medical College, New York, NY. 

P-554 DIRECT VISUALIZATION OF METAPHASE-II 

CHROMOSOMES IN HUMAN OOCYTES UNDER AN INVERTED 

MICROSCOPE. 

A. Tanaka 1 , M. Nagayoshi 1 , S. Awata 1 , M. Sasaki 1 , I. Tanaka 1 , H. 

Kusunoki 2 . 1 Saint Mother Hospital, Kitakyushu, Fukuoka, Japan; 


University, Kobe, Hyogo, Japan. 

P-555 OPTIMAL TIME FOR ICSI AFTER hCG ADMINISTRATION 

AND OOCYTE INCUBATION PERIOD. 

I. Obeso 1 , J. Rosales 1 , G. García 1 , R. M. D. Santos 1 , P. M. D. Galache 1 , 

P. Patrizio 2 . 1 Instituto para el Estudio de la Concepción Humana, 

Monterrey, Nuevo León, Mexico; 2 Yale Fertility Center, New Haven, 

CT. 

P-556 HIGHLY PURIFIED HUMAN MENOTROPIN (HP-hMG) 

VERSUS RECOMBINANT FOLLICLE STIMULATING HORMONE 

(rFSH): A SYSTEMATIC REVIEW AND META-ANALYSIS. 

S. Agramunt1 , M. A. Checa1 , J. J. Espinós2 , A. Requena3 , R. Carreras1 . 

1Obstetrics and Gynecology Department, Hospital del Mar - Parc 

de Salut Mar, Barcelona, Spain; 2Obstetrics and Gynecology 

Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 

3Instituto Valenciano de Infertilidad, IVI Madrid, Aravaca, Madrid, 

Spain. 

P-557 TRUNCATED IN VITRO FERTILIZATION (IVF) IN 

WOMEN WITH POLYCYSTIC OVARY SYNDROME RESULTS IN 

EQUIVALENT PREGNANCY RATES BUT LOWER RISK OF OVARIAN 

HYPERSTIMULATION SYNDROME COMPARED TO TRADITIONAL 

IVF. 

P. S. Uzelac1 , J. S. Archer2 , G. L. Christensen2 , H. C. Bohler2 , S. 

T. Nakajima2 . 1Napa Valley Fertility Center, Napa Valley, CA; 

2Obstetrics, Gynecology & Women’s Health, University of Louisville, 

Louisville, KY. 


159 

P-558 DEGENERATION AND POST-ICSI EMBRYONIC 

DEVELOPMENT OF HUMAN MII OOCYTE IN RELATION TO THEIR 

MATURITY AND MORPHOLOGICAL CHARACTERISTICS. 

C. Y. Park 1 , H. E. Ryu 1 , S. H. Min 1 , S. K. Choi 1 , C. Park 2 , K. R. Kim 2 . 

1 i-Dream (IVF) Laboratory, Mizmedi Hospital, Seoul, Korea; 2 i-Dream 

Clinic, Mizmedi Hospital, Seoul, Korea. 

__________________________________________________________ 

ART - PROCEDURES & TECHNIQUES, LABORATORY 

P-559 THE EFFECT OF LASER-ASSISTED HATCHING ON 

IMPLANTATION AND PREGNANCY RATES OF FROZEN-THAWED 

BLASTOCYSTS. 

B. E. Friedman1 , B. Behr1 , R. Sylla2 , V. L. Baker1 , L. M. Westphal1 , 

R. B. Lathi1 . 1Obstetrics and Gynecology, Stanford Fertility and 

Reproductive Medicine Center, Palo Alto, CA; 2School of Medicine, 

University of Toledo College of Medicine, Toledo, OH. 

P-560 A PROSPECTIVE RANDOMIZED STUDY COMPARING 

PERFORMANCE OF DAY 3 EMBRYOS UNDER A PHYSIOLOGICAL 

LOW OXYGEN ENVIRONMENT VS. A CONVENTIONAL CULTURE 

SYSTEM. 

M. Horton, M. Gomez Peña, D. S. Colaci, I. J. de Zuñiga, F. L. Sobral, 

C. A. Bisioli. Pregna Medicina Reproductiva, Buenos Aires, Caba, 

Argentina. 

P-561 INTRACYTOPLASMIC SPERM INJECTION OUTCOME 

VERSUS INTRACYTOPLASMIC MORPHOLOGICALLY SELECTED 

SPERM INJECTION OUTCOME: A META-ANALYSIS. 

A. Setti 1 , R. Ferreira 2 , D. Braga 1,2 , R. C. S. Figueira 2 , A. Iaconelli, Jr 2 , E. 

Borges, Jr 1,2 . 1 Sapientiae Institute - Educational and Research Center 

in Assisted Reproduction, Sao Paulo, SP, Brazil; 2 Fertility - Assisted 

Fertilization Center, Sao Paulo, SP, Brazil. 

P-562 HCV-POSITIVE INTENDED PARENTS MAY BE SAFELY 

USED FOR GESTATIONAL CARRIER CYCLES USING RT-PCR 

TESTING AND EXTENDED EMBRYO CULTURE. 

M. R. Thomas 1 , T. R. Ferguson 2 , D. Oliver 3 , D. G. Hammitt 2 , S. J. 

Chantilis 1 . 1 Dallas-Fort Worth Fertility Associates, Dallas, TX; 2 Texas 

Health Presbyterian Hospital Dallas, Dallas, TX; 3 Department of 

Pathology and Lab Medicine, UT Southwestern Medical School, 

Dallas, TX. 

P-563 DETERMINING THE EQUILIBRATION TIME OF HUMAN 

EMBRYO MICRODROP DISHES: IMPLICATIONS FOR THE IN 

VITRO FERTILIZATION (IVF) PRACTICE. 

J. Lowderman, C.-C. Chang, T. A. Elliott, J. Kahn, A. M. Fisher, Z. P. 


P-564 ODD CELL STAGE EMBRYOS: ARE THEY UNEQUAL? 

G. Paternot, S. Debrock, T. D’Hooghe, C. Spiessens. Gynecology, 

Leuven University Fertility Centre, UZ Leuven Gasthuisberg, Leuven, 

Belgium. 

P-565 COMPARISON OF 2 BLASTOCYST CULTURE MEDIA: 

BLASTASSIST AND GLOBAL MEDIA. 

T. V. Pam, H. Su, G. M. Grunert, R. C. Dunn, S. R. Chauhan, W.-S. A. 

Wun. Fertility Specialists of Houston, Houston, TX. 

__________________________________________________________ 

ART - OUTCOME PREDICTORS, CLINICAL 

P-566 CUMULATIVE LIVEBIRTH RATES (CLBR) IN INTRAUTERINE 

INSEMINATION (IUI) USING DONOR´S SPERM RELATED TO 

WOMEN´S AGE: A RETROSPECTIVE STUDY IN 7.122 CASES. 

A. Pacheco1 , N. Garrido2 , A. Pellicer2 , J. A. García-Velasco1 , E. 

Selles3 , C. Gonzalez-Ravina4 . 1Laboratory of Andrology, IVI Madrid, 

Madrid, Spain; 2Laboratory of Andrology, IVI Valencia, Valencia, 

Spain; 3Laboratory of Andrology, IVI Alicante, Alicante, Spain; 

4Laboratory of Andrology, IVI Sevilla, Sevilla, Spain. 

P-567 SERUM FSH MONITORING IN LETROZOLE-FSH IN VITRO 

FERTILIZATION CYCLES. 

K. Oktay 1 , S. Lee 1 , F. Moy 2 , E. Heytens 1 , H. M. Fourcade 1 . 1 Institute for 

Fertility Preservation/Department of Obstetrics & Gynecology, New

York Medical College, Valhalla, NY; 2 Biometrics, Data Management 

and PK/PD Unit/Department of Pathology, New York Medical 

College, Valhalla, NY. 

P-568 DONOR OOCYTE TO LIVE BIRTH EFFICIENCY IS 

ENHANCED BY DONOR SHARING. 

M. J. Levy, K. S. Richter, E. A. Widra, M. J. Tucker. Shady Grove Fertility 


P-569 HOW MANY MATURE EGGS FROM AN IN-VITRO 

FERTILIZATION CYCLE ARE ENOUGH TO TAKE HOME A BABY? 

B. McAvey 1,2 , A. Zapantis 2 , S. Jindal 1,2 , H. J. Lieman 1,2 , A. J. 

Polotsky 1,2 . 1 Obstetrics & Gynecology and Women’s Health, Albert 

Einstein College of Medicine, Bronx, NY; 2 Montefiore’s Institute for 

Reproductive Medicine and Health, Montefiore Medical Center, 

Hartsdale, NY. 

P-570 CYTOGENETIC STUDY IN EARLY SPONTANEOUS 

ABORTION AFTER IVF AND ICSI. 

S. Kawachiya 1 , Y. Takehara 1 , K. Kato 1 , H. Osada 1 , N. Aoyama 2 , O. 

Kato 1 . 1 Dept. of Reproduction, Kato Ladies Clinic, Tokyo, Japan; 

2 Perinatal Genetics, Kato Ladies Clinic, Tokyo, Japan. 

P-571 INTRAFOLLICULAR ANTI-MÜLLERIAN HORMONE 

CONCENTRATIONS OF THE PREOVULATORY FOLLICLE ARE 

PREDICTIVE OF THE IMPLANTATION POTENTIAL OF THE ENSUING 

EMBRYOS OBTAINED BY IN VITRO FERTILIZATION. 

A. Salerno, A. Nazzaro. Physiopathology of Human Reproduction, 

“G.Rummo” Hospital, Benevento, Italy. 

P-572 ANTIMULLERIAN HORMONE (AMH) EFFICIENCY 

CURVES: PREDICTING A THRESHOLD FOR PREGNANCY IN IN 

VITRO FERTILIZATION (IVF) CYCLES. 

R. H. Fogle 1 , O. R. Minkhorst 1 , J. P. Toner 1 , A. Z. Steiner 2 . 1 Atlanta 

Center for Reproductive Medicine, Atlanta, GA; 2 Obstetrics and 

Gynecology, University of North Carolina School of Medicine, 

Chapel Hill, NC. 


P-574 PREDICTORS OF PREGNANCY IN ASSISTED 

REPRODUCTIVE TECHNOLOGY (ART) BASED ON BASELINE 

CHARACTERISTICS: A RETROSPECTIVE ANALYSIS OF 9067 

CYCLES. 

P. Arvis1 , A. Guivarch1 , P. Lehert2 , E. Varlan3 . 1Clinique la Sagesse, 

Rennes, France; 2Faculty of Medecine, Melbourne, Victoria, 

Australia; 3Merck Serono, Lyon, France. 

P-575 ESTRADIOL (E2), PROGESTERONE (P), AND HUMAN 

CHORIONIC GONADOTROPIN (hCG) AS PREDICTORS OF 

PREGNANCY OUTCOME IN IN-VITRO FERTILIZATION (IVF). 

R. S. Weinerman, C. Mullin, J. A. Grifo. NYU Fertility Center, New York 

University School of Medicine, New York, NY. 

P-576 RACE SIGNIFICANTLY AFFECTS MULTIPLE PREGNANCY 

OUTCOMES IN AN IVF PROGRAM. 

I. B. Ressler, B. Scoccia, M. Fierro, N. Winston. Department of OB/ 

GYN, Division of Reproductive Endocrinology, University of Illinois 

College of Medicine, Chicago, IL. 

P-577 PREDICTORS OF CLINICAL PREGNANCY (CP) AFTER 

ELECTIVE SINGLE EMBRYO TRANSFER (eSBT). 

J. S. Mann, A. A. Elassar, N. E. Kummer, C. A. Benadiva, L. Engmann, 

J. C. Nulsen. Obstetrics and Gynecology, University of Connecticut, 

Farmington, CT. 

P-578 VARIATIONS IN GESTATIONAL AGE AT DELIVERY 

AND BIRTH WEIGHT IN INFANTS BORN AFTER ASSISTED 

REPRODUCTIVE TECHNOLOGIES BASED ON MATERNAL 

INFERTILITY DIAGNOSES. 

E. E. Eppsteiner, B. Stegmann, B. J. Van Voorhis, J. Blaine, A. Sparks. 

Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 

Iowa City, IA. 


160 

P-579 COMPARISON OF IVF OUTCOMES BETWEEN GnRH 

ANTAGONIST AND GnRH AGONIST LONG PROTOCOLS IN 

NORMO RESPONDER IVF PATIENTS. 

O. Oktem, R. Mercan, B. Balaban, B. Urman. Women’s Health 

Center Assisted Reproduction Unit, American Hospital, Istanbul, 

Turkey. 

P-580 OOCYTE TO BABY RATE: A NEW INDEX OF ART 

OUTCOME. 

G. de la Fuente, D. Agudo, M. Alonso, G. Kohls, A. Pellicer, J. García 

Velasco. Reproductive Medicine, IVI Madrid, Madrid, Spain. 

P-581 LIVE BIRTH RATES WITH INTRAUTERINE INSEMINATION 

(IUI) ARE NOT COMPROMISED WHEN THE SPECIMEN IS 

COLLECTED INTO DILUTING MEDIA (DM) AT HOME AND 

DELIVERED TO THE LAB UP TO 12 HOURS LATER. 

R. Pyrzak 1 , R. P. Dickey 1,2 . 1 The Fertility Institute of New Orleans, 

Mandeville, LA; 2 Obstetrics and Gynecology, Louisiana State 

University, New Orleans, LA. 

P-582 SINGLE BLASTOCYST TRANSFER MINIMIZES THE 

LIKELIHOOD OF MULTIPLE PREGNANCIES IN GOOD 

PROGNOSIS YOUNG IVF PATIENTS WITHOUT COMPROMISING 

PREGNANCY RATE. 

A. Nasseri1,2 , D. Chen1,2 , S. Talebian1,2 , K. B. Gleason1,2 . 1Obstetrics and Gynecology, The Valley Hospital Fertility Center, Paramus, NJ; 

2Obstetrics and Gynecology, New York University Fertility Center, 

New York, NY. 

P-583 CUMULATIVE LIVE BIRTH RATES (LBR) IN OOCYTE 

DONATION (DIVF) ARE NOT ADVERSELY AFFECTED BY AGE BUT 

DO REFLECT CLEAVAGE STAGE OF EMBRYOS TRANSFERRED. 

J. U. Klein, J. Gosselin, M. H. Thornton, M. V. Sauer. Obstetrics and 

Gynecology - Reproductive Endocrinology and Infertility, College of 

Physicians and Surgeons, Columbia University, New York, NY. 

P-584 DAY 7 b-hCG LEVEL AFTER FROZEN-THAWED 

BLASTOCYST TRANSFER CAN BE A PREDICTOR FOR 

PREGNANCY OUTCOMES? 

K. Kato, T. Segawa, H. Osada, T. Kobayashi, Y. Takehara, O. Kato. 

Kato Ladies Clinic, Shinjuku, Tokyo, Japan. 

P-585 COUNSELING PATIENTS REGARDING REDUCING 

CAFFEINE CONSUMPTION BEFORE IN VITRO FERTILIZATION 

(IVF) IS ASSOCIATED WITH A DECREASED NUMBER OF 

IMMATURE OOCYTES. 

S. A. Pauli, A. C. Browne, S. Seydafkan, D. R. Session. Department of 

Gynecology and Obstetrics: Division of Reproductive Endocrinology 

and Infertility, Emory University School of Medicine, Atlanta, GA. 

P-586 ELECTIVE SINGLE BLASTOCYST TRANSFERS (eSBT) 

IN OOCYTE DONOR IVF CYCLES (OD-IVF) RESULTS IN A 

REDUCTION OF MULTIPLES WITHOUT COMPROMISING THE LIVE 

BIRTH RATE (LBR). 

C. M. Mullin, F. Licciardi, C. McCaffrey, J. Knopman, J. A. Grifo. NYU 


P-587 EFFECT OF THE OOCYTE DONOR´S QUALITY: 

CUMULATIVE LIVEBIRTH RATES (CLBR) IN IVF CYCLES WITH 

DONOR SPERM IN OVUM DONATION VS. AUTOLOGOUS 

OOCYTES. 

C. Gonzalez-Ravina 1 , A. Pacheco 2 , A. Pellicer 3 , D. Pabon 4 , M. 

Fernandez-Sanchez 1 , N. Garrido 3 . 1 Laboratory of Andrology, IVI 

Sevilla, Sevilla, Spain; 2 Laboratory of Andrology, IVI Madrid, Madrid, 

Spain; 3 Laboratory of Andrology, IVI Valencia, Valencia, Spain; 

4 Laboratory of Andrology, IVI Vigo, Vigo, Pontevedra, Spain. 

P-588 ANTI-MÜLLERIAN HORMONE (AMH) IN NORMAL 

OVARIAN RESERVE WOMEN UNDERGOING IN VITRO 


B. S. Houmard 1 , R. Dunsmoor-Su 1 , L. B. Davis 2 , M. R. Soules 2 , P. C. Lin 2 . 

1 Obstetrics & Gynecology, University of Washington, Seattle, WA; 

2 Seattle Reproductive Medicine, Seattle, WA.

P-589 CHARACTERISTICS OF WOMEN WITH EXTREMLY 

LOW ANTI-MÜLLERIAN HORMONE (AMH) LEVELS WHO STILL 

CONCEIVE? 










P-590 “QUANTITY VS. QUALITY”: IS RESPONSE TO 

STIMULATION ASSOCIATED WITH IN VITRO FERTILIZATION 

(IVF) OUTCOMES IN PATIENTS AT THE OLDER EXTREME OF 

REPRODUCTIVE AGE? 

J. U. Klein, J. Gosselin, M. M. Guarnaccia, M. V. Sauer. Obtstetrics 

and Gynecology - Reproductive Endocrinology and Infertility, 

College of Physicians and Surgeons, Columbia University, New York, 

NY. 

P-591 CAN THE SOCIETY FOR ASSISTED REPRODUCTIVE 

TECHNOLOGY CLINIC OUTCOMES REPORTING SYSTEM (SART 

CORS) BE USED TO ACCURATELY REPORT CLINIC TOTAL 

REPRODUCTIVE POTENTIAL (TRP)? 

J. E. Stern 1 , T. N. Hickman 2 , C. B. Barrett 3 , A. S. Penzias 3 , G. D. Ball 4 , 

W. E. Gibbons 5 . 1 Department of Ob/Gyn, Dartmouth-Hitchcock 

Medical Center, Lebanon, NH; 2 Houston IVF, Houston, TX; 3 Boston 

IVF, Beth Isreal Deaconess, Waltham, MA; 4 Seattle Reproductive 

Medicine, Seattle,, WA; 5 Department of Ob/Gyn, Baylor College of 


__________________________________________________________ 

ART - OUTCOME PREDICTORS, LABORATORY 

P-592 IMPACT OF HIGH BASAL FSH/LH RATIO IN WOMEN 

WITH NORMAL FSH LEVELS ON IN VITRO FERTILIZATION 

OUTCOMES. 

S. W. Lyu, A. Kim, J. W. Kim, J. E. Han, H. H. Seok, I. P. Kawk. Fertility 

Center, Department of Obstetrics and Gynecology, CHA Gangnam 

Medical Center, CHA University, Seoul, Korea. 

P-593 IS CRYOPRESERVATION OF EMBRYOS A LEGITIMATE 

SURROGATE MARKER OF EMBRYO QUALITY IN STUDIES OF 

ASSISTED REPRODUCTIVE TECHNOLOGY CONDUCTED USING 

NATIONAL DATABASES? 

J. E. Stern 1 , E. S. Lieberman 2 , M. Macaluso 3 , C. Racowsky 2 . 1 Obstetrics 

and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, 

NH; 2 Obstetrics and Gynecology, Brigham & Women’s Hospital, 

Boston, MA; 3 Division of Reproductive Health, Centers for Disease 

Control and Prevention, Atlanta, GA. 


161 

P-594 CIRCULATING ANTI-MULLERIAN HORMONE LEVELS 

MAY PREDICT BLASTOCYST FORMATION RATES IN DONOR IVF 

CYCLES. 

J. H. Gilbert 1 , J. C. Settle 1 , J. E. Nichols 1 , T. H. Taylor 2 , J. D. Wininger 3 , 

W. E. Roudebush 4 . 1 Piedmont Reproductive Endocrinology Group, 

Greenville, SC; 2 Main Line Fertility, Bryn Mawr, PA; 3 Premier Fertility 

Center, High Point, NC; 4 Biology, Charleston Southern University, 

Charleston, SC. 

P-595 THE RELATIONSHIP BETWEEN THE CHANGE IN SERUM 

HIGH SENSITIVITY C-REACTIVE PROTEIN LEVELS AND IVF 

SUCCESS. 

B. Seckin, G. Ozaksit, S. Batioglu, M. Ozel, M. Aydogan, B. Senturk. 

Zekai Tahir Burak Women’s Health Research and Education Hospital, 


P-596 ELECTIVE SINGLE EMBRYO TRANSFER (eSET) ON DAY 3: 

WHEN ONE IS PLANNED, BUT TWO MAY BE APPROPRIATE. 

N. Acevedo, S. C. Pang, J. C. Patel, K. J. Go. Reproductive Science 

Center of New England, Lexington, MA. 

P-597 RESTRICTIVE LAW REGULATING ART IN ITALY 

SIGNIFICANTLY REDUCED DELIVERY RATE IN INFERTILE PATIENTS 

ART CYCLES. 

P. E. Levi Setti 1 , E. Morenghi 2 , C. Sonia 1 , S. Galliera 1 , V. Arfuso 1 , F. 

Menduni 1 . 1 Gynecology and Reproductive Medicine, IRCCS - Istituto 

Clinico Humanitas, Rozzano (Mi), Italy; 2 Unità di Biostatistica, IRCCS - 

Istituto Clinico Humanitas, Rozzano (Mi), Italy. 

P-598 PREDICTORS OF SPONTANEOUS REDUCTION (SR) IN 

ART CYCLES? 

Y. E. Sükür 1 , T. Altun 2 , L. Pal 3 . 1 Ankara University, Ankara, Turkey; 

2 Obstetrics and Gynecology, Kazan Government Hospital, Ankara, 

Turkey; 3 Obstetrics, Gynecology and Reproductive Sciences, Yale 

University, New Haven, CT. 

P-599 SINGLE EMBRYO TRANSFER (SET) USING GRADUATED 

EMBRYO SCORE (GES) AND SOLUBLE HUMAN LEUKOCYTE 

ANTIGEN-G (HLA-G): AN UPDATE. 

J. D. Fisch. Sher Institute for Reproductive Medicine, Las Vegas, NV. 

P-600 CAN THE NUMBER OF ANTRAL FOLLICLES BEFORE THE 

START OF GONADOTROPIN STIMULATION PREDICT THE NUMBER 

OF PREOVULATION FOLLICLES AND TOTAL OOCYTES IN IVF 

CYCLES? 

R. P. Dickey 1,2 , S. N. Taylor 1 , P. Y. Lu 1 , B. M. Sartor 1 , H. E. Dunaway, Jr 1 . 

1 The Fertility Institute of New Orleans, Mandeville, LA; 2 Obstetrics and 

Gynecology, Louisiana State University, New Orleans, LA.

NOTES 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________

MEET AND GREET 

THE ASRM PRESIDENT 

AND THE EDITOR OF 

FERTILITY AND STERILITY! 

Stop by the ASRM Booth (#835) and meet 

ASRM President William E. Gibbons, M.D., and 

Fertility and Sterility Editor Alan H. DeCherney, 

M.D. 

Dr. Gibbons will be at the booth during the 

Monday and Tuesday afternoon breaks 

from 3:30 pm to 4:15 pm. 

Dr. DeCherney will be at the booth during the 

Tuesday and Wednesday morning breaks 

from 10:30 am to 11:15 am. 

Photo Opportunity Available! 

ROUNDTABLE LUNCHEONS

Androgen Excess 

RTM01. Polytherapy in PCOS – How Much is Too Much? 


Assisted Reproductive Technology 

RTM02. Ovarian Stimulation in Older Women 

Bulent C. Urman, M.D. 

RTM03. Gamete Selection in Poor Prognosis Patients 


RTM04. Oocyte Donation: Past, Present, and Future 

Maria Bustillo, M.D. 

RTM05. Implantation Failure 

Wendy Y. Chang, M.D. 

Contraception 

RTM06. Contraceptive Controversies 

Bliss Kaneshiro, M.D., M.P.H. 

RTM07. Contraception for Women with Complex Medical 

Problems 

Stephanie B. Teal, M.P.H. 

RTM08. Contraception for Adolescents 

Tabetha Harken, M.D. 

Endometriosis 

RTM09. Optimizing ART for Endometriosis Patients 


Fertility Preservation 

RTM10. The Alphabet Soup of Chemotherapy and Biologic 

Therapy in Cancer Treatment: What is the Impact on 

Fertility? 

Irene Su, M.D. 

RTM11. Strategies in Ovarian Stimulation for Breast Cancer 

Patients 

Karen B. Glass, M.D. 

Fibroids 

RTM12. Where Do Fibroids Come From? The Stem Cell Origin 

of Uterine Fibroids. 

Gregory M. Christman, M.D. 

Legal 

RTM13. A Legal Update on Egg-Freezing and Genetic 

Screening 

Susan L. Crockin, J.D. 

Male Reproduction and Urology 

RTM14. Vibratory Stimulation and Electroejaculation in the 

SCI Male 

Charles M. Lynne, M.D. 

RTM15. Genetic Considerations for the Infertile Male 

Moshe Wald, M.D. 

RTM16. Varicocele Repair: Why the Debate Continues 

Harris M. Nagler, M.D. 

Menopause 

RTM17. Depression, Hot Flashes, and the Use of 

Antidepressants in the Menopausal Transition 

Veronica A. Ravnikar, M.D. 

RTM18. Emerging Issues in Breast Cancer and the 

Menopause 

Julia V. Johnson, M.D. 

ROUNDTABLE LUNCHEONS 


Hall F (Roundtable Area) 

163 

Mental Health 

RTM19. The Components of Ethical Decision Making in 

Fertility Counseling: Who are the Stakeholders? 

Judith E. Horowitz, Ph.D. 

RTM20. Dispelling the Myths About the Efficacy of 

Acupuncture with Infertility Patients 


RTM21. A Developmental Perspective for Building Healthy 

Donor-Conceived Families 

Madeline L. Feingold, Ph.D. 

Nurses 

RTM22. Gender Selection 

Lori Whalen, R.N. 

Nutrition 

RTM23. Diet and PCOS 

Gilbert B. Wilshire, M.D. 

Pediatric and Adolescent Gynecology 

RTM24. Challenges with Mullerian Varients: Novel Surgical 

Approaches 

David W. Lee, M.D. 


RTM25. Integrating New Technologies into the ART 

Laboratory: Vitrification, Egg Cryopreservation and 

Trophectoderm Biopsy 

Chad A. Johnson, Ph.D., H.C.L.D. 

RTM26. Mitochondria, Embryo Development and Stem Cells 

Mahendran M. Mahadevan, Ph.D. 

Reproductive Endocrinology and Infertility 

RTM27. Evaluation of Recurrent Pregnancy Loss 

Mary D. Stephenson, M.D., M.Sc. 

RTM28. The Role of Myomectomy in Fertility Enhancement 

Elizabeth A. Pritts, M.D. 

RTM29. Causes of Recurrent Pregnancy Loss 

Ruth B. Lathi, M.D. 

RTM30. Luteal Phase Support: When, Where and How 

Mohamed Aboulghar, M.D. 

Reproductive Immunology 

RTM31. The Use of Inseminations in Patients Who Are 

Serodiscordant for HIV-1 

Danny J. Schust, M.D. 

Reproductive Laboratory Technology 

RTM32. Moving Your Clinical ART Lab: Planning, New Lab 

Setup, Pre-Move, and Finally, the Big Day 

Tien-Cheng Arthur Chang, Ph.D. 

Reproductive Managers 

RTM33. Spermatogonial Stem Cells 


Surgery 

RTM34. Adenomyosis 

Charles C. Coddington, M.D. 

RTM35. Energy Sources in Endoscopic Surgery 

Magdy P. Milad, M.D.


RTT01. PCOS in China 

Xiaoke Wu, M.D., Ph.D. 


RTT02. Day 3 vs. Day 5 Embryo Transfer 

Orhan Bukulmez, M.D. 

RTT03. How to Improve the Probability of Pregnancy in Poor 

Responders Undergoing IVF: A Systematic Review 

and Meta-Analysis 

Basil C. Tarlatzis, M.D., Ph.D. 

RTT04. Embryo Transfer Technique 

Ragaa T. Mansour, M.D., Ph.D. 

RTT05. Improvements in Culture Technique Might Improve 

Clinical IVM Results 

Johan E. Smitz, M.D. 

Fibroids 

RTT06. Medical Treatment of Uterine Fibroids 


RTT07. Impact of Fibroids on IVF 


Genetic Counseling 

RTT08. PGD Results and Embryo Grading - Helping Couples 

Through Difficult Decisions 

Kimberly A. Amoroso, M.S. 

Imaging 

RTT09. The Pros and Cons of Automated Follicular Monitoring 

with 3-D Ultrasound and SonoAVC 

Todd D. Deutch, M.D. 


RTT10. Premature Ejaculation Treatments 

Hossein Sadeghi-Nejad, M.D. 

RTT11. The Complicated Vasectomy Reversal: How I Do It 

Marc Goldstein, M.D. 

RTT12. Testosterone Therapy in the Hypogonadal Male 

Mohit Khera, M.D. 

Mental Health 

RTT13. Double Jeopardy, Infertility, and Pregnancy Loss: 

Helping Patients and Staff Cope 

Joann P. Galst, Ph.D. 

RTT14. Non-traditional (Gay, Single and Lesbian) Family 

Building: What Practitioners Need to Know 


RTT15. Let’s Read this Story: Comparing the Picture Books 

that Introduce Young Children to ART 

Nancy M. Freeman-Carroll, Psy.D. 

RTT16. Support Groups for Infertile Women and/or Couples: 

Strategies, Resources, and Challenges 

Joan Manheimer, Ph.D. 

Nurses 

RTT17. Premature Ovarian Failure 

Catherine L. Corp, B.S.N., M.P.H. 

RTT18. The Complexities of Gestational Carrier Cycle 

Management 

Caroline Connor, R.N.C., M.S.N., W.H.N.P. 




164 

Nutrition 

RTT19. Antioxidants on Reproduction 

Kaylon L. Bruner-Tran, Ph.D. 


RTT20. Emerging Molecular Biology Methods in ART 

Nathan R. Treff, Ph.D. 

RTT21. PGS After Polar Body Biopsy 

Joep P. Geraedts, Ph.D. 


RTT22. Epigenetics and Sperm: Is It Clinically Relevant? 

Douglas T. Carrell, Ph.D. 

RTT23. Taking Quality to the Next Level: ISO 9001:2000 for 

the IVF lab and Clinic 

C. Brent Barrett, Ph.D., H.C.L.D. 

RTT24. DOR: Treatment Strategies 


RTT25. Elevated FSH: How to Evaluate 

Lawrence M. Nelson, M.D. 

RTT26. Long-term Strategies for Management of PCOS 

Kathleen M. Hoeger, M.D. 

Reproductive Immunology 

RTT27. Use of Progesterone in Patients with Luteal Phase 

Defects 

Steven L. Young, M.D., Ph.D. 

RTT28. Experimental Immune Therapies for Endometriosis 

Thomas M. D’Hooghe, M.D., Ph.D. 


RTT29. Mechanical Collapsing of Blastocoel Prior to 

Cryopreservation or Vitrification 

Susan E. Lanzendorf, Ph.D. 

RTT30. Tweaking of Standard Vitrification Protocol in Your 

Lab 


Reproductive Managers 

RTT31. Compliance Issues in the IVF Lab 

Carli W. Chapman, B.S. 

Sexuality 

RTT32. How to Do a Sexual History and Initial Evaluation of 

Sexual Dysfunction 

Terri L. Woodard, M.D. 

Surgery 

RTT33. Pediatric Surgery 

Joseph S. Sanfilippo, M.D. 

RTT34. Adhesion Prevention 

Celso P. Silva, M.D. 

RTT35. Simulation/FLS/Curriculum 

Daniel R. Grow, M.D.


RTW01. The Aging PCOS Patient 

Michael L. Lydic, M.D. 


RTW02. Progesterone Support and IVF 

Elena H. Yanushpolsky, M.D. 

RTW03. Elective Single Embryo Transfer 

Said T. Daneshmand, M.D. 

RTW04. Pitfalls in Egg Donor Screening and Treatment 

Rachel K. Ashby, M.D. 

RTW05. Ovarian Hyperstimulation 

Syndrome 

Pak H. Chung, M.D. 

Endometriosis 

RTW06. Managing the Pain of Endometriosis and 

Translational Research Strategies 

Sawsan As-Sanei, M.D. 

Environment and Reproduction 

RTW07. Do PCBs Contribute to Tissue Fibrosis? 


RTW08. Dioxins and Transgenerational Effects 

Kevin C. Osteen, Ph.D. 

Fertility Preservation 

RTW09. Fertility Preservation Strategies 

Mitchell P. Rosen, M.D. 

RTW10. Fertility Preservation for Female Cancer Patients 

Marybeth Gerrity, Ph.D. 

RTW11. Establishing and Promoting a Fertility Preservation 

Program 

G. Wright Bates, M.D. 

RTW12. To Vitrify or Not to Vitrify: Will Vitrification Save Fertility 

Preservation in its Current Form? 

Ertug Kovanci, M.D. 

Genetic Counseling 

RTW13. Fragile X: Ovarian Aging and Other Premutation 

Issues 


Imaging 

RTW14. 3-D Ultrasound of Uterine Anomalies in ART 


Legal 

RTW15. When ART Patients Become ART Legal Clients: 

Understanding the Complex Dual Track and Legal 

Advanced Family Building Issues/Implications 

Amelia Demma, J.D. 


RTW16. OTC Supplements for Male Infertility: 

Evidence-based Analysis 

Edmund S. Sabanegh, Jr., M.D. 

RTW17. Recreational Drug Abuse and Male Fertility 

Al Barqawi, M.D. 

RTW18. Robot Applications in Male Infertility: 

What is the Role? 

Sijo J. Parekattil, M.D. 




165 

Menopause 

RTW19. Vitamin D and Aging 

Lubna Pal, M.D. 

RTW20. Determinants of Cardiovascular Disease in Post 

Reproductive Women 

David H. Barad, M.D. 

RTW21. Sleep and Menopause 

Genevieve Neal-Perry, M.D., Ph.D. 

Mental Health 

RTW22. POF or POI: The Emotional Challenges Remain the 

Same 

Sharon N. Covington, M.S.W. 

Nurses 

RTW23. Cultural Resources for the Infertility Nurse 

Susan M. Schneider, R.N.C. 

RTW24. Education of Patients on Multiple Pregnancy Risks 

and eSET from a Nursing Perspective 

Jane N. Perkins, M.S.N., A.R.N.P. 


RTW25. PGD/PGS - When to Biopsy & What to Biopsy 

Z. Peter Nagy, Ph.D., M.D. 

RTW26. Microarrays and CGH: Promise and Pitfalls 

William G. Kearns, Ph.D. 


RTW27. Omics Technology 

Kathleen A. Miller, B.S. 


RTW28. New OCPs, New Uses 

Steven T. Nakajima, M.D. 


RTW29. To Bind or Not to Bind: Use of the HBA Assay and 

PICSI Technology to Improve Your Clinical Outcomes 

Kathryn C. Worrilow, Ph.D. 

RTW30. How to Implement Vitrification in IVF Lab? 

Wei-Hua Wang, Ph.D. 

Sexuality 

RTW31. Fertility Counseling in Transgendered Patients 

Gail Knudson, M.D. 

RTW32. Sexual Dysfunction and Infertility: The Intimate 

Interface 

William D. Petok, Ph.D. 

Surgery 

RTW33. Surgical Management of Advanced Endometriosis 

in Patients Who Desire Future Fertility 


RTW34. CPT Coding for Reproductive Surgeons: Five Areas 

for Improvement 

John T. Queenan, M.D. 

RTW35. Vasectomy Reversal: Predictors of Success 

Peter N. Kolettis, M.D.

FUTURE ASRM ANNUAL MEETINGS 

October 15-19, 2011 

Orlando, FL 

Orange County Convention Center 

October 20-24, 2012 

San Diego, CA 

San Diego Convention Center 

October 12-17, 2013 

Boston, MA 

Boston Convention and Exhibition Center 

In conjunction with the Meeting of the 

International Federation of Fertility Societies 

October 18-22, 2014 

Honolulu, HI 

Hawaii Convention Center

SERVICES AVAILABLE 

AT THE MEETING 

INTERNET CAFÉ 

Access the Internet and connect with various colleagues and 

attendees at the Internet Café. 

Location: Colorado Convention Center 

Hours of Operation: 

Friday 2:00 pm - 8:00 pm 

Saturday & Sunday 7:00 am - 7:00 pm 

Monday & Tuesday 7:00 am - 7:00 pm 

Wednesday 7:30 am - 5:00 pm 

ASRM BOOTH #835 

Stop by the ASRM Booth in the Exhibit Hall and join or renew your membership, 

browse our publications, and learn about all the Society has to offer. 

EXHIBIT HALL HOURS 

Monday 9:30 am - 5:00 pm 

Tuesday 9:00 am - 5:00 pm 


EXHIBIT HALL BREAKS 

Monday - Wednesday 10:30 am - 11:15 am 

Monday & Tuesday 3:30 pm - 4:15 pm 

EXHIBITS

EXHIBITS 

COLORADO CONVENTION CENTER 

Exhibit Hall Hours 

Monday 9:30 am - 5:00 pm 

Tuesday 9:00 am - 5:00 pm 


Exhibit Hall Breaks 

Monday - Wednesday 10:30 am - 11:15 am 

Monday and Tuesday 3:30 pm - 4:15 pm 

167

ASRM 2010 

October 25-27, 2010 


Denver, Colorado 

Exhibits - Halls E & F 

Posters - Hall D 

STORAGE 

FEC 

FEC 

FVC 

Open to 

Below 

FVC 

FEC 

FVC 

FEC 

505 506 507 508 

205 206 207 208 

504 503 502 

204 203 202 

402 401 400 

102 101 100 

301 

1 

302 

2 

303 

3 

399 

99 

304 

4 

398 

98 

305 

5 

10' 

Electrical 

Storage 

8'h drape 

6' 

6' 

20' 

23'-1" 

509 510 511 512 513 514 515 516 517 518 

209 210 211 212 213 214 215 216 217 218 

15' 

15'-3" 

FVC 

519 520 521 522 523 524 525 526 527 

FVC 

528 

219 220 221 222 223 224 225 226 227 228 

0" FE FE FE FE 

15' 12'-5" 

15' 10' 

17'-6" 

Roundtable Luncheon 

501 500 499 498 497 496 495 494 493 492 491 490 489 488 487 486 485 484 483 482 481 480 479 478 477 

201 200 199 198 197 196 195 194 193 192 191 190 189 188 187 186 185 184 183 182 181 180 179 178 177 

15' 

403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 

103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 

397 

97 

306 

6 

396 

96 

307 

7 

395 

95 

308 

8 

394 

94 

309 

9 

393 

93 

310 

10 

392 

92 

311 

11 

391 

91 

312 

12 

15' 

390 

90 

15' 

313 

13 

389 

89 

314 

14 

388 

88 

315 

15 

387 

87 

316 

16 

386 

86 

317 

17 

385 

85 

318 

18 

384 

84 

319 

19 

F&B Seating 

383 

83 

320 

20 

Total Posterboards: 300 

Total faces: 600 

20' 

382 

82 

321 

21 

381 

81 

322 

22 

380 

80 

323 

23 

379 

79 

324 

24 

378 

78 

325 

25 

60' 

377 

77 

326 

26 

Food 

Court 

376 

76 

327 

27 

FVC 

375 

75 

328 

28 

60' 

FVC FVC 

8'h drape 

16' 

20' 

10'-5" 

529 530 

229 230 

374 

74 

329 

29 

373 

73 

330 

30 

Storage 

531 532 533 534 535 

231 232 233 234 235 

372 

72 

331 

31 

48'-9" 

371 

71 

332 

32 

370 

70 

333 

33 

369 

69 

334 

34 

Future 

Escalators 

FEC FEC 

F&B Seating 

15' 

15' 

15' 

15' 

15' 

15' 

15' 

20' 

GE 

Healthcare 

20' 

575 

IVI 

Valencia 

IMT Int'l 

Limited 

576 574 572 

Vivere 

Ankh Data 

Health 

477 

Systems, 

LLC 

475 473 

20' 

Molecular 

Biometrics 

Inc 

20' 

375 

20' 

Clearblue 

20' 

275 

Storage 

600 599 598 597 596 595 594 593 592 591 590 589 588 587 586 585 584 

300 299 298 297 296 295 294 293 292 291 290 289 288 287 286 285 284 

567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 

267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 

566 565 564 563 562 561 560 559 558 557 556 555 554 553 552 

266 265 264 263 262 261 260 259 258 257 256 255 254 253 252 

368 

68 

335 

35 

367 

67 

336 

36 

366 

66 

337 

37 

536 537 538 539 540 541 542 543 544 

236 237 238 239 240 241 242 243 244 

365 

65 

338 

38 

364 

64 

339 

39 

363 

63 

340 

40 

362 

62 

341 

41 

361 

61 

342 

42 

360 

60 

343 

43 

20' 

359 

59 

344 

44 

358 

58 

345 

45 

21' 

357 

57 

346 

46 

356 

56 

347 

47 

551 550 549 548 

251 250 249 248 

355 

55 

348 

48 

545 546 547 

245 246 247 

476 475 474 473 472 471 470 469 468 467 466 465 464 463 462 461 460 459 458 457 456 455 454 

176 175 174 173 172 171 170 169 168 167 166 165 164 163 162 161 160 159 158 157 156 155 154 

431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 

131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 

354 

54 

349 

49 

353 

53 

350 

50 

Med 

Software 

Unilab of 

Dade 

668 666 664 

American 

20' 

Academy of 

Ob/Gyn & 

Upsher-Smith Labs Infertility 

Nurse 

569 

352 

52 

351 

51 

567 

KitaZato 

565 

Pathway 

Biogenics 

MedGyn Incept Bio 

Genomics Products Systems 

470 468 466 464 

Pamlab, Quick Int'l 20' 

LLC Courier Thomas Medical 

371 369 365 

MANDATORY FREIGHT FREE AISLE 

JRi 

Maxant 

Beitler 

Srv Inc 

568 566 564 

Olympus 

America 

469 467 465 

Sequenom 

Invitrocare Center for Sunlight 

Molecular Medical 

Medicine 

368 366 364 

Cryos Int'l- 

30' 

New York Conception Technologies 

271 

265 

Inventory as of 09/28/2010 

96% - 41,267 SqFt Rented 

4% - 1,900 SqFt Available 

Dimension 

10'x10' 

10'x20' 

17'x17' 

10'x30' 

20'x20' 

20'x30' 

30'x30' 

30'x40' 

30'x50' 

40'x40' 

50'x50' 

20' 

Smiths 

Medical 

Int'l Ltd 

20' 

659 

20' 

Warner 

Chilcott 

LLC 

20' 

559 

259 

20' 

Jaypee- 

CDC Division 

Nanopoint Highlights 

20' 

Medical 

of Reproductive 

ReproSource 

Health 

Publishers 

Sage InVitro 

Fertilization, 

274 272 270 268 266 264 a CooperSurgical 

20' 

European FDA/Center for 

Expecting 20' 

Com 

Biologics 

Sperm Bank Evaluation & 

Nikon Inst USA 

411 

Research (CB Reprogenetics 20' 

175 173 171 169 165 159 

20' 

17' 

17' 

17' 

ASRM ASRM ASRM 

17' 

17' 

17' 

959 10' 955 9' 949 

960 958 956 

FVC 

20' 

LabCorp- 

Viromed Labs 

948 

20' Orlando Donor Quadrant Cryo- Medison 

Labotect GmbH CVB Network HealthCom 

Alliance 

Cell America 

859 857 855 853 851 849 

257 

FVC 

Cambridge Abbott Abbott 

University 

Press Labs Labs 

860 858 856 

CryoGam 20' 

Colorado Femasys 

761 757 

Interlace 

Bayer Spectrum 

CryoLogic HealthCare 

Medical 

Technologies 


460 458 456 454 452 

Houston 20' Marina 

POF/POI Labs, Inc. Medical 

361 359 355 353 

Reproductive 

Possiblities, 

LLC/Melissa B. 

Brisman 

20' 

255 

30' 

253 

FVC 

20' 

Unisense 

Fertilitech 

A/S 

20' 

751 

Walgreens 

650 

New Life The New York Tosoh 

Stem Cell 

Agency Foundation Bioscience 

555 553 551 

Beckman Zander 

Coulter IVF 

254 252 

20' 

Smith & Nephew 

Endoscopy 

153 

651 

ConceiveAbilities 

FREIGHT FREE AISLE 

543 

Labs Inc 

537 535 

20' 

529 


40' 

30' Bayer 

40' 

30' 

40' Origio 

743 

Lippincott Roche Ambry 

Williams & Diagnostics 

Wilkins 

Genetics 

560 558 556 

20' 

MTG – Medical Reproductive Karl Storz 

Kivex Biotec Inc. Counsyl 

Sefi 

Tech Vertriebs- Genetics Endoscopy 

GmbH 

K-Systems USA 

Medical 

Institute America 

552 550 548 546 544 542 

Surrogacy Society of 

Gene Planer 

20' 

Nurses 

FemPartners Specialists of 

America, LLC/ 

Reproductive Yodle Security 

Salimetrics 

Professional 

Parenting Op Surgeons 

PLC 

Ascend Therapeutics 

Network 

Group 

461 459 457 455 453 451 449 445 443 

BioMed 

BabySentry 

Central 

Insightec 

FVC FVC 

360 358 356 

20' 

MedTech European Society Oxford 

of Human 

Genesis Genetics for Reproduction University 

and Embryol 

Institute Solutions 

Press 

Size 

100 

200 

289 

300 

400 

600 

900 

1,200 

1,500 

1,600 

2,500 

Totals: 

70' 

30' 

Qty 

146 

26 

3 

2 

19 

3 

1 

5 

1 

1 

1 

208 

Pfizer 

30' 

343 

Vitrolife, Inc. 

40' 

143 

SqFt 

14,600 

5,200 

867 

600 

7,600 

1,800 

900 

6,000 

1,500 

1,600 

2,500 

43,167 

60' 

ASRM 

FREIGHT FREE AISLE 

8' Drape 

20' 

Office 

835 

20' 

Abbott Labs 

20' Inc 

735 

Brown & 

Brown of PracticeHwy.com 

Texas 

736 734 

20' 

Embryotech Labs 

635 

Cryogenic 

Genzyme 

30' 

Watson 

433 

Narishige ITM Ureme National 

Sagligi Embryo 

Internatal Urunleri Donation 

USA LTD. STI Center 

436 434 432 

20' 

Idant 

Hamilton Thorne Laboratory 

335 333 

50' 

30' 

Rented 

127 

26 

3 

2 

19 

3 

1 

5 

1 

1 

1 

Irvine 

Scientific 

133 

189 

20' 

Teva 

Women's 

Health 

20' 

929 

20' 

Ultrasonix 

Medical 

Corporation 

20' 

829 

20' 

EMD 

Serono, 

Inc 

20' 629 

20' 

Freedom 

Fertility 

Pharmacy 

30' 

Available 

19 

0 

0 

0 

0 

0 

0 

0 

0 

0 

0 

40' 

19 

Cook 

Medical 

Service Desk 

20' 

Good Start 

Genetics 

20' 

923 

Univfy 

Inc 

924 

Pacific Coast The American 

Reproductive Fertility 

Society Association 

825 

Springer 

Science+Business 

Media 

922 

823 

Informa 

MicroSort 

Bethany 

Healthcare Christian 

Digital MD 

Systems 

830 828 826 824 822 

Fairfax Fairfax Reglera 20' 

CryoBank Egg Bank LLC ReproTech 

731 729 727 723 

20' 

EMD 

Serono, 

Inc 

20' 623 

20' 

EMD 

Serono, 

Inc 

20' 523 

40' 

Boehringer 

Ingelheim 


30' 

423 

40' 

Ferring 


30' 

322 

123 


8' Drape 

FEC 

Clinical 

Yale Rachel's Fibroid Int'l Prematue 

Embryology 

Endometriosis Int'l Council on 

Andrology MS 

Ovarian 

University 

Association Infertility 

Well, Inc SIG 

at EVMS 

Failure 

Information D 

1019 1017 1015 1013 1011 1009 1007 1005 1003 1001 

Special Interest 

918 916 

eBridge American 

Express 

Solutions Open 

819 817 

The Found 

BlueGnome Animals 

Foundation 

818 816 

20' 

Center for Surrogate Parenting, 

Inc. & Egg Donatio 

717 

20' 

Eppendorf 

20' 

Class Inventory as of 09/28/2010 

Special Interest 

Dimension 

10'x10' 

617 

Our Fairy NW Prosperity 

Godmother 

Specialty 

Cryobank Pharmacy 

618 616 614 

20' 

FertilityAuthority.com 

Rocket Medical PLC 

517 

Casmed American 

Association of 

Int'l LTD Bioanalysts 

518 516 

20' 

MDR Pharmaceutical 

Care 

417 

20' 


Cryobank 

20' 

317 

515 

20' 

IntegraMed 

America 

20' 

711 

20' 

Steptoe 

710 

20' 

Research 

611 

20' 

Village 

Fertility 

Pharmacy, 

Inc 

20' 411 

20' 

SCSA 20' 

Diagnostics Metro Drugs 

318 314 

Resolve: The Fertility Microptic Fertility 

National Source 

Infertility 

SL Tech 

Association Companies 

Resources 

219 217 215 213 

20' Thermo MVE- 

Intuitive Surgical Scientific Chart 

216 214 212 

20' Practice The 

Apothecary 

Xytex Cryo Dock Shop 

117 115 113 

30' 

IVFonline 

Society for the 

30' 

Study of 

Reproduction Richard Wolf Medical 

509 507 

501 

Boehringer 

Ingelheim 


309 

50' 

Size 

100 

Totals: 

80' 

Tokai Hit 

20' 

Co., Ltd 

Dre Inc. 

Med Market Link 

506 504 500 

Ascend Sanyo ART Memorial 

Specialty North Systems Blood 

Rx America 

Centers 

407 405 403 401 

Hologic, College of Elsevier, 

American 

Inc Pathologists Inc 

404 

20' 

402 400 

Siemens Medical 

Solutions USA, Inc 

303 301 

50' 

40' 

Product 

Theater 

Merck 

46' 

Qty 

10 

10 

Class Inventory as of 09/28/2010 

Management 

Dimension 

40'x80' 

60'x70' 

Size 

3,200 

4,200 

Totals: 

Qty 

1 

1 

2 

601 

101 

SqFt 

1,000 

1,000 

SqFt 

3,200 

4,200 

7,400 

Storage 

20' 

8' Drape 

FVC 

FVC 

FVC 

FEC 

Rented 

7 

FEC 

FVC 

Attendee 

Entrance 

7 

Rented 

0 

0 

0 

Available 

3 

Open to 

Below 

3 

Available 

1 

1 

*This floor plan is subject to fire marshal approval. 

2 

en to 

elow 

139 Campanelli Drive 

Middleborough, MA 02346 

Phone: 508.946.8500 

Fax: 508.923.1409 

Account Executive: Meredith Martin 

Revision Date: 09.28.10 

Rev. # 23 

Drawn By: Kelly Coutu 

Scale: Fit to page 

4' 

4' 

5'-4" 

4' 

8'-5" 

3'-6" 

BUILDING LEGEND 

3' - Columns 

- Electrical 

- Men 

- Woman 

- Telephone 

- Freight Elevator 

- Elevators 

- Concessions 

Low Steel Height 

34' 9" 

Beam Height 

29' 10" 

FA - Fire Alarm 

FE - Fire Extinguisher 

GAS TAP, 30' Above Floor 

Booths Are 10' x 10' 

(Unless Noted Otherwise) 

Aisles Are 10' 

(Unless Noted Otherwise) 

FLOOR PORT: 1-100 amp, 120/208V, 

3 Phase 

4 Wire Receptacle 2-20 amp, 

120, 1 Phase Receptacle 

Phone, 25 pr 

Floor Drain 

COLUMN PORT: Same as FLOOR 

w/ 1-60 amp, 277/480 v, 3 Phase 

Water-No Drain 

125psi Air Video 

STAGE POWER Same as FLOOR 

w/ 1-60 amp, 277/480v, 

3 Phase Water-No Drain 125psi Air 

1-1200 amp, 120/208V, 3 Phase 

2-400 amp, 3 Pole Circuit Brkr 

2-200 amp, 3 Pole Circuit Brkr 

1-1200 amp, 3 Pole, Brkr at Cat Walk 

Disclaimer 

Every effort has been made to ensure the 

accuracy of all information contained on 

this floor plan. However no warranties, 

either expressed or implied are made with 

respect to this floor plan. If the location of 

building columns, utilities or other 

architectural components of the facility is a 

consideration in the construction or usage 

of an exhibit, it is the sole responsibility of 

the exhibitor to physically inspect the 

facility to verify all dimensions and 

locations.

EXHIBIT COMPANY NAME INDEX 

Please note: ExpoCard information DOES contain email addresses. Swiping your card will share that information. 

Exhibitor write-ups on the following pages are printed as received with the exception that some have been edited for length. 

Ruby Supporters are listed in BOLD followed by an asterisk (*). 

A 

Abbott Laboratories 735, 856 & 858 

Ambry Genetics 556 

American Academy of 

Ob/Gyn & Infertility Nurses 567 

American Association of 

Bioanalysts 516 

ART Systems LLC 403 

Ascend Specialty Rx 407 

Ascend Therapeutics, Inc. 445 

American Society for 

Reproductive Medicine 

(ASRM) 949. 955 & 959 

B 

Baby Sentry Ltd. 356 

Bayer HealthCare 

Pharmaceuticals 343 & 454 

Beckman Coulter, Inc. 254 

Beitler Services, Inc. 564 

Bethany Christian Services 826 

BioMed Central 360 

BlueGnome Ltd 818 

Boehringer Ingelheim 

Pharmaceuticals, Inc. 423 & 509 

Brown & Brown of Texas 736 

C 

California Cryobank 317 

Cambridge University Press 860 

Casmed International LTD 518 

CDC Division of 

Reproductive Health 264 

Center for Surrogate Parenting, 

Inc. & Egg Donation, Inc. 717 

Clearblue 275 

Clinical Embryology Andrology 

MS at EVMS 1019 

College of American 

Pathologists 402 

Complete Medical 

Solutions, LLC 449 

ConceiveAbilities 650 

Conception Technologies 265 

Cook Medical 123 

Counsyl, Inc. 550 

Cryo-Cell International, Inc. 851 

CryoGam Colorado LLC 761 

Cryogenic Laboratories, Inc. 535 

CryoLogic 456 

Cryos International – 

New York, LLC 271 

D 

Digital MD Systems 822 

Donor Network Alliance 855 

Dre Inc. 504 

E 

eBridge Solutions 819 

Elsevier, Inc. 400 

Embryotech Laboratories, Inc. 635 

EMD Serono, Inc. 523, 623 & 629 

Eppendorf 617 

European Society of Human 

Reproduction and Embryology 

(ESHRE) 255 

European Sperm Bank USA 173 

Expecting 411 169 

F 

Fairfax Cryobank 731 

Fairfax Egg Bank 729 

FDA/Center for Biologics 

Evaluation & Research (CBER) 171 

Femasys Inc. 757 

FemPartners 461 

Ferring Pharmaceuticals Inc. 322 

FertilityAuthority.com LLC 515 

Fertility Source Companies 217 

Fertility Technology 

Resources, Inc. 213 

Fibroid SIG 1013 

Freedom Fertility Pharmacy 529 

G 

GE Healthcare 575 

Gene Security Network 453 

Genesis Genetics Institute 259 

Genzyme 537 

Good Start Genetics 923 

H 

Hamilton Thorne, Inc. 335 

Hologic, Inc. 404 

Houston POF/POI Inc. 359 

I 

Idant Laboratory 333 

Incept Bio Systems, Inc. 464 

Informa Healthcare 828 

INGfertility LLC 460 

Insightec 358 

IntegraMed America 711 

Interlace Medical 458 

International Premature 

Ovarian Failure Assoc. Inc. 

(IPOFA) 1011 

Intuitive Surgical 216 

Invitrocare, Inc. 368 

Irvine Scientific 133 

ITM Ureme Sagligi Urunleri 

LTD. STI 434 

IVFonline 309 

IVI Valencia 576 

J 

Jaypee-Highlights 

Medical Publisher 266 

K 

Karl Storz Endoscopy America 542 

KitaZato 565 

170 

Kivex Biotec Inc. K-Systems 

USA 552 

L 

LabCorp – Viromed 

Laboratories 948 

Labotect GmbH 859 

Labs, Inc. 355 

Lippincott Williams & Wilkins 560 

M 

Marina Medial Instruments 353 

MDR Pharmaceutical Care 417 

MedGyn Products 466 

Medison America, Inc. 849 

Med Market Link 500 

Med Software LLC 668 

MedTech for Solutions, Inc. 257 

Memorial Blood Centers 401 

Merck & Co, Inc.* 101 

Metro Drugs 314 

Microptic SL 215 

MicroSort 830 

Molecular Biometrics Inc. 375 

MTG – Medical Technology 

Vertriebs-GmbH 546 

MVE-Chart 212 

N 

Narishige International USA, Inc. 436 

National Embryo Donation 

Center 432 

New Life Agency, Inc. 555 

Nikon Instruments, Inc. 175 

Nurses Professional Group 443 

NW Cryobank 616 

O 

Olympus America 465 

Origio 543 

Orlando CVB 857 

Our Fairy Godmother 618 

Oxford University Press 253 

P 

Pacific Coast Reproductive 

Society 825 

Pamlab, LLC 371 

Pathway Genomics 470 

Pfizer* 743 

Planer PLC 451 

Practice Dock 115 

PracticeHwy.com 734 

Prosperity Specialty Pharmacy 614 

Q 

Quadrant HealthCom, Inc. 853 

Quick International Courier 951 

R 

Rachel’s Well, Inc. 1015 

Reglera LLC 727

Reproductive Genetics Institute 544 

Reproductive Possibilities, LLC/ 

Melissa B. Brisman Esq., LLC 361 

Reprogenetics 165 

ReproSource 274 

Reprotech Ltd 723 

Research Instruments LTD 611 

Resolve: The National Infertility 

Association 219 

Richard Wolf Medical 

Instruments Corporation 501 

Roche Diagnostics 558 

Rocket Medical PLC 517 

S 

SAGE In-Vitro Fertilization, 

A Cooper Surgical Company 159 

Sanyo North America 405 

SCSA Diagnostics 318 

Sefi Medical Instruments 548 

Sequenom Center for 

Molecular Medicine 366 

Siemens Medical Solutions 

USA, Inc. 303 

Smiths Medical International Ltd 659 

Smith & Nephew Endoscopy 153 

EXHIBIT COMPANY NAME INDEX 

Society of Reproductive 

Surgeons (SRS) 457 

Spectrum Technologies 452 

Springer Science+Business 

Media 922 

Springstone Patient Financing 301 

Steptoe 710 

Sunlight Medical Inc. 364 

Surrogacy Specialists of America, 

LLC/Parenting Options, LLC 459 

T 

Teva Women’s Health 929 

The American Fertility 

Association 823 

The Apothecary Shop 113 

The Found Animals Foundation 816 

The New York Stem Cell 

Foundation 553 

Thermo Scientific 214 

Thomas Medical 365 

Tokai Hit Co., Ltd. 506 

Tosoh Bioscience 551 

U 

Ultrasonix Medical Corporation 829 

Unilab of Dade 664 

Unisense Fertilitech A/S 751 

171 

Univfy Inc. 924 

Upsher-Smith Laboratories, Inc. 569 

V 

Village Fertility Pharmacy, Inc. 411 

Vitrolife, Inc. 143 

Vivere Health 477 

W 

Walgreens 651 

Warner Chilcott LLC 559 

Watson 433 

X 

Xytex Cryo International 117 

Y 

Yale University 1017 

Yodle 455 

Z 

Zander IVF, Inc. 252 

Please join us at Booth #601 for the ASRM Product Theater 

featuring special presentations by exhibiting companies. 

Monday, October 25, 2010 

10:30 am – 11:10 am 

“It’s Time to Talk: Recognizing Female Sexual Dysfunction 

and Diagnosing Hypoactive Sexual Desire Disorder” 

Supported by Boehringer Ingelheim Pharmaceuticals, Inc. 

Tuesday, October 26, 2010 

2:00 pm – 2:40 pm 

“The Clinical Potential of Time Lapse” 

Supported by Unisense FertiliTech 

3:30 pm – 4:10 pm 

“Pioneering Discoveries in Human Reproduction” 

Supported by EMD Serono, Inc.


Booth # 735, 856 & 858 

200 Abbott Park Road 

Abbott Park, IL 60064 

www.abbott.com 

john.hasemann@abbott.com 

__________________________________________________________ 

Ambry Genetics 

Booth # 556 

100 Columbia 200 

Aliso Viejo, CA 92656 

http://ambrygen.com 

bserna@ambrygen.com 

__________________________________________________________ 

American Academy of Ob/Gyn & Infertility Nurse 

Booth # 567 

241 Forsgate Drive 

Suite 205 D 

Monroe Twp, NJ 08831 

lisa@greenhillhc.com 

__________________________________________________________ 

American Association of Bioanalysts 

Booth # 516 

906 Olive Street 

Suite 1200 

St. Louis, MO 63101 

aab@aab.org 

__________________________________________________________ 

ART Systems LLC 

Booth # 403 

350 5th Avenue 

Suite 4519 

New York, NY 10018 

http://www.artsystememr.com 

eharary@eisny.com 

__________________________________________________________ 

Ascend Specialty Rx 

Booth # 407 

1555 Chase Hammock Rd 

Merritt Island, FL 32953 

www.ascendspecialtyrx.com 

susan.binder@sxc.com 

__________________________________________________________ 

Ascend Therapeutics, Inc. 

Booth # 445 

607 Herndon Parkway 

Suite 110 

Herndon, VA 20170 

bsisay@ascendtherapeutics.com 

__________________________________________________________ 

ASRM 

Booth # 835 

1209 Montgomery Highway 

Birmingham, AL 35216 

asrm@asrm.org 

__________________________________________________________ 

EXHIBITS 2010 

172 

Baby Sentry 

Booth # 356 

1121 S. Meyler 

San Pedro, CA 90731 

www.babysentry.com 

info@babysentry.com 

__________________________________________________________ 


Booth # 343 & 454 

6 West Belt 

Wayne, NJ 07470 

www.bayerus.com 

julia.noonan@bayer.com 

__________________________________________________________ 

Beckman Coulter, Inc. 

Booth # 254 

4300 N. Harbor Blvd. 

Fullerton, CA 92835 

www.beckmancoulter.com 

chuggins@beckman.com 

__________________________________________________________ 

Beitler Services, Inc. 

Booth # 564 

5 Marine View Plaza 

Hoboken, NJ 07030 

jmorrissette@aminsure.com 

__________________________________________________________ 

Bethany Christian Services 

Booth # 826 

901 Eastern Avenue NE 

Grand Rapids, MI 49503 

cneumair@bethany.org 

__________________________________________________________ 

BioMed Central 

Booth # 360 

236 Gray’s Inn Road 

London, WC1X 8H1 

www.biomedcentral.com 

sara.eve@biomedcentral.com 

__________________________________________________________ 

BlueGnome Ltd. 

Booth # 818 

Breaks House 

Mill Court 

Great Shelford, CB22 JLD 

www.24suretest.com 

nick.haan@cytochip.com 

__________________________________________________________ 

Boehringer Ingelheim Pharmaceuticals, Inc. 

Booth # 423 & 509 

900 Ridgebury Rd 

Ridgefield, CT 06877 

www.boehringer-ingelheim.com 

rebecca.madrid@boehringer-ingelheim.com 

__________________________________________________________

Brown & Brown of Texas, Inc. 

Booth # 736 

10700 N Freeway Ste 300 

Houston, TX 77037 

j.biondolillo@bbtexas.com 

__________________________________________________________ 

California Cryobank 

Booth # 317 

11915 La Grange Avenue 

Los Angeles, CA 90025 

mjacob@cryobank.com 

__________________________________________________________ 

Cambridge University Press 

Booth # 860 

32 Avenue of the Americas 


jmurphy@cambridge.org 

__________________________________________________________ 

Casmed International LTD 

Booth # 518 

Unit C Blenheim House 

1 Blenheim Road 

Epsom, Surrey KT19 9AP 

debbie@casmed.co.uk 

__________________________________________________________ 

CDC Division of Reproductive Health 

Booth # 264 

4770 Buford Highway 

MS K-40 

Atlanta, GA 30341 

dehinfo@cdc.gov 

__________________________________________________________ 

Center for Surrogate Parenting, Inc. & Egg Donation 

Booth # 717 

9 State Circle 

Suite 302 

Annapolis, MD 21401 

sherrie@creatingfamilies.com 

__________________________________________________________ 

Clearblue 

Booth # 275 

8700 Mason Montgomery Road 

Mason, OH 45040 

meinhardt.pj@pg.com 

__________________________________________________________ 

Clinical Embryology Andrology MS at EVMS 

Booth # 1019 

601 Colley Avenue 

Norfolk, VA 23507 

russelhi@evms.edu 

__________________________________________________________ 

College of American Pathologists 

Booth # 402 

325 Waukegan Road 

Northfield, IL 60093 

www.cap.org 

dweiss@cap.org 

__________________________________________________________ 

EXHIBITS 2010 

173 

Complete Medical Solutions, LLC 

Booth # 449 

11115 Industriplex Blvd. 

Suite 800 

Baton Rouge, LA 70809 

www.doctornetwork.com 

robin@doctornetworkcom 

__________________________________________________________ 

ConceiveAbilities 

Booth # 650 

2835 N. Sheffield Avenue 

Suite 304 

Chicago, IL 60657 

nazca@conceiveabilities.com 

__________________________________________________________ 

Conception Technologies 

Booth # 265 

6835 Flanders Drive 

500 

San Diego, CA 92121 

www.conceptiontechnologies.com 

russell@conceptiontechnologies.com 

__________________________________________________________ 

Cook Medical 

Booth # 123 

750 Daniels Way 

P.O. Box 489 

Bloomington, IN 47404 

www.cookmedical.com 

Jennifer.Moore@CookMedical.com 

__________________________________________________________ 

Counsyl 

Booth # 550 

2200 Bridge Parkway 

Suite 103 

Redwood City, CA 94065 

http://www.counsyl.com 

dan@counsyl.com 

__________________________________________________________ 

Cryo-Cell International, Inc. 

Booth # 851 

700 Brooker Creek Blvd. 

Suite 1800 

Oldsmar, FL 34677 

lsmith@cryo-cell.com 

__________________________________________________________ 

CryoGam Colorado LLC 

Booth # 761 

2216 Hoffman Drive 

Unit B 

Loveland, CO 80538 

www.cryogam.com 

jenell@cryogam.com 

__________________________________________________________ 

Cryogenic Laboratories, Inc. 

Booth # 535 

3015 Williams Drive 

110 

Fairfax, VA 22031 

www.cryolab.com 

sseitz@givf.com 

__________________________________________________________

CryoLogic 

Booth # 456 

54 Geddes Street 

Mulgrave, 03170 

www.CryoLogic.com 

ann@cryologic.com 

__________________________________________________________ 

Cryos International - New York, LLC 

Booth # 271 

90 Maiden Lane 

Suite 302 


www.ny.cryosinternational.com 

tk@cryosinternational.com 

__________________________________________________________ 

Digital MD Systems 

Booth # 822 

2350 Airport Frwy 

Suite 200 

Bodford, TX 76022 

dannya@digitalmd.com 

__________________________________________________________ 

Donor Network Alliance 

Booth # 855 

2111 N Seminary 


Donornetworkalliance@gmail.com 

donornetworkalliance@gmail.com 

__________________________________________________________ 

Dre Inc. 

Booth # 504 

1800 Willaimson Court 

Louisville, KY 40223 

www.dremed.com 

jclark@dremedical.com 

__________________________________________________________ 

eBridge Solutions 

Booth # 819 

1018 North Ward Street 

Tampa, FL 33607 

www.eBridgeSolutions.com 

sjones@eBridgesolutions.com 

__________________________________________________________ 

Elsevier, Inc. 

Booth # 400 

1600 JFK Blvd. 

Suite 1800 

Philadelphia, PA 19103 

www.elsevierhealth.com 

j.francis@elsevier.com 

__________________________________________________________ 

Embryotech Laboratories, Inc. 

Booth # 635 

140 Hale Street 

Haverhill, MA 01830 

www.embryotech.com 

mhoward@embryotech.com 

__________________________________________________________ 

EXHIBITS 2010 

174 


Booth # 523, 623 & 629 

One Technology Pl 

Rockland, MA 02370 

antonieta.barros@emdserono.com 

__________________________________________________________ 

Eppendorf 

Booth # 617 

102 Motor Parkway 

Hauppauge, NY 11788 

www.eppendorfna.com 

marrero.c@eppendorf.com 

__________________________________________________________ 

European Society of Human Reproduction and Embryology 

Booth # 255 

Meerstraat 60 

Grimbergen, 01852 

http://www.eshre.eu 

heidi@eshre.eu 

__________________________________________________________ 

European Sperm Bank USA 

Booth # 173 

4916 25th Avenue NE 

Suite 204 

Seattle, WA 98105 

gmoga@nordiccryobank.com 

__________________________________________________________ 

Expecting 411 

Booth # 169 

436 Pine Street 

Boulder, CO 80302 

http://www.expecting411.com 

authors@windsorpeak.com 

__________________________________________________________ 

Fairfax Cryobank 

Booth # 731 


110 


www.fairfaxcryobank.com 


__________________________________________________________ 

Fairfax Egg Bank 

Booth # 729 



www.fairfaxeggbank.com 


__________________________________________________________ 

FDA/Center for Biologics Evaluation & Research (CBER) 

Booth # 171 

1401 Rockville Pike Street 

Suite 200 

Rockville, MD 20852 

kate.luyegu@fda.hhs.gov 

__________________________________________________________

Femasys Inc. 

Booth # 757 

5000 Research Court 

Suite 100 

Suwanee, GA 30024 

www.femasys.com 

mdoyle@femasys.com 

__________________________________________________________ 

FemPartners 

Booth # 461 

1300 Post Oak Blvd. 

Suite 600 


mfaulkner@obgynmail.com 

__________________________________________________________ 

Ferring Pharmaceuticals Inc. 

Booth # 322 

4 Gatehall Dr 3rd Floor 

Parsippany, NJ 07054 

www.ferringUSA.com 

Booth # 322 

__________________________________________________________ 

Fertility Source Companies 

Booth # 217 

2151 Michelson Drive 

Suite 164 

Irvine, CA 92612 

www.fertilitysourcecompanies.com 

sbloom@fertilitysourcecompanies.com 

__________________________________________________________ 

Fertility Technology Resources, Inc. 

Booth # 213 

4343 Shallowford Road 

Suite D4 

Marietta, GA 30062 

www.fertilitystuff.com 

cwsturgeon@fertilitystuff.com 

__________________________________________________________ 

FertilityAuthority.com LLC 

Booth # 515 

150 E 49th St Ste 5A 


gina@fertilityauthority.com 

__________________________________________________________ 

Fibroid SIG 

Booth # 1013 

Meharry Medical College 

Ctr for Women’s Health Research 

Nashville, TN 37208 

ahendy@mmc.edu 

__________________________________________________________ 

Freedom Fertility Pharmacy 

Booth # 529 

12 Kent Ave 

Byfield, MA 01922 

www.freedomfertility.com 

catherine.craig@freedomfertility.com 

__________________________________________________________ 

EXHIBITS 2010 

175 

GE Healthcare 

Booth # 575 

9900 W. Innovation Drive 

Research Park - 2139 

Wauwatosa, WI 53226 

www.gehealthcare.com 

peter.boesen@ge.com 

__________________________________________________________ 

Gene Security Network 

Booth # 453 

2686 Middlefield Road 

Suite C 

Redwood City, CA 94063 

www.GeneSecurity.net 

jdikan@genesecurity.net 

__________________________________________________________ 


Booth # 259 

5555 Conner Avenue 

Detroit, MI 48213 

dorothy.twinney@genesisgenetics.org 

__________________________________________________________ 

Genzyme 

Booth # 537 

1700 West Park Drive 

Suite 400 

Westborough, MA 01581 

kimberly.mascaro@genzyme.com 

__________________________________________________________ 

Good Start Genetics 

Booth # 923 

8 Saint Mary’s Street 

Boston, MA 02215 

www.gsgenetics.com 

dhardison@gsgenetics.com 

__________________________________________________________ 

Hamilton Thorne, Inc. 

Booth # 335 

100 Cummings Center 

465E 

Beverly, MA 01915 

www.hamiltonthorne.com 

info@hamiltonthorne.com 

__________________________________________________________ 

Hologic, Inc. 

Booth # 404 

35 Crosby Drive 

Bedford, MA 01730 

www.hologic.com 

ldigangi@hologic.com 

__________________________________________________________ 

Houston POF/POI Inc. 

Booth # 359 

6624 Fannin Ste 1800 


mjheardmd@pol.net 

__________________________________________________________

Idant Laboratory 

Booth # 333 

350 5th Avenue 

Suite 7120 


stephen@daxor.com 

__________________________________________________________ 

Incept Bio Systems, Inc. 

Booth # 464 

401 West Morgan Road 

Ann Arbor, MI 48108 

j.dellagatta@inceptbio.com 

__________________________________________________________ 

Informa Healthcare 

Booth # 828 

69-77 Paul Street 

London, EC2A 4LQ 

www.informahealthcarebooks.com 

ushma.mistry@informa.com 

__________________________________________________________ 

Insightec 

Booth # 358 

4851 LBJ Freeway 

Suite 400 

Dallas, TX 75244 

taylors@insightec.com 

__________________________________________________________ 

IntegraMed America 

Booth # 711 

2 Manhattanville Road 

Purchase, NY 10577 

www.attainfertilitycenters.com 

jacquelyn.dunn@integramed.com 

__________________________________________________________ 

Interlace Medical 

Booth # 458 

135 Newbury Street 

Framingham, MA 01701 

www.myosure.com 

nicole@interlacemedical.com 

__________________________________________________________ 

International Prematue Ovarian Failure Assoc. Inc 

Booth # 1011 

133 Dale St 

Alexandria, VA 22305 

www.ipofa.org 

pof2@aol.com 

__________________________________________________________ 

Intuitive Surgical 

Booth # 216 

1266 Kifer Road 

Building 101 

Sunnyvale, CA 94086 

angie.lopez@intursurg.com 

__________________________________________________________ 

EXHIBITS 2010 

176 

InVitroCare, Inc. 

Booth # 368 

8415 Progress Drive 

Suite F 

Frederick, MD 21701 

www.invitrocare.com 

karyn@invitrocare.com 

__________________________________________________________ 

Irvine Scientific 

Booth # 133 

2511 Daimler Street 

Santa Ana, CA 92705 

www.irvinesci.com 

kcarlin@irvinesci.com 

__________________________________________________________ 

ITM Ureme Sagligi Urunleri LTD. STI 

Booth # 434 

Ceyhun Atif Kansu Caddesi GOzde Plaza 

130/70 

Ankara, 06520 

www.itmmedical.com 

onurozturk@itmmedical.com 

__________________________________________________________ 

IVFonline 

Booth # 309 

393 Soundview Road 

Guilford, CT 06437 

www.ivfonline.com 

exhibits@IVFonline.com 

__________________________________________________________ 

IVI Valencia 

Booth # 576 

Plaza de la PolicIa Local, 3 

Valencia, 46015 

nicolas.garrido@ivi.es 

__________________________________________________________ 

Jaypee-Highlights Medical Publishers 

Booth # 266 

City of Knowledge 

Building 237 P.B. 

Panama, 00000 

www.jphmedical.com 

creyes@jphmedical.com 

__________________________________________________________ 

Karl Storz Endoscopy America 

Booth # 542 

2151 E. Grand Avenue 

El Segundo, CA 90245 

www.ksea.com 

nmarinello@ksea.com 

__________________________________________________________ 

KITAZATO 

Booth # 565 

81 Nakajima 

Fuji, 416-0907 

http://www.kitazato-biopharma.com 

trading@kitazato-biopharma.com 

__________________________________________________________

Kivex Biotec Inc. K-Systems USA 

Booth # 552 

2420 4th Lane SW 

Vero Beach, FL 32962 

mk@k-system.dk 

__________________________________________________________ 

LabCorp - Viromed Laboratories 

Booth # 948 

6101 Blue Circle Drive 

Minnetonka, MN 55343 

www.labcorp.com 

raiken@labcorp.com 

__________________________________________________________ 

Labotect GmbH 

Booth # 859 

Willi-Eichler-Str. 25 

GOttingen, D-37079 

www.labotect.com 

martin@labotect.com 

__________________________________________________________ 

Labs, Inc. 

Booth # 355 

6933 - B.S. Revere Pkwy 

Centennial, CO 80112 

jonathan_bautista@labs-inc.org 

__________________________________________________________ 

Lippincott Williams & Wilkins 

Booth # 560 

Two Commerce Square 

2001 Market Street 

Philadelphia, PA 19103 

rebecca.russell@wolterskluwer.com 

__________________________________________________________ 

Marina Medical Instruments 

Booth # 353 

955 Shot Gun Road 

Sunrise, FL 33326 

laura@marinamedical.com 

__________________________________________________________ 

MDR Pharmaceutical Care 

Booth # 417 

16500 Ventura Blvd. 

Encino, CA 91436 

maria@mdrusa.com 

__________________________________________________________ 

Med Market Link 

Booth # 500 

2400 Broadway 

Denver, CO 80205 

http://www.medmarketlink.com 

gchipps@vanguardcommunications.net 

__________________________________________________________ 

Med Software LLC 

Booth # 668 

19 North Road 

Kinnelon, NJ 07405 

www.resourceuser.com 

johna@objectron.com 

__________________________________________________________ 

EXHIBITS 2010 

177 

MedGyn Products 

Booth # 466 

328 N. Eisenhower Lane 

Lombard, IL 60148 

www.medgyn.com 

a.dandrea@medgyn.com 

__________________________________________________________ 

Medison America, Inc. 

Booth # 849 

11075 Knott Avenue 

Suite C 

Cypress, CA 90630 

mgallin@mai.medison.com 

__________________________________________________________ 

MedTech for Solutions, Inc. 

Booth # 257 

475 Park Avenue South 


info@medtech4solutions.com 

__________________________________________________________ 

Memorial Blood Centers 

Booth # 401 

737 Pelham Blvd. 

St. Paul, MN 55114 

lmkatzung@mbc.org 

__________________________________________________________ 

Merck & Co., Inc. 

Booth # 101 

351 North Sumneytown Pike 

UG3A-203Q 

North Wales, PA 19454 

Gail_Griffith@Merck.com 

__________________________________________________________ 

Metro Drugs 

Booth # 314 

13 East 8th Street 


adriane@metrodrugs.com 

__________________________________________________________ 

Microptic SL 

Booth # 215 

Viladomat 321 

Barcelona, 08029 

www.micropticsl.com 

micropticsl@micropticsl.com 

__________________________________________________________ 

MicroSort 

Booth # 830 


Suite 101 


www.microsort.net 


__________________________________________________________

Molecular Biometrics Inc. 

Booth # 375 

1 Edgewater Drive 

Suite 110 

Norwood, MA 02062 

www.molecularbiometrics.com 

kpower@molecularbiometrics.com 

__________________________________________________________ 

MTG Medical Technology Vertriebs-GmbH 

Booth # 546 

Dr.-Pauling-Str. 9 

Bruckberg, D-84079 

www.mtg-de.com 

sschweitzer@mtg-de.com 

__________________________________________________________ 

MVE-Chart 

Booth # 212 

2200 Airport Industrial Drive 

Suite 500 

Ball Ground, GA 30107 

elizabeth.hofstetter@chart-ind.com 

__________________________________________________________ 

Narishige International USA, Inc. 

Booth # 436 

1710 Hempstead Turnpike 

East Meadow, NY 11554 

narishige-usa@pb.net 

__________________________________________________________ 

National Embryo Donation Center 

Booth # 432 

116 Concord Road 

Suite 400 

Knoxville, TN 37934 

www.embryodonation.org 

dfrederes@embryodonation.org 

__________________________________________________________ 

New Life Agency, Inc. 

Booth # 555 

6900 Aragon Circle 

Buena Park, CA 90620 

www.newlifeagency.com 

trish@newlifeagency.com 

__________________________________________________________ 

Nikon Instruments, Inc. 

Booth # 175 

1300 Walt Whitman Road 

Melville, NY 11747 

www.nikoninstruments.com 

jwenner@nikon.net 

__________________________________________________________ 

Nurses Professional Group 

Booth # 443 

6 Fieldstone Ln 

Beverly, MA 01915 

naharring@gmail.com 

__________________________________________________________ 

EXHIBITS 2010 

178 

NW Cryobank 

Booth # 616 

508 W. 6th Avenue 

Suite 610 

Spokane, WA 99204 

www.nwcryobank.com 

tammyz@nwcryobank.com 

__________________________________________________________ 

Olympus America 

Booth # 465 

3500 Corporate Parkway 

Center Valley, PA 18034 

www.olympusamerica.com 

tricia.duff@olympus.com 

__________________________________________________________ 

Origio 

Booth # 543 

77 Elbo Lane 

Mount Laurel, NJ 08054 

www.origio.com 

lmcnamara@midatlanticdiagnositcs.com 

__________________________________________________________ 

Orlando CVB 

Booth # 857 

6700 Forum Drive 

Suite 100 

Orlando, FL 32821 

terri.thompson@orlandocvb.com 

__________________________________________________________ 

Our Fairy Godmother 

Booth # 618 

5625 Strand Blvd Ste 501 

Naples, FL 34110 

www.ourfairygodmother.com 

cathyr@ourfairygodmother.com 

__________________________________________________________ 

Oxford University Press 

Booth # 253 

2001 Evans Road 

Cary, NC 27513 

www.oxfordjournals.org / www.oup.com 

erin.norris@oxfordjournals.org 

__________________________________________________________ 

Pacific Coast Reproductive Society 

Booth # 825 

P.O. Box 2223 

Sisters, OR 97759 

alexis@pcrsonline.org 

__________________________________________________________ 

Pamlab, LLC 

Booth # 371 

PO Box 8950 

Mandeville, LA 70470 

www.neevoprenatal.com 

conventions@pamlab.com 

__________________________________________________________

Pathway Genomics 

Booth # 470 

4045 Sorrento Valley Blvd 

San Diego, CA 92121 

www.Pathway.com 

julia.stegmeir@pathway.com 

__________________________________________________________ 

Pfizer 

Booth # 743 

500 Arcola Rd E 5221 

Collegeville, PA 19046 

www.pfizer.com 

ashley.arnold@pfizer.com 

__________________________________________________________ 

Planer PLC 

Booth # 451 

110 Windmill Road 

Sunbury-on-Thames, TW16 7HD 

rdattani@planer.co.uk 

__________________________________________________________ 

Practice Dock 

Booth # 115 

1060 Woodcock Road 

Orlando, FL 32803 

www.practicedock.com 

danadz@practicedock.com 

__________________________________________________________ 

PracticeHwy.com 

Booth # 734 

1505 LBJ 

Suite 200 

Dallas, TX 75234 

angela@practicehwy.com 

__________________________________________________________ 

Prosperity Specialty Pharmacy 

Booth # 614 

3026 Javier Road 


nina.franzke@att.net 

__________________________________________________________ 

Quadrant HealthCom, Inc. 

Booth # 853 

7 Century Drive 

Suite 302 

Parsippany, NJ 07054 

Quadrant HealthCom Inc. 

maria.walsh@qhc.com 

__________________________________________________________ 

Quick International Courier 

Booth # 369 

Chelsea Piers 

Pier 59 


www.quickintl.com 

barbara_bours@qintl.com 

__________________________________________________________ 

EXHIBITS 2010 

179 

Rachel’s Well, Inc. 

Booth # 1015 

1306 Baker Crest Court 

McLean, VA 22101 

www.rachelswell.org 

yoko_nelson@hotmail.com 

__________________________________________________________ 

Reglera LLC 

Booth # 727 

555 Zang Street 

Suite 100 

Lakewood, CO 80228 

salversonk@reglera.com 

__________________________________________________________ 

Reproductive Genetics Institute 

Booth # 544 

2825 N. Halsted Street 


www.reproductivegenetics.com 

rgiworld@gmail.com 

__________________________________________________________ 

Reproductive Possiblities, LLC/Melissa B. Brisman 

Booth # 361 

1 Pargan Drive 

Suite 160 

Montvale, NJ 07645 

www.reproductivepossibilities.com 

vwalker@reproductivepossibilities.com 

__________________________________________________________ 

Reprogenetics 

Booth # 165 

3 Regent Street 

Suite 301 

Livingston, NJ 07030 

www.reprogenetics.com 

kelly.ketterson@embryos.net 

__________________________________________________________ 

ReproSource 

Booth # 274 

106 Crosswaite Way 

Cary, NC 27518 

cjenkins@reprosource.com 

__________________________________________________________ 

Reprotech Ltd. 

Booth # 723 

110 Country Estates Circle 

Suite 2 

Reno, NV 89511 

dlbatastini@reprot.com 

__________________________________________________________ 

Research Instruments LTD. 

Booth # 611 

Bickland Industrial park 

Falmouth, TR11 4TA 

bill@research-instruments.com 

__________________________________________________________

Resolve: The National Infertility Association 

Booth # 219 

1760 Old Meadow Road 

Suite 500 

McLean, VA 22102 

__________________________________________________________ 

Richard Wolf Medical Instruments Corporation 

Booth # 501 

353 Corporate Woods Pkwy 

Vernon Hills, IL 60061 

conventions@richardwolfusa.com 

__________________________________________________________ 

Roche Diagnostics 

Booth # 558 

9115 Hague Road 

Indianapolis, IN 46250-0457 

www.mylabonline.com 

ellen.byrum@roche.com 

__________________________________________________________ 

Rocket Medical PLC 

Booth # 517 

150 Recreation Park Drive 

3 

Hingham, MA 02043 

www.rocketmedical.com 

bruce@rocketmedical.com 

__________________________________________________________ 

SAGE In-Vitro Fertilization, A Cooper Surgical Company 

Booth # 159 

95 Corporate Drive 

Trumbull, CT 06611 

kathy.marino@coopersurgical.com 

__________________________________________________________ 

Sanyo North America 

Booth # 405 

1300 Michael Drive 

Suite A 

Wood Dale, IL 60191 

http://us.sanyo.com/biomedical 

lrafson@sss.sanyo.com 

__________________________________________________________ 

SCSA Diagnostics 

Booth # 318 

807 32nd Avenue 

Brookings, SD 57006 

scsakris@brookings.net 

__________________________________________________________ 

Sefi Medical Instruments 

Booth # 548 

50A Disraeli Street 

P.O.Box 7295 

Haifa, 31070 

makler@netvision.net.ip 

__________________________________________________________ 

EXHIBITS 2010 

180 

Siemens Medical Solutions USA, Inc. 

Booth # 303 

51 Valley Stream Parkway 

Malvern, PA 19355 

www.usa.siemens.com/healthcare 

ruthann.crimmins@siemens.com 

__________________________________________________________ 

Smith & Nephew Endoscopy 

Booth # 153 

150 Minuteman Road 

Andover, MA 01810 

www.sntruclear.com 

sue.hanlon@smith-nephew.com 

__________________________________________________________ 

Smiths Medical International Ltd 

Booth # 659 

1500 Gureca Business Park 

Lower Pemberton 

Ashford, TN25 4BF 

smiths-medical.com 

sarah.fry@smith-medical.com 

__________________________________________________________ 

Society for the Study of Reproduction (SSR) 

Booth # 507 

1619 Monroe Street 

Madison, WI 53711 

ssradmin@ssr.org 

__________________________________________________________ 

Society of Reproductive Surgeons (SRS) 

Booth #457 

1209 Montgomery Highway 

Birmingham, AL 35216 

http://www.reprodsurgery.org/ 

cdavis@asrm.org 

__________________________________________________________ 

Spectrum Technologies 

Booth # 452 

1532 Chablis Road 

Suite 101 

Healdsburg, CA 95448 

www.consultstonline.com 

peter@consultstonline.com 

__________________________________________________________ 

Springer Science+Business Media 

Booth # 922 

233 Spring St 


www.springer.com 

exhibits-ny@springer.com 

__________________________________________________________ 

Steptoe 

Booth # 710 

99 Derby Street 

Suite 200 

Hingham, MA 02043-3009 

www.steptoetherapeutics.com - www.steptoemd.com - 

www.nutrafertil.com 

eduardo@steptoetherapeutics.com 

__________________________________________________________

Sunlight Medical Inc. 

Booth # 364 

12443 San Jose Blvd 

Suite 602 

Jacksonville, FL 32223 

firmdsyang@aol.com 

__________________________________________________________ 

Surrogacy Specialists of America, LLC/Parenting Op 

Booth # 459 

10777 Westheimer Ste 211 


www.ssa-agency.com 

gregssa@aol.com 

__________________________________________________________ 

Teva Women’s Health 

Booth # 929 

400 Chestnut Ridge Rd 

Woodcliffe Lake, NJ 07677 

www.tevawomenshealth.info 

joanna.specht@barrlabs.com 

__________________________________________________________ 

The American Fertility Association 

Booth # 823 

305 Madison Avenue 

Suite 449 


www.theafa.org 

lisav@theafa.org 

__________________________________________________________ 

The Apothecary Shop 

Booth # 113 

23620 N 20th Drive 

Suite 12 

Phoenix, AZ 85085 

www.theapothecaryshop.com 

lstrait@theapothecaryshop.com 

__________________________________________________________ 

The Found Animals Foundation 

Booth # 861 

P. O. Box 66370 

Los Angeles, CA 90066 

www.foundanimals.org 

k.palfrey@foundanimals.org 

__________________________________________________________ 

The New York Stem Cell Foundation 

Booth # 553 

1995 Broadway 

Suite 1201 


http://www.nyscf.org/ 

jbecht@nyscf.org 

__________________________________________________________ 

Thermo Scientific 

Booth # 214 

Fortune Blvd. 

Milford, MA 01757 

Catherine.bourque@thermofisher.com 

__________________________________________________________ 

EXHIBITS 2010 

181 

Thomas Medical 

Booth # 365 

5610 W 82nd Street 

Indianapolis, IN 46278 

www.thomasmedical.com 

jgreen@catheterresearch.com 

__________________________________________________________ 

Tokai Hit Co., Ltd. 

Booth # 506 

306-1, Gendoji-cho, Fujinomiya-shi 

Shizuoka-ken, 418-0074 

http://www.tokaihit.com/ 

sales-os@tokaihit.com 

__________________________________________________________ 

Tosoh Bioscience 

Booth # 551 

5000 Shoreline Ct. 

Suite 1010 

South San Francisco, CA 94080 

www.tosohbioscience.us 

melinda.vahedi@tosoh.com 

__________________________________________________________ 

Ultrasonix Medical Corporation 

Booth # 829 

F130-4311 Viking Way 

Richmond, BC V6V 2K9 

www.ultrasonix.com 

danielle.mccallum@ultrasonix.com 

__________________________________________________________ 

Unilab of Dade 

Booth # 664 

2145 W Davie Blvd 106 

Ft. Lauderdale, FL 33312 

http://www.infertilitylab.com 

unilabers@aol.com 

__________________________________________________________ 

Unisense Fertilitech A/S 

Booth # 751 

Tueager 1 

Aarhus, 08200 

fab@unisense.com 

__________________________________________________________ 

Univfy Inc. 

Booth # 924 

685 Jay Street 

Los Altos, CA 94022 

http://www.univfy.com 

kdogster96@gmail.com 

__________________________________________________________ 

Upsher-Smith Laboratories, Inc. 

Booth # 569 

6701 Evenstad Dr 

Maple Grove, MN 55369 

becky.bouley@upsher-smith.com 

__________________________________________________________ 

Village Fertility Pharmacy, Inc. 

Booth # 411 

1335 Bear Hill Road 

Waltham, MA 02451 

vsyat@villagepharmacy.com 

__________________________________________________________

Vitrolife, Inc. 

Booth # 143 

3601 S. Inca Street 

Englewood, CO 80110 

pstewart@vitrolife.com 

__________________________________________________________ 

Vivere Health 

Booth # 477 

720 Cool Springs Blvd 

Suite 520 

Frankline, TN 37067 

dbradley@viverehealth.com 

__________________________________________________________ 

Walgreens 

Booth # 651 

1411 Lake Cook Rd. 

Deerfield, IL 60015 

melissa.welch@walgreens.com 

__________________________________________________________ 

Warner Chilcott LLC 

Booth # 559 

100 Enterprise Drive 

Rockaway, NJ 07866 

tmuldoon@wcrx.com 

__________________________________________________________ 

Watson Pharma LLC 

Booth # 433 

F354 Eisenhower Pkwy 

Livingston, NJ 07039 

www.watson.com 

mvetrone@columbialabs.com 

__________________________________________________________ 

EXHIBITS 2010 

182 

Xytex Cryo International 

Booth # 117 

1100 Emmett Street 

Augusta, GA 30904 

srivers@xytex.com 

__________________________________________________________ 


Booth # 1017 

1300 George Street 

Suite 735 

New Haven, CT 06511 

http://info.med.yale.edu/obgyn/kliman/ 

harvey.kliman@yale.edu 

__________________________________________________________ 

Yodle 

Booth # 455 

150 West 23rd Street 

Suite 401 


www.yodle.com 

shows@yodle.com 

__________________________________________________________ 

Zander IVF, Inc. 

Booth # 252 

PO Box 650790 

Vero Beach, FL 32965-0790 

fzander@zanderIVF.com 

__________________________________________________________

Rebecca Gibbons 

Monday, October 25th 

9:00 am - 10:00 am 

SPOUSE/GUEST PROGRAM 

Margaret 

“Molly” Brown 

Debra Faulkner 

Historian 

From Hannibal hellion to Titanic 

heroine, the real Margaret 

Tobin Brown was even more 

colorful than the fictionalized 

“Unsinkable Molly” of musical 

and movie fame. One of 

Colorado’s most legendary 

ladies, Margaret was an 

outspoken but warm-hearted woman, in many ways 

ahead of her time. As a teen, she headed for the silver 

boom town of Leadville, determined to marry a rich 

man, but settling instead for love. Ironically, their happy 

home life was turned upside down when the discovery of 

gold in the Little Jonny Mine made J. J. Brown one of the 

wealthiest men in the West. 

Painfully conscious of her lack of education and 

refinement, Margaret set out to improve herself through 

world travel and private lessons in everything from foreign 

languages to acting. A generous philanthropist in her own 

right, she was also a crackerjack fundraiser for worthy 

causes of all sorts. Best known for surviving the Titanic 

disaster, Margaret parlayed her fame into a platform for 

championing the rights of women, children, minorities, 

and working-class families. The redoubtable Mrs. Brown 

even ran for political office before national women’s 

suffrage was granted. 

Colorado women’s historian, Debra Faulkner, presents 

Margaret’s story in a lively first person program, illustrated 

with vintage images of Mrs. Brown’s life and times. The 

“unsinkable” lady’s indomitable pluck, determination, 

courage and generosity will inspire and delight audiences 

of all ages. 

Welcome to Denver! Bill and I hope you will enjoy the time you are about 

to spend in this lovely city. 

Beginning Saturday, October 23rd through Wednesday, October 27th, 

registered spouses and guests of those attending the meeting are most 

welcome to join me for a continental breakfast in the Hospitality Suite 

located in the Hyatt Regency Convention Center Hotel in Denver. The 

room will be open between 8:00 and 10:00 each morning. 

We hope you will enjoy the programs that have been arranged to 

highlight areas of interest. In addition, information will be available to help 

you make plans to explore and enjoy the many attractions Denver has to 

offer. 

Our Hospitality Suite will be the perfect place to visit with friends and to 

make new acquaintances over a cup of coffee and a bite to eat. I look 

forward to seeing you there! 

Warmest Regards, 

Rebecca Gibbons 

183 

Tuesday, October 26th 

9:00 am - 10:00 am 

Who is Dr. Colorado?!? 

Thomas J. “Dr. Colorado” Noel, Ph.D. 

Professor of History 

Director of Public History, Preservation & 

Colorado Studies 


Thomas J. “Dr. Colorado” Noel, a Professor of History and 

Director of Public History, Preservation & Colorado Studies 

at the University of Colorado Denver (UCD), is the author of 

numerous books, articles and columns. Tom is a graduate 

of UCD and the University of Colorado at Boulder, where his 

mother (a psychiatrist) and grandmother (a teacher) also 

completed graduate work. 

Tom teaches Denver, Colorado, Heritage Tourism, Historic 

Preservation, Mining & Railroads, National Parks History, U.S. 

West, and Western Art & Architecture courses at UCD, as well 

as conducting tours of the highest state and the Mile High 

City for the Smithsonian Institute and the Colorado History 

Museum. Tom writes a regular column for the Sunday Denver 

Post Perspective section and also appears on Denver KUSA 

Channel 9’s “Colorado & Company” as Dr. Colorado. Tom 

co-directs UC Denver’s Center for Colorado & The West. 

The Spouse/Guest Hospitality Room 

will be located at the 

Hyatt Regency Hotel, Room Mineral A. 

This room is open from 8:00 a.m. to 10:00 a.m., 

Saturday, October 23rd through 

Wednesday, October 27th, and 

will be the site of the presentations. 

Spouse/Guest badge required for entry.

ASRM ADMINISTRATIVE STAFF 

1209 Montgomery Highway, Birmingham, AL 35216-2809 

Phone (205) 978-5000 • Fax (205) 978-5005 • Email asrm@asrm.org • URL www.asrm.org 

STAFF POSITION TEL EXT EMAIL 

Robert W. Rebar, M.D. Executive Director 114 rrebar@asrm.org 

Barbara Cancilla Executive Assistant to Executive 

Director; Staff support for Board 

of Directors, Executive, 

Internationall Affairs & ESHRE/ 

ASRM Liason Committees 

184 

114 bcancilla@asrm.org 

Nancy R. Frankel, M.B.A. Chief Operating Officer 125 nfrankel@asrm.org 

Andrew La Barbera, Ph.D., H.C.L.D. Scientific Director 144 alabarbera@asrm.org 

Pamela Gallagher Director of Development 121 pgallagher@asrm.org 

Deborah A. Hanson Director, Meetings and Exhibits 108 dhanson@asrm.org 

Mitzi Mize, M.S. Director, Communications 112 mmize@asrm.org 

Dorothy Beatty Membership Secretary 136 dbeatty@asrm.org 

Jacqueline Boohaker, M.A. Graphic Designer 157 jboohaker@asrm.org 

Nancy Bowers, B.S.N., R.N., M.P.H. Education Specialist 128 nbowers@asrm.org 

Michael J. Cochran Network Administrator 110 mcochran@asrm.org 

Christy Davis, B.S. Member Services Coordinator 113 cdavis@asrm.org 

Kim Farrington Member Services Coordinator 134 kfarrington@asrm.org 

Penelope Fenton Education Project Coordinator 106 pfenton@asrm.org 

Cathy Galloway Education Program Coordinator 116 cgalloway@asrm.org 

Cherie Holverstott Assistant to the Chief 

Operating Officer/ Human 

Resources Coordinator/Facility 

Management 

155 cholverstott@asrm.org 

Lee Hutchison, M.A. Education Program Administrator 137 lhutchison@asrm.org 

Kelley Jefferson Affiliate Society Manager, SART 109 kjefferson@asrm.org 

Lauren Mallory, B.A. Software Support Specialist 169 lmallory@asrm.org 

Angelia Pitman Web Site Manager 131 apitman@asrm.org 

Keith Ray, B.A. Manager, Grant Development and 

Coordination 

127 kray@asrm.org 

Susanna Scarbrough, B.A. Project Manager, Membership 119 sscarbrough@asrm.org 

Lennie Siegel, B.B.A., C.P.A. Controller 103 lsiegel@asrm.org 

Leigh Ann Simpson Industry Liaison 111 lsimpson@asrm.org 

Lou Ella Watkins Accounting Services 

Administrator 

104 lwatkins@asrm.org 

Cori Watts Member Services Coordinator 129 cwatts@asrm.org 

Eva Zhao, B.A. Education Instructional Technology 

Designer 

107 ezhao@asrm.org 

ASRM WASHINGTON STAFF 

409 12th Street SW, Suite 203, Washington, D.C. 20024 • Phone (202) 863-4958 • Fax (202) 484-4039 

STAFF POSITION TELEPHONE EMAIL 

Sean B. Tipton, M.A. Director, Public Affairs (202) 863-2494 stipton@asrm-dc.org 

Eleanor Nicoll, J.D. Public Affairs Manager (202) 863-2439 enicoll@asrm-dc.org 

Erin Kramer Public Affairs Associate (202) 863-4985 ekramer@asrm-dc.org 

NaTasha Driggers Admistrative Assistant (202) 863-4985 ndriggers@asrm-dc.org 

FERTILITY AND STERILITY EDITORIAL OFFICE 

1209 Montgomery Highway, Birmingham, AL 35216-2809 • Fax (205) 978-5005 

STAFF POSITION TELEPHONE EMAIL 

Alan DeCherney, M.D. Editor (301) 496-5800 decherney@gmail.com 

Eric Steinmehl, B.A. Managing Editor (205) 978-5000, ext. 139 esteinmehl@asrm.org 

Nancy Kucik Editorial Assistant (205) 978-5000, ext. 140 nkucik@asrm.org

ASRM thanks the 

Ruby Supporter 

for their support of the 

2010 Annual Meeting 

Merck 

Pfizer 

INDEXES

PARTICIPANT AND SPOUSE/PARTNER DISCLOSURES INDEX 2010 

Program participants are required to disclose commercial and financial relationships with manufacturers of pharmaceuticals, 

laboratory supplies, medical devices and with commercial providers of medically related services. Unless otherwise noted below, the 

participants have nothing to disclose. Additional disclosures can be found online. 

Adamson, G. David: CEO, Shareholder, Advanced Reproductive Care; Resarch Funds, IBSA, LabCorp; Past President, ASRM, 

Secretary Treasurer, ICMART; Board, IFFS, Chair, Reproductive Medicine Cmte - FIGO; President, WERF 

Armstrong, Joanne: Aetna, Employee of Aetna 

Aubuchon, Mira: Schering Plough, Speaker’s bureau 

Baker, Valerie L.: IBSA, research support 

Ball, G. David: Cooper Surgical, Scientific Advisor 

Barnhart, Kurt T.: Pfizer Inc., Legal consultant; Watson, Legal consultant; Swiss Precision Diagnostics, Legal consultant 

Bates, G. Wright: Genzyme Biosurgical, Inc, Speaker / Consultant 

Behr, Barry: Cooper Surgical, Consultant; EMB Serono, Spearkers Board; Origio, Consultant 

Benadiva, Claudio: Schering-Plough, Speakers bureau; Serono, Speakers bureau 

Berga, Sarah L.: Noven Advisory Board, Menopause Management, 2010, Consultant; Watson Pharmaceuticals, Women’s 

Health Strategic Advisory Board, 2010, Consultant; AHC Media, LLC, 2008-2010, Consultant; Promedica 

Communications - Bayer Pharmaceuticals Advisory Board Meeting, 2009, Consultant; Leydig, Voit & 

Mayer, Ltd - Representing Lupin Pharmaceuticals regarding patent for Ortho Tri-Cyclen Lo, January 

2010 - Present, Consultant; Reed Smith, LLC, Representing Schering Plough/Organon in NuvaRing 

Litigation, July 2009 - Present, Consultant 

Black, Lauri D.: McKesson, Per diem contractor 

Boivin, Jacky: Merck-Serono SA, Consultant; Schering-Plough, Consultant 

Brison, Daniel: Novocellus Ltd, Shareholder 

Bulun, Serdar E.: Meditrina, Consultant; Orphagen, Consultant; Novartis, Consultant; Endo, Consultant 

Bustillo, Maria: EMD Serono, Speaker’s bureau; Advanced Reproductive Care, Board of Directors 

Carr, Bruce R.: Teva, Grant; Neurocrine, Grant; Wyeth, Grant; Novo Nordisk, Consult 

Carrell, Douglas T.: Gamete Analytics, Inc, Stock 

Cataldo, Nicholas A.: Schering Plough (Merck), Faculty speaker 

Catherino, William H.: Bayer Schering Pharma, Research Grant and Speaking Fees; Ferring Pharmaceuticals, Research Grant; 

EMD Serono, Research Grant and Speaking Fees; Tokai Pharmaceuticals, Research Grant and Speaking 

Fees 

Centola, Grace M.: New England Cryogenic Center, Off-site lab director and tissue bank director; Cryos International-NY, Off 

site lab director and tissue bank director; Manhattan Reproductive Medicine, Consultant; Fertility Center of 

California, Consultant 

Chang, R. Jeffrey: Beckman-Coulter, Inc., Consultant 

Chang, Wendy Y.: Ferring Pharmaceuticals, Research grant; Serono Pharmaceuticals, Research grant 

Christman, Gregory M. M.:Bayer Schering Pharma, Berlin, Honorarium - Invited Lecture 

Coddington, Charles C.: Abbott, Stock; Genzyme, Stock; Stock 

Confino, Edmond: Serono Inc, Ad hoc consultant; Organon Inc, Ad hoc consultant 

Cooper, Amber R.: Beckman Coulter, Inc, They provide a small amount of support by supplying the serum assay kits to 

an outside lab. They have no role in the conception, design, execution or analysis of the study data. I 

receive no personal financial support, nor does my institution.; I have no other personal financial conflicts 

of interest or relationships 

Copperman, Kira: EMD Serono, Speakers Bureau; Schering Plough, Speakers Bureau 

Cowan, Barrett E.: Glaxo Smith Kline, Speakers Bureau, clinical research site; Astellas Pharmaceuticals, Speakers Bureau; 

Nymox, Clinical Research Site; Warner Chilcott, Clinical Research Site; Eli Lilly, Clinical Research Site 

Crockin, Susan L.: BMS, Bayer, Onyx, Novartis, Genzyme, Aveo, Consultant


Evers, Johannes L. H.: Schering Plough, Other relationship: My Department received research funding; Ferring, Other 

relationship: My Department received research funding 

Falcone, Tommaso: Gynesonics, Inc, Consultant 

Fazleabas, Asgerally: Abbot, Scientific Advisor; Bayer Schering AG, Consultant; Ferring, Consultant 

Feingold, Madeline L.: Merck, My hustand and I own a small amount of shares of Merck stock 

Galst, Joann Paley: Pfizer, Stock ownership; Merck, Stock ownership 

Giudice, Linda: Neurocrine Biosciences, Scientific Advisory Board Member; Endo Pharmaceuticals, Scientific Advisory 

Board Member; EMD-Serono, Scientific Advisory Board Member; Merck, Pfizer, Common Stock; Quest 

Diagnostics, Academic Advisor 

Go, Kathryn J.: Ferring Pharmaceuticals, Inc., Parsippany, NJ, Director, Medical Science Services 

Goldstein, Marc: Therologix, Advisory Board 

Goldstein, Steven R.: Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordis, Merck, Gyn Advisory Borad; Cook ObGyn, 

Consultant; Philips Ultrasound, Consultant; Eli Lilly & Co, Warner Chilcott, Speakers Bureau; Sonosite, 

Inc., Director 

Goverde, Angelique: Teaching and Speakers fees, Schering Plough 

Guidice, Linda C.: Neurocrine Biosciences, Scientific Advisory Board Member; Endo Pharmaceuticals, Scientific Advisory 

Board Member; EMD-Serono, Scientific Advisory Board Member; Merck, Pfizer, Common Stock; Quest 

Diagnostics, Academic Advisor 

Gunawardena, Shalini S.: Walgreen’s Nursing Advisory Board, Advisory board participant; Serono Advisory Board, Participant 

Hammond, Karen R.: Merke, Consultant, Speakers’ Bureau; Walgreen’s Speciality Pharmacy, Consultant, Speakers’ Bureau 

Heard, Michael J. J.: Sigma Tau Pharmaceuticals, Consultant/Speaker-Receive Honorarium; Warner Chilcott Pharmaceuticals, 

Speaker’s Bureau-Receive Honorarium; OB/GYN Board Prep, LLC, Faculty; Catobygn, LLC, Owner/ 

Medical Director 

Honig, Stanton C.: Serono, Consultant, Advisor; Auxilium, advisor, clinical trial; Slate, Consultant; Lilly, Pfizer, Sanofi, 

Novartis, Consultant; AMS, Coloplast, Consultant 

Hornstein, Mark D.: WINFertility, Medical Advisory Board; Up To Date, Contributor 

Isaacson, Keith: Karl Storz Endoscopy, Consultant 

Jackson, Maria: Walgreens, Consultant 

Jackson, Maria M.: Walgreens, Consultant 

Janik, Grace: Hologic, Research trial investigator; Storz, Consultant 

Jensen, Jeffrey T.: Bayer, Advisory Board, Consultant, Research Support, Speaker; Population Council, Resarch Support; 

Merck (Schering Plough), Advisory Board 

Joffe, Hadine: Sanofi-Aventis, Consultant; Pfizer, Consulting; Bayer HealthCare Pharmaceuticals, Grant support to 

research program; Forest Laboratories, Inc., Grant support to research program; GlaxoSmithKline, Grant 

support to research program 

Jungheim, Emily: Genentech, Speaker’s bureau 

Karabinus, David S.: Genetics & IVF Institute, Employee 

Katz, Eugene: EMD-Serono, Speaker’s bureau 

Ke, Raymond W.: Merck, Research grant; Columbia Laboratories, Research grant 

Kim, Edward D.: Eli Lilly, Advisory Board; Watson, Speaker; Astellas, Speaker; Eli Lilly, Speaker 

Kingsberg, Sheryl A. A.: Boehringer -Ingelheim, Consulting, Clinical research; Wyeth, Consulting; BioSante, Clincal trial 

investigator; Johnson and Johnson, consulting; Viveve, Scientific ad board, own stock options 

Klein, Nancy A.: Ferring Pharmaceuticals, Consultant 

Knudson, Gail A: Boehringer-Ingelheim, Consultant; Astra Zeneca, Recipient of Unrestrricted Educational Grants on behalf 

of CPATH 

Kolettis, Peter Nicholas: ISTA Pharmaceuticals, Stockholder 

Larman, Mark G.: Vitrolife AB, Receive research grant 

Lee, Michael A.: Cook Women’s Health, Consultant on laboratory products 

Leese, Henry: Novocellus Ltd UK, Scientific Advisor and shareholder 

Legro, Richard S.: Endo Soc; Clin Guidelines Subcomm; Endo Soc, SGI; Abstract Reviewer; ASRM; Plan Comm, Prog Chair; 

Fert & Steril, Hum Rep; Assoc Editor; Endo Rev, Sem in Rep; Editoral Board; NIH Grant Reviewer, 

NICHD Member of Obst & M Fetal Biology Subcomm 

Lehl, Kelly L.: EMD Serono, 2010 Reproductive Health National Speaker Bureau; Ferring, 2009 Nurse speaker Bureau 

Lipshultz, Larry I.: Allergan Pharmaceuticals, Clinical Trial; Auxilium Pharmaceuticals, Clinical Trial; AMS; Auxilium; 

Pfizer,Repros, Consultant; AMS; Auxilium, Speaker/Lecturer 

Lo, Kirk C.: Bayer Canada Inc., Medical Advisor 

Lynne, Charles M. M.: Novartis, Speaker 

Mahadevan, Mahendran: SAGE, Cooper Surgical, Presented “Sperm Freeze” at a Cryopreservation workshop 

McKeeby, Jeffrey L.: Ferring Pharmaceuticals, Speakers Bureau, Physician Advisory 

Milad, Magdy: Terumo medical, Consultant 

Milad, Magdy P.: Terumo medical, Consultant 

Miller, Kathleen A.: Gene Security Network, Consultant; Sage IVF Cooper Surgical, Consultant; MedTech For Solutions, Vice 

President 

Mills, Benjie B.: GSK, Speakers bureau for Cervarix; Schering Plough, Faculty trainer for Implanon; Merck, Speakers 

Bureau for Gardasil 

186


Moise, Kenneth J. J.: Sequenom, Inc., Provides research funding for a clinical trial; I serve as the PI of this trial. 

Muasher, Suheil J.: EMD Serono, Member of speaker bureau; Ferring Pharmaceuticals, Member of speaker bureau; Shering- 

Plough, Member of speaker bureau 

Nagy, Zsolt Peter: EMD Serono, SAB; National Speaker Program; Merck (SP), SAB; Origio, SAB; Molecular Biometrics, 

SAB; Unisense, SAB 

Nardo, Luciano G.: Ferring, Sponsorship, Grant Receiver; Merck Serono, Sponsorship, Grant Receiver, Invited speaker at 

national and international meetings; Schering-Plough, Sponsorship, Expert Adviser, Grant Receiver; 

Concepta Healthcare Ltd., Director, Share Holder 

Newton, Christopher R.: Serono Canada, Consultant in editing patient information booklet (Patient Tool Kit) 

Nezhat, Ceana: Karl Storz Endoscopy, Consultant; Plasma Surgical, Consultant; Ethicon Women’s Health and Urology, 

Speaker; Covidien; Conceptus, Speaker; Aragon, Stock 

Osteen, Kevin G.: ENDO Pharmaceuticals, Consultant 

Penzias, Alan S.: Ferring Pharmaceuticals, Speakers Bureau; Schering Plough, Research grant to company; EMD Serono, 

Research grant to company; ReproSource, Consultant 

Price, Thomas: Hologic, Pharma sponsored research; Abbott, Pharma sponsored research; Clinical Advisors, Consultant; 

Guidepoint, Consultant; MedaCorp, Consultant 

Puscheck, Elizabeth: Pfizer, Research in menopause; Ethicon, Resereach in device to treat fibroids 

Racowsky, Catherine: Origio, Scientific Advisory Board; Cambridge University Press, Author 

Rall, William F.: General Electric, Amgen,, Stockholder; Brystol Myers Squibb, Pfizer,, Stockholder; Johnson & Johnson, 

Kimberly Clark, Stockholder 

Richard-Davis, Gloria: Merck, Speaker’s Bureau; Boeingher Ingelheim, Speaker’s Bureau 

Sadeghi-Nejad, Hossein: Plethora Solutions, Grant Recipient / Clinical Investigator 

Schattman, Glenn L.: Ferring, Speaker; EMD- Serono, Speaker/Advisory Board; MSP-Organon, Speaker; Femasys, Medical 

advisory board; Theralogix, Medical advisory board 

Schlegel, Peter N.: Theralogix, Inc, Medical Advisory Board; Gnyutes, LLC, Manager 

Schneider, Suzanne S.: Walgreen’s, Nurse Advisory Board 

Scoccia, Bert: Nora Therapeutics, Consultant 

Seftel, Allen D.: Pfizer, Liily, sanofi, Palatin, Solvay-Abbott, Auxilium, Endo, Consultant; Lilly, Clinical drug studycompleted; 

Auxilium, Clincal drug study- to be commenced fall 2010; patient pocket, llc, Member; nature 

publishing, Journal editor-completed 

Seifer, David B.: Beckman Coulter/ UMDNJ / MGH, co-inventor AMH 

Seli, Emre: Molecular Biometrics, Inc., Member, Scientific Advisory Board, Stockholder 

Shepperson-Mills, Dian: Biocare, Supplements at discount for patients & secretarial support.; Nutri Centre, Supplements at discount 

for patients & secretarial support.; Specialist Herbal Supplies, Supplements at discount for patients & 

secretarial support. 

Sigman, Mark: Bristol Myers Squibb, Consultant for safety study; Toyama, Consultant for safety study 

Silverberg, Kaylen M.: Serono Laboratories, Advisory Board, Speakers Bureau; Columbia Laboratories, Speakers Bureau; 

Genzyme, Speakers Bureau, Consultant 

Simon, Carlos: Merck Serono, Consultant 

Sipe, Christopher: Merck, Speaker 

Stachecki, James J.: Tyho-Galileo Research Labs, Consultant; IVF Online, Consultant 

Stahler, Michael S.: International Stem Cell Corp, Collaborator-Research 

Steinkampf, Michael P.: Merck, Speaker’s bureau 

Stephenson, Mary D.: NoraTherapeutics, Consultant 

Stewart, Elizabeth A.: Insightec, Clinical Trial Investigator; Abbott, Consultant; Gynesonics, Consultant; Bayer Healthcare, 

Scientific Advisory Board 

Strickland, Robert: EMD Serono, Professional Management Advisory Group 

Sueldo, Carlos: BMT (Boston MA), Medical consultant 

Surrey, Eric: EMD Serono, Speaker’s Bureau; Abbot laboratories, Medical Advisory Board 

Swain, Jason E.: Irvine Scientific, Consultant 

Tarlatzis, Basil C.: MSD, Research Grants / Travel Grants/ Honoraria / Consultation; IBSA, Honoraria; Ferring, Research 

Grants / Travel Grants / Honororia; Merck Serono, Research Grants / Travel Grants 

Taylor, Hugh S.: Wyeth, Grant support and speaker honorarium; Organon, speaker honorarium 

Taylor, Robert N.: Bayer Schering Pharma, Berlin, Sponsored research grant 

Teal, Stephanie: Bayer pharmaceuticals, Advisory Board; Medicines 360, Research support 

Tobias, Tamara: EMD Serono, Speakers Bureau; Walgreen’s Specialty Pharmacy, Nurse Advisory Board 

Toner, James P.: Columbia Labs, Inc, sponsor of research 

Toner, James P.: Coumbia Labs, Advisory committee, research funding; Ferring Pharmaceuticals, advisory committee 

Toth, Thomas L.: GoodStart Genetics, Scientific Advisory Board 

Turek, Paul J.: BioQuiddity Inc, Medical Advsory Board; MandalMed Inc, Advisor; Gilead Sciences, Inc, Consultant 

Tur-Kaspa, Ilan: EMD Serono, Inc, Receipt of Independent Research Grant; Speakers Program; Fertility Advisory Board; 

Organon Schering-Plough, Speakers Program; Ferring Pharmaceuticals, Fertility Advisory Board 

Weiskopf, Richard: Reglera, LLC, Provide regulatory consulting & services - device industry 

Wells, Dagan: Reprogenetics LLC, Shareholder; EMD Serono, Grant recipient; Gema Diagnostics, Grant recipient 

West, Elizabeth B.: Merck, Consultant; EMD Serono, Advisory Board 

187


Weston, Aimee: Ferring Pharmaceuticals, Consultant; Serono, Nurse Advisory Board/ Speakers Bureau; Shering Plough/ 

Merck, consultant; Abington Reproductive Medicine, Abington IVF and Genetics, Private practice 

employee 

Westphal, Lynn: Merck, Advisory Board; EMD Serono, Advisory Board; Ferring, Study grant 

Whalen, Lori: EMD Serono, Advisory board 

Widra, Eric A.: Shady Grove Fertility RSC,

189

ABSTRACTS TOPIC INDEX 

ART-In Vitro Fertilization: O-01, O-07, O-69, O-74, O-79, O-80, O-81, O-93, O-94, O-97, O-98, O-103, 

O-109, O-177, O-179, O-189, O-194, O-245, O-277, O-278, O-279, O-280, O-282, O-283, O-284, O-285, 

O-289, O-295, O-297, O-310, O-311, P-122, P-215, P-217, P-219, P-221, P-223, P-224, P-227, P-228, P-230, 

P-238, P-240, P-242, P-249, P-468, P-515, P-516, P-517, P-518, P-519, P-520, P-521, P-522, P-523, P-524, 





P-596, P-597, P-598, P-599, P-600 

ART-Other: O-06, O-64, O-71, O-72, O-73, O-83, O-88, O-122, O-171, O-180, O-181, O-190, O-197, P-231, 


P-265, P-459, P-551, P-555, P-563, P-564, P-565, P-566, P-570, P-579, P-581, P-586 

Cancer O-36, O-157, O-206, P-26, P-27, P-28, P-29, P-30, P-31, P-32, P-33 

Contraception/Family Planning: O-08, O-09, O-10, O-11, O-12, O-13, O-14, O-15, P-1, P-2, P-3, P-4, P-5 

Cryopreservation: O-60, O-61, O-63, O-65, O-66, O-102, O-104, O-106, O-118, O-229, O-230, O-232, 

O-233, O-236, P-49, P-50, P-51, P-52, P-53, P-54, P-55, P-56, P-57, P-58, P-59, P-60, P-61, P-62, P-63, P-64, 

P-65, P-66, P-67, P-68, P-69, P-70, P-71, P-72, P-73, P-74, P-75, P-76, P-77, P-78, P-79, P-80, P-81, P-82, 

P-83, P-84, P-85, P-86, P-87, P-88, P-89, P-90, P-91, P-92 

Embryo Biology: O-31, O-75, O-86, O-91, O-116, O-231, O-267, O-299, O-300, P-188, P-189, P-190, P-191, 

P-192, P-193, P-194, P-196 

Embryo Culture: O-107, O-234, P-197, P-198, P-199, P-200, P-201, P-202, P-203, P-204, P-205, P-206 

Embryo Transfer: O-77, O-84, O-120, O-235, P-266, P-267, P-268, P-269, P-271, P-272, P-273, P-274, 

P-275, P-276, P-277, P-278, P-279, P-280, P-281 

Endometriosis: O-127, O-131, O-132, O-133, O-134, O-135, O-136, O-137, O-138, O-162, O-263, P-366, 


P-382, P-383, P-384, P-385, P-386, P-387, P-388, P-389, P-390, P-391, P-392, P-393 

Endometrium: O-182, O-294, O-296, O-316, P-416, P-417, P-418, P-419, P-420, P-421, P-422, P-423, P-424, 

P-425, P-426, P-427, P-428, P-429, P-430, P-431, P-432 

Environment and Toxicology: O-246, O-247, O-249, O-252, O-309, P-465, P-466, P-467, P-469, P-470, 

P-471, P-472, P-473, P-474, P-475, P-476, P-477 

Female Reproductive Endocrinology: O-90, O-114, O-173, O-198, O-204, O-215, O-290, P-301, P-302, 


P-318, P-319, P-320, P-321, P-322, P-323, P-324, P-325 

Female Reproductive Surgery: O-113, O-123, O-125, O-126, O-128, O-129, O-130, O-155, O-187, O-219, 

O-302, O-303, O-304, O-305, O-306, O-307, P-433, P-434, P-435, P-436, P-437 

Female Reproductive Tract: O-42, O-43, O-44, O-156, O-251, O-255, O-308, P-398, P-399, P-400, P-401, 

P-402, P-403 

190


Fertility Preservation: O-32, O-33, O-35, O-37, O-38, O-39, O-105, O-112, O-124, O-192, O-226, P-34, 

P-35, P-36, P-37, P-38, P-39, P-40, P-41, P-42, P-43, P-44, P-45, P-46, P-47, P-48, P-270 

Fertilization: O-117, P-185, P-186, P-187 

Genetic Counseling: O-67, O-139, O-140, O-141, O-142, O-144, O-145, P-93, P-94, P-95, P-96, P-97, P-98 

Imaging: O-262, O-264, O-265, O-266, O-268, P-404, P-405, P-406, P-407, P-408, P-409, P-410, P-411, 

P-412, P-413, P-414, P-415 

Implantation: O-158, O-184, O-220, O-248, O-261, O-293, P-282, P-283, P-284, P-285, P-286 

Leiomyoma: O-04, O-108, O-253, O-254, O-256, O-257, O-258, O-259, O-260, O-301, P-438, P-439, P-440, 

P-441, P-442, P-443, P-444, P-445, P-446, P-447, P-448, P-449 

Luteal Phase Support: O-41, O-68, P-287, P-288, P-289, P-290, P-291 

Male Factor: O-46, O-48, O-53, O-55, O-56, O-58, O-110, O-166, O-168, O-169, O-170, O-186, O-188, 

O-209, O-210, O-250, P-478, P-479, P-480, P-481, P-482, P-483, P-484, P-485, P-486, P-487, P-488, P-489, 

P-490, P-491, P-492, P-493, P-494, P-495, P-496, P-497, P-498, P-499, P-500, P-501, P-502, P-503 

Male Reproductive Endocrinology: P-120 

Male Reproductive Urology: O-59, O-167, O-208, O-211, P-121, P-123, P-124, P-125, P-126, P-127, P-129, 

P-130, P-131, P-132, P-133, P-134, P-135, P-136, P-137 

Menopause: O-147, O-148, O-149, O-151, O-312 

Mental Health: O-221, O-222, O-223, O-224, O-225, O-227, O-228, P-452, P-453, P-454, P-455, P-456, 

P-457, P-458 

Nursing: O-03, O-16, O-17, O-19, O-22, O-23, O-313 

Obesity and Metabolism: O-57, O-62, O-174, O-176, O-218, O-242, O-286, O-314, O-315, P-334, P-335, 

P-336, P-337, P-338 

Oocyte Biology: O-28, O-29, O-30, O-115, O-178, O-193, O-195, O-298, P-145, P-146, P-147, P-148, P-149, 

P-150, P-151, P-152, P-153, P-154, P-155, P-156, P-157, P-158, P-159, P-160, P-161 

Oocyte Maturation: O-101, O-281, P-162, P-163, P-164, P-165, P-166, P-167, P-168, P-169, P-170, P-171, 

P-172, P-173 

Ovarian Function: O-85, O-196, O-203, O-214, P-6, P-7, P-8 

Ovarian Reserve: O-70, O-76, O-87, O-150, O-152, O-153, O-172, O-213, O-216, O-287, O-288, P-9, P-10, 

P-11, P-12, P-13, P-14, P-15, P-16, P-17, P-18, P-19, P-20, P-21, P-22, P-23, P-24, P-25 

191


Ovarian Stimulation: O-92, O-95, O-96, O-119, O-121, O-175, O-185, O-291, O-292, P-207, P-208, P-209, 


P-235, P-236, P-237, P-239, P-243, P-244, P-245, P-246, P-247, P-248, P-250 

Oxidative Stress: P-174, P-175, P-176, P-177, P-178, P-179, P-180, P-181, P-182, P-183, P-184 

Polycystic Ovary Syndrome: O-21, O-82, O-111, O-154, O-183, O-217, O-237, O-238, O-239, O-240, O-241, 

O-243, O-244, P-339, P-340, P-341, P-342, P-343, P-344, P-345, P-346, P-347, P-348, P-349, P-350, P-351, 

P-352, P-353, P-354, P-355, P-356, P-357, P-358, P-359, P-360, P-361, P-362, P-363, P-364, P-365 

Practice Management: O-18, P-460, P-461, P-462, P-463, P-464 

Pregnancy Loss and Termination: O-20, O-40, O-159, O-161, P-292, P-293, P-294, P-295, P-296, P-297, 

P-298, P-299, P-300 

Preimplantation Genetic Diagnosis: O-05, O-50, O-78, O-143, O-146, O-269, O-270, O-271, O-272, O-273, 

O-274, O-275, O-276, P-99, P-100, P-101, P-102, P-103, P-104, P-105, P-106, P-107, P-108, P-109, P-110, 

P-111, P-112, P-113, P-114, P-115, P-116, P-117, P-118, P-119 

Reproductive Hormones: P-326, P-327, P-328, P-329, P-330, P-331, P-332, P-333 

Reproductive Immunology: O-99, O-160, O-163, O-164, O-165, P-394, P-395, P-396, P-397 

Sexuality: O-45, O-199, O-200, O-201, O-202, P-450, P-451 

Sperm Biology: O-49, O-51, O-52, P-138, P-139, P-140, P-141, P-142, P-143, P-144 

Sperm Preparation: O-47, O-89, P-504, P-505, P-506, P-507, P-508 

Stem Cells: O-02, O-24, O-25, O-26, O-27, O-34, O-100, O-191, O-205, O-207, P-509, P-510, P-511, P-512, 

P-513, P-514 

Testis: O-54, O-212, P-128 

192

Abbamonte, L. H. O-92, P-57 

Abdallah, M. O-309, P-247 

Abdallah, R. O-175, P-237, P-246, P-540 

Abdallah, R. T. P-522 

Abdel Megid, W. O-03, O-284 

AbdelHafez, F. P-88 

Abdelmonem, A. M. O-219 

Abdelraheem, M. S. O-253 

Abdo, G. P-239 

Abe, H. P-263 

Abeyta, M. J. V-2 

Abir, R. P-35 

Aboulghar, M. P-164 

Abou-Setta, A. M. P-43, P-218 

Abulafia, O. P-32 

Abu-Rafea, B. O-306 

Abuzeid, M. I. P-225 

Abuzeid, Y. M. P-225 

Acar, B. P-153 

Acevedo, N. P-596 

Acosta, M. O-18 

Acosta de la Greca, M. O-20 

Adamson, D. P-453 

Adawadkar, S. S. P-311 

Addai, J. B. O-208 

Addauan-Andersen, C. O-172, O-213, O-214, O-254 

Adib, M. P-51 

Adler, A. O-55, P-102 

Afek, A. P-308 

Agarwal, A. P-181, P-249, P-378, P-501 

Aghajanova, L. P-419, P-426 

Agramunt, S. P-217, P-556 

Agudo, D. P-580 

Aguirre, M. P-64, P-532 

Ahn, J.-W. P-214, P-216, P-346, P-518 

Ahn, Y. S. P-251 

Ahumada, A. P-72 

Akar, M. E. P-210 

Akbiyik, F. P-12 

Akhondi, M. M. O-02 

Albertini, D. O-60 

Alberto, T. P-193 

Albuz, F. O-295, O-296 

Alegretti, J. R. O-285 

Alessandri, F. O-04 

Alexander, C. P-365, P-538 

Alexandrova, N. P-296 

Al-Farawaty, S. O-31 

Alford, C. E. O-113, P-334, P-465 

Algur, N. O-290 

Al-Hendy, A. O-34, O-253, O-257, O-316, P-438 

Al-Inany, H. P-117, P-164 

Al-Inany, H. G. P-218 

Alladin, N. O-56 

Allan, R. W. P-124 

Allgood, A. P-328 

Allison, K. C. O-315 

Almahmoud, H. P-398 

Alnifaidy, R. P-367 

ABSTRACTS AUTHOR INDEX 

194 

Al-Obeed, O. O-306 

Alonso, M. P-580 

Alper, M. P-257, P-279, P-294 

Alper, M. M. O-01, P-119 

AlSheikh, A. O-306 

Altmäe, S. O-293 

Altun, T. P-598 

Alvarez, J. P-363 

Alvarez, S. P-318 

Alvarez Sedó, C. P-483 

Alvero, R. O-85 

Amarasiriwardena, C. P-468 

Amarosa, A. P-332 

Ambartsumyan, G. O-25, P-510 

Ambler, D. R. O-130 

Ambroggio, J. P-114 

Ameye, L. O-19 

Amit, A. P-241, P-499 

Amita, M. P-146 

Amo, A. P-77 

Amols, M. P-14 

An, S. J. P-288 

Anahory, T. O-297, P-222, P-260 

Anastasakis, D. O-119 

Anderson, J. P-411 

Anderson, J. E. O-180 

Anderson, R. E. P-83 

Anderson, S. P-423 

Andrade, A. Z. O-135, P-385 

Andreoli, C. G. O-163 

Andrey, D. P-296 

Angle, M. P-89 

Anserini, P. O-92, P-57 

Ao, A. P-170 

Aoki, T. P-382 

Aoyama, N. P-570 

Appt, S. E. O-148 

Apter-Danon, G. P-515 

Araki, Y. P-228 

Aravind, C. P-451 

Archer, D. F. O-13 

Archer, J. S. P-557 

Archibong, A. E. O-34 

Ardawi, M. S. P-343 

Arduini, D. O-268 

Arêas, P. C. F. P-471 

Arenas, G. P-72 

Arenas, L. P-160 

Arici, A. P-425 

Armstrong, A. O-62, P-441 

Armstrong, A. Y. O-113, P-38, P-460, P-465, P-517 

Arnold, N. P-153 

Arny, M. P-168 

Arny, M. J. P-205, P-267 

Arosh, J. A. O-136, P-375 

Arredondo, F. O-81 

Arrowood, J. A. P-311 

Arfuso, V. P-597 

Arvis, P. P-574

Asch, R. H. P-72 

Asemota, O. A. P-152 

Ashcraft, L. P-205 

Ashraf, M. P-225 

Assou, S. O-71, O-297, P-159, P-171, P-222, 

P-260 

Aston, K. I. O-169, P-184 

Ata, B. O-72, P-170, P-546 

Atabekoglu, C. P-242 

Atabekoglu, C. S. P-550, P-262 

Atalah, H. V-9, P-135 

Atalah, H. N. V-10, P-124, P-134 

Atamna, R. O-98, O-165 

Atay, S. O-164, P-395 

Ates, C. P-262 

Attaman, J. A. O-168, O-314 

Aubriot, F.-X. P-315 

Auda, M. P-117 

Auerbach, P. P-328 

Augé, L. M. P-531 

Austin, C. P-58, P-88 

Avendaño, C. O-249 

Avila, D. P-120, P-137, P-451 

Avila, R. P-140 

Awata, S. O-67, O-177, O-186, P-97, P-130, 

P-244, P-530, P-541, P-542, P-554 

Awonuga, A. O. O-97, P-434 

Aydin, S. P-301 

Aydogan, M. P-595 

Aydogmus, H. P-376 

Aytaç, R. P-262 

Aytac, R. P-521 

Azambuja, R. P-74 

Azem, F. P-241 

Azevedo, A. C. P-378 

Aziz, N. P-361 

Azziz, R. O-237, O-240, O-243, P-344, P-345, 

P-351, P-362 

Babayev, S. O-302 

Baca, Q. O-76 

Backman, K. L. O-225 

Badalotti, F. P-74 

Badalotti, M. P-74 

Bae, I. H. P-55 

Baek, K.-H. P-359 

Baerwald, A. P-413 

Baeza, K. P-485 

Bagley, R. J. O-125 

Baglione, G. O-300 

Bailey, A. P. O-126 

Baird, D. D. O-153, P-18 

Baker, L. P-433 

Baker, M. B. O-310 

Baker, V. P-21 

Baker, V. L. O-76, P-559 

Bakker, N. E. P-350 

Balaban, B. P-75, P-579 

Baldwin, M. K. P-3 

Ball, G. D. P-591 


195 

Ballesteros, A. O-50, P-196, P-486 

Ballesteros Boluda, A. P-148, P-203 

Balon, R. O-199 

Balthazar, U. P-37, P-40, P-417 

Banerjee, P. O-179, P-386 

Banks, N. K. P-253 

Banu, S. K. O-136, P-375 

Barad, D. H. O-287, P-94, P-157, P-255, P-325, 

P-589 

Barakat, E. E. O-129 

Baranowski, W. O-158 

Barber, S. O-99 

Bardenheuer, K. O-09 

Bardsley, T. P-37, P-40 

Barker, J. O-41 

Barmat, L. O-141 

Barmat, L. I. P-457 

Barnhart, K. O-43, O-114, O-173, P-306, P-437 

Barnhart, K. T. O-216, P-302, P-321, P-516 

Baronio, M. O-262, V-20, P-407, P-408, P-409, 

P-412, P-415 

Barr, D. O-250 

Barrett, B. P-119, P-257, P-279 

Barrett, C. B. P-591 

Barrier, B. F. P-394 

Barritt, J. P-48, P-103, P-505 

Barros, D. P-427 

Barroso, G. P-140 

Barshack, I. P-308 

Bartal, M. O-32 

Barton, S. E. P-552 

Baruffi, R. O-188, P-132, P-144, P-500 

Barut, T. O-90 

Basar, M. P-425 

Basile, N. P-206 

Baskind, E. N. O-99 

Bates, G. W. P-335, P-449, O-152 

Batioglu, S. P-595 

Batista, F. A. R. P-382 

Beattie, M. O-147 

Beck, L. N. P-39 

Bedaiwy, M. A. O-129, O-157, P-43, P-45 

Beer, L. O-173 

Beeson, D. R. P-264 

Behera, M. P-439 

Behr, B. P-78, P-115, P-559 

Belcik, T. O-258 

Bellés Fernández, M. P-203 

Bello, G. A. P-544 

Belloc, S. P-318 

Bellver, J. O-79 

Beltsos, A. O-272, P-200 

Ben Haroush, A. P-35 

Ben Khalifa, M. P-481 

Benadiva, C. P-280 

Benadiva, C. A. P-523, P-525, P-577 

Bendikson, K. O-245 

Bendikson, K. A. O-310 

Benedict, S. V-2

Benner, A. O-273, P-101, P-104 

Benoff, S. H. O-212 

Benson, C. B. P-552 

Bentley, S. W. P-463 

Bentov, Y. O-195 

Bentov, Y. H. O-291 

Ben-Yosef, D. P-499 

Berbey, R. P-198 

Bercaw, J. L. O-154, O-156 

Berger, D. S. P-11 

Berger, E. P-152 

Berger, M. J. P-529 

Bergh, C. M. O-22 

Bergh, P. A. O-22 

Berkeley, A. P-102 

Berkeley, A. S. O-55, O-95, O-280, P-431 

Berker, B. P-262, P-521 

Berkowitz, K. M. P-152 

Berlanga, O. P-428 

Berman, D. O-240 

Bermejo, A. O-93 

Bernal, D. P. O-61, O-105 

Berry, A. O-244 

Berry, K. O-174, P-456, P-468 

Berry, K. F. O-83, O-246, O-247, P-537 

Bertolla, R. P. O-49, O-57, O-211, P-129, P-470, 

P-548 

Bertoncini, C. R. A. P-378 

Beshay, V. E. P-330 

Bettahar, K. P-331 

Beutler, B. P-514 

Bhatt, H. P-413 

Bianchi, P. H. M. O-285, P-235 

Biben, A. P-448 

Bibi, G. P-241 

Biggs, J. P-496 

Biggs, J. M. P-508 

Bilibio, J. P. O-163 

Binkley, P. A. P-372 

Biscaldi, E. O-132 

Bishop, C. V. P-213 

Bisioli, C. P-56, P-176, P-520 

Bisioli, C. A. P-560 

Blaine, J. P-578 

Blair, H. E. P-348 

Blanco, L. P-491 

Blanco, L. A. P-72 

Blelloch, R. O-24 

Bletsa, R. P-192 

Blin, V. P-138 

Bloch, M. P-241 

Blockeel, C. P-226 

Bloechle, M. O-308 

Blumenthal, P. P-5 

Bocca, S. O-220, P-423 

Bock, I. O-106 

Bodenburg, Y. H. P-317 

Boehle, K. P-336 

Bohler, H. C. P-557 


196 

Boivin, J. P-458 

Bonetti, T. C. S. O-218, P-396 

Bonilla Egea, E. P-148 

Boone, W. R. O-292 

Borahay, M. P-370 

Bordás, R. P-390 

Borges, Jr, E. O-48, O-51, O-86, O-218, P-163, 

P-186, P-396, P-493, P-497, P-561 

Borgeson, J. P-141 

Borghi, M. P-407, P-415 

Borman, E. P-233 

Bormann, C. P-66 

Bosch, A. P-520 

Bosch, E. P-275 

Bose, G. P-386 

Botchorishvili, R. O-123 

Botes, A. P-219, P-221, P-223, P-238 

Bothan, A. P-499 

Botros, L. O-189, P-276 

Botros, L. D. O-88 

Bou, C. P-206 

Boumela, I. P-260 

Bourgain, C. O-296 

Boylan, C. F. P-99 

Boyle DiPaola, K. P-26, P-30 

Bozkurt, I. P-425 

Bozoklu, O. P-210 

Brache, V. O-12 

Bradshaw, H. B. P-428 

Braga, D. O-48, O-51, O-86, P-163, P-186, 

P-493, P-497, P-561 

Braga, D. P. A. F. O-218, P-396 

Brasile, D. P-405 

Braverman, A. M. O-110, O-223, O-228 

Bray, M. A. P-209 

Brayboy, L. M. P-457 

Brengauz, M. O-298, P-316 

Brennan, K. P-362 

Brennan, K. M. O-237, P-538 

Breyer, B. N. P-488 

Brezina, P. O-273 

Brienza, L. O-268 

Brigante, C. P-489 

Brito, M. M. O-302 

Briton-Jones, C. P-533 

Briton-Jones, C. M. P-539 

Britten, J. O-108, O-256 

Broadwell, C. E. P-297, P-329 

Broce, M. O-162 

Broder, M. S. O-128 

Brohammer, R. L. P-278 

Bronfenmajer, S. P-544 

Brossoit, M. P-416 

Brower, M. O-237 

Brower, M. A. P-362 

Brown, D. B. P-503 

Brown, M. B. O-176, O-278 

Brown, Z. P-494 

Browne, A. C. P-585

Bruner-Tran, K. L. O-252, P-366 

Brunialti, M. P-396 

Brzyski, R. G. P-473 

Buck Louis, G. M. O-250, P-472 

Buckett, W. P-170, P-245 

Buehler, N. P-533 

Buendia, P. P-108 

Bukulmez, O. O-176 

Bulun, S. E. O-206, O-259, P-444 

Bunting, L. E. P-458 

Burger, N. O-69 

Burger, N. Z. O-80 

Burgert, T. S. O-241 

Burns, M. P-34 

Burstein, E. O-195, O-291 

Bush, M. O-272 

Bush, M. R. O-68 

Butts, S. F. O-315 

Buyuk, E. P-6, P-10, P-11, P-16, P-24 

Cabrera, L. O-107, O-261 

Cadar, A. O-141 

Cai, X. P-477 

Calaf, J. P-390 

Calderón, G. P-486 

Calderón de Oya, G. P-148, P-203 

Calderon, G. O-50, P-196 

Caldiño, F. P-498 

Caldino, F. P-50 

Calhoun, K. C. P-9 

Calzi, F. P-489 

Camarano, L. P-453 

Camargo, M. P-470 

Campbell, B. O-23 

Campos, C. O. P-172 

Campos, H. O-311 

Campos, J. P-112 

Campos, J. R. P-63, P-172 

Camus, M. P-277 

Candrilli, S. D. P-1 

Canis, M. O-123, P-373 

Cao, S. P-90 

Capuñay, C. O-262, P-407, P-408, P-409, P-412, 

P-415, V-20 

Cardozo, E. P-444 

Carey, D. J. O-130 

Carlisle, A. B. P-454 

Carlson, N. O-08 

Carmely, A. O-32 

Carmo, B. L. P-382 

Carney, S. M. P-99 

Carr, B. R. P-306, P-330 

Carrascosa, J. O-262, P-408, P-409 

Carrascosa, P. O-262, V-20, P-407, P-408, P-409, 

P-412, P-415 

Carrell, D. O-209, O-251 

Carrell, D. T. O-169, P-150, P-184 

Carreras, R. P-556 

Carrilho, E. P-23 

Carrillo, A. P-210 


197 

Carson, S. A. O-101 

Carvalho, B. R. P-63 

Cary, M. S. P-302 

Case, A. P-413 

Casper, R. P-536 

Casper, R. F. O-195, O-291, P-71 

Casson, P. R. P-310 

Castellò, D. O-230 

Castora, F. J. O-194 

Cataldo, N. A. O-16 

Catenacci, M. O-305, V-15 

Catherino, W. H. O-108, O-256, O-260 

Cattaneo, A. R. P-475 

Causby, S. P-179 

Cavagna, M. P-231 

Cecile, M. P-52, P-283 

Cedars, M. O-147, O-254, P-204 

Cedars, M. I. O-07, O-33, O-40, O-172, O-213, 

O-214, O-221, P-36, P-96, P-155, 

P-422, P-460, P-480 

Cedenho, A. P. P-470, P-548 

Celia, G. P-219, P-221, P-223 

Celia, G. F. P-238 

Centola, G. M. O-212 

Cha, E.-M. P-85 

Cha, J.-H. P-55 

Cha, S. K. P-91 

Chacon, R. P-273 

Chae, H.-D. P-214 

Chakhtoura, N. P-437 

Chakravarty, B. P-347, P-386 

Chakravarty, B. N. O-160 

Chalfant, D. O-313 

Chalpe, A. J. P-383 

Chamié, L. P. O-263 

Chang, C.-C. O-61, O-105, P-62, P-147, P-232, 

P-563 

Chang, E. P-252 

Chang, E. Y. O-128 

Chang, G. P-456 

Chang, J. P-49 

Chang, L. P-230 

Chang, R. J. P-340 

Chang, T.-C. P-473 

Chantilis, S. O-65, O-102, O-104, O-232, O-236 

Chantilis, S. J. P-187, P-562 

Charles, C. P-389, P-391, P-440 

Charron, M. J. P-6, P-10 

Chason, R. J. O-82, P-441 

Chau, P. P-355 

Chaudhury, K. P-386 

Chauhan, S. R. P-526, P-565 

Chavarro, J. E. O-168, O-311, O-314 

Cheang, K. I. O-242, P-311 

Checa, M. P-217 

Checa, M. A. P-556 

Check, J. H. P-233, P-405 

Chen, D. P-582 

Chen, J. P-155

Chen, L. O-159 

Chen, L.-M. O-147 

Chen, S. O-159 

Chen, S.-L. P-535 

Chen, W.-C. P-447 

Chen, Z. O-250 

Chen, Z.-J. P-154, P-169 

Cheng, G. O-07 

Cheng, Y. V-8, P-4 

Cheung, J. P-287 

Chi, H. P-268 

Chi, H. J. P-194 

Chikawa, A. P-435 

Chilvers, R. A. P-317 

Chinchilla, M. O-277 

Chines, A. O-149 

Chipko, C. P-101, P-104, P-110 

Cho, J. D. P-250, P-289 

Cho, J. W. P-474 

Choe, J. K. P-405 

Choe, S. A. P-15 

Chohan, K. R. O-210 

Choi, A. P-440 

Choi, B. O-179 

Choi, B. C. P-359 

Choi, D. P-319, P-333 

Choi, D. H. P-312 

Choi, D.-H. P-258 

Choi, K. H. P-125 

Choi, M. P-312 

Choi, S. K. P-558 

Choi, S. Y. P-194 

Choi, T. V-2 

Choi, W. Y. P-167 

Choi, Y. P-312 

Choi, Y. M. P-15, P-380 

Cholst, I. O-87 

Christensen, G. L. P-557 

Christianson, H. J. P-506 

Chu, K. P-128 

Chung, D. P-268 

Chung, D. J. P-194, P-240, P-339 

Chung, D. Y. P-194 

Chung, H. Y. P-359 

Chung, J.-T. O-281 

Chung, K. O-43, O-114, O-245, O-310, P-302, 

P-321 

Cil, A. P. P-12, P-17 

Cinar, O. P-291, P-301 

Cino, I. P-489 

Clark, A. O-25, P-510 

Clark, R. L. P-406 

Clarkson, T. B. O-148 

Clemmer, M. O-196 

Cobo, A. O-66, O-230, O-233, P-76 

Coddington, C. P-14 

Coddington, C. C. O-197, P-327 

Codner, E. P-349 

Coffler, M. P-118 


198 

Cohen, A. O-06 

Cohen, J. P-285 

Cohen, J. D. P-457 

Cohen, M. S. V-9, V-10, P-124, P-134, P-135 

Cohen, R. P-233, P-405 

Cohen-Bacrie, M. P-315, P-318 

Cohen-Bacrie, P. O-215, P-315, P-318, P-481 

Colaci, D. P-176 

Colaci, D. S. P-175, P-560 

Colin, A. P-140 

Collier, G. M. O-182 

Colligs, A. O-15, P-1 

Collins, M. G. P-239 

Colls, P. P-111 

Conti, M. O-24, P-155 

Conway, D. P-510 

Conway, D. A. P-284 

Cook, C. P-178 

Cook, H. M. P-273 

Cooper, A. R. O-63 

Cooper, J. J. P-449 

Copland, S. D. P-20 

Copperman, A. B. O-18, O-20, O-70, O-81, P-39, P-48, 

P-103, P-234, P-236, P-505 

Copperman, K. B. O-18 

Coraluzzi, L. O-244 

Cordobilla, B. P-495 

Cornet, D. O-103 

Corrado, M. G. P-225 

Cortezzi, S. S. O-86 

Costa, A. L. S. R. P-471, P-476 

Costabile, R. A. O-167 

Costantini-Ferrando, M. F. P-442 

Cotton, H. I. G. O-20 

Couchman, G. P-290 

Coulter, B. O-170 

Coutifaris, C. P-306, P-342, P-356, P-516 

Covington, S. N. O-224, O-227 

Craig, L. B. P-19, P-414 

Cramer, D. W. O-83, O-311 

Creinin, M. D. O-14 

Crespo, J. P-76 

Cress, A. O-137, P-366 

Cress, A. B. O-111 

Criniti, A. R. O-289 

Crites, Y. P-358 

Critser, J. K. P-507 

Crochet, J. R. P-20 

Crocker, J. P-139, P-141 

Cruz, M. O-267, V-6 

Csokmay, J. O-62, P-400 

Csokmay, J. M. O-113, P-517 

Cuapio, P. O-190 

Cubillos, S. P-50, P-498 

Cuneo, S. P-50, P-498 

Cunha-Filho, J. S. L. O-163, P-98 

Cuthbertson, D. P-361 

da Silva, B. F. O-211, P-129, P-548 

Dahan, M. H. O-72, O-281, P-245

Dahl, S. K. P-466 

Dalloul, M. P-389, P-391 

Dalmazzo, A. P-493 

Dancet, E. A. F. O-19 

Daneshmand, S. T. P-64, P-532 

Daniels, J. K. O-238, P-348 

Daniels, K. P-459 

Danoff, A. P-326, P-332 

Danzer, H. P-533, P-539 

Darcha, C. P-373 

Darnell, B. E. O-312 

Dasig, J. P-78 

Davies, D. P-202 

D’Ávila, M. E. O. A. P-504 

Davis, G. P-96 

Davis, L. B. O-289, P-588 

Davis, O. O-175, P-237, P-246 

Dawley, B. L. P-178 

Dayal, M. P-114, P-116 

Dazin, P. F. P-128 

De Caro, R. V. P-478 

de Freitas, V. P-378 

de la Fuente, G. P-580 

de la Pena, M. O. P-473 

de los Santos, J. M. O-230, P-397 

de los Santos, M. P-76, P-397 

De los Santos, M. J. P-193 

De Mouzon, J. O-103, P-315, P-481 

de Paula, T. S. P-504 

de Rooij, D. G. O-02 

de Ruz, T. P-492 

De Santis, L. P-489 

de Souza, C. A. B. O-163, P-98 

de Souza, M. do C. B. P-471, P-476 

De Vos, J. O-71, P-52, P-159, P-222, P-260, 

P-283 

De Vos, M. O-295, O-296, P-226 

de Zúñiga, I. P-56, P-176 

de Zuñiga, I. J. P-175, P-560 

Deaton, J. P-227 

Debrock, S. P-564 

Decanter, C. O-112 

Dechanet, C. P-159 

Dechaud, H. O-71, O-297, P-159, P-222 

DeCherney, A. P-2, P-8, P-110, P-293, P-305 

DeCherney, A. H. P-253, P-441, P-465 

Dede, S. P-291 

Del Giudice, P. T. P-129, P-548 

Del Valle, A. P. P-53 

Delgado, A. P-108 

Demir, B. P-291 

Demirel, F. P-376 

Demirel, K. P-376 

Demirtas, E. O-281, P-245 

Demyttenaere, K. O-222 

Deng, J. P-514 

Denner, L. A. P-317 

Desai, N. P-43, P-58, P-88, P-509 

Desmarais, B. P-192 


199 

Detti, L. P-416 

DeUgarte, C. M. P-273 

Deutch, T. D. P-13 

Deveer, R. P-392 

Devine, K. O-171, P-102 

Devoto, L. P-427 

Devouche, E. P-515 

Devroey, P. O-295, O-296, P-82, P-226, P-265, 

P-277 

Dewailly, D. O-112 

Dey, D. O-240 

DeZarn, C. O-21 

D’Hooghe, T. O-222, P-564 

D’Hooghe, T. M. O-19 

Diamond, M. P-374 

Diamond, M. P. O-199, P-342, P-356, P-398, P-416, 

P-434, P-443 

Diaz, D. G. O-30, O-229, V-1 

Díaz, P. P-160 

Diaz Perez, S. O-25 

Díaz-Gimeno, P. P-429 

Dib, L. A. O-135, P-174, P-180, P-385 

Dickey, R. P. O-89, P-199, P-581, P-600 

Diep, D. P-514 

Dietrich, J. E. O-154, O-156 

Dietterich, C. P-405 

Dilbaz, S. P-291, P-301 

DiLiberti, C. P-287 

Diluigi, A. P-280 

DiMattina, M. P-219, P-221, P-223, P-238 

Dimitriadis, I. P-467 

Ding, J. P-281, P-393 

Ding, T. O-252 

Dinger, J. O-09 

Dmitrii, T. P-296 

Dmowski, W. P. P-281, P-393 

Dodds, R. O-127 

Dokras, A. O-315 

Dokuzeylul, N. O-53, P-545 

Domar, A. D. O-225 

Domingo, J. P-31 

Domingo, J. C. P-495 

Domingues, T. O-285, P-235 

Dominguez, F. O-230 

Donabela, F. C. O-135, P-385 

Donabella, F. C. P-174 

Donadio, N. F. P-231 

Donjacour, A. P-190 

Doody, K. J. O-68 

Dor, J. O-298, P-316 

Dorais, J. A. O-74 

Dordoni, D. P-266 

Dorsett, J. O. P-490 

dos Reis, R. M. P-352 

Dosiou, C. O-161 

Douard, S. O-103 

Dougherty, P. L. P-320 

Douglas, J. O-236, P-41, P-187, P-270 

Douglas, N. C. P-127, P-286

Dovey, S. L. O-39 

Doyle, J. V-4, P-220 

Doyle, J. O. P-243 

DuBeshter, B. V-19 

Dubey, A. K. P-114, P-116 

Dudley, P. S. O-289 

Duijkers, I. P-304 

Duke, M. P-48 

Duleba, A. J. O-111, O-137, P-366 

Dumas, J. A. P-329 

Dumesic, D. O-240 

Dumont, M. O-103, P-481 

Dunaway, Jr, H. E. P-600 

Duncan, D. P-205, P-267 

Duncan, F. P-161 

Dunn, R. P-261 

Dunn, R. C. O-181, P-526, P-565 

Dunning, K. R. P-156 

Dunsmoor-Su, R. P-588 

Duran, E. J. O-241 

Duran, F. S. O-194 

Durant, T. O-180, O-185 

Durante, M. O-42 

Dzik, A. P-231 

Eaton, J. L. O-277 

Ebbel, E. O-221 

Eberlin, M. N. O-49, O-86, O-211 

Eddy, C. A. P-473 

Edelman, A. O-08, P-3 

Edelman, A. B. O-10 

Egbuniwe, M. N. O-127 

Eggan, K. O-26 

Egleton, R. P-178 

Eguchi, N. O-96, P-313 

Ehrenburg, M. P-209 

Ehrlich, S. O-314, P-467, P-468 

Ehrlich, S. R. O-248 

Einarsson, J. I. P-462 

Eisenberg, M. L. O-58, P-126, P-254, P-488 

Ekpo, G. O-259 

Ekpo, G. E. O-303 

Ekwealor, L. P-440 

El Bahassi, M. P-26, P-30 

Elassar, A. P-280 

Elassar, A. A. P-523, P-525, P-577 

Eldar-Geva, T. O-290 

Eldridge, D. P-411 

Elkas, J. P-441 

Elkins, L. C. P-395 

Ellenbogen, A. O-46, O-98, O-165 

Elliot, M. O-41 

Elliott, T. A. P-62, P-563 

El-Nashar, S. A. P-43 

Elsner, C. W. O-61 

Emerson, G. P-528 

Emerson, G. M. P-27 

Engmann, L. P-280, P-577 

Engmann, L. L. P-523, P-525 

Epelboin, S. O-73, P-515 


200 

Eppsteiner, E. E. P-578 

Era, S. P-177 

Erb, T. M. P-513 

Erdem, O. P-377 

Erdogdu, A. P-261 

Ersahin, A. O-53, P-545 

Eryilmaz, O. G. P-392 

Esbert, M. O-50, P-486 

Esbert Algam, M. P-148 

Escobar, G. J. P-358 

Escobar, J. P-433 

Escobar, J. C. P-330 

Escobar, P. F. P-45 

Escribá, M. J. P-166 

Escribá, M. J. M. J. P-165 

Escrich, L. P-108, P-166, P-193 

Escrich, L. L. P-165 

Escudero, T. O-274, P-111 

Esfandiari, N. O-291, P-71, P-536 

Espinós, J. J. P-217, P-556 

Essah, P. A. P-311 

Esteves, S. C. P-133, P-484, P-487 

Evans, E. A. P-335 

Exacoustos, C. O-268 

Eyster, K. M. P-383 

Ezeh, U. O-237, O-240, O-243, P-345, P-351, 

P-362 

Faddy, M. O-215 

Fahrmann, J. P-178 

Fainaru, O. O-98, O-165 

Falcone, T. O-129, O-157, O-305, V-11, V-15, 

P-43, P-58, P-88, P-509 

Fallat, M. E. P-353 

Fallo, L. P-266 

Fan, K. P-538 

Fanchin, R. O-215, P-138, P-307 

Fangxian, L. P-370 

Faragi, G. O-46 

Fariello, R. M. O-57, P-470 

Farkouh, R. A. O-15, P-1 

Fassolas, G. P-534 

Fatemi, H. M. P-265 

Fathy, N. P-117 

Faustmann, T. A. P-304 

Fazleabas, A. T. P-369 

Feigenbaum, S. L. P-358 

Feinberg, R. F. P-99 

Feng, H. L. P-154, P-169 

Feng, L. O-255 

Fenton, B. W. O-201 

Ferguson, T. O-65, O-104, P-41 

Ferguson, T. R. P-562 

Ferin, M. P-286, P-337 

Fernandes, J. B. F. O-217 

Fernandez Peri, N. P-61 

Fernandez-Sanchez, M. P-492, P-587 

Ferrani, R. A. P-63 

Ferrara, A. P-358 

Ferrari, S. P-106

Ferreira, C. R. O-211 

Ferreira, R. P-497, P-561 

Ferrero, S. O-04, O-92, O-131, O-132, P-57, 

P-368 

Ferriani, R. A. O-217, P-172, P-174, P-180, P-352, 

P-381 

Ferro, J. P-397 

Ferry, K. O-78, P-100 

Ferry, K. M. O-05, P-112, P-113 

Fettback, P. P-23, P-235 

Fierro, M. P-576 

Figueira, R. C. S. O-48, O-51, P-163, P-186, P-561 

Filho, R. R. O-182 

Filippini, G. P-292 

Filonenko, A. P-420 

Finn, A. P-202 

Fino, E. O-95 

Fino, M. E. V-7 

Fisch, B. P-35 

Fisch, H. O-170 

Fisch, J. D. P-599 

Fischer, C. P-282 

Fischer, J. O-144, O-271, O-274 

Fisher, A. M. P-563 

Fissore, R. P-168 

Fitzgerald, C. O-303 

Flannery, C. A. O-241 

Fletcher, N. M. P-398, P-416 

Flisser, E. D. O-81 

Flood, L. J. O-13 

Foegh, M. O-13 

Fogle, R. H. P-572 

Ford, J. B. P-467 

Ford, W. E. O-194 

Forman, E. P-430 

Forstein, D. A. O-127, O-292 

Fortuño, S. O-233 

Fourcade, H. M. P-567 

Fowler, M. O-06 

Foyouzi, N. O-40, O-254, P-204 

Fragouli, E. O-31 

Fraietta, R. O-57, O-182, P-129, P-378 

Franco, Jr, J. G. O-188, P-132, P-144, P-500 

Frankfurter, D. P-114, P-116 

Frazier, L. P-42 

Frazier, L. M. P-452 

Frederick, J. P-118 

Fredrickson, J. R. O-197 

Freitas, G. C. P-231 

Frick, A. C. V-11 

Friedman, B. E. P-559 

Friscia, D. O-225 

Fritz, M. A. P-37, P-40, P-306, P-417 

Frolova, A. I. P-424 

Frydman, N. P-138, P-171 

Frydman, R. O-215, P-171, P-307 

Fu, P.-T. P-445 

Fujimoto, V. Y. P-96, P-422, P-460 

Fujino, Y. P-47 


201 

Fukuda, A. O-304, O-307 

Fukuda, A. I. O-183 

Fukuda, J. P-224 

Fumino, T. P-435 

Furuya, S. P-461 

G. Ribeiro, P. A. P-382 

Gabler, F. P-485 

Gacías, J. M. P-543 

Gada, R. P-14 

Gadisetti, C. P-369 

Galache, P. P-160 

Galache, P. M. D. P-555 

Galán, A. O-75, P-166 

Galen, B. O-110, O-223, O-228 

Galen, D. I. O-187 

Galliera, S. P-597 

Gallot, V. P-307 

Gamelin, A. P-413 

Gantt, P. O-162 

Garcea, M. P-520 

García, G. P-555 

Garcia, J. S. O-49, O-86, O-211 

Garcia, R. O-264 

Garcia, V. P-397 

Garcia-Bautista, A. P-166 

García-Bautista, A. A. P-165 

García-Guzman, R. O-261 

Garcia-Herrero, S. O-47, P-183, P-479 

García Velasco, J. P-31, P-388, P-580 

Garcia-Velasco, J. A. O-93, P-206, P-566 

Gardner, D. K. P-75 

Gargiulo, A. R. O-301, V-12, V-13, V-21, P-552 

Garner, F. P-64 

Garner, F. C. P-532 

Garnsey, H. O-269 

Garor, R. P-35 

Garrido, N. O-47, O-66, O-79, O-190, O-231, 

P-31, P-76, P-183, P-197, P-388, 

P-429, P-479, P-566, P-587 

Garrido, T. P-428 

Garrisi, J. P-294 

Garza-Cavazos, A. P-437 

Gearhart, J. D. O-205 

Gebhardt, J. P-78, P-115 

Gell, J. S. O-130 

Gelman, K. M. P-503 

Genis, M. V-18 

Genro, V. K. O-163, P-98, P-307 

Gerasimova, T. O-119, O-120 

Gercel-Taylor, C. O-164, P-395 

Gerhard, G. S. O-130 

Gersten, J. O-44, P-399 

Ghazal, S. P-243 

Ghilardi, F. P-266 

Ghosh Dastidar, B. O-94 

Ghosh Dastidar, S. O-94 

Gibbons, W. O-181 

Gibbons, W. E. O-121, O-278, P-591 

Gibson, M. O-74, O-251

Giddings, A. B. P-179 

Gilbert, J. H. P-594 

Gilden, M. O-108 

Gill, I. P-70, P-84 

Gindoff, P. P-114, P-116 

Ginsburg, E. S. O-109, O-174, P-537, P-552 

Giordana, S. M. P-61 

Gismano, E. P-489 

Gittens, P. R. P-120, P-451 

Giudice, L. P-422 

Giudice, L. C. O-161, P-419, P-426 

Givens, C. O-272 

Glassner, I. P. O-275, P-54 

Glassner, M. J. O-275, P-54, P-227 

Gleason, K. B. P-582 

Gleicher, N. O-287, P-94, P-157, P-255, P-325, 

P-589 

Go, K. J. P-596 

Go, Y. E. P-511 

Godby, C. P-247 

Goes, P. P-493 

Gogsen, O. P-436 

Gokmen, B. P-376 

Goktolga, U. P-291 

Gokturk, A. P-71 

Goldberg, J. P-58, P-88 

Goldberg, J. M. O-125 

Golden, A. M. O-130 

Goldfarb, J. O-109, O-180, P-58, P-88, P-509 

Goldfischer, E. R. O-200 

Goldman, M. B. O-01, P-529 

Goldschlag, D. O-87 

Goldstein, J. O-65, O-232, O-236 

Goldstein, J. M. D. O-102 

Goldstein, J. S. P-187 

Goldstein, M. V-8, P-121, P-131 

Gombein, J. O-240 

Gomes, C. M. P-23, P-235 

Gomez, N. P-140 

Gómez Peña, M. P-56, P-520, P-560 

Gong, L. P-70, P-84 

González, F. O-238, P-348 

Gonzalez, I. P-411 

Gonzalez-Ravina, C. O-190, P-492, P-566, P-587 

Goodall, N.-N. O-31 

Goodarzi, M. O. P-344 

Goodwin, S. P-438 

Gordon, J. D. P-219, P-221, P-223, P-238 

Gordon, K. P-211 

Gore-Langton, R. P-472 

Górski, A. O-158 

Gosden, R. G. O-124 

Gosselin, J. P-286, P-583, P-590 

Goswami, S. K. P-347 

Goto, K. P-263 

Goto, S. P-269 

Goudas, V. T. P-188 

Gouziomitrou, E. P-551 

Gozzo, F. C. P-129 


202 

Grafer, C. M. O-204 

Graham, J. O-15, P-1 

Graham, J. R. P-410 

Grainger, D. P-42 

Grainger, D. A. P-452 

Grau, N. O-231, P-166 

Grau, N. N. P-165 

Grazi, R. P-16, P-24 

Greenwald-Yarnell, M. L. O-198 

Greenwood, E. A. P-131 

Grifo, J. O-55, O-142, O-271, O-276, P-68, 

P-102, P-294, P-326, P-332 

Grifo, J. A. O-84, O-95, O-100, O-280, O-283, 

P-29, P-73, P-80, P-575, P-586 

Groisman, G. O-46 

Grotegut, C. P-439 

Grow, D. O-185, P-168 

Grow, D. R. P-205, P-267 

Grunert, G. P-261 

Grunert, G. M. O-181, P-526, P-565 

Grunfeld, L. O-20, O-70, P-103, P-234, P-236 

Grynberg, M. O-215 

Grynberg, M. W. P-307 

Gu, B.-H. P-359 

Gu, G. P-95 

Guarna, G. P-292 

Guarnaccia, M. M. P-590 

Guerrero, C. A. O-65, O-102, O-104, O-232, O-236, 

P-41, P-187, P-270 

Guerrero, J. O-264 

Guidobono, M. P-531 

Guilherme, P. P-534 

Guivarch, A. P-574 

Guler, Z. B. P-17 

Guner, H. P-377 

Gunsalus, K. C. V-7 

Guo, C.-Y. P-328 

Guo, W. P-302 

Guo, X. C. O-260 

Gupta, S. P-181, P-501 

Gurates, B. P-370 

Gurtcheff, S. E. O-74 

Gustofson, R. L. O-64, P-22 

Gutierrez, C. P-111 

Guvendag Guven, E. S. P-301 

Guzel, E. P-425 

Guzman, L. O-295, O-296 

Haddad, G. P-70, P-84 

Hahn, S. R. O-200 

Halder, S. K. O-257, P-438 

Hallowell, S. V. O-275, P-54 

Halvorson, L. M. O-204 

Hamai, H. P-435 

Hamamah, S. O-71, O-77, O-297, P-159, P-171, 

P-222, P-260 

Hammitt, D. O-65, O-102, O-104, O-232, O-236, 

P-41, P-270 

Hammitt, D. G. P-187, P-562 

Hammond, K. R. O-16

Hammoud, A. O-74, P-150 

Hammoud, A. O. O-251 

Hammoud, S. P-150 

Han, J. P-252 

Han, J. E. P-125, P-592 

Han, J. H. P-288 

Han, J. Y. P-474 

Hanafi, N. F. P-256 

Handyside, A. H. O-271 

Hanna, C. B. O-11 

Hansard, L. O-69 

Hansard, L. J. O-80 

Hansen, K. O-116 

Hansen, K. A. P-383 

Hansen, K. R. P-19, P-414 

Hansis, C. O-100 

Hantisteanu, S. O-165 

Haouzi, D. O-71, O-297, P-52, P-283 

Hara, S. P-146 

Harada, T. P-371 

Harats, D. P-308 

Harris, I. D. O-85 

Harris, M. O-266, O-310 

Harton, G. L. O-31, O-144 

Haruki, A. O-183, O-304, O-307 

Hashimoto, H. P-269 

Hashimoto, S. P-77 

Hatakeyama, N. O-96, P-313 

Hauser, R. O-168, O-246, O-247, O-248, O-314, 

P-467, P-468, P-499 

Hawkins, K. C. P-20 

Hayashi, T. P-224 

Hazout, A. P-318 

He, L. O-60 

He, Z. O-191, P-207, P-323 

Hedon, B. P-222, P-260 

Hendarto, H. H. H. P-387 

Henderson, E. J. D. O-155 

Heng, K. P-127 

Henne, M. B. P-253 

Hennebold, J. D. O-10, P-7 

Henriques, C. A. P-476 

Henson, M. O-189, P-276 

Henson, M. A. O-88 

Hermann, B. P. O-39 

Hermes, A. P-463 

Hernandez, C. P-440 

Hernández, J. O-261, O-264 

Herndon, C. N. P-426, P-480 

Herr, J. C. O-167 

Herrero, J. O-231, V-6, P-193, P-197 

Herring, A. O-153 

Herring, A. H. P-18 

Hershlag, A. P-154, P-169 

Hervé, D. P-52, P-283 

Hesters, L. P-138, P-171 

Heytens, E. O-36, O-226, P-46, P-567 

Hickey, M. P-92 

Hickman, T. N. P-591 


203 

Hidalgo, G. dos S. P-381 

Higdon III, H. L. O-292 

Hilary, B. E. O-238 

Hill, D. P-111, P-285 

Hill, D. L. P-533, P-539 

Hill, M. O-62 

Hiller, M. R. O-205 

Hilligsøe, K. M. P-197 

Himeno, T. O-307 

Hinds, P. P-136 

Hinoul, P. O-128 

Hirohama, J. O-96, P-313 

Hirshfeld-Cytron, J. E. P-161 

Hiura, E. O-96, P-313 

Ho, S. M. P-143 

Hoberman, S. O-153, P-18 

Hobson, D. T. O-97 

Hobson, D. T. G. P-434 

Hodes-Wertz, B. O-55, O-84, O-283, P-68 

Hofmann, G. O-309, P-247 

Höher, M. P-307 

Hojnowski-Diaz, P. V-4 

Holmes, R. J. P-257 

Holzer, H. O-281, P-245 

Honda, M. P-215 

Honjou, K. P-259 

Hopper, L. P-42 

Horcajadas, J. A. O-220, P-429 

Hornstein, M. D. O-83, O-311, P-456 

Horton, M. P-56, P-176, P-560 

Hossain, A. O-288 

Hotaling, J. M. P-126, P-506 

Hou, L. P-4 

Houmard, B. S. P-588 

Hourvitz, A. O-298, P-316 

Hovatta, O. O-293 

Hsiao, W. O-59, P-121, P-131 

Hsieh, M. P-155 

Hu, J. C. Y. O-54, P-67, P-86, P-185 

Huang, C.-C. P-191 

Huang, H. P-212 

Huang, J. O-143, P-522 

Huang, J. Y. P-208 

Huang, J. Y. J. O-175, O-286, P-237, P-246, P-540 

Huang, S. O-206 

Huddleston, H. P-96, P-422 

Huddleston, H. G. O-40 

Hudson, C. P-64, P-532 

Huffman, C. S. O-17 

Hughes, C. P-528 

Hukkelhoven, C. W. P. M. P-350 

Hunter, R. K. P-455 

Hur, C. P-59 

Hur, Y. P-59 

Hurd, W. O-157, P-43 

Hurley, I. R. O-212 

Hurst, B. P-179 

Hurst, B. S. O-41, P-406 

Huszar, G. B. P-502

Hwang, D. Y. P-25 

Hwang, H. K. P-87 

Hwang, K. P-120, P-137, P-451 

Hyman, J. H. O-290 

Iaconelli, Jr, A. O-48, O-51, P-163, P-186, P-497, 

P-561 

Iaconianni, L. O-264 

Iaizzo, R. P-475 

Iba, Y. O-299 

Ibrahim, Y. P-439 

Ida, M. O-183, O-307 

Idris, A. P-117 

Idriss, A. P-2 

Igarashi, H. P-146 

Ikebe, K. P-259 

Ikeda, Y. O-150 

Illions, E. P-16 

Illmensee, K. P-188 

Iltemir Duvan, C. P-521 

Im, S. P-332 

Imai, H. P-142 

Imudia, A. N. O-97, P-434 

Ingles, S. A. O-245 

Iñiguez, G. P-349 

Inmaculada, P.-C. O-267 

Insua, M. F. P-61 

Inza, R. C. O-265 

Irwin, A. P-361 

Isbacar, S. P-242 

Ishii, N. O-207 

Isiklar, A. P-75 

Ito, H. P-263 

Itoh, H. P-418 

Iwabe, T. P-371 

Iwamoto, H. O-117 

Iwata, K. O-299 

Izawa, M. P-371 

Izzo, C. P. M. P-534 

Izzo, C. R. P-534 

Jacoby, E. S. P-473 

Jaffey, J. P-274 

Jalalian, L. O-07 

Jana, S. K. P-386 

Janesch, A. P-139, P-295, P-300 

Jansen, K. A. M. O-235 

Jaramillo, S. R. P-437 

Jarodn, K. O-123 

Jarvi, K. O-56 

Javid, M. H. P-71 

Jayes, F. L. O-255 

Jayne, C. O-45 

Jeddi, M. P-420 

Jee, B. C. P-384 

Jellerette-Nolan, T. J. P-168 

Jemec, M. P-292 

Jenkins, T. G. P-184 

Jennings, P. K. P-264 

Jensen, J. O-08, P-14 

Jensen, J. T. O-11, O-258, P-420 


204 

Jeon, G.-H. P-85 

Jeong, H. J. P-240 

Jeria, F. P-485 

Jerzak, M. O-158 

Jesam Gaete, C. O-12 

Jiang, X. P-4 

Jiang, Z. P-374 

Jiang, Z. L. P-398 

Jill, F. O-274 

Jimenez, P. T. P-432 

Jindal, S. P-338, P-569 

Jindal, S. K. P-6, P-10, P-11 

Jinno, M. O-96, P-313 

Jo, J. H. P-511, P-512 

John, C. M. P-128 

John, D. V. P-52, P-283 

Johnson, D. P-118, P-299 

Johnson, L. P-439 

Johnstone, E. P-96, P-422 

Johnstone, E. B. O-172, O-213, O-214, O-254 

Johnston-MacAnanny, E. B. P-210 

Jolly, E. P-450 

Jones, H. P-361 

Jones, H. W. O-194 

Jones, M. R. P-344 

Jonsdottir, G. M. P-462 

Jordan, B. P-273 

Jordão, Jr, A. A. O-135, P-174, P-180, P-385 

Jorgensen, S. P-462 

Jorgez, C. J. O-166 

Joseph, S. P-225 

Jozefik, J. K. P-161 

Juarez Villanueva, A. M. O-249 

Judge, K. O-189, P-276 

Judge, K. H. O-88 

Junca, A.-M. O-103, P-481 

Jung, J. Y. P-288 

Jung, S.-H. O-255 

Jung, Y. H. P-250, P-289 

Jung, Y. J. P-87 

Jungheim, E. S. P-432 

Jurisicova, A. O-195 

Justen, R. P-231 

Kabouk, G. B. P-231 

Kadowaki, T. P-269 

Kagawa, N. O-124, O-150, P-28, P-201 

Kagawa, T. P-461 

Kahn, J. P-563 

Kahn, J. M. O-105 

Kahraman, K. P-242 

Kahraman, S. O-53, P-545 

Kakinuma, T. V-24 

Kamiya, H. P-47 

Kaneko-Tarui, T. P-145 

Kaneshiro, B. O-08 

Kang, A. P-87 

Kang, B.-M. P-214, P-216, P-346, P-518 

Kang, E. H. P-251 

Kang, H.-J. P-216, P-346, P-518

Kang, S. P-268 

Kang, S. M. P-272, P-339 

Kansal Kalra, S. P-516 

Kanzepolsky, L. P-491 

Karabacak, O. P-377 

Karabay, G. P-436 

Karabinus, D. P-118 

Karabulut, A. A. P-12 

Karagozoglu, H. O-53, P-545 

Karakaya, C. P-377 

Karchovski, E. O-165 

Karipcin, S. F. O-288, P-370 

Karl, S. O-30, V-1 

Karlikaya, G. O-53, P-545 

Karp, B. P-2 

Kasabwala, K. O-269, P-309 

Kashyap, S. P-204, P-274 

Kaskar, K. P-70, P-84 

Kassa, A. P-388 

Katagiri, Y. P-182 

Kato, K. V-24, P-271, P-570, P-584 

Kato, O. O-150, V-24, P-28, P-201, P-271, 

P-570, P-584 

Katz, P. O-222 

Katz, P. M. O-33, P-36 

Katz, P. P. O-58, O-221, P-254 

Katz-Jaffe, M. O-139, O-178 

Katz-Jaffe, M. G. O-64, O-78, O-91, O-116, O-118, 

P-22, P-69, P-139, P-141, P-189, 

P-295, P-300 

Kavoussi, P. K. O-167 

Kavoussi, S. K. O-136 

Kavrut, M. P-545 

Kawachiya, S. P-570 

Kawk, I. P. P-592 

Kaya, C. P-521 

Kaya, S. P-314 

Kayisli, U. P-282 

Kayisli, U. A. O-120, P-425 

Kearns, W. O-139 

Kearns, W. G. O-273, P-101, P-104, P-110 

Keator, C. S. O-258 

Kedem, A. P-35 

Keep, R. B. O-141 

Keller, J. P-299 

Keller, J. L. P-310 

Keller, P. P-418 

Kelly, P. B. P-528 

Kelly, S. O-242 

Keltz, J. P-338 

Keltz, M. D. O-42, P-355 

Kemp, G. J. P-361 

Kerr, C. L. O-205 

Kesner, J. O-153 

Ketefian, A. O-243, P-284, P-344, P-345, P-351 

Ketterson, K. P-285 

Khachikyan, I. O-134 

Khaldi, R. P-114, P-116 

Khalili, M. A. P-51 


205 

Khan, N. M. O-187 

Khan, Z. O-197 

Khatamee, M. A. O-192 

Khera, M. P-451 

Khoo, S. K. P-369 

Khoury, C. D. P-118 

Kiemele, L. O-116 

Kiessling, A. A. P-192 

Kilic, S. G. P-370 

Kim, A. P-592 

Kim, B. Y. P-91 

Kim, C.-H. P-214, P-216, P-346, P-518 

Kim, E. P-341 

Kim, E. S. P-251, P-339 

Kim, E.-A. P-258 

Kim, E.-H. P-258 

Kim, E.-K. P-258 

Kim, H. P-380 

Kim, H. J. P-512 

Kim, H. M. P-288 

Kim, H.-J. P-55 

Kim, J. P-268 

Kim, J. G. P-15, P-380 

Kim, J. S. P-251 

Kim, J. W. P-93, P-312, P-592 

Kim, J. Y. O-35 

Kim, J.-H. P-258 

Kim, K. C. P-25 

Kim, K. R. P-558 

Kim, M. P-252 

Kim, M. H. P-240, P-250, P-289 

Kim, M. J. P-319, P-333 

Kim, M. K. P-65, P-167 

Kim, M. S. P-272 

Kim, M.-R. P-384 

Kim, M.-S. P-359 

Kim, N. Y. P-319, P-333 

Kim, S. O-250 

Kim, S. S. O-60 

Kim, S. H. P-15, P-25, P-380, P-384 

Kim, S.-H. P-214 

Kim, S.-K. P-85 

Kim, Y. S. P-93, P-511 

Kim, Y. Y. P-250, P-289 

Kim, Y.-S. P-359 

Kimura, T. O-45 

King, H. P-178 

Kingsberg, S. A. O-200, O-202 

Kinzer, D. P-257 

Kinzer, D. R. P-119, P-279 

Kiray, S. P-436 

Kirma, N. B. P-372 

Kissner, M. O-24 

Klaine, J. P. O-218, P-396 

Klatsky, P. C. O-101 

Klein, J. U. P-286, P-583, P-590 

Klein, N. A. O-289, P-19 

Klein, S. F. P-304 

Klepac Pulanic, T. P-446

Klipping, C. P-304 

Klochowicz, M. O-158 

Klock, S. C. O-227 

Kloos, B. P-202 

Knee, A. B. O-151, O-312 

Knochenhauer, E. S. P-455, P-573 

Knopman, J. O-283, P-102, P-586 

Knopman, J. M. O-84, O-95, P-73, P-80 

Knudtson, J. F. P-372 

Ko, D. S. P-474 

Kobayashi, H. O-207 

Kobayashi, T. P-584 

Koca, G. P-376 

Kocak, M. P-12 

Kocent, J. O-52, P-67, P-185, P-553 

Koch, R. A. O-30, V-1 

Kohen, P. P-427 

Kohls, G. P-580 

Koike, M. P-263 

Kokeguchi, S. P-269 

Kolibianakis, E. P-551 

Komai, M. O-304 

Komatsubara, C. O-304 

Kondapalli, L. A. O-315 

Konialis, C. P-188 

Konopnicki, S. O-298 

Kook, M. J. P-87 

Koong, M. K. P-474 

Kopcow, L. P-56, P-175 

Kordus, R. J. P-503 

Korkmaz, M. P-376 

Kort, H. I. P-49, P-62, P-147, P-232 

Kotikela, S. V-14, V-23 

Kovalevsky, G. P-99 

Kovanci, E. O-121, P-261 

Koyner, P. P-198 

Kramer, W. P-264, P-459 

Kramer, Y. V-7, P-29 

Kreiner, D. O-294 

Kresowik, J. D. K. P-549 

Krey, L. O-283 

Krey, L. C. O-84 

Krieg, S. O-161 

Krishnamurthy, R. O-156 

Krishnamurthy, S. P-546 

Kruger, M. L. P-416 

Krychman, M. L. O-202 

Ku, S.-Y. P-15, P-380 

Kuang, Y. P-90 

Kubaney, H. R. O-157 

Kubatova, A. P-466 

Kubonoya, K. P-461 

Kudesia, R. P-522 

Kulkarni, A. O-185 

Kulp, J. L. P-158, P-421 

Kumasako, Y. P-263 

Kummer, N. P-280 

Kummer, N. E. P-523, P-525, P-577 

Kunitake, K. P-259 


206 

Kuo, F.-T. P-538 

Kurachi, H. P-146 

Kurotaki, Y. P-142 

Kuston, E. O-244 

Kusunoki, H. O-67, O-177, P-530, P-542, P-554 

Kuswojo, H. H. K. P-387 

Kutz, A. M. P-329 

Kuvalsky, D. P-241 

Kuwayama, M. O-124, O-150, P-28, P-201, P-271 

Kwak, I. P. P-125 

Kwak, K. H. P-91 

Kwon, H. C. P-288 

Kyono, K. P-215 

Kyrou, D. P-265 

La, A.-T. H. O-30, O-229, V-1 

Labarta, E. P-275 

LaBella, P. P-80 

Labella, P. A. P-29 

LaBrie, S. P-267 

Lagoo, J. P-439 

Laird, D. O-24 

Lalioti, M. O-119, O-120 

Lam, H.-M. P-143 

Lamazou, F. O-215 

Lamb, D. J. O-166, O-208, P-137 

Lamb, J. D. O-07 

Lancellotti, C. L. P. P-382 

Landeras, J. P-495 

Lane, S. P-406 

Lannon, B. M. O-26 

Lanzendorf, S. E. O-63 

Lao, M. T. P-81 

Lara, E. P-160 

Larman, M. G. P-75 

Laskin, C. P-294 

Lathi, R. B. O-161, O-179, P-115, P-299, P-559 

Laufer, M. R. O-155 

Laven, J. S. E. P-350, P-494 

Lavolpe, M. P-483 

Law, A. W. P-420 

Law, C. P-383 

Lawlor, D. A. O-279 

Lawson, M. S. O-37 

Le Meaux, E. P-159 

Leach, R. O-176, P-104 

Leader, A. P-211 

Leader, B. O-76, P-21 

Leake, K. A. O-41 

Lebovic, D. I. O-136, P-66 

Lederman, A. O-278 

Lee, C.-H. P-447 

Lee, D. P-34 

Lee, D. M. O-38 

Lee, D. R. P-91, P-125, P-167, P-511, P-512 

Lee, D.-R. P-341 

Lee, D.-Y. P-319, P-333 

Lee, H. C. P-168 

Lee, H. J. P-511 

Lee, H. S. P-240

Lee, H.-S. P-65, P-474 

Lee, I. P-94, P-325 

Lee, J. O-136, P-59, P-375 

Lee, J. H. P-87, P-125 

Lee, J. R. P-25, P-384 

Lee, J. W. P-339 

Lee, J.-H. P-85 

Lee, J.-W. P-518 

Lee, K. O-65, O-102, O-232, O-236, P-270 

Lee, K.-A. P-341 

Lee, K.-H. P-85 

Lee, M.-S. P-191 

Lee, R. P-121 

Lee, S. O-35, O-226, O-302, P-229, P-567 

Lee, S. G. P-272 

Lee, S. H. P-251, P-339 

Lee, S. J. P-87, P-288 

Lee, S. W. P-272 

Lee, S.-H. P-65 

Lee, T.-H. P-191 

Lee, W. P-59, P-252 

Lee, W. D. P-25 

Lee, W. S. P-167 

Lee, W.-D. P-55 

Lee, W.-S. P-341 

Lee, Y.-C. P-32 

Lee, Y.-J. P-447 

Lefebvre, C. O-112 

Legro, R. S. P-342, P-356 

Lehert, P. P-574 

Lehmann, R. O-100 

Lei, Z. P-353 

Leira, V. H. P-180 

Leonid, K. P-296, P-298 

Leppert, P. C. O-255 

Lesko, L. O-45 

Lessey, B. A. O-127, O-292, P-417, P-427 

Letourneau, J. M. O-33, O-221, P-36 

Leung, C. P-536 

Levanduski, M. P-188 

Leventoglu, A. P-17 

Levi, S. O-92, P-57 

Levy, B. O-269, P-112 

Levy, M. J. O-282, P-334, P-568 

Levy, S. O-23 

Lewis, C. E. O-152 

Lewis, J. E. P-152 

Lewis, M. L. V-14, V-23 

Lewis, R. P-5 

Li, F. O-194 

Li, H. O-159 

Li, L. P-337 

Li, P. S. V-8 

Li, X. P-213, P-514 

Li, Y. P-324, P-354 

Li, Y. Q. P-30 

Liang, X. P-156, P-324, P-354, P-364 

Librach, C. L. O-56 

Licciardi, F. O-283, P-80, P-431, P-586 


207 

Lieberman, E. S. O-277, P-593 

Liebermann, J. P-200, P-278 

Lieman, H. P-16, P-24, P-338 

Lieman, H. J. P-569 

Lim, C. K. P-474 

Lim, H. P-413 

Lim, J. P-59 

Lim, J. H. P-272 

Lim, J. J. P-512 

Lim, J.-H. P-55 

Lima, C. F. O-57 

Limback, D. O-60 

Lin, C.-J. P-147 

Lin, C.-K. P-445 

Lin, K. O-216 

Lin, P. C. P-588 

Lin, W. P-190 

Lin, W. T. O-147 

Lin, Y.-S. P-445 

Linda, G. C. O-161 

Lindemann, M. O-15 

Linden, M. O-139 

Lindner, J. R. O-258 

Lindqvist, A. P-418 

Lipshultz, L. I. O-166, O-208, P-120, P-137, P-451 

Liu, C.-H. P-191 

Liu, F. F. O-205 

Liu, H.-C. O-87, O-191, P-207, P-323 

Liu, J.-Y. P-445, P-447 

Liu, L. P-150 

Liu, S. P-2, P-154, P-169 

Liu, X. P-190 

Lo, J. C. P-358 

Lo, K. C. O-56 

Lo Turco, E. G. O-49, P-470, P-548 

Lobo, R. A. P-337 

Lombardi, E. P. P-478, P-531 

Lonczak, A. O-115 

Loper, R. P-189 

Lopez, P. P-349 

Loring, M. P-299 

Losonczi, E. O-106 

Lotti, B. P-61 

Loutradis, D. P-192 

Louwers, Y. V. P-350 

Lowderman, J. P-563 

Lu, P. Y. P-600 

Lu, Q. P-477 

Lu, Z. P-536 

Lucena, E. E. O-122 

Luciano, D. O-268 

Luk, J. P-379 

Luke, B. O-03, O-176, O-278, O-284 

Lukes, A. O-44, P-399 

Luna, M. O-70, O-81, P-48, P-234, P-236 

Luo, C. O-159 

Lynch, C. D. P-472 

Lynch, K. A. P-205, P-267 

Lynen, R. O-15, P-1

Lysiak, J. J. O-167 

Lyu, Q. P-90 

Lyu, S. W. P-93, P-592 

Maas, K. H. O-161 

Mabey, R. G. O-44, P-399 

Macaluso, M. O-180, O-185, P-593 

MacCutcheon, K. O-26 

Madaschi, C. P-534 

Madjid, T. H. P-448 

Magaosjo, M. V-24 

Mage, G. O-123, P-373 

Maguire, M. O-62 

Maguire, M. F. P-293 

Mahalingaiah, S. O-83, O-246, O-247, V-13 

Mahfouz, R. Z. O-157 

Mahony, M. P-211 

Maity, A. O-246, O-247 

Maity, S. O-94 

Mak, W. O-03, O-284 

Makita, M. P-228 

Maleysson, E. O-123, P-373 

Mali, W. P. Th. M. P-494 

Malik, M. O-108, O-256, O-260 

Malik, S. O-201 

Maman, E. O-298, P-316 

Mancebo, A. C. A. P-471, P-476 

Mangal, R. K. P-526 

Mann, J. S. P-523, P-525, P-577 

Mansour, R. P-164 

Manuel, M. O-267 

María, C. O-267 

Marcelli, M. O-154 

Marconi, M. O-265 

Marcos, M. O-267 

Marcus, J. O-266 

Marello, E. C. P-107 

Margalioth, E. J. O-290 

Mark, H. D. P-456 

Marmar, J. L. O-212 

Marotta, J. P-453 

Marquard, K. L. P-336 

Marr, S. G. O-308 

Marsburn, P. B. P-406 

Marsh, E. E. O-259, P-444 

Marshburn, P. P-179 

Marshburn, P. B. O-41 

Martin, J. P-397 

Martina, P. P-520 

Martinez, A. G. P-475 

Martinez, A. M. P-441 

Martinez, E. P-31 

Martinez, J. C. O-190 

Martinez, M. C. P-109 

Martinez, O. O-312 

Martínez, S. P-428 

Martínez, V. S. O-249 

Martinez-Burgos, M. P-206 

Martinez-Conejero, J. A. P-429, P-479 

Martinez-Escribano, S. O-220 


208 

Martinez-Salazar, J. O-93 

Martinez-Soto, J. C. P-495 

Martinez-Zapata, M. J. P-217 

Martinhago, C. O-51 

Martins, W. P. O-217 

Marut, E. O-276 

Maruyama, T. P-322 

Masker, K. K. O-130 

Masouridou, S. P-551 

Massaro, F. C. O-188 

Massie, J. A. M. P-115, P-299 

Masson, P. V-8 

Mata, A. O-249 

Mateu, E. P-109 

Matsuyama, Y. P-177 

Matsuzaki, S. O-123, P-373 

Matte, U. S. P-98 

Matthews, J. M. P-200, P-278 

Matthews, M. P-406 

Mátyás, S. O-106 

Mauri, A. L. O-188, P-132, P-144, P-500 

Mazmanian, G. P-273 

McAdory, E. F. O-292 

McAvey, B. P-569 

McCaffrey, C. O-84, O-171, O-283, P-68, P-586, V-7 

McCallie, B. P-139, P-295, P-300 

McCarthy-Keith, D. O-108 

McCarthy-Keith, D. M. O-256 

McConaha, M. E. O-252 McCormick, S. 

O-91, O-118, O-178 

McCoy, T. W. P-353 

McCulloch, C. O-213, O-214 

McCulloch, C. E. P-36 

McDonald, C. A. O-20, P-103, P-505 

McGee, E. O-196, O-203 

McGuire, A. O-22 

McIntyre, M. G. O-170 

McReynolds, S. O-116, P-141 

McShane, P. O-85 

Meadows, J. W. O-153 

Mediwala, S. N. O-154 

Meeker, J. P-220 

Meeker, J. D. O-248, P-243 

Mehta, J. O-243 

Meier, U. T. O-294 

Meirow, D. O-32, V-16 

Melamed, A. P-5 

Melnick, A. O-143, P-208 

Mendes, C. M. P-504 

Menduni, F. P-597 

Menezo, Y. P-481 

Meola, J. P-381 

Mercader, A. P-108 

Mercan, R. P-579 

Merhi, Z. O. P-338 

Merino, M. P-446 

Merino, P. P-349 

Merkatz, R. B. O-12 

Mersereau, J. E. P-37, P-40

Meseguer, M. O-47, O-231, O-233, V-6, P-183, 

P-193, P-197, P-479 

Mesner, A. P-138 

Metabolomics Study 

Group O-88, O-189, P-276 

Mettler, L. P-153 

Meyer, L. J. P-442 

Meyer, W. P-290 

Michael, A. P-81 

Michael, E. S. P-81 

Michael, T. P-81 

Michaeli, M. O-98, O-165 

Michelon, J. P-74 

Michelon, T. O-163 

Mielnik, A. O-166, P-482 

Milad, M. O-303, V-17 

Milán, M. O-270 

Milki, A. A. P-115 

Miller, C. E. O-68, O-266, V-18 

Miller, J. Z. P-210 

Miller, P. B. O-127, O-292 

Millstein, S. O-222 

Millstein, S. G. O-58, P-254 

Milroy, C. O-74, P-150 

Min, S. H. P-558 

Minami, T. P-177 

Mindes, E. J. O-224 

Minjarez, D. A. O-64, P-22 

Minkhorst, O. R. P-572 

Minter, T. O-69, O-80 

Mio, Y. O-299, V-5 

Mir, P. O-270 

Mirkin, S. O-149 

Mishell, D. O-12, P-5 

Mishell, D. R. O-13 

Missmer, S. O-174 

Missmer, S. A. O-83, O-176, O-246, O-247, O-311, 

P-456, P-537 

Mitalipov, S. V-3 

Mitchell-Leef, D. O-105, P-49 

Mitsoli, A. P-551 

Mittal, S. P-145 

Miura, Y. O-299 

Miyatani, S. P-215 

Miyazaki, K. P-322 

Mocanu, E. P-27, P-528 

Mochida, T. O-299 

Moehner, S. O-09 

Moeller, B. C. O-111 

Moffat, S. D. O-199 

Mogami, H. P-418 

Moley, K. H. O-193, P-336, P-424 

Molina, J. M. P-196 

Molina Sabater, J. M. P-203 

Molinaro, T. O-28 

Molla, M. M. P-543 

Mollamahmutoglu, L. P-392 

Monahan, D. P-173, P-185, P-553 

Montaner, D. O-75 


209 

Moody, J. E. O-229 

Moon, J. M. P-384 

Moon, K. S. P-38, P-517, P-519 

Moon, S. Y. P-15 

Moore, K. O-44 

Moraloglu, O. P-547 

Moran, A. M. O-122 

Morbeck, D. P-14 

Morbeck, D. E. O-197 

Moreau, L. P-331 

Moreira, M. de F. R. P-471, P-476 

Morel, K. S. O-242 

Morenghi, E. P-597 

Moreno, D. A. P-352 

Morgan, M. O-233 

Mori, C. P-28, P-201 

Morimoto, Y. O-183, O-304, O-307, P-77 

Morita, M. P-182 

Morrison, L. S. P-99 

Morschhauser, F. O-112 

Moskovtsev, S. I. O-56 

Motta, A. P-175, P-176 

Motta, E. L. A. O-285, P-23, P-235, P-504 

Mottla, G. L. P-410 

Moulder, J. P-220 

Moy, F. O-35, O-226, P-567 

Moy, I. O-206 

Mucko, S. E. P-513 

Mugica, A. P-196 

Mukherjee, S. O-160, O-208, P-347 

Mukherjee, T. O-70, P-48, P-103 

Mullen, B. P-53 

Mullen, J. B. M. O-56 

Muller, C. H. P-506 

Mullin, C. O-55, O-95, P-68, P-575 

Mullin, C. M. O-280, P-73, P-431, P-586 

Mumford, S. P-38 

Muneyyirci-Delale, O. P-32, P-389, P-391, P-440 

Munne, S. O-144, O-271, O-276, P-107, P-285, 

P-294 

Munoz, E. P-31, P-388 

Muñoz, E. E. P-543 

Murk, W. P-502 

Murphy, E. M. P-457 

Muse, K. O-44, P-399 

Myers, Jr, M. G. O-198 

Nacharaju, V. L. P-32 

Nachtigall, R. P-254 

Nachtigall, R. D. O-58 

Nagai, Y. P-177 

Nagamatsu, T. P-394 

Nagao, K. O-207 

Nagashima, H. O-150, P-77 

Nagata, Y. P-259 

Nagayoshi, M. O-67, O-177, P-97, P-130, P-244, 

P-530, P-541, P-542, P-554 

Nagayoshi, M. M. D. O-186 

Nagy, Z. P. O-61, O-105, P-49, P-62, P-147, 

P-232, P-563

Nah, H.-Y. P-214 

Nair, K. S. O-238, P-348 

Nair, S. O-316 

Najeemuddin, R. O-06, O-145, O-146 

Nakajima, S. T. O-164, P-353, P-395, P-557 

Nakajo, Y. P-215 

Nanassy, L. O-209 

Nangia, A. K. O-03, O-284 

Nass, T. E. P-107 

Nasseri, A. P-582 

Nassetti, D. K. O-192 

Natalia, A. P-298 

Natavio, M. P-5 

Nathan, C. P-318 

Navarro, D. E. O-122 

Navarro, P. A. O-135, P-385 

Navarro, P. A. A. P-180 

Navarro, P. A. A. S. P-174 

Nayak, N. O-161 

Nayak, S. O-303 

Nayar, K. D. E. V. P-249 

Nazemian, Z. P-71 

Nazzaro, A. P-404, P-571 

Neiman, L. P-367 

Nejat, E. J. P-11 

Nelson, L. P-293 

Nelson, L. M. P-305 

Nelson, S. M. O-279 

Neri, Q. V. O-52, O-54, O-184, P-67, P-86, P-173, 

P-185, P-553 

Nessetti, M. B. R. O-192 

Nestler, J. E. O-242, P-311 

Neuspiller, F. D. P-61 

Neves, H. C. P-471, P-476 

Newhouse, P. A. P-329 

Newton, L. P-507 

Nezam, H. O-251 

Nezhat, C. V-14, V-23 

Nguyen, K.-H. D. O-273, P-104 

Ni, L. P-323 

Nichi, M. P-493 

Nichols, J. E. P-527, P-594 

Nichols, M. O-08 

Nicholson, R. O-228 

Nicholson, R. A. O-110, O-223 

Nicolás, G. O-267 

Nicolai, H. P-485 

Nicoletti, A. J. P-57 

Niels, R. O-267 

Nikolovski, J. O-225 

Nishikawa-Uchida, S. P-322 

Noblia, F. P-483 

Noda, Y. P-182 

Nodar, F. P-483 

Nodler, J. L. P-449 

Noel, M. O-143, P-208 

Nohr Beck, L. O-18 

Norian, J. M. O-260, P-253 

Norman, R. J. P-156 


210 

Northrop, L. E. P-151, P-303, P-309 

Nowak, N. T. O-199 

Nowak, R. P-444 

Noyes, N. O-84, O-95, O-171, V-7, P-29, P-68, 

P-73, P-80 

Nugent, N. P-79, P-83 

Nulsen, J. P-280 

Nulsen, J. C. P-523, P-525, P-577 

Nutter, B. O-129, O-305 

Obeso, I. P-555 

Ocak, N. S. P-425 

Ocali, O. P-202 

Ochalski, M. E. O-140 

Ochi, M. P-47 

Ochuiuto Teixeira 

de Resende, L. P-352 

O’Connor, A. P-274 

Oda, H. P-322 

Odem, R. R. O-63, P-432 

Oehninger, S. O-220, P-140, P-423 

O’Flynn O’Brien, K. P-321 

Oh, I. W. P-251 

Ohl, J. P-331 

O’Horo, S. K. V-12 

Ojeda, M. P-388 

Ojeda, M. M. P-543 

Oka, Y. O-207 

Okada, L. P-74 

Oktay, K. O-33, O-35, O-36, O-147, O-226, 

O-302, P-12, P-17, P-46, P-229, P-567 

Oktem, M. P-377 

Oktem, O. O-90, P-579 

Okubo, T. P-224, P-271 

Oleg, B. P-296, P-298 

Oliveira, J. B. A. O-188, P-132, P-144, P-500 

Olivennes, F. O-73, P-315 

Oliver, D. P-562 

Olivieri, M. T. P-544 

Olson, M. R. P-369 

Omari, S. O-195 

Omodei, U. P-266 

Onalan, G. P-314 

O’Neill, K. E. O-63, P-424 

Oppenheimer, K. H. P-297 

Opper, N. O-310 

Opsahl, M. O-276 

Orav, J. O-225 

Ormanji, M. S. P-378 

Orris, J. J. O-275, P-54, P-227 

Orsi, N. O-99 

Ortega, C. O-295 

Ortega, I. O-111 

Ortiz, R. O-134 

Orwig, K. O-39 

Osada, H. V-24, P-570, P-584 

Osei-Tutu, N. P-389, P-391 

Osés, R. P-478 

Osheroff, J. P-496, P-508 

Oskowitz, S. P. P-529

Osteen, K. G. O-252, P-366 

Ota, K. P-182 

Otsuki, J. P-177 

Ou, C.-C. P-447 

Ouandaogo, G. P-171 

Ouandaogo, Z. G. O-297 

Oubiña, A. M. P-175 

Owen, C. M. O-260 

Owen, D. O-286 

Ozaksit, G. P-392, P-595 

Ozcan, P. P-377 

Ozdegirmenci, O. P-291, P-301 

Ozdener, T. P-547 

Ozel, M. P-595 

Ozkan, S. O-53 

Ozkavukcu, S. O-226, O-302, P-550 

Ozmen, B. P-242, P-550 

Pabon, D. P-587 

Pabón, D. D. P-543 

Pacheco, A. O-190, P-566, P-587 

Paduch, D. A. P-482 

Pae, S. P-89 

Paffoni, A. P-106 

Pagel, E. R. P-506 

Pagidas, K. P-95 

Pal, L. O-244, P-11, P-598 

Palaoglu, E. O-90 

Palbero, L. P-495 

Pale, J. R. P-131 

Palermo, G. D. O-52, O-54, O-184, P-67, P-86, P-173, 

P-185, P-553 

Pall, M. O-237, O-243, P-345, P-351, P-362 

Pall, M. E. P-365 

Palomino, W. A. P-427 

Palumbo, A. O-261, O-264 

Pam, T. V. P-565 

Pang, S. C. P-211, P-596 

Pangalos, C. P-188 

Papaioannou, V. E. P-127 

Papier, S. V-20, P-407, P-409, P-412, P-483 

Papuccu, E. G. P-550 

Paracchini, V. P-106 

Paraiso, M. F. R. V-11 

Parekattil, S. J. V-9, V-10, P-124, P-134, P-135 

Parés, P. P-390 

Parish, S. J. O-200 

Pariz, J. R. O-57, P-470 

Park, C. P-558 

Park, C. Y. P-194, P-558 

Park, E. P-216 

Park, E. A. P-167 

Park, I.-H. P-85 

Park, J. K. P-290 

Park, J. H. P-145, P-162 

Park, S.-Y. P-258 

Park, Y.-S. P-65 

Parker, A. K. P-432 

Parker, J. P-411 

Parker, K. P-274 


211 

Parks, J. C. P-189, P-295, P-300 

Parsons, A. K. O-266 

Partanen, A. P-446 

Pasch, L. O-222 

Paschal, A. P-42 

Pasqualotto, E. P-497 

Pasqualotto, F. O-48, P-163, P-497 

Patel, A. P-33 

Patel, J. C. P-596 

Patel, P. R. P-152 

Patel, S. S. P-330 

Paternot, G. P-564 

Patrizio, P. O-120, P-158, P-160, P-555 

Patterson, C. M. O-198 

Pauli, S. A. P-149, P-585 

Paulson, R. O-245 

Paulson, R. J. O-310 

Pavone, M. E. V-17 

Paz, C. C. P. P-381 

Peak, D. P-116 

Peart, M. M. O-210 

Peavey, M. C. P-20 

Pedersen, K. S. V-6, P-197 

Pedraza, J. P-50, P-498 

Peinado, V. O-270 

Pejoan, H. P-515 

Pellestor, F. O-71 

Pellicer, A. O-47, O-50, O-66, O-79, O-93, O-190, 

O-270, P-31, P-61, P-76, P-108, 

P-109, P-166, P-183, P-196, P-206, 

P-275, P-388, P-397, P-428, P-429, 

P-479, P-486, P-492, P-495, P-566, 

P-580, P-587 

Pellicer, A. A. P-165, P-543 

Pellicer Martínez, A. P-148, P-203 

Pelts, E. J. P-200, P-278 

Peluffo, M. C. P-7 

Pen, R. P-101 

Peng, Q. P-90 

Peng, W. P-44 

Peng, Y. V-8 

Penrose, L. P-469 

Penzias, A. S. O-26, P-591 

Pepperell, J. R. P-95 

Perco, M. P-491 

Pere, C. O-274 

Pereira, F. S. P-98 

Pereira, R. M. A. O-263 

Perelló, J. P-390 

Perelman, M. A. O-200 

Perez, O. O-102, P-41 

Perez-y-Perez, M. P-459 

Perkins, R. P-202 

Perle, M. A. O-142 

Perloe, M. O-21 

Petersen, C. G P-144 

Petersen, C. G. O-188, P-132, P-500 

Peterson, C. M. O-74, O-251 

Petracco, A. P-74

Petrozza, J. O-248, O-314, V-4, P-220 

Petrozza, J. C. P-243, P-467 

Pfaff, A. C. P-329 

Pham, K. N. P-123 

Phelps, J. Y. O-288 

Phillippe, M. P-297 

Phillips, D. P-463 

Philosof-Kalich, L. O-32 

Phy, J. L. P-490 

Piccioni, G. P-266 

Pigny, P. O-112 

Pike, J. W. P-309 

Pilla, F. O-220 

Pinho, J. P-261 

Pino, J. P-198 

Pisarska, M. P-365 

Pisarska, M. D. P-538 

Plante, B. P-95 

Plautz, G. E. O-157 

Polak-Charcon, S. P-308 

Politch, J. A. P-552 

Polotsky, A. J. P-338, P-569 

Póo, M. E. O-75 

Porter, B. W. P-414 

Portmann, M. P. P-99 

Potter, D. O-272 

Potter, D. A. P-118 

Potts, A. P-199 

Poüs, C. P-138 

Prados, N. P-492 

Prates, R. O-271, O-274 

Pregenzer, G. P-136 

Pribenszky, C. O-106 

Price, T. M. P-20 

Prien, S. P-469 

Prien, S. D. P-60 

Priola, K. B. V-9, P-135 

Priola, K. J. V-10, P-124, P-134 

Prisant, N. O-103, P-315 

Privamera, M. R. O-92, P-57 

Privitera, L. P-275 

Proctor, M. P-164 

Prudencio, C. P-133, P-484, P-487 

Pulido, C. A. O-122 

Purcell, S. P-336 

Purcell, S. H. O-193 

Puscheck, E. E. O-97, P-443 

Puvvula, P. O-29 

Pyke, R. O-45 

Pyrzak, R. O-89, P-581 

Qiu, Y. O-159 

Quan, S. O-159 

Quezada, M. O-203 

Rabellotti, E. P-489 

Rabinowich, G. A. P-128 

Rabinowitz, M. O-272, P-299 

Rabinowitz, R. O-290 

Rachmawati, A. P-448 

Rackow, B. W. O-241 


212 

Racowsky, C. O-109, O-174, O-277, P-537, P-593 

Radeke, E. P-33 

Ragni, G. P-106 

Rajani, S. O-160, P-347 

Rajkovic, A. O-140 

Ramasamy, R. O-59 

Ramelan, W. W. R. P-387 

Ramezani, M. P-51 

Ramirez, E. R. O-192 

Ramirez, H. A. O-192 

Ramirez, V. Z. O-192 

Ramos-Haggan, A. P-340 

Ramsing, N. B. O-231, V-6, P-193 

Ramsing, N. N. P-165 

Rana, N. P-281, P-393 

Randall, G. O-162 

Raque-Bogdan, T. L. O-224 

Rasheed, S. M. O-219 

Rasillo, L. J. O-72 

Ratcliffe, S. J. O-14, P-516 

Ratts, V. S. P-432 

Rauch, E. O-87, P-540 

Rausch, M. E. O-114, O-173 

Rawe, V. P-491 

Rawlins, M. O-91, O-118 

Reagan, A. P-227 

Reape, K. Z. P-287, P-524 

Reddy, J. V-11 

Reddy, S. Y. V-19 

Reddy, V. P-78 

Regan, M. M. O-01, P-529 

Register, T. C. O-148 

Reh, A. O-142, O-171, P-29, P-326, P-332 

Reichman, D. E. P-537 

Reijo Pera, R. O-172 

Reimand, J. O-293 

Reinblatt, S. L. P-546 

Reindollar, R. H. O-01, P-529 

Remohí, J. O-66, O-230, O-233, O-270, P-76, 

P-275 

Remohi, J. O-79, P-109 

Remorgida, V. O-04, O-131, O-132, P-368 

Ren, Y. P-70 

Repping, S. O-02 

Reproductive Medicine 

Network P-342, P-356 

Requena, A. O-93, P-217, P-556 

Resau, J. H. P-369 

Ressler, I. B. P-576 

Rey Valzacchi, G. P-72 

Reynolds, K. A. O-309, P-247 

Reynolds-May, M. F. P-454 

Reynoso, M. O-229 

Rezk, A. P-117 

Ribeiro, M. P-533 

Ricci, J. A. O-59 

Rice, C. E. O-100 

Richter, K. S. O-82, O-224, O-282, P-8, P-110, 

P-334, P-400, P-401, P-410, P-496,

P-508, P-568 

Rien, D. P-502 

Rijnders, E. M. O-235 

Rinaudo, P. P-190, P-204 

Riqueros, M. O-50, P-196 

Riqueros Arévalo, M. I. P-148 

Riqueros Arevalo, M. P-203 

Riva, A. P-226, P-265 

Rivera, J. P-485 

Rizk, P. B. P-225 

Robin, G. O-112 

Robins, J. O-101 

Robins, J. C. P-466 

Robinson, D. O-128 

Robinson, N. O-301 

Robker, R. L. P-156 

Rocha, A. M. O-263, O-285, P-23, P-504 

Rocrigues, J. K. P-180 

Rodini, G. P. P-98 

Rodríguez, M. G. P-544 

Rodrigo, L. P-109, P-486 

Rodrigues, F. P. O-182 

Rodrigues, J. K. O-135, P-174, P-385 

Rodriguez, A. O-104, P-41, P-187, P-270 

Rodriguez-Karl, M. C. O-30, O-229, V-1 

Roh, S. P-268 

Roh, S. I. P-194 

Rollandi, G. A. O-132 

Rollene, N. P-14 

Rollene, N. L. P-327 

Rolnitzky, L. P-332 

Romany, L. O-47, P-183, P-479 

Romijn, H. C. P-494 

Roness, H. O-32 

Rongieres, C. P-331 

Roos, P. O-189, P-276 

Rosa e Silva, J. C. P-63, P-381 

Rosa-e-Silva, A. C. J. S. P-63 

Rosa-e-Silva, C. C. J. S. P-172 

Rosales, J. P-555 

Roseff, S. O-266 

Roseff, S. J. P-503 

Rosemberg, E. H. P-544 

Rosen, A. O-226 

Rosen, M. O-40, O-147, O-254, P-204 

Rosen, M. P. O-07, O-33, O-172, O-213, O-214, 

O-221, P-36, P-480 

Rosencrantz, M. A. P-340 

Rosenwaks, Z. O-27, O-29, O-52, O-54, O-87, O-143, 

O-175, O-184, O-191, O-286, P-67, 

P-86, P-105, P-173, P-185, P-207, 

P-208, P-237, P-246, P-323, P-442, 

P-522, P-540, P-553 

Rosoff, J. A. P-131 

Ross, R. O-273 

Rossi, B. V. O-155, V-12, V-13, P-456 

Rossi, L. M. P-382 

Roth, L. O-85 

Rothfarb, N. O-98 


213 

Roudebush, W. E. P-594 

Rouhanifard, S. O-29 

Rouleau, D. P-413 

Rouzi, A. A. P-343 

Rubal, L. A. O-43 

Rubin, A. O-13 

Rubio, C. O-270, P-109 

Rudick, B. O-245 

Ruhlmann, C. P-475 

Ruiz, A. P-275 

Ruiz, M. O-229 

Ruiz, V. O-75 

Ruiz-Flores, F. O-93 

Ruman, J. P-236 

Rumohr, J. A. P-120 

Rushania, G. P-298 

Russell, J. B. O-313 

Ryan, D. O-18 

Ryan, G. L. P-549 

Rybak, E. A. O-294 

Ryu, C. P-268 

Ryu, C. S. P-339 

Ryu, H. E. P-558 

Sá, M. F. S. P-172 

Saa, A. M. O-122 

Sa’adi, A. A. S. P-387 

Sabanegh, E. P-181, P-501 

Sadetsky, N. O-58, P-254 

Sadovsky, R. O-200 

Sadri-Ardekani, H. O-02 

Saed, G. P-374 

Saed, G. M. P-398, P-416 

Sahakian, V. P-273 

Said, A. P-52, P-283 

Said, T. M. P-53 

Saiz, M. J. P-390 

Sakkas, D. O-119, O-120, O-189, P-276 

Sakkas, D. H. O-88 

Salame, G. P-32 

Saleh, H. P-256 

Salerno, A. P-404, P-571 

Salih, S. P-66 

Salmassi, A. P-153 

Salomao, R. O-218 

Salumets, A. O-293 

Samantha, B. O-216 

Samir, H. P-52, P-283 

Sammak, P. J. P-513 

Sammel, M. O-114, O-173 

Sammel, M. D. O-43, O-216, P-302, P-321 

San Roman, G. A. P-209 

Sanchez, L. P-411 

Sanchez, S. P-50, P-498 

Sanchez, S. R. P-200, P-278 

Sanchez Sarmiento, C. A. O-249 

Sand, M. P-450 

Sandler, B. O-70, O-81, P-48, P-103, P-234, 

P-236 

Sandlow, J. I. P-123

Santana, L. F. P-352 

Santanam, N. P-178 

Santi, M. P-111 

Santiago, M. O-274 

Santoro, N. O-294, P-6, P-10 

Santos, L. F. A. P-129 

Santos, R. M. D. P-555 

Santos, X. M. O-156 

Sarikaya, E. P-392 

Sarkar, H. S. P-347 

Sartor, B. M. P-600 

Sarwer, D. B. O-315 

Sasaki, M. O-186, P-97, P-130, P-244, P-541, 

P-554 

Sasayama, N. P-77 

Satiroglu, H. P-521 

Sato, S. P-228 

Sauer, M. V. P-127, P-286, P-337, P-583, P-590 

Saunders, R. D. O-164 

Sawant, A. P-443 

Sawmiller, J. P-411 

Sayan, C. D. P-392 

Sayme, N. P-502 

Sbracia, M. O-133 

Scarduelli, C. P-106 

Scarpellini, F. O-133 

Schattman, G. L. P-442 

Schenk, L. M. P-526 

Schenken, R. S. P-372, P-473 

Schiewe, M. C. P-79, P-83 

Schindler, L. P-331 

Schisterman, E. F. P-472 

Schlaff, W. D. O-85, P-342, P-356 

Schlegel, P. N. O-54, O-59, O-166, P-482 

Schlenker, T. O-118, O-178, P-69 

Schmutzler, A. G. P-153 

Schneider, C. P-513 

Schon, S. B. P-432 

Schoolcraft, W. B. O-64, O-78, O-91, O-116, O-118, 

O-139, O-178, P-22, P-69, P-139, 

P-141, P-189, P-295, P-300 

Schrader, S. M. O-250 

Schreiber, C. A. O-14 

Schreiner, P. O-152 

Schroeder, D. R. P-327 

Schuett, B. P-304 

Schust, D. J. P-394 

Schutt, A. K. O-126 

Schwartz, T. A. O-17 

Scientific Committee 

AMP-Vigilance Reseau 

Follow-Up P-515 

Scobey, J. O-68 

Scoccia, B. P-363, P-576 

Scott, K. L. P-100 

Scott, L. P-202 

Scott, R. T. O-22, O-78, O-269, P-100, P-189 

Scott, Jr, R. T. O-05, O-28, O-110, O-115, O-223, 

O-228, O-300, P-112, P-113, P-151, 


214 

P-303, P-309, P-430 

Seckin, B. P-547, P-595 

Segars, J. O-62, O-108, O-134, P-446 

Segars, J. H. O-82, O-113, O-256, O-260, P-8, 

P-38, P-305, P-334, P-400, P-401, 

P-517, P-519 

Segawa, T. P-584 

Seia, M. P-106 

Seifer, D. O-76, P-21 

Seifer, D. B. P-16, P-24 

Seli, E. O-88, O-119 

Selles, E. P-566 

Senturk, B. P-595 

Seo, J. T. P-65 

Seok, H. H. P-341, P-592 

Seol, B. P-133, P-484 

Seoul, B. P-487 

Sepúlveda, J. P-160 

Serafini, P. O-263, O-285, P-23, P-235, P-504 

Serletti, J. V-19 

Sermeus, W. O-19 

Serra, V. O-233 

Session, D. R. P-149, P-585 

Setti, A. O-48, O-51, P-163, P-186, P-493, 

P-561 

Setti, P.E. P-597 

Settle, J. C. P-594 

Seydafkan, S. P-585 

Seyhan, A. P-546 

Shade, G. P-434 

Shah, D. K. O-174 

Shah, J. O-134 

Shah, R. P-335 

Shah, T. P-32, P-440 

Shahin, A. Y. P-464 

Shaish, A. P-308 

Shalom Paz, E. P-546 

Shamonki, M. P-284 

Shangold, G. P-399 

Shapiro, B. S. P-64, P-532 

Shapiro, D. B. O-266, P-49, P-62, P-232 

Sharan, C. O-34, O-257 

Sharara, F. I. P-239, P-248 

Sharlip, I. D. P-488 

Sharma, R. K. P-181, P-501 

Sharma, S. P-347 

Sharma, V. O-99 

Shaunik, A. O-114, O-173, P-321 

Shavell, V. I. O-97, P-443 

Shaw, J. O-244 

Shaw, K. A. O-10 

Shea, L. D. P-161 

Shen, H. P-477 

Shen, S. O-07, V-2, P-204, P-274, P-480 

Shen, Z. O-138 

Sheng, J. P-212 

Sherbahn, R. O-234, P-13 

Sherwin, J. R. A. P-417 

Shi, X.-Y. P-535

Shibuya, Y. P-215 

Shigeta, M. P-435 

Shim, M. S. P-512 

Shim, S. H. P-93 

Shimizu, T. P-182 

Shin, D. P-136 

Shindel, A. W. P-488 

Shiotani, M. P-269 

Shirasawa, T. P-182 

Shlush, E. O-46, O-98 

Shomento, S. H. P-449 

Shu, H. P-524 

Shu, Y. P-44 

Sícaro, L. V. P-478, P-531 

Sidell, N. O-138, P-149 

Sikirica, V. O-128 

Silber, S. J. O-124, O-150, V-16, V-24, P-28, 

P-201, P-230 

Sileo, M. O-18, P-39 

Silva, I. D. C. G. O-218, P-396 

Silva-de-Sá, M. F. O-217 

Silverberg, K. O-69 

Silverberg, K. M. O-80 

Simón, C. O-75, O-79, O-230, P-108, P-428, 

P-429 

Simon, J. O-45 

Simons, E. J. V-19 

Simpson, T. H. O-224 

Sinaii, N. O-134, P-389, P-391 

Singer, T. O-87, O-143, O-175, O-286, P-208, 

P-237, P-246, P-522, P-540 

Singh, M. P-443 

Singh, T. P-152 

Singhania, N. P-573 

Siow, Y. P-353 

Siscovick, D. O-152 

Sistrun, S. N. O-242 

Sites, C. K. O-151, O-312, P-205, P-306 

Sitruk-Ware, R. O-12 

Skorupski, J. C. O-198 

Slayden, O. D. O-258 

Slayden, S. M. P-147, P-232 

Slifkin, R. E. P-505 

Smith, G. D. O-107 

Smith, J. F. O-03, O-33, O-58, O-221, O-284, 

P-36, P-254, P-488 

Smith, K. M. P-367 

Smith, L. K. P-490 

Smith, R. O-91, O-178, P-485 

Smith, R. P. O-167 

Smitz, J. O-295, O-296 

Smotrich, D. O-272 

Soares, G. M. O-217 

Sobel, M. O-141, P-457 

Sober, S. P. O-14 

Sobral, F. P-176 

Sobral, F. L. P-560 

Sohn, S. M. P-93 

Sokalska, A. O-111, O-137, P-366 


215 

Soleimani, R. O-36, O-302, P-46 

Soler, T. B. O-49, P-548 

Somkuti, S. G. O-141, P-457 

Son, W. Y. O-72 

Son, W.-Y. O-281, P-170, P-245 

Sonia, C. P-597 

Sone, Y. P-230 

Song, H.-J. P-216, P-346 

Song, I. O. P-65 

Song, S. H. P-511 

Sonmezer, M. P-12, P-17, P-242, P-262, P-550 

Sophonsritsuk, A. O-148 

Soto, E. P-234 

Soules, M. R. O-289, P-588 

Souter, I. P-220, P-467 

Souter, I. C. P-243 

Souza, G. H. M. F. O-49, O-86, O-211 

Spaine, D. M. O-57 

Spalvieri, S. P-292 

Spandorfer, S. O-286, P-540 

Spandorfer, S. D. O-143 

Spandorfer, S. M. D. P-522 

Sparks, A. P-578 

Sparks, A. E. T. P-549 

Sparman, M. V-3 

Speicher, D. O-173 

Spendorfer, S. D. P-208 

Spiessens, C. P-564 

Spitzer, J. C. O-315 

Spitzer, T. P-96 

Spitzer, T. L. B. P-422, P-460 

Sprung, V. S. P-361 

Sreedevi, M. P-33 

Srouji, S. S. O-301, V-12, V-13, V-21 

Stachecki, J. J. P-83 

Stadtmauer, L. A. P-524 

Stahl, P. J. P-482 

Stalling, J. C. P-452 

Stambrook, P. P-26, P-30 

Stanca, C. O-106 

Stanczyk, F. O-43, O-245 

Stanczyk, F. Z. O-13, P-18 

Stanley, S. D. O-111 

Stavreus-Evers, A. O-293 

Stearns, C. O-277 

Steers, W. D. O-167 

Stegmann, B. P-578 

Stegmann, B. J. P-517, P-519, P-549 

Stein, R. J. V-11 

Steiner, A. Z. O-153, P-9, P-18, P-306, P-572 

Stelling, J. R. P-209 

Stephen, S. D. O-136 

Stephenson, M. P-363 

Sterling, E. W. O-21 

Stern, J. E. O-03, O-109, O-176, O-278, O-284, 

P-591, P-593 

Sternfeld, B. O-152, O-172, O-213, O-214, O-254 

Steuerwald, N. P-179 

Stevens, J. O-91, O-116, O-118, O-139, O-178,

P-69, P-139 

Stevens, J. M. O-64, O-78, P-22, P-295 

Stewart, E. A. O-197 

Stoop, D. P-82, P-277 

Stouffer, R. O-38, P-34 

Stouffer, R. L. P-7, P-213 

Stovall, D. W. O-126, P-311, P-320 

Stratton, P. O-134, P-2, P-389, P-391, P-446 

Straub, R. J. O-105 

Stull, D. E. P-420 

Su, H. P-565 

Su, H. I. P-340 

Su, J. O-28, O-115, O-269, O-300 

Suastegui, W. P-50 

Subit, M. J. O-162 

Suchich, G. P-296 

Sudiana, I. K. I. K. S. P-387 

Sueldo, C. O-262, V-20, P-408, P-412, P-415, 

P-491 

Sueldo, C. M. V-20, P-491 

Sueyoshi, T. P-224, P-271 

Sugihara, K. O-183, O-304, O-307 

Suh, C. S. P-25, P-384 

Sukhdeo, S. O-72 

Sükür, Y. E. P-262, P-598 

Sullivan, S. P-305 

Sullivan, S. D. P-293 

Sultan, A. P-71 

Sultan, R. P-121 

Sun, L. P-514 

Sun, Y. P-536 

Sundaram, R. P-472 

Sung, L. P-209 

Supramanyam, D. O-24 

Surrey, E. S. O-64, P-22 

Surrey, M. O-276, P-533, P-539 

Surti, U. O-140 

Suzuki, H. O-117 

Swain, J. E. O-107 

Swanson, J. R. O-194 

Swanson, K. M. O-17 

Sweeney, A. M. O-250, P-472 

Sweet, L. M. P-297 

Swelstad, B. B. O-205 

Sylla, R. P-559 

Szeptycki, J. P-509 

Szmyga, M. O-294 

Tabak, M. S. O-120 

Tachibana, M. V-3 

Tagge, I. P-213 

Tai, T. O-207 

Takacs, P. O-43, O-114, P-302, P-321, P-437 

Takahashi, M. P-77 

Takahashi, T. P-146 

Takehara, Y. P-28, P-201, P-570, P-584 

Takeuchi, T. O-117, P-142 

Tal, R. P-308 

Talebian, S. P-582 

Tan, O. O-171 


216 

Tan, S. L. O-72, O-281, P-170, P-245, P-546 

Tanaka, A. O-67, O-177, O-186, P-97, P-130, 

P-244, P-530, P-541, P-542, P-554 

Tanaka, I. O-67, O-177, O-186, P-97, P-130, 

P-244, P-530, P-541, P-542, P-554 

Tanaka, M. O-117 

Tanaka, S. P-269 

Tanaka, Y. P-145 

Tancer, M. E. O-199 

Tang, Y. O-191, P-207, P-323 

Taniguchi, F. P-371 

Tantravahi, U. P-95 

Tanwar, P. S. P-145 

Tao, T. P-81 

Tao, X. O-05, O-300, P-112, P-113 

Tarlatzis, B. P-551 

Taskin, S. P-242 

Tatpati, L. L. P-452 

Taylor, D. O-05, O-12, O-28, O-110, O-115, 

O-223, O-228, P-5, P-100, P-113, 

P-151, P-303 

Taylor, D. D. O-164, P-395 

Taylor, D. M. P-309 

Taylor, H. P-282, P-379 

Taylor, H. S. O-149, P-421 

Taylor, L. O-45 

Taylor, R. N. P-149 

Taylor, S. N. P-600 

Taylor, T. H. O-275, O-276, P-54, P-227, P-594 

Taylor, T. N. O-15, P-1 

Tazon-Vega, B. P-105 

te Velde, E. R. P-494 

Teixeira, J. P-145 

Teixeira, J. M. P-162 

Tejera, A. O-231, V-6, P-197 

Tekcan, M. P-502 

Tekedereli, I. P-370 

Terakawa, N. P-371 

Teramoto, S. P-47, P-224, P-271 

Teranishi, A. P-435 

Terrado, G. P-56, P-175 

Thakur, M. P-443 

Thiyagarajan, A. P-181, P-501 

Thomas, C. O-38, P-34 

Thomas, M. A. P-143, P-466 

Thomas, M. R. P-562 

Thomas, R. L. O-204 

Thompson, C. P-141 

Thornton, K. L. O-01 

Thornton, M. H. P-286, P-583 

Thorp, J. P-450 

Thyer, A. C. O-289 

Tian, L. V-8 

Tian, X. C. P-147 

Ting, A. Y. O-37 

Tisdale, R. L. P-454 

Tkachenko, N. O-06 

Toledo, A. A. O-61, P-49, P-232 

Toll, C. B. O-224

Tomari, H. P-259 

Tombesi, S. P-266 

Toner, J. P. P-572 

Tormasi, S. O-31, O-271, O-274 

Torralba, C. A. O-237, P-345, P-351 

Toth, M. J. P-310 

Toth, T. L. O-168, O-314, P-468 

Tougias, E. M. P-267 

Tournaye, H. P-265 

Toyama, A. P-453 

Tran, N. D. O-24 

Traub, M. P-573 

Traub, M. L. P-455 

Treff, N. P-100 

Treff, N. R. O-05, O-28, O-78, O-115, O-269, 

O-300, P-112, P-113, P-151, P-189, 

P-303, P-309 

Triantafillidis, S. P-551 

Troendle, J. P-293 

Tsafrir, A. O-290 

Tsibulsky, I. P-458 

Tsulaia, T. P-509 

Tucker, K. E. O-235 

Tucker, M. J. O-282, P-410, P-568 

Turek, P. J. P-128 

Tur-Kaspa, I. O-06, O-145, O-146 

Turkcapar, A. F. P-547 

Turley, F. O-309 

Turner, K. P-454 

Turner, T. O-80 

Tuschl, T. O-29 

Uchida, H. P-322 

Uchimura, K. P-259 

Ugur, M. P-547 

Uhler, M. P-278 

Urban, R. J. P-317 

Uriondo, H. P-483 

Urman, B. O-90, P-75, P-579 

Usadi, R. P-179 

Usadi, R. S. O-41, P-406 

Usman, A. O-141 

Utsunomiya, T. P-47, P-263 

Uy, A. P-33 

Uzdogan, A. P-17 

Uzelac, P. S. P-557 

Vadlapatla, N. M. P-369 

Vagnini, L. D. P-132, P-144, P-500 

Vaid, P. P-573 

Vajta, G. O-106 

Valbuena, D. O-75 

Valcarcel, A. O-265, P-478 

Valenton, K. P-365 

Vallejos, J. O-262, P-407, P-408, P-409, P-412, 

P-415 

Valli, H. O-39 

Valluzzo, L. P-505 

Van den Abbeel, E. P-82, P-277 

Van den Broeck, U. E. O-222 

van der Veen, F. O-02 


217 

Van Landuyt, L. P-82, P-277 

van Pelt, A. M. M. O-02 

Van Thillo, G. O-265 

Van Voorhis, B. J. P-549, P-578 

VanDenEden, S. K. P-126 

Vanderhoof, V. P-293 

Vanderhoof, V. H. P-305 

Van-Gheem, A. P-469 

Vaquero, E. O-268 

Varlan, E. P-574 

Vaughn, T. C. O-69, O-80 

Vázquez, J. P-217 

Ved, S. P-249 

Veeraswamy, A. V-14, V-23 

Veis, A. P-444 

Vela, G. O-20, O-70, O-81, P-234, P-236 

Velazquez, M. P-140 

Veldhuis, J. D. P-327 

Venkatesan, A. P-446 

Venkatesan, A. M. P-441 

Venturini, P. L. O-92, O-131, O-132, P-368 

Verheyen, G. P-82, P-277 

VerMilyea, M. D. P-410 

Verpoest, W. P-82, P-265 

Verza, Jr, S. P-133, P-487 

Vidal, F. O-50, P-486 

Vieira, C. S. O-217 

Vieira, M. R. P-2 

Vigo, F. M. O-182 

Villanueva, J. O-137 

Villarroel, C. P-349 

Vilo, J. O-293 

Vilos, G. A. O-306 

Vincent, J. P-510 

Vincent, T. O-21 

Vingris, L. P-186 

Viot, G. P-515 

Viot, G. B. O-73 

Vireque, A. A. P-63, P-172, P-352 

Virji, N. P-209 

Viscasillas, P. P-390 

Vitek, W. P-95 

Vithoulkas, A. P-188 

Vitonis, A. F. O-311 

Vladimir, B. P-298 

Vo, K. C. P-426 

Von Wald, T. P-42 

Von Wald, T. A. P-452 

Wagman, I. P-241 

Wagner, C. P-285 

Wagner, L. E. P-66 

Wagner, Y. P-200 

Wakim, A. N. G. O-140 

Waldbaum, A. O-44, P-399 

Walker, D. L. O-197 

Walmer, D. K. P-20 

Walsh, T. J. P-126, P-506 

Wambach, C. M. P-365 

Wang, H. O-220

Wang, L.-L. P-535 

Wang, Q. P-336 

Wang, S. O-85 

Wang, W. P-70, P-84, P-323 

Wang, X. P-477 

Wantman, E. O-278 

Ward, D. O-232, P-270 

Warikoo, P. P-247 

Warren, K. M. O-313 

Wasiak, R. P-420 

Watanabe, A. O-96, P-313 

Watanabe, S. O-67, O-177, P-530, P-542 

Watt, J. P-78 

Weathers, J. P-60 

Webster, B. O-68 

Weedin, J. W. O-166, O-208, P-120, P-137 

Weghofer, A. O-287, P-94, P-157, P-255, P-325, 

P-589 

Wei, L. P-364 

Wei, Q. P-367 

Weimer, J. P-153 

Weinerman, R. S. V-7, P-575 

Welch, A. P-199 

Welch, L. P-469 

Welkenhuysen, M. O-19 

Wellons, M. O-152 

Wells, D. O-31, P-285 

Wells, G. P-274 

Wensing, C. J. G. P-494 

Werlin, L. P-294 

Werlin, L. B. P-107 

Werner, M. D. O-142, P-29 

Wessel, G. M. O-101 

West, A. V-4 

West, J. R. P-527 

Westphal, L. M. O-179, P-115, P-454, P-559 

White, J. P-374 

Whitman-Elia, G. F. P-503 

Whitney, J. B. P-107 

Widra, E. P-104 

Widra, E. A. O-82, O-282, P-8, P-110, P-334, 

P-400, P-401, P-496, P-508, P-568 

Wiemer, K. P-111 

Wieser, F. O-138 

Wilkins, H. L. P-329 

Williams, D. B. P-466 

Williams, N. O-244 

Williams, P. L. O-246, O-247, O-248 

Williams, Z. O-29, O-175, O-286, P-237, P-246 

Williams III, J. P-538 

Williams IV, D. H. P-66 

Wilson, C. P-233 

Wilson, E. P-433 

Wilson, M. O-128 

Wininger, J. D. O-275, P-54, P-227, P-594 

Winston, N. P-576 

Witjes, H. P-211 

Witt, M. A. P-503 

Wittemer, C. P-331 


218 

Wittmyer, J. O-101 

Wolf, D. P. O-38 

Wolff, E. F. P-400, P-401 

Won, H. P-252 

Won, H. J. P-312 

Wong, W. H. O-179 

Woodard, T. O-97 

Woodard, T. L. O-199 

Woodruff, T. K. P-161 

Woods, E. J. P-507 

Word, R. A. P-418 

Wortham, Jr, J. W. E. P-199 

Wright, D. O-248 

Wright, D. L. P-468 

Wright, G. O-61, P-62 

Wright, K. N. P-462 

Wright, Jr, R. W. P-402, P-403 

Wu, A. P-363 

Wu, C.-C. P-447 

Wu, D. H. P-143, P-466 

Wu, F.-R. P-535 

Wu, G.-J. P-445 

Wu, J. O-259, P-149, P-444 

Wu, L. L. P-156 

Wu, W.-J. P-445 

Wu, X. O-11, O-239, P-357, P-360 

Wu, Y.-Q. P-535 

Wun, C.-C. C. O-181 

Wun, W.-S. P-261 

Wun, W.-S. A. O-181, P-526, P-565 

Xiomara, S. M. O-154 

Xu, G. P-212 

Xu, J. P-509 

Xu, K. P-105 

Xu, M. P-161 

Xu, X. O-107, P-393 

Xue, S. P-90 

Yalcinkaya, T. M. P-210 

Yamakami, L. Y. P-534 

Yamamoto, M. P-358 

Yamamoto, N. P-435 

Yan, C. C. P-128 

Yang, H.-M. P-328 

Yang, X. V-2, P-156 

Yang, Y. H. P-125 

Yano, K. P-47 

Yantorno, O. P-520 

Yanushpolsky, E. H. V-21 

Yao, M. W. M. O-179 

Yao, S. O-11 

Yauger, B. J. P-519 

Yavetz, H. P-499 

Yavorska, T. O-195 

Yelian, F. P-224 

Yeoman, R. O-38, P-34 

Yeoman, R. R. O-37 

Yin, M. P-26 

Yogev, L. P-499 

Yokota, H. P-228

Yokota, M. P-228 

Yokota, Y. P-228 

Yoon, H.-J. P-55 

Yoon, J.-W. P-346, P-518 

Yoon, S. P-59, P-91 

Yoon, T. P-252 

Yoon, T. K. P-91, P-93, P-167, P-312, P-512 

Yoon, T.-K. P-341 

Yoshida, A. O-117, P-142 

Yoshimura, Y. P-322 

Young, D. O-139 

Young, E. O-265, P-531 

Young, R. O-104 

Young, R. L. O-154 

Young, S. L. P-417, P-427 

Youssef, M. A. F. M. P-164 

Yu, B. P-8, P-110, P-305 

Yu, J. P-149 

Yuan, X. O-205 

Yumoto, K. O-299 

Yung, Y. O-298, P-316 

Yuri, M. G. O-265 

Yuri, S.-S. P-215 

Zabala, A. E. P-72 

Zaino, R. J. P-417 

Zamah, A. M. P-155, P-480 

Zanatta, A. O-263 

Zaninovic, N. O-27 

Zapantis, A. P-338, P-569 

Zapantis, G. O-294 

Zappacosta, M. P. P-531 

Zaren, H. P-33 

Zattas, D. O-119 

Zbella, E. O-68 

Zeleznik, A. O-196 

Zelinski, M. O-38, P-34 

Zelinski, M. B. O-37, P-7 

Zeyneloglu, H. P-314, P-436 

Zhan, Q. O-27 

Zhang, C. P-105 

Zhang, D. P-212 

Zhang, H. P-342, P-356 

Zhang, J. O-124, P-44, P-230 

Zhang, K. P-514 

Zhang, R. P-212 

Zhang, X. Y. P-170 

Zhao, Q. P-78 

Zhao, Y. O-273, P-4, P-477 

Zheng, H.-Y. P-535 

Zheng, W. O-204 

Zhou, Y. P-38, P-90 

Zhu, J. J. P-92 

Zhu, Y. P-212 

Zimberg, S. O-129 

Zimmerer, N. P-60 

Zipfel, L. P-328 

Zitek, E. M. P-454 

Zozula, S. P-79, P-83 

Zuk, J. P-73 


219 

Zupi, E. O-268 

Zurakowski, D. O-155 

Zweifel, J. E. P-66 

Zylbersztejn, D. S. O-182

PROGRAM PARTICIPANTS - NON-ORAL/POSTER PRESENTERS 

Participants are indexed by page number. 

Abdala, L. T., p96 

Abeyta, M. J., p89 

Aboulghar, Mohamed, p41, p163 

Adamson, G. David, p4, p24, p26, p31, 

p68, p71 

Agarwal, Ashok, p5, p31 

Albertini, David F., p24, p67 

Al-Hendy, Ayman, p5, p116, p164 

Ali, Larissa, p5 

Allen, Brian, p40 

Allen, Rebecca H., p5, p98 

Amado, Maria Elena, p47 

Amoroso, Kimberly A., p164 

Anchan, Raymond M., p25, p69 

Anderson, Anthony, p5 

Andou, M., p96 

Applegarth, Linda D., p5 

Archer, David F., p5 

Armstrong, Joanne C., p24, p66 

Arnaud, W., p96 

Arredondo, Francisco, p47 

Ashby, Rachel K., p165 

As-Sanei, Sawsan, p165 

Atalah, H. N., p91, p92 

Attaran, Marjan, p5 

Aubuchon, Mira, p5, p108, p115 

Austin, Cynthia, p5 

Badawy, Shawky Z., p24, p66 

Bail, E., p96 

Baker, Valerie L., p5, p22, p31, p36, p57, 

p101, p164 

Baldus, Sara, p 

Ball, G. David, p5, p31 

Barad, David H., p165 

Barber, M. D., p96 

Barnhart, Kurt T., p5, p113 

Barone, Samuel, p23, p59 

Baronio, M., p94 

Barqawi, Al, p165 

Barrett, C. Brent , p164 

Bates, G. Wright, p5, p100, p165 

Battaglia, David E., p5 

Behr, Barry D., p5 

Behmyer, Kristin R., p5 

Belker, Arnold M., p26, p72 

Bello, Sandra M., p5 

Benadiva, Claudio A., p24, p81 

Bendikson, Kristin A., p5 

Benedict, S., p89 

Benoff, Susan H., p5, p22, p31, p76, p109 

Berga, Sarah L., p22, p50, p74 

Bernhisel, Marc, p5 

Bevilacqua, Kris, p114 

Bhagavath, Bala, p106 

Black, Lauri D., p5, p107 

Blacker, Charla M., p5, p111 

Bocca, Silvina M., p5, p119, p165 

Boivin, Jacky, p34 

Bradley, Linda, p55 

Brackett, Nancy L., p4, p5, p31, p49, p109 

Brannian, John D., p5 

Brannigan, Robert E., p24, p80 

Braverman, Andrea M., p23, p31, p42, p64 

Brisman, Melissa B., p24, p83 

Bruner-Tran, Kaylon L., p5, p115, p164 

Bukulmez, Orhan, p5, p118, p164 

Bulun, Serdar E., p5, p22, p48, p73 

Buster, John E., p22, p44, p77 

Bustillo, Maria, p163 

Butts, Samantha F., p5 

Capunay, C., p94 

Carr, Bruce R., p5, p112 

Carrascosa, P, p94 

Carrell, Douglas T., p113, p164 

Casey, Colleen L., p5 

Casson, Peter R., p5, p28 

Cataldo, Nicholas A., p46 

Catenacci, M., p93 

Catherino, William H., p5, p112 

Cedars, Marcelle I., p5, p22, p24, p28, 

p36, p57, p78, p109 

Centola, Grace M., p5, p104 

Chan, Peter T.K., p42 

Chang, R. Jeffrey, p24, p67 

Chang, Tien-Cheng “Arthur”, p5, p89, 

p90, p163 

Chang, Wendy Y., p163 

Chapman, Carli W., p164 

Chauduri, Guatam, p5 

Chavarro, Jorge E., p38 

Cheng, Y., p91 

Chian, Ri-Cheng, p24, p67 

Childress-Beatty, Lindsay, p42 

Choi, T., p89 

Cholkeri-Singh, A., p96 

Christensen, Greg L., p5 

Christman, Gregory M., p5, p23, p60, 

p163 

Chung, Karine, p5, p22, p73 

Chung, Pak H., p5, p165 

Coddington, Charles C., p5, p31, p110, 

p117, p163 

Cohen, Glenn, p59 

Cohen, M. S., p91, p92 

Comizzoli, Pierre, p38 

Confino, Edmond, p37 

Connor, Caroline, p164 

Cooke, Ian D., p24, p68 

Cooper, Amber R., p5, p25, p69 

Copperman, Kira, p23, p65 

Corp, Catherine L., p164 

Cousineau, Tara, p34 

Covington, Sharon N., p5, p165 

Cowan, Barrett, p101 

Cowan, Glenn, p23 

Craig, Latasha B., p5 

221 

Crockin, Susan, p42, p163 

Crosignani, Pier-Giorgio, p23, p61 

Cruz, M., p90 

Curole, David, p31 

Curtis, Kathryn M., p22, p27, p58 

D’Hooghe, Thomas M., p164 

Daar, Judith F., p23, p59, p64 

Daneshmand, Said T., p165 

Davis, Ann J., p4 

Davis, Gina M., p5, p22, p74, p107, p165 

Davis, Owen K., p5 

de Mouzon, Jacques, p24, p68 

DeCherney, Alan H., p26, p30, p88 

Demma, Amelia, p165 

DePaolo, Louis V., p23, p60 

Desai, Nina N., p5 

Desai, Nidhi, p24, p82 

Detti, Laura, p5, p108, p117 

Deura, I., p96 

Deutch, Todd D., p5, p117, p164 

DeVane, Gary, p5 

Diamond, Michael P., p4, p5, p24, p51, 

p119, p165 

Diaz, D. G., p89 

Dickey, Richard P., p31 

Dmowski, W. P., p31 

Doody, Kevin J., p20 

Dokras-Jagasia, Anuja, p24, p35, p67, 

p163 

Domar, Alice D., p26, p34, p87, p163 

Donnez, Jacques G., p22, p73, p99 

Doyle, J., p90 

Dozortsev, Dimitri, p5, p114 

Drury, Ken, p5 

DuBeshter, D., p94 

Dubey, Anil K., p5, p100, p164 

Duleba, Antoni J., p5, p35 

Dumesic, Daniel A., p5, p22, p31, p75 

Dumesic, David A., p5 

Dunaif, Andrea, p23, p24, p50, p78 

Duncan, Dawn, p39 

Edelman, Alison B., p5 

Edwards, Sharon G., p5 

Einarsson, J. I., p96 

Esfandiari, Navid, p5 

Espinosa, H., p96 

Esposito, Melissa Ann, p20 

Evers, Johannes L., p23, p61 

Fahy, Gregory M., p38 

Falcone, Tomasso, p5, p26, p71, p92, p93, 

p95, p96, p165 

Faulkner, Debra, p183 

Fazleabas, Asgerally T., p26, p53 

Fedele, L., p96 

Feingold , Madeline L., p163 

Feng, Huai Liang, p5 

Fenton, Penelope, p5 

Fernandez, Emilio, p5



Fino, M. E., p91 

Fisher, Jill M., p26, p70 

Fogle, Robin N., p5 

Francis, Leslie P., p23, p59 

Frankel, Nancy R., p4 

Freeman-Carroll, Nancy M., p, p164 

Frick, A. C., p92 

Frishman, Gary N., p5, p22, p24, p27, 

p57, p80 

Fritz, Marc A., p31 

Frontino, G., p96 

Fujimoto, Victor, p115 

Galst, Joann P., p164 

Gargiulo, Antonio R., p5, p92, p93, p95 

Garrisi, Margaret G., p23, p64 

Genis, M., p94 

Geraedts, Joep P., p164 

Gerrity, Marybeth, p44, p165 

Ghazeeri, Ghina S., p5, p100 

Gianaroli, Luca, p45, p117, p163 

Gibbons, Rebecca, p183 

Gibbons, William E., p4, p5, p29, p48, p53 

Giles, D., p96 

Ginsberg, Jill P., p22, p44 

Ginsburg, Elizabeth S., p5, p23, p34, p63, 

p73 

Giudice, Linda C., p23, p24, p53, p60, p66 

Glass, Karen B., p163 

Glover, Douglas D., p31 

Go, Kathryn J., p5, p103 

Gocial, Benjamin, p5 

Goldberg, Jeff, p31, p119 

Goldfarb, James M., p4, p5, p106 

Goldstein, Marc, p5, p91, p164 

Goldstein, Steven, p37, p43 

Gonzalez, Frank, p5, p35, p115 

Gordon, Elaine R., p22, p55, p164 

Gosta-Nygien, Karl, p24, p68 

Goverde, Angelique J., p41 

Gracia, Clarisa R., p24, p44, p81 

Grainger, David, Grainger, David, p31 

p31 

Granai, Cornelius O., p44 

Greenfield, Dorothy A., p5, p114 

Greenhouse, Stephen J., p5 

Grill, Elizabeth, p42 

Grow, Daniel R., p5, p164 

Gruber, Rita, p25, p69 

Gunawardena, Shalini S., p46 

Gunsalus, K. C., p91 

Gutmann, Jacqueline N., p22, p56 

Hada, T., p96 

Halvorson, Lisa M., p5 

Hammond, Karen R., p31, p39, p46 

Harken, Tabetha, p27, p163 

Harrington, Nancy A., p5 

Harris, Lisa H., p26, p87 

Hartman, Alexander, p5, p43 

Hauser, Russ B., p22, p38, p76 

Heard, Michael J., p5, p108 

Heidemann, N. L., p96 

Helm, W., p96 

Herrero, J., p90 

Hershberger, Patricia, p26, p70 

Hesla, John S., p5, p101 

Hickman, Timothy, p5, p31 

Hill, George A., p5, p31, p40 

Hoeger, Kathleen M., p24, p67, p164 

Hohl, M. K., p96 

Hojnowski-Diaz, P., p90 

Honig, Stanton C., p24, p80 

Hopps, Carin V., p5 

Hornstein, Mark D., p5 

Horowitz, Judith E., p163 

Howards, Stuart S., p4, p31 

Huddleston, Heather, p5, p110 

Hudgens, J. L., p5, p96 

Hughes, Mark R., p24, p79 

Hurd, William, p31 

Hurst, Bradley, p31 

Hutchison, C. Lee, p5 

Isaacson, Keith B., p22, p26, p40, p55, 

p71 

Isachenko, Vladimir, p46 

Ishida, Elaine, p31 

Ishihara, Osamu, p24, p68 

Ivani, Kristen, p99, p.114 

Jackson, Maria, p5, p39, p98 

Janik, Grace M., p5, p26, p40, p55, p71, 

p96 

Jarvi, Keith, p113 

Jensen, Jeffrey T., p5, p27, p98, p99 

Jesudason, Sujatha, p26, p87 

Jindal, Sangita K., p5, p22, p46, p75 

Joffe, Hadine, p23, p28, p62 

Johhnson, Chad A., p, p163 

Johnson, Julia V., p5, p163 

Johnstone, Erica B., p25, p69 

Joseph, N., p96 

Jungheim, Emily, p5, p103 

Justice, T., p96 

Kakinuma, T., p95 

Kalfoglou, Andrea, p5 

Kanao, H., p96 

Kaneshiro, Bliss, p27, p163 

Kang, Hey Joo, p5 

Karabinus, David S., p5 

Karl, S., p89 

Kasim-Karakas, Sidaka E., p35 

Kato, K., p95 

Kato, O., p95 

Katz, Eugene, p5 

Katz-Jaffe, Mandy, p5 

Ke, Raymond W., p5 

Kearns, Ann E., p23, p62 

Kearns, William G., p28, p165 

222 

Kelk, Dawn A., p5 

Khera, Mohit, p164 

Kim, Edward D., p5, p36 

Kingsberg, Sheryl A., p6, p44 

Kipersztok, Simon, p6 

Klein, Nancy A., p6 

Knochenhauer, Eric, p20 

Knudson, Gail, p6, p111, p165 

Koch, R. A., p89 

Koh, Charles, p40, p96 

Kold Jensen, Tina, p38 

Kolettis, Peter N., p6, p165 

Kotikela, S., p93, p95 

Kottick, Judith, p22, p55 

Kovanci, Ertug, p165 

Kramer, Adrienne J., p25, p70 

Kramer, Y., p91 

Kutteh, William H., p26, p86 

La, A. T. H., p89 

La Barbera, Andrew R., p4, p5 

Lamb, Dolores J., p4, p6, p23, p26, p60, 

p71 

Lamb, Julie D., p22, p56 

Lanzendorf, Susan E., p6, p164 

Larman, Mark G., p6, p111 

Larsen, Nina, p24, p66 

Lathi, Ruth B., p163 

Lebovic, Dan I., p6, p107 

Lee, David W., p99, p163 

Lee, Michael A., p46 

Lee, Shelley S., p22, p55 

Leese, Henry, p45 

Legro, Richard S., p5, p6, p50 

Lehl, Kelly L., p25, p70 

Leridon, Henri, p23, p61 

Lesser, Carol B., p23, p63 

Levens, Eric, p97 

Levy, Michael J., p6 

Lewis, M. L., p93, p95 

Li, Philip S., p5, p42, p91 

Licciardi, Frederick L., p6 

Lin, Paul C., p6, p102, p164 

Lipshultz, Larry I., p36 

Liu, C. Y., p96 

Lo, Kirk Cheng, p5, p26, p71 

Lobo, Rogerio A., p4, p50 

Longley, Teresa Barry, p6 

Luciano, Anthony A., p4, p24, p51, p80 

Lutz, Wolfgang, p23, p61 

Lydic, Michael L., p6, p165 

Lynne, Charles M., p163 

Ma, Caihong, p26, p84 

Macaluso, Maurizo, p24 

Magaosjo, M., p95 

Magli, M. Cristina, p45 

Mahadevan, Mahendran M., p163 

Mahalingaiah, S., p93 

Malizia, Beth A., p6



Manheimer, Joan, p164 

Mansour, Ragaa T., p24, p68, p164 

Marconi, Guillermo, p31 

Marks, Sheldon, p101 

Marquard, Kerri L., p6 

Marshall, Lorna A., p23, p59 

Masson, P., p91 

Matteson, Kristen A., p22, p27, p57 

Mayer, Jacob F., p23, p24, p31, p59, p82 

McCaffrey, C., p91 

McClamrock, Howard, p31 

McClure, R. Dale, p4 

McCoy, Megan, p6 

McGee, Elizabeth A., p6, p113 

McKeeby, Jeffrey L., p6 

McKenzie, Laurie J., p6 

McLaren, Janet, p6 

Meeker, John D., p6, p38 

Megid, Wael Abdel, p6, p111 

Meintjes, Marius, p5, p89, p90 

Meirow, Dror, p22, p73, p93 

Mendell, Patricia A., p23, p64 

Meng, Li, p6 

Meseguer, M., p90 

Metzinger, D., p96 

Milad, Magdy P., p6, p93, p163 

Miller, Charles E., p5, p94, p96 

Miller, Kathleen A., p165 

Miller, Virginia M., p23, p28, p50, p63 

Mills, Benjie B., p44 

Miki, M., p96 

Mio, Y., p90 

Missmer, Stacey A., p22, p76 

Mitalipov, S., p89 

Moise, Kenneth J., p26, p72 

Moore, Edward E., p31 

Morales, Arlene J., p6, p24, p83 

Morbeck, Dean E., p6, p119 

Muasher, Suheil J., p6, p41, p100 

Munne, Santiago, p6 

Nagler, Harris M., p163 

Nagy, Z. Peter, p165 

Nakajima, Steven T., p20, p165 

Nangia, Ajay K., p36 

Nardo, Luciano, p24, p66 

Neal-Perry, Genevieve, p165 

Nelson, Lawrence M., p36, p164 

Nelson, Linda R., p5 

Newton, Christopher, p34 

Nezhat, Camran, p93, p95, p106 

Nezhat, Ceana, p5, p6, p24, p40, p80, p93, 

p95, p96 

Niederberger, Craig, p6, p31 

Noel, Thomas J., p183 

Noyes, Nicole L., p6, p24, p81, p91 

Oates, Robert D., p5, p36 

Odem, Randall R., p6, p110 

Ohl, Dana A., p5, p6, p23, p60, p91 

O’Horo, S. K., p92 

Ohta, Y., p96 

Oktay, Kutluk, p31 

Olive, David L., p5, p96 

Olivier, G., p96 

O’Malley, Bert W., p22, p48 

Osada, H., p95 

Osteen, Kevin C., p6, p165 

Osuga, Yutaka, p6 

Pal, Lubna, p6, p23, p28, p62, p165 

Palter, Steven J., p5 

Papier, S., p94 

Paraiso, M. F. R., p92 

Parekattil, Sijo J., p91, p92, p165 

Park, A. J., p96 

Parrott, Estella, p116 

Pasch, Lori A., p22, p26, p70, p75 

Pasic, R., p96 

Pauli, Samuel A., p22, p74 

Paulson, Richard J., p4, p23, p64 

Pavone, M. E., p93 

Pedersen, K. S., p90 

Peng, Y., p91 

Penzias, Alan S., p6, p25, p69 

Perkins, Jane N., p165 

Petok, William D., p165 

Petrozza, J., p90 

Pinborg, Anja, p26, p72 

Plancha, Carlos E., p45 

Polak de Fried, Ester, p31 

Pollack, Staci, p108 

Pomeroy, Kimball O., p6, p103 

Portman, Marc P., p5 

Price, Thomas M., p5 

Priola, K. B., p91 

Priola, K. J., p92 

Pritts, Elizabeth A., p163 

Puscheck, Elizabeth E., p6, p22, p37, p43, 

p77 

Quass, Alexander M., p6 

Queenan, John T., p31, p40, p165 

Racowsky, Catherine, p4, p6, p26, p72 

Rall, William F., p38 

Ramsing, N. B., p90 

Ravnikar, Veronica A., p6, p28, p163 

Rebar, Robert W., p4, p5 

Reddy, J., p92 

Reddy, S. Y., p94 

Rhoton, Alice, p6 

Richard-Davis, Gloria, p26, p85 

Riley, David A., p20 

Rinaudo, Paolo F., p6 

Rinehart, John S., p22, p56 

Rinehart, Lisa A., p20, p22, p25, p47, p56, 

p69 

Rizk, Botros B., p24, p66 

Rodriguez-Karl, M. C., p89 

Rosen, Mitchell P., p6, p165 

223 

Ross, Lawrence S., p24, p66 

Rossi, B. V., p92, p93 

Ruiz, J. A., p96 

Sabanegh, Jr., Edmund S., p165 

Sadeghi-Nejad, Hossein, p164 

Saitis, D., p96 

Salih, Sana M., p25, p69 

Sandlow, Jay I., p6, p42 

Sanfilippo, Joseph S., p164 

San Roman, Gabe, p20 

Santoro, Nanette F., p4, p22, p24, p28, 

p52, p77, p109 

Satava, Richard M., p22, p49 

Schattman, Glenn L., p6, p22, p34, p74, 

p102 

Schiewe, Mitchel C., p38, p46 

Schlaff, William D., p4, p24, p31, p80 

Schlegel, Peter N., p24, p42, p68 

Schneider, Susan M., p165 

Schoyer, Katherine D., p6 

Schust, Danny J., p6, p26, p86, p163 

Scoccia, Bert, p6 

Scott, Jr., Richard T., p23, p26, p31, p64, 

p86 

Seftel, Allen, p44 

Segars, James H., p6, p26, p72 

Seifer, David B., p6, p118 

Seli, Emre, p22, p75, p105 

Serletti, J., p94 

Sharpe-Timms, Kathy, p6 

Shen, Shehua, p31, p89 

Shepperson-Mills, Dian, p6, p26, p86, 

p120 

Sigman, Mark, p5, p6, p42 

Silber, S. J., p93, p95 

Silva, Celso P., p164 

Silverberg, Kaylen M., p6 

Simmons, E. J., p94 

Simpson, Joe Leigh, p6 

Simon, Carlos A., p26, p71 

Sipe, Christopher S., p26, p87 

Smith, Deborah L., p24, p83 

Smith, Roy G., p25, p26, p53, p84 

Smitz, Johan E., p164 

Sokol, Rebecca Z., p4 

Spandorfer, Steven D., p6 

Sparks, Amy E. T., p6 

Sparman, M., p89 

Speroff, Leon, p22, p27, p49 

Srouji, S. S., p92, p93, p95 

Stadtmauer, Laurel A., p6, p26, p85 

Stahler, Michael S., p5, p6, p24, p82 

Stanford, E. J., p96 

Stein, R. J., p92 

Steinkampf, Michael P., p6 

Stephenson, Mary D., p163 

Stern, Judy, p6, p31 

Stewart, Elizabeth A., p26, p85



Stratton, Pamela, p6, p26, p84, p107 

Strickland, Robert R., p23, p47, p65 

Su, H. Irene, p6, p25, p69, p163 

Sueldo, Carlos E., p24, p31, p81, p94 

Sueldo, C. M., p94 

Sunde, Arne, p45 

Surrey, Eric S., p6, p24, p31, p34, p81, 

p102, p163 

Suzuki, Y., p96 

Swain, Jason, p6 

Swain, Margaret, p5 

Tachibana, M., p89 

Takaki, Y., p96 

Takeuchi, Takumi, p31 

Tarlatzis, Basil C., p164 

Taylor, Hugh S., p5, p6, p23, p28, p63 

Taylor, Robert N., p5, p48, p53 

Teal, Stephanie B., p27, p163 

Tejera, A., p90 

Teufelberger, G., p96 

Thibodeaux, J. Kevin, p6 

Thomas, Michael A., p6 

Tian, L., p91 

Timor-Tritsch, Ilan, p43 

Toner, James P., p6, p41 

Toth, Thomas L., p24, p67 

Travia, Joseph J., p22, p56 

Treff, Nathan R., p6, p117, p164 

Tremellen, Kelton, p6 

Tulandi, Togas, p5, p92, p93, p95 

Turek, Paul J., p5, p6, p23, p61, p91, p163 

Tur-Kaspa, Ilan, p31, p37, p43 

Tzeng, Chii-Ruey, p31 

Urman, Bulent C., p163 

Van Voorhis, Bradley J., p22, p37, p57 

Vanderpoel, Sheryl, p24, p68 

Veeraswamy, A., p93, p95 

Venier, William C., p6 

Vernon, Michael, p6, p104 

Wald, Moshe, p163 

Wang, Wei-Hua, p165 

Weinerman, R. S., p91 

Weiskopf, Richard, p23, p59 

Wells, Dagan, p22, p75 

Wells, Martha, p23, p59 

West, A., p90 

West, Elizabeth B., p6, p98 

Weston, Aimee, p39 

Westphal, Lynn, p6, p31 

Whalen, Lori, p163 

Widra, Eric A., p6 

Williams, R. Standford, p5, p6, p106 

Wilshire , Gilbert B., p6, p26, p86, p120, 

p163 

Wininger, David, p6 

Wirth, Julie J., p6 

Woodard, Terri L., p6, p164 

Worrilow, Kathryn C., p165 

Wright, Kristen, p108 

Wu, Xiaoke, p164 

Xia, E., p96 

Yang, Linda C., p25, p69 

Yang, X., p89 

Yanushpolsky, Elena H., p95, p165 

Yee, Bill, p6, p31, p110 

Yeung, Miriam W., p26, p87 

Young, Danielle, p25, p70 

Young, Steven L., p108, p164 

Zegers-Hochschild, Fernando, p24, p68 

Zornetzer, Sarah, p6 

Zurawin, R. K., p96 

Zweifel, Julianne E., p5, p26, p70 

224

NOTES 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________

NOTES 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 

_________________________________________________________________________________________

ASRM would like to thank those 

who purchased advertisements in the 

2010 Annual Meeting Final Program 

Brown & Brown of Texas, Inc. 


Femasys 

Genesis Genetics 

Merck & Co., Inc. 

Narishige International USA, Inc. 

Ultrasonix 

Watson Pharmaceuticals 

Vivere Health

Take home a 

Special Edition 

ASRM 2010 

Teddy Bear! 

Soft, cuddly, and each with a 

personality of its own, the ASRM 

teddy bear makes a perfect gift 

for a child, collector, or a great 

addition to your office desk or 

bookcase. Dressed in a 2010 

ASRM Denver logo t-shirt he (or 

she) sits 10” high. • $10 USD 

Available at the ASRM Booth #835 


1209 Montgomery Highway •Birmingham, AL 35216 

TEL (205) 978-5000 • FAX (205) 978-5005 • asrm@asrm.org 

www.asrm.org

Wish you had a better ultrasound solution? 

Custom Configurations 

� Start with a premium B&W 

configuration 

� Upgrade at any time with PW 

and Color Doppler 

IVF 

� Add a 3D endovaginal transducer 

Wish Granted! 

Complete Ultrasound Solutions 

To learn more, visit: ultrasonix.com/asrm 

Visit us at ASRM 

Booth #829 

Improved Work Flow Seamless Connectivity 

� 1-touch automatic follicle 

measurement 

� Cascading follicle measurements 

� IVF Touchscreen interface with 

only the controls you need 

� DICOM Compliant 

� Compatible with leading IVF 

EMR (Electronic Medical 

Records) Systems

Vivere Health partners with specialists in Reproductive Endocrinology to 

develop Ambulatory Surgery Centers and IVF Laboratories. Vivere will 

joint venture with you in ownership of your ASC/IVF Lab, which can 

generate income to fuel the future growth of your fertility practice, as you 

focus on providing the best fertility services for your patients. 

If you are interested in finding out more about Vivere Health 

and the benefits of ASC/IVF lab partnerships, 

please visit us at booth 477. 

Win a 

Free Golf 

Weekend 

for Two * 

*Drawing during reception: 7:00-9:00 pm on Monday, Oct. 25 at Osteria Marco, 1453 Larimer Square

Progesterone 

Fact # 5 

Only one progesterone is FDA approved 

for progesterone replacement. 

CRINONE 8% (progesterone gel) is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment 

for infertile women with progesterone deficiency. 

Important Safety Information 

The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. 

CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, 

missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest 

manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No evidence is available to show that progesterone and progestins are effective 

in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast 

and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, 

diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a 

history of psychic depression, and those with diabetes. 

Please see brief summary of full prescribing information on the following page. 

Toll-free support line: 1-888-PRO-GEL8 (1-888-776-4358) 

© 2010, Watson Laboratories, Inc. 

The only ONE ONE ONE 

It’s a fact. 

When you need to replace 

progesterone in your patients 

undergoing donor egg cycles, 

only CRINONE offers the 

confidence of FDA approval for 

progesterone replacement. 1 

In fact, CRINONE has 

demonstrated comparable 

pregnancy rates to IM P in a 

prospective, randomized trial of 

women in a donor egg cycle. 2 

Before you prescribe, 

check the facts. 

Visit us at ASRM 

Booth #433

Crinone ® 4% 

Crinone ® 8% 

(progesterone gel) 

For vaginal use only. Rx only 

BRIEF SUMMARY 

For full prescribing information, see package insert. 

INDICATIONS AND USAGE 


Crinone 8% is indicated for progesterone supplementation or replacement as part of 

an Assisted Reproductive Technology (“ART”) treatment for infertile women with 

progesterone deficiency. 

Secondary Amenorrhea 

Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% is indicated 

for use in women who have failed to respond to treatment with Crinone 4%. 

CONTRAINDICATIONS 

Crinone should not be used in individuals with any of the following conditions: known 

sensitivity to Crinone (progesterone or any of the other ingredients); undiagnosed vaginal 

bleeding; liver dysfunction or disease; known or suspected malignancy of the breast or 

genital organs; missed abortion; active thrombophlebitis or thromboembolic disorders, 

or a history of hormone-associated thrombophlebitis or thromboembolic disorders. 

WARNINGS 

The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, 

cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). 

Should any of these occur or be suspected, the drug should be discontinued immediately. 

Progesterone and progestins have been used to prevent miscarriage in women with a history 

of recurrent spontaneous pregnancy losses. No adequate evidence is available to show 

that they are effective for this purpose. 

PRECAUTIONS 

General 

1. The pretreatment physical examination should include special reference to breast and 

pelvic organs, as well as Papanicolaou smear. 

2. In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional 

causes should be considered. In cases of undiagnosed vaginal bleeding, 

adequate diagnostic measures should be undertaken. 

3. Because progestogens may cause some degree of fluid retention, conditions which 

might be influenced by this factor (e.g., epilepsy, migraine, asthma, cardiac or renal 

dysfunction) require careful observation. 

4. The pathologist should be advised of progesterone therapy when relevant specimens 

are submitted. 

5. Patients who have a history of psychic depression should be carefully observed and 

the drug discontinued if the depression recurs to a serious degree. 

6. A decrease in glucose tolerance has been observed in a small percentage of patients 

on estrogen-progestin combination drugs. The mechanism of this decrease is not 

known. For this reason, diabetic patients should be carefully observed while receiving 

progestin therapy. 

Information for Patients 

The product should not be used concurrently with other local intravaginal therapy. If other 

local intravaginal therapy is to be used concurrently, there should be at least a 6-hour 

period before or after Crinone administration. Small, white globules may appear as a 

vaginal discharge possibly due to gel accumulation, even several days after usage. 

Drug Interactions 

No drug interactions have been assessed with Crinone. 

Carcinogenesis, Mutagenesis, Impairment of Fertility 

Nonclinical toxicity studies to determine the potential of Crinone to cause carcinogenicity 

or mutagenicity have not been performed. The effect of Crinone on fertility has not been 

evaluated in animals. 

Pregnancy 

Crinone 8% has been used to support embryo implantation and maintain pregnancies 

through its use as part of ART treatment regimens in two clinical studies (studies 

COL1620-007US and COL1620-F01). In the first study (COL1620-007US), 54 Crinonetreated 

women had donor oocyte transfer procedures, and clinical pregnancies occurred 

in 26 women (48%). The outcomes of these 26 pregnancies were as follows: one woman 

had an elective termination of pregnancy at 19 weeks due to congenital malformations 

(omphalocele) associated with a chromosomal abnormality; one woman pregnant with 

triplets had an elective termination of her pregnancy; seven women had spontaneous abortions; 

and 17 women delivered 25 apparently normal newborns. 

In the second study (COL1620-F01), Crinone 8% was used in the luteal phase support of 

women undergoing in vitro fertilization (“IVF”) procedures. In this multi-center, openlabel 

study, 139 women received Crinone 8% once daily beginning within 24 hours of 

embryo transfer and continuing through Day 30 post-transfer. 

Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. 

Thirty-two women (23%) delivered newborns and four women (3%) had spontaneous 

abortions. Of the 47 newborns delivered, one had a teratoma associated with a cleft 

palate; one had respiratory distress syndrome; 44 were apparently normal and one was 

lost to follow-up. 

Geriatric Use 

The safety and effectiveness in geriatric patients (over age 65) have not been established. 

Pediatric Use 

Safety and effectiveness in pediatric patients have not been established. 

Nursing Mothers 

Detectable amounts of progestins have been identified in the milk of mothers receiving 

them. The effect of this on the nursing infant has not been determined. 

ADVERSE REACTIONS 


In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure 

receiving Crinone 8% twice daily, treatment-emergent adverse events occurring in 5% or 

more of the women were: bloating (7%), cramps not otherwise specified (15%), pain (8%), 

dizziness (5%), headache (13%), nausea (7%), breast pain (13%), moniliasis genital (5%), 

vaginal discharge (7%), pruritus genital (5%). 

In a second clinical study of 139 women using Crinone 8% once daily for luteal phase 

support while undergoing an IVF procedure, treatment-emergent adverse events reported 

in 5% or greater of the women were: abdominal pain (12%), perineal pain female (17%), 

headache (17%), constipation (27%), diarrhea (8%), nausea (22%), vomiting (5%), arthralgia 

(8%), depression (11%), libido decreased (10%), nervousness (16%), somnolence 

(27%), breast enlargement (40%), dyspareunia (6%), nocturia (13%). 


In three studies, 127 women with secondary amenorrhea received estrogen replacement 

therapy and Crinone 4% or 8% every other day for six doses. Treatment-emergent 

adverse events during estrogen and Crinone treatment that occurred in 5% or more of 

women treated with Crinone 4% or Crinone 8% respectively were: abdominal pain (5%, 

9%), appetite increased (5%, 8%), bloating (13%, 12%), cramps not otherwise specified 

(19%, 26%), fatigue (21%, 22%), headache (19%, 15%), nausea (8%, 6%), back pain 

(8%, 3%), myalgia (8%, 0%), depression (19%, 15%), emotional lability (23%, 22%), 

sleep disorder (18%, 18%), vaginal discharge (11%, 3%), upper respiratory tract infection 

(5%, 8%), and pruritus genital (2%, 6%). 

Additional adverse events reported in women at a frequency of less than 5% in Crinone 

ART and secondary amenorrhea studies and not listed above include: autonomic nervous 

system–mouth dry, sweating increased; body as a whole–abnormal crying, allergic reaction, 

allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenza-like 

symptoms, water retention, xerophthalmia; cardiovascular, general–syncope; central and 

peripheral nervous system–migraine, tremor; gastro-intestinal–dyspepsia, eructation, 

flatulence, gastritis, toothache; metabolic and nutritional–thirst; musculo-skeletal system– 

cramps legs, leg pain, skeletal pain; neoplasm–benign cyst; platelet, bleeding & clotting– 

purpura; psychiatric–aggressive reactions, forgetfulness, insomnia; red blood cell– 

anemia; reproductive, female–dysmenorrhea, premenstrual tension, vaginal dryness; 

resistance mechanism–infection, pharyngitis, sinusitis, urinary tract infection; respiratory 

system–asthma, dyspnea, hyperventilation, rhinitis; skin and appendages–acne, pruritus, 

rash, seborrhea, skin discoloration, skin disorder, urticaria; urinary system–cystitis, 

dysuria, micturition frequency; vision disorders–conjunctivitis. 

OVERDOSAGE 

There have been no reports of overdosage with Crinone. In the case of overdosage, however, 

discontinue Crinone, treat the patient symptomatically, and institute supportive 

measures. 

As with all prescription drugs, this medicine should be kept out of the reach of children. 

DOSAGE AND ADMINISTRATION 


Crinone 8% is administered vaginally at a dose of 90 mg once daily in women who require 

progesterone supplementation. Crinone 8% is administered vaginally at a dose of 90 mg 

twice daily in women with partial or complete ovarian failure who require progesterone 

replacement. If pregnancy occurs, treatment may be continued until placental autonomy 

is achieved, up to 10-12 weeks. 


Crinone 4% is administered vaginally every other day up to a total of six doses. For 

women who fail to respond, a trial of Crinone 8% every other day up to a total of six 

doses may be instituted. 

It is important to note that a dosage increase from the 4% gel can only be accomplished 

by using the 8% gel. Increasing the volume of gel administered does not increase the 

amount of progesterone absorbed. 

HOW SUPPLIED 

Crinone is available in the following strengths: 

4% gel (45 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator 

with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel. 

NDC 52544-283-24 - 6 Single-use prefilled applicators. 

8% gel (90 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator 

with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel. 

NDC 52544-284-12 - 15 Single-use prefilled applicators. 

Each applicator is wrapped and sealed in a foil overwrap. 

Store at 20-25°C (68-77°F). [See USP controlled room temperature.] 

Rx only 

References: 1. CRINONE ® prescribing information. Morristown, NJ: Watson Pharmaceuticals, Inc. June 2010. 2. Gibbons WE, 

Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 

1998;69:96-101. 

Address medical inquiries to: 

WATSON 

Medical Communications 

P.O. Box 1953 

Morristown, NJ 07962-1953 

800-272-5525 

Distributed by: Watson Pharma, Inc., Morristown, NJ 07962 USA 

Manufactured by: Fleet Laboratories Ltd., Watford, Herts WD18 7JJ UK 

Revised: July 2010

The Leaders in PGD 


20 Years of Experience in Single Gene Testing 

Founded by Dr. Mark Hughes 

Genesis • 24 

24 Chromosomes Tested in 24 Hours 

with DNA Microarrays 

booth 259 

www.genesisgenetics.org 

Helping Couples Build Healthy Families 

Brasil Jordan Taiwan United States United Kingdom

find out 

if your patients’ tubes are patent 

in your office, using saline & air as contrast. 

Changing the way infertile women are evaluated. 

With the FemVue Saline-Air Device, you can now assess your patients’ fallopian tubes in your office. 

The FemVue device is designed to deliver a consistent flow of saline and air as contrast visible 

under ultrasound imaging. Using existing sonography equipment and your choice of a 

standard intrauterine catheter, FemVue is easily adopted into your practice. 

Use FemVue to expand the breadth of services for your patients and the 

capabilities of your practice today. 

Learn more at www.FemVue.com 

Saline-Air Device 

© 2010 Femasys Inc. All rights reserved. 02565 Rev 00 10.Aug.2010

Our Fund Development Program is a 

great opportunity for you to step up and 

become a donor and a champion for ASRM. 

As remarkable as the advances in 

reproductive medicine have been over the 

last 66 years, we believe the Next Chapter 

has the potential to yield even more innovation. 

For more information on 

Write the Next Chapter 

contact: 

Pam Gallagher 

ASRM Director of Development 

(205) 612-4375 • pgallagher@asrm.org 

Or visit the Fund Development Booth 

in the lobby of the Colorado Convention Center 

ASRM Fund Development • Write the Next Chapter 

Buy a raffle ticket for a chance to win an iPad 

One chance for $5 

or 

Six chances for $25 

Visit the Fund Development Booth located in 

the Colorado Convention Center lobby for tickets 

It’s not too late to register for the Run…. 

but space is limited! 

ASRM’s Inaugural 5 K Run and 1 Mile Walk 

Monday, October 25, 2010 

Registration is $50 

Participants receive a long sleeved technical t-shirt 

Visit the Fund Development Booth in the lobby 

of the Colorado Convention Center to register 

ASRM 

Write the Next Chapter 

Networking Event & 

Silent Auction 

Saturday, October 23 rd 

Rock Bottom Brewery 

1001 16 th Street, Denver, CO 

7:00 pm to 9:00 pm 

Beer • Wine • Heavy hors d’oeuvres 

Tickets………$66.00 

Tickets may be purchased prior to the event 

at the ASRM Registration Counter located inside 

the Colorado Convention Center or onsite 

at the back entrace to Rock Bottom Brewery.

GONAL-f (follitropin alfa for injection) 

For subcutaneous injection 

Brief Summary of prescribing information 

Gonal-f ® (follitropin alfa for injection) is a human follicle stimulating hormone (FSH) preparation of recombinant 

DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the a- and b- 

subunits. The a- and b- subunits have 92 and 111 amino acids, respectively, and their primary and tertiary structure 

are indistinguishable from those of human follicle stimulation hormone. Gonal-f ® contains no luteinizing hormone 

(LH) activity. Based on available data derived from physico-chemical tests and bioassays, follitropin alfa and 

follitropin beta, another recombinant follicle stimulation hormone product, are indistinguishable. 

INDICATIONS AND USAGE 

Women: Gonal-f ® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the 

anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. 

Gonal-f ® is also indicated for the development of multiple follicles in the ovulatory patient participating in an 

Assisted Reproductive Technology (ART) program. Men: Gonal-f ® (follitropin alfa for injection) is indicated for the 

induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the 

cause of infertility is not due to primary testicular failure. 

CONTRAINDICATIONS 

Gonal-f ® (follitropin alfa for injection) is contraindicated in women and men who exhibit: 1. Prior hypersensitivity to 

recombinant FSH preparations or one of their excipients. 2. High levels of FSH indicating primary gonadal failure. 

3. Uncontrolled thyroid or adrenal dysfunction. 4. Sex hormone dependent tumors of the reproductive tract and 

accessory organs. 5. An organic intracranial lesion such as a pituitary tumor. And in women who exhibit: 

6. Abnormal uterine bleeding of undetermined origin 7. Ovarian cyst or enlargement of undetermined origin 

8. Pregnancy. 

WARNINGS 

Gonal-f ® (follitropin alfa for injection) should only be used by physicians who are thoroughly familiar with 

infertility problems and their management. Gonal-f ® is a potent gonadotropic substance capable of causing Ovarian 

Hyperstimulation Syndrome (OHSS) with or without pulmonary or vascular complications. Gonadotropin therapy 

requires a certain time commitment by physicians and supportive health professionals and requires the availability 

of appropriate monitoring facilities (see PRECAUTIONS/Laboratory Tests). Safe and effective use of Gonal-f ® in 

women requires monitoring of ovarian response with serum estradiol and vaginal ultrasound on a regular basis. The 

lowest effective dose should be used. 

Overstimulation of the Ovary During FSH Therapy: 

Ovarian Enlargement: Mild to moderate uncomplicated ovarian enlargement which may be accompanied by 

abdominal distension and/or abdominal pain occurs in approximately 20% of those treated with urofollitropin and 

hCG, and generally regresses without treatment within two or three weeks. Careful monitoring of ovarian response 

can further minimize the risk of overstimulation. If the ovaries are abnormally enlarged on the last day of FSH 

therapy, hCG should not be administered in this course of therapy. This will reduce the chances of development of 

Ovarian Hyperstimulation Syndrome. 

Ovarian Hyperstimulation Syndrome (OHSS): OHSS is a medical event distinct from uncomplicated ovarian 

enlargement. Severe OHSS may progress rapidly (within 24 hours to several days) to become a serious medical 

event. It is characterized by an apparent dramatic increase in vascular permeability which can result in a rapid 

accumulation of fluid in the peritoneal cavity, thorax and potentially the pericardium. The early warning signs of 

development of OHSS are severe pelvic pain, nausea, vomiting and weight gain. 

OHSS occurred in 9 of 228 (3.9%) Gonal-f ® treated women during ovulation induction clinical trials and of this 

number 1 of 228 (0.4%) was classified as severe. In ART clinical studies, OHSS occurred in 0 of 116 Gonal-f ® treated 

women. OHSS may be more severe and more protracted if pregnancy occurs. OHSS develops rapidly; therefore, 

patients should be followed for at least two weeks after hCG administration. If there is evidence that OHSS may be 

developing prior to hCG administration (see PRECAUTIONS/Laboratory Tests), the hCG must be withheld. If severe 

OHSS occurs, treatment must be stopped and the patient should be hospitalized. 

Pulmonary and Vascular Complications: 

Serious pulmonary conditions (e.g. atelectasis, acute respiratory distress syndrome and exacerbation of asthma) 

have been reported. In addition, thromboembolic events both in association with and separate from Ovarian 

Hyperstimulation Syndrome have been reported. Intravascular thrombosis and embolism can result in reduced blood 

flow to critical organs or the extremities. Sequelae of such events have included venus thrombophlebitis, pulmonary 

embolism, pulmonary infarction, cerebral vascular occlusion (stroke) and arterial occlusion resulting in loss of limb. 

In rare cases, pulmonary complications and/or thromoembolic events have resulted in death. 

Multiple Births: Reports of multiple births have been associated with Gonal-f ® treatment. In ovulation induction 

clinical trials, 12.3% of live births were multiple births in women receiving Gonal-f ® and 14.5% of live births were 

multiple births in women receiving urofollitropin. In IVF/ET clinical trials 44.0% of live births were multiple births 

in women receiving Gonal-f and 41.0% of live births were multiple births in women receiving urofollitropin and is 

dependent on the number of embryos transferred. The patient should be advised of the potential risk of multiple 

births before starting treatment. 

PRECAUTIONS 

General: Careful attention should be given to the diagnosis of infertility in candidates for Gonal-f ® (follitropin alfa 

for injection) therapy. 

Information for Patients: Prior to therapy with Gonal-f ® , patients should be informed of the duration of treatment 

and monitoring of their condition that will be required. The risks of ovarian hyperstimulation syndrome and multiple 

births in women (see WARNINGS) and other possible adverse reactions (see ADVERSE REACTIONS) should also 

be discussed. 

A ‘Patient’s Information Leaflet’ is provided for patients prescribed Gonal-f ® Multi-Dose. 

Laboratory Tests: In most instances, treatment with Gonal-f ® results only in follicular recruitment and 

development. In the absence of an endogenous LH surge, hCG is given when monitoring of the patient indicates 

that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination 

with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement 

are useful for monitoring the development of follicles, for timing of the ovulatory trigger as well as for detecting 

ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation. It is 

recommended that the number of growing follicles be confirmed using ultrasonography because plasma estrogens 

do not give an indication of the size or number of follicles. The clinical confirmation of ovulation, with the exception 

of pregnancy, is obtained by direct and indirect indices of progesterone production. The indices most generally used 

are a rise in basal body temperature, increase in serum progesterone and menstruation following a shift in basal 

body temperature. 

When used in conjunction with the indices of progesterone production, sonographic visualization of the ovaries 

will assist in determining if ovulation has occurred. Sonographic evidence of ovulation may include fluid in the 

cul-de-sac, ovarian stigmata, collapsed follicle, and secretory endometrium. 

Accurate interpretation of the indices of follicle development and maturation require a physician who is experienced 

in the interpretation of these tests. 

Drug Interactions: No drug/drug interaction studies have been performed. 

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed 

to evaluate the carcinogenic potential of Gonal-f ® . However, follitropin alfa showed no mutagenic activity in a series 

of tests performed to evaluate its potential genetic toxicity including, bacterial and mammalian cell mutation tests, 

a chromosomal aberration test and a micronucleus test. Impaired fertility has been reported in rats, exposed to 

pharmacological doses of follitropin alfa (≥40 IU/kg/day) for extended periods, through reduced fecundity. 

Pregnancy: Pregnancy Category X (see CONTRAINDICATIONS). 

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted 

in human milk and because of the potential for serious adverse reactions in the nursing infant from Gonal-f ® , a 

decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the 

importance of the drug to the mother. 

Pediatric Use: Safety and effectiveness in pediatric patients have not been established. 

ADVERSE REACTIONS 

Women: The safety of Gonal-f was examined in four clinical studies that enrolled 691 patients into two studies for 

ovulation induction (454 patients) and two studies for ART (237 patients). 

Adverse events occurring in more than 10% of patients were headache, ovarian cyst, nausea and upper 

respiratory tract infection in the U.S. ovulation induction study and headache in the U.S. ART study. Adverse events 

(without regard to causality assessment) occurring in at least 2% of patients are listed in Table 1 and Table 2. 

Table 1 US Controlled Trial in Ovulation Induction, Study 5727 

Body System 

Preferred Term 

Reproductive, Female 

Intermenstrual Bleeding 

Breast Pain Female 

Ovarian Hyperstimulation** 

Dysmenorrhea 

Ovarian Disorder 

Cervix Lesion 

Menstrual Disorder 

Gastro-intestinal System 

Abdominal Pain 

Nausea 

Flatulence 

Diarrhea 

Vomitting 

Dyspepsia 

Central and Peripheral Nervous System 

Headache 

Dizziness 

Neoplasm 

Ovarian Cyst 

Body as a Whole- General 

Pain 

Back Pain 

Influenza-like Symptoms 

Fever 

Respiratory System 

Upper Respiratory Tract Infection 

Sinusitis 

Pharyngitis 

Coughing 

Rhinitis 

Skin and Appendages 

Acne 

Psychiatric 

Emotional Lability 

Urinary System 

Urinary Tract Infection 

Resistance Mechanism 

Moniliasis Genital 

Application Site 

Injection Site Pain 

Gonal-f Patients (%) 

Experiencing Events 

Treatment cycles = 288* 

n=118 

9.3% 

4.2% 

6.8% 

2.5% 

1.7% 

2.5% 

2.5% 

9.3% 

13.6% 

6.8% 

7.6% 

2.5% 

1.7% 

22.0% 

2.5% 

15.3% 

5.9% 

5.1% 

4.2% 

4.2% 

11.9% 

5.1% 

2.5% 

1.7% 

0.8% 

4.2% 

5.1% 

1.4% 

Urofollitropin Patients (%) 


Treatment cycles = 277 

n=114 

4.4% 

6.1% 

3.5% 

6.1% 

2.6% 

0.9% 

0.9% 

12.3% 

3.5% 

8.8% 

3.5% 

2.6% 

3.5% 

20.2% 

0.0% 

28.9% 

6.1% 

1.8% 

2.6% 

1.8% 

7.9% 

5.3% 

3.5% 

4.4% 

2.6% 

2.6% 

2.6% 

4.4% 

0.9% 

0.9% 

2.5% 

2.5% 

* up to 3 cycles of therapy ** Severe = 0.8% of 118 patients in Study 5727 

Additional adverse events not listed in Table 1 that occurred in 1 to 2% of Gonal-f ® treated patients in the U.S. 

ovulation induction study included the following: leukorrhea, vaginal hemorrhage, migraine, fatigue, asthma, 

nervousness, somnolence and hypotension. 

Table 2 US Controlled Trial in ART, Study 5533 

Body System 

Preferred Term 

Reproductive, Female 

Intermenstrual Bleeding 

Leukorrhea 

Vaginal Hemorrhage 

Gastro-intestinal System 

Nausea 

Flatulence 

Central and Peripheral Nervous System 

Headache 

Body as a Whole- General 

Abdominal Pain 

Pelvic Pain Female 

Respiratory System 

Upper Respiratory Tract Infection 

Metabolic and Nutritional 

Weight Increase 

Gonal-f Patients (%) 


n= 59 

3.6% 

1.7% 

3.6% 

5.4% 

3.6% 

Urofollitropin Patients (%) 


n=61 

5.2% 

3.4% 

3.4% 

1.7% 

0.0% 

12.5% 

3.4% 

8.9% 

3.4% 

7.1% 

1.7% 

3.6% 

1.7% 

3.6% 

0.0% 

Additional adverse events not listed in Table 2 that occurred in 1 to 2% of Gonal-f ® treated patients in the 

US ART study included the following: D&C following delivery or abortion, dysmenorrhea, vaginal hemorrhage, 

diarrhea, tooth disorder, vomiting, dizziness, paraesthesia, abdomen enlarged, chest pain, fatigue, dyspnea, 

anorexia, anxiety, somnolence, injection site inflammation, injection site reaction, pruritus, pruritus genital, 

myalgia, thirst and palpitation. The safety profiles from two European studies were comparable. 

The following medical events have been reported subsequent to pregnancies resulting from gonadotropin therapy in 

controlled clinical studies: spontaneous abortion, ectopic pregnancy, premature labor, postpartum fever and 

congenital abnormalities. There have been infrequent reports of ovarian neoplasms, both benign and malignant in 

women who have undergone multiple drug regimens for ovulation induction however a causal relationship has not been 

established. Men: One hundred twenty-three adverse events, including 7 serious adverse events were reported in 34 

of the 56 patients during Gonal-f ® treatment. Serious adverse events included: testicular surgery for cryptorchidism, 

which existed prestudy, hemoptysis, an infected pilonidal cyst, and lymphadenopathy associated with Epstein-Barr 

viral infection. The most common events occurring in more than 2 patients were acne (59% of patients), breast pain 

(13.6% of patients), and fatigue, gynecomastia and injection site pain (each reported in 9.1% of patients). A total of 

12,026 injections of Gonal-f ® were administered by the 56 patients who received Gonal-f ® combined. The injections 

were well-tolerated with no or mild reactions (redness, swelling, bruising and itching) reported by patients for 93.3% 

of injections. Moderate and severe reactions, consisting primarily of pain, were reported for 4.8% of injections and 

no self-assessment was available for 1.9% of injections. 

OVERDOSAGE 

Aside from possible ovarian hyperstimulation and multiple gestations (see WARNINGS), there is no information on the 

consequences of acute overdosage with Gonal-f ® (follitropin alfa for injection). 

HOW SUPPLIED 

Gonal-f ® (follitropin alfa for injection) is supplied in a sterile, lyophilized form in multiple dose vials filled with 600 IU 

or 1200 IU in order to deliver 450 IU and 1050 IU, FSH, respectivelyafter reconstitution with diluent (Bacteriostatic 

Water for Injection, USP, containing 0.9% benzyl alcohol as a preservative). Each carton contains syringes with 

mounted 27G x 0.5 inch needle, calibrated in FSH units (IU FSH) which should be used for administration. 

Lyophilized Multi-Dose vials may be stored refrigerated or at room temperature (2º-25ºC/36º-77ºF). Following 

reconstitution, the Multi-Dose vials may be stored refrigerated or at room temperature (2º-8ºC/36º-46ºF). 

Protect from light. Discard unused reconstituted solution after 28 days. 

Rx only 

Manufactured for: EMD Serono, Inc., Rockland, MA 02370 USA Revised: August 2009 

©2009 EMD Serono, Inc. 090722-130146 

GONA9L0148_Gonal_f_MBS_August_09.indd 1 9/1/09 9:59 AM

Come to booth 523 and be inspired by the pioneers of fertility 

Howard W. Jones, Jr., M.D. 

and Susan L. Crockin, J.D. 

Book Signing 

Mon and Tues 

10:30Am - 11:15Am 

1:15pm - 2:45pm 

Bruno 

Lunenfeld, M.D. 

Q&A in Booth 523 

Tues 1:15pm - 2:45pm 

At Product Theater 

(Booth 601) 

Tues 3:30pm - 4:10pm 

Race for 

Hope 

Fundraising Event 

Mon and Tues 

9:30Am - 5:00pm 

Wed 

9:30Am - 2:00pm 

Faces of 

Fertility 

Photo Essays 

Mon and Tues 

9:30Am - 5:00pm 

Wed 

9:30Am - 2:00pm 

Indication: for women, Gonal-f ® (follitropin alfa for injection), Gonal-f ® rff (follitropin alfa injection), and Gonal-f ® rff pen (follitropin alfa injection) are indicated 

for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian 

failure and 2) for the development of multiple follicles in the ovulatory patient participating in an Assisted reproductive technology (Art) program. 

for men, Gonal-f ® is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the 

cause of infertility is not due to primary testicular failure. 

Important Safety Information: 

these products should only be prescribed by physicians specializing in fertility or reproductive health. use of Gonal-f ® or Gonal-f ® rff by women can 

result in multiple births. Gonal-f ® and Gonal-f ® rff are potent gonadotropins capable of causing mild to severe adverse reactions, including ovarian 

hyperstimulation Syndrome (ohSS) in women with or without pulmonary complications. Gonal-f ® and Gonal-f ® rff are contraindicated in women and 

men who exhibit prior hypersensitivity to recombinant fSh preparations or one of their excipients, high levels of fSh indicating primary gonadal failure, 

uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial 

lesion such as a pituitary tumor. Additionally, Gonal-f ® and Gonal-f ® rff should not be given to women with abnormal bleeding, presence or enlargement of 

an ovarian cyst of undetermined origin, or who are pregnant or nursing. the most common side effects reported in women using Gonal-f ® and Gonal-f ® rff 

include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections. men using Gonal-f ® have commonly reported 

acne, breast pain and growth, and fatigue. injection site reactions have been reported. 

For product details, see brief summary of full prescribing information on inside back cover. 

WelCome to the AmeriCAn SoCiety for reproduCtive mediCine 66th Annual meeting 

©2010 emd Serono, inc. 100816-173705

scientific program • symposia - American Society for Reproductive ...

Create successful ePaper yourself

Delete template?

Save as template?